PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Constable, BL				Constable, BL			Patients' accounts of being removed from their general practitioner's list: qualitative study - Response - "Being removed without knowing why is very distressing"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2003	326	7402					1319	1319		10.1136/bmj.326.7402.1319	http://dx.doi.org/10.1136/bmj.326.7402.1319			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805174	Bronze, Green Published			2022-12-28	WOS:000183626500038
J	Antoniou, J				Antoniou, J			"He treats you as a person not just like a number" - How important is personal care in general practice? Response - "I have a chronic illness and I would much rather see the same person all the time"	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1313	1313		10.1136/bmj.326.7402.1313	http://dx.doi.org/10.1136/bmj.326.7402.1313			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805170	Green Published, Bronze			2022-12-28	WOS:000183626500033
J	Brumfiel, G				Brumfiel, G			Pumping row erodes hopes for underground lab	NATURE			English	News Item																		2003, NATURE, V423, P579	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					674	674						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802300				2022-12-28	WOS:000183443400009
J	Brumfiel, G				Brumfiel, G			Physicists doubt that 'corking' could help baseball's big hitter	NATURE			English	News Item																		Nathan AM, 2003, AM J PHYS, V71, P134, DOI 10.1119/1.1522699	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					674	674						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802300				2022-12-28	WOS:000183443400008
J	Saeed, R				Saeed, R			Patients' accounts of being removed from their general practitioner's list: qualitative study - Response - "Being removed without knowing why is very distressing"	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1319	1319		10.1136/bmj.326.7402.1319	http://dx.doi.org/10.1136/bmj.326.7402.1319			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805174	Bronze, Green Published			2022-12-28	WOS:000183626500037
J	Wilkins, D				Wilkins, D			"He treats you as a person not just like a number" - How important is personal care in general practice? Response - "I have a chronic illness and I would much rather see the same person all the time"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Mens Hlth Forum, London WC1H 9HR, England		Wilkins, D (corresponding author), Mens Hlth Forum, London WC1H 9HR, England.	david.wilkins@menshealthforum.org.uk							0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2003	326	7402					1313	1313		10.1136/bmj.326.7402.1313	http://dx.doi.org/10.1136/bmj.326.7402.1313			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805170	Green Published, Bronze			2022-12-28	WOS:000183626500034
J	Graf, P				Graf, P			Hive beetle causes a buzz in Europe	NATURE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					793	793		10.1038/423793b	http://dx.doi.org/10.1038/423793b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815395	Bronze			2022-12-28	WOS:000183585300012
J	Wilson, AH; Shirey, SB; Carlson, RW				Wilson, AH; Shirey, SB; Carlson, RW			Archaean ultra-depleted komatiites formed by hydrous melting of cratonic mantle	NATURE			English	Article							ABITIBI GREENSTONE-BELT; KAAPVAAL CRATON; 3.8 GA; RE-OS; PLUME; PERIDOTITE; EVOLUTION; ISOTOPE; MAGMAS; DIFFERENTIATION	Komatiites are ultramafic volcanic rocks containing more than 18 per cent MgO (ref. 1) that erupted mainly in the Archaean era (more than 2.5 gigayears ago). Although such compositions occur in later periods of Earth history (for example, the Cretaceous komatiites of Gorgona Island(2)), the more recent examples tend to have lower MgO content than their Archaean equivalents. Komatiites are also characterized by their low incompatible-element content, which is most consistent with their generation by high degrees of partial melting (30-50 per cent(3)). Current models for komatiite genesis include the melting of rock at great depth in plumes of hot, diapirically rising mantle(4) or the melting of relatively shallow mantle rocks at less extreme, but still high, temperatures caused by fluxing with water(5). Here we report a suite of ultramafic lava flows from the Commondale greenstone belt, in the southern part of the Kaapvaal Craton, which represents a previously unrecognized type of komatiite with exceptionally high forsterite content of its igneous olivines, low TiO2/Al2O3 ratio, high silica content, extreme depletion in rare-earth elements and low Re/Os ratio. We suggest a model for their formation in which a garnet-enriched residue left by earlier cratonic volcanism was melted by hydration from a subducting slab.	Univ KwaZulu Natal, Sch Geol & Comp Sci, ZA-4041 Durban, South Africa; Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA	University of Kwazulu Natal; Carnegie Institution for Science	Wilson, AH (corresponding author), Univ KwaZulu Natal, Sch Geol & Comp Sci, ZA-4041 Durban, South Africa.	wilsona@nu.ac.za						Bennett VC, 2002, GEOCHIM COSMOCHIM AC, V66, P2615, DOI 10.1016/S0016-7037(02)00862-1; CAMPBELL IH, 1989, NATURE, V339, P697, DOI 10.1038/339697a0; CAMPBELL IH, 1990, EARTH PLANET SC LETT, V99, P79, DOI 10.1016/0012-821X(90)90072-6; Carlson R.W., 1999, P 7 INT KIMBERLITE C, P99; Crawford A. J., 1989, BONINITES RELATED RO, P1; de Wit MJ, 1998, PRECAMBRIAN RES, V91, P181, DOI 10.1016/S0301-9268(98)00043-6; Fan J, 1997, GEOCHIM COSMOCHIM AC, V61, P4723, DOI 10.1016/S0016-7037(97)00269-X; Herzberg C, 2002, J PETROL, V43, P1857, DOI 10.1093/petrology/43.10.1857; Irvine GJ, 2001, GEOPHYS RES LETT, V28, P2505, DOI 10.1029/2000GL012411; Kawamoto T, 1997, SCIENCE, V276, P240, DOI 10.1126/science.276.5310.240; Kerr AC, 2001, J PETROL, V42, P2169, DOI 10.1093/petrology/42.11.2169; KINZLER RJ, 1985, AM MINERAL, V70, P40; KUSHIRO I, 1972, J PETROL, V13, P311, DOI 10.1093/petrology/13.2.311; Meisel T, 1996, NATURE, V383, P517, DOI 10.1038/383517a0; MORGAN JW, 1986, J GEOPHYS RES-SOLID, V91, P2375, DOI 10.1029/JB091iB12p12375; MORGAN JW, 1985, NATURE, V317, P703, DOI 10.1038/317703a0; Nagler TF, 1997, GEOLOGY, V25, P983, DOI 10.1130/0091-7613(1997)025<0983:GOSLMB>2.3.CO;2; Parman SW, 1997, EARTH PLANET SC LETT, V150, P303, DOI 10.1016/S0012-821X(97)00104-0; Revillon S, 2000, J PETROL, V41, P1127, DOI 10.1093/petrology/41.7.1127; Schmidt MW, 1998, EARTH PLANET SC LETT, V163, P361, DOI 10.1016/S0012-821X(98)00142-3; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; Smith H. S., 1982, KOMATIITES, P347; SUN SS, 1978, CONTRIB MINERAL PETR, V65, P301, DOI 10.1007/BF00375516; TAYLOR RN, 1994, J PETROL, V35, P577, DOI 10.1093/petrology/35.3.577; Walter MJ, 1998, J PETROL, V39, P29, DOI 10.1093/petrology/39.1.29; WILSON AH, 1989, EARTH PLANET SC LETT, V96, P89, DOI 10.1016/0012-821X(89)90125-8; XIE QL, 1994, J GEOPHYS RES-SOL EA, V99, P15799, DOI 10.1029/94JB00544; Zegers TE, 1996, PRECAMBRIAN RES, V80, P89, DOI 10.1016/S0301-9268(96)00007-1	28	76	78	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					858	861		10.1038/nature01701	http://dx.doi.org/10.1038/nature01701			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815428				2022-12-28	WOS:000183585300042
J	Kessler, RC; Berglund, P; Demler, O; Jin, R; Koretz, D; Merikangas, KR; Rush, AJ; Walters, EE; Wang, PS				Kessler, RC; Berglund, P; Demler, O; Jin, R; Koretz, D; Merikangas, KR; Rush, AJ; Walters, EE; Wang, PS			The epidemiology of major depressive disorder - Results from the National Comorbidity Survey Replication (NCS-R).	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNATIONAL DIAGNOSTIC INTERVIEW; RANDOMIZED CONTROLLED TRIAL; IMPULSE-CONTROL DISORDERS; UNITED-STATES; PRIMARY-CARE; PSYCHIATRIC-DISORDERS; MENTAL-DISORDERS; QUALITY IMPROVEMENT; ANXIETY DISORDERS; BIPOLAR DISORDER	Context Uncertainties exist about prevalence and correlates of major depressive disorder (MDD). Objective To present nationally representative data on prevalence and correlates of MDD by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, and on study patterns and correlates of treatment and treatment adequacy from the recently completed National Comorbidity Survey Replication (NCS-R). Design Face-to-face household survey,conducted from February 2001 to December 2002. Setting The 48 contiguous United States. Participants Household residents ages 18 years or older (N =9090) who responded to the NCS-R survey. Main Outcome Measures Prevalence and correlates of MDD using the World Health Organization's (WHO) Composite International Diagnostic Interview (CIDI), 12-month severity with the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), the Sheehan Disability Scale (SDS), and the WHO disability assessment scale (WHO-DAS). Clinical reinterviews used the Structured Clinical Interview for DSM-IV. Results The prevalence of CIDI MDD for lifetime was 16.2% (95% confidence interval [CI], 15.1-17.3) (32.6-35.1 million US adults) and for 12-month was 6.6% (95% CI; 5.9-7.3) (13.1-14.2 million US adults). Virtually all CIDI 12-month cases were independently classified as clinically significant using the QIDS-SR, with 10.4% mild, 38.6% moderate, 38.0% severe, and 12.9% very severe. Mean episode duration was 16 weeks (95% Cl, 15.1-17.3). Role impairment as measured by SIDS was substantial as indicated by 59.3 % of 12-month cases with severe or very severe role impairment. Most lifetime (72.1 %) and 12-month (78.5%) cases had comorbid CIDI/DSM-IV disorders, with MDD only rarely primary. Although 51.6% (95% Cl, 46.1-57.2) of 12-month cases received health care treatment for MDD, treatment was adequate in only 41.9% (95% Cl, 35.9-47.9) of these cases, resulting in 21.7% (95% Cl, 18.1-25.2) of 12-month MDD being adequately treated. Sociodemographic correlates of treatment were far less numerous than those of prevalence. Conclusions Major depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment. While the recent increase in treatment is encouraging, inadequate treatment is a serious concern. Emphasis on screening and expansion of treatment needs to be accompanied by a parallel emphasis on treatment quality improvement.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Univ Michigan, Inst Social Res, Ann Arbor, MI USA; NIMH, Div Mental Dosorders Behav Res & AIDS, Rockville, MD 20857 USA; NIMH, Intramural Res Program, Rockville, MD 20857 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kessler, RC (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.		Culwell, M. Shaun/F-5156-2010; Demler, Olga/AAE-8436-2019	Demler, Olga/0000-0003-3355-3210; Merikangas, Kathkeen/0000-0002-4667-2414; Rush, Augustus/0000-0003-2004-2382	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002806, U01MH060220, ZIAMH002806] Funding Source: NIH RePORTER; NIMH NIH HHS [U01-MH60220] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Agency for Health Care Policy and Research, 1993, DEPR PRIM CAR, V2; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andrade L, 2003, INT J METH PSYCH RES, V12, P3, DOI 10.1002/mpr.138; Angst J, 1997, J AFFECT DISORDERS, V45, P31, DOI 10.1016/S0165-0327(97)00057-8; [Anonymous], WORLD HLTH REP 2002; BLAND RC, 1988, ACTA PSYCHIAT SCAND, V77, P338; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; CANINO GJ, 1987, ARCH GEN PSYCHIAT, V44, P727; CHRISTIE KA, 1988, AM J PSYCHIAT, V145, P971; COMSTOCK GW, 1976, PSYCHOL MED, V6, P551, DOI 10.1017/S0033291700018171; First M. B., 1997, STRUCTURED CLIN INTE; GIUFFRA LA, 1994, PSYCHOL MED, V24, P375, DOI 10.1017/S0033291700027355; Hamilton M., 1960, J NEUROL NEUROSUR PS, V23-56; HELGASON T, 1964, ACTA PSYCHIAT SCAND, V40, P115; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; HOSMER DW, 1989, APPL LOGISTIC REGRES; HWU HG, 1989, ACTA PSYCHIAT SCAND, V79, P136, DOI 10.1111/j.1600-0447.1989.tb08581.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karasu T.B., 2000, PRACTICE GUIDELINE T, V2nd; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KELLER MB, 1985, CHRONIC TREATMENTS N; Kessler R. C., 2000, GENDER ITS EFFECTS P, P61; Kessler R.C., 1998, INT J METH PSYCH RES, V7, P33, DOI [DOI 10.1002/MPR.33, 10.1016/j.jad.2006.08.018]; KESSLER RC, 1994, J AFFECT DISORDERS, V30, P15, DOI 10.1016/0165-0327(94)90147-3; Kessler RC, 1999, AM J PSYCHIAT, V156, P115, DOI 10.1176/ajp.156.1.115; KESSLER RC, 1993, PSYCHOL MED, V23, P679, DOI 10.1017/S0033291700025460; Kessler RC, 2001, J OCCUP ENVIRON MED, V43, P218, DOI 10.1097/00043764-200103000-00009; Kessler RC, 1996, BRIT J PSYCHIAT, V168, P17, DOI 10.1192/S0007125000298371; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KESSLER RC, IN PRESS SHOULD MILD; Kessler RC, 1997, TREATMENT STRATEGIES; Kessler RC, 2002, TXB PSYCHIAT EPIDEMI, P343; KOUZIS AC, 1994, AM J PUBLIC HEALTH, V84, P1304, DOI 10.2105/AJPH.84.8.1304; LEE CK, 1990, J NERV MENT DIS, V178, P242, DOI 10.1097/00005053-199004000-00004; Lejoyeux M, 2002, J NERV MENT DIS, V190, P310, DOI 10.1097/00005053-200205000-00007; Leon AC, 1997, INT J PSYCHIAT MED, V27, P93, DOI 10.2190/T8EM-C8YH-373N-1UWD; LEPINE J P, 1989, Psychiatrie and Psychobiologie, V4, P267; LIN TY, 1953, PSYCHIATRY, V16, P315; Loeber R., 1988, ANTISOCIAL BEHAV MEN; McElroy SL, 1996, COMPR PSYCHIAT, V37, P229, DOI 10.1016/S0010-440X(96)90001-2; Merikangas KR, 1996, BRIT J PSYCHIAT, V168, P58, DOI 10.1192/S0007125000298425; MURPHY JM, 1984, ARCH GEN PSYCHIAT, V41, P990; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; *NAT COMM QUAL ASS, 1997, HEDIS 3 0 NARR WHATS; Office of the Surgeon General, 2019, SURG GEN ADV MAR US; Olfson M, 2002, JAMA-J AM MED ASSOC, V287, P203, DOI 10.1001/jama.287.2.203; Perugi G, 1998, COMPR PSYCHIAT, V39, P63, DOI 10.1016/S0010-440X(98)90080-3; Pincus HA, 2003, INT J METH PSYCH RES, V12, P54, DOI 10.1002/mpr.142; Regier DA, 1998, ARCH GEN PSYCHIAT, V55, P109, DOI 10.1001/archpsyc.55.2.109; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; REGIER DA, 1988, AM J PSYCHIAT, V145, P1351; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; Rehm J., 1999, INT J METH PSYCH RES, V8, P110, DOI DOI 10.1002/MPR.61; Research Triangle Institute, 2002, SUD REL 8 0 1; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINS LN, 1991, PSYCHIAT DISORDERS A; Rush A.J., 2000, INT J METH PSYCH RES, V9, P45, DOI [DOI 10.1002/MPR.79, 10.1002/mpr.79]; Rush AJ, 1996, PSYCHOL MED, V26, P477, DOI 10.1017/S0033291700035558; RUSH AJ, IN PRESS BIOL PSYCHI; Schoenbaum M, 2001, JAMA-J AM MED ASSOC, V286, P1325, DOI 10.1001/jama.286.11.1325; SIMON GE, 1995, EPIDEMIOL REV, V17, P221, DOI 10.1093/oxfordjournals.epirev.a036180; *SUBST AB MENT HLT, 1996, CONS OR MENT HLTH RE; Valenstein M, 2001, ANN INTERN MED, V134, P345, DOI 10.7326/0003-4819-134-5-200103060-00007; Wang PS, 2003, INT J METH PSYCH RES, V12, P22, DOI 10.1002/mpr.139; Warner V, 1999, J AM ACAD CHILD PSY, V38, P289, DOI 10.1097/00004583-199903000-00016; WEISSMAN MM, 1978, ARCH GEN PSYCHIAT, V35, P1304; WEISSMAN MM, 1992, JAMA-J AM MED ASSOC, V268, P3098, DOI 10.1001/jama.1992.03490210080039; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; Weissman MM, 1991, PSYCHIAT DISORDERS A, P53; WELLS JE, 1989, AUST NZ J PSYCHIAT, V23, P315, DOI 10.3109/00048678909068289; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; WITTCHEN HU, 1992, EUR ARCH PSY CLIN N, V241, P247, DOI 10.1007/BF02190261; Zimmerman M, 2002, J CLIN PSYCHIAT, V63, P187, DOI 10.4088/JCP.v63n0303	79	5693	5898	24	623	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3095	3105		10.1001/jama.289.23.3095	http://dx.doi.org/10.1001/jama.289.23.3095			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690QM	12813115				2022-12-28	WOS:000183560400024
J	Cinatl, J; Morgenstern, B; Bauer, G; Chandra, P; Rabenau, H; Doerr, HW				Cinatl, J; Morgenstern, B; Bauer, G; Chandra, P; Rabenau, H; Doerr, HW			Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus	LANCET			English	Article							NITRIC-OXIDE	The outbreak of SARS warrants the search for antiviral compounds to treat the disease. At present, no specific treatment has been identified for SARS-associated coronavirus Infection. We assessed the antiviral potential of ribavirin, 6-azauridine, pyrazofurin, mycophenolic acid, and glycyrrhizin against two clinical Isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany. Of all the compounds, glycyrrhizin was the most active in inhibiting replication of the SARS-associated virus. Our findings suggest that glycyrrhizin should be assessed for treatment of SARS.	Goethe Univ Frankfurt, Sch Med, Inst Med Virol, D-60596 Frankfurt, Germany	Goethe University Frankfurt	Cinatl, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Inst Med Virol, Paul Ehrlich Str 40, D-60596 Frankfurt, Germany.	cinatl@em.uni-frankfurt.de						Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Jeong HG, 2002, FEBS LETT, V513, P208, DOI 10.1016/S0014-5793(02)02311-6; Lin YL, 1997, J VIROL, V71, P5227, DOI 10.1128/JVI.71.7.5227-5235.1997	5	760	874	4	85	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2045	2046		10.1016/S0140-6736(03)13615-X	http://dx.doi.org/10.1016/S0140-6736(03)13615-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814717	Bronze, Green Published			2022-12-28	WOS:000183488900013
J	Kennedy, I				Kennedy, I			Patients are experts in their own field	BRITISH MEDICAL JOURNAL			English	Editorial Material									Dept Hlth, Commiss Healthcare Audit & Inspect, London SE1 6TE, England		Kennedy, I (corresponding author), Dept Hlth, Commiss Healthcare Audit & Inspect, London SE1 6TE, England.								0	58	59	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1276	1276		10.1136/bmj.326.7402.1276	http://dx.doi.org/10.1136/bmj.326.7402.1276			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805126	Green Published			2022-12-28	WOS:000183626500002
J	Persaud, R				Persaud, R			'Both sides need to keep the relationship going'	BRITISH MEDICAL JOURNAL			English	Article									Maudsley Hosp & Inst Psychiat, London SE5 8AZ, England	South London & Maudsley NHS Trust; University of London; King's College London	Persaud, R (corresponding author), Maudsley Hosp & Inst Psychiat, London SE5 8AZ, England.								0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1337	1337		10.1136/bmj.326.7402.1337	http://dx.doi.org/10.1136/bmj.326.7402.1337			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805197	Green Published			2022-12-28	WOS:000183626500062
J	Hariharan, IK; Haber, DA				Hariharan, IK; Haber, DA			Yeast, flies, worms, and fish in the study of human disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOSOMAL-DOMINANT HEMOCHROMATOSIS; CELL-DIVISION CYCLE; CAENORHABDITIS-ELEGANS; GENETIC SCREENS; DROSOPHILA-MELANOGASTER; HUMAN HOMOLOG; CANCER; MUTATIONS; ZEBRAFISH; DESIGN		Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Hariharan, IK (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.							Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; [Anonymous], 1999, SCIENCE, V285, P1493; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bale AE, 2000, NATURE, V406, P944, DOI 10.1038/35023197; Blaxter M, 1999, SCIENCE, V283, P2103; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Erdman D., 1988, COMPLETE POETRY PROS, P173; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500; Fortini ME, 2000, TRENDS GENET, V16, P161, DOI 10.1016/S0168-9525(99)01939-3; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hamosh A, 2002, NUCLEIC ACIDS RES, V30, P52, DOI 10.1093/nar/30.1.52; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jorgensen EM, 2002, NAT REV GENET, V3, P356, DOI 10.1038/nrg794; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468; Njajou OT, 2001, NAT GENET, V28, P213, DOI 10.1038/90038; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Patton EE, 2001, NAT REV GENET, V2, P956, DOI 10.1038/35103567; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; PTASHNE M, 1982, SCI AM, V247, P128, DOI 10.1038/scientificamerican1182-128; PTASHNE M, 1982, SCI AM, V247, P132; PTASHNE M, 1982, SCI AM, V247, P134; Reiter LT, 2001, GENOME RES, V11, P1114, DOI 10.1101/gr.169101; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shin JT, 2002, ANNU REV GENOM HUM G, V3, P311, DOI 10.1146/annurev.genom.3.031402.131506; Spruck CH, 2002, CANCER RES, V62, P4535; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Venter JC, 2001, SCIENCE, V292, P1838; Verlinsky Y, 2003, NEW ENGL J MED, V348, P1449, DOI 10.1056/NEJMoa022652; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3	59	29	31	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2457	2463		10.1056/NEJMon023158	http://dx.doi.org/10.1056/NEJMon023158			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802034				2022-12-28	WOS:000183428900014
J	Kaindl, RA; Carnahan, MA; Hagele, D; Lovenich, R; Chemla, DS				Kaindl, RA; Carnahan, MA; Hagele, D; Lovenich, R; Chemla, DS			Ultrafast terahertz probes of transient conducting and insulating phases in an electron-hole gas	NATURE			English	Article							EXCITON FORMATION; QUANTUM; GAAS; DYNAMICS; RELAXATION; ABSORPTION; ENERGY	Many-body systems in nature exhibit complexity and self-organization arising from seemingly simple laws. For example, the long-range Coulomb interaction between electrical charges has a simple form, yet is responsible for a plethora of bound states in matter, ranging from the hydrogen atom to complex biochemical structures. Semiconductors form an ideal laboratory for studying many-body interactions of electronic quasiparticles among themselves and with lattice vibrations and light(1-4). Oppositely charged electron and hole quasiparticles can coexist in an ionized but correlated plasma, or form bound hydrogen-like pairs called excitons(5,6). The pathways between such states, however, remain elusive in near-visible optical experiments that detect a subset of excitons with vanishing centre-of-mass momenta. In contrast, transitions between internal exciton levels, which occur in the far-infrared at terahertz (10(12) s(-1)) frequencies(7-9), are independent of this restriction, suggesting(10) their use as a probe of electron-hole pair dynamics. Here we employ an ultrafast terahertz probe to investigate directly the dynamical interplay of optically-generated excitons and unbound electron-hole pairs in GaAs quantum wells. Our observations reveal an unexpected quasi-instantaneous excitonic enhancement, the formation of insulating excitons on a 100-ps timescale, and the conditions under which excitonic populations prevail.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA; Leibniz Univ Hannover, Inst Festkorperphys, D-30167 Hannover, Germany	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Leibniz University Hannover	Kaindl, RA (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	RAKaindl@lbl.gov		Hagele, Daniel/0000-0003-0149-0817				Bayer M, 2000, NATURE, V405, P923, DOI 10.1038/35016020; Beard MC, 2000, PHYS REV B, V62, P15764, DOI 10.1103/PhysRevB.62.15764; Betz M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.085314; BLOM PWM, 1993, PHYS REV LETT, V71, P3878, DOI 10.1103/PhysRevLett.71.3878; Cerne J, 1996, PHYS REV LETT, V77, P1131, DOI 10.1103/PhysRevLett.77.1131; Chemla DS, 2001, NATURE, V411, P549, DOI 10.1038/35079000; DAMEN TC, 1990, PHYS REV B, V42, P7434, DOI 10.1103/PhysRevB.42.7434; DEVEAUD B, 1993, J PHYS IV, V3, P11, DOI 10.1051/jp4:1993502; DRESSEL M, 2002, ELECTRODYNAMICS SOLI, P61; Gerlach B, 1998, PHYS REV B, V58, P10568, DOI 10.1103/PhysRevB.58.10568; GROENEVELD RHM, 1994, J OPT SOC AM B, V11, P2502, DOI 10.1364/JOSAB.11.002502; Haug H., 1994, QUANTUM THEORY OPTIC; Huber R, 2001, NATURE, V414, P286, DOI 10.1038/35104522; Kira M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.176401; Kumar R, 1996, PHYS REV B, V54, P4891, DOI 10.1103/PhysRevB.54.4891; Landau L, 1943, ACTA PHYSICOCHIM URS, V18, P194; Lovenich R, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.045306; Lundstrom T, 1999, SCIENCE, V286, P2312, DOI 10.1126/science.286.5448.2312; Mott N.F., 1990, METAL INSULATOR TRAN; Nuss MC, 1998, TOP APPL PHYS, V74, P7; Oh IK, 2000, PHYS REV B, V62, P2045, DOI 10.1103/PhysRevB.62.2045; Perakis IE, 2002, NATURE, V417, P33, DOI 10.1038/417033a; Rashba EI., 1982, EXCITONS; Selbmann PE, 1996, PHYS REV B, V54, P4660, DOI 10.1103/PhysRevB.54.4660; Shah J., 1999, ULTRAFAST SPECTROSCO; Siantidis K, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.035303; Siarkos A, 2000, PHYS REV B, V61, P10854, DOI 10.1103/PhysRevB.61.10854; TIMUSK T, 1976, PHYS REV B, V13, P3511, DOI 10.1103/PhysRevB.13.3511; TZOAR N, 1979, PHYS REV B, V20, P4189, DOI 10.1103/PhysRevB.20.4189; WEGENER M, 1989, PHYS REV B, V39, P12794, DOI 10.1103/PhysRevB.39.12794	30	302	309	2	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					734	738		10.1038/nature01676	http://dx.doi.org/10.1038/nature01676			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802330	Green Submitted			2022-12-28	WOS:000183443400039
J	Szostak, JW				Szostak, JW			Molecular messages	NATURE			English	Editorial Material									Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	Szostak, JW (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA.							Adami C, 2000, PHYSICA D, V137, P62, DOI 10.1016/S0167-2789(99)00179-7; HAMMING RW, 1987, CODING INFORMATION T; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; ZUREK WH, 1991, STUDIES SCI COMPLEXI, V8	4	57	61	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					689	689		10.1038/423689a	http://dx.doi.org/10.1038/423689a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802312	Bronze			2022-12-28	WOS:000183443400022
J	Cooper, NJ; Sutton, AJ; Abrams, KR; Wailoo, A; Turner, DA; Nicholson, KG				Cooper, NJ; Sutton, AJ; Abrams, KR; Wailoo, A; Turner, DA; Nicholson, KG			Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							RIMANTADINE; OSELTAMIVIR; AMANTADINE; ZANAMIVIR; EFFICACY; QUALITY; SAFETY	Objective To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and prevention of influenza A and B. Design Systematic review and meta-analyses of randomised controlled trials. Data sources Published studies were retrieved from electronic bibliographic databases; supplementary data were obtained from the manufacturers. Selection of studies Randomised controlled, double blind trials that were published in English, had data available before 31 December 2001, evaluated treatment or prevention of naturally occurring influenza with zanamivir or oseltamivir (if given using the formulation and dosage licensed for clinical use), and reported at least one end point of relevance. Review methods The main outcome measures were the median time to the alleviation of symptoms (for treatment trials) and number of flu episodes avoided (for prevention trials). Three population groups were defined: children aged 12 years and under; otherwise healthy individuals aged 12 to 65 years; and "high risk" individuals (those with certain chronic medical conditions or aged 65 years and older). Results Seventeen treatment trials and seven prevention trials identified met the inclusion criteria. All trials included compared one of the drugs against placebo or standard care. Treatment of children, otherwise healthy individuals, and high risk populations with zanamivir reduced the median duration of symptoms in days respectively by 1.0 (95% confidence interval 0.5 to 1.5), 0.8 (0.3 to 1.3), and 0.9 (- 0.1 to 1.9) for the intention to treat population. The corresponding results, in days, for oseltamivir were 0.9 (0.3 to 1.5), 0.9 (0.3 to 1.4), and 0.4 (- 0.7 to 1.4). The effect of giving zanamivir and oseltamivir prophylactically resulted in a relative reduction of 70-90% in the odds of developing flu, depending on the strategy adopted and the population studied. Conclusions Evidence from randomised controlled trials consistently supports the view that both oseltamivir and zanamivir are clinically effective for treating and preventing flu. However, evidence is limited for the treatment of certain populations and for all prevention strategies.	Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Univ Sheffield, Sch Hlth & Related Res, Sheffield Hlth Econ Grp, Sheffield S1 4DA, S Yorkshire, England; Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England	University of Leicester; University of Sheffield; University of Leicester	Cooper, NJ (corresponding author), Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England.		Turner, David A/E-1847-2013; Abrams, Keith/AAA-2557-2020	Turner, David A/0000-0002-1689-4147; Wailoo, Allan/0000-0002-9324-1617; Abrams, Keith/0000-0002-7557-1567; Sutton, Alexander/0000-0002-8934-9940				BRADY B, 2001, EC EVALUATION ZANAMI; BURLS A, 2000, HLTH TECHNOLOGY ASSE, V6; COCHRAN KW, 1965, ANN NY ACAD SCI, V130, P432, DOI 10.1111/j.1749-6632.1965.tb12579.x; HAYDEN FG, 1983, ANTIMICROB AGENTS CH, V23, P458, DOI 10.1128/AAC.23.3.458; HUSEREAU DR, 2001, OSELTAMIVIR TREATMEN; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jefferson T., 2000, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001265; Lalezari J, 2001, ARCH INTERN MED, V161, P212, DOI 10.1001/archinte.161.2.212; Lievre M, 2002, CURR CONTR TRIALS C, V3, DOI 10.1186/1468-6708-3-6; MILLET VM, 1982, ANTIMICROB AGENTS CH, V21, P1; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Monto AS, 1999, J ANTIMICROB CHEMOTH, V44, P23, DOI 10.1093/jac/44.suppl_2.23; *NAT I CLIN EXC, 2003, 58 NAT I CLIN EXC; *NAT I CLIN EXC, 2003, 58 NAT I CLIN EX; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Nicholson KG, 1998, TXB INFLUENZA, P219; SIMPSON EH, 1951, J ROY STAT SOC B, V13, P238; Sutton AJAK, 2000, METHODS METAANALYSIS; Tsunoda A, 1965, Antimicrob Agents Chemother (Bethesda), V5, P553; TURNER D, 2002, SYSTEMIC REV EC DECI; TURNER D, 2002, NICE ASSESSENT REPOR; Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002	22	242	264	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1235	+		10.1136/bmj.326.7401.1235	http://dx.doi.org/10.1136/bmj.326.7401.1235			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791735	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000183480700012
J	Sperschneider, T; Kleinert, S; Horton, R				Sperschneider, T; Kleinert, S; Horton, R			Appealing to editors?	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sperschneider, T (corresponding author), The Lancet, London NW1 7BY, England.							Callaham ML, 2003, ANN EMERG MED, V41, P82, DOI 10.1067/mem.2003.42; *INT COMM MED J ED, 2001, UN REQ MAN SUBM BIOM; Williamson A, 2003, LEARN PUBL, V16, P15, DOI 10.1087/095315103320995041	3	4	4	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1926	1926		10.1016/S0140-6736(03)13602-1	http://dx.doi.org/10.1016/S0140-6736(03)13602-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801734				2022-12-28	WOS:000183359700006
J	Jarvik, JG; Hollingworth, W; Martin, B; Emerson, SS; Gray, DT; Overman, S; Robinson, D; Staiger, T; Wessbecher, F; Sullivan, SD; Kreuter, W; Deyo, RA				Jarvik, JG; Hollingworth, W; Martin, B; Emerson, SS; Gray, DT; Overman, S; Robinson, D; Staiger, T; Wessbecher, F; Sullivan, SD; Kreuter, W; Deyo, RA			Rapid magnetic resonance imaging vs radiographs for patients with low back pain - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH SURVEY SF-36; LUMBAR SPINE; DISABILITY; QUALITY; IMAGES; TESTS; CARE	Context Faster magnetic resonance imaging (MRI) scanning has made MRI a potential cost-effective replacement for radiographs for patients with low back pain. However, whether rapid MRI scanning results in better patient outcomes than radiographic evaluation or a cost-effective alternative is unknown. Objective To determine the clinical and economic consequences of replacing spine radiographs with rapid MRI for primary care patients. Design, Setting, and Patients Randomized controlled trial of 380 patients aged 18 years or older whose primary physicians had ordered that their low back pain be evaluated by radiographs. The patients were recruited between November 1998 and June 2000 from 1 of 4 imaging centers in the Seattle, Wash, area: a university-based teaching program, a nonuniversity-based teaching program, and 2 private clinics. Intervention Patients were randomly assigned to receive lumbar spine evaluation by rapid MRI or by radiograph. Main Outcome Measures Back-related disability measured by the modified Roland questionnaire. Secondary outcomes included Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), pain, preference scores, satisfaction, and costs. Results At 12 months, primary outcomes of functional disability were obtained from 337 (89%) of the 380 patients enrolled. The mean back-related disability modified Roland score for the 170 patients assigned to the radiograph evaluation group was 8.75 vs 9.34 for the 167 patients assigned the rapid MRI evaluation group (mean difference, -0.59; 95% CI, -1.69 to 0.87). The mean differences in the secondary outcomes were not statistically significant: pain bothersomeness (0.07; 95% CI -0.88 to 1.22), pain frequency (0.12; 95% CI, -0.69 to 1.37), and SF-36 subscales of bodily pain (1.25; 95% CI, -4.46 to 4.96), and physical functioning (2.73, 95% CI -4.09 to 6.22). Ten patients in the rapid MRI group vs 4 in the radiograph group had lumbar spine operations (risk difference, 0.34; 95% CI, -0.06 to 0.73). The rapid MRI strategy had a mean cost of $2380 vs $2059 for the radiograph strategy (mean difference, $321; 95% CI, -1100 to 458). Conclusions Rapid MRIs and radiographs resulted in nearly identical outcomes for primary care patients with low back-pain. Although physicians and patients preferred the rapid MRI, substituting rapid MRI for radiographic evaluations in the primary care setting may offer little additional benefit to patients, and it may increase the costs of care because of the increased number of spine operations that patients are likely to undergo.	Univ Washington, Dept Radiol, Seattle, WA 98195 USA; Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA; Minor & James Clin PLLC, Seattle, WA USA; Virginia Mason Med Ctr, Seattle, WA 98101 USA; Tacoma Radiol Associates, Tacoma, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Virginia Mason Medical Center	Jarvik, JG (corresponding author), Univ Washington, Dept Radiol, Box 357115, Seattle, WA 98195 USA.		Jarvik, Jeffrey/AAL-4292-2021	Hollingworth, William/0000-0002-0840-6254	AHRQ HHS [HS-09499] Funding Source: Medline; NIAMS NIH HHS [P60-AR48093] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR048093] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; Boos N, 1995, SPINE, V20, P2613, DOI 10.1097/00007632-199512150-00002; Briggs AH, 1999, HLTH TECHNOLOGY ASSE, V3, P1, DOI DOI 10.3310/hta3020; DEYO RA, 1986, SPINE, V11, P28, DOI 10.1097/00007632-198601000-00008; DEYO RA, 1988, J GEN INTERN MED, V3, P230, DOI 10.1007/BF02596337; GRAY DT, IN PRESS RADIOLOGY; Green C, 2000, PHARMACOECONOMICS, V17, P151, DOI 10.2165/00019053-200017020-00004; GRISTE JD, 1994, AM SOC NEUR NASHV TE; Haddix A, 1996, PREVENTION EFFECTIVE; *HLTH CAR FIN ADM, 2001, PHYS FEE SCHED; *HLTH CAR FIN ADM, 2001, DUR MED EQ PROSTH OR; *HLTH CAR FIN ADM, 2001, CLIN DIAGN LAB FEE S; Jarvik JG, 1997, RADIOLOGY, V204, P447, DOI 10.1148/radiology.204.2.9240534; Jarvik JG, 1996, ACAD RADIOL, V3, pS28, DOI 10.1016/S1076-6332(96)80473-9; Jarvik JJ, 2001, SPINE, V26, P1158, DOI 10.1097/00007632-200105150-00014; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Kendrick D, 2001, Health Technol Assess, V5, P1; Kendrick D, 2001, BRIT MED J, V322, P400, DOI 10.1136/bmj.322.7283.400; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; McNally EG, 2001, CLIN RADIOL, V56, P922, DOI 10.1053/crad.2001.0718; *MED EC INC, 2000, DRUG TOP 2000 RED BO; Nease RF, 1996, QUAL LIFE RES, V5, P175, DOI 10.1007/BF00435983; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; ROBERTSON W, 1993, RAD SOC N AM CHIC IL; Robertson WD, 1996, AM J ROENTGENOL, V166, P909, DOI 10.2214/ajr.166.4.8610572; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; *SAS I INC, 2000, SAS STAT SOFTW COMP; SOX HC, 1981, ANN INTERN MED, V95, P680, DOI 10.7326/0003-4819-95-6-680; *SPSS INC, 1999, SPSS WIND COMP PROGR; Stadnik TW, 1998, RADIOLOGY, V206, P49, DOI 10.1148/radiology.206.1.9423651; TRUST O, 1993, SF 36 HLTH SURVEY UP; *U MINN RES DAT AS, 2001, CALC HOSP SPEC DRG A; *UN MED PLAN, 2001, PROF PROV FEE SCHED; *US BUR LAB STAT, 2001, CONS PRIC IND; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; 2000, CURRENT PROCEDURAL T	37	231	233	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2810	2818		10.1001/jama.289.21.2810	http://dx.doi.org/10.1001/jama.289.21.2810			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KH	12783911	Bronze			2022-12-28	WOS:000183205500029
J	Burton, B; Rowell, A				Burton, B; Rowell, A			Unhealthy spin	BRITISH MEDICAL JOURNAL			English	Article											Burton, B (corresponding author), POB 157, Lyneham, ACT 2602, Australia.							COOK H, 2001, PHARM MARKETING, V6, P15; GREY A, 2000, PHARM MARKETING  NOV, P4; TAYLOR M, 2002, PHARM MARKETING	3	28	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2003	326	7400					1205	1207		10.1136/bmj.326.7400.1205	http://dx.doi.org/10.1136/bmj.326.7400.1205			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775626	Green Published			2022-12-28	WOS:000183309900028
J	Melander, H; Ahlqvist-Rastad, J; Meijer, G; Beermann, B				Melander, H; Ahlqvist-Rastad, J; Meijer, G; Beermann, B			Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DOUBLE-BLIND TRIAL; MAJOR DEPRESSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; PUBLICATION BIAS; CLINICAL-TRIALS; PAROXETINE; IMIPRAMINE; OUTPATIENTS; FLUOXETINE; EFFICACY	Objectives To investigate the relative impact on publication bias caused by multiple publication, selective publication, and selective reporting in studies sponsored by pharmaceutical companies. Design 42 placebo controlled studies of five selective serotonin reuptake inhibitors submitted to the Swedish drug regulatory authority as a basis for marketing approval for treating major depression were compared with the studies actually published (between 1983 and 1999). Results Multiple publication: 21 studies contributed to at least two publications each, and three studies contributed to five publications. Selective publication: studies showing significant effects of drug were published as stand alone publications more often than studies with non-significant results. Selective reporting: many publications ignored the results of intention to treat analyses and reported the more favourable per protocol analyses only. Conclusions The degree of multiple publication, selective publication, and selective reporting differed between products. Thus, any attempt to recommend a specific selective serotonin reuptake inhibitor from the publicly available data only is likely to be based on biased evidence.	Med Prod Agcy, S-75103 Uppsala, Sweden	Medical Products Agency	Melander, H (corresponding author), Med Prod Agcy, Box 23, S-75103 Uppsala, Sweden.	hans.Melander@mpa.se						AMIN MM, 1984, CLIN NEUROPHARMAC S1, V7, P580; BECH P, 1992, INT CLIN PSYCHOPHARM, V6, P45, DOI 10.1097/00004850-199206005-00005; BYERLEY WF, 1988, J CLIN PSYCHOPHARM, V8, P112; CLAGHORN J, 1992, INT CLIN PSYCHOPHARM, V6, P25, DOI 10.1097/00004850-199206004-00006; CLAGHORN JL, 1992, J CLIN PSYCHIAT, V53, P33; CLAGHORN JL, 1992, J CLIN PSYCHIAT, V53, P434; COHN JB, 1992, J CLIN PSYCHIAT, V53, P52; COHN JB, 1985, J CLIN PSYCHIAT, V46, P26; Davidoff F, 2001, LANCET, V358, P854, DOI 10.1016/S0140-6736(01)06035-4; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1405; DOMINGUEZ RA, 1985, J CLIN PSYCHIAT, V46, P84; DOOGAN DP, 1994, INT CLIN PSYCHOPHARM, V9, P95, DOI 10.1097/00004850-199400920-00005; DUNBAR GC, 1991, BRIT J PSYCHIAT, V159, P394, DOI 10.1192/bjp.159.3.394; DUNBAR GC, 1993, ACTA PSYCHIAT SCAND, V87, P302, DOI 10.1111/j.1600-0447.1993.tb03376.x; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EDWARDS JG, 1993, HUM PSYCHOPHARM CLIN, V8, P203, DOI 10.1002/hup.470080306; FABRE LF, 1985, CURR THER RES CLIN E, V37, P115; FABRE LF, 1992, J CLIN PSYCHIAT, V53, P40; FEIGHNER JP, 1989, INT CLIN PSYCHOPHARM, V4, P127, DOI 10.1097/00004850-198904000-00004; FEIGHNER JP, 1989, INT CLIN PSYCHOPHARM, V4, P239, DOI 10.1097/00004850-198907000-00006; FEIGHNER JP, 1992, J CLIN PSYCHIAT, V53, P44; FEIGHNER JP, 1993, J AFFECT DISORDERS, V28, P71, DOI 10.1016/0165-0327(93)90035-I; FEIGHNER JP, 1992, INT CLIN PSYCHOPHARM, V6, P31, DOI 10.1097/00004850-199206004-00007; FEIGHNER JP, 1993, ACTA PSYCHIAT S S350, V80, P125; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; ITIL TM, 1983, BRIT J CLIN PHARMACO, V15, pS433, DOI 10.1111/j.1365-2125.1983.tb02134.x; KIEV A, 1992, J CLIN PSYCHIAT, V53, P27; LAPIERRE YD, 1987, J CLIN PSYCHIAT, V48, P65; Mendels J, 1999, Depress Anxiety, V9, P54, DOI 10.1002/(SICI)1520-6394(1999)9:2<54::AID-DA2>3.3.CO;2-K; MILLER SM, 1993, ACTA PSYCHIAT S S350, V80, P143; MONTGOMERY SA, 1992, INT CLIN PSYCHOPHARM, V6, P65, DOI 10.1097/00004850-199206005-00007; NORTON KRW, 1984, J AFFECT DISORDERS, V7, P297, DOI 10.1016/0165-0327(84)90051-X; Olie JP, 1997, EUR PSYCHIAT, V12, P34, DOI 10.1016/S0924-9338(97)86377-8; OTTEVANGER EA, 1994, PROG NEURO-PSYCHOPH, V18, P731, DOI 10.1016/0278-5846(94)90080-9; PESELOW ED, 1989, PSYCHOPHARMACOL BULL, V25, P267; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; RICKELS K, 1986, CURR THER RES CLIN E, V39, P559; RICKELS K, 1992, J CLIN PSYCHIAT, V53, P30; RICKELS K, 1993, ACTA PSYCHIAT S S350, V80, P117; SHRIVASTAVA RK, 1992, J CLIN PSYCHIAT, V53, P48; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SMITH WT, 1992, J CLIN PSYCHIAT, V53, P36; STARK P, 1985, J CLIN PSYCHIAT, V46, P53; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635	51	425	437	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2003	326	7400					1171	1173		10.1136/bmj.326.7400.1171	http://dx.doi.org/10.1136/bmj.326.7400.1171			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	686FC	12775615	Green Published, Bronze			2022-12-28	WOS:000183309900015
J	Reddel, RR; Bryan, TM				Reddel, RR; Bryan, TM			Alternative lengthening of telomeres: dangerous road less travelled	LANCET			English	Editorial Material							MECHANISM; CELLS		Childrens Med Res Inst, Canc Res Unit, Sydney, NSW 2145, Australia; Childrens Med Res Inst, Cell Biol Unit, Sydney, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney; Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, Sydney, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014; Bryan, Tracy M/B-8468-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chang S, 2003, GENE DEV, V17, P88, DOI 10.1101/gad.1029903; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Greenwood E, 2003, NAT REV CANCER, V3, P84, DOI 10.1038/nrc1008; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Ulaner GA, 2003, CANCER RES, V63, P1759	10	32	34	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1840	1841		10.1016/S0140-6736(03)13538-6	http://dx.doi.org/10.1016/S0140-6736(03)13538-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788566				2022-12-28	WOS:000183205800004
J	Stanley, B; Fraser, J				Stanley, B; Fraser, J			Uptake of HIV screening in genitourinary medicine after change to "opt-out" consent	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANSMISSION		Cumberland Infirm, N Cumbria Acute Hosp Trust, Dept Genitourinary Med, Carlisle CA2 7HY, England; N Cumbria Acute Hosp Trust, Dept Dermatol, Carlisle, England		Stanley, B (corresponding author), Cumberland Infirm, N Cumbria Acute Hosp Trust, Dept Genitourinary Med, Carlisle CA2 7HY, England.	Belinda.Stanley@ncumbria-acute.nhs.uk						Bird SM, 2001, BMJ-BRIT MED J, V323, P1174, DOI 10.1136/bmj.323.7322.1174; Carne C, 2000, SEX TRANSM INFECT, V76, P307, DOI 10.1136/sti.76.4.307; Catchpole MA, 1996, BRIT MED J, V312, P539, DOI 10.1136/bmj.312.7030.539; Department of Health, 2001, NAT STRAT SEX HLTH H; *UNL AN SURV STEER, 2001, PREV HIV HEP INF UK	5	37	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2003	326	7400					1174	1174		10.1136/bmj.326.7400.1174	http://dx.doi.org/10.1136/bmj.326.7400.1174			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775616	Green Published, Bronze			2022-12-28	WOS:000183309900018
J	Cavaleri, F; Scholer, HR				Cavaleri, F; Scholer, HR			Nanog: A new recruit to the embryonic stem cell orchestra	CELL			English	Editorial Material							LEUKEMIA INHIBITORY FACTOR; ACTIVATION; DEPENDS; STAT3		Univ Penn, New Bolton Ctr, Sch Vet Med, Ctr Anim Transgenesis & Germ Cell Res, Kennett Sq, PA 19348 USA	University of Pennsylvania	Cavaleri, F (corresponding author), Univ Penn, New Bolton Ctr, Sch Vet Med, Ctr Anim Transgenesis & Germ Cell Res, 382 W St Rd, Kennett Sq, PA 19348 USA.		, HS/AAB-4434-2019	, HS/0000-0003-2643-5136				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; BOIANI M, 2002, PRINCIPLES CLONING; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0	11	108	141	0	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					551	552		10.1016/S0092-8674(03)00394-5	http://dx.doi.org/10.1016/S0092-8674(03)00394-5			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787492	Bronze			2022-12-28	WOS:000183397600001
J	Schattner, A; Zimhony, O; Avidor, B; Giladi, M				Schattner, A; Zimhony, O; Avidor, B; Giladi, M			Asking the right question	LANCET			English	Editorial Material							ENDOCARDITIS; DIAGNOSIS		Kaplan Med Ctr, Dept Med, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel; Tel Aviv Med Ctr & Sch Med, Bernard Pridan Lab Mol Biol Infect Dis, Tel Aviv, Israel	Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine	Schattner, A (corresponding author), Kaplan Med Ctr, Dept Med, IL-76100 Rehovot, Israel.		Giladi, Michael/AAQ-6176-2020; Schattner, Ami/ABI-1894-2020; Giladi, Michael/GVU-6295-2022	Schattner, Ami/0000-0002-1413-8858; 				Choi HK, 2000, ARTHRITIS RHEUM, V43, P226, DOI 10.1002/1529-0131(200001)43:1<226::AID-ANR27>3.0.CO;2-Q; Giladi M, 2001, CLIN INFECT DIS, V33, P1852, DOI 10.1086/324162; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; Raoult D, 2003, ARCH INTERN MED, V163, P226, DOI 10.1001/archinte.163.2.226; SANDLER G, 1980, AM HEART J, V100, P928, DOI 10.1016/0002-8703(80)90076-9	5	12	13	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1786	1786		10.1016/S0140-6736(03)13415-0	http://dx.doi.org/10.1016/S0140-6736(03)13415-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781538				2022-12-28	WOS:000183074800011
J	Aerts, C; Thoul, A; Daszynska, J; Scuflaire, R; Waelkens, C; Dupret, MA; Niemczura, E; Noels, A				Aerts, C; Thoul, A; Daszynska, J; Scuflaire, R; Waelkens, C; Dupret, MA; Niemczura, E; Noels, A			Asteroseismology of HD 129929: Core overshooting and nonrigid rotation	SCIENCE			English	Article							ROSSELAND-MEAN OPACITIES; BETA-CEPHEI STARS	We have gathered and analyzed 1493 high-quality multicolor Geneva photometric data taken over 21 years of the B3V star HD 129929. We detect six frequencies, among which appear the effects of rotational splitting with a spacing of similar to0.0121 cycles per day, which implies that the star rotates very slowly. A nonadiabatic analysis of the oscillations allows us to constrain the metallicity of the star to Z is an element of[0.017,0.022], which agrees with a similar range derived from spectroscopic data. We provide evidence for the occurrence of core convective overshooting in the star, with alpha(ov) = 0.10 +/- 0.05, and we rule out rigid rotation.	Katholieke Univ Leuven, Inst Sterrenkunde, B-3001 Heverlee, Belgium; Univ Liege, Inst Astrophys & Geophys, B-4000 Liege, Belgium; Univ Wroclaw, Astron Inst, PL-51622 Wroclaw, Poland	KU Leuven; University of Liege; University of Wroclaw	Aerts, C (corresponding author), Katholieke Univ Leuven, Inst Sterrenkunde, Celestijnenlaan 200, B-3001 Heverlee, Belgium.	conny@ster.kuleuven.ac.be	Niemczura, Ewa/L-4689-2019; Niemczura, Ewa/X-9089-2019	Thoul, Anne/0000-0002-8107-118X; Niemczura, Ewa/0000-0001-7290-5800; Aerts, Conny/0000-0003-1822-7126				ALEXANDER DR, 1994, ASTROPHYS J, V437, P879, DOI 10.1086/175039; Bouchy F, 2001, ASTRON ASTROPHYS, V374, pL5, DOI 10.1051/0004-6361:20010792; DASZYNSKA J, UNPUB; Dupret MA, 2003, ASTRON ASTROPHYS, V398, P677, DOI 10.1051/0004-6361:20021679; Dupret MA, 2002, ASTRON ASTROPHYS, V385, P563, DOI 10.1051/0004-6361:20020193; Dupret MA, 2001, ASTRON ASTROPHYS, V366, P166, DOI 10.1051/0004-6361:20000219; Dziembowski W., 1977, Acta Astronomica, V27, P95; DZIEMBOWSKI WA, 1991, ASTRON ASTROPHYS, V248, pL11; Grevesse N., 1993, ORIGIN EVOLUTION ELE, P15; HEYNDERICKX D, 1994, ASTRON ASTROPHYS SUP, V105, P447; HEYNDERICKX D, 1992, ASTRON ASTROPHYS SUP, V96, P207; MERMILLIOD JC, 1986, ASTRON ASTROPHYS, V158, P45; Paczynski B., 1970, Acta Astronomica, V20, P47; Pamyatnykh AA, 1999, ACTA ASTRONOM, V49, P119; ROGERS FJ, 1992, ASTROPHYS J, V401, P361, DOI 10.1086/172066; Rufener F., 1981, Astronomy & Astrophysics Supplement Series, V45, P207; SCARGLE JD, 1982, ASTROPHYS J, V263, P835, DOI 10.1086/160554; SCUFLAIRE R, UNPUB; Seaton MJ, 1996, MON NOT R ASTRON SOC, V279, P95, DOI 10.1093/mnras/279.1.95; SHOBBROOK RR, 1985, MON NOT R ASTRON SOC, V214, P33, DOI 10.1093/mnras/214.1.33; STELLINGWERF RF, 1978, ASTROPHYS J, V224, P953, DOI 10.1086/156444; WAELKENS C, 1983, ASTRON ASTROPHYS, V119, P279; WINGET DE, 1991, ASTROPHYS J, V378, P326, DOI 10.1086/170434	23	145	145	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1926	1928		10.1126/science.1084993	http://dx.doi.org/10.1126/science.1084993			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12775845	Green Published			2022-12-28	WOS:000183619400040
J	Zhou, ZY; Zheng, SL				Zhou, ZY; Zheng, SL			Palaeobiology: The missing link in Ginkgo evolution - The modern maidenhair tree has barely changed since the days of the dinosaurs.	NATURE			English	Editorial Material									Chinese Acad Sci, Nanjing Inst Geol & Palaeontol, Nanjing 210008, Peoples R China; Minist Natl Land & Resources, Shenyang Inst Geol & Mineral Resources, Shenyang 110032, Peoples R China	Chinese Academy of Sciences	Zhou, ZY (corresponding author), Chinese Acad Sci, Nanjing Inst Geol & Palaeontol, Nanjing 210008, Peoples R China.							ALBERCH P, 1979, PALEOBIOLOGY, V5, P296, DOI 10.1017/S0094837300006588; Chang M.M., 2001, JEHOL BIOTA; Crane P.R., 1990, FIELDIANA GEOLOGY, V20, P1, DOI [10.5962/bhl.title.100826, DOI 10.5962/BHL.TITLE.100826]; Fuji K, 1896, BOT MAG TOKYO, V10, P104; Harris T.M., 1974, YORKSHIRE JURASSIC F, V4; Rothwell G.W., 1997, GINKGO BILOBA GLOBAL, P223; Seward A.C., 1919, FOSSIL PLANTS, V4; Swisher CC, 2002, CHINESE SCI BULL, V47, P135; Zhou Z. Y., 1994, ACTA PALAEONTOL SIN, V33, P131; Zhou ZY, 1989, PALAEONTOGR ABT B, V211, P113	10	147	185	6	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					821	822		10.1038/423821a	http://dx.doi.org/10.1038/423821a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815417				2022-12-28	WOS:000183585300030
J	Keller, MB				Keller, MB			Past, present, and future directions for defining optimal treatment outcome in depression - Remission and beyond	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PROSPECTIVE FOLLOW-UP; PLACEBO-CONTROLLED TRIAL; TREATMENT-RESISTANT DEPRESSION; MAJOR DEPRESSION; DOUBLE-BLIND; PRIMARY-CARE; HIPPOCAMPAL VOLUME; RESIDUAL SYMPTOMS; MAINTENANCE THERAPIES; DIFFERENTIAL RELAPSE	During the past decade, evidence from research on mood disorders has demonstrated that remission is the optimal outcome of treatment. However, there continues to be considerable variability in the specific characteristics that are accepted as indicators of remission. Increasing knowledge of mood disorders and their underlying mechanisms may allow for the development of a new diagnostic and assessment system that no longer is based solely on symptoms and other descriptive phenomena. Continued advances in neuroscience may allow for more knowledge of the underlying neurobiological status and more accurate assessments of the underlying disease state and response to treatment, thus enabling physicians to use treatments that will most effectively bring patients back to euthymia and a truly disease-free healthy state. Until then, remission should continue to be based on the descriptive and experiential phenomena of symptoms and psychosocial functioning.	Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02906 USA	Brown University	Keller, MB (corresponding author), Brown Univ, Sch Med, Dept Psychiat & Human Behav, Box G-BH,Sawyer Bldg,345 Blackstone Blvd, Providence, RI 02906 USA.	martin_keller@brown.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH025478] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH025478] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Agosti V, 1999, J AFFECT DISORDERS, V55, P215, DOI 10.1016/S0165-0327(98)00200-6; American Diabetes Association, 2002, DIABETES CARE S1, V25, pS33, DOI DOI 10.2337/DIACARE.25.2007.S33; Anderson IM, 2000, J PSYCHOPHARMACOL, V14, P3, DOI 10.1177/026988110001400101; Andreoli V, 2002, J CLIN PSYCHOPHARM, V22, P393, DOI 10.1097/00004714-200208000-00010; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; BALDESSARINI RJ, 1999, JAMA-J AM MED ASSOC, V281, P323; Ballus C, 2000, INT CLIN PSYCHOPHARM, V15, P43, DOI 10.1097/00004850-200015010-00007; Beasley C M Jr, 1993, Ann Clin Psychiatry, V5, P199, DOI 10.3109/10401239309148983; BEASLEY CM, 1993, INT CLIN PSYCHOPHARM, V8, P143, DOI 10.1097/00004850-199300830-00002; Berk M, 1997, INT CLIN PSYCHOPHARM, V12, P137, DOI 10.1097/00004850-199705000-00003; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Carpenter LL, 2002, BIOL PSYCHIAT, V51, P183, DOI 10.1016/S0006-3223(01)01262-8; Charney DS, 2002, RESEARCH AGENDA FOR DSM-V, P31; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; CORYELL W, 1991, AM J PSYCHIAT, V148, P1353; Dawson R, 1998, J AFFECT DISORDERS, V49, P31, DOI 10.1016/S0165-0327(97)00181-X; Detke MJ, 2002, J CLIN PSYCHIAT, V63, P308, DOI 10.4088/JCP.v63n0407; DOOGAN DP, 1992, BRIT J PSYCHIAT, V160, P217, DOI 10.1192/bjp.160.2.217; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; Entsuah AR, 1996, INT CLIN PSYCHOPHARM, V11, P137, DOI 10.1097/00004850-199611020-00008; EVANS MD, 1992, ARCH GEN PSYCHIAT, V49, P802; Everson SA, 1998, ARCH INTERN MED, V158, P1133, DOI 10.1001/archinte.158.10.1133; FARAVELLI C, 1986, AM J PSYCHIAT, V143, P888; FARAVELLI C, 1986, J AFFECT DISORDERS, V11, P245, DOI 10.1016/0165-0327(86)90076-5; Fava GA, 1998, ARCH GEN PSYCHIAT, V55, P816, DOI 10.1001/archpsyc.55.9.816; Fava GA, 1998, AM J PSYCHIAT, V155, P1443, DOI 10.1176/ajp.155.10.1443; Finkel SI, 1999, AM J GERIAT PSYCHIAT, V7, P221, DOI 10.1097/00019442-199908000-00006; Finkelstein SN, 1996, PSYCHOPHARMACOL BULL, V32, P33; FRANK E, 1993, J AFFECT DISORDERS, V27, P139, DOI 10.1016/0165-0327(93)90001-Z; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; Frank E, 2002, GEN HOSP PSYCHIAT, V24, P12, DOI 10.1016/S0163-8343(01)00173-6; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GARLOW SJ, 1999, NEUROBIOLOGY MENTAL, P348; Golden RN, 2002, J CLIN PSYCHIAT, V63, P577, DOI 10.4088/JCP.v63n0707; Goldstein DJ, 2002, J CLIN PSYCHIAT, V63, P225, DOI 10.4088/JCP.v63n0309; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hirschfeld RMA, 2002, BIOL PSYCHIAT, V51, P123, DOI 10.1016/S0006-3223(01)01291-4; Hirschfeld RMA, 2002, J CLIN PSYCHIAT, V63, P826, DOI 10.4088/JCP.v63n0913; HOLSBOER F, 1999, NEUROBIOLOGY MENTAL, P317; Ickovics JR, 2001, JAMA-J AM MED ASSOC, V285, P1466, DOI 10.1001/jama.285.11.1466; Judd LL, 1998, ARCH GEN PSYCHIAT, V55, P694, DOI 10.1001/archpsyc.55.8.694; Judd LL, 2000, AM J PSYCHIAT, V157, P1501, DOI 10.1176/appi.ajp.157.9.1501; Judd LL, 2000, ARCH GEN PSYCHIAT, V57, P375, DOI 10.1001/archpsyc.57.4.375; Judd LL, 1996, AM J PSYCHIAT, V153, P1411; Judd LL, 1998, J AFFECT DISORDERS, V50, P97, DOI 10.1016/S0165-0327(98)00138-4; Karasu T.B., 2000, PRACTICE GUIDELINE T, V2nd; KELLER MB, 1982, ARCH GEN PSYCHIAT, V39, P911; KELLER MB, 1987, ARCH GEN PSYCHIAT, V44, P540; Keller MB, 1998, BIOL PSYCHIAT, V44, P348, DOI 10.1016/S0006-3223(98)00110-3; KELLER MB, 1982, AM J PSYCHIAT, V139, P438; Keller MB, 1998, JAMA-J AM MED ASSOC, V280, P1665, DOI 10.1001/jama.280.19.1665; KELLER MB, 1983, JAMA-J AM MED ASSOC, V250, P3299, DOI 10.1001/jama.250.24.3299; Keller MB, 2000, NEW ENGL J MED, V342, P1462, DOI 10.1056/NEJM200005183422001; KELLER MB, 1992, ARCH GEN PSYCHIAT, V49, P371; KELLER MB, 1992, ARCH GEN PSYCHIAT, V49, P809; KELLER MB, 1981, J NERV MENT DIS, V169, P761, DOI 10.1097/00005053-198112000-00003; Kendler KS, 2000, AM J PSYCHIAT, V157, P1243, DOI 10.1176/appi.ajp.157.8.1243; KUPFER DJ, 1992, ARCH GEN PSYCHIAT, V49, P769; LAVORI PW, 1984, J PSYCHIATR RES, V18, P13, DOI 10.1016/0022-3956(84)90045-1; Lee AL, 2002, BIPOLAR DISORD, V4, P117, DOI 10.1034/j.1399-5618.2002.01144.x; Lin EHB, 1998, ARCH FAM MED, V7, P443, DOI 10.1001/archfami.7.5.443; Lustman PJ, 2000, DIABETES CARE, V23, P934, DOI 10.2337/diacare.23.7.934; Lustman PJ, 2000, DIABETES CARE, V23, P618, DOI 10.2337/diacare.23.5.618; Massana J, 1999, INT CLIN PSYCHOPHARM, V14, P73, DOI 10.1097/00004850-199903000-00003; McIntyre R, 2002, J PSYCHIATR NEUROSCI, V27, P235; Mehtonen OP, 2000, J CLIN PSYCHIAT, V61, P95, DOI 10.4088/JCP.v61n0204; Mervaala E, 2000, PSYCHOL MED, V30, P117, DOI 10.1017/S0033291799001567; Miller IW, 1998, J CLIN PSYCHIAT, V59, P608, DOI 10.4088/JCP.v59n1108; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; Mojtabai R, 2001, AM J PSYCHIAT, V158, P1645, DOI 10.1176/appi.ajp.158.10.1645; MONTGOMERY SA, 1993, INT CLIN PSYCHOPHARM, V8, P189, DOI 10.1097/00004850-199300830-00009; Mueller TI, 1999, AM J PSYCHIAT, V156, P1000; Mueller TI, 1996, ARCH GEN PSYCHIAT, V53, P794; Muller MB, 2001, EUR J NEUROSCI, V14, P1603, DOI 10.1046/j.0953-816x.2001.01784.x; MURPHY JM, 1987, ARCH GEN PSYCHIAT, V44, P473; NAIR NPV, 1995, J AFFECT DISORDERS, V33, P1, DOI 10.1016/0165-0327(94)00047-D; *NAT ASTHM ED PREV, 1997, NIH PUBL NAT ASTHM E; Navarro V, 2001, ACTA PSYCHIAT SCAND, V103, P435, DOI 10.1034/j.1600-0447.2001.00228.x; Nierenberg AA, 1999, J CLIN PSYCHIAT, V60, P7; Nierenberg Andrew A., 2001, Journal of Clinical Psychiatry, V62, P5; NOFZINGER EA, 1999, NEUROBIOLOGY MENTAL, P915; ORMEL J, 1993, ARCH GEN PSYCHIAT, V50, P759; Paykel ES, 1998, PSYCHOPATHOLOGY, V31, P5, DOI 10.1159/000029018; PAYKEL ES, 1995, PSYCHOL MED, V25, P1171, DOI 10.1017/S0033291700033146; PAYKEL ES, 1973, ARCH GEN PSYCHIAT, V28, P659; Penninx BWJH, 2001, ARCH GEN PSYCHIAT, V58, P221, DOI 10.1001/archpsyc.58.3.221; PESELOW ED, 1991, PROG NEURO-PSYCHOPH, V15, P71, DOI 10.1016/0278-5846(91)90042-Y; Petracca GM, 2001, INT PSYCHOGERIATR, V13, P233, DOI 10.1017/S104161020100761X; Poirier MF, 1999, BRIT J PSYCHIAT, V175, P12, DOI 10.1192/bjp.175.1.12; PRIEN RF, 1991, ARCH GEN PSYCHIAT, V48, P796; RAMANA R, 1995, PSYCHOL MED, V25, P1161, DOI 10.1017/S0033291700033134; Reesal RT, 2001, CAN J PSYCHIAT, V46, p21S; Reimherr FW, 1998, AM J PSYCHIAT, V155, P1247, DOI 10.1176/ajp.155.9.1247; REYNOLDS CF, 1994, AM J PSYCHIAT, V151, P1740; REYNOLDS CF, 1992, AM J PSYCHIAT, V149, P1687; Riso LP, 1997, J AFFECT DISORDERS, V43, P131, DOI 10.1016/S0165-0327(96)01420-6; Rudolph RL, 1999, J AFFECT DISORDERS, V56, P171, DOI 10.1016/S0165-0327(99)00067-1; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Schatzberg AF, 2002, AM J GERIAT PSYCHIAT, V10, P541, DOI 10.1176/appi.ajgp.10.5.541; SHAPIRO RW, 1981, J AFFECT DISORDERS, V3, P205, DOI 10.1016/0165-0327(81)90023-9; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Sheline YI, 1999, J NEUROSCI, V19, P5034; Silverstone PH, 1999, J CLIN PSYCHIAT, V60, P796, DOI 10.4088/JCP.v60n1122; Simon GE, 2000, GEN HOSP PSYCHIAT, V22, P153, DOI 10.1016/S0163-8343(00)00072-4; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; Solomon DA, 1997, ARCH GEN PSYCHIAT, V54, P1001; Solomon DA, 2000, AM J PSYCHIAT, V157, P229, DOI 10.1176/appi.ajp.157.2.229; Souery D, 1999, EUR NEUROPSYCHOPHARM, V9, P83, DOI 10.1016/S0924-977X(98)00004-2; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; Spitzer RL, 1977, RES DIAGNOSTIC CRITE; Stewart JW, 1998, ARCH GEN PSYCHIAT, V55, P334, DOI 10.1001/archpsyc.55.4.334; Sullivan PF, 2000, AM J PSYCHIAT, V157, P1552, DOI 10.1176/appi.ajp.157.10.1552; Suri RA, 2000, J CLIN PSYCHIAT, V61, P942, DOI 10.4088/JCP.v61n1209; THASE ME, 1992, AM J PSYCHIAT, V149, P1046; Thase ME, 1999, J CLIN PSYCHIAT, V60, P15; Thase ME, 2002, ARCH GEN PSYCHIAT, V59, P233, DOI 10.1001/archpsyc.59.3.233; Thase Michael E, 2002, Psychopharmacol Bull, V36, P12; TOLLEFSON GD, 1993, INT CLIN PSYCHOPHARM, V8, P253, DOI 10.1097/00004850-199300840-00008; Tzanakaki M, 2000, INT CLIN PSYCHOPHARM, V15, P29, DOI 10.1097/00004850-200015010-00004; *US DEP HHS, 1993, AHRQ PUBL US DEP HHS; Vaccarino V, 2001, J AM COLL CARDIOL, V38, P199, DOI 10.1016/S0735-1097(01)01334-1; Vakili K, 2000, BIOL PSYCHIAT, V47, P1087, DOI 10.1016/S0006-3223(99)00296-6; Van Londen L, 1998, PSYCHOL MED, V28, P731, DOI 10.1017/S0033291797006466; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Wickramaratne PJ, 2000, AM J MED GENET, V96, P93, DOI 10.1002/(SICI)1096-8628(20000207)96:1<93::AID-AJMG19>3.0.CO;2-5; Wittchen HU, 2001, J CLIN PSYCHIAT, V62, P23	127	286	306	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3152	3160		10.1001/jama.289.23.3152	http://dx.doi.org/10.1001/jama.289.23.3152			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690QM	12813121				2022-12-28	WOS:000183560400030
J	Kirkwood, T				Kirkwood, T			The most pressing problem of our age	BRITISH MEDICAL JOURNAL			English	Article									Newcastle Gen Hosp, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital; Newcastle University - UK	Kirkwood, T (corresponding author), Newcastle Gen Hosp, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.								0	16	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1297	1299		10.1136/bmj.326.7402.1297	http://dx.doi.org/10.1136/bmj.326.7402.1297			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805160	Green Published			2022-12-28	WOS:000183626500024
J	Sweet, M				Sweet, M			Brandy, bridge and other patient dilemmas	BRITISH MEDICAL JOURNAL			English	Article									Sweet Commun, Sydney, NSW, Australia		Sweet, M (corresponding author), Sweet Commun, Sydney, NSW, Australia.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1291	1292		10.1136/bmj.326.7402.1291	http://dx.doi.org/10.1136/bmj.326.7402.1291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805156	Green Published			2022-12-28	WOS:000183626500019
J	Gao, HX; Sengupta, J; Valle, M; Korostelev, A; Eswar, N; Stagg, SM; Van Roey, P; Agrawal, RK; Harvey, SC; Sali, A; Chapman, MS; Frank, J				Gao, HX; Sengupta, J; Valle, M; Korostelev, A; Eswar, N; Stagg, SM; Van Roey, P; Agrawal, RK; Harvey, SC; Sali, A; Chapman, MS; Frank, J			Study of the structural dynamics of the E-coli 70S ribosome using real-space refinement	CELL			English	Article							AMINOACYL-TRANSFER-RNA; CRYOELECTRON MICROSCOPY; SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; ATOMIC MODELS; 80S RIBOSOME; PROTEIN S1; PSI-BLAST; SUBUNIT	Cryo-EM density maps showing the 70S ribosome of E. coli in two different functional states related by a ratchet-like motion were analyzed using real-space refinement. Comparison of the two resulting atomic models shows that the ribosome changes from a compact structure to a looser one, coupled with the rearrangement of many of the proteins. Furthermore, in contrast to the unchanged inter-subunit bridges formed wholly by RNA, the bridges involving proteins undergo large conformational changes following the ratchet-like motion, suggesting an important role of ribosomal proteins in facilitating the dynamics of translation.	Hlth Res Inc, Howard Hughes Med Inst, Albany, NY 12201 USA; Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA; Florida State Univ, Inst Mol Biophys, Kasha Lab, Tallahassee, FL 32306 USA; Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Calif Inst Quantitat Biomed Res, San Francisco, CA 94143 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	Health Research Inc; Howard Hughes Medical Institute; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University System of Florida; Florida State University; State University System of Florida; Florida State University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Georgia; Georgia Institute of Technology	Frank, J (corresponding author), Hlth Res Inc, Howard Hughes Med Inst, Albany, NY 12201 USA.	joachim@wadsworth.org	Stagg, Scott/AAW-9294-2020; Valle, Mikel/F-7598-2011	Valle, Mikel/0000-0001-8268-6912; Korostelev, Andrei/0000-0003-1588-717X; Chapman, Michael/0000-0001-8525-8585	NIGMS NIH HHS [R01 GM061576, R01 GM54762, R01 GM53827, P01 GM64676, R01 GM61576, R37 GM29169, R01 GM55440, P50 GM62529] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029169, R01GM054762, R01GM053827, R01GM061576, R01GM055440, P50GM062529, P01GM064676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Brodersen DE, 2002, J MOL BIOL, V316, P725, DOI 10.1006/jmbi.2001.5359; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHAPMAN MS, 1995, ACTA CRYSTALLOGR A, V51, P69, DOI 10.1107/S0108767394007130; Chen LF, 2001, J STRUCT BIOL, V133, P221, DOI 10.1006/jsbi.2000.4321; Cooperman BS, 1995, BIOCHEM CELL BIOL, V73, P1087, DOI 10.1139/o95-117; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; Frank J, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P45; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Frank J, 2001, COLD SPRING HARB SYM, V66, P67, DOI 10.1101/sqb.2001.66.67; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gabashvili IS, 1999, EMBO J, V18, P6501, DOI 10.1093/emboj/18.22.6501; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAUGHREA M, 1977, J MOL BIOL, V112, P399, DOI 10.1016/S0022-2836(77)80189-7; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Moore PB, 2002, NATURE, V418, P229, DOI 10.1038/418229a; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pieper U, 2002, NUCLEIC ACIDS RES, V30, P255, DOI 10.1093/nar/30.1.255; Roseman AM, 2000, ACTA CRYSTALLOGR D, V56, P1332, DOI 10.1107/S0907444900010908; Rossmann MG, 2000, ACTA CRYSTALLOGR D, V56, P1341, DOI 10.1107/S0907444900009562; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; Schaffer AA, 1999, BIOINFORMATICS, V15, P1000; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Tung CS, 2002, NAT STRUCT BIOL, V9, P750, DOI 10.1038/nsb841; Uhlein M, 1998, BIOCHEM J, V331, P423; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Volkmann N, 1999, J STRUCT BIOL, V125, P176, DOI 10.1006/jsbi.1998.4074; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wriggers W, 2001, J STRUCT BIOL, V133, P193, DOI 10.1006/jsbi.2000.4350; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	51	233	287	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2003	113	6					789	801		10.1016/S0092-8674(03)00427-6	http://dx.doi.org/10.1016/S0092-8674(03)00427-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809609	Bronze			2022-12-28	WOS:000183514400013
J	Lauber, K; Bohn, E; Krober, SM; Xiao, YJ; Blumenthal, SG; Lindemann, RK; Marini, P; Wiedig, C; Zobywalski, A; Baksh, S; Xu, Y; Autenrieth, IB; Schulze-Osthoff, K; Belka, C; Stuhler, G; Wesselborg, S				Lauber, K; Bohn, E; Krober, SM; Xiao, YJ; Blumenthal, SG; Lindemann, RK; Marini, P; Wiedig, C; Zobywalski, A; Baksh, S; Xu, Y; Autenrieth, IB; Schulze-Osthoff, K; Belka, C; Stuhler, G; Wesselborg, S			Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal	CELL			English	Article							RETRACTED ARTICLE. SEE; SECRETORY PHOSPHOLIPASE A(2); MORPHOLOGICAL-CHANGES; DISTINCT ROLES; ACID RELEASE; MEMBRANE; LYSOPHOSPHATIDYLCHOLINE; RECEPTOR; BINDING; SPHINGOSYLPHOSPHORYLCHOLINE	Efficient engulfment of the intact cell corpse is a critical end point of apoptosis, required to prevent secondary necrosis and inflammation. The presentation of "eat-me" signals on the dying cell is an important part of this process of recognition and engulfment by professional phagocytes. Here, we present evidence that apoptotic cells secrete chemotactic factor(s) that stimulate the attraction of monocytic cells and primary macrophages. The activation of caspase-3 in the apoptotic cell was found to be required for the release of this chemotactic factor(s). The putative chemoattractant was identified as the phospholipid, lysophosphatidylcholine. Further analysis showed that lysophosphatidylcholine was released from apoptotic cells due to the caspase-3 mediated activation of the calcium-independent phospholipase A(2). These data suggest that in addition to eat-me signals, apoptotic cells display attraction signals to ensure the efficient removal of apoptotic cells and prevent postapoptotic necrosis.	Univ Tubingen, Dept Internal Med 1, D-72074 Tubingen, Germany; Univ Tubingen, Inst Med Microbiol, D-72074 Tubingen, Germany; Univ Tubingen, Inst Pathol, D-72074 Tubingen, Germany; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Gynecol & Obstet, Cleveland, OH 44195 USA; Univ Tubingen, Dept Radiat Oncol, D-72074 Tubingen, Germany; Univ Tubingen, Dept Internal Med 2, D-72074 Tubingen, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Hosp, Dept Med, Boston, MA 02115 USA; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Heinrich Heine University Dusseldorf	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, D-72074 Tubingen, Germany.	snwessel@med.uni-tuebingen.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029; Brown S, 2002, NATURE, V418, P200, DOI 10.1038/nature00811; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hengartner MO, 2001, CELL, V104, P325, DOI 10.1016/S0092-8674(01)00219-7; HOFFMAN RD, 1982, P NATL ACAD SCI-BIOL, V79, P3285, DOI 10.1073/pnas.79.10.3285; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Rosen A, 1999, CELL DEATH DIFFER, V6, P6, DOI 10.1038/sj.cdd.4400460; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Segundo C, 1999, BLOOD, V94, P1012, DOI 10.1182/blood.V94.3.1012.415k05_1012_1020; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	34	664	694	1	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2003	113	6					717	730		10.1016/S0092-8674(03)00422-7	http://dx.doi.org/10.1016/S0092-8674(03)00422-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809603	Bronze			2022-12-28	WOS:000183514400007
J	Gould, JB; Qin, C; Marks, AR; Chavez, G				Gould, JB; Qin, C; Marks, AR; Chavez, G			Neonatal mortality in weekend vs weekday births	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Increases in neonatal mortality for infants born on the weekend were last noted several decades ago. Although the current health care environment has raised concern about the adequacy of weekend care, there have been no contemporary evaluations of daily patterns of births, obstetric intervention, and case mix-adjusted neonatal mortality. Objective To compare the neonatal mortality of infants born on weekdays and weekends. Design, Setting, and Participants Case series of 1615041 live births (weight greater than or equal to500 g) in California between 1995-1997 to determine patterns of births, cesarean deliveries, and neonatal deaths. Analyses were stratified by birth weight and delivery method. To assess the role of weekend differences in case mix, observed and birth weight-adjusted odds ratios (ORs) for increased weekend mortality were estimated using logistic regression. Main Outcome Measure Birth weight-adjusted neonatal mortality. Results There was a 17.5% decrease in births on weekends, accompanied by a decrease in the proportion of cesarean deliveries from 22% on weekdays to 16% on weekends. Weekend decreases in births were least pronounced in smaller infants, resulting in a weekend concentration of high-mortality, very low-birth-weight (<1500 g) births. Observed neonatal mortality increased from 2.80 per 1000 weekday births to 3.12 per 1000 weekend births (OR, 1.12; 95% confidence interval [CI], 1.05-1.19; P=.001) for all births, and from 4.94 to 6.85 (OR, 1.39; 95% CI, 1.25-1.55; P<.001) for cesarean deliveries. After adjusting for birth weight, the increased odds of death for infants born on the weekend were no longer significant. Conclusions The provision of optimal care regardless of the day of week is an important goal for perinatal medicine. Comparing the neonatal mortality of infants born on weekdays and weekends provides a straightforward assessment of this goal. After controlling for birth weight, we found no evidence that the quality of perinatal care in California was compromised during the weekend.	Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Calif Dept Hlth Serv, Maternal & Child Hlth Branch, Sacramento, CA USA	University of California System; University of California Berkeley; California Department of Health Care Services	Gould, JB (corresponding author), Stanford Univ, Div Neonatal & Dev Med, 750 Welch Rd,Suite 315, Palo Alto, CA 94304 USA.				PHS HHS [99-85027] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Curtin SC, 1998, BIRTH-ISS PERINAT C, V25, P259, DOI 10.1046/j.1523-536X.1998.00259.x; HENDRY RA, 1981, BRIT J OBSTET GYNAEC, V88, P1200, DOI 10.1111/j.1471-0528.1981.tb01197.x; KIELY JL, 1985, AM J OBSTET GYNECOL, V153, P721, DOI 10.1016/0002-9378(85)90331-X; MACFARLANE A, 1979, BRIT MED J, V1, P750, DOI 10.1136/bmj.1.6165.750-b; MACFARLANE A, 1978, BRIT MED J, V2, P1670, DOI 10.1136/bmj.2.6153.1670; MANGOLD WD, 1981, AM J PUBLIC HEALTH, V71, P601, DOI 10.2105/AJPH.71.6.601; Martin Joyce A, 2002, Natl Vital Stat Rep, V50, P1; MATHERS CD, 1983, J EPIDEMIOL COMMUN H, V37, P57, DOI 10.1136/jech.37.1.57; Mathews T J, 2000, Natl Vital Stat Rep, V48, P1; PAUL RH, 1995, AM J OBSTET GYNECOL, V172, P1903, DOI 10.1016/0002-9378(95)91430-7; Richardson D, 1999, Pediatrics, V103, P255; RINDFUSS RR, 1976, MED CARE, V14, P685, DOI 10.1097/00005650-197608000-00005; RINDFUSS RR, 1979, INT J HEALTH SERV, V9, P439, DOI 10.2190/C8CF-GLPC-6LBW-9KWA; SAS, 1999, SAS STAT US GUID VER, P3884; TASHIRO M, 1999, TAPE DOCUMENTATION P; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; 2002, LAW WATCH, V2, P1	18	90	91	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					2958	2962		10.1001/jama.289.22.2958	http://dx.doi.org/10.1001/jama.289.22.2958			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	687XZ	12799403	Bronze			2022-12-28	WOS:000183403400018
J	Feder, HM; Mitchell, PR; Seeley, MZ				Feder, HM; Mitchell, PR; Seeley, MZ			A warble in Connecticut	LANCET			English	Editorial Material							MYIASIS		Connecticut Childrens Med Ctr, Div Pediat Infect Dis, Hartford, CT 06106 USA	Connecticut Children's Medical Center	Feder, HM (corresponding author), Connecticut Childrens Med Ctr, Div Pediat Infect Dis, Hartford, CT 06106 USA.							AROSEMENA R, 1993, J AM ACAD DERMATOL, V28, P254, DOI 10.1016/S0190-9622(08)81145-0; BAIRD JK, 1989, J AM ACAD DERMATOL, V21, P763, DOI 10.1016/S0190-9622(89)70252-8; BREWER TF, 1993, JAMA-J AM MED ASSOC, V270, P2087, DOI 10.1001/jama.270.17.2087; GUILLOZET N, 1980, JAMA-J AM MED ASSOC, V244, P698, DOI 10.1001/jama.244.7.698; Sherman RA, 2000, ARCH INTERN MED, V160, P2004, DOI 10.1001/archinte.160.13.2004	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1952	1952		10.1016/S0140-6736(03)13584-2	http://dx.doi.org/10.1016/S0140-6736(03)13584-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801739				2022-12-28	WOS:000183359700011
J	Loff, B; Overs, C; Longo, P				Loff, B; Overs, C; Longo, P			Can health programmes lead to mistreatment of sex workers?	LANCET			English	Editorial Material									Monash Univ, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia; Int HIV AIDS Alliance, Brighton, E Sussex, England; Network Sex Work Proects, Rio De Janeiro, Brazil	Monash University	Loff, B (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia.		Loff, Bebe/G-9241-2014	Loff, Bebe/0000-0003-1963-6503				Dutta M., 1999, RES SEX WORK, V2; LOWE D, 2003, PERCEPTIONS CAMBODIA; *UNAIDS, STI HIV 100 PERC CON; *UNAIDS, 2002, TECHN UPD SEX WORK H, P12; 2002, HORIZONS REPORT  MAY, P7	5	14	14	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1982	1983		10.1016/S0140-6736(03)13595-7	http://dx.doi.org/10.1016/S0140-6736(03)13595-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801756				2022-12-28	WOS:000183359700027
J	Carr, AM				Carr, AM			Beginning at the end	SCIENCE			English	Editorial Material							DNA-DAMAGE; IN-VIVO; REPAIR; LESIONS; ARREST		Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Sussex	Carr, AM (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.			Carr, Antony Michael/0000-0002-2028-2389				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Melo JA, 2001, GENE DEV, V15, P2809; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	10	14	15	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1512	1513		10.1126/science.1085689	http://dx.doi.org/10.1126/science.1085689			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791969				2022-12-28	WOS:000183333100029
J	Nemani, RR; Keeling, CD; Hashimoto, H; Jolly, WM; Piper, SC; Tucker, CJ; Myneni, RB; Running, SW				Nemani, RR; Keeling, CD; Hashimoto, H; Jolly, WM; Piper, SC; Tucker, CJ; Myneni, RB; Running, SW			Climate-driven increases in global terrestrial net primary production from 1982 to 1999	SCIENCE			English	Article							VARIABILITY; RESOLUTION; BUDGET; INDEX	Recent climatic changes have enhanced plant growth in northern mid-latitudes and high latitudes. However, a comprehensive analysis of the impact of global climatic changes on vegetation productivity has not before been expressed in the context of variable limiting factors to plant growth. We present a global investigation of vegetation responses to climatic changes by analyzing 18 years (1982 to 1999) of both climatic data and satellite observations of vegetation activity. Our results indicate that global changes in climate have eased several critical climatic constraints to plant growth, such that net primary production increased 6% (3.4 petagrams of carbon over 18 years) globally. The largest increase was in tropical ecosystems. Amazon rain forests accounted for 42% of the global increase in net primary production, owing mainly to decreased cloud cover and the resulting increase in solar radiation.	Univ Montana, Sch Forestry, Missoula, MT 59801 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92037 USA; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 113, Japan; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Boston Univ, Dept Geog, Boston, MA 02215 USA	University of Montana System; University of Montana; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Tokyo; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Boston University	Nemani, RR (corresponding author), Univ Montana, Sch Forestry, Missoula, MT 59801 USA.		Mitchard, Edward T A/C-6346-2009; Zhong, Hong Lin/C-2633-2012; Noojipady, Praveen/B-2511-2010; Myneni, Ranga B/F-5129-2012; Myneni, Ranga B./AAU-6088-2021	Mitchard, Edward T A/0000-0002-5690-4055; Myneni, Ranga B/0000-0002-0234-6393; Hashimoto, Hirofumi/0000-0001-7706-1854				[Anonymous], 2000, EARTH INTERACT, DOI DOI 10.1175/1087-3562(2000)004%3C0003:PASAOT%3E2.0.CO;2; BARRETT DJ, 2002, GLOBAL BIOGEOCHEM CY, V16; Churkina G, 1998, ECOSYSTEMS, V1, P206, DOI 10.1007/s100219900016; Costa MH, 1999, J GEOPHYS RES-ATMOS, V104, P14189, DOI 10.1029/1998JD200126; Curtis PS, 1998, OECOLOGIA, V113, P299, DOI 10.1007/s004420050381; De Fries RS, 1998, INT J REMOTE SENS, V19, P3141, DOI 10.1080/014311698214235; FAN SM, 1990, J GEOPHYS RES-ATMOS, V95, P16851, DOI 10.1029/JD095iD10p16851; FRIEDLINGSTEIN P, 1995, GLOBAL BIOGEOCHEM CY, V9, P541, DOI 10.1029/95GB02381; Graham EA, 2003, P NATL ACAD SCI USA, V100, P572, DOI 10.1073/pnas.0133045100; Gu LH, 2003, SCIENCE, V299, P2035, DOI 10.1126/science.1078366; HICKE JA, 2002, GEOPHYS RES LETT, V29; Houghton J. T., 2001, CLIMATE CHANGE 2001; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; JAMES ME, 1994, INT J REMOTE SENS, V15, P3347, DOI 10.1080/01431169408954335; KEELING CD, 2001, SIO REFERENCE SERIES, V21; Kistler R, 2001, B AM METEOROL SOC, V82, P247, DOI 10.1175/1520-0477(2001)082<0247:TNNYRM>2.3.CO;2; Kumar KK, 1999, SCIENCE, V284, P2156, DOI 10.1126/science.284.5423.2156; Lucht W, 2002, SCIENCE, V296, P1687, DOI 10.1126/science.1071828; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Myneni RB, 1997, IEEE T GEOSCI REMOTE, V35, P1380, DOI 10.1109/36.649788; NEMANI RR, 2002, GEOPHYS RES LETT; Phillips OL, 1998, SCIENCE, V282, P439, DOI 10.1126/science.282.5388.439; Potter C, 2001, J GEOPHYS RES-ATMOS, V106, P10423, DOI 10.1029/2000JD900563; Prince SD, 1995, J BIOGEOGR, V22, P815, DOI 10.2307/2845983; Running SW, 2000, METHODS IN ECOSYSTEM SCIENCE, P44; Townsend AR, 1996, ECOL APPL, V6, P806, DOI 10.2307/2269486; Trigo RM, 2002, CLIMATE RES, V20, P9, DOI 10.3354/cr020009; Wielicki BA, 2002, SCIENCE, V295, P841, DOI 10.1126/science.1065837; Wolter K., 1998, WEATHER, V53, P315, DOI DOI 10.1002/J.1477-8696.1998.TB06408.X	30	2393	2729	75	1148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1560	1563		10.1126/science.1082750	http://dx.doi.org/10.1126/science.1082750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791990				2022-12-28	WOS:000183333100052
J	Shojania, KG; Burton, EG; McDonald, KM; Goldman, L				Shojania, KG; Burton, EG; McDonald, KM; Goldman, L			Changes in rates of autopsy-detected diagnostic errors over time - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INTENSIVE-CARE UNIT; INSTITUTES-OF-HEALTH; 1152 HOSPITAL AUTOPSIES; POST-MORTEM FINDINGS; 3 MEDICAL ERAS; CLINICAL DIAGNOSES; CONSECUTIVE AUTOPSIES; UNEXPECTED FINDINGS; QUALITY ASSURANCE; PERINATAL AUTOPSY	Context Substantial discrepanies exist between clinical diagnoses and findings at autopsy. Autopsy may be used as a tool for quality management to analyze diagnostic discrepanies. Objective To determine the rate at which autopsies detect important, clinically missed diagnoses, and the extent to which this rate has changed over time. Data Sources A systematic literature search for English-language articles available on MEDLINE from 1966 to April 2002, using the search terms autopsy, postmortem changes, post-mortem, postmortem, necropsy, and posthumous, identified 45 studies reporting 53 distinct autopsy series meeting prospectively defined criteria. Reference lists were reviewed to identify additional studies, and the final bibliography was distributed to experts in the field to identify missing or unpublished studies. Study Selection Included studies reported clinically missed diagnoses involving a primary cause of death (major errors), with the most serious being those likely to have affected patient outcome (class I errors). Data Extraction Logistic regression was performed using data from 53 distinct autopsy series over a 40-year period and adjusting for the effects of changes in autopsy rates, country, case mix (general autopsies; adult medical; adult intensive care; adult or pediatric surgery; general pediatrics or pediatric inpatients; neonatal or pediatric intensive care; and other autopsy), and important methodological features of the primary studies. Data Synthesis Of 53 autopsy series identified, 42 reported major errors and 37 reported class I errors. Twenty-six autopsy series reported both major and class I error rates. The median error rate was 23.5% (range, 4.1%-49.8%) for major errors and 9.0% (range, 0%-20.7%) for class I errors. Analyses of diagnostic error rates adjusting for the effects of case mix, country, and autopsy rate yielded relative decreases per decade of 19.4% (95% confidence interval [CI], 1.8%-33.8%) for major errors and 33.4% (95% [CI],.8.4%=51.6%) for class I errors. Despite these decreases, we estimated that a contemporary US institution (based on autopsy rates ranging from 100% [the extrapolated extreme at which clinical selection is eliminated] to 5% [roughly the national average]), could observe a major error rate from 8.4% to 24.4% and a class I error rate from 4.1% to 6.7%. Conclusion The possibility that a given autopsy will reveal important unsuspected diagnoses has decreased overtime, but remains sufficiently high that encouraging ongoing use of the autopsy appears warranted.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Baylor Hlth Care Syst, Dept Pathol & Lab Med, Dallas, TX USA; Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Baylor Health Care System; Stanford University	Shojania, KG (corresponding author), Univ Calif San Francisco, Dept Med, 533 Parnassus Ave,Room U137,Box 0131, San Francisco, CA 94143 USA.	shojania@medicine.ucsf.edu			PHS HHS [290-970013] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AG HEALTHC RES QU, 1999 NAT STAT; AHRONHEIM JC, 1983, JAMA-J AM MED ASSOC, V250, P1182, DOI 10.1001/jama.250.9.1182; *AM HOSP ASS, 2002, HOSP STAT; ANDERSON RE, 1989, JAMA-J AM MED ASSOC, V261, P1610, DOI 10.1001/jama.261.11.1610; Baker PB, 1996, ARCH PATHOL LAB MED, V120, P1003; Barr P, 1999, J PAEDIATR CHILD H, V35, P185, DOI 10.1046/j.1440-1754.1999.t01-1-00338.x; BATTLE RM, 1987, JAMA-J AM MED ASSOC, V258, P339, DOI 10.1001/jama.258.3.339; BEDELL SE, 1986, ARCH INTERN MED, V146, P1725, DOI 10.1001/archinte.146.9.1725; Bernicker EH, 1996, AM J MED SCI, V311, P215, DOI 10.1097/00000441-199605000-00004; Blosser SA, 1998, CRIT CARE MED, V26, P1332, DOI 10.1097/00003246-199808000-00015; BOERS M, 1988, EUR J CLIN INVEST, V18, P314, DOI 10.1111/j.1365-2362.1988.tb01265.x; BRITTON M, 1974, ACTA MED SCAND, V196, P203; BURKE MC, 1990, ANN EMERG MED, V19, P363, DOI 10.1016/S0196-0644(05)82334-0; BURTON EC, 2000, MEDSCAPE GEN MED, pE8; Cabot RC, 1912, J AMER MED ASSOC, V59, P2295; CAMERON HM, 1980, BRIT MED J, V281, P985, DOI 10.1136/bmj.281.6246.985; CAMERON HM, 1981, J PATHOL, V133, P285, DOI 10.1002/path.1711330403; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; Carvalho F M, 1991, Bull Pan Am Health Organ, V25, P41; Davis C J, 1979, PAS Rep, V16, P31; Dhar V, 1998, J PEDIATR-US, V132, P75, DOI 10.1016/S0022-3476(98)70488-3; FERNANDEZSEGOVIANO P, 1988, CRIT CARE MED, V16, P683, DOI 10.1097/00003246-198807000-00007; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; Goldstein B, 1996, CRIT CARE MED, V24, P683, DOI 10.1097/00003246-199604000-00022; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; Hagerstrand I, 1993, Qual Assur Health Care, V5, P295; HARRIS MD, 1991, J CLIN PATHOL, V44, P862, DOI 10.1136/jcp.44.10.862; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; HEASMAN MA, 1966, ACCURACY CERTIFICATI; Kabra NS, 2001, J TROP PEDIATRICS, V47, P295, DOI 10.1093/tropej/47.5.295; Kirch W, 1996, MEDICINE, V75, P29, DOI 10.1097/00005792-199601000-00004; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; Kohn L.T., 2000, TO ERR IS HUMAN BUIL; Kumar P, 2000, ARCH PEDIAT ADOL MED, V154, P38; Kumar P, 1998, ARCH PEDIAT ADOL MED, V152, P558; Lamarre-Cliche M, 2001, CLIN INVEST MED, V24, P83; LANDEFELD CS, 1988, NEW ENGL J MED, V318, P1249, DOI 10.1056/NEJM198805123181906; MALENKA DJ, 1994, J CLIN EPIDEMIOL, V47, P1027, DOI 10.1016/0895-4356(94)90118-X; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; MCKELVIE PA, 1992, MED J AUSTRALIA, V156, P456, DOI 10.5694/j.1326-5377.1992.tb126470.x; MEIER PR, 1986, OBSTET GYNECOL, V67, P349; MIDDLETON K, 1989, ARCH INTERN MED, V149, P1809, DOI 10.1001/archinte.149.8.1809; Mort TC, 1999, CRIT CARE MED, V27, P299, DOI 10.1097/00003246-199902000-00035; Nichols L, 1998, AM J CLIN PATHOL, V110, P210; Ong AW, 2002, J AM COLL SURGEONS, V194, P401, DOI 10.1016/S1072-7515(02)01123-7; PAPADAKIS MA, 1991, JAMA-J AM MED ASSOC, V265, P885, DOI 10.1001/jama.265.7.885; Pham B, 2001, EVAL HEALTH PROF, V24, P109, DOI 10.1177/016327870102400202; Podbregar M, 2001, INTENS CARE MED, V27, P1750, DOI 10.1007/s00134-001-1129-x; POLI L, 1993, GERONTOLOGY, V39, P55; POUNDER DJ, 1983, AUST NZ J MED, V13, P478, DOI 10.1111/j.1445-5994.1983.tb02697.x; PUXTY JAH, 1983, LANCET, V1, P1262; Romano P S, 1993, Med Care Rev, V50, P451, DOI 10.1177/002570879305000404; Rosenbaum GE, 2000, ARCH INTERN MED, V160, P374, DOI 10.1001/archinte.160.3.374; SALLER DN, 1995, JAMA-J AM MED ASSOC, V273, P663, DOI 10.1001/jama.273.8.663; SANNER MA, 1995, ARCH PATHOL LAB MED, V119, P851; SARODE VR, 1993, HUM PATHOL, V24, P194, DOI 10.1016/0046-8177(93)90300-6; *SAS I, SAS SOFTW VERS 8 2; SCHNED AR, 1986, AM J CLIN PATHOL, V86, P133, DOI 10.1093/ajcp/86.2.133; Shanks JH, 1991, IARC SCI PUBL, V112, P115; SHOJANIA KG, 2002, PUBLICATION AGENCY H; Sinard JH, 2001, EXP MOL PATHOL, V70, P333, DOI 10.1006/exmp.2001.2371; Sonderegger-Iseli K, 2000, LANCET, V355, P2027, DOI 10.1016/S0140-6736(00)02349-7; Sox H C Jr, 2000, Eff Clin Pract, V3, P277; STAMBOULY JJ, 1993, PEDIATRICS, V92, P248; STEVANOVIC G, 1986, HUM PATHOL, V17, P1225, DOI 10.1016/S0046-8177(86)80564-0; Stolman C J, 1995, N J Med, V92, P794; STOTHERT JC, 1991, AM J SURG, V162, P585, DOI 10.1016/0002-9610(91)90114-S; Tai DYH, 2001, CHEST, V119, P530, DOI 10.1378/chest.119.2.530; Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4; THURLBECK WM, 1981, CAN MED ASSOC J, V125, P443; Tse G. M. K., 2000, Hong Kong Medical Journal, V6, P190; Twigg SJ, 2001, INTENS CARE MED, V27, P706, DOI 10.1007/s001340100903; Varmus H, 1999, NEW ENGL J MED, V340, P1914, DOI 10.1056/NEJM199906173402411; Veress B, 1993, Qual Assur Health Care, V5, P281; VERESS B, 1994, HUM PATHOL, V25, P140, DOI 10.1016/0046-8177(94)90269-0; Veress B, 1993, Qual Assur Health Care, V5, P333; WALSH CJ, 1974, PAS REP, V12, P1; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455; WHITEHOUSE SR, 1994, PEDIATR EMERG CARE, V10, P72, DOI 10.1097/00006565-199404000-00002; Zehr KJ, 1997, ANN THORAC SURG, V64, P380, DOI 10.1016/S0003-4975(97)00551-1	81	450	463	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2849	2856		10.1001/jama.289.21.2849	http://dx.doi.org/10.1001/jama.289.21.2849			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KH	12783916				2022-12-28	WOS:000183205500034
J	Evers, JLH; Collins, JA				Evers, JLH; Collins, JA			Assessment of efficacy of varicocele repair for male subfertility: a systematic review	LANCET			English	Review							SPERMATIC VEIN LIGATION; SUBCLINICAL VARICOCELE; CLOMIPHENE CITRATE; VENA SPERMATICA; FERTILITY; PARAMETERS; OCCLUSION; TRIAL	Background Varicocele repair is a widely used treatment for subfertility. Our aim was to identify and combine the results from randomised controlled trials published to ascertain whether the pregnancy rates after varicocele repair are higher than those with no treatment. Methods We did a systematic review of seven studies identified by searching Medline and a register of controlled trials. We also searched the contents of specialist journals and the annual meeting programmes of relevant societies by hand. Inclusion criteria were treatment of varicocele in subfertile couples, random allocation to treatment and control groups, and pregnancy or livebirth rates as an outcome measure. We pooled data by use of fixed and random effects models. Findings None of seven eligible studies published between 1979 and 2002 described a strategy for concealment of the allocation sequence. There were 61 pregnancies among 281 treated couples and 50 pregnancies among 259 controls. The overall relative benefit of treatment was 1.01 (95% CI 0.73-1.40) by the fixed effects model and 1.04 (0.62-1.75) by the random effects model. The overall risk difference was 0.2% (-7 to 7) and 3% (-7 to 14), respectively. In subgroup analyses, varicocele treatment was not effective in trials restricted to male subfertility with clinical varicocele, or in those that included men with subclinical varicocele or normal semen analysis. However, this systematic review, done with a meta-analytical method, might have had insufficient power to detect small effects because of the small number of patients in some subgroups. Interpretation Varicocele repair does not seem to be an effective treatment for male or unexplained subfertility.	Univ Maastricht, Acad Ziekenhuis Maastricht, GROW Res Inst, Dept Obstet & Gynaecol, NL-6202 AZ Maastricht, Netherlands; McMaster Univ, Dept Obstet & Gynaecol, Hamilton, ON, Canada	Maastricht University; Maastricht University Medical Centre (MUMC); McMaster University	Evers, JLH (corresponding author), Univ Maastricht, Acad Ziekenhuis Maastricht, GROW Res Inst, Dept Obstet & Gynaecol, POB 5800, NL-6202 AZ Maastricht, Netherlands.		Evers, Johannes L/F-6000-2012	Evers, Johannes/0000-0001-8079-1436				ABEL BJ, 1982, BRIT J UROL, V54, P780, DOI 10.1111/j.1464-410X.1982.tb13647.x; BREZNIK R, 1993, ARCH ANDROLOGY, V30, P157, DOI 10.3109/01485019308987750; CLARKE BG, 1966, J AMER MED ASSOC, V198, P1121, DOI 10.1001/jama.198.10.1121; Comhaire F, 2000, HUM REPROD, V15, P2067, DOI 10.1093/humrep/15.10.2067; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUBIN L, 1975, J UROLOGY, V113, P640, DOI 10.1016/S0022-5347(17)59542-7; GLEZERMAN M, 1997, ACTA OBSTET GYN S167, V76, P2; Grasso M, 2000, BJU INT, V85, P305, DOI 10.1046/j.1464-410x.2000.00437.x; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Hargreave TB, 1997, CURRENT ADVANCES IN ANDROLOGY, P31; HOMONNAI ZT, 1980, INT J ANDROL, V3, P447, DOI 10.1111/j.1365-2605.1980.tb00133.x; MADGAR I, 1995, FERTIL STERIL, V63, P120, DOI 10.1016/S0015-0282(16)57306-3; NIESCHLAG E, 1995, HUM REPROD, V10, P347, DOI 10.1093/oxfordjournals.humrep.a135941; Nieschlag E, 1998, HUM REPROD, V13, P2147, DOI 10.1093/humrep/13.8.2147; NILSSON S, 1979, BRIT J UROL, V51, P591, DOI 10.1111/j.1464-410X.1979.tb03609.x; OSTER J, 1971, Scandinavian Journal of Urology and Nephrology, V5, P27, DOI 10.3109/00365597109133569; PRYOR JL, 1987, UROL CLIN N AM, V14, P499; RUSSELL JK, 1954, BRIT MED J, V1, P1231, DOI 10.1136/bmj.1.4873.1231; SAID SA, 1992, FERTIL STERIL, V57, P1289; SAYPOL DC, 1981, J ANDROL, V2, P61; SEGENREICH E, 1986, INT J FERTIL, V31, P200; Unal D, 2001, INT J UROL, V8, P227, DOI 10.1046/j.1442-2042.2001.00289.x; VERMEULEN A, 1984, FERTIL STERIL, V42, P249; Yamamoto M, 1996, J UROLOGY, V155, P1636, DOI 10.1016/S0022-5347(01)66149-4; ZINI A, 1997, MALE INFERTILITY SEX, P201	25	192	213	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1849	1852		10.1016/S0140-6736(03)13503-9	http://dx.doi.org/10.1016/S0140-6736(03)13503-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788571				2022-12-28	WOS:000183205800009
J	Prag, G; Misra, S; Jones, EA; Ghirlando, R; Davies, BA; Horazdovsky, BF; Hurley, JH				Prag, G; Misra, S; Jones, EA; Ghirlando, R; Davies, BA; Horazdovsky, BF; Hurley, JH			Mechanism of ubiquitin recognition by the CUE domain of Vps9p	CELL			English	Article							INTERACTING MOTIF; UBA DOMAINS; BINDS UBIQUITIN; PROTEIN; SURFACE; DEGRADATION; PATHWAY; COMPLEX; REPAIR; RECEPTOR	Coupling of ubiquitin conjugation to ER degradation (CUE) domains are similar to50 amino acid monoubiquitin binding motifs found in proteins of trafficking and ubiquitination pathways. The 2.3 Angstrom structure of the Vps9p-CUE domain is a dimeric domain-swapped variant of the ubiquitin binding UBA domain. The 1.7 Angstrom structure of the CUE:ubiquitin complex shows that one CUE dimer binds one ubiquitin molecule. The bound CUE dimer is kinked relative to the unbound CUE dimer and wraps around ubiquitin. The CUE monomer contains two ubiquitin binding surfaces on opposite faces of the molecule that cannot bind simultaneously to a single ubiquitin molecule. Dimerization of the CUE domain allows both surfaces to contact a single ubiquitin molecule, providing a mechanism for high-affinity binding to monoubiquitin.	NIDDKD, Mol Biol Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Mayo Clinic; Mayo Clinic	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.	james.hurley@nih.gov	Ghirlando, Rodolfo/A-8880-2009	Misra, Saurav/0000-0002-1385-8554	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; BONIFACINO JS, 2003, IN PRESS ANN REV BIO; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Burdon MA, 1996, CURR OPIN NEUROL, V9, P16, DOI 10.1097/00019052-199602000-00004; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; DAVIES BA, 2003, VPS9P CUE DOMAIN UBI; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Longenecker KL, 2001, ACTA CRYSTALLOGR D, V57, P679, DOI 10.1107/S0907444901003122; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Ponting CP, 2002, NUCLEIC ACIDS RES, V30, P3643, DOI 10.1093/nar/gkf498; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a	57	181	184	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2003	113	5					609	620		10.1016/S0092-8674(03)00364-7	http://dx.doi.org/10.1016/S0092-8674(03)00364-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787502	Bronze			2022-12-28	WOS:000183397600011
J	Maki, M; Mustalahti, K; Kokkonen, J; Kulmala, P; Haapalahti, M; Karttunen, T; Ilonen, J; Laurila, K; Dahlbom, I; Hansson, T; Hopfl, P; Knip, M				Maki, M; Mustalahti, K; Kokkonen, J; Kulmala, P; Haapalahti, M; Karttunen, T; Ilonen, J; Laurila, K; Dahlbom, I; Hansson, T; Hopfl, P; Knip, M			Prevalence of celiac disease among children in Finland	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMALL-BOWEL BIOPSY; TISSUE TRANSGLUTAMINASE; DIABETES-MELLITUS; VILLOUS ATROPHY; ANTIBODY TESTS; FOLLOW-UP; SCHOOLCHILDREN; NETHERLANDS; RETICULIN; ICEBERG	BACKGROUND: Wheat, rye, and barley proteins induce celiac disease, an autoimmune type of gastrointestinal disorder, in genetically susceptible persons. Because the disease may be underdiagnosed, we estimated the prevalence of the disease and tested the hypothesis that assays for serum autoantibodies can be used to detect untreated celiac disease and that positive findings correlate with specific HLA haplotypes. METHODS: Serum samples were collected from 3654 students (age range, 7 to 16 years) in 1994 and screened in 2001 for endomysial and tissue transglutaminase antibodies. HLA typing was also performed on stored blood samples. All antibody-positive subjects were asked to undergo small-bowel biopsy in 2001. RESULTS: Of the 3654 subjects, 56 (1.5 percent) had positive antibody tests, as determined in 2001. Results of the two antibody tests were highly concordant. As of 1994, none of the subjects had received a clinical diagnosis of celiac disease, but 10 who had positive tests for both antibodies in serum obtained in 1994 received the diagnosis between 1994 and 2001. Of the 36 other subjects with positive antibody assays who agreed to undergo biopsy in 2001, 27 had evidence of celiac disease on biopsy. Thus, the estimated biopsy-proved prevalence was 1 case in 99 children. All but two of the antibody-positive subjects had either the HLA-DQ2 or the HLA-DQ8 haplotype. The prevalence of the combination of antibody positivity and an HLA haplotype associated with celiac disease was 1 in 67. CONCLUSIONS: The presence of serum tissue transglutaminase and endomysial autoantibodies is predictive of small-bowel abnormalities indicative of celiac disease. There is a good correlation between autoantibody positivity and specific HLA haplotypes. We estimate that the prevalence of celiac disease among Finnish schoolchildren is at least 1 case in 99 children.	Univ Tampere, Sch Med, Pediat Res Ctr, Celiac Dis Study Grp, Tampere, Finland; Tampere Univ Hosp, Dept Pediat, Tampere, Finland; Oulu Univ Hosp, Dept Pediat, Oulu, Finland; Oulu Univ Hosp, Dept Pathol, Oulu, Finland; Univ Turku, Turku Immunol Ctr, Turku, Finland; Univ Turku, Dept Virol, Turku, Finland; Pharmacia Diagnost AB, S-75182 Uppsala, Sweden; Pharmacia Diagnost AB, Freiburg, Germany; Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland	Tampere University; Tampere University; Tampere University Hospital; University of Oulu; University of Oulu; University of Turku; University of Turku; Pfizer; Pharmacia Corporation; Pfizer; University of Helsinki	Maki, M (corresponding author), Univ Tampere, Sch Med, Pediat Res Ctr, Celiac Dis Study Grp, Bldg FM3, Tampere, Finland.	markku.maki@uta.fi	Knip, Mikael/AAL-3773-2020	Karttunen, Tuomo/0000-0002-8843-7957; Hyytinen, Mila Maarit/0000-0001-5361-6421; Knip, Mikael/0000-0003-0474-0033				CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; COLLIN P, 1993, SCAND J GASTROENTERO, V28, P595, DOI 10.3109/00365529309096094; Collin P, 1997, SCAND J GASTROENTERO, V32, P1129, DOI 10.3109/00365529709002992; Collin P, 2002, ENDOCR REV, V23, P464, DOI 10.1210/er.2001-0035; Csizmadia CGDS, 1999, LANCET, V353, P813, DOI 10.1016/S0140-6736(99)00243-3; Dieterich W, 1998, GASTROENTEROLOGY, V115, P1317, DOI 10.1016/S0016-5085(98)70007-1; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; GEORGE EK, 1995, PEDIATR RES, V37, P213, DOI 10.1203/00006450-199502000-00015; Hansson T, 2002, PEDIATR RES, V51, P700, DOI 10.1023/01.PDR.0000015105.38277.9B; Hill I, 2000, J PEDIATR-US, V136, P86, DOI 10.1016/S0022-3476(00)90055-6; Iltanen S, 1999, AUTOIMMUNITY, V29, P179, DOI 10.3109/08916939908998533; Kaukinen K, 1998, SCAND J GASTROENTERO, V33, P944; Kaukinen K, 2001, DIGEST DIS SCI, V46, P879, DOI 10.1023/A:1010729207320; Kaukinen K, 2000, SCAND J GASTROENTERO, V35, P942, DOI 10.1080/003655200750022995; Korponay-Szabo IR, 1999, J PEDIATR GASTR NUTR, V28, P26, DOI 10.1097/00005176-199901000-00008; Kulmala P, 2001, DIABETES CARE, V24, P171, DOI 10.2337/diacare.24.1.171-a; KUTLU T, 1993, GUT, V34, P208, DOI 10.1136/gut.34.2.208; MAKI M, 1991, LANCET, V338, P1350, DOI 10.1016/0140-6736(91)92234-S; Maki M, 1997, LANCET, V349, P1755, DOI 10.1016/S0140-6736(96)70237-4; Meloni G, 1999, LANCET, V353, P37, DOI 10.1016/S0140-6736(05)74871-6; Mustalahti K, 2002, SCAND J GASTROENTERO, V37, P161, DOI 10.1080/003655202753416812; Mustalahti Kirsi, 2002, Eff Clin Pract, V5, P105; Nejentsev S, 1999, DIABETIC MED, V16, P985, DOI 10.1046/j.1464-5491.1999.00186.x; PAGANO M, 1993, PRINCIPLES BIOSTATIS; ROSSI TM, 1993, J PEDIATR-US, V123, P262, DOI 10.1016/S0022-3476(05)81699-3; Sblattero D, 2000, AM J GASTROENTEROL, V95, P1253; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; Stern M, 2000, J PEDIATR GASTR NUTR, V31, P513, DOI 10.1097/00005176-200011000-00012; Sulkanen S, 1998, GASTROENTEROLOGY, V115, P1322, DOI 10.1016/S0016-5085(98)70008-3; Sulkanen S, 1998, SCAND J GASTROENTERO, V33, P251; Troncone R, 1996, ACTA PAEDIATR, V85, P10, DOI 10.1111/j.1651-2227.1996.tb14240.x; Valdimarsson T, 1996, DIGEST DIS SCI, V41, P83, DOI 10.1007/BF02208588	33	733	759	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2517	2524		10.1056/NEJMoa021687	http://dx.doi.org/10.1056/NEJMoa021687			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815137				2022-12-28	WOS:000183577200006
J	Viswanath, V; Story, GM; Peier, AM; Petrus, MJ; Hwang, SW; Patapoutian, A; Jegla, T				Viswanath, V; Story, GM; Peier, AM; Petrus, MJ; Hwang, SW; Patapoutian, A; Jegla, T			Ion channels - Opposite thermosensor in fruitfly and mouse	NATURE			English	Editorial Material							TRP CHANNEL; DROSOPHILA; RECEPTOR		Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Novartis; Scripps Research Institute	Viswanath, V (corresponding author), Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.			Jegla, Timothy/0000-0001-8616-2390; Hwang, Sun Wook/0000-0001-8460-7480				Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Guler AD, 2002, J NEUROSCI, V22, P6408; Liu L, 2003, NAT NEUROSCI, V6, P267, DOI 10.1038/nn1009; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Sayeed O, 1996, P NATL ACAD SCI USA, V93, P6079, DOI 10.1073/pnas.93.12.6079; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; Tracey WD, 2003, CELL, V113, P261, DOI 10.1016/S0092-8674(03)00272-1; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229	11	203	215	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					822	823		10.1038/423822a	http://dx.doi.org/10.1038/423822a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815418				2022-12-28	WOS:000183585300031
J	Stewart, WF; Ricci, JA; Chee, E; Hahn, SR; Morganstein, D				Stewart, WF; Ricci, JA; Chee, E; Hahn, SR; Morganstein, D			Cost of lost productive work time among US workers with depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; ALLERGIC RHINITIS; UNITED-STATES; MENTAL-DISORDERS; MAJOR DEPRESSION; ECONOMIC BURDEN; IMPACT; MIGRAINE; HEALTH; DISABILITY	Context Evidence consistently indicates that depression has adversely affected work productivity. Estimates of the cost impact in lost labor time in the US workforce, however, are scarce and dated. Objective To estimate the impact of depression on labor costs (ie, work absence and reduced performance while at work) in the US workforce. Design, Setting, and Participants All employed individuals who participated in the American Productivity Audit (conducted August 1, 2001-July 31, 2002) between May 20 and July 11, 2002, were eligible for the Depressive Disorders Study. Those who responded affirmatively to 2 depression-screening questions (n =692), as well as a 1:4 stratified random sample of those responding in the negative (n=435), were recruited for and completed a supplemental interview using the Primary Care Evaluation of Mental Disorders Mood Module for depression, the Somatic Symptom Inventory, and a medical and treatment history for depression. Excess lost productive time (LPT) costs from depression were derived as the difference in LPT among individuals with depression minus the expected LPT in the absence of depression projected to the US workforce. Main Outcome Measure Estimated LPT and associated labor costs (work absence and reduced performance while at work) due to depression. Results Workers with depression reported significantly more total health-related LPT than those without depression (mean, 5.6 h/wk vs an expected 1.5 h/wk, respectively). Eighty-one percent of the LPT costs are explained by reduced performance while at work. Major depression accounts for 48% of the LPT among those with depression, again with a majority of the cost explained by reduced performance while at work. Self-reported use of antidepressants in the previous 12 months among those with depression was low (<30%) and the mean reported treatment effectiveness was only moderate. Extrapolation of these survey results and self-reported annual incomes to the population of US workers suggests that US workers with depression employed in the previous week cost employers an estimated $44 billion per year in LPT, an excess of $31 billion per year compared with peers without depression. This estimate does not include labor costs associated with short- and long-term disability. Conclusions A majority of the LPT costs that employers face from employee depression is invisible and explained by reduced performance while at work. Use of treatments for depression appears to be relatively low. The combined LPT burden among those with depression and the low level of treatment suggests that there may be cost-effective opportunities for improving depression-related outcomes in the US workforce.	Geisinger Hlth Syst, Outcomes Res Inst, Danville, PA 17822 USA; Adv PCS Ctr Work & Hlth, Hunt Valley, MD USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Westat Corp, Rockville, MD USA	Geisinger Health System; Yeshiva University; Albert Einstein College of Medicine; Westat	Stewart, WF (corresponding author), Geisinger Hlth Syst, Outcomes Res Inst, 100 N Acad Ave, Danville, PA 17822 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BARSKY AJ, 1986, ARCH GEN PSYCHIAT, V43, P493; Berger ML, 2001, J OCCUP ENVIRON MED, V43, P18, DOI 10.1097/00043764-200101000-00005; Berndt ER, 2000, HEALTH AFFAIR, V19, P244, DOI 10.1377/hlthaff.19.4.244; Blaiss MS, 2000, ALLERGY ASTHMA PROC, V21, P7, DOI 10.2500/108854100778248953; Blanc PD, 2001, J CLIN EPIDEMIOL, V54, P610, DOI 10.1016/S0895-4356(00)00349-8; Borchardt PJ, 2001, AM J GASTROENTEROL, V96, pS62, DOI 10.1016/S0002-9270(01)02585-0; Brick J M, 1996, Stat Methods Med Res, V5, P215, DOI 10.1177/096228029600500302; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; Burton WN, 1998, J OCCUP ENVIRON MED, V40, P702, DOI 10.1097/00043764-199808000-00007; Burton WN, 2001, J OCCUP ENVIRON MED, V43, P64, DOI 10.1097/00043764-200101000-00013; Cockburn I M, 1999, Bus Health, V17, P49; CONTI DJ, 1994, J OCCUP ENVIRON MED, V36, P983; Crystal-Peters J, 2000, AM J MANAG CARE, V6, P373; Cull RE, 1992, BRIT J EC, V2, P103; Dasbach EJ, 2000, CEPHALALGIA, V20, P830, DOI 10.1046/j.1468-2982.2000.00126.x; Davies GM, 1999, CEPHALALGIA, V19, P497, DOI 10.1046/j.1468-2982.1999.019005497.x; EATON WW, 1990, J OCCUP ENVIRON MED, V32, P1079, DOI 10.1097/00043764-199011000-00006; Fautrel B, 2002, CURR OPIN RHEUMATOL, V14, P121, DOI 10.1097/00002281-200203000-00008; Finkelstein SN, 1996, PSYCHOPHARMACOL BULL, V32, P33; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; Gerth WC, 2001, PHARMACOECONOMICS, V19, P197, DOI 10.2165/00019053-200119020-00006; Goetzel RZ, 2003, J OCCUP ENVIRON MED, V45, P5, DOI 10.1097/00043764-200301000-00007; GOFF VV, 2002, DEPRESSION DECADE PR; GRAVES EJ, 1989, VITAL HLTH STAT 13, V100, P1; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; Henke CJ, 2000, AM J GASTROENTEROL, V95, P788; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; Judd FK, 1996, AUST NZ J PSYCHIAT, V30, P104, DOI 10.3109/00048679609076077; KARASEK R, 1986, JOB CONTENT INSTRUME; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KELLER MB, 1992, ARCH GEN PSYCHIAT, V49, P809; Kessler RC, 1999, HEALTH AFFAIR, V18, P163, DOI 10.1377/hlthaff.18.5.163; Kessler RC, 2001, ANN ALLERG ASTHMA IM, V87, P289, DOI 10.1016/S1081-1206(10)62242-9; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KIRMAYER LJ, 1993, AM J PSYCHIAT, V150, P734; KOZAK LJ, 2002, VITAL HLTH STAT 13, V153, P1; McCunney RJ, 2001, J OCCUP ENVIRON MED, V43, P30, DOI 10.1097/00043764-200101000-00007; Merkesdal S, 2001, ARTHRITIS RHEUM-US, V44, P528, DOI 10.1002/1529-0131(200103)44:3<528::AID-ANR100>3.0.CO;2-U; MORGADO A, 1989, ACTA PSYCHIAT SCAND, V80, P541, DOI 10.1111/j.1600-0447.1989.tb03023.x; Murray DJ, 1996, GLOBAL BURDEN DIS CO; Ng YC, 2001, DIABETES CARE, V24, P257, DOI 10.2337/diacare.24.2.257; Olfson M, 2002, JAMA-J AM MED ASSOC, V287, P203, DOI 10.1001/jama.287.2.203; Osterhaus J T, 1992, Pharmacoeconomics, V2, P67, DOI 10.2165/00019053-199202010-00008; PARSONS T, 1950, SOCIAL SYSTEM; RICCI JA, 2001, VALUE HEALTH, V4, P460, DOI DOI 10.1016/S1098-3015(11)71634-5; RIEDEL JE, 2001, PREVENTING DIS PROMO; Schulberg HC, 1996, ARCH GEN PSYCHIAT, V53, P913; Schulman EA, 2000, MAYO CLIN PROC, V75, P782, DOI 10.4065/75.8.782; Simon GE, 2000, GEN HOSP PSYCHIAT, V22, P153, DOI 10.1016/S0163-8343(00)00072-4; Simon GE, 2001, J OCCUP ENVIRON MED, V43, P2, DOI 10.1097/00043764-200101000-00002; Slavin RG, 1998, ALLERGY ASTHMA PROC, V19, P277, DOI 10.2500/108854198778557700; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Stahl SM, 2002, J CLIN PSYCHIAT, V63, P273, DOI 10.4088/JCP.v63n0401; Stang P, 2001, PHARMACOECONOMICS, V19, P231, DOI 10.2165/00019053-200119030-00002; STANG PE, 1993, HEADACHE, V33, P29, DOI 10.1111/j.1526-4610.1993.hed3301029.x; STOUDEMIRE A, 1986, GEN HOSP PSYCHIAT, V8, P387, DOI 10.1016/0163-8343(86)90018-6; *US BUR CENS, 2003, BUR LAB STAT; Wahlqvist P, 2001, AM J GASTROENTEROL, V96, pS57, DOI 10.1016/S0002-9270(01)02590-4; Zhang ML, 1999, PSYCHIATR SERV, V50, P1209, DOI 10.1176/ps.50.9.1209	61	875	892	4	91	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3135	3144		10.1001/jama.289.23.3135	http://dx.doi.org/10.1001/jama.289.23.3135			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690QM	12813119	Bronze			2022-12-28	WOS:000183560400028
J	Camerer, CF				Camerer, CF			Strategizing in the brain	SCIENCE			English	Editorial Material							NORMAL-FORM GAMES; ULTIMATUM GAME; NEURAL BASIS; COOPERATION; BEHAVIOR		CALTECH, Div Humanities & Social Sci 228 77, Pasadena, CA 91125 USA	California Institute of Technology	Camerer, CF (corresponding author), CALTECH, Div Humanities & Social Sci 228 77, Pasadena, CA 91125 USA.	camerer@hss.caltech.edu						Camerer C, 1999, ECONOMETRICA, V67, P827, DOI 10.1111/1468-0262.00054; Camerer C.F., 2011, BEHAV GAME THEORY EX, DOI 10.1257/jep.9.2.209; Camerer CF, 2004, ROUNDTABLE SER BEHAV, P1; CAMERER CF, IN PRESS AM EC REV; Costa-Gomes M, 2001, ECONOMETRICA, V69, P1193, DOI 10.1111/1468-0262.00239; Fehr E, 2000, J ECON PERSPECT, V14, P159, DOI 10.1257/jep.14.3.159; Glimcher PW, 2003, BRADFORD BOOKS, P1; Henrich J, 2000, AM ECON REV, V90, P973, DOI 10.1257/aer.90.4.973; HILL EH, UNPUB; Johnson EJ, 2002, J ECON THEORY, V104, P16, DOI 10.1006/jeth.2001.2850; Lo AW, 2002, J COGNITIVE NEUROSCI, V14, P323, DOI 10.1162/089892902317361877; McCabe K, 2001, P NATL ACAD SCI USA, V98, P11832, DOI 10.1073/pnas.211415698; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; ZAK P, UNPUB	15	121	124	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1673	1675		10.1126/science.1086215	http://dx.doi.org/10.1126/science.1086215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805527				2022-12-28	WOS:000183459700028
J	Harris, RS; Bishop, KN; Sheehy, AM; Craig, HM; Petersen-Mahrt, SK; Watt, IN; Neuberger, MS; Malim, MH				Harris, RS; Bishop, KN; Sheehy, AM; Craig, HM; Petersen-Mahrt, SK; Watt, IN; Neuberger, MS; Malim, MH			DNA determination mediates innate immunity to retroviral infection	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SINGLE-STRANDED-DNA; VIRAL VIF PROTEIN; REVERSE TRANSCRIPTION; SOR GENE; TYPE-1; HYPERMUTATION; CELLS; HIV-1; TRANSMISSION	CEM15/APOBEC3G is a cellular protein required for resistance to infection by virion infectivity factor (Vif)-deficient human immunodeficiency virus (HIV). Here, using a murine leukemia virus (MLV)-based system, we provide evidence that CEM15/APOBEC3G is a DNA deaminase that is incorporated into virions during viral production and subsequently triggers massive deamination of deoxycytidine to deoxyuridine within the retroviral minus (first)-strand cDNA, thus providing a probable trigger for viral destruction. Furthermore, HIV Vif can protect MLV from this CEM15/APOBEC3G-dependent restriction. These findings imply that targeted DNA deamination is a major strategy of innate immunity to retroviruses and likely also contributes to the sequence variation observed in many viruses (including HIV).	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Infect Dis, London SE1 9RT, England	MRC Laboratory Molecular Biology; University of London; King's College London	Harris, RS (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	rsharris@mrc-imb.cam.ac.uk		Malim, Michael/0000-0002-7699-2064				Bock M, 2000, J VIROL, V74, P7422, DOI 10.1128/JVI.74.16.7422-7430.2000; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; HARRIS RS, 2003, IN PRESS NAT IMMUNOL; Janini M, 2001, J VIROL, V75, P7973, DOI 10.1128/JVI.75.17.7973-7986.2001; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; NEUBERGER MS, 2003, IN PRESS TRENDS 0523; Petersen-Mahrt SK, 2003, J BIOL CHEM, V278, P19583, DOI 10.1074/jbc.C300114200; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993	23	1095	1137	3	35	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 13	2003	113	6					803	809		10.1016/S0092-8674(03)00423-9	http://dx.doi.org/10.1016/S0092-8674(03)00423-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809610	Bronze			2022-12-28	WOS:000183514400014
J	Tromp, TK; Shia, RL; Allen, M; Eiler, JM; Yung, YL				Tromp, TK; Shia, RL; Allen, M; Eiler, JM; Yung, YL			Potential environmental impact of a hydrogen economy on the stratosphere	SCIENCE			English	Article							MOLECULAR-HYDROGEN; TROPOSPHERE; H-2	The widespread use of hydrogen fuel cells could have hitherto unknown environmental impacts due to unintended emissions of molecular hydrogen, including an increase in the abundance of water vapor in the stratosphere ( plausibly by as much as similar to1 part per million by volume). This would cause stratospheric cooling, enhancement of the heterogeneous chemistry that destroys ozone, an increase in noctilucent clouds, and changes in tropospheric chemistry and atmosphere-biosphere interactions.	CALTECH, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Yung, YL (corresponding author), CALTECH, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	yly@gps.caltech.edu	Yung, Yuk/AAM-4850-2021	Yung, Yuk/0000-0002-4263-2562				Austin J, 2001, Q J ROY METEOR SOC, V127, P959, DOI 10.1002/qj.49712757313; CRUTZEN PJ, 1977, GEOPHYS RES LETT, V4, P321, DOI 10.1029/GL004i008p00321; DEFORSTER PM, 2002, GEOPHYS RES LETT, V29, P10; DeMore W.B., 1997, CHEM KINETICS PHOTOC; EHHALT DH, 1976, S MICR PROD UT GAS H, P23; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; LETEXIER H, 1988, Q J ROY METEOR SOC, V114, P281, DOI 10.1002/qj.49711448002; Novelli PC, 1999, J GEOPHYS RES-ATMOS, V104, P30427, DOI 10.1029/1999JD900788; Ogden JM, 1999, ANNU REV ENERG ENV, V24, P227, DOI 10.1146/annurev.energy.24.1.227; Rahn T, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015118; Rahn T, 2002, GEOCHIM COSMOCHIM AC, V66, P2475, DOI 10.1016/S0016-7037(02)00858-X; RAHN T, IN PRESS NATURE; Schiller C, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000463; SCHMIDT U, 1974, TELLUS, V26, P78, DOI 10.1111/j.2153-3490.1974.tb01954.x; Sherif SA, 1997, INT J HYDROGEN ENERG, V22, P683, DOI 10.1016/S0360-3199(96)00201-7; SHIA RL, 1989, J GEOPHYS RES-ATMOS, V94, P18467, DOI 10.1029/JD094iD15p18467; Solomon S, 1999, REV GEOPHYS, V37, P275, DOI 10.1029/1999RG900008; *WORLD MET ORG GLO, 2002, 47 WORLD MET ORG GLO; Yung Y.L., 1999, PHOTOCHEMISTRY PLANE; Yung YL, 1997, SCIENCE, V278, P1778, DOI 10.1126/science.278.5344.1778; ZITTEL MA, 1996, P 11 WORLD HYDR EN C; Zurek RW, 1996, GEOPHYS RES LETT, V23, P289, DOI 10.1029/95GL03336	22	204	215	4	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1740	1742		10.1126/science.1085169	http://dx.doi.org/10.1126/science.1085169			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805546				2022-12-28	WOS:000183459700049
J	Butler, D				Butler, D			Quake triggers research expedition	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					673	673		10.1038/423673b	http://dx.doi.org/10.1038/423673b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802297	Bronze			2022-12-28	WOS:000183443400007
J	Diehl, V; Franklin, J; Pfreundschuh, M; Lathan, B; Paulus, U; Hasenclever, D; Tesch, H; Herrmann, R; Dorken, B; Muller-Hermelink, H; Duhmke, E; Loeffler, M				Diehl, V; Franklin, J; Pfreundschuh, M; Lathan, B; Paulus, U; Hasenclever, D; Tesch, H; Herrmann, R; Dorken, B; Muller-Hermelink, H; Duhmke, E; Loeffler, M		German Hodgkin's Lymphoma Study Gr	Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOMA STUDY-GROUP; ADJUVANT RADIOTHERAPY; PROGNOSTIC SCORE; MOPP; REGIMEN; TRIAL; LEUKEMIA; MALIGNANCIES; ESCALATION; TOXICITY	Background: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. Methods: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or stage IIIB or IV were randomly assigned to receive eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP); or increased-dose BEACOPP, each followed by local radiotherapy when indicated. Enrollment in the COPP-ABVD group was stopped in 1996 owing to inferior results. Results: For the final analysis, 1195 of 1201 patients could be evaluated: 260 in the COPP-ABVD group, 469 in the BEACOPP group, and 466 in the increased-dose BEACOPP group; the median follow-up was 72, 54, and 51 months, respectively. The rate of freedom from treatment failure at five years was 69 percent in the COPP-ABVD group, 76 percent in the BEACOPP group, and 87 percent in the increased-dose BEACOPP group (P=0.04 for the comparison of the COPP-ABVD group with the BEACOPP group and P<0.001 for the comparison of the increased-dose BEACOPP group with the COPP-ABVD group and with the BEACOPP group), and the five-year rates of overall survival were 83 percent, 88 percent, and 91 percent, respectively (P=0.16 for the comparison of the COPP-ABVD group with the BEACOPP group, P=0.06 for the comparison of the BEACOPP group with the increased-dose BEACOPP group, and P=0.002 for the comparison of the COPP-ABVD group with the increased-dose BEACOPP group). Rates of early progression were significantly lower with increased-dose BEACOPP than with COPP-ABVD or standard BEACOPP. Conclusions: Increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD. .	Univ Cologne, Innere Med Klin 1, Dept Internal Med 1, D-50924 Cologne, Germany; Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany; Canton Hosp, Basel, Switzerland; Charite Hosp, Berlin, Germany; Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany; Univ Munich, Dept Radiotherapy, Munich, Germany	University of Cologne; Leipzig University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Munich	Diehl, V (corresponding author), Univ Cologne, Innere Med Klin 1, Dept Internal Med 1, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	v.diehl@uni-koeln.de		Franklin, Jeremy/0000-0003-1536-0925				[Anonymous], 1992, DESIGN ANAL SEQUENTI; Bonfante V, 1997, J CLIN ONCOL, V15, P528, DOI 10.1200/JCO.1997.15.2.528; Brusamolino E, 2000, HAEMATOLOGICA, V85, P1032; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Carde P, 2000, Hematol J, V1, P282, DOI 10.1038/sj.thj.6200037; Connors, 1997, J CLIN ONCOL, V15, P2762, DOI 10.1200/JCO.1997.15.7.2762; Connors JM, 1997, J CLIN ONCOL, V15, P1638, DOI 10.1200/JCO.1997.15.4.1638; CULLEN MH, 1994, J CLIN ONCOL, V12, P779, DOI 10.1200/JCO.1994.12.4.779; Diehl V, 1998, J CLIN ONCOL, V16, P3810, DOI 10.1200/JCO.1998.16.12.3810; Diehl V, 1997, ANN ONCOL, V8, P143, DOI 10.1023/A:1008294312741; Diehl V, 2001, LEUK LYMPHOMA S2, V42, P16; DUGGAN D, 1997, P AN M AM SOC CLIN, V16, pA12; Engel C, 2000, ANN ONCOL, V11, P1105, DOI 10.1023/A:1008301225839; Franklin J, 2002, ANN ONCOL, V13, P98, DOI 10.1093/annonc/13.S1.98; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; HANCOCK BW, 1992, J CLIN ONCOL, V10, P1252, DOI 10.1200/JCO.1992.10.8.1252; Hasenclever D, 1996, ANN ONCOL, V7, P95; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; HESS CF, 1994, EUR J CANCER, V30A, P1441, DOI 10.1016/0959-8049(94)00284-C; Horning SJ, 2002, J CLIN ONCOL, V20, P630, DOI 10.1200/JCO.20.3.630; Josting A, 2002, J CLIN ONCOL, V20, P221, DOI 10.1200/JCO.20.1.221; KHALIFA E, 1992, HUM REPROD, V7, P105, DOI 10.1093/oxfordjournals.humrep.a137539; KREUSER ED, 1992, ANN ONCOL, V3, pS105, DOI 10.1093/annonc/3.suppl_4.S105; Loeffler M, 1998, ANN ONCOL, V9, P73, DOI 10.1023/A:1008413113949; Loeffler M, 1998, J CLIN ONCOL, V16, P818, DOI 10.1200/JCO.1998.16.3.818; LONGO DL, 1991, J CLIN ONCOL, V9, P1409, DOI 10.1200/JCO.1991.9.8.1409; Micallef INM, 2000, J CLIN ONCOL, V18, P947, DOI 10.1200/JCO.2000.18.5.947; Radford JA, 2002, J CLIN ONCOL, V20, P2988, DOI 10.1200/JCO.2002.11.107; Raemaekers J, 1997, ANN ONCOL, V8, P111, DOI 10.1023/A:1008286824606; Tesch H, 1998, BLOOD, V92, P4560, DOI 10.1182/blood.V92.12.4560.424k07_4560_4567; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P1063, DOI 10.1200/JCO.1994.12.5.1063; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; Walshe R, 2001, LEUK LYMPHOMA S2, V42, P106	34	598	629	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2386	2395		10.1056/NEJMoa022473	http://dx.doi.org/10.1056/NEJMoa022473			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802024	Bronze, Green Accepted			2022-12-28	WOS:000183428900004
J	Golder, M; Burleigh, DE; Belai, A; Ghali, L; Ashby, D; Lunniss, PJ; Navsaria, HA; Williams, NS				Golder, M; Burleigh, DE; Belai, A; Ghali, L; Ashby, D; Lunniss, PJ; Navsaria, HA; Williams, NS			Smooth muscle cholinergic denervation hypersensitivity in diverticular disease	LANCET			English	Article							IRRITABLE-COLON-SYNDROME; INTRALUMINAL PRESSURE; SIGMOID COLON; MOTILITY; FOOD	Background Evidence from clinical and laboratory investigations into the causes of diverticular disease suggests that disturbances in cholinergic activity are important, the effector mechanisms of which have yet to be established. We aimed to investigate the role of smooth muscle and neural cholinergic activity in the pathogenesis of this disease. Methods Two investigators independently did a blinded immunohistochemical image analysis of localising antibodies to choline acetyltransferase, co-localised with protein gene product (PGP)-a marker of general neural tissue-and smooth muscle muscarinic M3 receptors, on three histological sections of sigmoid colons from ten patients with diverticular disease and ten controls, after resections for rectal tumours. We also did isotonic organ bath experiments to assess muscle strip sensitivities to exogenous acetylcholine. Findings In circular muscle, activity of choline acetyltransferase was lower in patients with diverticular disease than in controls: median percentage surface area of choline acetyltransferase over PGIP was 17.5% (range 10.0-37.0) in patients with diverticular disease and 47.0% (29.0-54.0) in controls (p<0.0001). M3 receptors were upregulated in patients with diverticular disease compared with controls: the median surface area was 13.2% (6.0-23.3) in patients with diverticular disease and 2.5% (1.6-3.7) in controls (p<0.0001). The sensitivity to exogenous acetylcholine was increased in patients with diverticular disease (mean -log EC50 5.6 [SD 0.3]) compared with controls (4.9 [0.5]; difference 0.7 [95% Cl 0.3-1.1], p=0.006). In longitudinal muscle, choline acetyltransferase activity was lower in patients with diverticular disease (median 19.5%, range 12.0-30.0) than in controls (47.0%, 35.0-60.0; p<0.0001), with upregulation of M3 receptors in diverticular disease (diverticular disease 7.8% [1.9-20.4], controls 1.7% [0-8-3.0]; p<0.0001). However, sensitivity to exogenous acetylcholine did not differ between the two groups (diverticular disease mean 5.6% [SD 0.3], controls 5.2% [0.4]; difference 0.4% [95% Cl -0.02-0.7], p=0.06). Interpretation Our results suggest that cholinergic denervation hypersensitivity can affect smooth muscle. Upregulation of smooth muscle M3 receptors might account for specific clinical, physiological, and pharmacological abnormalities associated with diverticular disease.	Barts & London Queen Marys Sch Med & Dent, Acad Dept Surg, London, England; Barts & London Queen Marys Sch Med & Dent, Dept Adult & Paediat Gastroenterol, London, England; Barts & London Queen Marys Sch Med & Dent, Ctr Cutaneous Res, London, England; Barts & London Queen Marys Sch Med & Dent, Dept Environm & Prevent Med, London, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London	Golder, M (corresponding author), Royal London Hosp, Acad Dept Surg, 4th Floor Alex Wing, London E1 1BB, England.	m.s.golder@qmul.ac.uk		Belai, Abi (Abebech)/0000-0001-9113-006X				BELAI A, 1988, GASTROENTEROLOGY, V95, P1234, DOI 10.1016/0016-5085(88)90356-3; BURLEIGH DE, 1990, DIGEST DIS SCI, V35, P617, DOI 10.1007/BF01540410; Delahaye N, 2001, CIRCULATION, V104, P2911, DOI 10.1161/hc4901.100380; DOYLE JR, 1981, J HAND SURG-AM, V6, P40, DOI 10.1016/S0363-5023(81)80009-3; Eggenberger, 1999, Curr Treat Options Gastroenterol, V2, P507, DOI 10.1007/s11938-999-0054-x; Gomes OA, 1997, GERONTOLOGY, V43, P210, DOI 10.1159/000213852; HAVIA T, 1971, ACTA CHIR SCAND, V137, P569; Huizinga JD, 1999, SCAND J GASTROENTERO, V34, P683; KERR PM, 1995, BRIT J PHARMACOL, V115, P1518, DOI 10.1111/j.1476-5381.1995.tb16645.x; Kobayashi S, 2001, JPN J PHARMACOL, V86, P281, DOI 10.1254/jjp.86.281; Li JC, 2001, WORLD J GASTROENTERO, V7, P16; Lin WM, 1997, NEUROREPORT, V8, P2999, DOI 10.1097/00001756-199709290-00002; MANOUSOS O, 1985, GUT, V26, P544, DOI 10.1136/gut.26.6.544; MANOUSOS ON, 1967, BRIT MED J, V3, P760, DOI 10.1136/bmj.3.5568.760; OTTE JJ, 1986, AM J GASTROENTEROL, V81, P529; PAINTER NS, 1971, BMJ-BRIT MED J, V2, P450, DOI 10.1136/bmj.2.5759.450; PAINTER NS, 1964, GUT, V5, P201, DOI 10.1136/gut.5.3.201; PARKS TG, 1969, GUT, V10, P534, DOI 10.1136/gut.10.7.534; Porter AJ, 1996, GASTROENTEROLOGY, V111, P401, DOI 10.1053/gast.1996.v111.pm8690205; REES BI, 1980, BRIT J CLIN PHARMACO, V9, P229, DOI 10.1111/j.1365-2125.1980.tb04831.x; SMITH AN, 1986, CLIN GASTROENTEROL, V15, P917; STRETTON CD, 1990, AM REV RESPIR DIS, V142, P1030, DOI 10.1164/ajrccm/142.5.1030; SUCHOWIECKY M, 1987, DIGEST DIS SCI, V32, P833, DOI 10.1007/BF01296705; SUGIHARA K, 1983, GUT, V24, P1130, DOI 10.1136/gut.24.12.1130; Tomita R, 1999, HEPATO-GASTROENTEROL, V46, P2839; TROTMAN IF, 1988, GUT, V29, P218, DOI 10.1136/gut.29.2.218; WEINREICH J, 1976, SCAND J GASTROENTERO, V11, P581; WHITEWAY J, 1985, GUT, V26, P258, DOI 10.1136/gut.26.3.258; WHITEWAY J, 1985, CLIN GASTROENTEROL, V14, P829; YAP I, 1991, SMJ Singapore Medical Journal, V32, P218	30	90	90	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1945	1951		10.1016/S0140-6736(03)13583-0	http://dx.doi.org/10.1016/S0140-6736(03)13583-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801738				2022-12-28	WOS:000183359700010
J	Ishii, D; Kinbara, K; Ishida, Y; Ishii, N; Okochi, M; Yohda, M; Aida, T				Ishii, D; Kinbara, K; Ishida, Y; Ishii, N; Okochi, M; Yohda, M; Aida, T			Chaperonin-mediated stabilization and ATP-triggered release of semiconductor nanoparticles	NATURE			English	Article							CADMIUM-SULFIDE; THERMOPHILIC BACTERIUM; THERMUS-THERMOPHILUS; CDS NANOCRYSTALLITES; HOLO-CHAPERONIN; QUANTUM DOTS; GROEL; PROTEIN; NANOCOMPOSITES; NANOCLUSTERS	Various properties of semiconductor nanoparticles, including photoluminescence and catalytic activity, make these materials attractive for a range of applications(1,2). As nanoparticles readily coagulate and so lose their size-dependent properties, shape-persistent three-dimensional stabilizers that enfold nanoparticles have been exploited(3-9). However, such wrapping approaches also make the nanoparticles insensitive to external stimuli, and so may limit their application. The chaperonin proteins GroEL (from Escherichia coli) and T.th ('T.th cpn', from Thermus thermophilus HB8) encapsulate denatured proteins inside a cylindrical cavity; after refolding, the encapsulated proteins are released by the action of ATP inducing a conformational change of the cavity(10,11). Here we report that GroEL and T.th cpn can also enfold CdS semiconductor nanoparticles, giving them high thermal and chemical stability in aqueous media. Analogous to the biological function of the chaperonins, the nanoparticles can be readily released from the protein cavities by the action of ATP. We expect that integration of such biological mechanisms into materials science will open a door to conceptually new bioresponsive devices.	Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan; Tokyo Univ Agr & Technol, Fac Technol, Dept Biotechnol, Tokyo 1848588, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo University of Agriculture & Technology	Aida, T (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.		Kinbara, Kazushi/E-6347-2017; Yohda, Masafumi/A-5149-2013; Aida, Takuzo/I-9117-2012; Ishii, Noriyuki/E-5661-2011; Ishida, Yasuhiro/I-8204-2012	Kinbara, Kazushi/0000-0002-5945-9612; Yohda, Masafumi/0000-0001-8307-9671; Ishii, Noriyuki/0000-0002-4120-6203; 				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; AMADA K, 1995, J BIOCHEM-TOKYO, V118, P347, DOI 10.1093/oxfordjournals.jbchem.a124913; Balogh L, 1998, J AM CHEM SOC, V120, P7355, DOI 10.1021/ja980861w; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUS LE, 1984, J CHEM PHYS, V80, P4403, DOI 10.1063/1.447218; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HENGLEIN A, 1982, J PHYS CHEM-US, V86, P2291, DOI 10.1021/j100210a010; Hosokawa H, 1996, J PHYS CHEM-US, V100, P6649, DOI 10.1021/jp952603g; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; Lemon BI, 2000, J AM CHEM SOC, V122, P12886, DOI 10.1021/ja0031321; Llorca O, 1998, J BIOL CHEM, V273, P32587, DOI 10.1074/jbc.273.49.32587; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; McMillan RA, 2002, NAT MATER, V1, P247, DOI 10.1038/nmat775; MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086; Murakoshi K, 1998, J CHEM SOC FARADAY T, V94, P579, DOI 10.1039/a707192b; RAMSDEN JJ, 1984, J CHEM SOC FARAD T 1, V80, P919, DOI 10.1039/f19848000919; Ranson NA, 2001, CELL, V107, P869, DOI 10.1016/S0092-8674(01)00617-1; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Schmid G, 1999, CHEM SOC REV, V28, P179, DOI 10.1039/a801153b; Shenton W, 1997, NATURE, V389, P585, DOI 10.1038/39287; Shenton W, 2001, ANGEW CHEM INT EDIT, V40, P442, DOI 10.1002/1521-3773(20010119)40:2<442::AID-ANIE442>3.0.CO;2-2; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Wong KKW, 1996, ADV MATER, V8, P928, DOI 10.1002/adma.19960081114	26	198	204	0	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					628	632		10.1038/nature01663	http://dx.doi.org/10.1038/nature01663			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789335				2022-12-28	WOS:000183301200037
J	Nadareishvili, Z; Hallenbeck, J				Nadareishvili, Z; Hallenbeck, J			Neuronal regeneration after stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEURAL STEM-CELLS; NEUROGENESIS		NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Nadareishvili, Z (corresponding author), NINDS, Stroke Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.			Nadareishvili, Zurab/0000-0002-5526-1342	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002924, ZIANS002924] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Liu JL, 1998, J NEUROSCI, V18, P7768; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Panchision DM, 2002, CURR OPIN GENET DEV, V12, P478, DOI 10.1016/S0959-437X(02)00329-5	5	24	25	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2355	2356		10.1056/NEJMcibr023192	http://dx.doi.org/10.1056/NEJMcibr023192			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12789002				2022-12-28	WOS:000183296300014
J	Keimer, B				Keimer, B			Broken Cooper pairs caught bouncing around	SCIENCE			English	Editorial Material							QUASI-PARTICLE DYNAMICS; NONEQUILIBRIUM SUPERCONDUCTIVITY; NEUTRON RESONANCE; SPECTROSCOPY		Max Planck Inst Solid State Res, D-70569 Stuttgart, Germany	Max Planck Society	Keimer, B (corresponding author), Max Planck Inst Solid State Res, D-70569 Stuttgart, Germany.			Keimer, Bernhard/0000-0001-5220-9023				Abanov A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.177002; Averitt RD, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.140502; Carr GL, 2000, PHYS REV LETT, V85, P3001, DOI 10.1103/PhysRevLett.85.3001; Collet E, 2003, SCIENCE, V300, P612, DOI 10.1126/science.1082001; Feenstra BJ, 1997, PHYS REV LETT, V79, P4890, DOI 10.1103/PhysRevLett.79.4890; Gedik N, 2003, SCIENCE, V300, P1410, DOI 10.1126/science.1083038; He H, 2002, SCIENCE, V295, P1045, DOI 10.1126/science.1067877; Hoffman JE, 2002, SCIENCE, V297, P1148, DOI 10.1126/science.1072640; Hosseini A, 1999, PHYS REV B, V60, P1349, DOI 10.1103/PhysRevB.60.1349; Kaindl RA, 2000, SCIENCE, V287, P470, DOI 10.1126/science.287.5452.470; KAPLAN SB, 1976, PHYS REV B, V14, P4854, DOI 10.1103/PhysRevB.14.4854; Kee HY, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.257002; Kiryukhin V, 1997, NATURE, V386, P813, DOI 10.1038/386813a0; Molegraaf HJA, 2002, SCIENCE, V295, P2239, DOI 10.1126/science.1069947; Wang YY, 2003, SCIENCE, V299, P86, DOI 10.1126/science.1078422	15	0	0	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1381	1382		10.1126/science.1084939	http://dx.doi.org/10.1126/science.1084939			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775829				2022-12-28	WOS:000183181800031
J	Nitzan, A; Ratner, MA				Nitzan, A; Ratner, MA			Electron transport in molecular wire junctions	SCIENCE			English	Review							CURRENT-VOLTAGE CHARACTERISTICS; CARBON NANOTUBES; COULOMB-BLOCKADE; CHARGE-TRANSFER; CONDUCTANCE; TRANSMISSION	Molecular conductance junctions are structures in which single molecules or small groups of molecules conduct electrical current between two electrodes. In such junctions, the connection between the molecule and the electrodes greatly affects the current-voltage characteristics. Despite several experimental and theoretical advances, including the understanding of simple systems, there is still limited correspondence between experimental and theoretical studies of these systems.	Tel Aviv Univ, Sch Chem, IL-69978 Tel Aviv, Israel; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Tel Aviv University; Northwestern University	Nitzan, A (corresponding author), Tel Aviv Univ, Sch Chem, IL-69978 Tel Aviv, Israel.							Alavi S, 2002, CHEM PHYS, V281, P293, DOI 10.1016/S0301-0104(02)00567-0; Alhassid Y, 2000, REV MOD PHYS, V72, P895, DOI 10.1103/RevModPhys.72.895; AVIRAM A, 2002, ANN NY ACAD SCI, V960; Beebe JM, 2002, J AM CHEM SOC, V124, P11268, DOI 10.1021/ja0268332; Bixon M, 1999, ADV CHEM PHYS, V106, P35, DOI 10.1002/9780470141656.ch3; Brandbyge M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165401; Burin AL, 2001, J PHYS CHEM A, V105, P2652, DOI 10.1021/jp0037697; CARON LG, 1986, PHYS REV B, V33, P3027, DOI 10.1103/PhysRevB.33.3027; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Cuniberti G, 2002, ADV SOLID STATE PHYS, V42, P133, DOI 10.1007/3-540-45618-X_11; Datta S., 1997, ELECT TRANSPORT MESO; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Di Ventra M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.139902; Di Ventra M, 2000, PHYS REV LETT, V84, P979, DOI 10.1103/PhysRevLett.84.979; Emberly EG, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.269701; Ghosh AW, 2002, CHEM PHYS, V281, P225, DOI 10.1016/S0301-0104(02)00627-4; Giese B, 2001, NATURE, V412, P318, DOI 10.1038/35085542; Hall LE, 2000, J CHEM PHYS, V112, P1510, DOI 10.1063/1.480696; Hanggi P, 2002, CHEM PHYS, V281, P111, DOI 10.1016/S0301-0104(02)00403-2; HERSAM M, COMMUNICATION; Hersam MC, 2000, NANOTECHNOLOGY, V11, P70, DOI 10.1088/0957-4484/11/2/306; Heurich J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.256803; Hong S, 2000, SUPERLATTICE MICROST, V28, P289, DOI 10.1006/spmi.2000.0916; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Kergueris C, 1999, PHYS REV B, V59, P12505, DOI 10.1103/PhysRevB.59.12505; Kim P, 2002, PHYSICA B, V323, P67, DOI 10.1016/S0921-4526(02)00969-9; KUEKES PJ, 2001, Patent No. 6314019; Kushmerick JG, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.086802; LANDAUER R, 1957, IBM J RES DEV, V1, P223, DOI 10.1147/rd.13.0223; Larade B, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.075420; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; MANN B, 1971, J APPL PHYS, V42, P4398, DOI 10.1063/1.1659785; MICHL J, UNPUB; Mujica V, 1996, J CHEM PHYS, V104, P7296, DOI 10.1063/1.471396; Ness H, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.125422; Nitzan A, 2002, J CHEM PHYS, V117, P10837, DOI 10.1063/1.1522406; Nitzan A, 2001, J PHYS CHEM A, V105, P2677, DOI 10.1021/jp003884h; Nitzan A, 2001, ANNU REV PHYS CHEM, V52, P681, DOI 10.1146/annurev.physchem.52.1.681; Nitzan A, 2000, J PHYS CHEM B, V104, P5661, DOI 10.1021/jp0007235; NITZAN A, IN PRESS ISRAEL J CH; Patitsas SN, 2000, SURF SCI, V457, pL425, DOI 10.1016/S0039-6028(00)00468-4; PERSSON BNJ, 1987, PHYS REV LETT, V59, P339, DOI 10.1103/PhysRevLett.59.339; Rampi MA, 2002, CHEM PHYS, V281, P373, DOI 10.1016/S0301-0104(02)00445-7; Reed MA, 1998, ANN NY ACAD SCI, V852, P133, DOI 10.1111/j.1749-6632.1998.tb09868.x; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Seminario JM, 2002, J CHEM PHYS, V116, P1671, DOI 10.1063/1.1429236; Slowinski K, 2000, J ELECTROANAL CHEM, V491, P139, DOI 10.1016/S0022-0728(00)00305-3; Solak AO, 2003, ANAL CHEM, V75, P296, DOI 10.1021/ac026107h; Stipe BC, 1997, PHYS REV LETT, V78, P4410, DOI 10.1103/PhysRevLett.78.4410; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; TERSOFF J, 1985, PHYS REV B, V31, P805, DOI 10.1103/PhysRevB.31.805; Tian WD, 1998, J CHEM PHYS, V109, P2874, DOI 10.1063/1.476841; Troisi A, 2002, J AM CHEM SOC, V124, P14528, DOI 10.1021/ja028281t; Vager Z, 2002, CHEM PHYS, V281, P305, DOI 10.1016/S0301-0104(02)00374-9; WALKUP RE, 1993, NATO ADV SCI INST SE, V239, P97; Wang CK, 2001, PHYS CHEM CHEM PHYS, V3, P5017, DOI 10.1039/b105279a; WEBER H, UNPUB; Weber HB, 2002, CHEM PHYS, V281, P113, DOI 10.1016/S0301-0104(02)00343-9; Xu BQ, 2002, J AM CHEM SOC, V124, P13568, DOI 10.1021/ja027810q; Xue YQ, 2001, J CHEM PHYS, V115, P4292, DOI 10.1063/1.1391253	60	2076	2093	12	648	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1384	1389		10.1126/science.1081572	http://dx.doi.org/10.1126/science.1081572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775831				2022-12-28	WOS:000183181800033
J	Hattar, S; Lucas, RJ; Mrosovsky, N; Thompson, S; Douglas, RH; Hankins, MW; Lem, J; Biel, M; Hofmann, F; Foster, RG; Yau, KW				Hattar, S; Lucas, RJ; Mrosovsky, N; Thompson, S; Douglas, RH; Hankins, MW; Lem, J; Biel, M; Hofmann, F; Foster, RG; Yau, KW			Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice	NATURE			English	Article							RETINAL GANGLION-CELLS; CIRCADIAN-RHYTHMS; RETINOHYPOTHALAMIC TRACT; LIGHT; RESPONSES; MASKING; LACKING; CLOCK; PHOTOTRANSDUCTION; PHOTOSENSITIVITY	In the mammalian retina, besides the conventional rod-cone system, a melanopsin-associated photoreceptive system exists that conveys photic information for accessory visual functions such as pupillary light reflex and circadian photo-entrainment(1-7). On ablation of the melanopsin gene, retinal ganglion cells that normally express melanopsin are no longer intrinsically photosensitive(8). Furthermore, pupil reflex(8), light-induced phase delays of the circadian clock(9,10) and period lengthening of the circadian rhythm in constant light(9,10) are all partially impaired. Here, we investigated whether additional photoreceptive systems participate in these responses. Using mice lacking rods and cones, we measured the action spectrum for phase-shifting the circadian rhythm of locomotor behaviour. This spectrum matches that for the pupillary light reflex in mice of the same genotype(11), and that for the intrinsic photosensitivity of the melanopsin-expressing retinal ganglion cells(7). We have also generated mice lacking melanopsin coupled with disabled rod and cone phototransduction mechanisms. These animals have an intact retina but fail to show any significant pupil reflex, to entrain to light/dark cycles, and to show any masking response to light. Thus, the rod-cone and melanopsin systems together seem to provide all of the photic input for these accessory visual functions.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Integrat & Mol Neurosci, Div Neurosci & Psychol Med, London W6 8RF, England; Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 3G5, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 3G5, Canada; City Univ London, Dept Optometry & Visual Sci, Appl Vis Res Ctr, London EC1V 0HB, England; Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA; Univ Munich, Zentrum Pharmaforsch, Lehrstuhl Pharmakol Nat Wissensch, D-81377 Munich, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Imperial College London; University of Toronto; University of Toronto; University of Toronto; City University London; Tufts University; University of Munich; Technical University of Munich	Yau, KW (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.		Biel, Martin/G-1175-2014; Hattar, Samer/W-6927-2019	Biel, Martin/0000-0002-9974-3052; FOSTER, RUSSELL/0000-0001-6055-2067; Lucas, Robert/0000-0002-1088-8029	NEI NIH HHS [R37 EY006837, R37 EY006837-13, R37 EY006837-14, R01 EY006837-16A1, R37 EY006837-15, R01 EY006837, R01 EY014596, R37 EY006837-15S1, R01 EY014596-01] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014596, R01EY006837, R37EY006837] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aschoff J., 1988, Advances in the Biosciences, V73, P149; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; Bradley J, 2001, SCIENCE, V294, P2095, DOI 10.1126/science.294.5549.2095; Brockerhoff SE, 2003, J NEUROSCI, V23, P470, DOI 10.1523/JNEUROSCI.23-02-00470.2003; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; CONE RA, 1967, SCIENCE, V155, P1128, DOI 10.1126/science.155.3766.1128; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hannibal J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0002.2002; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Mrosovsky N, 2001, J BIOL RHYTHM, V16, P585, DOI 10.1177/074873001129002277; Mrosovsky N, 2001, CHRONOBIOL INT, V18, P613, DOI 10.1081/CBI-100106076; Mrosovsky N, 1999, CHRONOBIOL INT, V16, P415, DOI 10.3109/07420529908998717; MURAKAMI M, 1970, VISION RES, V10, P965, DOI 10.1016/0042-6989(70)90074-X; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; PROVENCIO I, 1995, BRAIN RES, V694, P183, DOI 10.1016/0006-8993(95)00694-L; Redlin U, 1999, J COMP PHYSIOL A, V184, P429, DOI 10.1007/s003590050342; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; Selby CP, 2000, P NATL ACAD SCI USA, V97, P14697, DOI 10.1073/pnas.260498597; Van Gelder R N, 2001, Ophthalmic Genet, V22, P195, DOI 10.1076/opge.22.4.195.2215; Van Gelder RN, 2003, SCIENCE, V299, P222, DOI 10.1126/science.1079536; Wee R, 2002, J NEUROSCI, V22, P10427; Yoshimura T, 1996, J COMP PHYSIOL A, V178, P797	32	858	884	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					76	81		10.1038/nature01761	http://dx.doi.org/10.1038/nature01761			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12808468	Green Accepted			2022-12-28	WOS:000183912800043
J	Berkman, LF; Blumenthal, J; Burg, M; Carney, RM; Catellier, D; Cowan, MJ; Czajkowski, SM; DeBusk, R; Hosking, J; Jaffe, A; Kaufmann, PG; Mitchell, P; Norman, J; Powell, LH; Raczynski, JM; Schneiderman, N				Berkman, LF; Blumenthal, J; Burg, M; Carney, RM; Catellier, D; Cowan, MJ; Czajkowski, SM; DeBusk, R; Hosking, J; Jaffe, A; Kaufmann, PG; Mitchell, P; Norman, J; Powell, LH; Raczynski, JM; Schneiderman, N		Writing Comm ENRICHD Investigators	Effects of treating depression and low-perceived social support on clinical events after myocardial infarction - The enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRIEF GROUP-THERAPY; MAJOR DEPRESSION; FOLLOW-UP; ARTERY DISEASE; MORTALITY RISK; A BEHAVIOR; REHABILITATION; SYMPTOMS; IMPACT; NORTRIPTYLINE	Context Depression and low perceived social support (LPSS) after myocardial infarction (MI) are associated with higher morbidity and mortality, but little is known about whether this excess risk can be reduced through treatment. Objective To determine whether mortality and recurrent infarction are reduced by. treatment of depression and LPSS with cognitive behavior therapy (CBT), supplemented with a selective serotonin reuptake inhibitor (SSRI) antidepressant when indicated, in patients enrolled within 28 days after MI. Design, Setting, and Patients Randomized clinical trial conducted from October 1996 to April 2001 in 2481 MI patients (1084 women, 1397 men) enrolled from 8 clinical centers. Major or minor depression was diagnosed by modified Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and severity by the 17-item Hamilton Rating Scale for Depression (HRSD); LPSS was determined by the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Social Support Instrument (ESSI). Random allocation was to usual medical care or CBT-based psychosocial intervention. Intervention Cognitive behavior therapy was initiated at a median of 17 days after the index MI for a median of 11 individual sessions throughout 6 months, plus group therapy when feasible, with SSRIs for patients scoring higher than 24 on the HRSD or having a less than 50% reduction in Beck Depression Inventory scores after 5 weeks. Main Outcome Measures Composite primary end point of death or recurrent MI; secondary outcomes included change in HRSD (for depression),or ESSI scores (for LPSS) at 6 months. Results Improvement in psychosocial outcomes at 6 months favored treatment: mean (SD) change in HRSD score, -10.1 (7.8) in the depression and psychosocial intervention group vs -8.4 (7.7) in the depression and usual care group (P<.001); mean (SD) change in ESSI score, 5.1 (5.9) in the LPSS and psychosocial intervention group vs 3.4 (6.0) in the LPSS and usual care group (P<.001). After an average follow-up of 29 months, there was no significant difference in event-free survival between-usual care (75.9%) and psychosocial intervention (75.8%). There were also no differences in survival between the psychosocial intervention and usual care arms in any of the 3 psychosocial risk groups (depression, LPSS, and depression and LPSS patients). Conclusions The intervention did not increase event-free survival. The intervention improved depression and social isolation, although the relative improvement in the psychosocial intervention group compared with the usual care group was less than expected due to substantial improvement in usual care patients.	Univ N Carolina, ENRICHD Coordinating Ctr, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC 27514 USA; Harvard Univ, Boston, MA 02115 USA; Duke Univ, Durham, NC USA; Yale Univ, New Haven, CT USA; Washington Univ, St Louis, MO USA; Univ Calif Los Angeles, Los Angeles, CA USA; NHLBI, Bethesda, MD 20892 USA; Stanford Univ, Palo Alto, CA 94304 USA; Mayo Clin, Rochester, MN USA; Univ Washington, Seattle, WA 98195 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Miami, Coral Gables, FL 33124 USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Duke University; Yale University; Washington University (WUSTL); University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Stanford University; Mayo Clinic; University of Washington; University of Washington Seattle; Rush University; University of Alabama System; University of Alabama Birmingham; University of Miami	Czajkowski, SM (corresponding author), Univ N Carolina, ENRICHD Coordinating Ctr, Dept Biostat, Collaborat Studies Coordinating Ctr, CB 8030,137 E Franklin St, Chapel Hill, NC 27514 USA.	czajkows@nhlbi.nih.gov	Catellier, Diane/AAN-2219-2021	Catellier, Diane/0000-0002-3082-628X	NHLBI NIH HHS [N01-HC-55141, N01-HC-55144, N01-HC-55140, N01-HC-55148, N01-HC-55143,, N01-HC-55142, N01-HC-55146, N01-HC-55147, N01-HC-55145] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055141, N01HC055146, N01HC055143, N01HC055148, N01HC055144, N01HC055147, N01HC055145, N01HC055142, N01HC055140] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; *AM HEART ASS, 1990, ACT PARTN HLTH YOUR; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Arntz HR, 2000, AM J CARDIOL, V86, P1293, DOI 10.1016/S0002-9149(00)01230-3; Barefoot JC, 1996, AM J CARDIOL, V78, P613, DOI 10.1016/S0002-9149(96)00380-3; Beck AT, 1987, COGNITIVE THERAPY DE; Beck J.S., 2011, COGNITIVE BEHAV THER, V(2nd); Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; Berkman L, 2001, PSYCHOSOM MED, V63, P747; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Berkman LF, 2000, AM HEART J, V139, P1; BLUMENTHAL JA, 1987, PSYCHOSOM MED, V49, P331, DOI 10.1097/00006842-198707000-00002; Blumenthal JA, 2001, AM J CARDIOL, V88, P316; Brummett BH, 1998, PSYCHOSOM MED, V60, P707, DOI 10.1097/00006842-199811000-00008; Bush DE, 2001, AM J CARDIOL, V88, P337, DOI 10.1016/S0002-9149(01)01675-7; CARNEY RM, 1987, AM J CARDIOL, V60, P1273, DOI 10.1016/0002-9149(87)90607-2; Carney RM, 2000, PSYCHOSOM MED, V62, P639, DOI 10.1097/00006842-200009000-00007; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; COX DR, 1972, J R STAT SOC B, V34, P187; CROW RS, 1989, AM J CARDIOL, V64, P454, DOI 10.1016/0002-9149(89)90420-7; DHoore W, 1996, J CLIN EPIDEMIOL, V49, P1429, DOI 10.1016/S0895-4356(96)00271-5; DOBSON KS, 1989, J CONSULT CLIN PSYCH, V57, P414, DOI 10.1037/0022-006X.57.3.414; Dusseldorp E, 1999, HEALTH PSYCHOL, V18, P506, DOI 10.1037/0278-6133.18.5.506; FORRESTER AW, 1992, INT J PSYCHIAT MED, V22, P33, DOI 10.2190/CJ9D-32C2-8CM7-FT3D; Frasure-Smith N, 1999, PSYCHOSOM MED, V61, P26, DOI 10.1097/00006842-199901000-00006; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FrasureSmith N, 1997, LANCET, V350, P473, DOI 10.1016/S0140-6736(97)02142-9; FRASURESMITH N, 1985, PSYCHOSOM MED, V47, P431, DOI 10.1097/00006842-198509000-00003; Freedland KE, 2002, PSYCHOSOM MED, V64, P897, DOI 10.1097/01.PSY.0000028826.64279.29; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; Holahan CJ, 1997, J PERS SOC PSYCHOL, V72, P918, DOI 10.1037/0022-3514.72.4.918; IBRAHIM MA, 1974, INT J PSYCHIAT MED, V5, P253, DOI 10.2190/DW1M-9N7K-EXJF-JEYB; Jones DA, 1996, BRIT MED J, V313, P1517, DOI 10.1136/bmj.313.7071.1517; Kawachi I, 1996, J EPIDEMIOL COMMUN H, V50, P245, DOI 10.1136/jech.50.3.245; LaghrissiThode F, 1997, BIOL PSYCHIAT, V42, P290, DOI 10.1016/S0006-3223(96)00345-9; Lesperance F, 2000, ARCH INTERN MED, V160, P1354, DOI 10.1001/archinte.160.9.1354; Lesperance F, 2002, CIRCULATION, V105, P1049, DOI 10.1161/hc0902.104707; Linden W, 1996, ARCH INTERN MED, V156, P745, DOI 10.1001/archinte.156.7.745; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Mendes de Leon C F, 2001, J Cardiopulm Rehabil, V21, P353; Milani RV, 1996, AM HEART J, V132, P726, DOI 10.1016/S0002-8703(96)90304-X; Musselman DL, 1996, AM J PSYCHIAT, V153, P1313; Nelson JC, 1999, AM J PSYCHIAT, V156, P1024; Ormel J, 2000, ARCH GEN PSYCHIAT, V57, P381, DOI 10.1001/archpsyc.57.4.381; Oxman TE, 1997, J GERONTOL B-PSYCHOL, V52, pP1, DOI 10.1093/geronb/52B.1.P1; PEDERSEN TR, 1994, LANCET, V344, P1383; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POST RM, 1992, AM J PSYCHIAT, V149, P999; RAHE RH, 1975, INT J PSYCHIAT MED, V6, P349, DOI 10.2190/T9C0-E5L6-0BJ1-5QF1; RAHE RH, 1979, PSYCHOSOM MED, V41, P229, DOI 10.1097/00006842-197905000-00006; ROBINSON LA, 1990, PSYCHOL BULL, V108, P30, DOI 10.1037/0033-2909.108.1.30; Roose SP, 1998, JAMA-J AM MED ASSOC, V279, P287, DOI 10.1001/jama.279.4.287; Rowe J.W., 1994, ANN BEHAV MED, V16, P95, DOI DOI 10.1093/abm/16.2.95; Sacks FM, 2001, JAMA-J AM MED ASSOC, V285, P1758, DOI 10.1001/jama.285.13.1758; Sauer WH, 2001, CIRCULATION, V104, P1894, DOI 10.1161/hc4101.097519; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Serebruany VL, 2001, PHARMACOL RES, V43, P453, DOI 10.1006/phrs.2001.0817; SoRelle R, 2000, Circulation, V102, pE9050; Spertus JA, 2000, AM HEART J, V140, P105, DOI 10.1067/mhj.2000.106600; Strik JTMH, 2000, PSYCHOSOM MED, V62, P783, DOI 10.1097/00006842-200011000-00007; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; VEITH RC, 1982, NEW ENGL J MED, V306, P954, DOI 10.1056/NEJM198204223061603; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520	67	1249	1271	5	153	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3106	3116						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690QM	12813116				2022-12-28	WOS:000183560400025
J	Davison, S; Philp, I				Davison, S; Philp, I			Time to deliver with dignity	BRITISH MEDICAL JOURNAL			English	Article									Univ Sheffield, Sheffield Inst Studies Ageing, Sheffield, S Yorkshire, England	University of Sheffield				philp, ian/0000-0002-3972-6496					0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1300	1300		10.1136/bmj.326.7402.1300	http://dx.doi.org/10.1136/bmj.326.7402.1300			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805161	Green Published			2022-12-28	WOS:000183626500025
J	Jadad, AR; Enkin, MW				Jadad, AR; Enkin, MW			I am a good patient believe it or not	BRITISH MEDICAL JOURNAL			English	Article									Univ Hlth Network, Ctr Global Hlth Innovat, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Jadad, AR (corresponding author), Univ Hlth Network, Ctr Global Hlth Innovat, Toronto, ON M5G 2C4, Canada.								0	46	50	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1293	1294		10.1136/bmj.326.7402.1293	http://dx.doi.org/10.1136/bmj.326.7402.1293			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805157	Green Published			2022-12-28	WOS:000183626500020
J	Jadad, AR; Rizo, CA; Enkin, MW				Jadad, AR; Rizo, CA; Enkin, MW			What patients want from their doctors	BRITISH MEDICAL JOURNAL			English	Article																			0	13	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1294	1294		10.1136/bmj.326.7402.1294	http://dx.doi.org/10.1136/bmj.326.7402.1294			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805136	Green Published			2022-12-28	WOS:000183626500021
J	Baker, KD; Shewchuk, LM; Kozlova, T; Makishima, M; Hassell, A; Wisely, B; Caravella, JA; Lambert, MH; Reinking, JL; Krause, H; Thummel, CS; Willson, TM; Mangelsdorf, DJ				Baker, KD; Shewchuk, LM; Kozlova, T; Makishima, M; Hassell, A; Wisely, B; Caravella, JA; Lambert, MH; Reinking, JL; Krause, H; Thummel, CS; Willson, TM; Mangelsdorf, DJ			The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway	CELL			English	Article							RETINOID-X-RECEPTOR; LIGAND-BINDING DOMAIN; ECDYSONE RECEPTOR; NGFI-B; CRYSTAL-STRUCTURE; COACTIVATOR RECRUITMENT; MOLECULAR-BASIS; MANDUCA-SEXTA; ULTRASPIRACLE; MELANOGASTER	Ecdysteroid pulses trigger the major developmental transitions during the Drosophila life cycle. These hormonal responses are thought to be mediated by the ecdysteroid receptor (EcR) and its heterodimeric partner Ultraspiracle (USP). We provide evidence for a second ecdysteroid signaling pathway mediated by DHR38, the Drosophila ortholog of the mammalian NGFI-B subfamily of orphan nuclear receptors. DHR38 also heterodimerizes with USP, and this complex responds to a distinct class of ecdysteroids in a manner that is independent of EcR. This response is unusual in that it does not involve direct binding of ecdysteroids to either DHR38 or USP. X-ray crystallographic analysis of DHR38 reveals the absence of both a classic ligand binding pocket and coactivator binding site, features that seem to be common to all NGFI-B subfamily members. Taken together, these data reveal the existence of a separate structural class of nuclear receptors that is conserved from fly to humans.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; GlaxoSmithKline, Discovery Res, Res Triangle Pk, NC 27709 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C4, Canada; Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; GlaxoSmithKline; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu	feinstein, doug/M-9414-2019; ID, IMCACAT/D-5867-2014	Baker, Keith/0000-0002-6755-1697; Krause, Henry/0000-0002-6182-7074; Mangelsdorf, David/0000-0002-4355-0796				ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1992, DEVELOPMENT, V116, P865; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; Baker KD, 2000, INSECT BIOCHEM MOLEC, V30, P1037, DOI 10.1016/S0965-1748(00)00075-8; BASHIRULLAH A, 2003, IN PRESS DEV BI 0325, DOI DOI 10.1016/S0012-1606(3)00063-0; BENYAJATI C, 1983, CELL, V33, P125, DOI 10.1016/0092-8674(83)90341-0; Billas IML, 2001, J BIOL CHEM, V276, P7465, DOI 10.1074/jbc.M008926200; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; Botling J, 1997, J BIOL CHEM, V272, P9443; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Champlin DT, 1998, DEVELOPMENT, V125, P269; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CHERBAS L, 1970, BIOL BULL, V138, P115, DOI 10.2307/1540196; CHERBAS L, 1980, ROUX ARCH DEV BIOL, V189, P1, DOI 10.1007/BF00848562; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DELACRUZ EM, 1996, J AESTHET EDUC, V30, P85, DOI 10.2307/3333235; Dinan L, 2001, PHYTOCHEMISTRY, V57, P325, DOI 10.1016/S0031-9422(01)00078-4; FISK GJ, 1995, P NATL ACAD SCI USA, V92, P10604, DOI 10.1073/pnas.92.23.10604; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Gilbert Lawrence I., 1997, Invertebrate Neuroscience, V3, P205, DOI 10.1007/BF02480376; Gilbert LI, 2002, ANNU REV ENTOMOL, V47, P883, DOI 10.1146/annurev.ento.47.091201.145302; GILLILAND GL, 1984, METHOD ENZYMOL, V104, P370; GRAU V, 1994, INSECT BIOCHEM MOLEC, V24, P49, DOI 10.1016/0965-1748(94)90122-8; Hall BL, 1998, DEVELOPMENT, V125, P4709; HENRICH VC, 1994, DEV BIOL, V165, P38, DOI 10.1006/dbio.1994.1232; Hiruma K, 1997, GEN COMP ENDOCR, V107, P84, DOI 10.1006/gcen.1997.6901; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KOELLE MR, 1992, THESIS STANFORD U ST; Kozlova T, 1998, GENETICS, V149, P1465; Kozlova T, 2002, DEVELOPMENT, V129, P1739; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MOUGNEAU E, 1993, MOL CELL BIOL, V13, P184, DOI 10.1128/MCB.13.1.184; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Paulsen RE, 1995, J MOL NEUROSCI, V6, P249, DOI 10.1007/BF02736784; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PERRIMON N, 1985, GENETICS, V111, P23; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; RACHINSKY A, 1990, GEN COMP ENDOCR, V79, P31, DOI 10.1016/0016-6480(90)90085-Z; Riddiford L M, 2000, Vitam Horm, V60, P1, DOI 10.1016/S0083-6729(00)60016-X; RIDDIFORD LM, 1996, DEV DROSOPHILA MELAN, P899; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; SOMMEMARTIN G, 1990, ARCH INSECT BIOCHEM, V15, P43, DOI 10.1002/arch.940150105; SOMMEMARTIN G, 1988, INSECT BIOCHEM, V18, P729, DOI 10.1016/0020-1790(88)90082-0; SUTHERLAND JD, 1995, P NATL ACAD SCI USA, V92, P7966, DOI 10.1073/pnas.92.17.7966; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656	64	182	197	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2003	113	6					731	742		10.1016/S0092-8674(03)00420-3	http://dx.doi.org/10.1016/S0092-8674(03)00420-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809604	Green Published, Bronze			2022-12-28	WOS:000183514400008
J	Shashok, K				Shashok, K			Pitfalls of editorial miscommunication	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Shashok, K (corresponding author), Compositor Ruiz Aznar 12,2-A, Granada 18008, Spain.	kashashok@wanadoo.es						ANAND JK, 2002, BMJ; Arnaiz-Villena A, 2001, HUM IMMUNOL, V62, P1051, DOI 10.1016/S0198-8859(01)00300-7; Arnaiz-Villena A, 2001, HUM IMMUNOL, V62, P869, DOI 10.1016/S0198-8859(01)00285-3; GUTERMAN L, 2001, CHRONICLE HIGHE 1214, pA14; KERANS ME, 2002, IBERICA, V4, P29; Klarreich E, 2001, NATURE, V414, P382, DOI 10.1038/35106696; Krimsky S, 2002, NAT GENET, V30, P139, DOI 10.1038/ng0202-139; MCKIE R, 2001, OBSERVER        1125; PAGE G, 1997, J PUBLISHING, P59; Plutchak TS, 2002, J MED LIBR ASSOC, V90, P161; POLDERMAN A, 2002, EUROPEAN SCI EDITING, V28, P82; RICHMOND S, 2002, BMJ; Suciu-Foca N, 2002, NAT GENET, V30, P140, DOI 10.1038/ng0202-140; Suciu-Foca N, 2001, Hum Immunol, V62, P1063, DOI 10.1016/S0198-8859(01)00350-0; TAYLOR PW, 2002, BMJ; Tyan DB, 2001, HUM IMMUNOL, V62, P1064, DOI 10.1016/S0198-8859(01)00357-3; WHITE C, 2002, BRIT MED J, V324, P384	17	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2003	326	7401					1262	1264		10.1136/bmj.326.7401.1262	http://dx.doi.org/10.1136/bmj.326.7401.1262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791749	Green Published			2022-12-28	WOS:000183480700026
J	Beiersdorfer, P; Boyce, KR; Brown, GV; Chen, H; Kahn, SM; Kelley, RL; May, M; Olson, RE; Porter, FS; Stahle, CK; Tillotson, WA				Beiersdorfer, P; Boyce, KR; Brown, GV; Chen, H; Kahn, SM; Kelley, RL; May, M; Olson, RE; Porter, FS; Stahle, CK; Tillotson, WA			Laboratory simulation of charge exchange-produced x-ray emission from comets	SCIENCE			English	Article							IONS; COLLISIONS	In laboratory experiments using the engineering spare microcalorimeter detector from the ASTRO-E satellite mission, we recorded the x-ray emission of highly charged ions of carbon, nitrogen, and oxygen, which simulates charge exchange reactions between heavy ions in the solar wind and neutral gases in cometary comae. The spectra are complex and do not readily match predictions. We developed a charge exchange emission model that successfully reproduces the soft x-ray spectrum of comet Linear C/1999 S4, observed with the Chandra X-ray Observatory.	Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Columbia Univ, Dept Phys, New York, NY 10027 USA; Univ Missouri, Dept Phys, Rolla, MO 65409 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Columbia University; University of Missouri System; Missouri University of Science & Technology	Beiersdorfer, P (corresponding author), Lawrence Livermore Natl Lab, 7000 East Ave,L-260, Livermore, CA 94550 USA.		Kelley, Richard/K-4474-2012; Porter, Frederick S/D-3501-2012	Porter, Frederick S/0000-0002-6374-1119; Brown, Gregory/0000-0001-6338-9445				ALI R, 1994, PHYS REV A, V49, P3586, DOI 10.1103/PhysRevA.49.3586; Beiersdorfer P, 2000, PHYS REV LETT, V85, P5090, DOI 10.1103/PhysRevLett.85.5090; Beiersdorfer P, 1996, REV SCI INSTRUM, V67, P3818, DOI 10.1063/1.1147276; Beiersdorfer P, 2001, ASTROPHYS J, V549, pL147, DOI 10.1086/319143; Bingham R, 2000, ASTROPHYS J SUPPL S, V127, P233, DOI 10.1086/313361; Cravens TE, 2002, SCIENCE, V296, P1042, DOI 10.1126/science.1070001; Dennerl K, 1997, SCIENCE, V277, P1625, DOI 10.1126/science.277.5332.1625; Greenwood JB, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.062707; Greenwood JB, 2000, ASTROPHYS J, V533, pL175, DOI 10.1086/312615; Haberli RM, 1997, SCIENCE, V276, P939, DOI 10.1126/science.276.5314.939; Hasan AA, 2001, ASTROPHYS J, V560, pL201, DOI 10.1086/324058; Kelley RL, 1999, P SOC PHOTO-OPT INS, V3765, P114, DOI 10.1117/12.366493; Kharchenko V, 2003, ASTROPHYS J, V585, pL73, DOI 10.1086/374209; Kharchenko V, 2001, ASTROPHYS J, V554, pL99, DOI 10.1086/320929; Krasnopolsky V, 1997, ICARUS, V128, P368, DOI 10.1006/icar.1997.5722; Krasnopolsky VA, 2002, ICARUS, V160, P437, DOI 10.1006/icar.2002.6965; Lisse CM, 1996, SCIENCE, V274, P205, DOI 10.1126/science.274.5285.205; Lisse CM, 2001, SCIENCE, V292, P1343, DOI 10.1126/science.292.5520.1343; Mumma MJ, 1997, ASTROPHYS J, V491, pL125, DOI 10.1086/311071; Perez JA, 2001, J PHYS B-AT MOL OPT, V34, P3063, DOI 10.1088/0953-4075/34/15/312; Schwadron NA, 2000, ASTROPHYS J, V544, P558, DOI 10.1086/317176; Wegmann R, 1998, PLANET SPACE SCI, V46, P603, DOI 10.1016/S0032-0633(97)00196-7	22	146	148	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1558	1559		10.1126/science.1084373	http://dx.doi.org/10.1126/science.1084373			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791989				2022-12-28	WOS:000183333100051
J	Kimmel, AR; Parent, CA				Kimmel, AR; Parent, CA			The signal to move: D-discoideum go orienteering	SCIENCE			English	Editorial Material							DICTYOSTELIUM; CHEMOTAXIS; CELLS; SUPPRESSOR; GRADIENTS; MODEL	Cells migrating directionally toward a chemoattractant source display a highly polarized cytoskeletal organization, with F-actin localized predominantly at the anterior and myosin II at the lateral and posterior regions. Dictyostelium discoideum has proven a useful system for elucidating signaling pathways that regulate this chemotactic response. During development, extracellular adenosine 3', 5' monophosphate (cAMP) functions as a primary signal to activate cell surface cAMP receptors (cARs). These receptors transduce different signals depending on whether or not they are coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins) (see the STKE Connections Maps). Multiple G protein-stimulated pathways interact to establish polarity in chemotaxing D. discoideum cells by localizing F-actin at their leading edge and by regulating the phosphorylation state and assembly of myosin II. Many of the molecular interactions described are fundamental to the regulation of chemotaxis in other eukaryotic cells.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Parent, CA (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC010418, ZIABC010418] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aubry L, 1999, ANNU REV CELL DEV BI, V15, P469, DOI 10.1146/annurev.cellbio.15.1.469; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; DELAROCHE MA, IN PRESS J MUSCLE RE; DRAYER AL, 1994, EMBO J, V13, P1601, DOI 10.1002/j.1460-2075.1994.tb06423.x; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; KIMMEL AR, 2003, SCI STKE; Kreppel L, 2002, NUCLEIC ACIDS RES, V30, P84, DOI 10.1093/nar/30.1.84; Kriebel PW, 2003, CELL, V112, P549, DOI 10.1016/S0092-8674(03)00081-3; Levchenko A, 2002, BIOPHYS J, V82, P50, DOI 10.1016/S0006-3495(02)75373-3; Narang A, 2001, ANN BIOMED ENG, V29, P677, DOI 10.1114/1.1385805; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Postma M, 2001, BIOPHYS J, V81, P1314, DOI 10.1016/S0006-3495(01)75788-8; Traynor D, 2000, EMBO J, V19, P4846, DOI 10.1093/emboj/19.17.4846; Wessels DJ, 2000, MOL BIOL CELL, V11, P2803, DOI 10.1091/mbc.11.8.2803; Wilkins A, 2001, TRENDS GENET, V17, P41, DOI 10.1016/S0168-9525(00)02181-8; Zhang H, 2003, EUKARYOT CELL, V2, P62, DOI 10.1128/EC.2.1.62-75.2003; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606	22	67	68	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1525	1527		10.1126/science.1085439	http://dx.doi.org/10.1126/science.1085439			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791977				2022-12-28	WOS:000183333100037
J	Yu, YS; Rambo, T; Currie, J; Saski, C; Kim, HR; Collura, K; Thompson, S; Simmons, J; Yang, TJ; Nah, G; Patel, AJ; Thurmond, S; Henry, D; Oates, R; Palmer, M; Pries, G; Gibson, J; Anderson, H; Paradkar, M; Crane, L; Dale, J; Carver, MB; Wood, T; Frisch, D; Engler, F; Soderlund, C; Palmer, LE; Tetylman, L; Nascimento, L; de la Bastide, M; Spiegel, L; Ware, D; O'Shaughnessy, A; Dike, S; Dedhia, N; Preston, R; Huang, E; Ferraro, K; Kuit, K; Miller, B; Zutavern, T; Katzenberger, F; Muller, S; Balija, V; Martienssen, RA; Stein, L; Minx, P; Johnson, D; Cordum, H; Mardis, E; Cheng, ZK; Jiang, JM; Wilson, R; McCombie, WR; Wing, RA; Yuan, QP; Shu, OY; Liu, J; Jones, KM; Gansberger, K; Moffat, K; Hill, J; Tsitrin, T; Overton, L; Bera, J; Kim, M; Jin, SH; Tallon, L; Ciecko, A; Pai, G; Van Aken, S; Utterback, T; Reidmuller, S; Bormann, J; Feldblyum, T; Hsiao, J; Zismann, V; Blunt, S; de Vazeilles, A; Shaffer, T; Koo, H; Suh, B; Yang, Q; Haas, B; Peterson, J; Pertea, M; Volfovsky, N; Wortman, J; White, O; Salzberg, SL; Fraser, CM; Buell, CR; Messing, J; Song, RT; Fuks, G; Llaca, V; Kovchak, S; Young, S; Bowers, JE; Paterson, AH; Johns, MA; Mao, L; Pan, HQ; Dean, RA				Yu, YS; Rambo, T; Currie, J; Saski, C; Kim, HR; Collura, K; Thompson, S; Simmons, J; Yang, TJ; Nah, G; Patel, AJ; Thurmond, S; Henry, D; Oates, R; Palmer, M; Pries, G; Gibson, J; Anderson, H; Paradkar, M; Crane, L; Dale, J; Carver, MB; Wood, T; Frisch, D; Engler, F; Soderlund, C; Palmer, LE; Tetylman, L; Nascimento, L; de la Bastide, M; Spiegel, L; Ware, D; O'Shaughnessy, A; Dike, S; Dedhia, N; Preston, R; Huang, E; Ferraro, K; Kuit, K; Miller, B; Zutavern, T; Katzenberger, F; Muller, S; Balija, V; Martienssen, RA; Stein, L; Minx, P; Johnson, D; Cordum, H; Mardis, E; Cheng, ZK; Jiang, JM; Wilson, R; McCombie, WR; Wing, RA; Yuan, QP; Shu, OY; Liu, J; Jones, KM; Gansberger, K; Moffat, K; Hill, J; Tsitrin, T; Overton, L; Bera, J; Kim, M; Jin, SH; Tallon, L; Ciecko, A; Pai, G; Van Aken, S; Utterback, T; Reidmuller, S; Bormann, J; Feldblyum, T; Hsiao, J; Zismann, V; Blunt, S; de Vazeilles, A; Shaffer, T; Koo, H; Suh, B; Yang, Q; Haas, B; Peterson, J; Pertea, M; Volfovsky, N; Wortman, J; White, O; Salzberg, SL; Fraser, CM; Buell, CR; Messing, J; Song, RT; Fuks, G; Llaca, V; Kovchak, S; Young, S; Bowers, JE; Paterson, AH; Johns, MA; Mao, L; Pan, HQ; Dean, RA		Rice Chromosome 10 Sequencing Cons	In-depth view of structure, activity, and evolution of rice chromosome 10	SCIENCE			English	Article							GENOME SEQUENCE; DRAFT SEQUENCE; RESISTANCE; GENES	Rice is the world's most important food crop and a model for cereal research. At 430 megabases in size, its genome is the most compact of the cereals. We report the sequence of chromosome 10, the smallest of the 12 rice chromosomes (22.4 megabases), which contains 3471 genes. Chromosome 10 contains considerable heterochromatin with an enrichment of repetitive elements on 10S and an enrichment of expressed genes on 10L. Multiple insertions from organellar genomes were detected. Collinearity was apparent between rice chromosome 10 and sorghum and maize. Comparison between the draft and finished sequence demonstrates the importance of finished sequence.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Arizona, Arizona Genom Inst, Tucson, AZ 85721 USA; Univ Arizona, Arizona Genom Computat Lab, Dept Plant Sci, Tucson, AZ 85721 USA; Clemson Univ, Genom Inst, Clemson, SC 29634 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; Inst Genome Res, Rockville, MD 20850 USA; Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Rutgers State Univ, PGIR Waksman Inst, Piscataway, NJ 08854 USA; Univ Georgia, Plant Genome Mapping Lab, Athens, GA 30602 USA; No Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA; N Carolina State Univ, Ctr Integrated Fungal Res, Raleigh, NC 27695 USA	Cold Spring Harbor Laboratory; University of Arizona; University of Arizona; Clemson University; Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; J. Craig Venter Institute; Johns Hopkins University; Johns Hopkins University; Rutgers State University New Brunswick; University System of Georgia; University of Georgia; Northern Illinois University; University of North Carolina; North Carolina State University	McCombie, WR (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	mccombie@cshl.edu; rwing@ag.arizona.edu; rbuell@tigr.org; messing@waksman.rutgers.edu	Song, Rentao/AAG-9107-2021; Song, Rentao/A-6544-2012; Wing, Rod A/Z-2885-2019; Salzberg, Steven/Q-6514-2019; Yang, Tae-Jin/AAT-5274-2020; Bowers, John/B-9245-2009; Jiang, Jiming/V-6060-2019; Pertea, Mihaela/AAT-2705-2021; Jiang, Jiming/A-9614-2009; Salzberg, Steven L/F-6162-2011; Bowers, John/AAD-7601-2019; Mardis, Elaine/W-2202-2019	Song, Rentao/0000-0003-1810-9875; Song, Rentao/0000-0003-1810-9875; Wing, Rod A/0000-0001-6633-6226; Salzberg, Steven/0000-0002-8859-7432; Bowers, John/0000-0001-8984-9796; Jiang, Jiming/0000-0002-6435-6140; Pertea, Mihaela/0000-0003-0762-8637; Jiang, Jiming/0000-0002-6435-6140; Salzberg, Steven L/0000-0002-8859-7432; Fraser, Claire/0000-0003-1462-2428; Pan, Huaqin/0000-0002-7166-108X; Iobst, Stacey E./0000-0002-6954-2903; Yuan, Qiaoping/0000-0002-5880-8702; McCombie, W. Richard/0000-0003-1899-0682; Messing, Joachim/0000-0001-8260-2643; Buell, C Robin/0000-0002-6727-4677	NLM NIH HHS [R01-LM06845] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R01LM006845] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Arumuganathan K, 1991, PLANT MOL BIOL REP, V9, P208, DOI DOI 10.1007/BF02672069; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; Barry GF, 2001, PLANT PHYSIOL, V125, P1164, DOI 10.1104/pp.125.3.1164; BOWERS JE, IN PRESS GENETICS; Cheng ZK, 2001, GENOME RES, V11, P2133, DOI 10.1101/gr.194601; Cheng ZK, 2002, PLANT CELL, V14, P1691, DOI 10.1105/tpc.003079; Feng Q, 2002, NATURE, V420, P316, DOI 10.1038/nature01183; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Harushima Y, 1998, GENETICS, V148, P479; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; McCombie WR, 2000, CELL, V100, P377, DOI 10.1016/S0092-8674(00)80673-X; Meyers BC, 1999, PLANT J, V20, P317, DOI 10.1046/j.1365-313X.1999.t01-1-00606.x; Pan QL, 2000, J MOL EVOL, V50, P203, DOI 10.1007/s002399910023; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; Song R, 2002, GENOME RES, V12, P1549, DOI 10.1101/gr.268302; Thomas CM, 1998, PHILOS T ROY SOC B, V353, P1413, DOI 10.1098/rstb.1998.0296; Yamazaki M, 2001, MOL GENET GENOMICS, V265, P336, DOI 10.1007/s004380000421; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Yuan Q, 2002, MOL GENET GENOMICS, V267, P713, DOI 10.1007/s00438-002-0706-1	22	148	353	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1566	1569						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791992				2022-12-28	WOS:000183333100054
J	Snaith, HA; Sawin, KE				Snaith, HA; Sawin, KE			Fission yeast mod5p regulates polarized growth through anchoring of tea1p at cell tips	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; MICROTUBULAR CYTOSKELETON; PROTEINS; MECHANISMS; DYNAMICS; ESTABLISHMENT; END	Microtubules have a central role in eukaryotic cell polarity(1), in part through interactions between microtubule end-binding proteins and the cell cortex(2,3). In the fission yeast Schizosaccharomyces pombe, microtubules and the polarity modulator tea1p maintain cylindrical cell shape and strictly antipodal cell growth(4-7). The tea1p protein is transported to cell tips by association with growing microtubule plus ends(8); once at cell tips, tea1p releases from microtubule ends and associates with the cell cortex, where it coordinates polarized growth(4,6). Here we describe a cortical protein, mod5p, that regulates the dynamic behaviour of tea1p. In mod5Delta cells, tea1p is efficiently transported on microtubules to cell tips but fails to anchor properly at the cortex and thus fails to accumulate to normal levels. mod5p contains a signal for carboxy-terminal prenylation and in wildtype cells is associated with the plasma membrane at cell tips. However, in tea1Delta cells, although mod5p remains localized to the plasma membrane, mod5p is no longer restricted to the cell tips. We propose that tea1p and mod5p act in a positive-feedback loop in the microtubule-mediated regulation of cell polarity.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Sawin, KE (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Swann Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	ken.sawin@ed.ac.uk		Snaith, Hilary/0000-0003-4863-8436; Sawin, Kenneth/0000-0002-2607-2219				ADACHI Y, 1986, MOL CELL BIOL, V6, P2168, DOI 10.1128/MCB.6.6.2168; Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Arellano M, 2002, CURR BIOL, V12, P751, DOI 10.1016/S0960-9822(02)00821-7; Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Behrens R, 2002, J CELL BIOL, V157, P783, DOI 10.1083/jcb.200112027; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Browning H, 2000, J CELL BIOL, V151, P15, DOI 10.1083/jcb.151.1.15; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Chang F, 2001, TRENDS GENET, V17, P273, DOI 10.1016/S0168-9525(01)02279-X; Ding DQ, 1998, J CELL SCI, V111, P701; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Drummond DR, 2000, CURR BIOL, V10, P766, DOI 10.1016/S0960-9822(00)00570-4; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Glynn JM, 2001, CURR BIOL, V11, P836, DOI 10.1016/S0960-9822(01)00235-4; Gundersen GG, 2002, NAT REV MOL CELL BIO, V3, P296, DOI 10.1038/nrm777; Hayles J, 2001, NAT REV MOL CELL BIO, V2, P647, DOI 10.1038/35089520; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Komarova YA, 2002, J CELL BIOL, V159, P589, DOI 10.1083/jcb.200208058; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; Miller RK, 2000, MOL BIOL CELL, V11, P2949, DOI 10.1091/mbc.11.9.2949; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Sawin KE, 1998, J CELL BIOL, V142, P457, DOI 10.1083/jcb.142.2.457; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; WOODS A, 1989, J CELL SCI, V93, P491; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	30	98	101	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2003	423	6940					647	651		10.1038/nature01672	http://dx.doi.org/10.1038/nature01672			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789340	Green Published			2022-12-28	WOS:000183301200042
J	Larson, DR; Zipfel, WR; Williams, RM; Clark, SW; Bruchez, MP; Wise, FW; Webb, WW				Larson, DR; Zipfel, WR; Williams, RM; Clark, SW; Bruchez, MP; Wise, FW; Webb, WW			Water-soluble quantum dots for multiphoton fluorescence imaging in vivo	SCIENCE			English	Article							CORRELATION SPECTROSCOPY; MICROSCOPY; NANOCRYSTALS; EXCITATION; INTERMITTENCY	The use of semiconductor nanocrystals (quantum dots) as fluorescent labels for multiphoton microscopy enables multicolor imaging in demanding biological environments such as living tissue. We characterized water-soluble cadmium selenide-zinc sulfide quantum dots for multiphoton imaging in live animals. These fluorescent probes have two-photon action cross sections as high as 47,000 Goeppert-Mayer units, by far the largest of any label used in multiphoton microscopy. We visualized quantum dots dynamically through the skin of living mice, in capillaries hundreds of micrometers deep. We found no evidence of blinking (fluorescence intermittency) in solution on nanosecond to millisecond time scales.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Quantum Dot Corp, Hayward, CA 94545 USA	Cornell University	Webb, WW (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.		Larson, Daniel R/B-9829-2008; Bruchez, Marcel P/C-2271-2009; Webb, Watt W./B-5905-2011	Larson, Daniel R/0000-0001-9253-3055; Bruchez, Marcel P/0000-0002-7370-4848; Williams, Rebecca/0000-0002-1391-5846	NATIONAL CANCER INSTITUTE [R44CA088391] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004224] Funding Source: NIH RePORTER; NCI NIH HHS [R44CA8839102] Funding Source: Medline; NCRR NIH HHS [RR10675, NCRR P41-RR04224] Funding Source: Medline; PHS HHS [R33-645644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Albota M, 1998, SCIENCE, V281, P1653, DOI 10.1126/science.281.5383.1653; BLANTON SA, 1994, CHEM PHYS LETT, V229, P317, DOI 10.1016/0009-2614(94)01057-9; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; CHAN W, 2002, CURR OPIN BIOTECH, V13, P140; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Ebenstein Y, 2002, APPL PHYS LETT, V80, P4033, DOI 10.1063/1.1482785; Gerion D, 2001, J PHYS CHEM B, V105, P8861, DOI 10.1021/jp0105488; Kuno M, 2000, J CHEM PHYS, V112, P3117, DOI 10.1063/1.480896; Lounis B, 2000, CHEM PHYS LETT, V329, P399, DOI 10.1016/S0009-2614(00)01042-3; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y; Neuhauser RG, 2000, PHYS REV LETT, V85, P3301, DOI 10.1103/PhysRevLett.85.3301; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; WIDENGREN J, 1995, J PHYS CHEM-US, V99, P13368, DOI 10.1021/j100036a009; Williams RM, 2001, CURR OPIN CHEM BIOL, V5, P603, DOI 10.1016/S1367-5931(00)00241-6; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Yoder EJ, 2002, MICROSC RES TECHNIQ, V56, P304, DOI 10.1002/jemt.10002	20	2003	2124	14	901	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1434	1436		10.1126/science.1083780	http://dx.doi.org/10.1126/science.1083780			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775841				2022-12-28	WOS:000183181800046
J	Wang, ZL; Benoit, G; Liu, JS; Prasad, S; Aarnisalo, P; Liu, XH; Xu, HD; Walker, NPC; Perlmann, T				Wang, ZL; Benoit, G; Liu, JS; Prasad, S; Aarnisalo, P; Liu, XH; Xu, HD; Walker, NPC; Perlmann, T			Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors	NATURE			English	Article							BINDING DOMAIN; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; SUPERFAMILY; ACTIVATION; EVOLUTION	Members of the nuclear receptor (NR) superfamily of transcription factors modulate gene transcription in response to small lipophilic molecules(1). Transcriptional activity is regulated by ligands binding to the carboxy-terminal ligand-binding domains (LBDs) of cognate NRs. A subgroup of NRs referred to as 'orphan receptors' lack identified ligands, however, raising issues about the function of their LBDs(2). Here we report the crystal structure of the LBD of the orphan receptor Nurr1 at 2.2 Angstrom resolution. The Nurr1 LBD adopts a canonical protein fold resembling that of agonist-bound, transcriptionally active LBDs in NRs(3), but the structure has two distinctive features. First, the Nurr1 LBD contains no cavity as a result of the tight packing of side chains from several bulky hydrophobic residues in the region normally occupied by ligands. Second, Nurr1 lacks a 'classical' binding site for coactivators. Despite these differences, the Nurr1 LBD can be regulated in mammalian cells. Notably, transcriptional activity is correlated with the Nurr1 LBD adopting a more stable conformation. Our findings highlight a unique structural class of NRs and define a model for ligand-independent NR function.	Tularik Inc, Dept Biol Struct, San Francisco, CA 94080 USA; Karolinska Inst, Dept Cell Biol, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Mol Biol, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet; Ludwig Institute for Cancer Research	Walker, NPC (corresponding author), Tularik Inc, Dept Biol Struct, 1120 Vet Blvd, San Francisco, CA 94080 USA.	walker@tularik.com; thomas.perlmann@licr.ki.se		BENOIT, Gerard/0000-0001-9462-6570				Aarnisalo P, 2002, J BIOL CHEM, V277, P35118, DOI 10.1074/jbc.M201707200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DESCOTEAUX A, 1993, METHODS MOL GENETICS, V1, P22; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maruyama K, 1998, INT J ONCOL, V12, P1237; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	30	442	465	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2003	423	6939					555	560		10.1038/nature01645	http://dx.doi.org/10.1038/nature01645			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774125				2022-12-28	WOS:000183162900047
J	Hardiman, P; Pillay, OS; Atiomo, W				Hardiman, P; Pillay, OS; Atiomo, W			Polycystic ovary syndrome and endometrial carcinoma	LANCET			English	Review							CANCER-RISK; INSULIN; WOMEN; ADENOCARCINOMA; HYPERTENSION; BINDING; LIFE	Context An association between polycystic ovary syndrome (PCOS) and endometrial carcinoma was first suggested in 1949, 14 years after the original description of the syndrome. Since then several studies have been published that seem to support this association. The prescription of hormonal treatment to reduce the risk of this complication is supported by the Guidelines for Good Clinical Practice of the Royal College of Obstetricians and Gynaecologists, UK, the Health Information website of the National Library of Medicine, USA, and in textbooks of gynaecological oncology. Starting point A recent practice bulletin from the American College of Obstetricians and Gynaecologists on the clinical management of PCOS (Obstet Gynecol 2002; 100: 1389-402) says that there is still no consensus on the "optimal progestin, duration and frequency of treatment to prevent endometrial cancer in women with PCOS". Chronic anovulation, obesity, and hypennsulinaemia carcinoma. It has been assumed that PCOS predisposes to endometrial cancer. However, the evidence for such an association is inconclusive. Although PCOS is associated with risk factors for endometrial cancer, it does not necessarily follow that the incidence or mortality from endometrial cancer is increased. Where next Large-scale studies of morbidity and mortality in unselected populations of women with PCOS are needed. Women with PCOS are increasingly aware of the possible risks, and it will be necessary to identify which of them, if any, are at increased risk and how this risk can be effectively reduced.	UCL Royal Free & Univ Coll Med Sch, Univ Dept Obstet & Gynaecol, London NW3 2PF, England; Univ Nottingham, Sch Human Dev, Acad Dept Obstet & Gynaecol, Nottingham NG7 2RD, England	University of London; University College London; UCL Medical School; University of Nottingham	Hardiman, P (corresponding author), UCL Royal Free & Univ Coll Med Sch, Univ Dept Obstet & Gynaecol, London NW3 2PF, England.	hardiman@rfc.ucl.ac.uk	Atiomo, William U/C-7324-2009	Atiomo, William/0000-0002-5027-3504				American Collegeof Obstetricians and Gynecologists, 2002, Obstet Gynecol, V100, P1389; Berstein L. M., 2000, Voprosy Onkologii (St. Petersburg), V46, P191; Chang RJ, 2002, POLYCYSTIC OVARY SYNDROME, P361; COULAM CB, 1983, OBSTET GYNECOL, V61, P403; DAHLGREN E, 1991, EUR J OBSTET GYN R B, V41, P143, DOI 10.1016/0028-2243(91)90092-Y; DOCKERTY MB, 1951, AM J OBSTET GYNECOL, V61, P966, DOI 10.1016/0002-9378(51)90298-0; ESCOBEDO LG, 1991, OBSTET GYNECOL, V77, P124; Furberg AS, 2003, INT J CANCER, V104, P669, DOI 10.1002/ijc.10974; GALLUP DG, 1984, OBSTET GYNECOL, V64, P417; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Ho S. P., 1997, SMJ, V38, P11; JACKSON RL, 1957, AM J OBSTET GYNECOL, V73, P161, DOI 10.1016/S0002-9378(16)37277-5; JAFARI K, 1978, OBSTET GYNECOL, V51, P97; Konishi I, 1997, GYNECOL ONCOL, V65, P273, DOI 10.1006/gyno.1997.4656; LINCOLN SR, 2002, J CLIN ENDOCR METAB, V76, P1140; NAGAMANI M, 1991, AM J OBSTET GYNECOL, V165, P1865, DOI 10.1016/0002-9378(91)90047-U; Nagamani M, 1998, AM J OBSTET GYNECOL, V179, P6, DOI 10.1016/S0002-9378(98)70244-3; Nestler JE, 2001, J CLIN ENDOCR METAB, V86, P1430, DOI 10.1210/jc.86.3.1430; Pierpoint T, 1998, J CLIN EPIDEMIOL, V51, P581, DOI 10.1016/S0895-4356(98)00035-3; RAMZY I, 1979, AM J CLIN PATHOL, V71, P253; RANDOLPH JF, 1987, AM J OBSTET GYNECOL, V157, P1534, DOI 10.1016/S0002-9378(87)80258-2; SPEERT H, 1949, SURG GYNECOL OBSTET, V88, P332; Weiderpass E, 2000, CANCER CAUSE CONTROL, V11, P185, DOI 10.1023/A:1008946825313; Wild Sarah, 2000, Hum Fertil (Camb), V3, P101, DOI 10.1080/1464727002000198781	24	238	257	1	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2003	361	9371					1810	1812		10.1016/S0140-6736(03)13409-5	http://dx.doi.org/10.1016/S0140-6736(03)13409-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781553				2022-12-28	WOS:000183074800023
J	Chung, HJ; Steinberg, JP; Huganir, RL; Linden, DJ				Chung, HJ; Steinberg, JP; Huganir, RL; Linden, DJ			Requirement of AMPA receptor GluR2 phosphorylation for cerebellar long-term depression	SCIENCE			English	Article							KINASE-C INHIBITOR; PURKINJE-CELLS; GLUTAMATE SENSITIVITY; PROTEIN; PKC; EXPRESSION; BINDING; LTD; NSF; ACTIVATION	Cerebellar long-term depression (LTD) is a model of synaptic memory that requires protein kinase C (PKC) activation and is expressed as a reduction in the number of postsynaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate ( AMPA) receptors. LTD was absent in cultured cerebellar Purkinje cells from mutant mice lacking the AMPA receptor GluR2 subunit and could be rescued by transient transfection with the wild-type GluR2 subunit. Transfection with a point mutant that eliminated PKC phosphorylation of Ser(880) in the carboxyterminal PDZ ligand of GluR2 failed to restore LTD. In contrast, transfection with a point mutant that mimicked phosphorylation at Ser(880) occluded subsequent LTD. Thus, PKC phosphorylation of GluR2 Ser(880) is a critical event in the induction of cerebellar LTD.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Linden, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	dlinden@jhmi.edu	Steinberg, Jordan P./AAP-5568-2020	Steinberg, Jordan P./0000-0001-7930-3394; Chung, Hee Jung/0000-0002-5555-9907	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH051106, R01MH051106, R29MH051106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036715] Funding Source: NIH RePORTER; NIMH NIH HHS [MH51106, MH01590] Funding Source: Medline; NINDS NIH HHS [NS36715, R01 NS036715] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bear MF, 2001, SYNAPSES, P455; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Chung HJ, 2000, J NEUROSCI, V20, P7258; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; De Zeeuw CI, 1998, NEURON, V20, P495, DOI 10.1016/S0896-6273(00)80990-3; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Eto M, 2002, NEURON, V36, P1145, DOI 10.1016/S0896-6273(02)01107-8; Freeman JH, 1998, NEUROREPORT, V9, P2237, DOI 10.1097/00001756-199807130-00016; Goossens J, 2001, J NEUROSCI, V21, P5813, DOI 10.1523/JNEUROSCI.21-15-05813.2001; Hansel C, 2001, NAT NEUROSCI, V4, P467, DOI 10.1038/87419; HARTELL NA, 1994, NEUROREPORT, V5, P833, DOI 10.1097/00001756-199403000-00024; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; Ito M, 2001, PHYSIOL REV, V81, P1143, DOI 10.1152/physrev.2001.81.3.1143; Jia ZP, 1996, NEURON, V17, P945, DOI 10.1016/S0896-6273(00)80225-1; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kim CH, 2001, P NATL ACAD SCI USA, V98, P11725, DOI 10.1073/pnas.211132798; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Linden D J, 1994, Learn Mem, V1, P121; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; Linden DJ, 2001, P NATL ACAD SCI USA, V98, P14066, DOI 10.1073/pnas.241384598; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Narasimhan K, 1996, NEURON, V17, P333, DOI 10.1016/S0896-6273(00)80164-6; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8	33	253	272	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1751	1755		10.1126/science.1082915	http://dx.doi.org/10.1126/science.1082915			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805550				2022-12-28	WOS:000183459700053
J	Stadler, WM; Lerner, SP				Stadler, WM; Lerner, SP			Perloperative chemotherapy in locally advanced bladder cancer	LANCET			English	Editorial Material							PHASE-III; METHOTREXATE; VINBLASTINE; DOXORUBICIN; CARCINOMA; CISPLATIN; P53		Univ Chicago, Dept Med, Sect Hematol Oncol & Urol, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Sect Hematol Oncol & Urol, Chicago, IL 60637 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA	University of Chicago; University of Chicago; Baylor College of Medicine	Stadler, WM (corresponding author), Univ Chicago, Dept Med, Sect Hematol Oncol & Urol, 5841 S Maryland Ave, Chicago, IL 60637 USA.							Bajorin DF, 1999, J CLIN ONCOL, V17, P3173, DOI 10.1200/JCO.1999.17.10.3173; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Cote RJ, 1999, CANCER J, V5, P2; DENNEY E, 2002, LUNG CANC TRIAL RESU; Lerner SP, 2000, COMPREHENSIVE TXB GE, P425; Saxman SB, 1997, J CLIN ONCOL, V15, P2564, DOI 10.1200/JCO.1997.15.7.2564; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068	8	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1922	1923		10.1016/S0140-6736(03)13598-2	http://dx.doi.org/10.1016/S0140-6736(03)13598-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801730				2022-12-28	WOS:000183359700002
J	Adams, RB; Gordon, HL; Baird, AA; Ambady, N; Kleck, RE				Adams, RB; Gordon, HL; Baird, AA; Ambady, N; Kleck, RE			Effects of gaze on amygdala sensitivity to anger and fear faces	SCIENCE			English	Article									Dartmouth Coll, Dept Psychol & Brain Sci, Hanover, NH 03755 USA; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Dartmouth College; Harvard University	Adams, RB (corresponding author), Dartmouth Coll, Dept Psychol & Brain Sci, 6207 Moore Hall, Hanover, NH 03755 USA.		Tudusciuc, Oana/C-1339-2011		NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH067294] Funding Source: NIH RePORTER; NIMH NIH HHS [1F32MH067294-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS RB, IN PRESS PSYCHOL SCI; Adolphs R, 1999, NEUROPSYCHOLOGIA, V37, P1111, DOI 10.1016/S0028-3932(99)00039-1; Whalen PJ, 2001, EMOTION, V1, P70, DOI 10.1037/1528-3542.1.1.70; Wicker B, 2003, NEUROPSYCHOLOGIA, V41, P139, DOI 10.1016/S0028-3932(02)00144-6; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15	5	325	329	0	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1536	1536		10.1126/science.1082244	http://dx.doi.org/10.1126/science.1082244			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791983				2022-12-28	WOS:000183333100043
J	Xiang, Y; Kobilka, BK				Xiang, Y; Kobilka, BK			Myocyte adrenoceptor signaling pathways	SCIENCE			English	Editorial Material							CARDIAC MYOCYTES; RECEPTOR INTERNALIZATION; ADENYLYL-CYCLASE; MICE; HYPERTROPHY; APOPTOSIS; PROTEINS; HEART; ASSOCIATION; CAVEOLAE	Adrenoceptors (ARs), members of the G protein-coupled receptor superfamily, form the interface between the sympathetic nervous system and the cardiovascular system, with integral roles in the rapid regulation of myocardial function. However, in heart failure, chronic catecholamine stimulation of adrenoceptors has been linked to pathologic cardiac remodeling, including myocyte apoptosis and hypertrophy. In cardiac myocytes, activation of AR subtypes results in coupling to different G proteins and induction of specific signaling pathways, which is partly regulated by the subtype-specific distribution of receptors in plasma membrane compartments containing distinct complexes of signaling molecules. The Connections Maps of the Adrenergic and Myocyte Adrenergic Signaling Pathways bring into focus the specific signaling pathways of individual AR subtypes and their relevant functions in vivo.	Stanford Med Ctr, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Kobilka, BK (corresponding author), Stanford Med Ctr, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990				Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chalothorn D, 2003, J PHARMACOL EXP THER, V305, P1045, DOI 10.1124/jpet.102.048553; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; Devic E, 2001, MOL PHARMACOL, V60, P577; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; Hein L, 1997, TRENDS CARDIOVAS MED, V7, P137, DOI 10.1016/S1050-1738(97)00034-0; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Kohout TA, 2001, CIRCULATION, V104, P2485, DOI 10.1161/hc4501.098933; Marks AR, 2002, CIRCULATION, V105, P272, DOI 10.1161/circ.105.3.272; OCONNELL TD, 2000, AM HEART ASS NEW ORL; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Piascik MT, 2001, J PHARMACOL EXP THER, V298, P403; Reiken S, 2003, J BIOL CHEM, V278, P444, DOI 10.1074/jbc.M207028200; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Singh K, 2001, J CELL PHYSIOL, V189, P257, DOI 10.1002/jcp.10024; Steinberg SF, 2002, J MOL CELL CARDIOL, V34, P1141, DOI 10.1006/jmcc.2002.2057; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Sugden PH, 2001, ANN MED, V33, P611; Tanoue A, 2003, TRENDS ENDOCRIN MET, V14, P107, DOI 10.1016/S1043-2760(03)00026-2; Vecchione C, 2002, CIRCULATION, V105, P1700, DOI 10.1161/01.CIR.0000012750.08480.55; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; XIANG Y, 2003, SCI STKE; Xiao RP, 2000, CIRC RES, V87, P635, DOI 10.1161/01.RES.87.8.635; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Zhu WZ, 2003, J CLIN INVEST, V111, P617, DOI 10.1172/JCI200316326; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	36	169	174	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1530	1532		10.1126/science.1079206	http://dx.doi.org/10.1126/science.1079206			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791980				2022-12-28	WOS:000183333100040
J	Zou, L; Elledge, SJ				Zou, L; Elledge, SJ			Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes	SCIENCE			English	Article							REPLICATION PROTEIN-A; SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; CHECKPOINT PROTEINS; GENOTOXIC STRESS; BINDING-PROTEIN; BUDDING YEAST; HUMAN RAD17; IN-VIVO; PHOSPHORYLATION	The function of the ATR (ataxia-telangiectasia mutated- and Rad3-related) ATRIP (ATR-interacting protein) protein kinase complex is crucial for the cellular response to replication stress and DNA damage. Here, we show that replication protein A (RPA), a protein complex that associates with single-stranded DNA (ssDNA), is required for the recruitment of ATR to sites of DNA damage and for ATR-mediated Chk1 activation in human cells. In vitro, RPA stimulates the binding of ATRIP to ssDNA. The binding of ATRIP to RPA-coated ssDNA enables the ATR-ATRIP complex to associate with DNA and stimulates phosphorylation of the Rad17 protein that is bound to DNA. Furthermore, Ddc2, the budding yeast homolog of ATRIP, is specifically recruited to double-strand DNA breaks in an RPA-dependent manner. A checkpoint-deficient mutant of RPA, rfa1-t11, is defective for recruiting Ddc2 to ssDNA both in vivo and in vitro. Our data suggest that RPA-coated ssDNA is the critical structure at sites of DNA damage that recruits the ATR-ATRIP complex and facilitates its recognition of substrates for phosphorylation and the initiation of checkpoint signaling.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA.				NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Kim HS, 2001, MOL CELL BIOL, V21, P3725, DOI 10.1128/MCB.21.11.3725-3737.2001; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu QH, 2000, GENE DEV, V14, P1448; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Melo JA, 2001, GENE DEV, V15, P2809; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Paciotti V, 2000, GENE DEV, V14, P2046; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Post S, 2001, P NATL ACAD SCI USA, V98, P13102, DOI 10.1073/pnas.231364598; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sutton MD, 2000, ANNU REV GENET, V34, P479, DOI 10.1146/annurev.genet.34.1.479; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Umezu K, 1998, GENETICS, V148, P989; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; ZOU L, 1906, UNPUB	38	1983	2037	5	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1542	1548		10.1126/science.1083430	http://dx.doi.org/10.1126/science.1083430			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791985				2022-12-28	WOS:000183333100046
J	Clark, JS; McLachlan, JS				Clark, JS; McLachlan, JS			Stability of forest biodiversity	NATURE			English	Article							EASTERN NORTH-AMERICA; SOUTHERN ONTARIO; COMPETITION; HISTORY; POLLEN; DIVERSITY; DISTURBANCE; DYNAMICS	Two hypotheses to explain potentially high forest biodiversity have different implications for the number and kinds of species that can coexist and the potential loss of biodiversity in the absence of speciation. The first hypothesis involves stabilizing mechanisms, which include tradeoffs between species in terms of their capacities to disperse to sites where competition is weak(1-4), to exploit abundant resources effectively(5,6) and to compete for scarce resources(7). Stabilization results because competitors thrive at different times and places. An alternative, 'neutral model' suggests that stabilizing mechanisms may be superfluous. This explanation emphasizes 'equalizing' mechanisms(8), because competitive exclusion of similar species is slow. Lack of ecologically relevant differences means that abundances experience random 'neutral drift', with slow extinction(9-11). The relative importance of these two mechanisms is unknown, because assumptions and predictions involve broad temporal and spatial scales. Here we demonstrate that predictions of neutral drift are testable using palaeodata. The results demonstrate strong stabilizing forces. By contrast with the neutral prediction of increasing variance among sites over time, we show that variances in post-Glacial tree abundances among sites stabilize rapidly, and abundances remain coherent over broad geographical scales.	Duke Univ, Ctr Global Change, Durham, NC 27708 USA; Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA	Duke University; Duke University	Clark, JS (corresponding author), Duke Univ, Ctr Global Change, Durham, NC 27708 USA.	jimclark@duke.edu	Bond, Alexander L/A-3786-2010					ALLISON TD, 1986, ECOLOGY, V67, P1101, DOI 10.2307/1939835; BENNETT KD, 1987, CAN J BOT, V65, P1792, DOI 10.1139/b87-248; Bennett KD, 2002, HOLOCENE, V12, P421, DOI 10.1191/0959683602hl556rp; Bolker BM, 1999, AM NAT, V153, P575, DOI 10.1086/303199; BURDEN ET, 1986, CAN J EARTH SCI, V23, P43, DOI 10.1139/e86-005; Bush MB, 2000, HOLOCENE, V10, P543, DOI 10.1191/095968300672647521; Chesson P, 2000, ANNU REV ECOL SYST, V31, P343, DOI 10.1146/annurev.ecolsys.31.1.343; CLARK JS, IN PRESS ECOLOGY; CLARK JS, IN PRESS ECOLOGICAL; DENNIS B, 1994, ECOL MONOGR, V64, P205, DOI 10.2307/2937041; DICKEY DA, 1979, J AM STAT ASSOC, V74, P427, DOI 10.2307/2286348; Fuller JL, 1997, CAN J BOT, V75, P1714, DOI 10.1139/b97-886; HASTINGS A, 1980, THEOR POPUL BIOL, V18, P363, DOI 10.1016/0040-5809(80)90059-3; Hixon MA, 2002, ECOLOGY, V83, P1490, DOI 10.2307/3071969; HORN HS, 1972, ECOLOGY, V53, P749, DOI 10.2307/1934797; Hubbell S.P., 1986, COMMUNITY ECOLOGY, P314; Hubbell SP, 1999, SCIENCE, V283, P554, DOI 10.1126/science.283.5401.554; Hubbell Stephen P., 2001, V32, pi; Huntley B., 1983, ATLAS PAST PRESENT P; HUSTON M, 1987, AM NAT, V130, P168, DOI 10.1086/284704; Jackson ST, 1997, QUATERNARY SCI REV, V16, P1, DOI 10.1016/S0277-3791(96)00047-9; JACOBSON GL, 1981, QUATERNARY RES, V16, P80, DOI 10.1016/0033-5894(81)90129-0; McAndrews JH, 1993, CANADIAN GLOBAL CHAN, P22; Pacala SW, 1998, AM NAT, V152, P729, DOI 10.1086/286203; PRENTICE IC, 1985, QUATERNARY RES, V23, P76, DOI 10.1016/0033-5894(85)90073-0; Rees M, 2001, SCIENCE, V293, P650, DOI 10.1126/science.1062586; SZEICZ JM, 1991, CAN J BOT, V69, P1507, DOI 10.1139/b91-195; TILMAN D, 1994, ECOLOGY, V75, P2, DOI 10.2307/1939377; Tilman D., 1998, PLANT STRATEGIES DYN	29	141	153	3	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2003	423	6940					635	638		10.1038/nature01632	http://dx.doi.org/10.1038/nature01632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789337	Bronze			2022-12-28	WOS:000183301200039
J	Cerdan, PD; Chory, J				Cerdan, PD; Chory, J			Regulation of flowering time by light quality	NATURE			English	Article							PHYTOCHROME-B; ARABIDOPSIS-THALIANA; CONSTANS; GENE; DOMAIN; ROLES	The transition to flowering in plants is regulated by environmental factors such as temperature and light(1). Plants grown under dense canopies or at high density perceive a decrease in the ratio of red to far-red incoming light. This change in light quality serves as a warning of competition, triggering a series of responses known collectively as the 'shade-avoidance syndrome'. During shade avoidance, stems elongate at the expense of leaf expansion, and flowering is accelerated(2,3). Of the five phytochromes-a family of red/far-red light photoreceptors-in Arabidopsis, phytochrome B (phyB) has the most significant role in shade-avoidance responses(4,5), but the mechanisms by which phyB regulates flowering in response to altered ratios of red to far-red light are largely unknown. Here we identify PFT1(PHYTOCHROME AND FLOWERING TIME 1), a nuclear protein that acts in a phyB pathway and induces flowering in response to suboptimal light conditions. PFT1 functions downstream of phyB to regulate the expression of FLOWERING LOCUS T (FT), providing evidence for the existence of a light-quality pathway that regulates flowering time in plants.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; Salk Institute	Chory, J (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM52413] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aukerman MJ, 1997, PLANT CELL, V9, P1317, DOI 10.1105/tpc.9.8.1317; Ballare CL, 1999, TRENDS PLANT SCI, V4, P201, DOI 10.1016/S1360-1385(99)01408-9; Blazquez MA, 2002, PLANT PHYSIOL, V130, P1770, DOI 10.1104/pp.007625; Blazquez MA, 1999, PLANT PHYSIOL, V120, P1025, DOI 10.1104/pp.120.4.1025; Cerdan PD, 1999, PLANT J, V18, P499, DOI 10.1046/j.1365-313X.1999.00475.x; Devlin PF, 1998, PLANT CELL, V10, P1479, DOI 10.1105/tpc.10.9.1479; Escher D, 2000, MOL CELL BIOL, V20, P2774, DOI 10.1128/MCB.20.8.2774-2782.2000; HALLIDAY KJ, 1994, PLANT PHYSIOL, V104, P1311, DOI 10.1104/pp.104.4.1311; Hennig L, 2001, PLANT PHYSIOL, V125, P1036, DOI 10.1104/pp.125.2.1036; Hepworth SR, 2002, EMBO J, V21, P4327, DOI 10.1093/emboj/cdf432; Hinshelwood J, 2000, J MOL BIOL, V298, P135, DOI 10.1006/jmbi.2000.3632; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; KOORNNEEF M, 1995, PHYSIOL PLANTARUM, V95, P260, DOI 10.1111/j.1399-3054.1995.tb00836.x; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; Levy YY, 1998, CURR OPIN PLANT BIOL, V1, P49, DOI 10.1016/S1369-5266(98)80127-1; Levy YY, 2002, SCIENCE, V297, P243, DOI 10.1126/science.1072147; Lin CT, 2000, PLANT PHYSIOL, V123, P39, DOI 10.1104/pp.123.1.39; Mockler T, 2003, P NATL ACAD SCI USA, V100, P2140, DOI 10.1073/pnas.0437826100; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996	27	359	403	13	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					881	885		10.1038/nature01636	http://dx.doi.org/10.1038/nature01636			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815435				2022-12-28	WOS:000183585300049
J	Harisinghani, MG; Barentsz, J; Hahn, PF; Deserno, WM; Tabatabaei, S; van de Kaa, CH; de la Rosette, J; Weissleder, R				Harisinghani, MG; Barentsz, J; Hahn, PF; Deserno, WM; Tabatabaei, S; van de Kaa, CH; de la Rosette, J; Weissleder, R			Noninvasive detection of clinically occult lymph-node metastases in prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPERPARAMAGNETIC IRON-OXIDE; PELVIC LYMPHADENECTOMY; RADICAL PROSTATECTOMY; CONTRAST AGENT; MRI; SPECTROSCOPY; DIAGNOSIS; CARCINOMA; THERAPY	BACKGROUND: Accurate detection of lymph-node metastases in prostate cancer is an essential component of the approach to treatment. We investigated whether highly lymphotropic superparamagnetic nanoparticles, which gain access to lymph nodes by means of interstitial-lymphatic fluid transport, could be used in conjunction with high-resolution magnetic resonance imaging (MRI) to reveal small nodal metastases. METHODS: Eighty patients with presurgical clinical stage T1, T2, or T3 prostate cancer who underwent surgical lymph-node resection or biopsy were enrolled. All patients were examined by MRI before and 24 hours after the intravenous administration of lymphotropic superparamagnetic nanoparticles (2.6 mg of iron per kilogram of body weight). The imaging results were correlated with histopathological findings. RESULTS: Of the 334 lymph nodes that underwent resection or biopsy, 63 (18.9 percent) from 33 patients (41 percent) had histopathologically detected metastases. Of these 63 nodes, 45 (71.4 percent) did not fulfill the usual imaging criteria for malignancy. MRI with lymphotropic superparamagnetic nanoparticles correctly identified all patients with nodal metastases, and a node-by-node analysis had a significantly higher sensitivity than conventional MRI (90.5 percent vs. 35.4 percent, P<0.001) or nomograms. CONCLUSIONS: High-resolution MRI with magnetic nanoparticles allows the detection of small and otherwise undetectable lymph-node metastases in patients with prostate cancer.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; Univ Med Ctr, Nijmegen, Netherlands	Harvard University; Harvard Medical School; Massachusetts General Hospital; Radboud University Nijmegen	Weissleder, R (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Ctr Mol Imaging Res, Bldg 149,13th St,Rm 5403, Charlestown, MA 02129 USA.		Barentsz, Jelle/D-3515-2009; Harisinghani, Mukesh/D-7590-2011; de Kaa, Christina A Hulsbergen-van/L-4399-2015; Harisinghani, Mukesh/G-1347-2010	/0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [R01CA059649] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA59649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZAI Y, 1994, RADIOLOGY, V192, P709, DOI 10.1148/radiology.192.3.7520182; Begg CB, 2002, NEW ENGL J MED, V346, P1138, DOI 10.1056/NEJMsa011788; Beissner RS, 2002, UROLOGY, V59, P721, DOI 10.1016/S0090-4295(02)01531-5; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; CAMPBELL SC, 1995, UROLOGY, V46, P352, DOI 10.1016/S0090-4295(99)80219-2; Cheng L, 1998, AM J SURG PATHOL, V22, P1491, DOI 10.1097/00000478-199812000-00006; D'Amico AV, 2001, NEW ENGL J MED, V344, P776, DOI 10.1056/NEJM200103083441017; de Jong IJ, 2002, EUR UROL, V42, P18, DOI 10.1016/S0302-2838(02)00129-X; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P144; Harisinghani MG, 1999, AM J ROENTGENOL, V172, P1347, DOI 10.2214/ajr.172.5.10227514; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; HRICAK H, 1987, RADIOLOGY, V162, P331, DOI 10.1148/radiology.162.2.3797645; Jager GJ, 1996, AM J ROENTGENOL, V167, P1503, DOI 10.2214/ajr.167.6.8956585; Katz-Brull R, 2002, JNCI-J NATL CANCER I, V94, P1197; Kothari PS, 2001, AM J SURG PATHOL, V25, P1429, DOI 10.1097/00000478-200111000-00012; Kurhanewicz J, 2000, RADIOL CLIN N AM, V38, P115, DOI 10.1016/S0033-8389(05)70152-4; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Link RE, 2001, UROL CLIN N AM, V28, P491, DOI 10.1016/S0094-0143(05)70157-9; Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401; METZ CE, 1986, INVEST RADIOL, V21, P720, DOI 10.1097/00004424-198609000-00009; Michel SCA, 2002, RADIOLOGY, V225, P527, DOI 10.1148/radiol.2252011605; Pannu HK, 2000, J MAGN RESON IMAGING, V12, P899, DOI 10.1002/1522-2586(200012)12:6<899::AID-JMRI13>3.0.CO;2-R; Partin AW, 1997, JAMA-J AM MED ASSOC, V278, P118; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Perez JM, 2002, NAT BIOTECHNOL, V20, P816, DOI 10.1038/nbt720; SHEN T, 1993, MAGN RESON MED, V29, P599, DOI 10.1002/mrm.1910290504; Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845; Stets C, 2002, J MAGN RESON IMAGING, V16, P60, DOI 10.1002/jmri.10134; Tempany CMC, 2001, JAMA-J AM MED ASSOC, V285, P562, DOI 10.1001/jama.285.5.562; Walsh PC, 2002, NEW ENGL J MED, V347, P839, DOI 10.1056/NEJMe020089; WEISSLEDER R, 1990, RADIOLOGY, V175, P494, DOI 10.1148/radiology.175.2.2326475; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Wunderbaldinger P, 2002, MAGN RESON MED, V47, P292, DOI 10.1002/mrm.10068	37	1467	1553	5	238	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2491	U5		10.1056/NEJMoa022749	http://dx.doi.org/10.1056/NEJMoa022749			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815134				2022-12-28	WOS:000183577200003
J	Lee, MV; Minotti, A				Lee, MV; Minotti, A			Acute vertebral osteomyelitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Metrohlth Med Ctr, Cleveland, OH 44109 USA	MetroHealth System	Lee, MV (corresponding author), Metrohlth Med Ctr, Cleveland, OH 44109 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2525	2525		10.1056/NEJMicm020830	http://dx.doi.org/10.1056/NEJMicm020830			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815138				2022-12-28	WOS:000183577200007
J	Ashraf, H				Ashraf, H			Alliance offers healthy diet	LANCET			English	News Item																			0	2	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2051	2051						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814720				2022-12-28	WOS:000183488900017
J	Finucane, TE; Greenough, WB				Finucane, TE; Greenough, WB			Group practice	LANCET			English	Editorial Material									Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Finucane, TE (corresponding author), Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2077	2077		10.1016/S0140-6736(03)13645-8	http://dx.doi.org/10.1016/S0140-6736(03)13645-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814732				2022-12-28	WOS:000183488900027
J	MacDonald, CC; McMahon, KW				MacDonald, CC; McMahon, KW			The flowers that bloom in the spring: RNA processing and seasonal flowering	CELL			English	Editorial Material							PRE-MESSENGER-RNA; POLY(A) POLYMERASE; REPEAT PROTEIN; POLYADENYLATION; AUTOREGULATION; DROSOPHILA; CLEAVAGE; COMPLEX; CELLS		Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	MacDonald, CC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.			MacDonald, Clinton/0000-0003-3209-1982	NICHD NIH HHS [R01 HD037109] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037109] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; Elliott BJ, 2003, PLANT MOL BIOL, V51, P373, DOI 10.1023/A:1022035219500; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; Ito S, 2001, BIOCHEM BIOPH RES CO, V280, P656, DOI 10.1006/bbrc.2000.4163; Juge F, 2000, RNA, V6, P1529, DOI 10.1017/S1355838200001266; Ohnacker M, 2000, EMBO J, V19, P37, DOI 10.1093/emboj/19.1.37; QUESADA V, 2003, IN PRESS EMBO J; Simpson GG, 2003, CELL, V113, P777, DOI 10.1016/S0092-8674(03)00425-2; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Wallace AM, 1999, P NATL ACAD SCI USA, V96, P6763, DOI 10.1073/pnas.96.12.6763; Yao YL, 2002, J EXP BOT, V53, P2277, DOI 10.1093/jxb/erf073	11	3	3	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 13	2003	113	6					671	672		10.1016/S0092-8674(03)00426-4	http://dx.doi.org/10.1016/S0092-8674(03)00426-4			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809597	Bronze			2022-12-28	WOS:000183514400001
J	Ranz, JM; Castillo-Davis, CI; Meiklejohn, CD; Hartl, DL				Ranz, JM; Castillo-Davis, CI; Meiklejohn, CD; Hartl, DL			Sex-dependent gene expression and evolution of the Drosophila transcriptome	SCIENCE			English	Article							MELANOGASTER SUBGROUP; SPECIATION; DIVERGENCE; DIMORPHISM	Comparison of the gene-expression profiles between adults of Drosophila melanogaster and Drosophila simulans has uncovered the evolution of genes that exhibit sex-dependent regulation. Approximately half the genes showed differences in expression between the species, and among these, similar to83% involved a gain, loss, increase, decrease, or reversal of sex-biased expression. Most of the interspecific differences in messenger RNA abundance affect male-biased genes. Genes that differ in expression between the species showed functional clustering only if they were sex-biased. Our results suggest that sex-dependent selection may drive changes in expression of many of the most rapidly evolving genes in the Drosophila transcriptome.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Harvard University	Hartl, DL (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.	dhartl@oeb.harvard.edu	jose, ranz/A-5432-2008	Meiklejohn, Colin/0000-0003-2708-8316				Andrews J, 2000, GENOME RES, V10, P2030, DOI 10.1101/gr.10.12.2030; Arbeitman MN, 2002, SCIENCE, V297, P2270, DOI 10.1126/science.1072152; Betran E, 2002, GENOME RES, V12, P1854, DOI 10.1101/gr.6049; Biemont C, 1999, GENETICA, V105, P43, DOI 10.1023/A:1003718520490; CACCONE A, 1988, GENETICS, V118, P671; CARSON HL, 1985, SYST BOT, V10, P380, DOI 10.2307/2419132; Castillo-Davis CI, 2003, BIOINFORMATICS, V19, P891, DOI 10.1093/bioinformatics/btg114; Civetta A, 1999, GENOME, V42, P1033, DOI 10.1139/gen-42-6-1033; Darwin C., 1874, DESCENT MAN SELECTIO; DING D, 1994, GENET RES, V64, P167, DOI 10.1017/S0016672300032833; Eberhard W.G., 1985, SEXUAL SELECTION ANI; GROSSFIELD J, 1971, P NATL ACAD SCI USA, V68, P2669, DOI 10.1073/pnas.68.11.2669; Hollocher H, 2000, EVOLUTION, V54, P2046, DOI 10.1111/j.0014-3820.2000.tb01248.x; JALLON JM, 1987, EVOLUTION, V41, P294, DOI 10.1111/j.1558-5646.1987.tb05798.x; Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766; Kliman RM, 2000, GENETICS, V156, P1913; Kopp A, 2000, NATURE, V408, P553, DOI 10.1038/35046017; Larson MA, 2001, P NATL ACAD SCI USA, V98, P9677, DOI 10.1073/pnas.171305398; LIVAK KJ, 1984, GENETICS, V107, P611; MANNING AUBREY, 1959, BEHAVIOUR, V15, P123; MEIKLEJOHN CD, UNPUB; Parisi M, 2003, SCIENCE, V299, P697, DOI 10.1126/science.1079190; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; Rice WR, 2002, GENETICA, V116, P179, DOI 10.1023/A:1021205130926; SIMMONS MJ, 1977, ANNU REV GENET, V11, P49, DOI 10.1146/annurev.ge.11.120177.000405; Sturtevant AH, 1920, GENETICS, V5, P488; TOWNSEND JP, 2002, GENOME BIOL, V3; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927; Wolfenbarger LL, 2001, EVOLUTION, V55, P103; Wu CI, 2001, J EVOLUTION BIOL, V14, P851, DOI 10.1046/j.1420-9101.2001.00335.x; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070	31	489	497	4	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1742	1745		10.1126/science.1085881	http://dx.doi.org/10.1126/science.1085881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805547				2022-12-28	WOS:000183459700050
J	Kuzmich, A; Bowen, WP; Boozer, AD; Boca, A; Chou, CW; Duan, LM; Kimble, HJ				Kuzmich, A; Bowen, WP; Boozer, AD; Boca, A; Chou, CW; Duan, LM; Kimble, HJ			Generation of nonclassical photon pairs for scalable quantum communication with atomic ensembles	NATURE			English	Article							STATE; LIGHT	Quantum information science attempts to exploit capabilities from the quantum realm to accomplish tasks that are otherwise impossible in the classical domain(1). Although sufficient conditions have been formulated for the physical resources required to achieve quantum computation and communication(2), there is a growing understanding of the power of quantum measurement combined with the conditional evolution of quantum states for accomplishing diverse tasks in quantum information science(3-5). For example, a protocol has recently been developed(6) for the realization of scalable long-distance quantum communication and the distribution of entanglement over quantum networks. Here we report the first enabling step in the realization of this protocol, namely the observation of quantum correlations for photon pairs generated in the collective emission from an atomic ensemble. The nonclassical character of the fields is demonstrated by the violation of an inequality involving their normalized correlation functions. Compared to previous investigations of non-classical correlations for photon pairs produced in atomic cascades(7) and in parametric down-conversion(8), our experiment is distinct in that the correlated photons are separated by a programmable time interval (of about 400 nanoseconds in our initial experiments).	CALTECH, Norman Bridge Lab Phys 12 33, Pasadena, CA 91125 USA	California Institute of Technology	Kimble, HJ (corresponding author), CALTECH, Norman Bridge Lab Phys 12 33, Pasadena, CA 91125 USA.	hjkimble@caltech.edu	Bowen, Warwick P/A-7630-2010	Bowen, Warwick P/0000-0001-8127-1715				Alexandrov EB, 1996, LASER PHYS, V6, P244; Bose S, 1999, PHYS REV LETT, V83, P5158, DOI 10.1103/PhysRevLett.83.5158; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; CLAUSER JF, 1974, PHYS REV D, V9, P853, DOI 10.1103/PhysRevD.9.853; DiVincenzo DP, 2000, FORTSCHR PHYS, V48, P771, DOI 10.1002/1521-3978(200009)48:9/11<771::AID-PROP771>3.0.CO;2-E; Duan LM, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.170402; Duan LM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.023818; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; Fleischhauer M, 2000, PHYS REV LETT, V84, P5094, DOI 10.1103/PhysRevLett.84.5094; Hald J, 1999, PHYS REV LETT, V83, P1319, DOI 10.1103/PhysRevLett.83.1319; Harris SE, 1999, PHYS REV LETT, V82, P4611, DOI 10.1103/PhysRevLett.82.4611; Julsgaard B, 2001, NATURE, V413, P400, DOI 10.1038/35096524; KITAGAWA M, 1991, PHYS REV LETT, V67, P1852, DOI 10.1103/PhysRevLett.67.1852; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kuzmich A, 2000, PHYS REV LETT, V85, P1594, DOI 10.1103/PhysRevLett.85.1594; Kuzmich A, 1998, EUROPHYS LETT, V42, P481, DOI 10.1209/epl/i1998-00277-9; Kuzmich A, 1997, PHYS REV LETT, V79, P4782, DOI 10.1103/PhysRevLett.79.4782; Mandel L, 1999, REV MOD PHYS, V71, pS274, DOI 10.1103/RevModPhys.71.S274; Mandel L, 1995, OPTICAL COHERENCE QU; Metcalf HJ., 1999, LASER COOLING TRAPPI; Molmer K, 1999, EUR PHYS J D, V5, P301, DOI 10.1007/s100530050259; PRESKILL JP, LECT NOTES PHYSICS, V219; Schori C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.057903; Solomon GS, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.229702; van der Wal CH, 2003, SCIENCE, V301, P196, DOI 10.1126/science.1085946; van Enk SJ, 1998, SCIENCE, V279, P205, DOI 10.1126/science.279.5348.205; Zibrov AS, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.103601	29	546	562	2	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					731	734		10.1038/nature01714	http://dx.doi.org/10.1038/nature01714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802329	Green Submitted, Green Accepted			2022-12-28	WOS:000183443400038
J	Yaghi, OM; O'Keeffe, M; Ockwig, NW; Chae, HK; Eddaoudi, M; Kim, J				Yaghi, OM; O'Keeffe, M; Ockwig, NW; Chae, HK; Eddaoudi, M; Kim, J			Reticular synthesis and the design of new materials	NATURE			English	Review							METAL-ORGANIC FRAMEWORKS; 3-DIMENSIONAL COORDINATION POLYMER; SECONDARY BUILDING UNITS; CRYSTAL-STRUCTURE; PHASE-TRANSITION; PORE-SIZE; CHEMISTRY; SOLIDS; NETWORK; SORPTION	The long-standing challenge of designing and constructing new crystalline solid-state materials from molecular building blocks is just beginning to be addressed with success. A conceptual approach that requires the use of secondary building units to direct the assembly of ordered frameworks epitomizes this process: we call this approach reticular synthesis. This chemistry has yielded materials designed to have predetermined structures, compositions and properties. In particular, highly porous frameworks held together by strong metal-oxygen-carbon bonds and with exceptionally large surface area and capacity for gas storage have been prepared and their pore metrics systematically varied and functionalized.	Univ Michigan, Mat Design & Discovery Grp, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Arizona State Univ, Dept Chem, Tempe, AZ 85287 USA; Hankuk Univ Foreign Studies, Seoul, South Korea	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Arizona State University; Arizona State University-Tempe; Hankuk University Foreign Studies	Yaghi, OM (corresponding author), Univ Michigan, Mat Design & Discovery Grp, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	oyaghi@umich.edu	Yaghi, Omar M/C-6749-2013; Eddaoudi, Mohamed/D-2298-2009	Eddaoudi, Mohamed/0000-0003-1916-9837; Yaghi, Omar/0000-0002-5611-3325				AUMULLER A, 1986, ANGEW CHEM INT EDIT, V25, P740, DOI 10.1002/anie.198607401; Barthelet K, 2002, CHEM COMMUN, P1492, DOI 10.1039/b202749f; Batten SR, 1998, ANGEW CHEM INT EDIT, V37, P1460, DOI 10.1002/(SICI)1521-3773(19980619)37:11<1460::AID-ANIE1460>3.0.CO;2-Z; Bennett MV, 2001, J AM CHEM SOC, V123, P8022, DOI 10.1021/ja0110473; Bhatia S., 2020, ZEOLITE CATALYSIS PR; Biradha K, 2000, ANGEW CHEM INT EDIT, V39, P3843, DOI 10.1002/1521-3773(20001103)39:21<3843::AID-ANIE3843>3.0.CO;2-#; Blake AJ, 1999, COORDIN CHEM REV, V183, P117, DOI 10.1016/S0010-8545(98)00173-8; Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b; BRIMAH AK, 1994, J ORGANOMET CHEM, V475, P85, DOI 10.1016/0022-328X(94)84010-5; Carlucci L, 2000, J CHEM SOC DALTON, P3821, DOI 10.1039/b003092i; Carlucci L, 1997, CHEM COMMUN, P631, DOI 10.1039/a700446j; Carlucci L, 1998, CHEM COMMUN, P1837, DOI 10.1039/a803662d; Carlucci L, 2001, CHEM COMMUN, P1198, DOI 10.1039/b103736f; Caulder DL, 1999, ACCOUNTS CHEM RES, V32, P975, DOI 10.1021/ar970224v; Chae HK, 2001, J AM CHEM SOC, V123, P11482, DOI 10.1021/ja011692+; Chen BL, 2001, SCIENCE, V291, P1021, DOI 10.1126/science.1056598; Chen BL, 2000, J AM CHEM SOC, V122, P11559, DOI 10.1021/ja003159k; Chui SSY, 1999, SCIENCE, V283, P1148, DOI 10.1126/science.283.5405.1148; COREY EJ, 1988, CHEM SOC REV, V17, P111, DOI 10.1039/cs9881700111; Cotton FA, 2001, ACCOUNTS CHEM RES, V34, P759, DOI 10.1021/ar010062+; DAVIS ME, 1989, J AM CHEM SOC, V111, P3919, DOI 10.1021/ja00193a024; Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785; Diskin-Posner Y, 2000, ANGEW CHEM INT EDIT, V39, P1288, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1288::AID-ANIE1288>3.0.CO;2-Y; Dunbar KR, 1997, PROG INORG CHEM, V45, P283; Eddaoudi M, 2000, J AM CHEM SOC, V122, P1391, DOI 10.1021/ja9933386; Eddaoudi M, 2002, SCIENCE, V295, P469, DOI 10.1126/science.1067208; Eddaoudi M, 2001, ACCOUNTS CHEM RES, V34, P319, DOI 10.1021/ar000034b; Eddaoudi M, 2002, J AM CHEM SOC, V124, P376, DOI 10.1021/ja017154e; Eddaoudi M, 2002, P NATL ACAD SCI USA, V99, P4900, DOI 10.1073/pnas.082051899; Eddaoudi M, 2001, J AM CHEM SOC, V123, P4368, DOI 10.1021/ja0104352; ERMER O, 1988, J AM CHEM SOC, V110, P3747, DOI 10.1021/ja00220a005; Evans OR, 2002, ACCOUNTS CHEM RES, V35, P511, DOI 10.1021/ar0001012; Evans OR, 1999, INORG CHEM, V38, P2969, DOI 10.1021/ic990022q; FARRELL RP, 1995, INORG CHEM, V34, P757, DOI 10.1021/ic00108a001; Ferey G, 2000, J SOLID STATE CHEM, V152, P37, DOI 10.1006/jssc.2000.8667; FISCHER W, 1983, INT TABLES CRYSTAL A, pCH14; Friedrichs OD, 2003, ACTA CRYSTALLOGR A, V59, P22, DOI 10.1107/S0108767302018494; Friedrichs OD, 2000, DISCRETE COMPUT GEOM, V24, P279, DOI 10.1007/s004540010035; Friedrichs OD, 1999, NATURE, V400, P644, DOI 10.1038/23210; Fujita M, 1996, CHEM COMMUN, P1535, DOI 10.1039/cc9960001535; GRAMACCIOLI CM, 1966, ACTA CRYSTALLOGR, V21, P600, DOI 10.1107/S0365110X66003529; GREGG S. J., 1982, AUFLAGE, V2nd; HIRSCH KA, 1995, J CHEM SOC CHEM COMM, P2199, DOI 10.1039/C39950002199; Holman KT, 2001, ACCOUNTS CHEM RES, V34, P107, DOI 10.1021/ar970272f; HOSKINS BF, 1989, J AM CHEM SOC, V111, P5962, DOI 10.1021/ja00197a079; Husing N, 1998, ANGEW CHEM INT EDIT, V37, P23, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<22::AID-ANIE22>3.0.CO;2-I; JARVIS JAJ, 1962, ACTA CRYSTALLOGR, V15, P964, DOI 10.1107/S0365110X62002558; Kahn O, 2000, ACCOUNTS CHEM RES, V33, P647, DOI 10.1021/ar9703138; Keller SW, 1997, ANGEW CHEM INT EDIT, V36, P247, DOI 10.1002/anie.199702471; Kepert CJ, 2000, J AM CHEM SOC, V122, P5158, DOI 10.1021/ja993814s; Kiang YH, 1999, J AM CHEM SOC, V121, P8204, DOI 10.1021/ja991100b; Kim J, 2001, J AM CHEM SOC, V123, P8239, DOI 10.1021/ja010825o; KINOSHITA Y, 1959, B CHEM SOC JPN, V32, P1221, DOI 10.1246/bcsj.32.1221; Kitagawa S, 1998, B CHEM SOC JPN, V71, P1739, DOI 10.1246/bcsj.71.1739; Kitaura R, 2002, ANGEW CHEM INT EDIT, V41, P133, DOI 10.1002/1521-3773(20020104)41:1<133::AID-ANIE133>3.0.CO;2-R; KITAZAWA T, 1995, J CHEM SOC DALTON, P3715, DOI 10.1039/dt9950003715; Klein C, 2001, NEW J CHEM, V25, P207, DOI 10.1039/b008259g; LEHN JM, 1988, CHEM SCRIPTA, V28, P237; Li H, 1998, J AM CHEM SOC, V120, P8571, DOI 10.1021/ja981669x; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; LI H, 2001, J AM CHEM SOC, V121, P6096; Li HL, 1999, SCIENCE, V283, P1145, DOI 10.1126/science.283.5405.1145; Lin WB, 1999, J AM CHEM SOC, V121, P11249, DOI 10.1021/ja9928327; MACGILLIVRAY LR, 1994, J CHEM SOC CHEM COMM, P1325, DOI 10.1039/c39940001325; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; Manson JL, 1998, CHEM COMMUN, P251, DOI 10.1039/a707289i; Millange F, 2002, CHEM COMMUN, P822, DOI 10.1039/b201381a; Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432; Moulton B, 2001, CHEM COMMUN, P863, DOI 10.1039/b102714j; Noro S, 2000, ANGEW CHEM INT EDIT, V39, P2082; O'Keeffe M, 1999, NATURE, V400, P617, DOI 10.1038/23139; O'Keeffe M, 2000, J SOLID STATE CHEM, V152, P3, DOI 10.1006/jssc.2000.8723; OKADA K, 1966, J CHEM PHYS, V44, P1648, DOI 10.1063/1.1726904; OKEEFFE M, 1992, ACTA CRYSTALLOGR A, V48, P663, DOI 10.1107/S0108767392001260; OKEEFFE M, 1983, INORG CHEM, V22, P177, DOI 10.1021/ic00143a040; OKEEFFE M, 1996, CRYSTAL STRUCTURES, V1; Reineke TM, 1999, ANGEW CHEM INT EDIT, V38, P2590, DOI 10.1002/(SICI)1521-3773(19990903)38:17<2590::AID-ANIE2590>3.0.CO;2-H; Reineke TM, 1999, J AM CHEM SOC, V121, P1651, DOI 10.1021/ja983577d; ROBL C, 1992, MATER RES BULL, V27, P99, DOI 10.1016/0025-5408(92)90047-4; Rosi NL, 2002, ANGEW CHEM INT EDIT, V41, P284, DOI 10.1002/1521-3773(20020118)41:2<284::AID-ANIE284>3.0.CO;2-M; Sato O, 1996, SCIENCE, V271, P49, DOI 10.1126/science.271.5245.49; Seki K, 2001, CHEM LETT, P332, DOI 10.1246/cl.2001.332; Seo JS, 2000, NATURE, V404, P982, DOI 10.1038/35010088; SIMARD M, 1991, J AM CHEM SOC, V113, P4696, DOI 10.1021/ja00012a057; Stang PJ, 1997, ACCOUNTS CHEM RES, V30, P502, DOI 10.1021/ar9602011; STEIN A, 1993, SCIENCE, V259, P1558, DOI 10.1126/science.259.5101.1558; STERLING C, 1964, SCIENCE, V146, P518, DOI 10.1126/science.146.3643.518; Szostak R., 1989, J MOL STRUCT; Tabares LC, 2001, J AM CHEM SOC, V123, P383, DOI 10.1021/ja002624a; WEISS A, 1986, Z NATURFORSCH B, V41, P18; Wells A.F., 1984, STRUCTURAL INORGANIC; Yaghi OM, 2000, J SOLID STATE CHEM, V152, P1, DOI 10.1006/jssc.2000.8733; Yaghi OM, 1998, ACCOUNTS CHEM RES, V31, P474, DOI 10.1021/ar970151f; YAGHI OM, 1994, J AM CHEM SOC, V116, P807, DOI 10.1021/ja00081a067; Yaghi OM, 1997, INORG CHEM, V36, P4292, DOI 10.1021/ic970423a; YAGHI OM, 1995, MATER RES SOC SYMP P, V371, P15; Yaghi OM, 1997, J AM CHEM SOC, V119, P2861, DOI 10.1021/ja9639473; Yang SY, 2002, CHEM MATER, V14, P3229, DOI 10.1021/cm025572s; 2002, CRYSTENGCOMM	99	7768	7919	146	4344	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					705	714		10.1038/nature01650	http://dx.doi.org/10.1038/nature01650			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802325	Green Published			2022-12-28	WOS:000183443400033
J	Clark, JM; Diehl, AM				Clark, JM; Diehl, AM			Nonalcoholic fatty liver disease - An underrecognized cause of cryptogenic cirrhosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; HEPATOCELLULAR-CARCINOMA; OVERWEIGHT PATIENTS; OBESE PATIENTS; IN-VIVO; STEATOHEPATITIS; PREVALENCE; HEPATITIS; PATHOLOGY; FIBROSIS	Cryptogenic cirrhosis is a common cause of liver-related morbidity and mortality in the United States. Nonalcoholic fatty liver disease (NAFLD) is now recognized as the most common cause of cryptogenic cirrhosis. However, the diagnosis of cirrhosis in patients with NAFLD appears to be delayed compared with those with other chronic liver diseases and thus carries a higher mortality rate. This delay in diagnosis is illustrated in our case of a 53-year-old man who presented with hepatic hydrothorax and ascites, whose workup revealed cirrhosis due to NAFLD. Although a diagnosis of presumed NAFLD can be made noninvasively, a definitive diagnosis requires a liver biopsy specimen. A biopsy specimen is also important for detecting histologically advanced disease, which may be clinically silent and undetected by aminotransferases or diagnostic imaging. Although there are no proven treatments, recommendations for patients with NAFLD include avoidance of hepatotoxins and aggressive management of associated conditions, such as hypertriglyceridemia and type 2 diabetes mellitus.	Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Clark, JM (corresponding author), Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-6, Baltimore, MD 21205 USA.							Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711; ACOSTA RC, 2001, GASTROENTEROLOGY S, V120, pA73; Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432; ALEXANDER JF, 1971, AM J GASTROENTEROL, V56, P515; ANDERSEN T, 1991, J HEPATOL, V12, P224, DOI 10.1016/0168-8278(91)90942-5; Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604; Angulo P, 2001, SEMIN LIVER DIS, V21, P81, DOI 10.1055/s-2001-12931; Basaranoglu M, 1999, J HEPATOL, V31, P384, DOI 10.1016/S0168-8278(99)80243-8; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; Brunt EM, 2001, SEMIN LIVER DIS, V21, P3, DOI 10.1055/s-2001-12925; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; CAPRON JP, 1982, DIGEST DIS SCI, V27, P265, DOI 10.1007/BF01296926; Clark JM, 2001, GASTROENTEROLOGY, V120, pA65; CLARK JM, IN PRESS AM J GASTRO; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Gholam PM, 2002, OBES SURG, V12, P49, DOI 10.1381/096089202321144577; Graif M, 2000, INVEST RADIOL, V35, P319, DOI 10.1097/00004424-200005000-00006; Gulbahar O, 2000, GASTROENTEROLOGY, V118, pA1444, DOI 10.1016/S0016-5085(00)81671-6; Laurin J, 1996, HEPATOLOGY, V23, P1464; Lavine JE, 2000, J PEDIATR-US, V136, P734, DOI 10.1016/S0022-3476(00)05040-X; Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Mendler MH, 1998, J HEPATOL, V28, P785, DOI 10.1016/S0168-8278(98)80228-6; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Nair S, 2002, HEPATOLOGY, V36, P150, DOI 10.1053/jhep.2002.33713; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; PALMER M, 1990, GASTROENTEROLOGY, V99, P1408, DOI 10.1016/0016-5085(90)91169-7; Poonawala A, 2000, HEPATOLOGY, V32, P689, DOI 10.1053/jhep.2000.17894; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Ratziu V, 2000, GASTROENTEROLOGY, V118, P1117, DOI 10.1016/S0016-5085(00)70364-7; Ratziu V, 2002, HEPATOLOGY, V35, P1485, DOI 10.1053/jhep.2002.33324; Ricci C, 1997, J HEPATOL, V27, P108, DOI 10.1016/S0168-8278(97)80288-7; Skelly MM, 2001, J HEPATOL, V35, P195, DOI 10.1016/S0168-8278(01)00094-0; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; Ueno T, 1997, J HEPATOL, V27, P103, DOI 10.1016/S0168-8278(97)80287-5	37	295	313	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					3000	3004		10.1001/jama.289.22.3000	http://dx.doi.org/10.1001/jama.289.22.3000			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687XZ	12799409				2022-12-28	WOS:000183403400024
J	Mason, S; Hussain-Gambles, M; Leese, B; Atkin, K; Brown, J				Mason, S; Hussain-Gambles, M; Leese, B; Atkin, K; Brown, J			Representation of south Asian people in randomised clinical trials: analysis of trials' data	BRITISH MEDICAL JOURNAL			English	Article									Univ Leeds, No & Yorkshire Clin Trials & Res Unit, Leeds LS2 9LN, W Yorkshire, England; Univ Leeds, Ctr Res Primary Care, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Mason, S (corresponding author), Univ Leeds, No & Yorkshire Clin Trials & Res Unit, Leeds LS2 9LN, W Yorkshire, England.			brown, julia/0000-0002-2719-7064				Ashcroft RE, 1997, HEALTH TECHNOL ASSES, V1, P1; Britton A, 1999, J Health Serv Res Policy, V4, P112; Kressin Nancy R., 2000, Journal of the National Medical Association, V92, P62; Matthews Hewitt W., 1995, Drug Metabolism and Drug Interactions, V12, P77; Scott A, 2001, Popul Trends, P6	5	73	73	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1244	1245		10.1136/bmj.326.7401.1244	http://dx.doi.org/10.1136/bmj.326.7401.1244			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791739	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000183480700016
J	Sakai, Y				Sakai, Y			Emphysematous cholecystitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Inatsuki Hosp, Fukuoka 8200207, Japan		Sakai, Y (corresponding author), Inatsuki Hosp, Fukuoka 8200207, Japan.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2329	2329		10.1056/NEJMicm030017	http://dx.doi.org/10.1056/NEJMicm030017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788997				2022-12-28	WOS:000183296300008
J	Assendelft, WJJ; Morton, SC; Yu, EI; Suttorp, MJ; Shekelle, PG				Assendelft, WJJ; Morton, SC; Yu, EI; Suttorp, MJ; Shekelle, PG			Spinal manipulative therapy for low back pain - A meta-analysis of effectiveness relative to other therapies	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CLINICAL-TRIAL; SYSTEMATIC REVIEWS; MANUAL THERAPY; NECK COMPLAINTS; FOLLOW-UP; OUTCOME MEASURES; PRIMARY-CARE; HEALTH-CARE; CONSERVATIVE TREATMENT; MULTICENTER TRIAL	Background: Low back pain is a costly illness for which spinal manipulative therapy is commonly recommended. Previous systematic reviews and practice guidelines have reached discordant results on the effectiveness of this therapy for low back pain. Purpose: To resolve the discrepancies related to use of spinal manipulative therapy and to update previous estimates of effectiveness by comparing spinal manipulative therapy with other therapies and then incorporating data from recent high-quality randomized, controlled trials (RCTs) into the analysis. Data Sources: MEDLINE, EMBASE, CINAHL, the Cochrane Controlled Trials Register, and previous systematic reviews. Study Selection: Randomized, controlled trials of patients with low back pain that evaluated spinal manipulative therapy with at least 1 day of follow-up and at least one clinically relevant outcome measure. Data Extraction: Two authors, who served as the reviewers for all stages of the meta-analysis, independently extracted data from unmasked articles. Comparison treatments were classified into the following seven categories: sham, conventional general practitioner care, analgesics, physical therapy, exercises, back school, or a collection of therapies judged to be ineffective or even harmful (traction, corset, bed rest, home care, topical gel, no treatment, diathermy, and minimal massage). Data Synthesis: Thirty-nine RCTs were identified. Meta-regression models were developed for acute or chronic pain and short-term and long-term pain and function. For patients with acute low back pain, spinal manipulative therapy was superior only to sham therapy (10-mm difference [95% CI, 2 to 17 mm] on a 100-mm visual analogue scale) or therapies judged to be ineffective or even harmful. Spinal manipulative therapy had no statistically or clinically significant advantage over general practitioner care, analgesics, physical therapy, exercises, or back school. Results for patients with chronic low back pain were similar. Radiation of pain, study quality, profession of manipulator, and use of manipulation alone or in combination with other therapies did not affect these results. Conclusions: There is no evidence that spinal manipulative therapy is superior to other standard treatments for patients with acute or chronic low back pain.	RAND Corp, Santa Monica, CA 90407 USA; Cochrane Back Review Grp, Toronto, ON, Canada; Dutch Coll Gen Practitioners, Utrecht, Netherlands; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Shekelle, PG (corresponding author), RAND Corp, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA.	shekelle@rand.org	Assendelft, W.J.J./H-8008-2014; assendelft, willem/AAW-1854-2021	Assendelft, W.J.J./0000-0002-2966-3778; assendelft, willem/0000-0002-2966-3778				ANDERSON R, 1992, J MANIP PHYSIOL THER, V15, P181; Andersson GBJ, 1999, NEW ENGL J MED, V341, P1426, DOI 10.1056/NEJM199911043411903; ARKUSZEWSKI Z, 1986, MANUAL MED, V2, P68; Assendelft W J, 1996, J Manipulative Physiol Ther, V19, P499; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND, P9; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Blomberg S, 1994, Eur Spine J, V3, P246, DOI 10.1007/BF02226573; BLOMBERG S, 1994, SPINE, V19, P569, DOI 10.1097/00007632-199403000-00013; BLOMBERG S, 1992, Scandinavian Journal of Primary Health Care, V10, P170, DOI 10.3109/02813439209014057; Blomberg S, 1993, CLIN REHABIL, V7, P49; Blomberg Stefan, 1993, Scandinavian Journal of Primary Health Care, V11, P83, DOI 10.3109/02813439308994908; BRENNAN PC, 1994, J MANIP PHYSIOL THER, V17, P219; Bronfort G, 1996, J Manipulative Physiol Ther, V19, P570; Bronfort G, 1999, NEUROL CLIN, V17, P91, DOI 10.1016/S0733-8619(05)70116-X; BRONFORT G, 1997, EFFICACY MANUAL THER; Bronfort G., 1989, AM J CHIROPRACTIC ME, V2, P145; BUERGER AA, 1980, MANUAL MED, V2, P17; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Cherkin DC, 1998, SPINE, V23, P607, DOI 10.1097/00007632-199803010-00015; CIBULKA MT, 1988, PHYS THER, V68, P1359, DOI 10.1093/ptj/68.9.1359; COTE P, 1994, J MANIP PHYSIOL THER, V17, P364; COXHEAD CE, 1981, LANCET, V1, P1065; COYER AB, 1955, BRIT MED J, V1, P705, DOI 10.1136/bmj.1.4915.705; CRAMER GD, 1993, J MANIP PHYSIOL THER, V16, P7; DELITTO A, 1993, PHYS THER, V73, P216, DOI 10.1093/ptj/73.4.216; DEYO RA, 1994, SPINE, V19, pS2032, DOI 10.1097/00007632-199409151-00003; DICKERSIN K, 1996, COCHRANE LIB; DIFABIO RP, 1992, PHYS THER, V72, P853, DOI 10.1093/ptj/72.12.853; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ELLESTAD SM, 1988, J AM OSTEOPATH ASSOC, V88, P991; ELLESTAD SM, 1990, MANUELLE MED, V28, P7; ERHARD RE, 1994, PHYS THER, V74, P1093, DOI 10.1093/ptj/74.12.1093; Ernst E, 2001, J PAIN SYMPTOM MANAG, V22, P879, DOI 10.1016/S0885-3924(01)00337-2; Ernst E, 2000, FAM PRACT, V17, P554, DOI 10.1093/fampra/17.6.554; EVANS DP, 1978, RHEUMATOL REHABIL, V17, P46, DOI 10.1093/rheumatology/17.1.46; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Ferreira ML, 2002, AUST J PHYSIOTHER, V48, P277, DOI 10.1016/S0004-9514(14)60167-7; GEMMELL HA, 1995, J MANIP PHYSIOL THER, V18, P453; GIBSON T, 1985, LANCET, V1, P1258; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; GLOVER JR, 1974, BRIT J IND MED, V31, P59; GODFREY CM, 1984, SPINE, V9, P301, DOI 10.1097/00007632-198404000-00015; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Haas M, 1995, J MANIP PHYSIOL THER, V18, P582; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; Hadler NM, 1990, MANUELLE MED, P2; HEDGES LV, 1984, PSYCHOL BULL, V96, P573, DOI 10.1037/0033-2909.96.3.573; HEDGES LV, 1985, STAT METHODS META AN; Helliwell PS, 1987, PHYSICIAN        APR, P187; Hemmila HM, 1997, ARCH PHYS MED REHAB, V78, P571, DOI 10.1016/S0003-9993(97)90420-2; HERZOG W, 1991, J MANIP PHYSIOL THER, V14, P104; HOEHLER FK, 1981, JAMA-J AM MED ASSOC, V245, P1535; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; Hunt DL, 1997, ANN INTERN MED, V126, P532, DOI 10.7326/0003-4819-126-7-199704010-00006; INDAHL A, 1995, SPINE, V20, P473, DOI 10.1097/00007632-199502001-00011; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; KHALIL TM, 1992, SPINE, V17, P311, DOI 10.1097/00007632-199203000-00012; Kinalski R, 1989, J MANUAL MED, V4, P44; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; KOKJOHN K, 1992, J MANIP PHYSIOL THER, V15, P279; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; Maher, 1993, J MANUAL MANIPULATIV, V1, P142, DOI 10.1179/jmt.1993.1.4.142; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Mood A., 1973, INTRO THEORY STAT; NWUGA VCB, 1982, AM J PHYS MED REHAB, V61, P273; ONGLEY MJ, 1987, LANCET, V2, P143; OTTENBACHER K, 1985, SPINE, V10, P833, DOI 10.1097/00007632-198511000-00010; Pengel HM, 2002, CLIN REHABIL, V16, P811, DOI 10.1191/0269215502cr562oa; Petty N J, 1995, Man Ther, V1, P25, DOI 10.1054/math.1995.0246; POPE MH, 1994, SPINE, V19, P2571, DOI 10.1097/00007632-199411001-00013; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; Rasmussen G. G., 1979, MANUAL MED, V17, P8; Rosenthal R, 1991, METAANALYTIC PROCEDU; RUPERT RL, 1985, ICA INT REV CHIR WIN, P58; SANDERS GE, 1990, J MANIP PHYSIOL THER, V13, P391; *SAS I INC, 1999, SAS STAT SOFTW MAN; SCHEER SJ, 1995, ARCH PHYS MED REHAB, V76, P966, DOI 10.1016/S0003-9993(95)80076-X; Scheer SJ, 1997, ARCH PHYS MED REHAB, V78, P414, DOI 10.1016/S0003-9993(97)90235-5; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Siehl D, 1971, J Am Osteopath Assoc, V70, P433; SIMSWILLIAMS H, 1978, BMJ-BRIT MED J, V2, P1338, DOI 10.1136/bmj.2.6148.1338; SIMSWILLIAMS H, 1979, BMJ-BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.6201.1318; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Skargren EI, 1998, PAIN, V77, P201, DOI 10.1016/S0304-3959(98)00101-8; Skargren EI, 1997, SPINE, V22, P2167, DOI 10.1097/00007632-199709150-00015; *STAT CORP, 1999, STAT STAT SOFTW MAN; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; TERRETT ACJ, 1984, AM J PHYS MED REHAB, V63, P217; TIMM KE, 1994, J ORTHOP SPORT PHYS, V20, P276, DOI 10.2519/jospt.1994.20.6.276; TOBIS JS, 1983, B NEW YORK ACAD MED, V59, P660; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; vanderWeide WE, 1997, SCAND J WORK ENV HEA, V23, P165, DOI 10.5271/sjweh.195; VANTULDER M, 2002, CLIN EVIDENCE; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; VANTULDER MW, 1995, PAIN, V62, P233, DOI 10.1016/0304-3959(94)00272-G; Waagen GN, 1986, MANUAL MED, V2, P63; Waddell G, 1996, SPINE, V21, P2820, DOI 10.1097/00007632-199612150-00002; WATERWORTH RF, 1985, NEW ZEAL MED J, V98, P372; Wreje Ullacarin, 1992, Scandinavian Journal of Primary Health Care, V10, P310, DOI 10.3109/02813439209014080; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176	117	253	257	3	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					871	881		10.7326/0003-4819-138-11-200306030-00008	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779297				2022-12-28	WOS:000183296400002
J	Linacre, A				Linacre, A			The UK National DNA Database	LANCET			English	Editorial Material									Univ Strathclyde, Forens Sci Unit, Glasgow G1 1XW, Lanark, Scotland	University of Strathclyde	Linacre, A (corresponding author), Univ Strathclyde, Forens Sci Unit, Glasgow G1 1XW, Lanark, Scotland.	a.m.t.linacre@strath.ac.uk	Linacre, Adrian/I-5377-2015	Linacre, Adrian/0000-0001-5890-5548				Barbour V, 2003, LANCET, V362, P418, DOI 10.1016/S0140-6736(03)14099-8; Butler J.M., 2001, FORENSIC DNA TYPING; EDWARDS A, 1991, AM J HUM GENET, V49, P746; *FOR SCI SERV, 2001, CAS FIL DNA PROF; *FOR SCI SERV, 1999, INTRO FOR SCI SERV; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; Gill P, 2002, BIOTECHNIQUES, V32, P366, DOI 10.2144/02322rv01; Lincoln PJ, 1997, FORENSIC SCI INT, V88, P23, DOI 10.1016/S0379-0738(97)00080-7; Martin PD, 2001, FORENSIC SCI INT, V119, P225, DOI 10.1016/S0379-0738(00)00436-9; Schneider PM, 2001, FORENSIC SCI INT, V119, P232, DOI 10.1016/S0379-0738(00)00435-7; Williamson R, 2002, NATURE, V418, P585, DOI 10.1038/418585a; 2001, BBC NEWS        0824	12	4	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	2003	361	9372					1841	1842		10.1016/S0140-6736(03)13539-8	http://dx.doi.org/10.1016/S0140-6736(03)13539-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788567				2022-12-28	WOS:000183205800005
J	Skumryev, V; Stoyanov, S; Zhang, Y; Hadjipanayis, G; Givord, D; Nogues, J				Skumryev, V; Stoyanov, S; Zhang, Y; Hadjipanayis, G; Givord, D; Nogues, J			Beating the superparamagnetic limit with exchange bias	NATURE			English	Article							MAGNETIC-PROPERTIES; CO; ANISOTROPY; NANOPARTICLES; FABRICATION; TRANSITION; FILMS	Interest in magnetic nanoparticles has increased in the past few years by virtue of their potential for applications in fields such as ultrahigh-density recording and medicine(1-4). Most applications rely on the magnetic order of the nanoparticles being stable with time. However, with decreasing particle size the magnetic anisotropy energy per particle responsible for holding the magnetic moment along certain directions becomes comparable to the thermal energy. When this happens, the thermal fluctuations induce random flipping of the magnetic moment with time, and the nanoparticles lose their stable magnetic order and become superparamagnetic(5). Thus, the demand for further miniaturization comes into conflict with the superparamagnetism caused by the reduction of the anisotropy energy per particle: this constitutes the so-called 'superparamagnetic limit'(6,7) in recording media. Here we show that magnetic exchange coupling induced at the interface between ferromagnetic and antiferromagnetic systems(8,9) can provide an extra source of anisotropy, leading to magnetization stability. We demonstrate this principle for ferromagnetic cobalt nanoparticles of about 4 nm in diameter that are embedded in either a paramagnetic or an antiferromagnetic matrix. Whereas the cobalt cores lose their magnetic moment at 10 K in the first system, they remain ferromagnetic up to about 290 K in the second. This behaviour is ascribed to the specific way ferromagnetic nanoparticles couple to an antiferromagnetic matrix.	Univ Delaware, Dept Phys & Astron, Newark, DE 19716 USA; CNRS, Lab Louis Neel, F-38042 Grenoble, France; Univ Autonoma Barcelona, ICREA, Bellaterra 08193, Spain; Univ Autonoma Barcelona, Dept Fis, Bellaterra 08193, Spain	University of Delaware; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Autonomous University of Barcelona; ICREA; Autonomous University of Barcelona	Skumryev, V (corresponding author), Univ Delaware, Dept Phys & Astron, Newark, DE 19716 USA.	vassil@udel.edu	Nogues, Josep/D-7791-2012; Skumryev, Vassil/B-1440-2012	Nogues, Josep/0000-0003-4616-1371; Skumryev, Vassil/0000-0003-1375-4824	ICREA Funding Source: Custom	ICREA(ICREA)		CHIKAZUMI S, 1997, PHYSICS FERROMAGNETI; COEY JMD, 1971, PHYS REV LETT, V27, P1140, DOI 10.1103/PhysRevLett.27.1140; GANGOPADHYAY S, 1993, J APPL PHYS, V73, P6964, DOI 10.1063/1.352398; Garcia-Otero J, 2000, PHYS REV LETT, V84, P167, DOI 10.1103/PhysRevLett.84.167; Gu E, 1999, PHYS REV B, V60, P4092, DOI 10.1103/PhysRevB.60.4092; HABERLAND H, 1992, J VAC SCI TECHNOL A, V10, P3266, DOI 10.1116/1.577853; Hafeli U., 1997, SCI CLIN APPL MAGNET; Held GA, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.012408; Jensen PJ, 2001, APPL PHYS LETT, V78, P2190, DOI 10.1063/1.1362282; KANAMORI J, 1957, PROG THEOR PHYS, V17, P177, DOI 10.1143/PTP.17.177; Kodama RH, 1999, J MAGN MAGN MATER, V200, P359, DOI 10.1016/S0304-8853(99)00347-9; Kodama RH, 1997, PHYS REV LETT, V79, P1393, DOI 10.1103/PhysRevLett.79.1393; Liu K, 2002, APPL PHYS LETT, V81, P4434, DOI 10.1063/1.1526458; Luis F, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.217205; Lund MS, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.054422; Martin JI, 2003, J MAGN MAGN MATER, V256, P449, DOI 10.1016/S0304-8853(02)00898-3; MEIKLEJOHN WH, 1956, PHYS REV, V102, P1413, DOI 10.1103/PhysRev.102.1413; Murray CB, 2001, MRS BULL, V26, P985, DOI 10.1557/mrs2001.254; Nogues J, 1999, J MAGN MAGN MATER, V192, P203, DOI 10.1016/S0304-8853(98)00266-2; Parent F, 1997, PHYS REV B, V55, P3683, DOI 10.1103/PhysRevB.55.3683; Peng DL, 2000, PHYS REV B, V61, P3103, DOI 10.1103/PhysRevB.61.3103; Sako S, 2001, J PHYS SOC JPN, V70, P2134, DOI 10.1143/JPSJ.70.2134; Schulthess TC, 1998, PHYS REV LETT, V81, P4516, DOI 10.1103/PhysRevLett.81.4516; Sort J, 1999, APPL PHYS LETT, V75, P3177, DOI 10.1063/1.125269; Stamps RL, 2000, J PHYS D APPL PHYS, V33, pR247, DOI 10.1088/0022-3727/33/23/201; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Takano K, 1997, PHYS REV LETT, V79, P1130, DOI 10.1103/PhysRevLett.79.1130; Thompson DA, 2000, IBM J RES DEV, V44, P311, DOI 10.1147/rd.443.0311; Weller D, 1999, IEEE T MAGN, V35, P4423, DOI 10.1109/20.809134; Woods SI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.137205	30	1364	1390	3	460	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					850	853		10.1038/nature01687	http://dx.doi.org/10.1038/nature01687			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815426				2022-12-28	WOS:000183585300040
J	Uemura, M; Kato, T; Ishioka, R; Yamaoka, H; Monard, B; Nogami, D; Maehara, H; Sugie, A; Takahashi, S				Uemura, M; Kato, T; Ishioka, R; Yamaoka, H; Monard, B; Nogami, D; Maehara, H; Sugie, A; Takahashi, S			Structure in the early afterglow light curve of the gamma-ray burst of 29 March 2003	NATURE			English	Article							EARLY OPTICAL-EMISSION; GRB 990510; PREDICTIONS	Gamma-ray bursts (GRBs) are energetic explosions that for 0.01-100 s are the brightest gamma-ray sources in the sky(1,2). Observations of the early evolution of afterglows are expected to provide clues about the nature of the bursts, but their rapid fading has hampered such studies; some recent rapid localizations(3-5) of bursts have improved the situation. Here we report an early detection of the very bright afterglow of the burst of 29 March 2003 (GRB030329). Our data show that, even early in the afterglow phase, the light curve shows unexpectedly complicated structures superimposed on the fading background.	Kyoto Univ, Dept Astron, Kyoto 6068502, Japan; Kyushu Univ, Fac Sci, Fukuoka 8108560, Japan; Bronberg Observ, ZA-0056 Tiegerpoort, South Africa; Kyoto Univ, Hida Observ, Gifu 5061314, Japan; VSOLJ, Kawaguchi, Saitama 3320034, Japan; Dun Astron Observ, Shiga 5220341, Japan	Kyoto University; Kyushu University; National Research Foundation - South Africa; Kyoto University	Uemura, M (corresponding author), Kyoto Univ, Dept Astron, Kyoto 6068502, Japan.	uemura@kusastro.kyoto-u.ac.jp	Nogami, Daisaku/Q-8582-2019	Uemura, Makoto/0000-0002-7375-7405				Beuermann K, 1999, ASTRON ASTROPHYS, V352, pL26; CALDWELL N, 2003, 2053 GRB; Fox DW, 2003, NATURE, V422, P284, DOI 10.1038/nature01504; Fox DW, 2003, ASTROPHYS J, V586, pL5, DOI 10.1086/374683; Frail DA, 2001, ASTROPHYS J, V562, pL55, DOI 10.1086/338119; Galama TJ, 1998, ASTROPHYS J, V497, pL13, DOI 10.1086/311268; Garnavich PM, 2000, ASTROPHYS J, V544, pL11, DOI 10.1086/317297; GREINER J, 2003, 2020 GRB; MALESANI D, 2002, 1607 GRB; Nakar E, 2003, NEW ASTRON, V8, P495, DOI 10.1016/S1384-1076(03)00044-7; PETERSON BA, 2003, 1985 GRB; Piro L, 1998, ASTRON ASTROPHYS, V331, pL41; Reichart DE, 1999, ASTROPHYS J, V521, pL111, DOI 10.1086/312203; Rhoads JE, 1999, ASTROPHYS J, V525, P737, DOI 10.1086/307907; Sari R, 1999, ASTROPHYS J, V520, P641, DOI 10.1086/307508; Sari R, 1998, ASTROPHYS J, V497, pL17, DOI 10.1086/311269; Stanek KZ, 1999, ASTROPHYS J, V522, pL39, DOI 10.1086/312219; STANEK KZ, IN PRESS ASTROPHYS J; Tinney C., 1998, 6896 IAU; TORII K, 2003, 1986 GRB; UEMURA M, 2003, 1989 GRB; VANDERSPEK R, 2003, 1997 GRB; Waxman E, 1997, ASTROPHYS J, V485, pL5, DOI 10.1086/310809; WEIDONG L, 2003, ASTROPHYS J, V586, pL9; Wijers R., 1997, MNRAS, V288, P51	25	51	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					843	844		10.1038/nature01735	http://dx.doi.org/10.1038/nature01735			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815423	Green Submitted			2022-12-28	WOS:000183585300037
J	Young-Fadok, TM; Farrugia, G				Young-Fadok, TM; Farrugia, G			Cholinergic denervation in diverticular disease	LANCET			English	Editorial Material									Mayo Clin, Div Colon & Rectal Surg, Rochester, MN 55905 USA; Mayo Clin, Enter Neurosci Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Young-Fadok, TM (corresponding author), Mayo Clin, Div Colon & Rectal Surg, Rochester, MN 55905 USA.	youngfadok.tonia@mayo.edu						American Gastroenterological Association, 2001, BURD GASTR DIS; Belmonte C, 1996, ARCH SURG-CHICAGO, V131, P612; Eglen RM, 2001, LIFE SCI, V68, P2573, DOI 10.1016/S0024-3205(01)01054-2; He CL, 2000, GASTROENTEROLOGY, V118, P14, DOI 10.1016/S0016-5085(00)70409-4; PAINTER NS, 1975, CLIN GASTROENTEROL, V4, P1; PARKS TG, 1975, CLIN GASTROENTEROL, V4, P53	6	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1923	1924		10.1016/S0140-6736(03)13599-4	http://dx.doi.org/10.1016/S0140-6736(03)13599-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801731				2022-12-28	WOS:000183359700003
J	Hasnaoui, A; Van Swygenhoven, H; Derlet, PM				Hasnaoui, A; Van Swygenhoven, H; Derlet, PM			Dimples on nanocrystalline fracture surfaces as evidence for shear plane formation	SCIENCE			English	Article							DEFORMATION; DUCTILITY; METALS	Tensile experiments of fully dense nanocrystalline structures with a mean grain size of less than 100 nanometers demonstrate a considerable increase in hardness but a remarkable drop in elongation-to-failure, indicating brittle behavior. However, dimple structures are often observed at the fracture surface, indicating some type of ductile fracture mechanism. Guided by large-scale atomistic simulations, we propose that these dimple structures result from local shear planes formed around clustered grains that, because of their particular misorientation, cannot participate in the grain boundary accommodation processes necessary to sustain plastic deformation. This raises the expectation that general high-angle grain boundaries are necessary for good ductility.	Paul Scherrer Inst, CH-5232 Villigen, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Van Swygenhoven, H (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.	helena.vs@psi.ch	hasnaoui, A./V-3598-2019; Van Swygenhoven, Helena/GZL-0225-2022	hasnaoui, A./0000-0002-7050-1535; 				Derlet PM, 2002, SCRIPTA MATER, V47, P719, DOI 10.1016/S1359-6462(02)00182-3; Farkas D, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.060101; Hahn H, 1997, PHILOS MAG B, V76, P559, DOI 10.1080/01418639708241122; Hasnaoui A, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.184112; Koch CC, 1999, MRS BULL, V24, P54, DOI 10.1557/S0883769400051551; Kumar KS, 2003, ACTA MATER, V51, P5743, DOI 10.1016/j.actamat.2003.08.032; Sanders PG, 1997, MAT SCI ENG A-STRUCT, V234, P77, DOI 10.1016/S0921-5093(97)00185-8; Schiotz J, 1999, PHYS REV B, V60, P11971, DOI 10.1103/PhysRevB.60.11971; Valiev RZ, 2002, J MATER RES, V17, P5, DOI 10.1557/JMR.2002.0002; Valiev RZ, 2000, PROG MATER SCI, V45, P103, DOI 10.1016/S0079-6425(99)00007-9; Van Petegem S, 2003, SCRIPTA MATER, V48, P17, DOI 10.1016/S1359-6462(02)00322-6; Van Swygenhoven H, 2000, PHYS REV B, V62, P831, DOI 10.1103/PhysRevB.62.831; Van Swygenhoven H, 2002, SCIENCE, V296, P66; Van Swygenhoven H, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.024101; Van Swygenhoven H, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.224105; VINOGRADOV A, 1999, J METAST NANOCRYST M, V2, P607; Wang YM, 2002, APPL PHYS LETT, V80, P2395, DOI 10.1063/1.1465528; Weertman JR, 2002, MECH BEHAV NANOCRYST; Wei Q, 2002, APPL PHYS LETT, V81, P1240, DOI 10.1063/1.1501158; Yamakovl V., 2002, NAT MATER, V1, P1; ZELIN MG, 1994, ACTA METALL MATER, V42, P119, DOI 10.1016/0956-7151(94)90054-X	21	190	194	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1550	1552		10.1126/science.1084284	http://dx.doi.org/10.1126/science.1084284			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791986				2022-12-28	WOS:000183333100048
J	van der Meijde, M; Marone, F; Giardini, D; van der Lee, S				van der Meijde, M; Marone, F; Giardini, D; van der Lee, S			Seismic evidence for water deep in earth's upper mantle	SCIENCE			English	Article							VELOCITY STRUCTURE; KM DISCONTINUITY; GAMMA-PHASE; BETA-PHASE; TRANSFORMATION; TOPOGRAPHY; SHARPNESS; MG2SIO4; MAGMAS; H2O	Water in the deep upper mantle can influence the properties of seismic discontinuities in the mantle transition zone. Observations of converted seismic waves provide evidence of a 20- to 35-kilometer-thick discontinuity near a depth of 410 kilometers, most likely explained by as much as 700 parts per million of water by weight.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Geophys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	van der Meijde, M (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Geophys, CH-8093 Zurich, Switzerland.		Giardini, Domenico/F-5406-2011; van der Lee, Suzan/GXN-3758-2022; van der Lee, Suzan/K-1144-2013; Marone, Federica/J-4420-2013; van der Meijde, Mark/AAJ-2787-2020; van der Meijde, Mark/D-3883-2009	van der Lee, Suzan/0000-0003-1884-1185; van der Meijde, Mark/0000-0002-8762-585X; van der Meijde, Mark/0000-0002-8762-585X				AKAOGI M, 1989, J GEOPHYS RES-SOLID, V94, P15671, DOI 10.1029/JB094iB11p15671; BENZ HM, 1993, NATURE, V365, P147, DOI 10.1038/365147a0; Bijwaard H, 1998, J GEOPHYS RES-SOL EA, V103, P30055, DOI 10.1029/98JB02467; BINA CR, 1994, J GEOPHYS RES-SOL EA, V99, P15853, DOI 10.1029/94JB00462; Chevrot S, 1999, J GEOPHYS RES-SOL EA, V104, P20203, DOI 10.1029/1999JB900087; Deuss A, 2001, SCIENCE, V294, P354, DOI 10.1126/science.1063524; Frost DJ, 1998, J GEOPHYS RES-SOL EA, V103, P7463, DOI 10.1029/98JB00077; Gudfinnsson GH, 1998, AM MINERAL, V83, P1037; HANKA W, 2001, EOS, V82, P910; Helffrich GR, 1996, GEOPHYS J INT, V126, pF7, DOI 10.1111/j.1365-246X.1996.tb05292.x; Higo Y, 2001, GEOPHYS RES LETT, V28, P3505, DOI 10.1029/2001GL013194; Inoue T, 1998, EARTH PLANET SC LETT, V160, P107, DOI 10.1016/S0012-821X(98)00077-6; Kohlstedt DL, 1996, CONTRIB MINERAL PETR, V123, P345, DOI 10.1007/s004100050161; MARONE F, UNPUB; Oncken O, 1999, NATURE, V397, P341, DOI 10.1038/16909; PAULSSEN H, 1988, J GEOPHYS RES-SOLID, V93, P10489, DOI 10.1029/JB093iB09p10489; Pino NA, 1997, J GEOPHYS RES-SOL EA, V102, P2953, DOI 10.1029/96JB03461; SIGMARSSON O, 1990, NATURE, V346, P163, DOI 10.1038/346163a0; Smyth J.R., 2002, GEOPHYS RES LETT, V29, P123; THOMPSON AB, 1992, NATURE, V358, P295, DOI 10.1038/358295a0; Ulmer P, 2001, PHYS EARTH PLANET IN, V127, P215, DOI 10.1016/S0031-9201(01)00229-1; van der Lee S, 2001, J GEOPHYS RES-SOL EA, V106, P30821, DOI 10.1029/2001JB000338; VANDERLEE S, 1994, PHYS EARTH PLANET IN, V86, P147, DOI 10.1016/0031-9201(94)05066-X; VANDERLEE S, 2001, EOS T AGU, V82, P637, DOI DOI 10.1029/01E000367; WOOD BJ, 1995, SCIENCE, V268, P74, DOI 10.1126/science.268.5207.74; YAMAZAKI A, 1994, GEOPHYS RES LETT, V21, P1811, DOI 10.1029/94GL01418; ZIELHUIS A, 1994, SCIENCE, V265, P79, DOI 10.1126/science.265.5168.79	27	128	128	5	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1556	1558		10.1126/science.1083636	http://dx.doi.org/10.1126/science.1083636			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791988				2022-12-28	WOS:000183333100050
J	Aravanis, AM; Pyle, JL; Tsien, RW				Aravanis, AM; Pyle, JL; Tsien, RW			Single synaptic vesicles fusing transiently and successively without loss of identity	NATURE			English	Article							FROG NEUROMUSCULAR JUNCTION; READILY RELEASABLE POOL; RETINAL BIPOLAR CELLS; HIPPOCAMPAL SYNAPSES; NERVE-TERMINALS; ENDOCYTOSIS; MEMBRANE; EXOCYTOSIS; TRANSMITTER; TURNOVER	Vesicle fusion and recycling are particularly critical for ongoing neurotransmitter release(1-4) in the small nerve terminals of the brain, which typically contain about 30 functional vesicles(4,5). However, the modes of exocytosis and endocytosis that operate at synapses of the central nervous system are incompletely understood. Here we show real-time visualization of a single vesicle fusing at a small synapse of the central nervous system, made possible by highly intensified charge-coupled device imaging of hippocampal synaptic terminals, in which a single vesicle was labelled with the fluorescent membrane marker FM1-43 (ref. 6). In a small number of cases, full loss of fluorescent membrane dye was elicited by a single action potential, consistent with classical complete collapse(1). In most cases, however, action potentials triggered only partial loss of fluorescence, suggesting vesicular retention of membrane marker, consistent with 'kiss-and-run' vesicle cycling(3,4,7-9). An alternative hypothesis of independent fusion of partially stained vesicles arising from endosomal splitting could be excluded by observations on the size and timing of successive fusion events. Thus, our experimental evidence supports a predominance of kiss-and-run fusion events(10-12) and rapid vesicular re-use(11).	Stanford Univ, Beckman Ctr, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA	Stanford University; Stanford University	Tsien, RW (corresponding author), Stanford Univ, Beckman Ctr, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.							CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; Murthy VN, 1999, NAT NEUROSCI, V2, P503, DOI 10.1038/9149; Neves G, 1999, J PHYSIOL-LONDON, V515, P181, DOI 10.1111/j.1469-7793.1999.181ad.x; Palfrey HC, 1998, NEUROSCIENCE, V83, P969, DOI 10.1016/S0306-4522(97)00453-3; Pyle JL, 2000, NEURON, V28, P221, DOI 10.1016/S0896-6273(00)00098-2; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; Sara Y, 2002, J NEUROSCI, V22, P1608, DOI 10.1523/JNEUROSCI.22-05-01608.2002; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Stevens CF, 1999, NEURON, V24, P1017, DOI 10.1016/S0896-6273(00)81047-8; Sudhof TC, 2000, NEURON, V28, P317, DOI 10.1016/S0896-6273(00)00109-4; Sun JY, 2002, NATURE, V417, P555, DOI 10.1038/417555a; Zenisek D, 2002, NEURON, V35, P1085, DOI 10.1016/S0896-6273(02)00896-6	23	309	316	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					643	647		10.1038/nature01686	http://dx.doi.org/10.1038/nature01686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789339				2022-12-28	WOS:000183301200041
J	Cyranoski, D				Cyranoski, D			Japanese team makes stem cells	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					577	577		10.1038/423577b	http://dx.doi.org/10.1038/423577b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789307	Bronze			2022-12-28	WOS:000183301200012
J	Hamilton, AS; Mack, TM				Hamilton, AS; Mack, TM			Puberty and genetic susceptibility to breast cancer in a case-control study in twins	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONAL RISK-FACTORS; FAMILY HISTORY; WOMEN; EPIDEMIOLOGY; CARCINOGENESIS; CARCINOMA; PROSTATE; MAMMARY	BACKGROUND: Breast cancer is thought to result from excessive cumulative exposure to ovarian hormones. Different predictors of hereditary and sporadic breast cancer suggest different pathogenic mechanisms. Affected twin pairs may help to illustrate such differences. METHODS: We obtained information from 1811 pairs of female twins, one or both of whom had breast cancer. The pairs were stratified according to concordance or discordance for breast cancer, zygosity, the presence or absence of a family history of breast cancer, and the presence of bilateral or unilateral disease. Disease-concordant monozygotic pairs were assumed to have a higher genetic susceptibility than other subgroups of pairs. Paired twins were compared with respect to age at puberty and other factors. We calculated adjusted odds ratios for the diagnosis of breast cancer when only one twin was affected and for the first of the two diagnoses when both were affected. RESULTS: Within disease-discordant monozygotic pairs, the twin with an earlier onset of puberty did not have an increased risk of breast cancer (adjusted odds ratio, 0.8; 95 percent confidence interval, 0.6 to 1.2). Within disease-concordant monozygotic pairs, the twin with earlier puberty was much more likely to receive the diagnosis first (adjusted odds ratio, 5.4; 95 percent confidence interval, 2.0 to 14.5). In contrast, a later first pregnancy, lower parity, and later menopause within the pair were associated with an increased risk of breast cancer when one twin was affected but did not predict an earlier diagnosis when both were affected. CONCLUSIONS: Within the most genetically susceptible subgroup of twin pairs, the strong influence of earlier puberty on the age at the diagnosis of breast cancer and the absence of linkage to hormonal milestones later in life suggest that most cases of hereditary breast cancer are not related to cumulative hormone exposure and that they may instead result from an unusual sensitivity to pubertal hormones. Associations between breast cancer and early menarche and those with reproductive milestones in adulthood may reflect different genotypes.	Univ So Calif, Norris Comprehens Canc Ctr, Keck SCh Med, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California	Hamilton, AS (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, Keck SCh Med, Dept Prevent Med, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.				NATIONAL CANCER INSTITUTE [R35CA042581, R01CA032262] Funding Source: NIH RePORTER; NCI NIH HHS [CA32262, CA42581] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adami H O, 1990, Int J Cancer Suppl, V5, P22; Aisenberg AC, 1997, CANCER, V79, P1203, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO;2-2; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; APTER D, 1989, INT J CANCER, V44, P783, DOI 10.1002/ijc.2910440506; BRINTON LA, 1982, J NATL CANCER I, V69, P817; Buchholz TA, 1999, RADIAT ONCOL INVESTI, V7, P55, DOI 10.1002/(SICI)1520-6823(1999)7:2<55::AID-ROI1>3.0.CO;2-#; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; Egan KM, 1998, CANCER EPIDEM BIOMAR, V7, P359; Ekbom A, 1998, SEMIN CANCER BIOL, V8, P237, DOI 10.1006/scbi.1998.0073; Ekbom A, 1997, JNCI-J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71; FAIMAN C, 1976, CLIN OBSTET GYNAECOL, V3, P467; FISHMAN J, 1983, CANCER RES, V43, P1884; Hamilton AS, 2000, AM J EPIDEMIOL, V152, P1093, DOI 10.1093/aje/152.11.1093; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427; HENDERSON BE, 1996, CANC EPIDEMIOLOGY PR, P1022; Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S; Mack T M, 2000, Twin Res, V3, P33, DOI 10.1375/136905200320565670; Mack TM, 2002, BRIT J CANCER, V87, P294, DOI 10.1038/sj.bjc.6600429; Magnusson C, 1998, CANCER CAUSE CONTROL, V9, P259, DOI 10.1023/A:1008817018942; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MILLER AB, 1986, INT J CANCER, V37, P173, DOI 10.1002/ijc.2910370202; MOOLGAVKAR SH, 1980, J NATL CANCER I, V65, P559; MURATA M, 1982, J NATL CANCER I, V69, P1229; NEYZI O, 1975, ANN HUM BIOL, V2, P49, DOI 10.1080/03014467500000561; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; Russo J, 1999, ONCOL RES, V11, P169; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; Shull JD, 1997, CARCINOGENESIS, V18, P1595, DOI 10.1093/carcin/18.8.1595; Swerdlow AJ, 2002, J NATL CANCER I, V94, P1238, DOI 10.1093/jnci/94.16.1238; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z	32	80	82	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2313	2322		10.1056/NEJMoa021293	http://dx.doi.org/10.1056/NEJMoa021293			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788995				2022-12-28	WOS:000183296300006
J	Turner, JL; Beck, SC; Crosthwaite, LP; Larkin, JE; McLean, IS; Meier, DS				Turner, JL; Beck, SC; Crosthwaite, LP; Larkin, JE; McLean, IS; Meier, DS			An extragalactic supernebula confined by gravity	NATURE			English	Article							H-II REGIONS; STAR-FORMING GALAXIES; NGC 5253; INFRARED-EMISSION; RADIO SUPERNEBULA; NGC-5253; GAS; ALPHA; POPULATION; STARBURST	Little is known about the origins of globular clusters, which contain hundreds of thousands of stars in a volume only a few light years across. Radiation pressure and winds from luminous young stars should disperse the star-forming gas and disrupt the formation of the cluster. Globular clusters in our Galaxy cannot provide answers; they are billions of years old. Here we report the measurement of infrared hydrogen recombination lines from a young, forming super star cluster in the dwarf galaxy NGC5253. The lines arise in gas heated by a cluster of about one million stars, including 4,000 -6,000 massive, hot 'O' stars(1,2). It is so young that it is still enshrouded in gas and dust, hidden from optical view(1,3-5 .) The gases within the cluster seem bound by gravity, which may explain why the windy and luminous O stars have not yet blown away those gases. Young clusters in 'starbursting' galaxies in the local and distant Universe may also be gravitationally confined and cloaked from view.	Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; Tel Aviv Univ, Sch Phys & Astron, Raymond & Beverly Sackler Fac Exact Sci, Ramat Aviv, Israel; Astute Networks, San Diego, CA 92127 USA; Univ Illinois, Dept Astron, Urbana, IL 61801 USA	University of California System; University of California Los Angeles; Tel Aviv University; University of Illinois System; University of Illinois Urbana-Champaign	Turner, JL (corresponding author), Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA.	turner@astro.ucla.edu		Beck, Sara/0000-0002-5770-8494; Meier, David/0000-0001-9436-9471				Beck SC, 1996, ASTROPHYS J, V457, P610, DOI 10.1086/176757; CALDWELL N, 1989, ASTROPHYS J, V338, P789, DOI 10.1086/167236; CHU YH, IN PRESS IAU S, V212; De Pree CG, 2000, ASTROPHYS J, V540, P308, DOI 10.1086/309315; Gorjian V, 2001, ASTROPHYS J, V554, pL29, DOI 10.1086/320923; GORJIAN V, 1996, ASTRON J, V1120, P1186; HARTMANN LW, 1984, ASTROPHYS J, V287, P487, DOI 10.1086/162707; KAWARA K, 1989, ASTROPHYS J, V337, P230, DOI 10.1086/167099; KENNICUTT RC, 1988, ASTRON J, V95, P720, DOI 10.1086/114669; Kunth D, 1998, ASTRON ASTROPHYS, V334, P11; MARTIN CL, 1995, ASTROPHYS J, V447, P171, DOI 10.1086/175863; McLean IS, 2000, P SOC PHOTO-OPT INS, V4008, P1048, DOI 10.1117/12.395422; MEIER DL, 1981, ASTROPHYS J, V246, pL109, DOI 10.1086/183565; Meier DS, 2002, ASTRON J, V124, P877, DOI 10.1086/341752; Melnick J, 1999, MON NOT R ASTRON SOC, V302, P677, DOI 10.1046/j.1365-8711.1999.02114.x; MILLS BY, 1978, MON NOT R ASTRON SOC, V185, P263, DOI 10.1093/mnras/185.2.263; Mohan NR, 2001, ASTROPHYS J, V557, P659, DOI 10.1086/322265; MOORWOOD AFM, 1982, ASTRON ASTROPHYS, V115, P84; RIEKE GH, 1985, ASTROPHYS J, V288, P618, DOI 10.1086/162827; Steidel CC, 1996, ASTROPHYS J, V462, pL17, DOI 10.1088/1538-4357/462/1/L17; STOREY PJ, 1995, MON NOT R ASTRON SOC, V272, P41, DOI 10.1093/mnras/272.1.41; Tenorio-Tagle G, 1999, MON NOT R ASTRON SOC, V309, P332, DOI 10.1046/j.1365-8711.1999.02809.x; Tremonti CA, 2001, ASTROPHYS J, V555, P322, DOI 10.1086/321436; Turner JL, 1998, ASTRON J, V116, P1212, DOI 10.1086/300485; Turner JL, 2000, ASTROPHYS J, V532, pL109, DOI 10.1086/312586; Walborn NR, 1999, IAU SYMP, P213; WALSH JR, 1989, MON NOT R ASTRON SOC, V239, P297, DOI 10.1093/mnras/239.2.297; WOOD DOS, 1989, ASTROPHYS J, V340, P265, DOI 10.1086/167390	29	57	57	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					621	623		10.1038/nature01689	http://dx.doi.org/10.1038/nature01689			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789332	Bronze, Green Submitted			2022-12-28	WOS:000183301200034
J	Aisen, PS; Schafer, KA; Grundman, M; Pfeiffer, E; Sano, M; Davis, KL; Farlow, MR; Jin, S; Thomas, RG; Thal, LJ				Aisen, PS; Schafer, KA; Grundman, M; Pfeiffer, E; Sano, M; Davis, KL; Farlow, MR; Jin, S; Thomas, RG; Thal, LJ		Alzheimer's Dis Cooperative Study	Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE-2 EXPRESSION; TRANSGENIC MICE; DOUBLE-BLIND; MOUSE MODEL; INFLAMMATION; PATHOLOGY; DEMENTIA; RISK	Context Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease. Objective To determine whether treatment with a selective cyclooxygenase (COX) -2 inhibitor (rofecoxib) or a traditional nonselective NSAID (naproxen) slows cognitive decline in patients with mild-to-moderate AD. Design Multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with 1-year exposure to study medications. Setting Forty ambulatory treatment centers affiliated with the Alzheimer's Disease Cooperative Study consortium: Participants Participants with mild-to-moderate AD (Mini-Mental State Examination score of 13-26) were recruited from December 1999 to November 2000 using clinic populations, referrals from community physicians, and local advertising. Stable use of cholinesterase inhibitors, estrogen, low-dose aspirin, and vitamin E was allowed. Participants with inflammatory diseases that might respond to the study medications were excluded. Of 474 participants screened, 351 were enrolled. Interventions Once-daily rofecoxib, 25 mg, or twice-daily naproxen sodium, 220 mg, or placebo. Main Outcome Measures The primary outcome measure was the 1-year change in the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score. Secondary outcome measures included the Clinical Dementia Rating scale sum-of-boxes the Neuropsychiatric Inventory, the Quality of Life-AD and the time to attainment of significant end points (4-point decline from baseline ADAS-Cog score, 1-step worsening on the global Clinical Dementia Rating scale, 15-point decline on the ADCS activities of daily living inventory, institutionalization, or death). Results The 1-year mean (SD) change in ADAS-Cog scores in participants treated with naproxen (5.8 [8.0]) or rofecoxib (7.6 [7.7]) was not significantly different from the change in participants treated with placebo (5.7 [8.2]). Results of secondary analyses showed no consistent benefit of either treatment. Fatigue, dizziness, and hypertension were more commonly reported in the active drug groups, and more serious adverse events were found in the active treatment group than in the placebo group. Conclusion The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD.	Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; Univ S Florida, Coll Med, Suncoast Gerontol Ctr, Tampa, FL USA; Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA	Georgetown University; University of California System; University of California San Diego; State University System of Florida; University of South Florida; Icahn School of Medicine at Mount Sinai; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California San Diego	Aisen, PS (corresponding author), Georgetown Univ, Med Ctr, Dept Neurol, Bldg D,Suite 207,4000 Reservoir Rd NW, Washington, DC 20057 USA.	psa@georgetown.edu			NCRR NIH HHS [5 M01-RR13297] Funding Source: Medline; NIA NIH HHS [U01-AG10483, U19 AG010483] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR013297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U19AG010483, U01AG010483] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen PS, 2000, NEUROLOGY, V54, P588, DOI 10.1212/WNL.54.3.588; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Andreasson KI, 2001, J NEUROSCI, V21, P8198; Bazan NG, 2002, J BIOL CHEM, V277, P30359, DOI 10.1074/jbc.M203201200; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Ho L, 2001, ARCH NEUROL-CHICAGO, V58, P487, DOI 10.1001/archneur.58.3.487; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197-4580(01)00299-8; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Logsdon R.G., 1999, J MENTAL HLTH AGING, V5, P21, DOI DOI 10.1037/T03352-000; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Van Gool WA, 2001, LANCET, V358, P455, DOI 10.1016/S0140-6736(01)05623-9; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xiang ZM, 2002, NEUROBIOL AGING, V23, P327, DOI 10.1016/S0197-4580(01)00282-2; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; PREVENTION ALZHEIMER	28	731	778	1	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2819	2826		10.1001/jama.289.21.2819	http://dx.doi.org/10.1001/jama.289.21.2819			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KH	12783912	Bronze			2022-12-28	WOS:000183205500030
J	Boustani, M; Peterson, B; Hanson, L; Harris, R; Lohr, KN				Boustani, M; Peterson, B; Hanson, L; Harris, R; Lohr, KN			Screening for dementia in primary care: A summary of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							MENTAL-STATE-EXAMINATION; MILD COGNITIVE IMPAIRMENT; CLOCK DRAWING TEST; QUALITY STANDARDS SUBCOMMITTEE; ALZHEIMERS-DISEASE PATIENTS; VERBAL-LEARNING TEST; DOUBLE-BLIND; VASCULAR DEMENTIA; CONTROLLED-TRIAL; GINKGO-BILOBA	Background: Dementia is a large and growing problem but is often not diagnosed in its earlier stages. Screening and earlier treatment could reduce the burden of suffering of this syndrome. Purpose: To review the evidence of benefits and harms of screening for and earlier treatment of dementia. Data Sources: MEDLINE, PsycINFO, EMBASE, the Cochrane Library, experts, and bibliographies of reviews. Study Selection: The authors developed eight key questions representing a logical chain between screening and improved health outcomes, along with eligibility criteria for admissible evidence for each question. Admissible evidence was obtained by searching the data sources. Data Extraction: Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to U.S. Preventive Services Task Force criteria. Data Synthesis: No randomized, controlled trial of screening for dementia has been completed. Brief screening tools can detect some persons with early dementia (positive predictive value less than or equal to50%). Six to 12 months of treatment with cholinesterase inhibitors modestly slows the decline of cognitive and global clinical change scores in some patients with mild to moderate Alzheimer disease. Function is minimally affected, and fewer than 20% of patients stop taking cholinesterase inhibitors because of side effects. Only limited evidence indicates that any other pharmacologic or nonpharmacologic intervention slows decline in persons with early dementia. Although intensive multicomponent caregiver interventions may delay nursing home placement of patients who have caregivers, the relevance of this finding for persons who do not yet have caregivers is uncertain. Other potential benefits and harms of screening have not been studied. Conclusions: Screening tests can detect undiagnosed dementia. In persons with mild to moderate clinically detected Alzheimer disease, cholinesterase inhibitors are somewhat effective in slowing cognitive decline. The effect of cholinesterase inhibitors or other treatments on persons with dementia detected by screening is uncertain.	Indiana Univ, Sch Med, Indianapolis, IN 46202 USA; Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; RTI Int, Res Triangle Pk, NC USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of New Mexico; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Research Triangle Institute	Boustani, M (corresponding author), Indiana Univ, Sch Med, Indianapolis, IN 46202 USA.		Boustani, Malaz/Q-3850-2019	Boustani, Malaz/0000-0003-0330-677X; Hanson, Laura/0000-0001-5120-6058; Lohr, Kathleen/0000-0002-3825-0713	PHS HHS [290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aisen PS, 2000, NEUROLOGY, V54, P588, DOI 10.1212/WNL.54.3.588; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Auchus AP, 1997, J NEUROPSYCH CLIN N, V9, P591; Barberger-Gateau P, 1999, J AM GERIATR SOC, V47, P456, DOI 10.1111/j.1532-5415.1999.tb07239.x; Belle SH, 1996, NEUROEPIDEMIOLOGY, V15, P321, DOI 10.1159/000109922; Birks J, 2000, COCHRANE DB SYST REV; Birks JS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001191.pub3; Birks JS, 2000, COCHRANE DB SYST REV; Blacker D, 1998, ARCH NEUROL-CHICAGO, V55, P294, DOI 10.1001/archneur.55.3.294; BOUSTANI M, 2002, SCREENING DEMENTIA S; BRAEKHUS A, 1995, J AM GERIATR SOC, V43, P656, DOI 10.1111/j.1532-5415.1995.tb07201.x; Brodaty H, 1998, ALZ DIS ASSOC DIS, V12, P1, DOI 10.1097/00002093-199803000-00001; Brodaty H, 1997, INT J GERIATR PSYCH, V12, P183; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Brooks J O 3rd, 1993, Int Psychogeriatr, V5, P135, DOI 10.1017/S1041610293001474; BURNS A, 1990, BRIT J PSYCHIAT, V157, P72, DOI 10.1192/bjp.157.1.72; Burns A, 1999, DEMENT GERIATR COGN, V10, P237, DOI 10.1159/000017126; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; Cooper B, 1996, PSYCHOL MED, V26, P411, DOI 10.1017/S0033291700034802; COSTA PT, 1996, AHCPR PUBLICATION, V702; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Davidson M, 2000, INT PSYCHOGERIATR, V12, P271, DOI 10.1017/S1041610200007134; Demers L, 2000, J GERIATR PSYCH NEUR, V13, P161, DOI 10.1177/089198870001300401; Devanand DP, 1998, AM J PSYCHIAT, V155, P1512, DOI 10.1176/ajp.155.11.1512; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; Dunkin JJ, 1998, NEUROLOGY, V51, pS53, DOI 10.1212/WNL.51.1_Suppl_1.S53; Eefsting JA, 1996, PSYCHOL MED, V26, P1223, DOI 10.1017/S0033291700035947; Erkinjuntti T, 2002, LANCET, V359, P1283, DOI 10.1016/S0140-6736(02)08267-3; Erkinjuntti T, 1997, NEW ENGL J MED, V337, P1667, DOI 10.1056/NEJM199712043372306; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; EVANS DA, 1991, AM J EPIDEMIOL, V134, P403, DOI 10.1093/oxfordjournals.aje.a116102; Frank RM, 2000, INT J GERIATR PSYCH, V15, P317, DOI 10.1002/(SICI)1099-1166(200004)15:4<317::AID-GPS116>3.3.CO;2-Z; FRATIGLIONI L, 1993, J CLIN EPIDEMIOL, V46, P281, DOI 10.1016/0895-4356(93)90076-D; Freidl W, 1996, J CLIN EPIDEMIOL, V49, P73, DOI 10.1016/0895-4356(95)00541-2; GOLD DP, 1995, J AM GERIATR SOC, V43, P10, DOI 10.1111/j.1532-5415.1995.tb06235.x; GRAFSTROM M, 1992, J CLIN EPIDEMIOL, V45, P861, DOI 10.1016/0895-4356(92)90069-Y; Greenberg SM, 2000, ARCH NEUROL-CHICAGO, V57, P94, DOI 10.1001/archneur.57.1.94; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HEBERT R, 1994, ARCH GERONTOL GERIAT, V18, P1, DOI 10.1016/0167-4943(94)90043-4; HEBERT R, 1995, ARCH GERONTOL GERIAT, V20, P129, DOI 10.1016/0167-4943(94)00590-4; Heun R, 1999, GENET EPIDEMIOL, V17, P151, DOI 10.1002/(SICI)1098-2272(1999)17:2<151::AID-GEPI5>3.0.CO;2-K; Heun R, 1998, INT J GERIATR PSYCH, V13, P368, DOI 10.1002/(SICI)1099-1166(199806)13:6<368::AID-GPS775>3.3.CO;2-0; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Hogervorst E, 2002, DEMENT GERIATR COGN, V13, P13, DOI 10.1159/000048628; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Jarvenpaa T, 2002, DEMENT GERIATR COGN, V13, P149, DOI 10.1159/000048646; Jha A, 2001, INT J GERIATR PSYCH, V16, P879, DOI 10.1002/gps.412; Jitapunkul S, 1996, INT J GERIATR PSYCH, V11, P715; Kirby M, 2001, INT J GERIATR PSYCH, V16, P935, DOI 10.1002/gps.445; KIRCHNER V, 2000, COCHRANE DB SYST REV; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; KRAMERGINSBERG E, 1988, PSYCHOPHARMACOL BULL, V24, P458; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; LAI F, 1989, ARCH NEUROL-CHICAGO, V46, P849, DOI 10.1001/archneur.1989.00520440031017; Lanctot KL, 1998, J CLIN PSYCHIAT, V59, P550, DOI 10.4088/JCP.v59n1010; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; LAW S, 1995, BRIT J PSYCHIAT, V167, P541, DOI 10.1192/bjp.167.4.541; Lawrence J, 2001, AM J GERIAT PSYCHIAT, V9, P205, DOI 10.1176/appi.ajgp.9.3.205; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Lindeboom J, 1996, J CLIN EPIDEMIOL, V49, P691, DOI 10.1016/0895-4356(95)00585-4; Longstreth WT, 1998, ARCH NEUROL-CHICAGO, V55, P1217, DOI 10.1001/archneur.55.9.1217; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P1686, DOI 10.1176/appi.ajp.157.10.1686; Marriott A, 2000, BRIT J PSYCHIAT, V176, P557, DOI 10.1192/bjp.176.6.557; Maurer K, 1997, J PSYCHIATR RES, V31, P645, DOI 10.1016/S0022-3956(97)00022-8; McCurry SM, 1998, J GERONTOL B-PSYCHOL, V53, pP122, DOI 10.1093/geronb/53B.2.P122; McDowell I, 1997, J CLIN EPIDEMIOL, V50, P377, DOI 10.1016/S0895-4356(97)00060-7; MCDOWELL I, 1994, CAN MED ASSOC J, V150, P899; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Mohs RC, 2001, NEUROLOGY, V57, P481, DOI 10.1212/WNL.57.3.481; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Mundt JC, 2001, ARCH INTERN MED, V161, P2481, DOI 10.1001/archinte.161.20.2481; OCONNOR DW, 1988, BMJ-BRIT MED J, V297, P1107, DOI 10.1136/bmj.297.6656.1107; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Olafsdottir M, 2000, DEMENT GERIATR COGN, V11, P223, DOI 10.1159/000017241; Olin J.T., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001747; Pantoni L, 2000, J NEUROL SCI, V175, P124, DOI 10.1016/S0022-510X(00)00300-2; Patterson CJS, 1999, CAN MED ASSOC J, V160, pS1; Patterson CJS, 2001, CAN J NEUROL SCI, V28, pS42, DOI 10.1017/S0317167100001190; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petracca G, 1996, J NEUROPSYCH CLIN N, V8, P270; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Powlishta KK, 2002, NEUROLOGY, V59, P898, DOI 10.1212/WNL.59.6.898; Qizilbash N, 1998, JAMA-J AM MED ASSOC, V280, P1777, DOI 10.1001/jama.280.20.1777; QIZILBASH N, 2000, COCHRANE DB SYST REV; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; Roman GC, 2002, MED CLIN N AM, V86, P477, DOI 10.1016/S0025-7125(02)00008-1; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Ross GW, 1997, JAMA-J AM MED ASSOC, V277, P800, DOI 10.1001/jama.277.10.800; SALMON DP, 1990, NEUROLOGY, V40, P1225, DOI 10.1212/WNL.40.8.1225; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Scanlan J, 2001, INT J GERIATR PSYCH, V16, P216, DOI 10.1002/1099-1166(200102)16:2<216::AID-GPS316>3.0.CO;2-B; Scanlan JM, 2002, INT J GERIATR PSYCH, V17, P14, DOI 10.1002/gps.516; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Schramm U, 2002, INT J GERIATR PSYCH, V17, P254, DOI 10.1002/gps.585; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Shulman KI, 2000, INT J GERIATR PSYCH, V15, P548, DOI 10.1002/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U; Solomon PR, 2000, INT PSYCHOGERIATR, V12, P483, DOI 10.1017/S1041610200006608; STERN RG, 1994, AM J PSYCHIAT, V151, P390; Sternberg SA, 2000, J AM GERIATR SOC, V48, P1430, DOI 10.1111/j.1532-5415.2000.tb02633.x; TAPPEN RM, 1994, RES NURS HEALTH, V17, P159, DOI 10.1002/nur.4770170303; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Teri L, 2000, NEUROLOGY, V55, P1271, DOI 10.1212/WNL.55.9.1271; THOMPSON C, 2000, COCHRANE DB SYST REV; UHLMANN RF, 1991, J AM GERIATR SOC, V39, P876, DOI 10.1111/j.1532-5415.1991.tb04454.x; *US FDA DEP HHS PH, 1989, 227 US FDA DEP HHS P; *US GAO, 1998, PUBL HEHS, V9816; *US OFF TECHN ASS, 1987, LOS MILL MINDS CONFR; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P531; Valcour VG, 2000, ARCH INTERN MED, V160, P2964, DOI 10.1001/archinte.160.19.2964; WILDER D, 1995, AM J GERIAT PSYCHIAT, V3, P96, DOI 10.1097/00019442-199500320-00002; Williams PS, 2000, COCHRANE DB SYST REV, pCD001296, DOI 10.1002/14651858.CD001296; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489	119	410	420	1	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					927	937		10.7326/0003-4819-138-11-200306030-00015	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00015			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	686AB	12779304				2022-12-28	WOS:000183296400009
J	Sobngwi, E; Boudou, P; Mauvais-Jarvis, F; Leblanc, H; Velho, G; Vexiau, P; Porcher, R; Hadjadj, S; Pratley, R; Tataranni, PA; Calvo, F; Gautier, JF				Sobngwi, E; Boudou, P; Mauvais-Jarvis, F; Leblanc, H; Velho, G; Vexiau, P; Porcher, R; Hadjadj, S; Pratley, R; Tataranni, PA; Calvo, F; Gautier, JF			Effect of a diabetic environment in utero on predisposition to type 2 diabetes	LANCET			English	Article							INSULIN SECRETORY DYSFUNCTION; IMPAIRED GLUCOSE-TOLERANCE; PIMA-INDIANS; LIFE-STYLE; MELLITUS; RESISTANCE; MOTHERS; PRECURSORS; NIDDM; RATS	Background Type 2 diabetes is affected by genetics and environmental factors. We aimed to assess the effect of an in-utero diabetic environment independently of the genetic background for type 2 diabetes. Methods We measured insulin sensitivity and insulin secretion in response to oral and intravenous glucose in 15 non-diabetic adult offspring of mothers with type 1 diabetes (exposed participants) and 16 offspring of type 1 diabetic fathers (controls). No participants had type 1 diabetes-associated autoantibodies. We also measured pancreatic polypeptide, a marker of parasympathetic drive to the pancreas. Findings There was no difference between the groups with respect to percent body fat and insulin sensitivity. Five of the 15 exposed participants, but none of the controls had impaired glucose tolerance (p=0.02). Early insulin secretion after an oral glucose tolerance test was lower in exposed participants than in controls: 8.6 IU/mmol (SD 5.4) in exposed participants with impaired glucose tolerance, 14.2 IU/mmol (6.5) in those with normal glucose tolerance and 17.7 IU/mmol (10.9) in controls (p=0.04). Mean insulin secretion rate during glucose infusion study was 4.7 pmol/kg per min (3.6) in people with impaired glucose tolerance, 5.5 pmol/kg per min (4.5) in exposed participants with normal glucose tolerance and 7.5 pmol/kg per min (6.1) in controls (p<0.0001). The area under the curve of pancreatic polypeptide 120 min after oral glucose ingestion was 1007 (429) in people with impaired glucose tolerance, 2829 (1701) in those with normal glucose tolerance, and 3224 (1352) in controls (p=0.04). Interpretation Exposure to a diabetic environment in utero is associated with increased occurence of impaired glucose tolerance and a defective insulin secretory response in adult offspring, independent of genetic predisposition to type 2 diabetes. This insulin secretory defect could be related to low parasympathetic tone. Epidemiological studies are needed to confirm our observations before therapeutic strategies can be devised.	Univ Paris 07, St Louis Hosp, Assistance Pub Hop Paris,Sch Med, Dept Endocrinol & Diabet, Paris, France; Univ Paris 07, St Louis Hosp, Assistance Pub Hop Paris,Sch Med, Clin Invest Ctr,INSERM CIC9504, Paris, France; Univ Paris 07, St Louis Hosp, Assistance Pub Hop Paris,Sch Med, Dept Biostat & Med Informat, Paris, France; Hop St Vincent de Paul, INSERM, U561, F-75674 Paris, France; Ctr Hosp Reg & Univ Poitiers, Dept Endocrinol & Diabet, Poitiers, France; NIDDKD, Phoenix Epidemiol & Clin Res Branch, NIH, Phoenix, AZ USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Universite de Poitiers; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gautier, JF (corresponding author), Hop St Louis, INSERM, Dept Endocrinol & Diabet, Ave Claude Vellefaux, F-75010 Paris, France.		Velho, Gilberto/Q-6724-2017	Velho, Gilberto/0000-0001-8811-363X; calvo, fabien/0000-0002-0298-7633; Porcher, Raphael/0000-0002-5277-4679	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK069015, ZIADK069015] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Boloker J, 2002, DIABETES, V51, P1499, DOI 10.2337/diabetes.51.5.1499; Dabelea D, 2000, DIABETES, V49, P2208, DOI 10.2337/diabetes.49.12.2208; DeFronzo RA, 1979, AM J PHYSIOL, V233, P214; EATON RP, 1980, J CLIN ENDOCR METAB, V51, P520, DOI 10.1210/jcem-51-3-520; Gautier JF, 2001, DIABETES, V50, P1828, DOI 10.2337/diabetes.50.8.1828; HAFFNER SM, 1995, DIABETES, V44, P1386, DOI 10.2337/diabetes.44.12.1386; HANSON RL, 1995, AM J HUM GENET, V57, P160; Harder T, 2001, NEUROSCI LETT, V299, P85, DOI 10.1016/S0304-3940(01)01495-1; Hovorka R, 1996, COMPUT METH PROG BIO, V50, P253, DOI 10.1016/0169-2607(96)01755-5; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; Plagemann A, 1999, DEV NEUROSCI-BASEL, V21, P58, DOI 10.1159/000017367; Plagemann A, 1997, DIABETOLOGIA, V40, P1094, DOI 10.1007/s001250050792; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; Teixeira AS, 1999, LIFE SCI, V64, P655, DOI 10.1016/S0024-3205(98)00607-9; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Van Assche FA, 2001, BRIT MED BULL, V60, P173, DOI 10.1093/bmb/60.1.173; VANCAUTER E, 1992, DIABETES, V41, P368, DOI 10.2337/diabetes.41.3.368; Weiss PAM, 2000, DIABETES CARE, V23, P905, DOI 10.2337/diacare.23.7.905; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; *WHO, 1985, DIAB MELL REP STUD G	23	205	208	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1861	1865		10.1016/S0140-6736(03)13505-2	http://dx.doi.org/10.1016/S0140-6736(03)13505-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788573				2022-12-28	WOS:000183205800011
J	Mallatt, J; Chen, JY; Holland, ND				Mallatt, J; Chen, JY; Holland, ND			Comment on "A new species of yunnanozoan with implications for deuterostome evolution"	SCIENCE			English	Editorial Material							VERTEBRATES; ORIGIN		Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Nanjing Inst Geol & Palaeontol, Nanjing 210008, Peoples R China; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	Washington State University; Chinese Academy of Sciences; University of California System; University of California San Diego; Scripps Institution of Oceanography	Mallatt, J (corresponding author), Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA.							BRIGGS DEG, 1994, LETHAIA, V26, P275, DOI DOI 10.1111/J.1502-3931.1993.TB01532.X); Chen JY, 1999, NATURE, V402, P518, DOI 10.1038/990080; GANS C, 1989, BIOL REV, V64, P221, DOI 10.1111/j.1469-185X.1989.tb00471.x; Holland ND, 2001, BIOESSAYS, V23, P142, DOI 10.1002/1521-1878(200102)23:2<142::AID-BIES1021>3.0.CO;2-5; Mallatt J, 2003, J MORPHOL, V258, P1, DOI 10.1002/jmor.10081; Shu D, 1996, NATURE, V380, P428, DOI 10.1038/380428a0; Shu DG, 2003, NATURE, V421, P526, DOI 10.1038/nature01264; Shu DG, 2003, SCIENCE, V299, P1380, DOI 10.1126/science.1079846; Shu DG, 2001, NATURE, V414, P419, DOI 10.1038/35106514	9	33	34	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775822				2022-12-28	WOS:000183181800023
J	Zuo, JM; Vartanyants, I; Gao, M; Zhang, R; Nagahara, LA				Zuo, JM; Vartanyants, I; Gao, M; Zhang, R; Nagahara, LA			Atomic resolution imaging of a carbon nanotube from diffraction intensities	SCIENCE			English	Article							ELECTRON-DIFFRACTION; PHASE RETRIEVAL; X-RAY; MICROSCOPY	Atomic imaging of three-dimensional structures has required a crystal in diffraction or a lens in electron imaging. Whereas diffraction achieves very high resolution by averaging over many cells, imaging gives localized structural information, such as the position of a single dopant atom. However, lens aberrations limit electron imaging resolution to about 1 angstrom. Resolution is reduced further by low contrast from weak scattering or from the limitations on electron dose for radiation-sensitive molecules. We show that both high resolution and high contrast can be achieved by imaging from diffraction with a nanometer-sized coherent electron beam. The phase problem is solved by oversampling and iterative phase retrieval. We apply this technique to image a double-wall carbon nanotube at 1-angstrom resolution, revealing the structure of two tubes of different helicities. Because the only requirement for imaging is a diffraction pattern sampled below the Nyquist frequency, our technique has the potential to image nonperiodic nanostructures, including biological macromolecules, at diffraction intensity-limited resolutions.	Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA; Univ Illinois, Dept Phys, F Seitz Mat Res Lab, Urbana, IL 61801 USA; Motorola Labs, Phys Sci Res Labs, Tempe, AZ 85284 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Legend Holdings; Lenovo	Zuo, JM (corresponding author), Univ Illinois, Dept Mat Sci & Engn, 1304 W Green St, Urbana, IL 61801 USA.			Zuo, Jian-Min/0000-0002-5151-3370				BATES RHT, 1982, OPTIK, V61, P247; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; FIENUP JR, 1982, APPL OPTICS, V21, P2758, DOI 10.1364/AO.21.002758; Gao M, 2003, APPL PHYS LETT, V82, P2703, DOI 10.1063/1.1569418; GERCHBERG RW, 1972, OPTIK, V35, P237; HENDERSON R, 1995, Q REV BIOPHYS, V28, P171, DOI 10.1017/S003358350000305X; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Jia CL, 2003, SCIENCE, V299, P870, DOI 10.1126/science.1079121; Jorio A, 2001, PHYS REV LETT, V86, P1118, DOI 10.1103/PhysRevLett.86.1118; Miao J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.155502; Miao JW, 1999, NATURE, V400, P342, DOI 10.1038/22498; Millane RP, 1997, J OPT SOC AM A, V14, P568, DOI 10.1364/JOSAA.14.000568; MILLANE RP, 1990, J OPT SOC AM A, V7, P394, DOI 10.1364/JOSAA.7.000394; O'Keefe MA, 2001, ULTRAMICROSCOPY, V89, P215, DOI 10.1016/S0304-3991(01)00094-8; SAYRE D, 1952, ACTA CRYSTALLOGR, V5, P843, DOI 10.1107/S0365110X52002276; Spence JCH, 2003, SCIENCE, V299, P839; Spence JCH, 2002, PHILOS T R SOC A, V360, P875, DOI 10.1098/rsta.2001.0972; Vartanyants IA, 2001, J PHYS-CONDENS MAT, V13, P10593, DOI 10.1088/0953-8984/13/47/305	18	386	398	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1419	1421		10.1126/science.1083887	http://dx.doi.org/10.1126/science.1083887			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775837				2022-12-28	WOS:000183181800041
J	Coyle, JT				Coyle, JT			Use it or lose it - Do effortful mental activities protect against dementia?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Coyle, JT (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.								0	46	48	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2489	2490		10.1056/NEJMp030051	http://dx.doi.org/10.1056/NEJMp030051			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815133				2022-12-28	WOS:000183577200002
J	Benson, J; Britten, N				Benson, J; Britten, N			Patients' views about taking antihypertensive drugs: questionnaire study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICATION		Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England; Peninsula Med Sch, Inst Clin Educ, Exeter EX1 2LU, Devon, England	University of Cambridge; University of Exeter	Benson, J (corresponding author), Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England.	jab62@medschl.cam.ac.uk						Benson J, 2002, BRIT MED J, V325, P873, DOI 10.1136/bmj.325.7369.873; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; ROST K, 1989, SOC SCI MED, V28, P315, DOI 10.1016/0277-9536(89)90032-4; Svensson S, 2000, INT J CARDIOL, V76, P157, DOI 10.1016/S0167-5273(00)00374-0; Wallenius SH, 1995, ANN PHARMACOTHER, V29, P1213, DOI 10.1177/106002809502901204	5	33	40	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2003	326	7402					1314	1315		10.1136/bmj.326.7402.1314	http://dx.doi.org/10.1136/bmj.326.7402.1314			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805171	Green Published, Bronze			2022-12-28	WOS:000183626500035
J	Mace, GM; Gittleman, JL; Purvis, A				Mace, GM; Gittleman, JL; Purvis, A			Preserving the Tree of Life	SCIENCE			English	Editorial Material							EXTINCTION RISK; HABITAT LOSS; CONSERVATION; HOTSPOTS	Phylogenies provide new ways to measure biodiversity, to assess conservation priorities, and to quantify the evolutionary history in any set of species. Methodological problems and a lack of knowledge about most species have so far hampered their use. In the future, as techniques improve and more data become accessible, we will have an expanded set of conservation options, including ways to prioritize outcomes from evolutionary and ecological processes.	Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ascot SL5 7PY, Berks, England	Zoological Society of London; University of Virginia; Imperial College London	Mace, GM (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.		Mace, Georgina M/I-3072-2016; Purvis, Andy/A-7529-2008	Mace, Georgina M/0000-0001-8965-5211; Purvis, Andy/0000-0002-8609-6204				Alroy J, 2001, P NATL ACAD SCI USA, V98, P6261, DOI 10.1073/pnas.111144698; Avise J.C., 2000, PHYLOGEOGRAPHY; Barraclough TG, 1998, PHILOS T R SOC B, V353, P241, DOI 10.1098/rstb.1998.0206; Bromham L, 1999, TRENDS ECOL EVOL, V14, P113, DOI 10.1016/S0169-5347(98)01507-9; Brooks TM, 2002, CONSERV BIOL, V16, P909, DOI 10.1046/j.1523-1739.2002.00530.x; Ceballos G, 2002, SCIENCE, V296, P904, DOI 10.1126/science.1069349; COLLAR LNJH, 1994, BIRDS WATCH, V2; Cooper A, 1998, TRENDS ECOL EVOL, V13, P151, DOI 10.1016/S0169-5347(97)01277-9; Cracraft J., 1983, Current Ornithology, V1, P159; Crandall KA, 2000, TRENDS ECOL EVOL, V15, P290, DOI 10.1016/S0169-5347(00)01876-0; FAITH DP, 1992, BIOL CONSERV, V61, P1, DOI 10.1016/0006-3207(92)91201-3; Gribaldo S, 2002, THEOR POPUL BIOL, V61, P391, DOI 10.1006/tpbi.2002.1593; Heard SB, 2002, SYST BIOL, V51, P889, DOI 10.1080/10635150290155917; HEYWOOD VH, 1994, NATURE, V368, P105, DOI 10.1038/368105a0; Hilton-Taylor C., 2000, 2000 IUCN RED LIST T; May Robert M., 1995, P1; Meegaskumbura M, 2002, SCIENCE, V298, P379, DOI 10.1126/science.298.5592.379; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Nee S, 1997, SCIENCE, V278, P692, DOI 10.1126/science.278.5338.692; Nee Sean, 1996, P230; Owens IPF, 2000, P NATL ACAD SCI USA, V97, P12144, DOI 10.1073/pnas.200223397; Peters SE, 2002, NATURE, V416, P420, DOI 10.1038/416420a; Purvis A, 2000, P ROY SOC B-BIOL SCI, V267, P1947, DOI 10.1098/rspb.2000.1234; Purvis A, 2000, SCIENCE, V288, P328, DOI 10.1126/science.288.5464.328; RODRIGUES ASL, PHYLOGENY CONSERVATI; Russell GJ, 1998, CONSERV BIOL, V12, P1365, DOI 10.1046/j.1523-1739.1998.96332.x; Schwartz MW, 2001, ECOL LETT, V4, P464, DOI 10.1046/j.1461-0248.2001.00241.x; Sechrest W, 2002, P NATL ACAD SCI USA, V99, P2067, DOI 10.1073/pnas.251680798; Soltis PS, 2002, P NATL ACAD SCI USA, V99, P4430, DOI 10.1073/pnas.032087199; Wilson EO, 2003, TRENDS ECOL EVOL, V18, P77, DOI 10.1016/S0169-5347(02)00040-X	30	258	271	1	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1707	1709		10.1126/science.1085510	http://dx.doi.org/10.1126/science.1085510			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805539				2022-12-28	WOS:000183459700040
J	Narita, M; Nunez, S; Heard, E; Narita, M; Lin, AW; Hearn, SA; Spector, DL; Hannon, GJ; Lowe, SW				Narita, M; Nunez, S; Heard, E; Narita, M; Lin, AW; Hearn, SA; Spector, DL; Hannon, GJ; Lowe, SW			Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence	CELL			English	Article							HUMAN-DIPLOID FIBROBLASTS; HISTONE H3; ONCOGENIC RAS; TUMOR-CELLS; X-CHROMOSOME; G(1) CONTROL; LYSINE 9; IN-VIVO; P53; HP1	Cellular senescence is an extremely stable form of cell cycle arrest that limits the proliferation of damaged cells and may act as a natural barrier to cancer progression. In this study, we describe a distinct heterochromatic structure that accumulates in senescent human fibroblasts, which we designated senescence-associated heterochromatic foci (SAHF). SAHF formation coincides with the recruitment of heterochromatin proteins and the retinoblastoma (Rb) tumor suppressor to E2F-responsive promoters and is associated with the stable repression of E2F target genes. Notably, both SAHF formation and the silencing of E2F target genes depend on the integrity of the Rb pathway and do not occur in reversibly arrested cells. These results provide a molecular explanation for the stability of the senescent state, as well as new insights into the action of Rb as a tumor suppressor.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA; Inst Curie, CNRS, UMR 218, F-75248 Paris 05, France	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)	Lowe, SW (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.edu	Hannon, Gregory/AAB-3568-2019; Heard, Edith/D-7197-2017	Heard, Edith/0000-0001-8052-7117; Narita, Masako/0000-0002-9774-4908; Narita, Masashi/0000-0001-7764-577X; Hearn, Stephen/0000-0002-2489-2424	NATIONAL CANCER INSTITUTE [P30CA008748, P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016379, R56AG016379] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106, P30 CA008748] Funding Source: Medline; NIA NIH HHS [AG16379] Funding Source: Medline; NIGMS NIH HHS [GM42694, R01 GM042694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang BD, 1999, CANCER RES, V59, P3761; CHENICLET C, 1990, J HISTOCHEM CYTOCHEM, V38, P551, DOI 10.1177/38.4.1690766; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Dimri GP, 1996, BIOL SIGNAL, V5, P154; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Ferbeyre G, 2000, GENE DEV, V14, P2015; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Good LF, 1996, J CELL PHYSIOL, V168, P580, DOI 10.1002/(SICI)1097-4652(199609)168:3<580::AID-JCP10>3.0.CO;2-3; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Henikoff S., 2000, BIOCHIM BIOPHYS ACTA, V1470, P01; Humbert PO, 2000, GENE DEV, V14, P690; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LEUBA SH, 1994, J MOL BIOL, V235, P871, DOI 10.1006/jmbi.1994.1045; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Spector DL, 2001, J CELL SCI, V114, P2891; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Takahashi Y, 2000, GENE DEV, V14, P804; te Poele RH, 2002, CANCER RES, V62, P1876; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806	52	1620	1685	6	105	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2003	113	6					703	716		10.1016/S0092-8674(03)00401-X	http://dx.doi.org/10.1016/S0092-8674(03)00401-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809602	Bronze			2022-12-28	WOS:000183514400006
J	Gorelick, PB; Richardson, D; Kelly, M; Ruland, S; Hung, E; Harris, Y; Kittner, S; Leurgans, S				Gorelick, PB; Richardson, D; Kelly, M; Ruland, S; Hung, E; Harris, Y; Kittner, S; Leurgans, S		AAASPS Investigators	Aspirin and ticlopidine for prevention of recurrent stroke in black patients - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; AFRICAN-AMERICANS; SECONDARY PREVENTION; ISCHEMIC-STROKE; CLINICAL-TRIAL; HIGH-RISK; THERAPY; MORTALITY; HEALTH; RECRUITMENT	Context Blacks are disproportionately affected by stroke, and they are about 2 times more likely than most other individuals in the United States to die of or experience stroke. Objective To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients. Design, Setting, and Patients Randomized, double-blind, investigator-initiated, multicenter trial of 1809 black men and women who recently had a noncardioembolic ischemic stroke and who were recruited between December 1992 and October 2001 from 62 academic and community hospitals in the United States and followed up for up to 2 years. Intervention A total of 902 patients received 500 mg/d of ticlopidine and 907 received 650 mg/d of aspirin. Main Outcome Measures Recurrent stroke, myocardial infarction, or vascular death was the composite primary end point (according to intention-to-treat analysis). The secondary outcome was fatal or nonfatal stroke. Results The blinded phase of the study was halted after about 6.5 years when futility analyses revealed a less than 1% probability of ticlopidine being shown superior to aspirin in the prevention of the primary outcome end point. The primary outcome of recurrent stroke, myocardial infarction, or vascular death was reached by 133 (14.7%) of 902 patients assigned to ticlopidine and 112 (12.3%) of 907 patients assigned to aspirin (hazard ratio, 1.22; 95% confidence interval, 0.94-1.57). Kaplan-Meier curves for time to event for the primary outcome did not differ significantly (P=.12 by log-rank test). Kaplan-Meier curves for time to the secondary outcome of fatal or nonfatal stroke approached a statistically significant reduction favoring aspirin over ticlopidine (P=.08 by log-rank test). The frequency of laboratory-determined serious neutropenia was 3.4% for patients receiving ticlopidine vs 2.2% for patients receiving aspirin (P=.12) and 0.3% vs 0.2% for thrombocytopenia, respectively (P=.69). One ticlopidine-treated patient developed thrombocytopenia, which was thought to be a case of possible thrombotic thrombocytopenia purpura, and recovered after therapy with plasmapheresis. Conclusions During a 2-year follow-up, we found no statistically significant difference between ticlopidine and aspirin in the prevention of recurrent stroke, myocardial infarction, or vascular death. However, there was a nonsignificant trend for reduction of fatal or nonfatal stroke among those in the aspirin group. Based on these data and the risk of serious adverse events with ticlopidine, we regard aspirin as a better treatment for aspirin-tolerant black patients with noncardioembolic ischemic stroke.	Rush Med Coll, Ctr Stroke Res, Dept Neurol Sci, Chicago, IL 60612 USA; Rush Med Coll, Dept Prevent Med, Chicago, IL 60612 USA; Lake Forest Coll, Dept Math & Comp Sci, Lake Forest, IL 60045 USA; Cook Cty Hosp, Dept Med, Div Neurol, Chicago, IL 60612 USA; Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA	Rush University; Rush University; John H Stroger Junior Hospital Cook County; University System of Maryland; University of Maryland Baltimore	Gorelick, PB (corresponding author), Rush Med Coll, Ctr Stroke Res, Dept Neurol Sci, 1645 W Jackson,Suite 400, Chicago, IL 60612 USA.	Philip_B_Gorelick@rush.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033430] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS33430] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers CW, 2001, CHEST, V119, p300S, DOI 10.1378/chest.119.1_suppl.300S; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1998, JAMA, V279, P1265; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; Bennett CL, 1998, LANCET, V352, P1036, DOI 10.1016/S0140-6736(05)60079-7; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; BRODERICK JP, 1992, NEW ENGL J MED, V326, P733, DOI 10.1056/NEJM199203123261103; Burroughs VJ, 2002, J NATL MED ASSOC, V94, P1; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; COX DR, 1972, J R STAT SOC B, V34, P187; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; FRIDAY G, 1989, NEUROLOGY, V39, P1165, DOI 10.1212/WNL.39.9.1165; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; GILES WH, 1995, ARCH INTERN MED, V155, P1319, DOI 10.1001/archinte.155.12.1319; Gillum RF, 1999, STROKE, V30, P1711, DOI 10.1161/01.STR.30.8.1711; Gorelick P B, 1998, J Stroke Cerebrovasc Dis, V7, P426, DOI 10.1016/S1052-3057(98)80127-4; Gorelick PB, 1998, STROKE, V29, P2656, DOI 10.1161/01.STR.29.12.2656; Gorelick PB, 1998, J NATL MED ASSOC, V90, P141; Gorelick PB, 1996, J NATL MED ASSOC, V88, P701; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Hankey GJ, 2000, STROKE, V31, P1779, DOI 10.1161/01.STR.31.7.1779; Harris Y, 1996, J NATL MED ASSOC, V88, P630; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HORNER RD, 1995, MILBANK Q, V73, P443, DOI 10.2307/3350374; Kim HS, 2000, J ROBOTIC SYST, V17, P63, DOI 10.1002/(SICI)1097-4563(200001)17:1<63::AID-ROB4>3.0.CO;2-R; KIM K, 1987, BIOMETRIKA, V74, P149, DOI 10.2307/2336029; KRISCHER JP, 1991, CONTROL CLIN TRIALS, V12, P367, DOI 10.1016/0197-2456(91)90017-G; Lynch GF, 2001, J NATL MED ASSOC, V93, P79; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Morgenstern LB, 1997, ANN NEUROL, V42, P919, DOI 10.1002/ana.410420614; Powers WJ, 2001, NEW ENGL J MED, V345, P1493, DOI 10.1056/NEJM200111153452012; Rennie D, 1996, JAMA-J AM MED ASSOC, V276, P649, DOI 10.1001/jama.276.8.649; Richardson D, 1998, NEUROEPIDEMIOLOGY, V17, P63, DOI 10.1159/000026154; Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445; Sharis PJ, 1998, ANN INTERN MED, V129, P394, DOI 10.7326/0003-4819-129-5-199809010-00009; Steinhubl SR, 1999, JAMA-J AM MED ASSOC, V281, P806, DOI 10.1001/jama.281.9.806; TEITELBAUM P, 1993, TICLOPIDINE PLATELET, P27; Warlow C, 2002, STROKE, V33, P2137, DOI 10.1161/01.STR.0000023120.91460.F3; WEISBERG LA, 1993, NEUROLOGY, V43, P27, DOI 10.1212/WNL.43.1_Part_1.27; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991	45	165	171	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					2947	2957		10.1001/jama.289.22.2947	http://dx.doi.org/10.1001/jama.289.22.2947			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687XZ	12799402	Bronze			2022-12-28	WOS:000183403400017
J	Hodson, J; Marsh, J				Hodson, J; Marsh, J			Quantitative ultrasound and risk factor enquiry as predictors of postmenopausal osteoporosis: comparative study in primary care	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GENERAL-PRACTICE; ECONOMIC-EVALUATION; METAANALYSIS; DEPRESSION; COUNSELOR; NEED		Bridge House Med Ctr, Stratford Upon Avon CV37 6HE, Warwick, England; Univ Warwick, Ctr Primary Hlth Care Studies, Coventry CV4 7AL, W Midlands, England	University of Warwick	Hodson, J (corresponding author), Bridge House Med Ctr, Scholars Lane, Stratford Upon Avon CV37 6HE, Warwick, England.							Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; Beck A.T., 1987, BECK DEPRESSION INVE; BOOT D, 1994, PATIENT EDUC COUNS, V24, P79, DOI 10.1016/0738-3991(94)90028-0; BOWER P, 2002, COCHRANE LIB; Briggs A, 2000, BRIT MED J, V321, P1362, DOI 10.1136/bmj.321.7273.1362; Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766; *BRIT MED ASS ROYA, 1998, BRIT NAT FORM; Chilvers C, 2001, BMJ-BRIT MED J, V322, P772, DOI 10.1136/bmj.322.7289.772; Department of Health, 2001, NAT SERV FRAM OLD PE; Efron B., 1994, MONOGRAPHS STAT APPL; FENWICK L, 2002, HEALTH ECON, V10, P779; Friedli K, 2000, BRIT J GEN PRACT, V50, P276; Gotzsche PC, 2000, BRIT MED J, V321, P585, DOI 10.1136/bmj.321.7261.585; Harvey I, 1998, BRIT J GEN PRACT, V48, P1043; Hemmings A, 1997, PATIENT EDUC COUNS, V32, P219, DOI 10.1016/S0738-3991(97)00035-9; Johnston K, 1999, HLTH TECHNOL ASSESS, V3; KALTENTHALER E, 2002, HLTH TECHNOL ASSESS, V6; KING M, 2000, HLTH TECHNOL ASSESS, V4; LAVE J, 1999, COST EFFECTIVENESS P, P75; Lovell K., 2000, BEHAV COGN PSYCHOTH, V28, P379, DOI [DOI 10.1017/S1352465800004070, 10.1017/S1352465800004070]; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; McGuire A, 2001, EC EVALUATION HLTH C, P172; Netten A, 1998, UNIT COSTS HLTH SOCI; Rost KM, 2001, GEN HOSP PSYCHIAT, V23, P239, DOI 10.1016/S0163-8343(01)00157-8; *ROYAL COLL PHYS L, 1999, OST CLIN GUID PREV T; SIMPSON S, 2000, HLTH TECHNOL ASSESS, V4; SPEIRS R, 1995, BRIT J GEN PRACT, V45, P31; Stewart A, 2000, BRIT J RADIOL, V73, P165, DOI 10.1259/bjr.73.866.10884730; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Sutton A, 1998, HLTH TECHNOL ASSESS, V2; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; Versluis RGJA, 2001, BRIT J GEN PRACT, V51, P806	32	17	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1250	1251		10.1136/bmj.326.7401.1250	http://dx.doi.org/10.1136/bmj.326.7401.1250			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	689FJ	12791742	Green Published, Bronze			2022-12-28	WOS:000183480700019
J	Kmietowicz, Z				Kmietowicz, Z			Commentary: Information for patients: removal of lice and eggs by combing	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ Publishing Grp, BestTreatments, London WC1H 9JR, England	BMJ Publishing Group Ltd	Kmietowicz, Z (corresponding author), BMJ Publishing Grp, BestTreatments, London WC1H 9JR, England.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1258	1258		10.1136/bmj.326.7401.1258	http://dx.doi.org/10.1136/bmj.326.7401.1258			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791747	Green Published			2022-12-28	WOS:000183480700023
J	Jacobsen, SB				Jacobsen, SB			How old is planet Earth?	SCIENCE			English	Editorial Material							RAPID ACCRETION; CORE FORMATION; TIMESCALE; AGES		Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Harvard University	Jacobsen, SB (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA.	jacobsen@neodymium.harvard.edu	Jacobsen, Stein/B-1759-2013; Jacobsen, Stein/ABA-1063-2021	Jacobsen, Stein/0000-0003-2164-0720				Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; Harper CL, 1996, GEOCHIM COSMOCHIM AC, V60, P1131, DOI 10.1016/0016-7037(96)00027-0; JACOBSEN SB, 1996, AM GEOPHYS UNION GEO, V95, P47; Kleine T, 2002, NATURE, V418, P952, DOI 10.1038/nature00982; Kleine T, 2002, GEOCHIM COSMOCHIM AC, V66, pA404; Lee DC, 1996, SCIENCE, V274, P1876, DOI 10.1126/science.274.5294.1876; Schoenberg R, 2002, GEOCHIM COSMOCHIM AC, V66, P3151, DOI 10.1016/S0016-7037(02)00911-0; WASSERBURG GJ, 1996, APJ, V466, P109; YIN Q, 2002, LUN PLAN SCI C, V33; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995	10	32	34	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1513	1514		10.1126/science.1080682	http://dx.doi.org/10.1126/science.1080682			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791970				2022-12-28	WOS:000183333100030
J	Kelly-Welch, AE; Hanson, EM; Boothby, MR; Keegan, AD				Kelly-Welch, AE; Hanson, EM; Boothby, MR; Keegan, AD			Interleukin-4 and interleukin-13 signaling connections maps	SCIENCE			English	Editorial Material							IL-4 RECEPTOR; STAT6	Cytokines are inflammatory mediators important in responding to pathogens and other foreign challenges. Interleukin-4 (IL-4) and IL-13 are two cytokines produced by T helper type 2 cells, mast cells, and basophils. In addition to their physiological roles, these cytokines are also implicated in pathological conditions such as asthma and allergy. IL-4 can stimulate two receptors, type I and type II, whereas IL-13 signaling is mediated only by the type II receptor (see the STKE Connections Maps). These cytokines activate the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling cascades, which may contribute to allergic responses. In addition, stimulation of the phosphatidylinositol 3-kinase (PI3K) pathway through recruitment of members of the insulin receptor substrate family may contribute to survival and proliferation.	Amer Red Cross, Dept Immunol, Holland Lab, Rockville, MD 20855 USA; George Washington Med Ctr, Inst Biomed Sci, Washington, DC 20037 USA; Vanderbilt Univ, Dept Microbiol, Nashville, TN 37232 USA	American Red Cross; George Washington University; Vanderbilt University	Keegan, AD (corresponding author), Amer Red Cross, Dept Immunol, Holland Lab, Rockville, MD 20855 USA.	keegana@usa.redcross.org			NHLBI NIH HHS [HL61752] Funding Source: Medline; NIAID NIH HHS [AI38985, AI49460, AI45662] Funding Source: Medline; NIGMS NIH HHS [GM42550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045662, R21AI049460, R01AI049460, R29AI038985, R01AI038985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042550, R29GM042550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON DS, 2003, SCI STKE; Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Boothby M, 2001, CRIT REV IMMUNOL, V21, P487; CANTLEY LC, 2003, SCI STKE; Chomarat P, 1998, Int Rev Immunol, V17, P1, DOI 10.3109/08830189809084486; Hanson EM, 2003, J BIOL CHEM, V278, P3903, DOI 10.1074/jbc.M211747200; Kashiwada M, 2001, J IMMUNOL, V167, P6382, DOI 10.4049/jimmunol.167.11.6382; KEEGAN AD, 2003, SCI STKE; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Perez-G M, 2002, J IMMUNOL, V168, P1428, DOI 10.4049/jimmunol.168.3.1428; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; Shelburne CP, 2002, CYTOKINE, V19, P218, DOI 10.1006/cyto.2002.1957; Sherman MA, 2002, J IMMUNOL, V169, P3811, DOI 10.4049/jimmunol.169.7.3811; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Wurster AL, 2002, J BIOL CHEM, V277, P27169, DOI 10.1074/jbc.M201207200; Wurster AL, 2002, MOL CELL BIOL, V22, P117, DOI 10.1128/MCB.22.1.117-126.2002; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Zhu JF, 2000, J EXP MED, V192, P1125, DOI 10.1084/jem.192.8.1125; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5	21	304	356	3	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1527	1528		10.1126/science.1085458	http://dx.doi.org/10.1126/science.1085458			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791978				2022-12-28	WOS:000183333100038
J	Selker, EU				Selker, EU			A self-help guide for a trim genome	SCIENCE			English	Editorial Material							PROGRAMMED DNA ELIMINATION; TETRAHYMENA-THERMOPHILA; HISTONE H3; METHYLATION; PROTEIN; REARRANGEMENT; SEQUENCES		Univ Oregon, Dept Biol, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Selker, EU (corresponding author), Univ Oregon, Dept Biol, Eugene, OR 97403 USA.							Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Chalker DL, 1996, MOL CELL BIOL, V16, P3658; Chalker DL, 2001, GENE DEV, V15, P1287, DOI 10.1101/gad.884601; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Nikiforov MA, 1999, GENE DEV, V13, P2852, DOI 10.1101/gad.13.21.2852; Nikiforov MA, 2000, MOL CELL BIOL, V20, P4128, DOI 10.1128/MCB.20.11.4128-4134.2000; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Smothers JF, 1997, DEVELOPMENT, V124, P4537; Taverna SD, 2002, CELL, V110, P701, DOI 10.1016/S0092-8674(02)00941-8; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yao MC, 2003, SCIENCE, V300, P1581, DOI 10.1126/science.1084737; YAO MC, 2002, MOBILE DNA, V2	16	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1517	1518		10.1126/science.1086053	http://dx.doi.org/10.1126/science.1086053			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791973				2022-12-28	WOS:000183333100033
J	Cyranoski, D				Cyranoski, D			Biologist gets minimum sentence in 'espionage' case	NATURE			English	News Item																		2001, NATURE, V411, P225; 2002, NATURE, V417, P108	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					575	575		10.1038/423575b	http://dx.doi.org/10.1038/423575b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789303	Bronze			2022-12-28	WOS:000183301200008
J	Rosenberg, AL; Hofer, TP; Strachan, C; Watts, CM; Hayward, RA				Rosenberg, AL; Hofer, TP; Strachan, C; Watts, CM; Hayward, RA			Accepting critically ill transfer patients: Adverse effect on a referral center's outcome and benchmark measures	ANNALS OF INTERNAL MEDICINE			English	Article							INTENSIVE-CARE-UNIT; QUALITY-OF-CARE; ACADEMIC-MEDICAL-CENTER; LEAD-TIME BIAS; MANAGED CARE; HOSPITAL MORTALITY; INTERHOSPITAL TRANSFERS; ACUTE PHYSIOLOGY; RISK ADJUSTMENT; SCORING SYSTEM	Background: Common methods of benchmarking clinical performance rarely, if ever, account for admission source and, in particular, the effect of a patient being transferred from one medical center to another. Small biases in comparisons of observed versus expected deaths can substantially affect how high-quality institutions compare with peer hospitals. With the most sophisticated and validated set of case-mix measures available for patients, the intensive care unit is an ideal setting in which to study the effect of a patient's being transferred from another hospital. Objective: To determine the extent of bias in benchmarking outcomes when performance measures do not account for transfer patients' greater severity of illness. Design: Prospectively developed cohort study. Setting: Medical intensive care unit (MICU) at a tertiary care university hospital. Patients: 4579 consecutive admissions for 4208 patients from 1 January 1994 to 1 April 1998. Measurements: MICU and hospital lengths of stay, MICU readmission, and hospital mortality rates. Results: Compared with directly admitted patients, MICU patients transferred from another hospital had significantly higher Acute Physiology Scores at the time of admission and discharge (P = 0.001). Even after full adjustment for case mix and severity of illness, transfer patients had a 38% longer MICU stay (95% CI, 32% to 45%), a 41% longer hospital stay (CI, 34% to 50%), and a 2.2 times greater odds of hospital mortality (CI, 1.7 to 2.8) than directly admitted patients. With identical efficiency and quality, a referral hospital with a 25% MICU transfer rate compared with another with a 0% transfer rate would be penalized by 14 excess deaths per 1000 admissions when a benchmarking program adjusts only for case mix and severity of illness and not for the source of admission. Conclusions: In a setting with the most thorough diagnostic-based, case-mix adjustment and the most physiologically precise severity-of-illness information, accepting transfer patients can adversely affect efficiency and quality benchmarks. Benchmarking and profiling efforts beyond intensive care units must also recognize and account for this phenomenon; otherwise, referral centers may have an incentive to refuse care for patients who could benefit from being transferred to their facility.	Univ Michigan, Ctr Med, Dept Anesthesiol & Crit Care, Ann Arbor, MI 48109 USA; Vet Affairs Ann Arbor Healthcare Syst, Dept Vet Affairs Hlth Serv Res & Dev Serv, Ann Arbor, MI USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Rosenberg, AL (corresponding author), Univ Michigan, Ctr Med, Dept Anesthesiol & Crit Care, Room 1G323,Box 0048, Ann Arbor, MI 48109 USA.	arosen@umich.edu	Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787				Albertson GA, 2000, J GEN INTERN MED, V15, P242, DOI 10.1111/j.1525-1497.2000.02208.x; Angus DC, 2000, CRIT CARE MED, V28, P2145, DOI 10.1097/00003246-200006000-00088; Bailey JE, 1999, JAMA-J AM MED ASSOC, V282, P1067, DOI 10.1001/jama.282.11.1067; Bernard AM, 1996, ACAD MED, V71, P262, DOI 10.1097/00001888-199603000-00019; Bindman AB, 1999, JAMA-J AM MED ASSOC, V281, P2142, DOI 10.1001/jama.281.22.2142; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; BORLASE BC, 1991, J TRAUMA, V31, P915, DOI 10.1097/00005373-199107000-00006; Chernew ME, 1998, MED CARE RES REV, V55, P259, DOI 10.1177/107755879805500301; CLEMMITT M, 2001, MED HLTH S, V55, P1; DRAGSTED L, 1989, CRIT CARE MED, V17, P418, DOI 10.1097/00003246-198905000-00008; DUNCAN RP, 1988, HOSP HEALTH SERV ADM, V33, P237; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; Fihn SD, 2000, JAMA-J AM MED ASSOC, V283, P1740, DOI 10.1001/jama.283.13.1740; FRANKLIN C, 1983, CRIT CARE MED, V11, P61, DOI 10.1097/00003246-198302000-00001; Goodman DC, 1996, JAMA-J AM MED ASSOC, V276, P1811, DOI 10.1001/jama.276.22.1811; Gordon HS, 1996, MED CARE, V34, P295, DOI 10.1097/00005650-199604000-00002; Green J, 1997, JAMA-J AM MED ASSOC, V277, P1152, DOI 10.1001/jama.277.14.1152; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HAYWARD RA, 1995, J GEN INTERN MED, V10, P504, DOI 10.1007/BF02602402; Hofer T P, 1997, Jt Comm J Qual Improv, V23, P455; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Hofer TP, 1996, MED CARE, V34, P737, DOI 10.1097/00005650-199608000-00002; Huerta J A, 1995, J Clin Eng, V20, P48; HURLEY J, 1990, HEALTH SERV RES, V25, P239; Iezzoni LI, 1996, AM J PUBLIC HEALTH, V86, P1379, DOI 10.2105/AJPH.86.10.1379; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JENCKS SF, 1988, MED CARE, V26, P948, DOI 10.1097/00005650-198810000-00003; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS W, 1989, CRIT CARE MED, V17, pS176, DOI 10.1097/00003246-198912001-00005; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Krakauer H, 1998, J Eval Clin Pract, V4, P11, DOI 10.1046/j.1365-2753.1998.t01-1-00002.x; Kulu-Glasgow I, 1998, HEALTH POLICY, V45, P221, DOI 10.1016/S0168-8510(98)00045-1; Langenbrunner J C, 1989, Health Care Financ Rev, V10, P91; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1994, JAMA-J AM MED ASSOC, V272, P1049, DOI 10.1001/jama.272.13.1049; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; MILLER MG, 1994, JAMA-J AM MED ASSOC, V271, P1493, DOI 10.1001/jama.271.19.1493; OBREMSKEY W, 1994, J TRAUMA, V36, P373, DOI 10.1097/00005373-199403000-00016; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; *PHC4, 1995, FOC HEART ATT W PENN; RAPOPORT J, 1990, CRIT CARE MED, V18, P1231, DOI 10.1097/00003246-199011000-00009; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; ROMANO PS, 1994, J CLIN EPIDEMIOL, V47, P249, DOI 10.1016/0895-4356(94)90006-X; Rosenberg AL, 2001, CRIT CARE MED, V29, P511, DOI 10.1097/00003246-200103000-00008; Rosenthal G E, 1997, Am J Med Qual, V12, P103, DOI 10.1177/0885713X9701200204; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; Rubenfeld GD, 1999, AM J RESP CRIT CARE, V160, P358, DOI 10.1164/ajrccm.160.1.9807118; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; Schroeder J, 1996, Am J Med Qual, V11, pS58; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SHAPIRO MF, 1994, HEALTH SERV RES, V29, P95; Spoeri RK, 1997, ANN INTERN MED, V127, P726, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00058; TERES D, 1993, CRIT CARE CLIN, V9, P543, DOI 10.1016/S0749-0704(18)30184-2; Tunnell RD, 1998, ANAESTHESIA, V53, P1045, DOI 10.1046/j.1365-2044.1998.00566.x; Weissman NW, 1999, J EVAL CLIN PRACT, V5, P269, DOI 10.1046/j.1365-2753.1999.00203.x; ZIMMERMAN JE, 1994, CRIT CARE MED, V22, P1373, DOI 10.1097/00003246-199409000-00005; Zimmerman JE, 1998, CRIT CARE MED, V26, P1317, DOI 10.1097/00003246-199808000-00012; Zimmerman JE, 2000, CRIT CARE MED, V28, P258, DOI 10.1097/00003246-200001000-00048; 2001, MED HEALTHC S, P6	62	171	172	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					882	890		10.7326/0003-4819-138-11-200306030-00009	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	686AB	12779298				2022-12-28	WOS:000183296400003
J	Herxheimer, A				Herxheimer, A			Relationships between the pharmaceutical industry and patients' organisations	BRITISH MEDICAL JOURNAL			English	Article											Herxheimer, A (corresponding author), 9 Pk Crescent, London N3 2NL, England.							BOSELEY S, 1999, GUARDIAN        0929; *CONS ASS, 2003, WHICH            APR, P24; HOGAN B, 2003, AARP B; JEFFRIES M, 2000, PHARM MARKETING  MAY, P4; *LMCA BOARD TRUST, 2000, WORK PHARM IND GUID; SILVERSTEIN K, 1999, MOTHER JONES     NOV; 2002, HELP GUIDE NATL SELF	7	83	86	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2003	326	7400					1208	1210		10.1136/bmj.326.7400.1208	http://dx.doi.org/10.1136/bmj.326.7400.1208			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775627	Green Published			2022-12-28	WOS:000183309900029
J	Massaga, JJ; Kitua, AY; Lemnge, MM; Akida, JA; Malle, LN; Ronn, AM; Theander, TG; Bygbjerg, IC				Massaga, JJ; Kitua, AY; Lemnge, MM; Akida, JA; Malle, LN; Ronn, AM; Theander, TG; Bygbjerg, IC			Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial	LANCET			English	Article							PLASMODIUM-FALCIPARUM PARASITEMIA; SULFADOXINE-PYRIMETHAMINE; MUHEZA DISTRICT; YOUNG-CHILDREN; 1ST YEAR; AREA; RESISTANCE; LEVEL; CHEMOPROPHYLAXIS; CHLOROQUINE	Background Malaria is a major cause of infant morbidity and mortality in sub-Saharan Africa, and is often complicated by severe anaemia. Resistance of Plasmodium falciparum to most affordable antimalarial drugs is an impediment to intermittent chemotherapy. We investigated the effect of presumptive intermittent treatment with amodiaquine and daily iron supplementation in infants on malarial fevers and anaemia, in a holoendemic area of Tanzania where malaria is largely resistant to chloroquine and sulfadoxine/ pyrimethamine. Methods 291 infants aged 12-16 weeks who attended three clinics were randomised to receive amodiaquine, iron supplementation, amodiaquine plus iron supplementation, or placebo. Over 6 months, we gave amodiaquine three times with intervals of 60 days; oral iron supplementation was given daily. Malarial fevers and anaemia were monitored at bimonthly treatment visits and by self-reporting to health centres. Findings The protective efficacy of intermittent amodiaquine treatment in prevention of malarial fevers and anaemia was 64.7% (95% Cl, 42.4-77-2) and 67.0% (95% Cl, 34.5-83.4), respectively. Protective efficacy was similar in the group receiving amodiaquine plus iron supplementation. Infants receiving iron supplementation only were partly protected against anaemia (protective efficacy 59.8%; 95% Cl, 23.4-78.9), but not against malarial fevers. 4 months' follow-up did not show rebound morbidity. We noted no haematological or clinical adverse effects. Interpretation Presumptive intermittent treatment for malaria with amodiaquine reduced malarial fevers and anaemia in infants, in an area with high resistance to other antimalarials. Intermittent treatment strategies for malaria in highly endemic areas could be of great benefit to public health.	Natl Inst Med Res, Amani Med Res Ctr, Amani, Tanzania; Natl Inst Med Res, Dar Es Salaam, Tanzania; Univ Copenhagen, Dept Int Hlth, Inst Publ Hlth, Copenhagen, Denmark; Univ Copenhagen, Dept Med Microbiol & Immunol, Ctr Med Parasitol, Copenhagen, Denmark	National Institute of Medical Research; National Institute of Medical Research; University of Copenhagen; University of Copenhagen	Massaga, JJ (corresponding author), Natl Inst Med Res, Amani Med Res Ctr, POB 4, Amani, Tanzania.	jmassaga@hotmail.com	; Theander, Thor G./F-6714-2015	Bygbjerg, Ib/0000-0001-9100-2754; Theander, Thor G./0000-0002-3509-7514				Achidi EA, 1996, AM J TROP MED HYG, V55, P138, DOI 10.4269/ajtmh.1996.55.138; BINKA FN, 1994, T ROY SOC TROP MED H, V88, P381, DOI 10.1016/0035-9203(94)90391-3; Breckenridge AM, 1997, ANN TROP MED PARASIT, V91, P727, DOI 10.1080/00034989760464; Cornet M, 1998, AM J TROP MED HYG, V58, P606, DOI 10.4269/ajtmh.1998.58.606; Dacie J., 1991, PRACTICAL HEMATOLOGY, V7th; Ellman R, 1998, ANN TROP MED PARASIT, V92, P741, DOI 10.1080/00034989858989; HATTON CSR, 1986, LANCET, V1, P411; Kitua AY, 1997, TROP MED INT HEALTH, V2, P325; Kitua AY, 1996, TROP MED INT HEALTH, V1, P475, DOI 10.1046/j.1365-3156.1996.d01-89.x; Koram KA, 2000, AM J TROP MED HYG, V62, P670, DOI 10.4269/ajtmh.2000.62.670; Krishna S, 1996, CLIN PHARMACOKINET, V30, P263, DOI 10.2165/00003088-199630040-00002; Lemnge MM, 1997, T ROY SOC TROP MED H, V91, P68, DOI 10.1016/S0035-9203(97)90401-6; LEMNGE MM, 1995, THESIS COPENHAGEN U; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; MNYIKA KS, 1995, TROP GEOGR MED, V47, P32; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; MUTABINGWA TK, 1992, TROP GEOGR MED, V44, P293; Nwanyanwu OC, 2000, TROP MED INT HEALTH, V5, P355, DOI 10.1046/j.1365-3156.2000.00554.x; Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4; Orrell C, 2001, T ROY SOC TROP MED H, V95, P517, DOI 10.1016/S0035-9203(01)90024-0; Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7; SALUM FM, 1994, ACTA TROP, V58, P29, DOI 10.1016/0001-706X(94)90119-8; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; Staedke SG, 2001, LANCET, V358, P368, DOI 10.1016/S0140-6736(01)05557-X; TRAPE JF, 1994, AM J TROP MED HYG, V51, P123, DOI 10.4269/ajtmh.1994.51.123; Vounatsou P, 2000, PARASITOLOGY, V120, P1, DOI 10.1017/S0031182099005211; Warsame M, 1999, T ROY SOC TROP MED H, V93, P312, DOI 10.1016/S0035-9203(99)90034-2; WERNSDORFER WH, 1994, ACTA TROP, V56, P143, DOI 10.1016/0001-706X(94)90060-4; *WHO, 1998, TDR NEWS, V55, P4; WHO Expert Committee on Malaria, 2000, WHO TECH REP SER, V892, P1	30	106	108	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	2003	361	9372					1853	1860		10.1016/S0140-6736(03)13504-0	http://dx.doi.org/10.1016/S0140-6736(03)13504-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788572				2022-12-28	WOS:000183205800010
J	Tovey, C; Wyatt, S				Tovey, C; Wyatt, S			Diagnosis, investigation, and management of deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							D-DIMER; VENOUS THROMBOSIS; ULTRASONOGRAPHY; OUTPATIENTS; VENOGRAPHY		Prince Charles Hosp, Merthyr Tudfil CF47 9DT, Mid Glamorgan, Wales; Prince Wales Hosp, Bridgend, Mid Glamorgan, Wales		Tovey, C (corresponding author), Prince Charles Hosp, Merthyr Tudfil CF47 9DT, Mid Glamorgan, Wales.	clive.tovey@nglam-tr.wales.nhs.uk						Aschwanden M, 1999, J VASC SURG, V30, P929, DOI 10.1016/S0741-5214(99)70019-4; Bernardi E, 1998, BRIT MED J, V317, P1037; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; CARTER CJ, 1996, DISORDERS THROMBOSIS, P159; DEVALOIS JC, 1990, EUR J RADIOL, V11, P131, DOI 10.1016/0720-048X(90)90162-5; Ebell MH, 2001, J FAM PRACTICE, V50, P167; Fraser DGW, 2002, ANN INTERN MED, V136, P89, DOI 10.7326/0003-4819-136-2-200201150-00006; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; Haemostasis and Thrombosis Task Force, 1998, BRIT J HAEMATOL, V101, P374; Kearon C, 2001, ANN INTERN MED, V135, P108, DOI 10.7326/0003-4819-135-2-200107170-00011; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Kraaijenhagen RA, 1998, BAILLIERE CLIN HAEM, V11, P541, DOI 10.1016/S0950-3536(98)80083-8; Maskell NA, 2002, BRIT J RADIOL, V75, P648, DOI 10.1259/bjr.75.896.750648; ODONNELL TF, 1980, SURG GYNECOL OBSTET, V150, P69; Palareti G, 2002, THROMB HAEMOSTASIS, V87, P7; Pittet JL, 1996, CLIN CHEM, V42, P410; ROGERS LQ, 1990, AM J MED, V88, P389, DOI 10.1016/0002-9343(90)90494-X; SCHRAIBMAN IG, 2002, COCHRANE LIB; Tan YK, 1999, EUR J VASC ENDOVASC, V18, P71, DOI 10.1053/ejvs.1999.0886; VANDENBELT AGM, 2002, COCHRANE LIB; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Yoshida S, 2001, BRIT J RADIOL, V74, P1013, DOI 10.1259/bjr.74.887.741013	25	77	89	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2003	326	7400					1180	1184		10.1136/bmj.326.7400.1180	http://dx.doi.org/10.1136/bmj.326.7400.1180			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775619	Green Published			2022-12-28	WOS:000183309900021
J	Bolton-Maggs, PHB; Pasi, KJ				Bolton-Maggs, PHB; Pasi, KJ			Haemophilias A and B	LANCET			English	Review							FACTOR-VIII GENE; VON-WILLEBRAND-DISEASE; PROTEASE INHIBITOR THERAPY; CENTRAL VENOUS CATHETERS; COAGULATION-FACTOR-VIII; HIV-POSITIVE PATIENTS; FACTOR-IX GENE; LIVER-DISEASE; PROPHYLACTIC TREATMENT; IMMUNE TOLERANCE	The haemophilias are inherited disorders in which one of the coagulation factors is deficient. Although deficiencies of factor VIII (haemophilia A) and factor IX (haemophilia B) are well recognised, von Willebrand's disease is much more common. Rare defects can occur in any of the coagulation factors. In the past, men with haemophilia were likely to die in their youth. With advances in diagnosis, and especially with development of safe and effective treatment, affected individuals can now look forward to a normal life expectancy. Complications of the disorder, particularly the development of antibodies that make treatment ineffective, and of treatment, such as transfusion-transmitted infections, have taken a severe toll on these patients. The future holds the realistic possibility of gene therapy. However, we must not forget that haemophilia Is a worldwide disorder that requires significant economic resources not available for the majority.	Royal Liverpool Childrens Hosp, Dept Haematol, Liverpool L12 2AP, Merseyside, England; Univ Leicester, Leicester Royal Infirm, Div Haematol, Leicester, Leics, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Leicester	Bolton-Maggs, PHB (corresponding author), Royal Liverpool Childrens Hosp, Dept Haematol, Alder Hey, Liverpool L12 2AP, Merseyside, England.	p.h.boltonmaggs@liv.ac.uk						ALEDORT LM, 1994, J INTERN MED, V236, P391, DOI 10.1111/j.1365-2796.1994.tb00815.x; Astermark J, 2001, HAEMOPHILIA, V7, P267, DOI 10.1046/j.1365-2516.2001.00510.x; Babu R, 2002, PEDIATR SURG INT, V18, P50, DOI 10.1007/s003830200011; Bagnall RD, 2002, BLOOD, V99, P168, DOI 10.1182/blood.V99.1.168; Barnes C, 2000, HAEMOPHILIA, V6, P693, DOI 10.1046/j.1365-2516.2000.00419.x; BEYABINA SH, 2003, NEW ENGL J MED, V348, P255; Birch CL, 1937, ILLINOIS MED DENT MO, V1, P1; Blanchfield JR, 1996, TRENDS FOOD SCI TECH, V7, P1, DOI 10.1016/0924-2244(96)81351-3; Bollard CM, 2000, HAEMOPHILIA, V6, P66; Bracho-Troconis C, 2000, J MATER SCI-MATER M, V11, P1, DOI 10.1023/A:1008979532764; Brettler DB, 1996, BAILLIERE CLIN HAEM, V9, P319, DOI 10.1016/S0950-3536(96)80066-7; BRIET E, 1982, NEW ENGL J MED, V306, P788, DOI 10.1056/NEJM198204013061306; Buchanan GR, 1999, J PEDIAT HEMATOL ONC, V21, P254, DOI 10.1097/00043426-199907000-00002; Collins PW, 1997, BRIT J HAEMATOL, V99, P206, DOI 10.1046/j.1365-2141.1997.3643178.x; Cooper HA, 2001, HAEMOPHILIA, V7, P517, DOI 10.1046/j.1365-2516.2001.00553.x; CRASKE J, 1978, J HYG-CAMBRIDGE, V80, P327, DOI 10.1017/S0022172400024773; CRASKE J, 1975, LANCET, V2, P221; Damiano ML, 2000, HAEMOPHILIA, V6, P526; Dimichele D, 2003, HAEMOPHILIA, V9, P145, DOI 10.1046/j.1365-2516.2003.00725.x; Dimichele D, 2002, HAEMOPHILIA, V8, P280, DOI 10.1046/j.1365-2516.2002.00626.x; Evatt BL, 2002, HAEMOPHILIA, V8, P221, DOI 10.1046/j.1365-2516.2002.00612.x; Freiburghaus C, 1999, HAEMOPHILIA, V5, P32; Giangrande PLF, 2003, HAEMOPHILIA, V9, P240, DOI 10.1046/j.1365-2516.2003.00759.x; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; Goedert JJ, 2002, BLOOD, V100, P1584; Gordon FH, 1998, GUT, V42, P744, DOI 10.1136/gut.42.5.744; Greengard JS, 1999, THROMB HAEMOSTASIS, V82, P555; HAY CRM, 1985, LANCET, V1, P1495; Hollestelle MJ, 2001, THROMB HAEMOSTASIS, V86, P855, DOI 10.1055/s-0037-1616143; Jones P, 2000, BRIT J HAEMATOL, V111, P719; Journeycake JM, 2001, BLOOD, V98, P1727, DOI 10.1182/blood.V98.6.1727; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Key NS, 1998, THROMB HAEMOSTASIS, V80, P912; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; Kren BT, 1999, P NATL ACAD SCI USA, V96, P10349, DOI 10.1073/pnas.96.18.10349; Kulkarni R, 2001, BRIT J HAEMATOL, V112, P264, DOI 10.1046/j.1365-2141.2001.02362.x; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; Lee C, 2002, HAEMOPHILIA, V8, P322, DOI 10.1046/j.1365-2516.2002.00620.x; Lee CA, 1999, SEMIN HEMATOL, V36, P21; Lethagen S, 2001, BRIT J HAEMATOL, V113, P87, DOI 10.1046/j.1365-2141.2001.02700.x; Liesner RJ, 1996, BRIT J HAEMATOL, V92, P973, DOI 10.1046/j.1365-2141.1996.420960.x; Lillicrap D, 1998, HAEMOPHILIA, V4, P350, DOI 10.1046/j.1365-2516.1998.440350.x; LJUNG R, 1994, ACTA PAEDIATR, V83, P609; Ljung R, 2000, HAEMOPHILIA, V6, P619, DOI 10.1046/j.1365-2516.2000.00427.x; Lusher JM, 1998, EUR J HAEMATOL, V61, P7; Lusher JM, 2000, BEST PRACT RES CL HA, V13, P457, DOI 10.1053/beha.2000.0088; Makris M, 1996, BRIT J HAEMATOL, V94, P746, DOI 10.1046/j.1365-2141.1996.02343.x; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; MANNUCCI PM, 1975, J CLIN PATHOL, V28, P620, DOI 10.1136/jcp.28.8.620; Mannucci PM, 2000, HAEMOPHILIA, V6, P60; MANNUCCI PM, 1978, J CLIN PATHOL, V31, P779, DOI 10.1136/jcp.31.8.779; Mazurier C, 2001, BEST PRACT RES CL HA, V14, P337, DOI 10.1053/beha.2001.0138; MILLER R, 2002, PSYCHOL HEALTH MED, V7, P163; Miners AH, 1998, J INTERN MED, V244, P515, DOI 10.1111/j.1365-2796.1998.00396.x; Naraine VS, 2002, HAEMOPHILIA, V8, P112, DOI 10.1046/j.1365-2516.2002.00591.x; NAYLOR J, 1993, HUM MOL GENET, V2, P1773, DOI 10.1093/hmg/2.11.1773; NILSSON IM, 1992, J INTERN MED, V232, P25, DOI 10.1111/j.1365-2796.1992.tb00546.x; O'Mahoney B, 2002, GLOBAL HAEMOPHILIA C; Pasi KJ, 2001, BRIT J HAEMATOL, V115, P744, DOI 10.1046/j.1365-2141.2001.03225.x; Petrini P, 1998, BLOOD COAGUL FIBRIN, V9, pS143; Petrini P, 2001, HAEMOPHILIA, V7, P99, DOI 10.1046/j.1365-2516.2001.00471.x; Peyvandi F, 2002, HAEMOPHILIA, V8, P308, DOI 10.1046/j.1365-2516.2002.00633.x; Pollmann H, 1999, EUR J PEDIATR, V158, pS166, DOI 10.1007/PL00014347; POWELL JS, 2001, THROMB HAEMOSTASIS, V86, pC2489; Prowse C, 1997, VOX SANG, V72, P1, DOI 10.1046/j.1423-0410.1997.00001.x; Racoosin JA, 1999, HAEMOPHILIA, V5, P266; REIJNEN MJ, 1994, BLOOD COAGUL FIBRIN, V5, P341; Rizza CR, 2001, HAEMOPHILIA, V7, P349, DOI 10.1046/j.1365-2516.2001.00521.x; Rodeghiero F, 2002, HAEMOPHILIA, V8, P292, DOI 10.1046/j.1365-2516.2002.00611.x; Rodeghiero F, 2001, BEST PRACT RES CL HA, V14, P321, DOI 10.1053/beha.2001.0136; Rodriguez-Merchan EC, 1999, HAEMOPHILIA, V5, P53, DOI 10.1046/j.1365-2516.1999.0050s1053.x; ROSSITER JP, 1994, HUM MOL GENET, V3, P1035, DOI 10.1093/hmg/3.7.1035; Roth DA, 2001, NEW ENGL J MED, V344, P1735, DOI 10.1056/NEJM200106073442301; Roth DA, 2000, BLOOD, V96, p590A; Royal S, 2002, HAEMOPHILIA, V8, P44, DOI 10.1046/j.1365-2516.2002.00581.x; Santagostino E, 1998, BRIT J HAEMATOL, V102, P1224; SELIGSOHN U, 1994, HAEMOSTASIS, V24, P81; Shapiro AD, 1998, THROMB HAEMOSTASIS, V80, P773; Tengborn L, 1998, HAEMOPHILIA, V4, P854; Thorland EC, 1999, HAEMOPHILIA, V5, P101, DOI 10.1046/j.1365-2516.1999.00303.x; Tizzano EF, 2002, HAEMOPHILIA, V8, P250, DOI 10.1046/j.1365-2516.2002.00623.x; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; *UK HAEM CTR DOCT, 2002, REP ANN RET 1999; van den Berg HM, 2002, HAEMOPHILIA, V8, P43, DOI 10.1046/j.1351-8216.2001.00120.x; VINE B, 2002, BLOOD DOCTOR; Warrier I, 1998, HAEMOPHILIA, V4, P574, DOI 10.1046/j.1365-2516.1998.440574.x; WARRIER I, 2002, INHIBITORS PATIENTS, P87; White GC, 2001, THROMB HAEMOSTASIS, V85, P560, DOI 10.1055/s-0037-1615621; Wilde JT, 1999, BRIT J HAEMATOL, V107, P556, DOI 10.1046/j.1365-2141.1999.01748.x; Wilde JT, 2000, HAEMOPHILIA, V6, P487; Yee TT, 2002, HAEMOPHILIA, V8, P76, DOI 10.1046/j.1365-2516.2002.00630.x; Yee TT, 1996, BRIT J HAEMATOL, V93, P457, DOI 10.1046/j.1365-2141.1996.5161062.x	93	496	537	2	83	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2003	361	9371					1801	1809		10.1016/S0140-6736(03)13405-8	http://dx.doi.org/10.1016/S0140-6736(03)13405-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781551				2022-12-28	WOS:000183074800021
J	Brakefield, PM; Gates, J; Keys, D; Kesbeke, F; Wijngaarden, PJ; Monteiro, A; French, V; Carroll, SB				Brakefield, PM; Gates, J; Keys, D; Kesbeke, F; Wijngaarden, PJ; Monteiro, A; French, V; Carroll, SB			Development, plasticity and evolution of butterfly eyespot patterns	NATURE			English	Article							WESTERN WHITE BUTTERFLIES; PRECIS-COENIA LEPIDOPTERA; REACTION NORMS; SEASONAL POLYPHENISM; QUANTITATIVE CHARACTER; PHENOTYPIC PLASTICITY; BICYCLUS BUTTERFLIES; WING PATTERNS; GENETICS; NUMBER	The developmental and genetic bases for the formation, plasticity and diversity of eyespot patterns in butterflies are examined. Eyespot pattern mutants, regulatory gene expression, and transplants of the eyespot developmental organizer demonstrate that eyespot position, number, size and colour are determined progressively in a developmental pathway largely uncoupled from those regulating other wing-pattern elements and body structures. Species comparisons and selection experiments suggest that the evolution of eyespot patterns can occur rapidly through modulation of different stages of this pathway, and requires only single, of very few, changes in regulatory genes.	UNIV WISCONSIN, HOWARD HUGHES MED INST, MADISON, WI 53706 USA; UNIV WISCONSIN, MOL BIOL LAB, MADISON, WI 53706 USA; UNIV EDINBURGH, INST CELL ANIM & POPULAT BIOL, EDINBURGH EH9 3JT, MIDLOTHIAN, SCOTLAND	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Edinburgh	Brakefield, PM (corresponding author), LEIDEN UNIV, INST EVOLUTIONARY & ECOL SCI, KAISERSTR 63, POSTBUS 9516, NL-2300 RA LEIDEN, NETHERLANDS.		Monteiro, Antonia/J-6452-2013	Monteiro, Antonia/0000-0001-9696-459X				BRAKEFIELD PM, 1993, ACTA BIOTHEOR, V41, P447, DOI 10.1007/BF00709376; BRAKEFIELD PM, 1995, J EVOLUTION BIOL, V8, P559, DOI 10.1046/j.1420-9101.1995.8050559.x; BRAKEFIELD PM, 1991, ECOL ENTOMOL, V16, P291, DOI 10.1111/j.1365-2311.1991.tb00220.x; BRAKEFIELD PM, 1984, BIOL J LINN SOC, V22, P1, DOI 10.1111/j.1095-8312.1984.tb00795.x; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; COCKERHAM CC, 1986, GENETICS, V114, P659; Cott H.B., 1940, ADAPTIVE COLORATION; Endler J.A., 1986, Monographs in Population Biology, pviii; Endler J.A., 1978, Evolutionary Biology (New York), V11, P319; FRENCH V, 1995, DEV BIOL, V168, P112, DOI 10.1006/dbio.1995.1065; HOLLOWAY GJ, 1993, HEREDITY, V70, P179, DOI 10.1038/hdy.1993.27; KING RB, 1993, CAN J ZOOL, V71, P1985, DOI 10.1139/z93-282; KINGSOLVER JG, 1995, EVOLUTION, V49, P942, DOI 10.1111/j.1558-5646.1995.tb02329.x; KINGSOLVER JG, 1995, EVOLUTION, V49, P932, DOI [10.2307/2410415, 10.1111/j.1558-5646.1995.tb02328.x]; Koch PB, 1996, J INSECT PHYSIOL, V42, P223, DOI 10.1016/0022-1910(95)00103-4; KOOI RE, 1994, PROCEEDINGS OF THE SECTION EXPERIMENTAL AND APPLIED ENTOMOLOGY OF THE NETHERLANDS ENTOMOLOGICAL SOCIETY (N.E.V.), VOL 5, 1994, P47; LANDE R, 1981, GENETICS, V99, P541; MONTEIRO AF, 1994, EVOLUTION, V48, P1147, DOI [10.1111/j.1558-5646.1994.tb05301.x, 10.2307/2410374]; Nijhout H.F., 1991, DEV EVOLUTION BUTTER; Nijhout H.F., 1994, INSECT HORMONES; NIJHOUT HF, 1980, DEV BIOL, V80, P275, DOI 10.1016/0012-1606(80)90404-2; Pigliucci M, 1996, TRENDS ECOL EVOL, V11, P168, DOI 10.1016/0169-5347(96)10008-2; ROUNTREE DB, 1995, J INSECT PHYSIOL, V41, P1141, DOI 10.1016/0022-1910(95)00051-U; ROUNTREE DB, 1995, J INSECT PHYSIOL, V41, P987, DOI 10.1016/0022-1910(95)00046-W; SCHLICHTING CD, 1995, EVOL ECOL, V9, P154, DOI 10.1007/BF01237754; SHAPIRO A.M., 1976, EVOL BIOL, V9, P259, DOI DOI 10.1007/978-1-4615-6950-3_6; SHEPPARD PM, 1960, NATURAL SELECTION HE; STEARNS SC, 1989, BIOSCIENCE, V39, P436, DOI 10.2307/1311135; VANNOORDWIJK AJ, 1989, BIOSCIENCE, V39, P453, DOI 10.2307/1311137; VIA S, 1995, TRENDS ECOL EVOL, V10, P212, DOI 10.1016/S0169-5347(00)89061-8; WINDIG JJ, 1994, ECOL ENTOMOL, V19, P285, DOI 10.1111/j.1365-2311.1994.tb00420.x; Wright S., 1968, EVOLUTION GENETICS P, P373; ZENG ZB, 1990, GENETICS, V126, P235; ZWEIFEL RG, 1981, J HERED, V72, P238, DOI 10.1093/oxfordjournals.jhered.a109487	34	365	376	0	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					236	242		10.1038/384236a0	http://dx.doi.org/10.1038/384236a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	12809139				2022-12-28	WOS:A1996VU38100042
J	Tremblay, S; Shiller, DM; Ostry, DJ				Tremblay, S; Shiller, DM; Ostry, DJ			Somatosensory basis of speech production	NATURE			English	Article							VOWEL-U; PERTURBATION; COMPENSATION; VARIABILITY; ADAPTATION; MODEL	The hypothesis that speech goals are defined acoustically and maintained by auditory feedback is a central idea in speech production research(1-6). An alternative proposal is that speech production is organized in terms of control signals that subserve movements and associated vocal-tract configurations(7-9). Indeed, the capacity for intelligible speech by deaf speakers suggests that somatosensory inputs related to movement play a role in speech production-but studies that might have documented a somatosensory component have been equivocal. For example, mechanical perturbations that have altered somatosensory feedback have simultaneously altered acoustics(10-14). Hence, any adaptation observed under these conditions may have been a consequence of acoustic change. Here we show that somatosensory information on its own is fundamental to the achievement of speech movements. This demonstration involves a dissociation of somatosensory and auditory feedback during speech production. Over time, subjects correct for the effects of a complex mechanical load that alters jaw movements (and hence somatosensory feedback), but which has no measurable or perceptible effect on acoustic output. The findings indicate that the positions of speech articulators and associated somatosensory inputs constitute a goal of speech movements that is wholly separate from the sounds produced.	McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada; Haskins Labs Inc, New Haven, CT 06511 USA	McGill University; Yale University; Haskins Laboratories	Ostry, DJ (corresponding author), McGill Univ, Dept Psychol, 1205 Dr Penfield Ave, Montreal, PQ H3A 1B1, Canada.		Galantucci, Bruno/E-5770-2010					BERNSTEIN LR, 1982, J ACOUST SOC AM, V71, P147, DOI 10.1121/1.387254; BROWMAN CP, 1992, PHONETICA, V49, P155, DOI 10.1159/000261913; Gandolfo F, 1996, P NATL ACAD SCI USA, V93, P3843, DOI 10.1073/pnas.93.9.3843; Goodbody SJ, 1998, J NEUROPHYSIOL, V79, P1825, DOI 10.1152/jn.1998.79.4.1825; Guenther FH, 1998, PSYCHOL REV, V105, P611, DOI 10.1037/0033-295X.105.4.611-633; GUENTHER FH, 1995, PSYCHOL REV, V102, P594, DOI 10.1037/0033-295X.102.3.594; Guenther FH, 1999, J ACOUST SOC AM, V105, P2854, DOI 10.1121/1.426900; Hamlet S. L, 1976, J PHONETICS, V4, P199; Houde JF, 1998, SCIENCE, V279, P1213, DOI 10.1126/science.279.5354.1213; Jones JA, 2000, J ACOUST SOC AM, V108, P1246, DOI 10.1121/1.1288414; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; LINDBLOM B, 1979, J PHONETICS, V7, P147, DOI 10.1016/S0095-4470(19)31046-0; MCFARLAND DH, 1995, J ACOUST SOC AM, V97, P1865, DOI 10.1121/1.412060; McFarland DH, 1996, J ACOUST SOC AM, V100, P1093, DOI 10.1121/1.416286; PERKELL JS, 1993, J ACOUST SOC AM, V93, P2948, DOI 10.1121/1.405814; PERKELL JS, 1985, J ACOUST SOC AM, V77, P1889, DOI 10.1121/1.391940; Saltzman E., 1989, ECOL PSYCHOL, V1, P333, DOI [10.1207/s15326969eco0104_2, DOI 10.1207/S15326969EC00104_]; SAVARIAUX C, 1995, J ACOUST SOC AM, V98, P2428, DOI 10.1121/1.413277; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Thoroughman KA, 2000, NATURE, V407, P742, DOI 10.1038/35037588	20	207	210	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					866	869		10.1038/nature01710	http://dx.doi.org/10.1038/nature01710			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	691BQ	12815431				2022-12-28	WOS:000183585300045
J	Raff, H; Findling, JW				Raff, H; Findling, JW			A Physiologic approach to diagnosis of the Cushing syndrome	ANNALS OF INTERNAL MEDICINE			English	Review							CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL AXIS; URINARY FREE CORTISOL; DEXAMETHASONE-SUPPRESSION TEST; NIGHTTIME SALIVARY CORTISOL; ECTOPIC ACTH SYNDROME; DIFFERENTIAL-DIAGNOSIS; ADRENOCORTICOTROPIC HORMONE; IMMUNORADIOMETRIC ASSAY; METABOLIC SYNDROME		Med Coll Wisconsin, St Lukes Med Ctr, Milwaukee, WI 53215 USA	Medical College of Wisconsin	Raff, H (corresponding author), Med Coll Wisconsin, St Lukes Med Ctr, 2801 W KK River Pkwy,Suite 245, Milwaukee, WI 53215 USA.	hraff@mcw.edu						Aguilera G, 2000, REGUL PEPTIDES, V96, P23, DOI 10.1016/S0167-0115(00)00196-8; ARCHARD C, 1921, B ACAD NATL MED, V86, P51; Aron DC, 1997, J CLIN ENDOCR METAB, V82, P1780, DOI 10.1210/jc.82.6.1780; BECKER M, 1994, ENDOCRIN METAB CLIN, V23, P585, DOI 10.1016/S0889-8529(18)30086-0; Bierwolf C, 2000, EXP CLIN ENDOCR DIAB, V108, P470, DOI 10.1055/s-2000-8143; Blevins L S Jr, 1998, Endocr Pract, V4, P365; Bonelli FS, 1999, AM J NEURORADIOL, V20, P306; Booth GL, 1998, J CLIN ENDOCR METAB, V83, P2291, DOI 10.1210/jc.83.7.2291; Born J, 1998, EXP CLIN ENDOCR DIAB, V106, P153, DOI 10.1055/s-0029-1211969; Castro M, 1999, J CLIN ENDOCR METAB, V84, P878, DOI 10.1210/jc.84.3.878; Castro M, 2000, BRAZ J MED BIOL RES, V33, P1171, DOI 10.1590/S0100-879X2000001000006; Cizza G, 1996, J CLIN ENDOCR METAB, V81, P3573, DOI 10.1210/jc.81.10.3573; Contreras LN, 2000, MEDICINA-BUENOS AIRE, V60, P326; Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137; DALLMAN MF, 1992, J NEUROENDOCRINOL, V4, P517, DOI 10.1111/j.1365-2826.1992.tb00200.x; DALLMAN MF, 1994, ANN NY ACAD SCI, V746, P22; DOPPMAN JL, 1988, J COMPUT ASSIST TOMO, V12, P728, DOI 10.1097/00004728-198809010-00002; DWYER AJ, 1987, RADIOLOGY, V163, P421, DOI 10.1148/radiology.163.2.3562821; Findling J. W, 1993, ENDOCRINE TUMORS, P554; Findling JW, 2001, ENDOCRIN METAB CLIN, V30, P729, DOI 10.1016/S0889-8529(05)70209-7; FINDLING JW, 1991, J CLIN ENDOCR METAB, V73, P408, DOI 10.1210/jcem-73-2-408; Findling JW, 1998, ENDOCRINOLOGIST, V8, P51, DOI 10.1097/00019616-199803000-00001; Findling JW, 1999, ENDOCRIN METAB CLIN, V28, P191, DOI 10.1016/S0889-8529(05)70063-3; Gafni RI, 2000, J PEDIATR-US, V137, P30, DOI 10.1067/mpd.2000.106226; Giraldi FP, 2001, CLIN ENDOCRINOL, V54, P601, DOI 10.1046/j.1365-2265.2001.01258.x; Gorges R, 1999, J ENDOCRINOL INVEST, V22, P241; HALL WA, 1994, ANN INTERN MED, V120, P817, DOI 10.7326/0003-4819-120-10-199405150-00001; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; Kaltsas GA, 2000, CLIN ENDOCRINOL, V53, P493, DOI 10.1046/j.1365-2265.2000.01117.x; Klose M, 2002, SCAND J CLIN LAB INV, V62, P33, DOI 10.1080/003655102753517181; Lacroix A, 2001, ENDOCR REV, V22, P75, DOI 10.1210/er.22.1.75; LANDOLT AM, 1994, CLIN ENDOCRINOL, V40, P485, DOI 10.1111/j.1365-2265.1994.tb02487.x; LAUDAT MH, 1988, J CLIN ENDOCR METAB, V66, P343, DOI 10.1210/jcem-66-2-343; Leibowitz G, 1996, CLIN ENDOCRINOL, V44, P717, DOI 10.1046/j.1365-2265.1996.737558.x; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; Lin CL, 1997, J CLIN ENDOCR METAB, V82, P151, DOI 10.1210/jc.82.1.151; Martinelli CE, 1999, CLIN ENDOCRINOL, V51, P67, DOI 10.1046/j.1365-2265.1999.00749.x; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McEwen BS, 1997, ANN NY ACAD SCI, V823, P201, DOI 10.1111/j.1749-6632.1997.tb48392.x; MEIKLE AW, IN PRESS J CLIN ENDO; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; Mericq MV, 1998, J CLIN ENDOCR METAB, V83, P682, DOI 10.1210/jc.83.2.682; MILLER DL, 1992, RADIOLOGY, V185, P143, DOI 10.1148/radiology.185.1.1523298; Murphy BEP, 2002, ENDOCRINOLOGIST, V12; NEWELLPRICE J, 1995, CLIN ENDOCRINOL, V43, P545, DOI 10.1111/j.1365-2265.1995.tb02918.x; NIEMAN LK, 1990, END SOC 72 ANN M ATL, P822; Obuobie K, 2000, J ENDOCRINOL INVEST, V23, P542, DOI 10.1007/BF03343772; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; Oldfield EH, 1998, J NEUROSURG, V89, P890; Oliverio PJ, 1996, AM J NEURORADIOL, V17, P1669; Papanicolaou DA, 2002, J CLIN ENDOCR METAB, V87, P4515, DOI 10.1210/jc.2002-020534; Papanicolaou DA, 1998, J CLIN ENDOCR METAB, V83, P1163, DOI 10.1210/jc.83.4.1163; Raff H, 1998, J CLIN ENDOCR METAB, V83, P2681, DOI 10.1210/jc.83.8.2681; Raff H, 2003, CLIN CHEM, V49, P203, DOI 10.1373/49.1.203; RAFF H, 1993, ANN NY ACAD SCI, V689, P411, DOI 10.1111/j.1749-6632.1993.tb55564.x; Raff H, 2002, CLIN CHEM, V48, P207; RAFF H, 1989, CLIN CHEM, V35, P596; Raff H, 1998, ENDOCRINOLOGIST, V8, P9, DOI 10.1097/00019616-199801000-00004; Raff J, 2000, ENDOCRINOLOGIST, V10, P9; RAMIREZ G, 1982, ARCH INTERN MED, V142, P1448, DOI 10.1001/archinte.142.8.1448; REINCKE M, 1992, J CLIN ENDOCR METAB, V75, P826, DOI 10.1210/jc.75.3.826; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; STARKMAN MN, 1981, ARCH INTERN MED, V141, P215, DOI 10.1001/archinte.141.2.215; STEWART PM, 1993, STEROIDS, V58, P614, DOI 10.1016/0039-128X(93)90104-U; Stratakis CA, 2001, J CLIN ENDOCR METAB, V86, P4041, DOI 10.1210/jc.86.9.4041; Terzolo M, 2002, J CLIN ENDOCR METAB, V87, P998, DOI 10.1210/jc.87.3.998; Terzolo M, 2001, CLIN ENDOCRINOL, V54, P609, DOI 10.1046/j.1365-2265.2001.01260.x; Tomlinson JW, 2002, J CLIN ENDOCR METAB, V87, P57, DOI 10.1210/jc.87.1.57; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wood PJ, 1997, ANN CLIN BIOCHEM, V34, P222, DOI 10.1177/000456329703400302; YANOVSKI JA, 1993, JAMA-J AM MED ASSOC, V269, P2232, DOI 10.1001/jama.269.17.2232	73	109	119	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2003	138	12					980	991		10.7326/0003-4819-138-12-200306170-00010	http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YM	12809455				2022-12-28	WOS:000183578100006
J	Tarrant, C; Windridge, K; Boulton, M; Baker, R; Freeman, G				Tarrant, C; Windridge, K; Boulton, M; Baker, R; Freeman, G			"He treats you as a person not just like a number" - How important is personal care in general practice?	BRITISH MEDICAL JOURNAL			English	Article							DOCTOR; COMMUNICATION		Univ Leicester, Dept Gen Practice & Primary Hlth Care, Clin Governance Res & Dev Unit, Leicester LE5 4PW, Leics, England; Oxford Brookes Univ, Sch Social Sci & Law, Oxford OX3 0BP, England; Univ London Imperial Coll Sci Technol & Med, Ctr Primary Care & Social Med, London W6 8RP, England	University of Leicester; Oxford Brookes University; Imperial College London	Tarrant, C (corresponding author), Univ Leicester, Dept Gen Practice & Primary Hlth Care, Clin Governance Res & Dev Unit, Gwendolen Rd, Leicester LE5 4PW, Leics, England.			Tarrant, Carolyn/0000-0001-7356-5342; Boulton, Mary/0000-0002-2247-8318				ARBORELIUS E, 1992, Scandinavian Journal of Primary Health Care, V10, P163, DOI 10.3109/02813439209014056; Baker R, 1997, BRIT J GEN PRACT, V47, P831; Barry CA, 2001, SOC SCI MED, V53, P487, DOI 10.1016/S0277-9536(00)00351-8; *CHAR CROSS CAMP, CTR PRIM CAR SOC MED; *DEP GEN PRACT PRI, CLIN GOV RES DEV UN; *DEP HLTH, 1996, CHOIC OPP PRIM CAR F; Eisner M, 1999, BRIT J GEN PRACT, V49, P103; Fitton F., 1979, DOCTOR PATIENT RELAT; Freeman G., 2000, CONTINUITY CARE REPO; *GEN MED SERV COMM, 1996, CAR SERV TAK IN; *GEN PRACT COMM, 2002, YOUR CONTR YOUR FUT; *GIPS LAN CAMP, SCH SOC SCI LAW OXF; Gray D J, 1979, J R Coll Gen Pract, V29, P666; Kearley KE, 2001, BRIT J GEN PRACT, V51, P712; Maguire P, 2002, BRIT MED J, V325, P697, DOI 10.1136/bmj.325.7366.697; Richie J., 1994, ANAL QUALITATIVE DAT; *ROYAL COLL GEN PR, 1972, FUT MED PRACT LEARN; Royal College of General Practitioners, 1996, NAT GEN MED PRACT; Schers H, 2002, BRIT J GEN PRACT, V52, P459; Secretary of State for Health, 2000, NHS PLAN; Wanless D, 2001, SECURING OUR FUTURE; *WHO EUR OFF, 2002, EUR DEF GEN PRACT FA	22	59	60	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1310	1312A		10.1136/bmj.326.7402.1310	http://dx.doi.org/10.1136/bmj.326.7402.1310			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805168	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000183626500032
J	Eisen, JA; Fraser, CM				Eisen, JA; Fraser, CM			Phylogenomics: Intersection of evolution and genomics	SCIENCE			English	Editorial Material							SEQUENCE; GENES; BACTERIAL; PROTEIN	Much has been gained from genomic and evolutionary studies of species. Combining the perspectives of these different approaches suggests that an integrated phylogenomic approach will be beneficial.	Inst Genome Res, Rockville, MD 20850 USA	J. Craig Venter Institute	Eisen, JA (corresponding author), Inst Genome Res, Rockville, MD 20850 USA.	jeisen@tigr.org	Eisen, Jonathan A./H-2706-2019	Eisen, Jonathan A./0000-0002-0159-2197; Fraser, Claire/0000-0003-1462-2428				Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Daubin V, 2002, GENOME RES, V12, P1080, DOI 10.1101/gr.187002; Doolittle WF, 1999, TRENDS CELL BIOL, V15, P5, DOI DOI 10.1016/S0168-9525(99)01877-6; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; Eisen JA, 1998, GENOME RES, V8, P163, DOI 10.1101/gr.8.3.163; Eisen JA, 2002, NATURE, V415, P845, DOI 10.1038/nature725; Eisen JA, 1998, NUCLEIC ACIDS RES, V26, P4291, DOI 10.1093/nar/26.18.4291; Eisen JA, 1997, NAT MED, V3, P1076, DOI 10.1038/nm1097-1076; Eisen JA, 2000, CURR OPIN GENET DEV, V10, P606, DOI 10.1016/S0959-437X(00)00143-X; Eisen JA, 2000, GENOME BIOL, V1; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HUENHOLTZ P, 2002, GENOME BIOL, V3; Jordan IK, 2001, GENOME RES, V11, P555, DOI 10.1101/gr.GR-1660R; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Read TD, 2002, SCIENCE, V296, P2028, DOI 10.1126/science.1071837; Roelofs J, 2001, NATURE, V411, P1013, DOI 10.1038/35082627; Rujan T, 2001, TRENDS GENET, V17, P113, DOI 10.1016/S0168-9525(00)02209-5; Salzberg SL, 2001, SCIENCE, V293, P1048; Stanhope MJ, 2001, NATURE, V411, P940, DOI 10.1038/35082058; Suyama M, 2001, TRENDS GENET, V17, P10, DOI 10.1016/S0168-9525(00)02159-4; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	30	212	229	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1706	1707		10.1126/science.1086292	http://dx.doi.org/10.1126/science.1086292			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805538				2022-12-28	WOS:000183459700039
J	Sanfey, AG; Rilling, JK; Aronson, JA; Nystrom, LE; Cohen, JD				Sanfey, AG; Rilling, JK; Aronson, JA; Nystrom, LE; Cohen, JD			The neural basis of economic decision-making in the ultimatum game	SCIENCE			English	Article							ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; COMPETITION; COOPERATION; SATIATION; FAIRNESS; DISGUST; PAIN	The nascent field of neuroeconomics seeks to ground economic decision-making in the biological substrate of the brain. We used functional magnetic resonance imaging of Ultimatum Game players to investigate neural substrates of cognitive and emotional processes involved in economic decision-making. In this game, two players split a sum of money; one player proposes a division and the other can accept or reject this. We scanned players as they responded to fair and unfair proposals. Unfair offers elicited activity in brain areas related to both emotion ( anterior insula) and cognition ( dorsolateral prefrontal cortex). Further, significantly heightened activity in anterior insula for rejected unfair offers suggests an important role for emotions in decision-making.	Princeton Univ, Ctr Study Brain Mind & Behav, Princeton, NJ 08544 USA; Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; Princeton Univ, Ctr Hlth & Well Being, Princeton, NJ 08544 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA	Princeton University; Princeton University; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sanfey, AG (corresponding author), Princeton Univ, Ctr Study Brain Mind & Behav, Princeton, NJ 08544 USA.		sarinopoulos, isidoros/B-5453-2010; Sanfey, Alan G/D-2350-2010	Sanfey, Alan/0000-0002-7421-8294				Bolton GE, 2000, AM ECON REV, V90, P166, DOI 10.1257/aer.90.1.166; BOLTON GE, 1995, GAME ECON BEHAV, V10, P95, DOI 10.1006/game.1995.1026; Bonetti S, 1998, J ECON PSYCHOL, V19, P377, DOI 10.1016/S0167-4870(98)00012-9; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Calder AJ, 2001, NAT REV NEUROSCI, V2, P352, DOI 10.1038/35072584; CAMERER C, 1995, J ECON PERSPECT, V9, P209, DOI 10.1257/jep.9.2.209; CAMERER C, IN PRESS ADV BEHAV E; Critchley HD, 2000, J NEUROSCI, V20, P3033; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; Denton D, 1999, P NATL ACAD SCI USA, V96, P5304, DOI 10.1073/pnas.96.9.5304; Derbyshire SWG, 1997, PAIN, V73, P431, DOI 10.1016/S0304-3959(97)00138-3; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Henrich J, 2001, AM ECON REV, V91, P73, DOI 10.1257/aer.91.2.73; Hertwig R, 2001, BEHAV BRAIN SCI, V24, P383, DOI 10.1017/S0140525X01004149; Iadarola MJ, 1998, BRAIN, V121, P931, DOI 10.1093/brain/121.5.931; Loewenstein G., 2003, HDB AFFECTIVE SCI; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; McCabe K, 2001, P NATL ACAD SCI USA, V98, P11832, DOI 10.1073/pnas.211415698; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Nowak MA, 2000, SCIENCE, V289, P1773, DOI 10.1126/science.289.5485.1773; Phillips ML, 1997, NATURE, V389, P495, DOI 10.1038/39051; Pillutla MM, 1996, ORGAN BEHAV HUM DEC, V68, P208, DOI 10.1006/obhd.1996.0100; Roth A.E., 1995, HDB EXPT EC; ROZIN P, 1987, PSYCHOL REV, V94, P23, DOI 10.1037/0033-295X.94.1.23; Tataranni PA, 1999, P NATL ACAD SCI USA, V96, P4569, DOI 10.1073/pnas.96.8.4569; THALER RH, 1988, J ECON PERSPECT, V2, P195, DOI 10.1257/jep.2.4.195; Wagner AD, 2001, NEUROIMAGE, V14, P1337, DOI 10.1006/nimg.2001.0936; [No title captured]	28	1970	2035	20	556	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1755	1758		10.1126/science.1082976	http://dx.doi.org/10.1126/science.1082976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805551				2022-12-28	WOS:000183459700054
J	Pelli, DG; Farell, B; Moore, DC				Pelli, DG; Farell, B; Moore, DC			The remarkable inefficiency of word recognition	NATURE			English	Article							PERCEPTION; MODEL; IDENTIFICATION; EXPERTISE; VISION	Do we recognize common objects by parts, or as wholes? Holistic recognition would be efficient, yet people detect a grating of light and dark stripes by parts. Thus efficiency falls as the number of stripes increases, in inverse proportion, as explained by probability summation among independent feature detectors(1). It is inefficient to detect correlated components independently. But gratings are uncommon artificial stimuli that may fail to tap the full power of visual object recognition. Familiar objects become special as people become expert at judging them(2,3), possibly because the processing becomes more holistic. Letters and words were designed to be easily recognized, and, through a lifetime of reading, our visual system presumably has adapted to do this as well as it possibly can. Here we show that in identifying familiar English words, even the five most common three-letter words, observers have the handicap predicted by recognition by parts: a word is unreadable unless its letters are separately identifiable. Efficiency is inversely proportional to word length, independent of how many possible words (5, 26 or thousands) the test word is drawn from. Human performance never exceeds that attainable by strictly letter-or feature-based models. Thus, everything seen is a pattern of features. Despite our virtuosity at recognizing patterns and our expertise from reading a billion letters, we never learn to see a word as a feature; our efficiency is limited by the bottleneck of having to rigorously and independently detect simple features.	NYU, New York, NY 10003 USA; Syracuse Univ, Inst Sensory Res, Syracuse, NY 13244 USA	New York University; Syracuse University	Pelli, DG (corresponding author), NYU, New York, NY 10003 USA.			Farell, Bart/0000-0003-0902-5290				BARLOW HB, 1953, J PHYSIOL-LONDON, V119, P69, DOI 10.1113/jphysiol.1953.sp004829; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; CAMPBELL FW, 1968, J PHYSIOL-LONDON, V197, P551, DOI 10.1113/jphysiol.1968.sp008574; Cattell James M. K., 1886, MIND, V11, P220, DOI DOI 10.1093/MIND/OS-XI.42.220; DIAMOND R, 1986, J EXP PSYCHOL GEN, V115, P107, DOI 10.1037/0096-3445.115.2.107; Gauthier I, 2000, NAT NEUROSCI, V3, P191, DOI 10.1038/72140; HADLEY JA, 1991, J EXP PSYCHOL LEARN, V17, P1062; Huey E.B., 1908, PSYCHOL PEDAGOGY REA; JOHNSTON JC, 1980, J VERB LEARN VERB BE, V19, P503, DOI 10.1016/S0022-5371(80)90573-3; JOHNSTON JC, 1974, SCIENCE, V184, P1192, DOI 10.1126/science.184.4142.1192; JOHNSTON JC, 1978, COGNITIVE PSYCHOL, V10, P123, DOI 10.1016/0010-0285(78)90011-7; Jordan TR, 1996, J EXP PSYCHOL HUMAN, V22, P1416, DOI 10.1037/0096-1523.22.6.1416; Kucera H., 1967, COMPUTATIONAL ANAL P; LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8; MAJAJ NJ, 2003, J VISION, V3; MCCLELLAND JL, 1981, PSYCHOL REV, V88, P375, DOI 10.1037/0033-295X.88.5.375; Pelli DG, 1999, J OPT SOC AM A, V16, P647, DOI 10.1364/JOSAA.16.000647; PELLI DG, IN PRESS J VISION; PELLI DG, IN PRESS VISION RES; PETERSON WW, 1954, IRE T INFORM THEOR, P171, DOI 10.1109/TIT.1954.1057460; PRINZMETAL W, 1994, PERCEPT PSYCHOPHYS, V55, P296, DOI 10.3758/BF03207601; REICHER GM, 1969, J EXP PSYCHOL, V81, P275, DOI 10.1037/h0027768; ROBSON JG, 1981, VISION RES, V21, P409, DOI 10.1016/0042-6989(81)90169-3; Selfridge O. G., 1959, S MECH THOUGHT PROC, P513; SOLOMON JA, 1994, NATURE, V369, P395, DOI 10.1038/369395a0; TANNER WP, 1958, J ACOUST SOC AM, V30, P922, DOI 10.1121/1.1909408; Tarr MJ, 1998, COGNITION, V67, P1, DOI 10.1016/S0010-0277(98)00026-2; TREISMAN A, 1982, COGNITIVE PSYCHOL, V14, P107, DOI 10.1016/0010-0285(82)90006-8; WATSON AB, 1981, VISION RES, V21, P1115, DOI 10.1016/0042-6989(81)90014-6; WHEELER DD, 1970, COGNITIVE PSYCHOL, V1, P59, DOI 10.1016/0010-0285(70)90005-8	30	200	201	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					752	756		10.1038/nature01516	http://dx.doi.org/10.1038/nature01516			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	688PA	12802334				2022-12-28	WOS:000183443400043
J	Butcher, K				Butcher, K			Confusion between prostitution and sex trafficking	LANCET			English	Editorial Material									John Snow Int UK, London NW5 1TL, England		Butcher, K (corresponding author), John Snow Int UK, Highgate Studios, London NW5 1TL, England.		Butcher, Ken/AEP-3693-2022; Butcher, Ken/ABC-6632-2020	Butcher, Ken/0000-0002-0590-7918; Butcher, Ken/0000-0002-0590-7918				*HUM RIGHTS CAUC, 2000, UN TRAFF PROT LOST O; KOTISWARAN P, 2001, BOSTON COLL 3 WORLD, V21; LUCKOO F, 2002, COMBATING TRAFFICKIN; *NETW SEX WORK PRO, MAK SEX WORK SAF	4	39	39	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1983	1983		10.1016/S0140-6736(03)13596-9	http://dx.doi.org/10.1016/S0140-6736(03)13596-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801757				2022-12-28	WOS:000183359700028
J	Yamamoto, Y; Verma, UN; Prajapati, S; Kwak, YT; Gaynor, RB				Yamamoto, Y; Verma, UN; Prajapati, S; Kwak, YT; Gaynor, RB			Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression	NATURE			English	Article							NF-KAPPA-B; KINASE COMPLEX; MICE LACKING; P65 SUBUNIT; ACTIVATION; PROTEINS; CBP/P300; GROWTH; ACETYLATION; PATHWAY	Cytokine-induced activation of the IkappaB kinases (IKK) IKK-alpha and IKK-beta is a key step involved in the activation of the NF-kappaB pathway(1-4). Gene-disruption studies of the murine IKK genes have shown that IKK-beta, but not IKK-alpha, is critical for cytokine-induced IkappaB degradation(5-7). Nevertheless, mouse embryo fibroblasts deficient in IKK- a are defective in the induction of NF-kappaB-dependent transcription(7-9). These observations raised the question of whether IKK-alpha might regulate a previously undescribed step to activate the NF-kappaB pathway that is independent of its previously described cytoplasmic role in the phosphorylation of IkappaBalpha. Here we show that IKK-alpha functions in the nucleus to activate the expression of NF-kappaB-responsive genes after stimulation with cytokines. IKK-alpha interacts with CREB-binding protein and in conjunction with Rel A is recruited to NF-kappaB-responsive promoters and mediates the cytokine-induced phosphorylation and subsequent acetylation of specific residues in histone H3. These results define a new nuclear role of IKK-alpha in modifying histone function that is critical for the activation of NF-kappaB-directed gene expression.	Univ Texas, SW Med Ctr, Harold Simmons Canc Ctr, Dept Med,Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Harold Simmons Canc Ctr, Dept Med,Div Hematol Oncol, Dallas, TX 75390 USA.							Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goodman RH, 2000, GENE DEV, V14, P1553; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	29	503	524	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					655	659		10.1038/nature01576	http://dx.doi.org/10.1038/nature01576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789342				2022-12-28	WOS:000183301200044
J	Bazzano, LA; He, J; Muntner, P; Vupputuri, S; Whelton, PK				Bazzano, LA; He, J; Muntner, P; Vupputuri, S; Whelton, PK			Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							C-REACTIVE PROTEIN; CORONARY-ARTERY-DISEASE; APPARENTLY HEALTHY-MEN; PLASMA HOMOCYSTEINE; LIQUID-CHROMATOGRAPHY; HEART-DISEASE; FIBRINOGEN; INFLAMMATION; ASSOCIATION; SMOKERS	Background: Few studies have examined the relationship between cigarette smoking and novel risk factors for cardiovascular disease in a general population or have included a biochemical marker of current smoking. Objective: To examine the relationship between cigarette smoking and serum C-reactive protein, fibrinogen, and homocysteine levels. Design: Cross-sectional study. Setting: The U.S. general population. Patients: 4187 current smokers, 4791 former smokers, and 8375 never-smokers 18 years of age or older who participated in the Third National Health and Nutrition Examination Survey conducted between 1988 and 1994. Measurements: serum C-reactive protein levels were categorized as detectable (2.2 to 9.9 mg/L) or clinically elevated (greater than or equal to10 mg/L), and fibrinogen and homocysteine levels were defined as elevated if in the 85th percentile or greater (11.1 mumol/L and 12.7 mmol/L, respectively). Results: After adjustment for traditional cardiovascular disease risk factors, cigarette smoking was related to elevated levels of C-reactive protein, fibrinogen, and homocysteine. Compared with never smoking cigarettes, self-reported current cigarette smoking was associated with a C-reactive protein level in the detectable (odds ratio, 1.66 [95% CI, 1.40 to 1.97]; P < 0.001) or clinically elevated (odds ratio, 1.98 [CI, 1.57 to 2.51]; P < 0.001) ranges, with elevated levels of fibrinogen (odds ratio, 2.15 [CI, 1.65 to 2.80]; P < 0.001) and homocysteine (odds ratio, 2.10 [CI, 1.62 to 2.74]; P < 0.001). There were positive and significant dose-response relationships between measures of cigarette smoking (cigarettes per day, pack-years, and serum cotinine levels) and elevated levels of novel risk factors. Conclusions: These findings suggest that inflammation and hyperhomocysteinemia may be important mechanisms by which smoking promotes atherosclerotic disease.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA	Tulane University; Tulane University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave SL18, New Orleans, LA 70112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060300] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL60300] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HEART ASS, 2001, 2002 HEART STROK STA; Anderson JL, 2000, CIRCULATION, V102, P1227, DOI 10.1161/01.CIR.102.11.1227; [Anonymous], 1994, VITAL HLTH STAT, P1; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Azar RR, 2000, AM J CARDIOL, V86, P205, DOI 10.1016/S0002-9149(00)00856-0; Bermudez EA, 2002, AM J CARDIOL, V89, P1117, DOI 10.1016/S0002-9149(02)02284-1; Bernert JT, 1997, CLIN CHEM, V43, P2281; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Campisi R, 1998, CIRCULATION, V98, P119, DOI 10.1161/01.CIR.98.2.119; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; DAS I, 1985, CLIN CHIM ACTA, V153, P9, DOI 10.1016/0009-8981(85)90133-0; de Bree A, 2001, AM J EPIDEMIOL, V154, P150, DOI 10.1093/aje/154.2.150; Erlinger TP, 2001, ARCH INTERN MED, V161, P1903, DOI 10.1001/archinte.161.15.1903; Fusegawa Y, 1999, THROMB RES, V93, P271, DOI 10.1016/S0049-3848(98)00184-4; GREEN D, 1994, ARTERIOSCLER THROMB, V14, P686, DOI 10.1161/01.ATV.14.5.686; Gunter EW, 1996, LAB PROCEDURES USED; He J, 2001, ARCH INTERN MED, V161, P996, DOI 10.1001/archinte.161.7.996; HUNG J, 1995, CIRCULATION, V92, P2432, DOI 10.1161/01.CIR.92.9.2432; Jacques PF, 2001, AM J CLIN NUTR, V73, P613; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; KROBOT K, 1992, ARTERIOSCLER THROMB, V12, P780, DOI 10.1161/01.ATV.12.7.780; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; MUSCAT JE, 1991, AM HEART J, V121, P141, DOI 10.1016/0002-8703(91)90967-M; Ockene IS, 1997, CIRCULATION, V96, P3243, DOI 10.1161/01.CIR.96.9.3243; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rohde LEP, 1999, AM J CARDIOL, V84, P1018, DOI 10.1016/S0002-9149(99)00491-9; SHAW ST, 1977, CRC CR REV CL LAB SC, V8, P145, DOI 10.3109/10408367709151695; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P2167, DOI 10.1161/01.ATV.17.10.2167; US Department of Health and Human Services [Internet], 1990, HLTH BEN SMOK CESS R	32	273	284	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					891	897		10.7326/0003-4819-138-11-200306030-00010	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779299				2022-12-28	WOS:000183296400004
J	Chambers, I; Colby, D; Robertson, M; Nichols, J; Lee, S; Tweedie, S; Smith, A				Chambers, I; Colby, D; Robertson, M; Nichols, J; Lee, S; Tweedie, S; Smith, A			Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells	CELL			English	Article							LEUKEMIA INHIBITORY FACTOR; PRIMORDIAL GERM-CELLS; SELF-RENEWAL; DIFFERENTIATION; GENE; RECEPTOR; MAINTENANCE; ACTIVATION; STAT3; GP130	Embryonic stem (ES) cells undergo extended proliferation while remaining poised for multilineage differentiation. A unique network of transcription factors may characterize self-renewal and simultaneously suppress differentiation. We applied expression cloning in mouse ES cells to isolate a self-renewal determinant. Nanog is a divergent homeodomain protein that directs propagation of undifferentiated ES cells. Nanog mRNA is present in pluripotent mouse and human cell lines, and absent from differentiated cells. In preimplantation embryos, Nanog is restricted to founder cells from which ES cells can be derived. Endogenous Nanog acts in parallel with cytokine stimulation of Stat3 to drive ES cell self-renewal. Elevated Nanog expression from transgene constructs is sufficient for clonal expansion of ES cells, bypassing Stat3 and maintaining Oct4 levels. Cytokine dependence, multilineage differentiation, and embryo colonization capacity are fully restored upon transgene excision. These findings establish a central role for Nanog in the transcription factor hierarchy that defines ES cell identity.	Univ Edinburgh, Inst Stem Cell Res, Edinburgh EH9 3JQ, Midlothian, Scotland	University of Edinburgh	Chambers, I (corresponding author), Univ Edinburgh, Inst Stem Cell Res, Kings Bldg,W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.	ichambers@ed.ac.uk	Tweedie, Susan/B-3695-2019; Chambers, Ian/H-5416-2011	Tweedie, Susan/0000-0003-1818-8243; Chambers, Ian/0000-0003-2605-1597; Nichols, Jennifer/0000-0002-8650-1388; Smith, Austin/0000-0002-3029-4682				ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Burdon T, 1999, CELLS TISSUES ORGANS, V165, P131, DOI 10.1159/000016693; Chambers I, 1997, BIOCHEM J, V328, P879, DOI 10.1042/bj3280879; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; GALLI G, 1981, NATURE, V294, P626, DOI 10.1038/294626a0; GASSMANN M, 1995, P NATL ACAD SCI USA, V92, P1292, DOI 10.1073/pnas.92.5.1292; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nichols J, 2001, DEVELOPMENT, V128, P2333; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; PERA MF, 1989, DIFFERENTIATION, V42, P10, DOI 10.1111/j.1432-0436.1989.tb00602.x; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; RYSKOV AP, 1983, NUCLEIC ACIDS RES, V11, P6541, DOI 10.1093/nar/11.18.6541; Smith A, 2001, COLD SPRING HARBOR M, P205; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; Wang SH, 2003, GENE EXPR PATTERNS, V3, P99, DOI 10.1016/S1567-133X(03)00005-X; Yoshida A, 1996, ASSIST REPROD REV, V67, P93; YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925-4773(94)90030-2	48	2470	2784	4	272	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2003	113	5					643	655		10.1016/S0092-8674(03)00392-1	http://dx.doi.org/10.1016/S0092-8674(03)00392-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787505	Green Submitted, Bronze			2022-12-28	WOS:000183397600014
J	Gedik, N; Orenstein, J; Liang, RX; Bonn, DA; Hardy, WN				Gedik, N; Orenstein, J; Liang, RX; Bonn, DA; Hardy, WN			Diffusion of nonequilibrium quasi-particles in a cuprate superconductor	SCIENCE			English	Article							OPTICAL HETERODYNE-DETECTION; STIMULATED RAMAN-SCATTERING; SURFACE; BI2SR2CACU2O8+DELTA; SPECTROSCOPY; LIFETIMES; GRATINGS; LIQUIDS	We report a transport study of nonequilibrium quasi-particles in a high-transition-temperature cuprate superconductor using the transient grating technique. Low-intensity laser excitation ( at a photon energy of 1.5 electron volts) was used to introduce a spatially periodic density of quasi-particles into a high-quality untwinned single crystal of YBa2Cu3O6.5. Probing the evolution of the initial density through space and time yielded the quasi-particle diffusion coefficient and the inelastic and elastic scattering rates. The technique reported here is potentially applicable to precision measurements of quasi-particle dynamics not only in cuprate superconductors but in other electronic systems as well.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA; Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of British Columbia	Orenstein, J (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.		Hardy, Walter Newbold/AAN-7827-2020; Orenstein, Joseph W/I-3451-2015					Booth NE, 1996, SUPERCOND SCI TECH, V9, P493, DOI 10.1088/0953-2048/9/7/001; CHANG YJ, 1995, J PHYS CHEM-US, V99, P7857, DOI 10.1021/j100020a004; CHWALEK JM, 1991, APPL PHYS LETT, V58, P980, DOI 10.1063/1.104462; EICHLER HJ, 1986, LACSER INDUCED DYNAM; Fedorov AV, 1999, PHYS REV LETT, V82, P2179, DOI 10.1103/PhysRevLett.82.2179; FISHMAN IM, 1991, J OPT SOC AM B, V8, P1880, DOI 10.1364/JOSAB.8.001880; Goodno GD, 1998, J OPT SOC AM B, V15, P1791, DOI 10.1364/JOSAB.15.001791; Hosseini A, 1999, PHYS REV B, V60, P1349, DOI 10.1103/PhysRevB.60.1349; KAPLAN SB, 1976, PHYS REV B, V14, P4854, DOI 10.1103/PhysRevB.14.4854; MARSHALL CD, 1992, PHYS REV B, V45, P10009, DOI 10.1103/PhysRevB.45.10009; Maznev AA, 1998, OPT LETT, V23, P1319, DOI 10.1364/OL.23.001319; QUINLAN SM, 1994, PHYS REV B, V49, P1470, DOI 10.1103/PhysRevB.49.1470; SEGRE GP, 2002, APPL PHYS LETT, V88, DOI UNSP 137001; SHEN ZX, 1993, PHYS REV LETT, V70, P1553, DOI 10.1103/PhysRevLett.70.1553; Valla T, 2000, PHYS REV LETT, V85, P828, DOI 10.1103/PhysRevLett.85.828; VOHRINGER P, 1995, J PHYS CHEM-US, V99, P2684; Zhang Y, 2001, PHYS REV LETT, V86, P890, DOI 10.1103/PhysRevLett.86.890	17	100	101	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1410	1412		10.1126/science.1083038	http://dx.doi.org/10.1126/science.1083038			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775834	Green Submitted			2022-12-28	WOS:000183181800038
J	Graef, IA; Wang, F; Charron, F; Chen, L; Neilson, J; Tessier-Lavigne, M; Crabtree, GR				Graef, IA; Wang, F; Charron, F; Chen, L; Neilson, J; Tessier-Lavigne, M; Crabtree, GR			Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons	CELL			English	Article							LYMPHOCYTE-T ACTIVATION; MOTOR-NEURON POOLS; LIM HOMEOBOX GENES; NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; CYCLOSPORINE-A; GROWTH; GUIDANCE; DROSOPHILA; PROTEIN	Axon outgrowth is the first step in the formation of neuronal connections, but the pathways that regulate axon extension are still poorly understood. We find that mice deficient in calcineurin-NFAT signaling have dramatic defects in axonal outgrowth, yet have little or no defect in neuronal differentiation or survival. In vitro, sensory and commissural neurons lacking calcineurin function or NFATc2, c3, and c4 are unable to respond to neurotrophins or netrin-1 with efficient axonal outgrowth. Neurotrophins and netrins stimulate calcineurin-dependent nuclear localization of NFATc4 and activation of NFAT-mediated gene transcription in cultured primary neurons. These data indicate that the ability of these embryonic axons to respond to growth factors with rapid outgrowth requires activation of calcineurin/NFAT signaling by these factors. The precise parsing of signals for elongation turning and survival could allow independent control of these processes during development.	Stanford Univ, Sch Med, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Tessier-Lavigne, M (corresponding author), Stanford Univ, Sch Med, Dept Biol Sci, 300 Pasteur Dr, Stanford, CA 94305 USA.		Charron, Frederic/O-8017-2019; Charron, Frederic/D-2140-2009	Charron, Frederic/0000-0003-3483-8672; Charron, Frederic/0000-0003-3483-8672; Neilson, Joel R./0000-0002-3408-608X	NATIONAL CANCER INSTITUTE [R01CA039612, R37CA039612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008973] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39612] Funding Source: Medline; NIDCR NIH HHS [P01 DE 08973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Brenman JE, 2001, DEV CELL, V1, P667, DOI 10.1016/S1534-5807(01)00072-7; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CAMPENOT RB, 1977, P NATL ACAD SCI USA, V74, P4516, DOI 10.1073/pnas.74.10.4516; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Gao FB, 1999, GENE DEV, V13, P2549, DOI 10.1101/gad.13.19.2549; Giger RJ, 2001, CELL, V105, P1, DOI 10.1016/S0092-8674(01)00290-2; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Haase G, 2002, NEURON, V35, P893, DOI 10.1016/S0896-6273(02)00864-4; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kania A, 2000, CELL, V102, P161, DOI 10.1016/S0092-8674(00)00022-2; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Ming GL, 2002, NATURE, V417, P411, DOI 10.1038/nature745; O'Connor R, 1999, NEURON, V24, P165, DOI 10.1016/S0896-6273(00)80830-2; Rao Y, 2000, P NATL ACAD SCI USA, V97, P5966, DOI 10.1073/pnas.110135297; Senti KA, 2000, DEVELOPMENT, V127, P2291; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Tucker KL, 2001, NAT NEUROSCI, V4, P29, DOI 10.1038/82868; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Weimann JM, 1999, NEURON, V24, P819, DOI 10.1016/S0896-6273(00)81030-2; Zeng HK, 2001, CELL, V107, P617, DOI 10.1016/S0092-8674(01)00585-2	52	303	314	0	13	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					657	670		10.1016/S0092-8674(03)00390-8	http://dx.doi.org/10.1016/S0092-8674(03)00390-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787506	Bronze			2022-12-28	WOS:000183397600015
J	Smith, AB				Smith, AB			Making the best of a patchy fossil record	SCIENCE			English	Editorial Material									Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England	Natural History Museum London	Smith, AB (corresponding author), Nat Hist Museum, Dept Palaeontol, Cromwell Rd, London SW7 5BD, England.	abs@nhm.ac.uk	Smith, Andrew B/B-9849-2009					Alroy J, 2001, P NATL ACAD SCI USA, V98, P6261, DOI 10.1073/pnas.111144698; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; Crampton JS, 2003, SCIENCE, V301, P358, DOI 10.1126/science.1085075; Peters SE, 2001, PALEOBIOLOGY, V27, P583, DOI 10.1666/0094-8373(2001)027<0583:BITPAR>2.0.CO;2; RAUP D M, 1976, Paleobiology, V2, P289	5	3	3	1	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	2003	301	5631					321	322		10.1126/science.1086420	http://dx.doi.org/10.1126/science.1086420			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	702CG	12805556				2022-12-28	WOS:000184207300026
J	Price, PA; Fox, DW; Kulkarni, SR; Peterson, BA; Schmidt, BP; Soderberg, AM; Yost, SA; Berger, E; Djorgovski, SG; Frail, DA; Harrison, FA; Sari, R; Blain, AW; Chapman, SC				Price, PA; Fox, DW; Kulkarni, SR; Peterson, BA; Schmidt, BP; Soderberg, AM; Yost, SA; Berger, E; Djorgovski, SG; Frail, DA; Harrison, FA; Sari, R; Blain, AW; Chapman, SC			The bright optical afterglow of the nearby gamma-ray burst of 29 March 2003	NATURE			English	Article							SUPERNOVA; EMISSION	Past studies of cosmological gamma-ray bursts (GRBs) have been hampered by their extreme distances, resulting in faint afterglows. A nearby GRB could potentially shed much light on the origin of these events, but GRBs with a redshift zless than or equal to0.2 have been estimated to occur only rarely, about once per decade(1). Here we report the discovery of the bright optical afterglow emission from the burst of 29 March 2003 (GRB030329; ref. 2). The brightness of the afterglow and the prompt report(3) of its position resulted in extensive follow-up observations at many wavelengths, along with the measurement of the redshift, z=0.169 (ref. 4). The gamma-ray and afterglow properties of GRB030329 are similar to those of GRBs at cosmological redshifts. Observations have already identified the progenitor as a massive star that exploded as a supernova(5,6).	ANU, Mt Stromlo Observ, RSAA, Weston, ACT 2611, Australia; CALTECH, Caltech Opt Observ 105 24, Pasadena, CA 91125 USA; CALTECH, Space Radiat Lab 220 47, Pasadena, CA 91125 USA; Natl Radio Astron Observ, Socorro, NM 87801 USA	Australian National University; California Institute of Technology; California Institute of Technology; National Radio Astronomy Observatory (NRAO)	Price, PA (corresponding author), ANU, Mt Stromlo Observ, RSAA, Via Cotter Rd, Weston, ACT 2611, Australia.	pap@mso.anu.edu.au		Schmidt, Brian/0000-0001-6589-1287				Akerlof C, 1999, NATURE, V398, P400, DOI 10.1038/18837; Berger E, 2000, ASTROPHYS J, V545, P56, DOI 10.1086/317814; BERGER E, 2003, 2014 GCN; BERGER E, UNPUB ASTROPHYS J; Bloom JS, 1999, NATURE, V401, P453, DOI 10.1038/46744; BURENIN R, 2003, 2024 GCN; Chevalier RA, 1999, ASTROPHYS J, V520, pL29, DOI 10.1086/312147; FITZGERALD JB, 2003, 2065 GCN; Fox DW, 2003, NATURE, V422, P284, DOI 10.1038/nature01504; Frail DA, 2001, ASTROPHYS J, V562, pL55, DOI 10.1086/338119; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; Garnavich PM, 2003, ASTROPHYS J, V582, P924, DOI 10.1086/344785; GARNAVICH PM, 2003, 2018 GCN; GOLENETSKII S, 2003, 2026 GCN; GREINER J, 2003, 2020 GCN; HENDEN AA, 2003, 2023 GCN; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; HOGE JC, 2003, 2088 GCN; KUNO N, 2003, 2089 GCN; LIPKIN Y, 2003, 2034 GCN; MARSHALL FE, 2003, 1996 GCN; PETERSON BA, 2003, 1985 GCN; POOLEY G, 2003, 2043 GCN; RAO AP, 2003, 2073 GCN; Sari R, 1998, ASTROPHYS J, V497, pL17, DOI 10.1086/311269; Schmidt M, 1999, ASTROPHYS J, V523, pL117, DOI 10.1086/312281; STANEK KZ, IN PRESS ASTROPHYS J; TORII K, 2003, 1986 GRB; VANDERSPEK R, 2003, 1997 GCN; ZHARIKOV S, 2003, 2022 GCN	30	118	118	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					844	847		10.1038/nature01734	http://dx.doi.org/10.1038/nature01734			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815424	Green Submitted, Green Accepted			2022-12-28	WOS:000183585300038
J	Irwig, L				Irwig, L			'This added to my multiple myopia'	BRITISH MEDICAL JOURNAL			English	Article									Univ Sydney, Sch Publ Hlth, Ecreening & Test Evaluat Program, Sydney, NSW 2006, Australia	University of Sydney	Irwig, L (corresponding author), Univ Sydney, Sch Publ Hlth, Ecreening & Test Evaluat Program, Sydney, NSW 2006, Australia.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1336	1336		10.1136/bmj.326.7402.1336	http://dx.doi.org/10.1136/bmj.326.7402.1336			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805196	Green Published			2022-12-28	WOS:000183626500061
J	Jones, T				Jones, T			Head to head - Should drug companies be allowed to talk directly to patients? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material									Assoc British Pharmaceut Ind, London SW1A 2DY, England		Jones, T (corresponding author), Assoc British Pharmaceut Ind, 12 Whitehall, London SW1A 2DY, England.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1302	1302		10.1136/bmj.326.7402.1302	http://dx.doi.org/10.1136/bmj.326.7402.1302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805163	Green Published			2022-12-28	WOS:000183626500027
J	Bailes, E; Gao, F; Bibollet-Ruche, F; Courgnaud, V; Peeters, M; Marx, PA; Hahn, BH; Sharp, PM				Bailes, E; Gao, F; Bibollet-Ruche, F; Courgnaud, V; Peeters, M; Marx, PA; Hahn, BH; Sharp, PM			Hybrid origin of SIV in chimpanzees	SCIENCE			English	Article							TROGLODYTES		Univ Nottingham, Nottingham NG7 2UH, England; Univ Alabama, Birmingham, AL 35294 USA; Duke Univ, Durham, NC 27710 USA; Univ Montpellier 1, F-34032 Montpellier 1, France; Tulane Natl Primate Res Ctr, Covington, LA 70433 USA	University of Nottingham; University of Alabama System; University of Alabama Birmingham; Duke University; Universite de Montpellier; Tulane University	Sharp, PM (corresponding author), Univ Nottingham, Nottingham NG7 2UH, England.	paul@evol.nott.ac.uk	Sharp, Paul/Y-3787-2019; Sharp, Paul M/F-5783-2010; Sharp, Paul M/GPX-1497-2022	Sharp, Paul M/0000-0001-9771-543X; Sharp, Paul M/0000-0001-9771-543X; Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI085338, R01AI050529, R01AI044596] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI50529, R01 AI44596, N01 AI85338] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beer BE, 2001, J VIROL, V75, P12014, DOI 10.1128/JVI.75.24.12014-12027.2001; Courgnaud V, 2002, J VIROL, V76, P8298, DOI 10.1128/JVI.76.16.8298-8309.2002; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Goldberg TL, 1997, MOL BIOL EVOL, V14, P976, DOI 10.1093/oxfordjournals.molbev.a025841; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Santiago ML, 2002, SCIENCE, V295, P465, DOI 10.1126/science.295.5554.465	6	271	277	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1713	1713		10.1126/science.1080657	http://dx.doi.org/10.1126/science.1080657			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805540				2022-12-28	WOS:000183459700041
J	Burt, D; Pourquie, O				Burt, D; Pourquie, O			Chicken genome - Science nuggets to come soon	SCIENCE			English	Editorial Material									Roslin Inst Edinburgh, Roslin EH25 9PS, Midlothian, Scotland; Stowers Inst Med Res, Kansas City, MO 64110 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Stowers Institute for Medical Research	Burt, D (corresponding author), Roslin Inst Edinburgh, Roslin EH25 9PS, Midlothian, Scotland.	dave.burt@bbsrc.ac.uk; OLP@Stowers-Institute.org	Pourquié, Olivier/CAJ-5443-2022; Burt, David W/C-7802-2013	Pourquié, Olivier/0000-0001-5189-1227; Burt, David W/0000-0002-9991-1028				Brown WRA, 2003, NAT REV GENET, V4, P87, DOI 10.1038/nrg998; Burt DW, 2003, MOL VIS, V9, P164; Clamp M, 2003, NUCLEIC ACIDS RES, V31, P38, DOI 10.1093/nar/gkg083; de Koning DJ, 2003, J ANIM SCI, V81, P1158; Hu J, 2001, NUCLEIC ACIDS RES, V29, P106, DOI 10.1093/nar/29.1.106; HUBBARD S, COMMUNICATION; MCPHERSON J, COMMUNICATION; Morisson M, 2002, GENET SEL EVOL, V34, P521, DOI [10.1051/gse:2002021, 10.1186/1297-9686-34-4-521]; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; Pitel F, 2000, GENET SEL EVOL, V32, P73, DOI 10.1051/gse:2000107; Schmid M, 2000, CYTOGENET CELL GENET, V90, P169, DOI 10.1159/000056772; WILSON S, COMMUNICATION	12	41	44	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1669	1669		10.1126/science.1086231	http://dx.doi.org/10.1126/science.1086231			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805524	Green Submitted			2022-12-28	WOS:000183459700025
J	Nishii, I; Ogihara, S; Kirk, DL				Nishii, I; Ogihara, S; Kirk, DL			A kinesin, InvA, plays an essential role in Volvox morphogenesis	CELL			English	Article							CYTOPLASMIC BRIDGE SYSTEM; PROTEIN; CARTERI; INVERSION; PATTERNS; DIFFERENTIATION; MECHANISMS; ENCODES; CELLS; LIGHT	In Volvox carted adults, reproductive cells called gonidia are enclosed within a spherical monolayer of biflagellate somatic cells. Embryos must "invert" (turn inside out) to achieve this configuration, however, because at the end of cleavage the gonidia are on the outside and the flagellar ends of all somatic cells point inward. Generation of a bend region adequate to turn the embryo inside out involves a dramatic change in cell shape, plus cell movements. Here, we cloned a gene called invA that is essential for inversion and found that it codes for a kinesin localized in the cytoplasmic bridges that link all cells to their neighbors. In invA null mutants, cells change shape normally, but are unable to move relative to the cytoplasmic bridges. A normal bend region cannot be formed and inversion stops. We conclude that the InvA kinesin provides the motile force that normally drives inversion to completion.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 560, Japan	Washington University (WUSTL); Osaka University	Kirk, DL (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	kirk@biology.wustl.edu						ADAMS CR, 1990, CURR GENET, V18, P141, DOI 10.1007/BF00312602; Asamiziu E, 2000, DNA RES, V7, P305, DOI 10.1093/dnares/7.5.305; GREEN KJ, 1981, J CELL BIOL, V91, P743, DOI 10.1083/jcb.91.3.743; GREEN KJ, 1981, J CELL BIOL, V91, P756, DOI 10.1083/jcb.91.3.756; Hallmann A, 2000, J CELL SCI, V113, P4605; Hasson T, 2001, CURR OPIN CELL BIOL, V13, P29, DOI 10.1016/S0955-0674(00)00170-8; Jarvik JW, 1998, ANNU REV GENET, V32, P601, DOI 10.1146/annurev.genet.32.1.601; KELLAND JL, 1977, J PHYCOL, V13, P373, DOI 10.1111/j.0022-3646.1977.00373.x; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; KIRK DL, 1983, DEV BIOL, V96, P493, DOI 10.1016/0012-1606(83)90186-0; Kirk DL, 2001, DEV GROWTH DIFFER, V43, P621; Kirk DL, 1982, DEV ORDER ITS ORIGIN, P247; Kirk DL., 1998, VOLVOX MOL GENETIC O; Kirk MM, 1999, DEVELOPMENT, V126, P639; KIRK MM, 1985, CELL, V41, P419, DOI 10.1016/S0092-8674(85)80015-5; KUSCHAKEWITSCH S, 1923, B ACAD SC OUKRAINE, V1, P32; MILLER SM, 1993, PLANT CELL, V5, P1125, DOI 10.1105/tpc.5.9.1125; Miller SM, 1999, DEVELOPMENT, V126, P649; Nishii I, 1999, DEVELOPMENT, V126, P2117; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Sambrook J., 2001, MOL CLONING LAB MANU; Schock F, 2002, ANNU REV CELL DEV BI, V18, P463, DOI 10.1146/annurev.cellbio.18.022602.131838; SESSOMS AH, 1973, P NATL ACAD SCI USA, V70, P1335, DOI 10.1073/pnas.70.5.1335; Starr R C, 1970, Symp Soc Dev Biol, V29, P59; Starr R. C., 1969, Archiv fuer Protistenkunde, V111, P204; Surrey T, 1998, P NATL ACAD SCI USA, V95, P4293, DOI 10.1073/pnas.95.8.4293; TAM LW, 1991, DEVELOPMENT, V112, P571; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIAMONTES GI, 1977, J CELL BIOL, V75, P719, DOI 10.1083/jcb.75.3.719; VIAMONTES GI, 1979, CELL, V17, P537, DOI 10.1016/0092-8674(79)90262-9	31	53	55	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2003	113	6					743	753		10.1016/S0092-8674(03)00431-8	http://dx.doi.org/10.1016/S0092-8674(03)00431-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809605	Bronze			2022-12-28	WOS:000183514400009
J	Luck, S; Torny, M; d'Agapeyeff, K; Pitt, A; Heath, P; Breathnach, A; Russell, AB				Luck, S; Torny, M; d'Agapeyeff, K; Pitt, A; Heath, P; Breathnach, A; Russell, AB			Estimated early-onset group B streptococcal neonatal disease	LANCET			English	Article							INFECTION	Estimates of incidence of early-onset group B streptococcal (EOGBS) infection are based on blood or cerebrospinal fluid culture-proven cases, which can be falsely negative and hence underestimate the true burden of disease. Probable EOGBS infection can be defined as colonisation by group B streptococci accompanied by features of clinical sepsis. Data collected prospectively in the UK over 1 year for neonates who required a septic screen in the first 72 h of life indicated a combined rate of definite and probable EOGBS infection of 3.6 per 1000 livebirths. This estimate Indicates a much greater disease burden in the UK than that suggested by figures of culture-proven sepsis, and lends support to the need for prevention strategies.	Univ London St Georges Hosp, London, England	St Georges University London	Russell, AB (corresponding author), Chelsea & Westminster Hosp, Dept Neonatol, 369 Fulham Rd, London SW10 9NH, England.			Heath, Paul/0000-0002-7540-7433				Ahmet Z, 1999, MOL CELL PROBE, V13, P349, DOI 10.1006/mcpr.1999.0262; Beardsall K, 2001, ARCH DIS CHILD-FETAL, V84, pF77; Nicoll A, 2000, ARCH DIS CHILD-FETAL, V82, pF207; Russell ARB, 2001, ARCH DIS CHILD-FETAL, V84, pF140, DOI 10.1136/fn.84.2.F140b; Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103	5	93	99	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1953	1954		10.1016/S0140-6736(03)13553-2	http://dx.doi.org/10.1016/S0140-6736(03)13553-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801740				2022-12-28	WOS:000183359700012
J	Plavinski, SL; Plavinskaya, SI; Klimov, AN				Plavinski, SL; Plavinskaya, SI; Klimov, AN			Social factors and increase in mortality in Russia in the 1990s: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the association between social factors and the increase in mortality in Russia in the 1990s. Design Prospective population cohort study. Setting Saint Petersburg, Russia. Participants Two cohorts of men aged 40-59 years randomly selected from district voting list: 3907 screened in 1975-7 and 1467 in 1986-8. Main outcome measures Education, various health related measures, alcohol intake. Mortality in subsequent 10 years. Results There was no recorded increase in mortality in men with university degrees. The relative risk in the second cohort compared with the first was 0.92 (95% confidence interval 0.67 to 1.24). For participants with only high school education it was significantly higher in the second cohort (1.32, 1.02 to 1.71). The most pronounced differences were found among participants with the lowest level of education, in which the relative risk was 1.75 (1.44 to 2.12). The same pattern held for coronary vascular disease and cancer mortality. Conclusion In Russia men in the lower socioeconomic groups were most affected by the sharp increases in mortality in the 1990s.	Med Acad Postgrad Studies, Coll Publ Hlth, St Petersburg, Russia; Inst Expt Med, Dept Biochem, St Petersburg, Russia	North-Western State Medical University named after I.I. Mechnikov; Institute of Experimental Medicine	Plavinski, SL (corresponding author), Med Acad Postgrad Studies, Coll Publ Hlth, St Petersburg, Russia.		Plavinskii, Sviatoslav/P-3194-2014	Plavinskii, Sviatoslav/0000-0001-9159-6177	NHLBI NIH HHS [N0-1HV08112/HV, N0-1HR12243-L/HR] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV008112] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acheson D., 1998, INDEPENDENT INQUIRY; Black D, 1980, INEQUALITIES HLTH RE; DENNIS BH, 1993, INT J EPIDEMIOL, V22, P420, DOI 10.1093/ije/22.3.420; Klimov A. N., 1989, EPIDEMIOLOGY RISK FA; *LIP RES CLIN POP, 1986, NIH PUBL, V3; PALOSUO H, 1997, DEMYSTIFYING RUSSIAN, P149; PLAVINSKAYA SI, 1993, THESIS I EXPT MED; SAHAI H, 1996, STAT EPIDEMIOLOGY; SHKOLNIKOV V, 1997, 9701 HARV CTR POP DE; SIMPURA J, 1999, IDANTUTKIMUS, V2, P49	10	69	73	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1240	1242		10.1136/bmj.326.7401.1240	http://dx.doi.org/10.1136/bmj.326.7401.1240			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791737	Green Published, Bronze			2022-12-28	WOS:000183480700014
J	Wolffers, I; van Beelen, N				Wolffers, I; van Beelen, N			Public health and the human rights of sex workers	LANCET			English	Editorial Material							WOMEN		Free Univ Amsterdam, Med Ctr, Dept Hlth Care & Culture, NL-1081 BT Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Wolffers, I (corresponding author), Free Univ Amsterdam, Med Ctr, Dept Hlth Care & Culture, NL-1081 BT Amsterdam, Netherlands.	wolffers.social@med.vu.nl						Ahmad K, 2001, LANCET, V358, P643, DOI 10.1016/S0140-6736(01)05819-6; Day S, 1997, GENITOURIN MED, V73, P161; Liao SS, 2003, AIDS EDUC PREV, V15, P109, DOI 10.1521/aeap.15.3.109.23834; Nairne D, 2000, RES SEX WORK, V3, P3; Sacks V, 1996, SOC SCI MED, V42, P59, DOI 10.1016/0277-9536(95)00079-8; THOMPSON N, 2003, BOSTON GLOBE    0105; Vanwesenbeeck I, 2002, ANN REV SEX RES, V12, P242; Wawer MJ, 1996, SOC SCI MED, V42, P453, DOI 10.1016/0277-9536(95)00150-6	8	38	39	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1981	1981		10.1016/S0140-6736(03)13594-5	http://dx.doi.org/10.1016/S0140-6736(03)13594-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	687DB	12801755				2022-12-28	WOS:000183359700026
J	Au, WWL; Benoit-Bird, KJ				Au, WWL; Benoit-Bird, KJ			Automatic gain control in the echolocation system of dolphins	NATURE			English	Article							SIGNALS	In bats(1) and technological sonars(2), the gain of the receiver is progressively increased with time after the transmission of a signal to compensate for acoustic propagation loss. The current understanding of dolphin echolocation indicates that automatic gain control is not a part of their sonar system(3). In order to test this understanding, we have performed field measurements of free-ranging echolocating dolphins. Here we show that dolphins do possess an automatic gain control mechanism, but that it is implemented in the transmission phase rather than the receiving phase of a sonar cycle. We find that the amplitude of the dolphins' echolocation signals are highly range dependent; this amplitude increases with increasing target range, R, in a 20 log(R) fashion to compensate for propagation loss. If the echolocation target is a fish school with many sound scatterers, the echoes from the school will remain nearly constant(4) with range as the dolphin closes in on it. This characteristic has the same effect as time-varying gain in bats and technological sonar when considered from a sonar system perspective.	Univ Hawaii, Hawaii Inst Marine Biol, Kailua, HI 96734 USA	University of Hawaii System	Au, WWL (corresponding author), Univ Hawaii, Hawaii Inst Marine Biol, POB 1106, Kailua, HI 96734 USA.	wau@hawaii.edu						Au W. W., 1993, SONAR DOLPHINS; Au WWL, 2003, J ACOUST SOC AM, V113, P598, DOI 10.1121/1.1518980; AU WWL, 2002, J ACOUST SOC AM, V111, P2343; Cranford T. W, 1988, ANIMAL SONAR PROCESS, P67; Cranford TW, 2000, SPR HDB AUD, V12, P109; EVANS WE, 1967, ANIMAL SONAR SYSTEMS, P363; HEITHAUS MR, 2002, ENCY MARINE MAMMALS, P411; HENSON OW, 1965, J PHYSIOL-LONDON, V180, P871, DOI 10.1113/jphysiol.1965.sp007737; Ketten DR, 2000, SPR HDB AUD, V12, P43; Medwin H., 1998, FUNDAMENTALS ACOUSTI; MOROZOV VP, 1972, BIOFIZIKA+, V17, P139; PENNER RH, 1988, ANIMAL SONAR PROCESS, P707; Rasmussen MH, 2002, J ACOUST SOC AM, V111, P1122, DOI 10.1121/1.1433814; Ridgway SH, 2001, J EXP BIOL, V204, P3829; SIMMONS JA, 1992, J ACOUST SOC AM, V91, P1150, DOI 10.1121/1.402641; SUGA N, 1975, J EXP BIOL, V62, P277; Urick RJ., 1983, PRINCIPLES UNDERWATE, V3	17	134	143	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					861	863		10.1038/nature01727	http://dx.doi.org/10.1038/nature01727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815429				2022-12-28	WOS:000183585300043
J	Bates, DW; Gawande, AA				Bates, DW; Gawande, AA			Patient safety: Improving safety with information technology	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVERSE DRUG EVENTS; PHYSICIAN ORDER ENTRY; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED TRIAL; ARTIFICIAL NEURAL NETWORKS; DECISION-SUPPORT SYSTEMS; MEDICATION ERRORS; HOSPITALIZED-PATIENTS; COMPUTER; OUTCOMES		Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Partners Healthcare Syst, Ctr Appl Med Informat Syst, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Partners Healthcare System; Harvard University; Harvard Medical School	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, 75 Francis St, Boston, MA 02115 USA.	dbates@partners.org	Bates, David/AAE-7283-2019; Tao, Youyou/D-2367-2014	Gawande, Atul/0000-0002-1824-9176	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS011534] Funding Source: NIH RePORTER; AHRQ HHS [P01 HS11534] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; Bates DW, 2003, J AM MED INFORM ASSN, V10, P115, DOI 10.1197/jamia.M1074; Bates DW, 2001, J AM MED INFORM ASSN, V8, P299, DOI 10.1136/jamia.2001.0080299; Bates DW, 1999, ARCH INTERN MED, V159, P2553, DOI 10.1001/archinte.159.21.2553; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; Baxt WG, 1996, LANCET, V347, P12, DOI 10.1016/S0140-6736(96)91555-X; *CA HLTH FDN, 2000, QUAL IN COMP PHYS OR; Celi LA, 2001, CRIT CARE MED, V29, pN183, DOI 10.1097/00003246-200108001-00007; Chassin MR, 2002, ANN INTERN MED, V136, P826, DOI 10.7326/0003-4819-136-11-200206040-00012; Chertow GM, 2001, JAMA-J AM MED ASSOC, V286, P2839, DOI 10.1001/jama.286.22.2839; CLASSEN DC, 1992, JAMA-J AM MED ASSOC, V267, P1922; Doolan DF, 2002, HEALTH AFFAIR, V21, P180, DOI 10.1377/hlthaff.21.4.180; Edworthy J., 1996, WARNING DESIGN RES P; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Frable WJ, 2001, CANCER CYTOPATHOL, V93, P171, DOI 10.1002/cncr.9025; GAWANDE AA, 2000, MEDGENMED       0214, pE13; GREENLAW J, 1982, RN, V45, P81; Heden B, 1997, CIRCULATION, V96, P1798, DOI 10.1161/01.CIR.96.6.1798; Honigman B, 2001, J AM MED INFORM ASSN, V8, P254, DOI 10.1136/jamia.2001.0080254; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Institute of Medicine, 2001, CROSSING QUALITY CHA; Johnston B, 2000, ARCH FAM MED, V9, P40, DOI 10.1001/archfami.9.1.40; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728; Kok MR, 1996, CANCER, V78, P112, DOI 10.1002/(SICI)1097-0142(19960701)78:1<112::AID-CNCR16>3.0.CO;2-2; KUPERMAN G, 1997, ASS HLTH SERV RES, V14, P224; Kuperman GJ, 1999, J AM MED INFORM ASSN, V6, P512, DOI 10.1136/jamia.1999.0060512; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; METZGER J, 2001, COMPUTERIZED PHYSICI; Montgomery AA, 2000, BRIT MED J, V320, P686, DOI 10.1136/bmj.320.7236.686; *NAT COMM VIT HLTH, 2002, INF HLTH STRAT BUILD; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Petrick N, 2002, RADIOLOGY, V224, P217, DOI 10.1148/radiol.2241011062; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; Raschke RA, 1999, JAMA-J AM MED ASSOC, V281, P420; RIND DM, 1994, ARCH INTERN MED, V154, P1511, DOI 10.1001/archinte.154.13.1511; Rosebraugh CJ, 2001, JAMA-J AM MED ASSOC, V286, P1019, DOI 10.1001/jama.286.9.1019; Rosenfeld BA, 2000, CRIT CARE MED, V28, P3925, DOI 10.1097/00003246-200012000-00034; Rothschild JM, 2002, J AM MED INFORM ASSN, V9, P223, DOI 10.1197/jamia.M1001; Schmidt IK, 2002, SOC SCI MED, V54, P1767, DOI 10.1016/S0277-9536(01)00146-0; Shabot MM, 2000, J AM MED INFORM ASSN, P789; SHAPIRO JP, 2000, US NEWS WORLD R 0717, P56; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; TATE KE, 1990, M D COMPUT, V7, P296; TATE KE, 1995, P ANN S COMPUT APPL, V19, P164; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; TIERNEY WM, 1995, J AM MED INFORM ASSN, V2, P316, DOI 10.1136/jamia.1995.96073834; WANLASS RL, 1992, ARCH PHYS MED REHAB, V73, P477; WEEKS WB, 2000, EFFECTIVE CLIN PRACT, V6, P270; Weitzel R, 1991, Healthc Inform, V8, P26; WEITZEL R, 1991, HLTHC INFORM, V8, P26	56	861	884	1	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2526	2534		10.1056/NEJMsa020847	http://dx.doi.org/10.1056/NEJMsa020847			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690YC	12815139				2022-12-28	WOS:000183577200008
J	Bignall, J				Bignall, J			Monkeying with Shakespeare	LANCET			English	Editorial Material																		Bignall J, 1999, LANCET, V353, P610, DOI 10.1016/S0140-6736(99)00058-6; Bignall J, 2002, LANCET, V360, P504, DOI 10.1016/S0140-6736(02)09761-1; HUXLEY TH, 1862, LANCET, V1, P166; LISTER S, 2003, TIMES           0509, P3; SHAPIRO RD, 1986, ORIGINS SKEPTICS GUI, P169	5	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2004	2004						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814709				2022-12-28	WOS:000183488900006
J	Ford, N				Ford, N			Public health and company wealth	BRITISH MEDICAL JOURNAL			English	Article									Med Sans Frontieres, London EC1N 8QX, England	Doctors Without Borders	Ford, N (corresponding author), Med Sans Frontieres, London EC1N 8QX, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1296	1296		10.1136/bmj.326.7402.1296	http://dx.doi.org/10.1136/bmj.326.7402.1296			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805159	Green Published			2022-12-28	WOS:000183626500023
J	Mann, E				Mann, E			Managing pain	BRITISH MEDICAL JOURNAL			English	Article									Poole Hosp NHS Trust, Poole BH21 2JB, Dorset, England; Bournemouth Univ, IHCS, Poole BH21 2JB, Dorset, England	Bournemouth University	Mann, E (corresponding author), Poole Hosp NHS Trust, Poole BH21 2JB, Dorset, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1320	1321		10.1136/bmj.326.7402.1320	http://dx.doi.org/10.1136/bmj.326.7402.1320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805176	Green Published			2022-12-28	WOS:000183626500039
J	Chothia, C; Gough, J; Vogel, C; Teichmann, SA				Chothia, C; Gough, J; Vogel, C; Teichmann, SA			Evolution of the protein repertoire	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; ENZYMES; PERSPECTIVE; GENOMICS; METABOLISM; BEHAVIOR; FAMILY	Most proteins have been formed by gene duplication, recombination, and divergence. Proteins of known structure can be matched to about 50% of genome sequences, and these data provide a quantitative description and can suggest hypotheses about the origins of these processes.	MRC, Mol Biol Lab, Struct Studies Div, Cambridge CB2 2QH, England; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	MRC Laboratory Molecular Biology; Stanford University	Chothia, C (corresponding author), MRC, Mol Biol Lab, Struct Studies Div, Hills Rd, Cambridge CB2 2QH, England.			Teichmann, Sarah/0000-0002-6294-6366				Alves R, 2002, J MOL BIOL, V320, P751, DOI 10.1016/S0022-2836(02)00546-6; Apic G, 2001, J MOL BIOL, V310, P311, DOI 10.1006/jmbi.2001.4776; APIC G, IN PRESS J STRUCT FU; Bashton M, 2002, J MOL BIOL, V315, P927, DOI 10.1006/jmbi.2001.5288; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; COUGH J, 2001, J MOL BIOL, V313, P903; Dandekar T, 1999, BIOCHEM J, V343, P115, DOI 10.1042/0264-6021:3430115; HOROWITZ N. H., 1965, P15; Huynen MA, 1998, MOL BIOL EVOL, V15, P583, DOI 10.1093/oxfordjournals.molbev.a025959; Jardine O, 2002, GENOME RES, V12, P916, DOI 10.1101/gr.228002; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Koonin EV, 2000, CELL, V101, P573, DOI 10.1016/S0092-8674(00)80867-3; Koonin EV, 2002, NATURE, V420, P218, DOI 10.1038/nature01256; Koonin EV, 1996, TRENDS GENET, V12, P334, DOI 10.1016/0168-9525(96)20010-1; Koonin EV, 2003, SEQUENCE EVOLUTION F; Kuznetsov VA, 2002, J BIOL SYST, V10, P381, DOI 10.1142/S0218339002000767; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Muller A, 2002, GENOME RES, V12, P1625, DOI 10.1101/gr.221202; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; Qian J, 2001, J MOL BIOL, V313, P673, DOI 10.1006/jmbi.2001.5079; Riley M, 2000, ANNU REV MICROBIOL, V54, P341, DOI 10.1146/annurev.micro.54.1.341; Rison SCG, 2002, J MOL BIOL, V318, P911, DOI 10.1016/S0022-2836(02)00140-7; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Teichmann SA, 1998, P NATL ACAD SCI USA, V95, P14658, DOI 10.1073/pnas.95.25.14658; Teichmann SA, 2001, J MOL BIOL, V311, P693, DOI 10.1006/jmbi.2001.4912; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; VOGEL C, UNPUB; Wilson CA, 2000, J MOL BIOL, V297, P233, DOI 10.1006/jmbi.2000.3550; Wolf YI, 1999, GENOME RES, V9, P17; Wuchty S, 2001, MOL BIOL EVOL, V18, P1694, DOI 10.1093/oxfordjournals.molbev.a003957	31	384	402	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1701	1703		10.1126/science.1085371	http://dx.doi.org/10.1126/science.1085371			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805536				2022-12-28	WOS:000183459700037
J	Ely, EW; Truman, B; Shintani, A; Thomason, JWW; Wheeler, AP; Gordon, S; Francis, J; Speroff, T; Gautam, S; Margolin, R; Sessler, CN; Dittus, RS; Bernard, GR				Ely, EW; Truman, B; Shintani, A; Thomason, JWW; Wheeler, AP; Gordon, S; Francis, J; Speroff, T; Gautam, S; Margolin, R; Sessler, CN; Dittus, RS; Bernard, GR			Monitoring sedation status over time in ICU patients - Reliability and validity of the Richmond Agitation-Sedation Scale (RASS)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; CLINICAL-PRACTICE GUIDELINES; CONFUSION ASSESSMENT METHOD; BISPECTRAL INDEX; NEUROMUSCULAR BLOCKADE; ANALGESIA; ADULT; DELIRIUM	Context Goal-directed delivery of sedative and analgesic medications is recommended as standard care in intensive care units (ICUs) because of the impact these medications have on ventilator weaning and ICU length of stay, but few of the available sedation scales have been appropriately tested for reliability and validity. Objective To test the reliability and validity of the Richmond Agitation-Sedation Scale (RASS). Design Prospective cohort study. Setting Adult medical and coronary ICUs of a university-based medical center. Participants Thirty-eight medical ICU patients enrolled for reliability testing (46% receiving mechanical ventilation) from July 21, 1999, to September 7, 1999, and an independent cohort of 275 patients receiving mechanical ventilation were enrolled for validity testing from February 1, 2000, to May 3, 2001. Main Outcome Measures Interrater reliability of the RASS, Glasgow Coma Scale (GCS), and Ramsay Scale (RS); validity of the RASS correlated with reference standard ratings, assessments of content of consciousness, GCS scores, doses of sedatives and analgesics, and bispectral electroencephalography. Results In 290-paired observations by nurses, results of both the RASS and IRS demonstrated excellent interrater reliability (weighted kappa, 0.91 and 0.94, respectively), which were both superior to the GCS (weighted K, 0.64; P<.001 for both comparisons). Criterion validity was tested in 411-paired observations in the first 96 patients of the validation cohort, in whom the RASS showed significant differences between levels of consciousness (P<.001 for all) and correctly identified fluctuations within patients over time (P<.001). In addition, 5 methods were used to test the construct validity of the RASS, including correlation with an attention screening examination (r=0.78, P<.001), GCS scores (r=0.91, P<.001), quantity of different psychoactive medication dosages 8 hours prior to assessment (eg, lorazepam: r=-0.31, P<.001), successful extubation (P=.07), and bispectral electroencephalography (r=0.63, P<.001). Face validity was demonstrated via a survey of 26 critical care nurses, which the results showed that 92% agreed or strongly agreed with the RASS scoring scheme, and 81% agreed or strongly agreed that the instrument provided a consensus for goal-directed delivery of medications. Conclusions The RASS demonstrated excellent interrater reliability and criterion, construct, and face validity. This is the first sedation scale to be validated for its ability to detect changes in sedation status over consecutive days of ICU care, against constructs of level of consciousness and delirium, and correlated with the administered dose of sedative and analgesic medications.	Vanderbilt Univ, Tennessee Valley Vet Affairs Healthcare Syst, Ctr Geriatr Res Educ & Clin,Ctr Hlth Serv Res, Dept Med,Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; St Vincent Hosp Hlth Syst, Dept Prevent Med, Div Biostat, Indianapolis, IN USA; St Vincent Hosp Hlth Syst, Div Qual & Data Management, Indianapolis, IN USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA	Geriatric Research Education & Clinical Center; Vanderbilt University; Virginia Commonwealth University	Ely, EW (corresponding author), Vanderbilt Univ, Tennessee Valley Vet Affairs Healthcare Syst, Ctr Geriatr Res Educ & Clin,Ctr Hlth Serv Res, Dept Med,Div Allergy Pulm & Crit Care Med, 221 Kirkland Hall, Nashville, TN 37232 USA.	wes.ely@vanderbilt.edu	Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172	NIA NIH HHS [AG01023-01A1] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bair N, 2000, CRIT CARE MED, V28, P707, DOI 10.1097/00003246-200003000-00018; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Brattebo G, 2002, BMJ-BRIT MED J, V324, P1386, DOI 10.1136/bmj.324.7350.1386; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; CAMMARANO WB, 1998, PRINCIPLES CRITICAL, P90; Carmines E. G., 1979, RELIABILITY VALIDITY, DOI DOI 10.4135/9781412985642; Carnes M, 2003, J AM GERIATR SOC, V51, P234, DOI 10.1046/j.1532-5415.2003.51063.x; COLLER Z, 2003, AM J RESP CRIT CARE, V167, pA970; De Jonghe B, 2000, INTENS CARE MED, V26, P275, DOI 10.1007/s001340051150; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Eappen T, 1999, CRIT CARE MED, V27, pA134, DOI 10.1097/00003246-199912001-00378; Eilers H, 2001, ANESTH ANALG, V93, P213, DOI 10.1097/00000539-200107000-00042; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, CHEST, V120, p454S, DOI 10.1378/chest.120.6_suppl.454S; ELY EW, IN PRESS CRIT CARE M; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Fraser GL, 2000, PHARMACOTHERAPY, V20, P75, DOI 10.1592/phco.20.1.75.34663; Frenzel D, 2002, INTENS CARE MED, V28, P178, DOI 10.1007/s00134-001-1183-4; Hall RI, 2001, CHEST, V119, P1151, DOI 10.1378/chest.119.4.1151; Hall-Lord ML, 1998, HEART LUNG, V27, P123, DOI 10.1016/S0147-9563(98)90020-6; HANSENFLASCHEN J, 1994, CRIT CARE MED, V22, P732; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; JOHANSEN JW, 2002, ANESTHESIOLOGY, P1336; *JOINT COMM ACCR H, 2003, COMPR ACCR MAN HOSP; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Lieberman J, 1999, CRIT CARE MED, V27, P1395, DOI 10.1097/00003246-199907000-00045; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; Mascia MF, 2000, CRIT CARE MED, V28, P2300, DOI 10.1097/00003246-200007000-00019; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; Nasraway SA, 2002, CRIT CARE MED, V30, P117, DOI 10.1097/00003246-200201000-00019; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Park G, 2001, CRIT CARE CLIN, V17, P1015, DOI 10.1016/S0749-0704(05)70192-5; PARONE SV, 2002, AM J PSYCHIAT, V151, P650; PAYNE JP, 2001, CRIT CARE MED, V29, P2258; Plum F, 1980, DIAGNOSIS STUPOR COM, Vthird; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Riker RR, 2002, CRIT CARE MED, V30, P1661, DOI 10.1097/00003246-200207000-00049; Riker RR, 2001, INTENS CARE MED, V27, P853, DOI 10.1007/s001340100912; Rosow C, 2001, Anesthesiol Clin North Am, V19, P947; Rotondi AJ, 2002, CRIT CARE MED, V30, P746, DOI 10.1097/00003246-200204000-00004; Sacket D, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; Scragg P, 2001, ANAESTHESIA, V56, P9, DOI 10.1046/j.1365-2044.2001.01714.x; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sessler CN, 2001, SEMIN RESP CRIT CARE, V22, P211, DOI 10.1055/s-2001-13834; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; Slomka J, 2000, Am J Crit Care, V9, P412; TEASDALE G, 1974, LANCET, V2, P81; TRUJILLO KA, 1991, NEW BIOL, V3, P915; TRUMAN B, 2003, AM J RESP CRIT CARE, V167, pA969; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; WHEELER AP, 1993, CHEST, V104, P566, DOI 10.1378/chest.104.2.566; Wittbrodt ET, 1999, CRIT CARE MED, V27, P1384, DOI 10.1097/00003246-199907000-00037; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041	64	955	1014	0	44	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					2983	2991		10.1001/jama.289.22.2983	http://dx.doi.org/10.1001/jama.289.22.2983			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	687XZ	12799407	Bronze			2022-12-28	WOS:000183403400022
J	Abol-Enein, H; Bono, AV; Boyer, M; Clarke, NW; Coppin, CML; Cortesi, E; Goebell, PJ; Groshen, S; Hall, RR; Horwich, A; Malmstrom, PU; Martinez-Pineiro, JA; Parmar, MKB; Raghavan, D; Roberts, JTG; Sengelov, L; Sherif, A; Stewart, LA; Stockle, M; Sylvester, R; Tierney, JF; Torti, FM; Vale, CL; Wallace, DMA				Abol-Enein, H; Bono, AV; Boyer, M; Clarke, NW; Coppin, CML; Cortesi, E; Goebell, PJ; Groshen, S; Hall, RR; Horwich, A; Malmstrom, PU; Martinez-Pineiro, JA; Parmar, MKB; Raghavan, D; Roberts, JTG; Sengelov, L; Sherif, A; Stewart, LA; Stockle, M; Sylvester, R; Tierney, JF; Torti, FM; Vale, CL; Wallace, DMA		ABC Meta-Anal Collaboration	Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis	LANCET			English	Article							TRANSITIONAL-CELL-CARCINOMA; RADICAL CYSTECTOMY; PROSPECTIVE TRIAL; CISPLATIN; THERAPY	Background Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment 06 survival in patients with this disease. Methods We analysed updated data for 2688 individual patients from ten available randomised trials. Findings Platinum-based combination chemotherapy showed a significant benefit to overall survival (combined hazard ratio [HR] 0.87 [95% Cl 0.78-0.98, p=0.016]; 13% reduction in risk of death; 5% absolute benefit at 5 years [1-7]; overall survival increased from 45% to 50%). This effect was observed irrespective of the type of local treatment, and did not vary between subgroups of patients. The HR for all trials, including those using single-agent cisplatin, tended to favour neoadjuvant chemotherapy (HR=0.91, 95% Cl 0.83-1.01) although this tendency was not significant (p=0.084). Although platinum based combination chemotherapy was beneficial, there was no evidence to support the use of single-agent platinum; indeed, there was a significant difference in the effect between these groups of trials (p=0.044). Interpretation This improvement in survival encourages the use of platinum-based combination chemotherapy for patients with invasive bladder cancer.	MRC, Clin Trials Unit, Metaanal Grp, London NW1 2DA, England; Urol & Nephrol Ctr, Mansoura, Egypt; Univ Padua, Sch Med, Padua, Italy; Osped Circolo & Fdn Macchi, Varese, Italy; Sydney Canc Ctr, Sydney, NSW, Australia; Christie Hosp, Manchester, Lancs, England; Fraser Valley Canc Ctr, Surrey, BC, Canada; Univ Roma La Sapienza, Rome, Italy; Univ Essen Gesamthsch, Urol Clin, Essen, Germany; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Freeman Rd Hosp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Royal Marsden NHS Trust, Surrey, England; Univ Uppsala Hosp, Uppsala, Sweden; La Luz Clin, Madrid, Spain; No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England; Herlev Univ Hosp, DK-2730 Herlev, Denmark; Univ Uppsala Hosp, Uppsala, Sweden; Biostat Abt, Mannheim, Germany; EORTC Data Ctr, Brussels, Belgium; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England	Medical Research Council Clinical Trials Unit; University of Padua; Ospedale Circolo & Fondazione Macchi; University of Sydney; Christie NHS Foundation Trust; Christie Hospital; Sapienza University Rome; University of Duisburg Essen; University of Southern California; Newcastle Freeman Hospital; Newcastle University - UK; Royal Marsden NHS Foundation Trust; Uppsala University; Uppsala University Hospital; University of Copenhagen; Herlev & Gentofte Hospital; Uppsala University; Uppsala University Hospital; European Organisation for Research & Treatment of Cancer; Wake Forest University; University of Birmingham	Vale, CL (corresponding author), MRC, Clin Trials Unit, Metaanal Grp, 222 Euston Rd, London NW1 2DA, England.	cv@ctu.mrc.ac.uk	Cortesi, Enrico/AAA-2983-2019	Vale, Claire/0000-0001-5157-0634; Stewart, Lesley/0000-0003-0287-4724; Tierney, Jayne/0000-0002-4734-3014				ABOLENEIN H, 1997, BR J UROL S4, V79, P174; *ADV OV CANC TRIAL, 1991, BMJ-BRIT MED J, V303, P844; [Anonymous], 1999, Lancet, V354, P533; Bassi P, 1999, J UROLOGY, V161, P1494, DOI 10.1016/S0022-5347(05)68936-7; Clarke M, 1998, ANN ONCOL, V9, P827, DOI 10.1023/A:1008468705492; Coppin CML, 1996, J CLIN ONCOL, V14, P2901, DOI 10.1200/JCO.1996.14.11.2901; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FAGG SL, 1984, BRIT J UROL, V56, P296, DOI 10.1111/j.1464-410X.1984.tb05390.x; GHERSI D, 1995, BRIT J UROL, V75, P206; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Malmstrom PU, 1996, J UROLOGY, V155, P1903, DOI 10.1016/S0022-5347(01)66042-7; Martinez-Pineiro JA, 1998, BRIT J UROL, V82, P33; MARTINEZPINEIRO JA, 1995, J UROLOGY, V153, P964, DOI 10.1016/S0022-5347(01)67614-6; Millikan R, 2001, J CLIN ONCOL, V19, P4005, DOI 10.1200/JCO.2001.19.20.4005; NATALE RB, 2001, P AN M AM SOC CLIN, V20, P3; OZONO S, 1991, UROL INT, V47, P116, DOI 10.1159/000282268; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; PARMAR M, 1995, SURVIVAL ANAL PRACTI; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PARMAR MKB, 1999, CLIN MANAGEMENT BLAD, P249; RAGHAVAN D, 1984, MED J AUSTRALIA, V140, P276, DOI 10.5694/j.1326-5377.1984.tb104036.x; Sengelov L, 2002, ACTA ONCOL, V41, P447, DOI 10.1080/028418602320405041; SHEARER RJ, 1988, BRIT J UROL, V62, P558, DOI 10.1111/j.1464-410X.1988.tb04426.x; Sherif A, 2002, SCAND J UROL NEPHROL, V36, P419, DOI 10.1080/003655902762467567; Shipley WU, 1998, J CLIN ONCOL, V16, P3576, DOI 10.1200/JCO.1998.16.11.3576; SOLOWAY MS, 1981, CANCER, V47, P476, DOI 10.1002/1097-0142(19810201)47:3<476::AID-CNCR2820470309>3.0.CO;2-8; Sternberg CN, 2001, J CLIN ONCOL, V19, p21S; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; STEWART LA, 1993, LANCET, V341, P964; WALLACE DMA, 1991, BRIT J UROL, V67, P608, DOI 10.1111/j.1464-410X.1991.tb15225.x; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	31	470	479	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1927	1934						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801735				2022-12-28	WOS:000183359700007
J	Grech, ED; Ramsdale, DR				Grech, ED; Ramsdale, DR			ABC of interventional cardiology - Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction	BRITISH MEDICAL JOURNAL			English	Review							TASK-FORCE; MANAGEMENT		Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Winnipeg, MB, Canada; Ctr Cardiothorac, Liverpool, Merseyside, England	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Grech, ED (corresponding author), Hlth Sci Ctr, Winnipeg, MB, Canada.							Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Bertrand ME, 2000, EUR HEART J, V21, P1406, DOI 10.1053/euhj.2000.2301; Braunwald E, 2002, J AM COLL CARDIOL, V40, P1366, DOI 10.1016/S0735-1097(02)02336-7; RAMSDALE DR, 2002, PRACTICAL INTERVENTI, P165	4	102	123	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1259	1261		10.1136/bmj.326.7401.1259	http://dx.doi.org/10.1136/bmj.326.7401.1259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791748	Green Published			2022-12-28	WOS:000183480700025
J	Bevan, M				Bevan, M			Surprises inside a green grass genome	SCIENCE			English	Editorial Material							DRAFT SEQUENCE; RICE		John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UJ, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Bevan, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Colney Lane, Norwich NR4 7UJ, Norfolk, England.	michael.bevan@bbsrc.ac.uk						Blanc G, 2003, GENOME RES, V13, P137, DOI 10.1101/gr.751803; DANGL J, 2002, PLANT PHYSIOL, V130, P1741; Feng Q, 2002, NATURE, V420, P316, DOI 10.1038/nature01183; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; Yamazaki M, 2001, MOL GENET GENOMICS, V265, P336, DOI 10.1007/s004380000421; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Yu YS, 2003, SCIENCE, V300, P1566, DOI 10.1126/science.1083523; MULTINATIONAL ARABID	10	6	6	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1514	1515		10.1126/science.1086162	http://dx.doi.org/10.1126/science.1086162			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791971				2022-12-28	WOS:000183333100031
J	Vaudry, D; Falluel-Morel, A; Leuillet, S; Vaudry, H; Gonzalez, BJ				Vaudry, D; Falluel-Morel, A; Leuillet, S; Vaudry, H; Gonzalez, BJ			Regulators of cerebellar granule cell development act through specific signaling pathways	SCIENCE			English	Editorial Material							GROWTH-FACTOR-I; APOPTOSIS; NEURONS; DEATH; DEPOLARIZATION; INVOLVEMENT; INDUCTION; POTASSIUM; SURVIVAL; MANNER	The proper development of the central nervous system depends upon a finely tuned balance between cell proliferation and programmed cell death (PCD). Although PCD was initially believed to depend solely on the inability of certain neurons to obtain access to a limited supply of trophic factors, it has become apparent that the local production of death signals is also critical. In this Viewpoint, we discuss several pathways implicated in the survival of cerebellar granule cells-both pathways that protect from apoptosis and pathways that promote apoptosis-and describe how these disparate pathways converge on the final common mediators of PCD. Information on other important pathways implicated in granule cell survival may be found in the Connections Maps.	Univ Rouen, INSERM,U413, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, F-76821 Mont St Aignan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Vaudry, D (corresponding author), Univ Rouen, INSERM,U413, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, F-76821 Mont St Aignan, France.		VAUDRY, David/M-1454-2018; Gonzalez, Bruno/E-6103-2016	VAUDRY, David/0000-0003-3567-7452; Gonzalez, Bruno/0000-0002-7176-1320; Anthony, FALLUEL-MOREL/0000-0002-4081-6704				ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; Armstrong RC, 1997, J NEUROSCI, V17, P553; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Chen RW, 1999, J NEUROSCI, V19, P9654; Chen RW, 2003, J NEUROCHEM, V84, P566, DOI 10.1046/j.1471-4159.2003.01548.x; Chrysis D, 2001, J NEUROSCI, V21, P1481, DOI 10.1523/JNEUROSCI.21-05-01481.2001; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; deLuca A, 1996, J NEUROSCI, V16, P4174; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lafon-Cazal M, 2002, EUR J NEUROSCI, V16, P575, DOI 10.1046/j.1460-9568.2002.02124.x; LEUILLET S, 2003, SCI STKE; Linseman DA, 2002, J NEUROSCI, V22, P9287; Luo J, 2003, J BIOL CHEM, V278, P4542, DOI 10.1074/jbc.M208295200; Marx J, 2001, SCIENCE, V293, P2192, DOI 10.1126/science.293.5538.2192; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PEARSON H, 1992, EUR J NEUROSCI, V4, P1369, DOI 10.1111/j.1460-9568.1992.tb00162.x; Persengiev SP, 2001, J STEROID BIOCHEM, V77, P151, DOI 10.1016/S0960-0760(01)00037-1; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Skaper SD, 1998, J NEUROCHEM, V70, P1859, DOI 10.1046/j.1471-4159.1998.70051859.x	20	51	52	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1532	1534		10.1126/science.1085260	http://dx.doi.org/10.1126/science.1085260			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791981				2022-12-28	WOS:000183333100041
J	Jones, JH; Handcock, MS				Jones, JH; Handcock, MS			Sexual contacts and epidemic thresholds	NATURE			English	Article							PARTNERSHIPS		Univ Washington, Ctr Stat & Social Sci, Seattle, WA 98195 USA; Univ Washington, Ctr AIDS & Sexually Transmitted Dis, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Jones, JH (corresponding author), Univ Washington, Ctr Stat & Social Sci, Seattle, WA 98195 USA.	jameshj@stat.washington.edu	Handcock, Mark S./AAY-3318-2021	Handcock, Mark S./0000-0002-9985-2785; Jones, James/0000-0003-1680-6757				Adimora AA, 2002, EPIDEMIOLOGY, V13, P320, DOI 10.1097/00001648-200205000-00013; ANDERSON R M, 1986, IMA Journal of Mathematics Applied in Medicine and Biology, V3, P229; ANDERSON R M, 1991; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Johnson N.L., 1992, BIOMETRICAL J, V36, P565, DOI [10.1002/bimj.4710360207, DOI 10.1002/BIMJ.4710360207]; Jones JH, 2003, P ROY SOC B-BIOL SCI, V270, P1123, DOI 10.1098/rspb.2003.2369; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; Lewin B, 1996, SEX SWEDEN; Liljeros F, 2001, NATURE, V411, P907, DOI 10.1038/35082140; May RM, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.066112; Morris M, 1997, AIDS, V11, P641, DOI 10.1097/00002030-199705000-00012; Pastor-Satorras R, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.035108; SIMON HA, 1955, BIOMETRIKA, V42, P425	13	59	61	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2003	423	6940					605	606		10.1038/423605a	http://dx.doi.org/10.1038/423605a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789329	Green Published			2022-12-28	WOS:000183301200030
J	Garattini, S; Bertele, V; Li Bassi, L				Garattini, S; Bertele, V; Li Bassi, L			How can research ethics committees protect patients better?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PLACEBO; TRIALS; SCHIZOPHRENIA; IMIPRAMINE; EQUIVALENCE; RISPERIDONE; FLUVOXAMINE; OUTPATIENTS; DEPRESSION		Mario Negri Inst Pharmacol Res, Lab Regulatory Policies, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, S (corresponding author), Mario Negri Inst Pharmacol Res, Lab Regulatory Policies, Via Eritrea 62, I-20157 Milan, Italy.	garattini@marionegri.it	Bertele, Vittorio/AAA-6461-2020; Garattini, Silvio/AAA-6390-2020	Bertele, Vittorio/0000-0002-0032-7033; Garattini, Silvio/0000-0003-0647-9297				6World Medical Association, 2000, DECL HELS; Barbui C, 2000, EUR PSYCHIAT, V15, P268, DOI 10.1016/S0924-9338(00)00233-9; Barbui C, 2002, EUR J CLIN PHARMACOL, V58, P379, DOI 10.1007/s00228-002-0497-7; Bertele V, 1999, HEART, V81, P675, DOI 10.1136/hrt.81.6.675; Born GVR, 1997, LANCET, V349, P806, DOI 10.1016/S0140-6736(05)60237-1; DUNBAR GC, 1991, BRIT J PSYCHIAT, V159, P394, DOI 10.1192/bjp.159.3.394; Farmer JA, 2001, LANCET, V358, P1383, DOI 10.1016/S0140-6736(01)06489-3; Fontaine KR, 2001, PSYCHIAT RES, V101, P277, DOI 10.1016/S0165-1781(01)00234-7; Geddes J, 2000, BRIT MED J, V321, P1371, DOI 10.1136/bmj.321.7273.1371; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Koro CE, 2002, BMJ-BRIT MED J, V325, P243, DOI 10.1136/bmj.325.7358.243; Lewis JA, 2002, LANCET, V359, P1337, DOI 10.1016/S0140-6736(02)08277-6; LYDIARD RB, 1989, PSYCHOPHARMACOL BULL, V25, P68; MARCH JS, 1990, J CLIN PSYCHIAT, V51, P200; Margreiter R, 2002, LANCET, V359, P741, DOI 10.1016/S0140-6736(02)07875-3; Meltzer HY, 2001, ANN NY ACAD SCI, V932, P44, DOI 10.1111/j.1749-6632.2001.tb05797.x; PEDERSEN TR, 1994, LANCET, V344, P1383; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Schieppati A, 2002, LANCET, V360, P799, DOI 10.1016/S0140-6736(02)09907-5; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Simpson GM, 1997, J CLIN PSYCHOPHARM, V17, P194, DOI 10.1097/00004714-199706000-00010; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Vanina Y, 2002, PSYCHIATR SERV, V53, P842, DOI 10.1176/appi.ps.53.7.842; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	24	32	34	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2003	326	7400					1199	1201		10.1136/bmj.326.7400.1199	http://dx.doi.org/10.1136/bmj.326.7400.1199			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	686FC	12775624	Green Published			2022-12-28	WOS:000183309900026
J	Amieva, MR; Vogelmann, R; Covacci, A; Tompkins, LS; Nelson, WJ; Falkow, S				Amieva, MR; Vogelmann, R; Covacci, A; Tompkins, LS; Nelson, WJ; Falkow, S			Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; PATHOGENICITY ISLAND; IN-VIVO; CELLS; PROTEIN; TRANSLOCATION; PHOSPHATASE; INFECTION; INDUCTION; STRAINS	Helicobacter pylori translocates the protein CagA into gastric epithelial cells and has been linked to peptic ulcer disease and gastric carcinoma. We show that injected CagA associates with the epithelial tight-junction scaffolding protein ZO-1 and the transmembrane protein junctional adhesion molecule, causing an ectopic assembly of tight-junction components at sites of bacterial attachment, and altering the composition and function of the apical-junctional complex. Long-term CagA delivery to polarized epithelia caused a disruption of the epithelial barrier function and dysplastic alterations in epithelial cell morphology. CagA appears to target H. pylori to host cell intercellular junctions and to disrupt junction-mediated functions.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Ist Ric Immunobiol Siena Chiron Vaccines, I-53100 Siena, Italy	Stanford University; Stanford University; Stanford University; Stanford University; Novartis	Amieva, MR (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.		Amieva, Manuel/U-2581-2017	Amieva, Manuel/0000-0002-5601-4490	NCI NIH HHS [CA92229, R01 CA092229] Funding Source: Medline; NIAID NIH HHS [AI38459, R01 AI038459] Funding Source: Medline; NIDCD NIH HHS [DDC DK56339] Funding Source: Medline; NIDDK NIH HHS [P30 DK056339] Funding Source: Medline; NIGMS NIH HHS [R01GM35227, R01 GM035527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIEVA MR, UNPUB; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BLASER MJ, 1995, CANCER RES, V55, P2111; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Collares-Buzato CB, 1998, EUR J CELL BIOL, V76, P85, DOI 10.1016/S0171-9335(98)80020-4; Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; HAZELL SL, 1986, J INFECT DIS, V153, P658, DOI 10.1093/infdis/153.4.658; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Papini E, 1998, J CLIN INVEST, V102, P813, DOI 10.1172/JCI2764; Peek RM, 1995, LAB INVEST, V73, P760; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; STEER HW, 1984, GUT, V25, P1203, DOI 10.1136/gut.25.11.1203; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088	22	569	598	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1430	1434		10.1126/science.1081919	http://dx.doi.org/10.1126/science.1081919			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775840	Green Accepted			2022-12-28	WOS:000183181800045
J	Ohashi, Y; Oka, A; Rodrigues-Pousada, R; Possenti, M; Ruberti, I; Morelli, G; Aoyama, T				Ohashi, Y; Oka, A; Rodrigues-Pousada, R; Possenti, M; Ruberti, I; Morelli, G; Aoyama, T			Modulation of phospholipid signaling by GLABRA2 in root-hair pattern formation	SCIENCE			English	Article							CELL-DIFFERENTIATION; TRANSGENIC PLANTS; ARABIDOPSIS ROOT; GENE-EXPRESSION; EPIDERMIS; PROTEIN; FAMILY	The root-hair pattern of Arabidopsis is determined through a regulatory circuit composed of transcription factor genes. The homeobox gene GLABRA2 (GL2) has been considered a key component, acting farthest downstream in this regulation. GL2 modified to include a transactivating function caused epidermal cells to develop ectopic root hairs or root hair-like structures. With this system, the phospholipase Dzeta1 gene (AtPLDzeta1) was identified as a direct target of GL2. Inducible expression of AtPLDzeta1 promoted ectopic root-hair initiation. We conclude that GL2 exerts its regulatory effect on root-hair development through modulation of phospholipid signaling.	Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Ist Nazl Ric Alimenti & Nutr, I-00178 Rome, Italy; Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Ctr Studio Acidi Nucl, I-00185 Rome, Italy	Kyoto University; Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); Sapienza University Rome	Aoyama, T (corresponding author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.		Morelli, Giorgio/P-3334-2019; Ohashi, Yohei/AAT-4006-2021; Morelli, Giorgio/A-5559-2016	Morelli, Giorgio/0000-0002-8994-4838; Ohashi, Yohei/0000-0002-2288-130X; Morelli, Giorgio/0000-0002-8994-4838; RODRIGUES POUSADA, Renato Alberto/0000-0003-2551-4705; Possenti, Marco/0000-0001-6707-3245				Abe M, 2001, PLANT J, V26, P487, DOI 10.1046/j.1365-313x.2001.01047.x; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Cho HT, 2002, PLANT CELL, V14, P3237, DOI 10.1105/tpc.006437; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; Di Cristina M, 1996, PLANT J, V10, P393, DOI 10.1046/j.1365-313X.1996.10030393.x; DOLAN L, 1994, DEVELOPMENT, V120, P2465; Dolan L, 2001, CURR OPIN PLANT BIOL, V4, P550, DOI 10.1016/S1369-5266(00)00214-4; GALWAY ME, 1994, DEV BIOL, V166, P740, DOI 10.1006/dbio.1994.1352; Hung CY, 1998, PLANT PHYSIOL, V117, P73, DOI 10.1104/pp.117.1.73; Lee MM, 1999, CELL, V99, P473, DOI 10.1016/S0092-8674(00)81536-6; Lee MM, 2002, PLANT CELL, V14, P611, DOI 10.1105/tpc.010434; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Masucci JD, 1996, DEVELOPMENT, V122, P1253; Qin CB, 2002, PLANT PHYSIOL, V128, P1057, DOI 10.1104/pp.010928; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; RODRIGUESPOUSAD.R, UNPUB; Schiefelbein JW, 2000, PLANT PHYSIOL, V124, P1525, DOI 10.1104/pp.124.4.1525; Wada T, 1997, SCIENCE, V277, P1113, DOI 10.1126/science.277.5329.1113; Wang XM, 2000, PROG LIPID RES, V39, P109, DOI 10.1016/S0163-7827(00)00002-3; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x	20	211	235	3	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1427	1430		10.1126/science.1083695	http://dx.doi.org/10.1126/science.1083695			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775839				2022-12-28	WOS:000183181800044
J	Zavialov, AV; Berglund, J; Pudney, AF; Fooks, LJ; Ibrahim, TM; MacIntyre, S; Knight, SD				Zavialov, AV; Berglund, J; Pudney, AF; Fooks, LJ; Ibrahim, TM; MacIntyre, S; Knight, SD			Structure and biogenesis of the capsular F1 antigen from Yersinia pestis: Preserved folding energy drives fiber formation	CELL			English	Article							PILUS BIOGENESIS; MACROMOLECULAR STRUCTURES; CHAPERONE FUNCTION; ESCHERICHIA-COLI; CAF1M; CRYSTALLOGRAPHY; REFINEMENT; PROTEINS; SURFACE; BINDING	Most gram-negative pathogens express fibrous adhesive virulence organelles that mediate targeting to the sites of infection. The F1 capsular antigen from the plague pathogen Yersinia pestis consists of linear fibers of a single subunit (Caf1) and serves as a prototype for nonpilus organelles assembled via the chaperone/usher pathway. Genetic data together with high-resolution X-ray structures corresponding to snapshots of the assembly process reveal the structural basis of fiber formation. Comparison of chaperone bound Caf1 subunit with the subunit in the fiber reveals a novel type of conformational change involving the entire hydrophobic core of the protein. The observed conformational change suggests that the chaperone traps a high-energy folding intermediate of Caf1. A model is proposed in which release of the subunit allows folding to be completed, driving fiber formation.	Univ Reading, Sch Anim & Microbial Sci, Div Microbiol, Reading RG6 6AJ, Berks, England; Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Mol Biosci Struct Biol, SE-75124 Uppsala, Sweden	University of Reading; Swedish University of Agricultural Sciences	MacIntyre, S (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Div Microbiol, Reading RG6 6AJ, Berks, England.		Zavialov, Anton V./C-7664-2015; Knight, Stefan/D-4315-2015	Zavialov, Anton V./0000-0001-6191-5931; Knight, Stefan/0000-0002-7180-8758				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CCP4, 1994, ACTA CRYSTALLOGR D, V50, P780; Chapman DAG, 1999, J BACTERIOL, V181, P2422, DOI 10.1128/JB.181.8.2422-2429.1999; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Du YD, 2002, INFECT IMMUN, V70, P1453, DOI 10.1128/IAI.70.3.1453-1460.2002; ESHDAT Y, 1981, J BACTERIOL, V148, P308, DOI 10.1128/JB.148.1.308-314.1981; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; JACOBDUBUISSON F, 1994, J BIOL CHEM, V269, P12447; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keeling MJ, 2000, NATURE, V407, P903, DOI 10.1038/35038073; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Knight SD, 2000, CURR OPIN CHEM BIOL, V4, P653, DOI 10.1016/S1367-5931(00)00144-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; MacIntyre S, 2001, MOL MICROBIOL, V39, P12, DOI 10.1046/j.1365-2958.2001.02199.x; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Saibil H, 2000, CURR OPIN STRUC BIOL, V10, P251, DOI 10.1016/S0959-440X(00)00074-9; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; Thanassi DG, 1998, CURR OPIN MICROBIOL, V1, P223, DOI 10.1016/S1369-5274(98)80015-5; Thanassi DG, 2002, J BACTERIOL, V184, P6260, DOI 10.1128/JB.184.22.6260-6269.2002; Titball RW, 2001, VACCINE, V19, P4175, DOI 10.1016/S0264-410X(01)00163-3; Vetsch M, 2002, J MOL BIOL, V322, P827, DOI 10.1016/S0022-2836(02)00845-8; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117; Zavialov A, 2003, ACTA CRYSTALLOGR D, V59, P359, DOI 10.1107/S0907444902021054; Zavialov AV, 2002, MOL MICROBIOL, V45, P983, DOI 10.1046/j.1365-2958.2002.03066.x; ZavYalov VP, 1997, BIOCHEM J, V324, P571, DOI 10.1042/bj3240571	33	213	229	0	17	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					587	596		10.1016/S0092-8674(03)00351-9	http://dx.doi.org/10.1016/S0092-8674(03)00351-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787500	Bronze			2022-12-28	WOS:000183397600009
J	Musgrove, P				Musgrove, P			Judging health systems: reflections on WHO's methods	LANCET			English	Editorial Material									NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Musgrove, P (corresponding author), NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.							[Anonymous], 1996, GLOBAL BURDEN DIS CO; *COMM MACR HLTH, 2001, 5 WHO LOND SCH HYG; DESILVA A, 2000, 21 WHOGPE; GAKIDON E, 2000, 18 WHOGPE; HSIAO WC, 2000, 3 COMM MACR HLTH; *I HLTH SECT DEV, 2000, IMPR HLTH SYST MEAS; JHA P, 2002, 2 WHO COMM MACR HLTH; LAUER JA, 2001, HLTH SYSTEM PERFORMA, pCH23; Murray CJL, 2001, HEALTH ECON, V10, P277, DOI 10.1002/hec.623; MURRAY CJL, 2001, 24 WHOGPE, pCH16; MURRAY CJL, 2001, HLTH SYSTEM PERFORMA; MURRAY CJL, 2001, 25 WHOGPE, pCH17; VALENTINE NP, 2000, 22 WHOGPE; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2000, WORLD HLTH REP 2000; XU K, 2000, 26 WHOGPE	16	25	27	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1817	1820		10.1016/S0140-6736(03)13408-3	http://dx.doi.org/10.1016/S0140-6736(03)13408-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781555				2022-12-28	WOS:000183074800025
J	McManus, R; Kelleher, D				McManus, R; Kelleher, D			Celiac disease - The villain unmasked?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St James Hosp, Trinity Ctr Hlth Sci, Dublin Mol Med Ctr, Dublin 8, Ireland	Trinity College Dublin; University College Dublin	McManus, R (corresponding author), St James Hosp, Trinity Ctr Hlth Sci, Dublin Mol Med Ctr, Dublin 8, Ireland.		McManus, Ross/AAE-9236-2020	McManus, Ross/0000-0002-0529-9617				Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; GOGGINS M, 1994, AM J GASTROENTEROL, V89, pS2; Maki M, 2003, NEW ENGL J MED, V348, P2517, DOI 10.1056/NEJMoa021687; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Molberg O, 1998, NAT MED, V4, P974, DOI 10.1038/nm0898-974b; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885	7	23	23	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2573	2574		10.1056/NEJMcibr035033	http://dx.doi.org/10.1056/NEJMcibr035033			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815145				2022-12-28	WOS:000183577200014
J	Ogita, S; Uefuji, H; Yamaguchi, Y; Koizumi, N; Sano, H				Ogita, S; Uefuji, H; Yamaguchi, Y; Koizumi, N; Sano, H			RNA interference - Producing decaffeinated coffee plants	NATURE			English	Editorial Material							CAFFEINE; GENE		Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300192, Japan	Nara Institute of Science & Technology	Ogita, S (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300192, Japan.		Yamaguchi, Yube/B-9594-2012					Ashihara H, 1996, PLANT PHYSIOL, V111, P747, DOI 10.1104/pp.111.3.747; Ashihara H, 2001, TRENDS PLANT SCI, V6, P407, DOI 10.1016/S1360-1385(01)02055-6; Hatanaka T, 1999, PLANT CELL REP, V19, P106, DOI 10.1007/s002990050719; Ogawa M, 2001, J BIOL CHEM, V276, P8213, DOI 10.1074/jbc.M009480200; OHTA S, 1990, PLANT CELL PHYSIOL, V31, P805; Uefuji H, 2003, PLANT PHYSIOL, V132, P372, DOI 10.1104/pp.102.019679	6	149	196	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					823	823		10.1038/423823a	http://dx.doi.org/10.1038/423823a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815419	Bronze			2022-12-28	WOS:000183585300032
J	Schiermeier, Q				Schiermeier, Q			Researchers rattled as Kyoto Protocol hangs in the balance	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					792	792		10.1038/423792b	http://dx.doi.org/10.1038/423792b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815393	Bronze			2022-12-28	WOS:000183585300010
J	Verghese, J; Lipton, RB; Katz, MJ; Hall, CB; Derby, CA; Kuslansky, G; Ambrose, AF; Sliwinski, M; Buschke, H				Verghese, J; Lipton, RB; Katz, MJ; Hall, CB; Derby, CA; Kuslansky, G; Ambrose, AF; Sliwinski, M; Buschke, H			Leisure activities and the risk of dementia in the elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALZHEIMERS-DISEASE; PHYSICAL-ACTIVITY; COGNITIVE IMPAIRMENT; DIETARY-INTAKE; LATE-LIFE; MEMORY; ASSOCIATION; PREVALENCE; DIAGNOSIS; EDUCATION	BACKGROUND: Participation in leisure activities has been associated with a lower risk of dementia. It is unclear whether increased participation in leisure activities lowers the risk of dementia or participation in leisure activities declines during the preclinical phase of dementia. METHODS: We examined the relation between leisure activities and the risk of dementia in a prospective cohort of 469 subjects older than 75 years of age who resided in the community and did not have dementia at base line. We examined the frequency of participation in leisure activities at enrollment and derived cognitive-activity and physical-activity scales in which the units of measure were activity-days per week. Cox proportional-hazards analysis was used to evaluate the risk of dementia according to the base-line level of participation in leisure activities, with adjustment for age, sex, educational level, presence or absence of chronic medical illnesses, and base-line cognitive status. RESULTS: Over a median follow-up period of 5.1 years, dementia developed in 124 subjects (Alzheimer's disease in 61 subjects, vascular dementia in 30, mixed dementia in 25, and other types of dementia in 8). Among leisure activities, reading, playing board games, playing musical instruments, and dancing were associated with a reduced risk of dementia. A one-point increment in the cognitive-activity score was significantly associated with a reduced risk of dementia (hazard ratio, 0.93 [95 percent confidence interval, 0.90 to 0.97]), but a one-point increment in the physical-activity score was not (hazard ratio, 1.00). The association with the cognitive-activity score persisted after the exclusion of the subjects with possible preclinical dementia at base line. Results were similar for Alzheimer's disease and vascular dementia. In linear mixed models, increased participation in cognitive activities at base line was associated with reduced rates of decline in memory. CONCLUSIONS: Participation in leisure activities is associated with a reduced risk of dementia, even after adjustment for base-line cognitive status and after the exclusion of subjects with possible preclinical dementia. Controlled trials are needed to assess the protective effect of cognitive leisure activities on the risk of dementia.	Albert Einstein Coll Med, Einstein Aging Study, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Phys Med & Rehabil, Bronx, NY 10467 USA; Syracuse Univ, Dept Psychol, Syracuse, NY USA; Syracuse Univ, Ctr Hlth & Behav, Syracuse, NY USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Syracuse University; Syracuse University	Verghese, J (corresponding author), Albert Einstein Coll Med, Einstein Aging Study, 1165 Morris Pk Ave, Bronx, NY 10461 USA.	jverghes@aecom.yu.edu	Lipton, Richard Bruce/AAY-2818-2021; Ambrose, Anne Felicia/ABE-4161-2020; Sliwinski, Martin/HGC-5907-2022; Ambrose, Anne Felicia/AAQ-9668-2021; Lipton, Richard B/B-5060-2011; Hall, Charles B./AAX-8216-2020	Hall, Charles/0000-0001-9982-8120	NATIONAL INSTITUTE ON AGING [P01AG003949] Funding Source: NIH RePORTER; NIA NIH HHS [AGO3949-15] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Christmas C, 2000, J AM GERIATR SOC, V48, P318, DOI 10.1111/j.1532-5415.2000.tb02654.x; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; COX DR, 1972, J R STAT SOC B, V34, P187; Elias MF, 2000, ARCH NEUROL-CHICAGO, V57, P808, DOI 10.1001/archneur.57.6.808; Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223; FABRIGOULE C, 1995, J AM GERIATR SOC, V43, P485, DOI 10.1111/j.1532-5415.1995.tb06093.x; Fleiss J, 1981, STAT METHODS RATES P, P38; Fratiglioni L, 1999, DRUG AGING, V15, P365, DOI 10.2165/00002512-199915050-00004; Friedland RP, 2001, P NATL ACAD SCI USA, V98, P3440, DOI 10.1073/pnas.061002998; FULD PA, 1990, J CLIN EXP NEUROPSYC, V12, P520, DOI 10.1080/01688639008400998; Fuld PA., 1978, ALZHEIMERS DIS SENIL, V7, P185; Grober E, 1999, NEUROBIOL AGING, V20, P573, DOI 10.1016/S0197-4580(99)00063-9; Hall CB, 2001, STAT MED, V20, P3695, DOI 10.1002/sim.1113; Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; KONDO K, 1994, DEMENTIA, V5, P314, DOI 10.1159/000106741; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Mazzeo RS, 1998, MED SCI SPORT EXER, V30, P992, DOI 10.1097/00005768-199806000-00033; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Morris MC, 2002, JAMA-J AM MED ASSOC, V287, P3230, DOI 10.1001/jama.287.24.3230; National Collaborative Group for the Revision of the Wechsler Adult Intelligence Scale, 1983, MANUAL WECHSLER ADUL, V03, P362; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; ROGERS RL, 1990, J AM GERIATR SOC, V38, P123, DOI 10.1111/j.1532-5415.1990.tb03472.x; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Small BJ, 2000, ARCH NEUROL-CHICAGO, V57, P839, DOI 10.1001/archneur.57.6.839; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; Verghese J, 2002, NEW ENGL J MED, V347, P1761, DOI 10.1056/NEJMoa020441; Wang HX, 2002, AM J EPIDEMIOL, V155, P1081, DOI 10.1093/aje/155.12.1081; Wilson RS, 2002, NEUROLOGY, V59, P1910, DOI 10.1212/01.WNL.0000036905.59156.A1; Wilson RS, 2002, J NEUROL NEUROSUR PS, V73, P672, DOI 10.1136/jnnp.73.6.672; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742; ZUNG WWK, 1967, PSYCHOSOMATICS, V8, P287	43	1130	1161	10	329	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2508	2516		10.1056/NEJMoa022252	http://dx.doi.org/10.1056/NEJMoa022252			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690YC	12815136				2022-12-28	WOS:000183577200005
J	Guevara, JP; Wolf, FM; Grum, CM; Clark, NM				Guevara, JP; Wolf, FM; Grum, CM; Clark, NM			Learning about asthma - Educational programmes improve the ability of children and teenagers to manage their asthma	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INNER-CITY CHILDREN; HEALTH-EDUCATION; CHILDHOOD ASTHMA; PEDIATRIC ASTHMA; CONTROLLED TRIAL; YOUNG-CHILDREN; INTERVENTION; IMPACT; POPULATION; PARENTS		Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Washington, Sch Med, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA	University of Pennsylvania; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guevara, JP (corresponding author), Childrens Hosp Philadelphia, Div Gen Pediat, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	guevara@email.chop.edu	Praena-Crespo, Manuel/E-7172-2010	Praena-Crespo, Manuel/0000-0002-1928-9663; Guevara, James/0000-0003-1665-4503	FOGARTY INTERNATIONAL CENTER [F06TW002123] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH065696] Funding Source: NIH RePORTER; FIC NIH HHS [1 F06 TW02123] Funding Source: Medline; NHLBI NIH HHS [1 K07 HL 03046] Funding Source: Medline; NIMH NIH HHS [K23 MH065696] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alexander J S, 1988, J Pediatr Nurs, V3, P312; Carswell F, 1989, Bristol Med Chir J, V104, P11; CHARLTON I, 1994, ARCH DIS CHILD, V70, P313, DOI 10.1136/adc.70.4.313; Christiansen SC, 1997, J ALLERGY CLIN IMMUN, V100, P613, DOI 10.1016/S0091-6749(97)70164-7; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; COLLAND VT, 1993, PATIENT EDUC COUNS, V22, P141, DOI 10.1016/0738-3991(93)90094-D; DAHL J, 1990, J ASTHMA, V27, P41, DOI 10.3109/02770909009073293; DEAVES DM, 1993, J ADV NURS, V18, P354, DOI 10.1046/j.1365-2648.1993.18030354.x; EVANS D, 1987, HEALTH EDUC QUART, V14, P267, DOI 10.1177/109019818701400302; FIREMAN P, 1981, PEDIATRICS, V68, P341; HILL R, 1991, BRIT MED J, V303, P1169, DOI 10.1136/bmj.303.6811.1169; Holzheimer L, 1998, CHILD CARE HLTH DEV, V24, P85; HUGHES DM, 1991, PEDIATRICS, V87, P54; Kubly L S, 1984, Issues Compr Pediatr Nurs, V7, P121, DOI 10.3109/01460868409009050; LEBARON S, 1985, ANN ALLERGY, V55, P811; LEWIS CE, 1984, PEDIATRICS, V74, P478; Madge P, 1997, THORAX, V52, P223, DOI 10.1136/thx.52.3.223; MCNABB WL, 1985, AM J PUBLIC HEALTH, V75, P1219, DOI 10.2105/AJPH.75.10.1219; MITCHELL EA, 1986, ARCH DIS CHILD, V61, P1184, DOI 10.1136/adc.61.12.1184; Parcel G S, 1980, J Dev Behav Pediatr, V1, P128; PERRIN JM, 1992, J DEV BEHAV PEDIATR, V13, P241; Persaud DI, 1996, J ASTHMA, V33, P37, DOI 10.3109/02770909609077761; RAKOS RF, 1985, J PSYCHOSOM RES, V29, P101, DOI 10.1016/0022-3999(85)90014-5; Ronchetti R, 1997, EUR RESPIR J, V10, P1248, DOI 10.1183/09031936.97.10061248; RUBIN DH, 1986, PEDIATRICS, V77, P1; SHIELDS MC, 1990, AM J PUBLIC HEALTH, V80, P36, DOI 10.2105/AJPH.80.1.36; Szczepanski R, 1996, Pneumologie, V50, P544; TALABERE LR, 1993, KEY ASPECTS CARING C, P319; TOELLE BG, 1993, MED J AUSTRALIA, V158, P742, DOI 10.5694/j.1326-5377.1993.tb121954.x; WEINGARTEN MA, 1985, J ASTHMA, V22, P261, DOI 10.3109/02770908509077458; WHITMAN N, 1985, HEALTH EDUC QUART, V12, P333, DOI 10.1177/109019818501200312; Wilson SR, 1996, J ASTHMA, V33, P239, DOI 10.3109/02770909609055365	32	340	356	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2003	326	7402					1308	1309		10.1136/bmj.326.7402.1308	http://dx.doi.org/10.1136/bmj.326.7402.1308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	691VK	12805167	Green Published, Bronze			2022-12-28	WOS:000183626500031
J	Smith, R				Smith, R			Do patients need to read research?	BRITISH MEDICAL JOURNAL			English	Article									BMJ, London WC1H 9JR, England		Smith, R (corresponding author), BMJ, London WC1H 9JR, England.								0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1307	1307		10.1136/bmj.326.7402.1307	http://dx.doi.org/10.1136/bmj.326.7402.1307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805166	Green Published, Bronze			2022-12-28	WOS:000183626500030
J	Brooker, RA; Du, Z; Blundy, JD; Kelley, SP; Allan, NL; Wood, BJ; Chamorro, EM; Wartho, JA; Purton, JA				Brooker, RA; Du, Z; Blundy, JD; Kelley, SP; Allan, NL; Wood, BJ; Chamorro, EM; Wartho, JA; Purton, JA			The 'zero charge' partitioning behaviour of noble gases during mantle melting	NATURE			English	Article							OLIVINE GLASS; COEFFICIENTS; CONSTRAINTS; EVOLUTION; ARGON; SOLUBILITY; SIMULATION; HELIUM; BASALT; SPINEL	Noble-gas geochemistry is an important tool for understanding planetary processes from accretion to mantle dynamics and atmospheric formation(1-4). Central to much of the modelling of such processes is the crystal-melt partitioning of noble gases during mantle melting, magma ascent and near-surface degassing(5). Geochemists have traditionally considered the 'inert' noble gases to be extremely incompatible elements, with almost 100 per cent extraction efficiency from the solid phase during melting processes. Previously published experimental data on partitioning between crystalline silicates and melts has, however, suggested that noble gases approach compatible behaviour, and a significant proportion should therefore remain in the mantle during melt extraction(5-8). Here we present experimental data to show that noble gases are more incompatible than previously demonstrated, but not necessarily to the extent assumed or required by geochemical models. Independent atomistic computer simulations indicate that noble gases can be considered as species of 'zero charge' incorporated at crystal lattice sites. Together with the lattice strain model(9,10), this provides a theoretical framework with which to model noble-gas geochemistry as a function of residual mantle mineralogy.	Univ Bristol, Dept Earth Sci, CETSEI, Bristol BS8 1RJ, Avon, England; Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England; Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England; SERC, Daresbury Lab, CLRC, Warrington WA4 4AD, Cheshire, England	University of Bristol; University of Bristol; Open University - UK; STFC Daresbury Laboratory	Brooker, RA (corresponding author), Univ Bristol, Dept Earth Sci, CETSEI, Wills Mem Bldg, Bristol BS8 1RJ, Avon, England.	r.a.brooker@bristol.ac.uk	Kelley, Simon/AAR-7075-2020; Facility, Edinburgh Ion Microprobe/AAD-8512-2020	Kelley, Simon/0000-0002-1756-0480; Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657; Brooker, Richard/0000-0003-4931-9912; ALLAN, NEIL/0000-0001-9342-6198				ALLEGRE CJ, 1987, EARTH PLANET SC LETT, V81, P127, DOI 10.1016/0012-821X(87)90151-8; Allegre CJ, 1996, GEOPHYS RES LETT, V23, P3555, DOI 10.1029/96GL03373; Anderson DL, 2001, EARTH PLANET SC LETT, V193, P77, DOI 10.1016/S0012-821X(01)00507-6; BEATTIE P, 1993, EARTH PLANET SC LETT, V117, P379, DOI 10.1016/0012-821X(93)90091-M; BLUNDY J, 1994, NATURE, V372, P452, DOI 10.1038/372452a0; BRICE JC, 1975, J CRYST GROWTH, V28, P249, DOI 10.1016/0022-0248(75)90241-9; BROADHURST CL, 1992, GEOCHIM COSMOCHIM AC, V56, P709, DOI 10.1016/0016-7037(92)90092-W; BROADHURST CL, 1990, GEOCHIM COSMOCHIM AC, V54, P299, DOI 10.1016/0016-7037(90)90319-G; Brooker RA, 1998, CHEM GEOL, V147, P185, DOI 10.1016/S0009-2541(97)00181-2; Chamorro EM, 2002, GEOCHIM COSMOCHIM AC, V66, P507, DOI 10.1016/S0016-7037(01)00784-0; Frenkel D., 1996, UNDERSTANDING MOL SI, V2; Gale JD, 1997, J CHEM SOC FARADAY T, V93, P629, DOI 10.1039/a606455h; Geiger, 2001, EMU NOTES MINERALOGY, P251; Harper CL, 1996, SCIENCE, V273, P1814, DOI 10.1126/science.273.5283.1814; HIYAGON H, 1994, CHEM GEOL, V112, P119, DOI 10.1016/0009-2541(94)90108-2; HIYAGON H, 1986, GEOCHIM COSMOCHIM AC, V50, P2045, DOI 10.1016/0016-7037(86)90258-9; Macedonia MD, 2000, LANGMUIR, V16, P3823, DOI 10.1021/la9912500; MARTY B, 1993, CHEM GEOL, V106, P1, DOI 10.1016/0009-2541(93)90162-C; ONIONS RK, 1983, NATURE, V306, P429, DOI 10.1038/306429a0; ONUMA N, 1968, EARTH PLANET SC LETT, V5, P47, DOI 10.1016/S0012-821X(68)80010-X; Ozima M, 2000, EARTH PLANET SC LETT, V176, P219, DOI 10.1016/S0012-821X(00)00005-4; PELLENQ RJM, 1995, LANGMUIR, V11, P1626, DOI 10.1021/la00005a035; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Shibata T., 1994, NOBLE GAS GEOCHEMIST, P343; TURNER G, 1989, J GEOL SOC LONDON, V146, P147, DOI 10.1144/gsjgs.146.1.0147; VALBRACHT PJ, 1994, NOBLE GAS GEOCHEMIST, P373; van Keken PE, 1999, J GEOPHYS RES-SOL EA, V104, P7137, DOI 10.1029/1999JB900003; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; WATANABE K, 1995, MOL SIMULAT, V15, P197, DOI 10.1080/08927029508022335; Wood BJ, 2001, EARTH PLANET SC LETT, V188, P59, DOI 10.1016/S0012-821X(01)00294-1; ZHANG YX, 1995, AM MINERAL, V80, P670	31	82	82	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					738	741		10.1038/nature01708	http://dx.doi.org/10.1038/nature01708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802331				2022-12-28	WOS:000183443400040
J	Ham, C				Ham, C			Improving the performance of health services: the role of clinical leadership	LANCET			English	Editorial Material							STRATEGIC CHANGE		Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Ham, C (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.	chris.ham@doh.gsi.gov.uk						BATE SP, 2002, REPORT BREAKTHROUGH; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; Bowns I.R., 1999, REENGINEERING LEICES; Denis J-L, 1999, RESTRUCTURING PROFES, P105; Denis JL, 1996, ORGAN STUD, V17, P673, DOI 10.1177/017084069601700406; Denis JL, 2001, ACAD MANAGE J, V44, P809, DOI 10.2307/3069417; EISENBERG JM, 1988, DOCTORS DECISIONS CO; GRAHAM A, 2001, OPTIMISING VALUE; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; HAM C, 2002, CAPACITY CULTURE LEA; JOSS R, 1995, ADV QUALITY; Langley GJ, 1996, IMPROVEMENT GUIDE; McNulty T, 2002, REENGINEERING HLTH C; Mintzberg H., 1979, STRUCTURING ORG; *NAT PRIM CAR DEV, 2002, NAT PRIM CAR COLL 1; *NHS CTR REV DISS, 1999, EFF HLTH CAR GETT EV; RUNDALL T, 1998, AFTER RESTRUCTURING; Shortell Stephen M, 2002, J Health Serv Res Policy, V7, P193; SILVERSIN J, 2000, LEADING PHYSICIANS C; WRIGHT O, 2002, TIMES LONDON    1029, P4	20	158	158	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1978	1980		10.1016/S0140-6736(03)13593-3	http://dx.doi.org/10.1016/S0140-6736(03)13593-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	687DB	12801754				2022-12-28	WOS:000183359700025
J	Ritvo, H				Ritvo, H			Fighting for Thirlmere - The roots of environmentalism	SCIENCE			English	Editorial Material									MIT, Dept Hist, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Ritvo, H (corresponding author), MIT, Dept Hist, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							BATEMAN JFL, 1884, HIST DESCRIPTION MAN, P216; BICKNELL P, 1984, ILLUSTRATED WORDSWOR, P186; HARWOOD JJ, 1895, HIST DESCRIPTION THI, P179; *THIRLM DEF ASS, 1878, EXTR LEAD J MANCH WA, P15	4	10	10	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1510	1511		10.1126/science.1079920	http://dx.doi.org/10.1126/science.1079920			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791968				2022-12-28	WOS:000183333100028
J	Enquist, BJ; Economo, EP; Huxman, TE; Allen, AP; Ignace, DD; Gillooly, JF				Enquist, BJ; Economo, EP; Huxman, TE; Allen, AP; Ignace, DD; Gillooly, JF			Scaling metabolism from organisms to ecosystems	NATURE			English	Article							CARBON-DIOXIDE; WATER-VAPOR; TEMPERATURE; RESPIRATION; SIZE; EXCHANGE; ECOLOGY; FLUXES; RATES; SOIL	Understanding energy and material fluxes through ecosystems is central to many questions in global change biology and ecology(1-11). Ecosystem respiration is a critical component of the carbon cycle(1,5-7) and might be important in regulating biosphere response to global climate change(1-3). Here we derive a general model of ecosystem respiration based on the kinetics of metabolic reactions(11-13) and the scaling of resource use by individual organisms(14,15). The model predicts that fluxes of CO2 and energy are invariant of ecosystem biomass, but are strongly influenced by temperature, variation in cellular metabolism and rates of supply of limiting resources (water and/or nutrients). Variation in ecosystem respiration within sites, as calculated from a network of CO2 flux towers(5,7), provides robust support for the model's predictions. However, data indicate that variation in annual flux between sites is not strongly dependent on average site temperature or latitude. This presents an interesting paradox with regard to the expected temperature dependence. Nevertheless, our model provides a basis for quantitatively understanding energy and material flux between the atmosphere and biosphere.	Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA; Ctr Appl Biodivers Sci, Washington, DC 20036 USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA	University of Arizona; University of New Mexico	Enquist, BJ (corresponding author), Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA.	benquist@u.arizona.edu	Allen, Andrew/B-8045-2011; Enquist, Brian J/B-6436-2008	Allen, Andrew/0000-0003-0304-7544; Enquist, Brian J/0000-0002-6124-7096				Baldocchi D, 2001, B AM METEOROL SOC, V82, P2415, DOI 10.1175/1520-0477(2001)082<2415:FANTTS>2.3.CO;2; BALDOCCHI DD, 1988, ECOLOGY, V69, P1331, DOI 10.2307/1941631; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; CONOVER DO, 1995, TRENDS ECOL EVOL, V10, P248, DOI 10.1016/S0169-5347(00)89081-3; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; EARNSHAW MJ, 1981, ARCTIC ALPINE RES, V13, P425, DOI 10.2307/1551053; Enquist BJ, 2001, NATURE, V410, P655, DOI 10.1038/35070500; ENQUIST BJ, IN PRESS MACROECOLOG; Falge E, 2001, AGR FOREST METEOROL, V107, P43, DOI 10.1016/S0168-1923(00)00225-2; Giardina CP, 2000, NATURE, V404, P858, DOI 10.1038/35009076; Gillooly JF, 2001, SCIENCE, V293, P2248, DOI 10.1126/science.1061967; Gillooly JF, 2002, NATURE, V417, P70, DOI 10.1038/417070a; HEMMINGSEN AXEL M., 1960, REPTS STENO HOSP COPENHAGEN, V9, P7; Huxman TE, 2003, OECOLOGIA, V134, P537, DOI 10.1007/s00442-002-1131-1; JORDAN CF, 1971, AM SCI, V59, P425; Keeling C.D., 1994, TRENDS 93 COMPENDIUM, P16; Law BE, 2002, AGR FOREST METEOROL, V113, P97, DOI 10.1016/S0168-1923(02)00104-1; Lovegrove BG, 2000, AM NAT, V156, P201, DOI 10.1086/303383; Luo YQ, 2001, NATURE, V413, P622, DOI 10.1038/35098065; MOONEY HA, 1961, ECOL MONOGR, V31, P1, DOI 10.2307/1950744; Nelson DL, 2000, LEHNINGER PRINCIPLES; Niklas KJ, 2001, P NATL ACAD SCI USA, V98, P2922, DOI 10.1073/pnas.041590298; NOBEL PS, 1999, PHYSIOCHEMICAL ENV P; PEARCY RW, 1977, PLANT PHYSIOL, V59, P795, DOI 10.1104/pp.59.5.795; RAISON J K, 1976, Australian Journal of Plant Physiology, V3, P291; RAVEN JA, 1988, NEW PHYTOL, V110, P441, DOI 10.1111/j.1469-8137.1988.tb00282.x; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Running SW, 1999, REMOTE SENS ENVIRON, V70, P108, DOI 10.1016/S0034-4257(99)00061-9; SCHULZE ED, 1994, ANNU REV ECOL SYST, V25, P629, DOI 10.1146/annurev.es.25.110194.003213; Valentini R, 2000, NATURE, V404, P861, DOI 10.1038/35009084; VETTER RAH, 1995, J COMP PHYSIOL B, V165, P46, DOI 10.1007/BF00264685; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; West GB, 2002, P NATL ACAD SCI USA, V99, P2473, DOI 10.1073/pnas.012579799	33	272	289	6	155	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2003	423	6940					639	642		10.1038/nature01671	http://dx.doi.org/10.1038/nature01671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789338	Bronze			2022-12-28	WOS:000183301200040
J	Cherkin, DC; Sherman, KJ; Deyo, RA; Shekelle, PG				Cherkin, DC; Sherman, KJ; Deyo, RA; Shekelle, PG			A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and spinal manipulation for back pain	ANNALS OF INTERNAL MEDICINE			English	Article							SYSTEMATIC REVIEWS; TRIAL; HEALTH; CARE; COMPLICATIONS; EXPECTATIONS; METAANALYSIS; MANAGEMENT; QUALITY; NECK	Background: Few treatments for back pain are supported by strong scientific evidence. Conventional treatments, although widely used, have had limited success. Dissatisfied patients have, therefore, turned to complementary and alternative medical therapies and providers for care for back pain. Purpose: To provide a rigorous and balanced summary of the best available evidence about the effectiveness, safety, and costs of the most popular complementary and alternative medical therapies used to treat back pain. Data Sources: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Study Selection: Systematic reviews of randomized, controlled trials (RCTs) that were published since 1995 and that evaluated acupuncture, massage therapy, or spinal manipulation for nonspecific back pain and RCTs published since the reviews were conducted. Data Extraction: Two authors independently extracted data from the reviews (including number of RCTs, type of back pain, quality assessment, and conclusions) and original articles (including type of pain, comparison treatments, sample size, outcomes, follow-up intervals, loss to follow-up, and authors' conclusions). Data Synthesis: Because the quality of the 20 RCTs that evaluated acupuncture was generally poor, the effectiveness of acupuncture for treating acute or chronic back pain is unclear. The three RCTs that evaluated massage reported that this therapy is effective for subacute and chronic back pain. A meta-regression analysis of the results of 26 RCTs evaluating spinal manipulation for acute and chronic back pain reported that spinal manipulation was superior to sham therapies and therapies judged to have no evidence of a benefit but was not superior to effective conventional treatments. Conclusions: Initial studies have found massage to be effective for persistent back pain. Spinal manipulation has small clinical benefits that are equivalent to those of other commonly used therapies. The effectiveness of acupuncture remains unclear. All of these treatments seem to be relatively safe. Preliminary evidence suggests that massage, but not acupuncture or spinal manipulation, may reduce the costs of care after an initial course of therapy.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Seattle, WA 98195 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA; RAND Corp, Santa Monica, CA USA	Group Health Cooperative; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; RAND Corporation	Cherkin, DC (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009989] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000606, R01AT000622] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS 09989] Funding Source: Medline; NCCIH NIH HHS [AT00622, AT00606] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Assendelft WJJ, 1996, J FAM PRACTICE, V42, P475; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Bigos SJ, 1994, AHCPR PUBLICATION, V95-0642; Bronfort G, 1999, NEUROL CLIN, V17, P91, DOI 10.1016/S0733-8619(05)70116-X; Carlsson CPO, 2001, CLIN J PAIN, V17, P296, DOI 10.1097/00002508-200112000-00003; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P463; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; Coulter ID, 2002, SPINE, V27, P291, DOI 10.1097/00007632-200202010-00018; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1999, J PAIN SYMPTOM MANAG, V17, P65, DOI 10.1016/S0885-3924(98)00129-8; Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235; Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9; ERNST E, 2001, DESKTOP GUIDE COMPLE, P60; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; FURLAN AD, 2000, COCHRANE DB SYST REV, P1929; Giles LGF, 1999, J MANIP PHYSIOL THER, V22, P376, DOI 10.1016/S0161-4754(99)70082-5; Grant DJ, 1999, PAIN, V82, P9, DOI 10.1016/S0304-3959(99)00027-5; Hernandez-Reif M, 2001, INT J NEUROSCI, V106, P131, DOI 10.3109/00207450109149744; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jensen GA, 1998, MED CARE, V36, P544, DOI 10.1097/00005650-199804000-00010; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kittang G, 2001, Tidsskr Nor Laegeforen, V121, P1207; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Lytle C, 1993, OVERVIEW ACUPUNCTURE; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; MILNE S, 2001, COCHRANE DB SYST REV; Mondloch MV, 2001, CAN MED ASSOC J, V165, P174; Nyiendo J, 2001, J MANIP PHYSIOL THER, V24, P92, DOI 10.1067/mmt.2001.112565; Odsberg A, 2001, COMPLEMENT THER MED, V9, P17, DOI 10.1054/ctim.2000.0418; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; SANDEFUR R, 1997, AHCPR PUBLICATION, P33; Senstad O, 1997, SPINE, V22, P435, DOI 10.1097/00007632-199702150-00017; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Sternbach RA, 1986, CLIN J PAIN, V2, P49, DOI DOI 10.1097/00002508-198602010-00008; van Tulder MW, 1999, SPINE, V24, P1113, DOI 10.1097/00007632-199906010-00011; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485; 1995, CONSUMER REPORTS FEB, P81	47	259	269	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					898	906		10.7326/0003-4819-138-11-200306030-00011	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779300				2022-12-28	WOS:000183296400005
J	Kalliomaki, M; Salminen, S; Poussa, T; Arvilommi, H; Isolauri, E				Kalliomaki, M; Salminen, S; Poussa, T; Arvilommi, H; Isolauri, E			Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial	LANCET			English	Article							CHILDREN	Perinatal administration of the problotic Lactobacillus rhamnosus strain GG (ATCC 53103), reduces incidence of atopic eczema in at-risk children during the first 2 years of life (infancy). We have therefore assessed persistence of the potential to prevent atopic eczema at 4 years. Atopic disease was diagnosed on the basis of a questionnaire and a clinical examination. 14 of 53 children receiving lactobacillus had developed atopic eczema, compared with 25 of 54 receiving placebo (relative risk 0.57, 95% Cl 0.33-0.97). Skin prick test reactivity was the same in both groups: ten of 50 children previously given lactobacillus compared with nine of 50 given placebo tested positive. Our results suggest that the preventive effect of lactobacillus GG on atopic eczema extends beyond infancy.	Univ Turku, Dept Paediat, Turku, Finland; Univ Turku, Dept Biochem & Food Chem, Turku, Finland; STAT Consulting, Tampere, Finland; Natl Publ Hlth Inst, Turku, Finland	University of Turku; University of Turku; Finland National Institute for Health & Welfare	Kalliomaki, M (corresponding author), Turku Univ Hosp, Dept Paediat, POB 52, FI-20521 Turku, Finland.							Avital A, 2001, PEDIATR PULM, V32, P308, DOI 10.1002/ppul.1124; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 2003, CURR OPIN ALLERGY CL, V3, P15, DOI [10.1097/00130832-200302000-00003, 10.1097/01.all.0000053262.39029.a1]; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1	5	852	923	2	93	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1869	1871		10.1016/S0140-6736(03)13490-3	http://dx.doi.org/10.1016/S0140-6736(03)13490-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788576				2022-12-28	WOS:000183205800014
J	Riemsma, RP; Pattenden, J; Bridle, C; Sowden, A; Mather, L; Watt, IS; Walker, A				Riemsma, RP; Pattenden, J; Bridle, C; Sowden, A; Mather, L; Watt, IS; Walker, A			Systematic review of the effectiveness of stage based interventions to promote smoking cessation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED-TRIAL; GENERAL-PRACTICE; SMOKERS; PROGRAM; EFFICACY; EXPOSURE	Objective To evaluate the effectiveness of interventions using a stage based approach in bringing about positive changes in smoking behaviour. Design Systematic review Data sources 35 electronic databases, catalogues, and internet resources (from inception to July 2002). Bibliographies of retrieved references were scanned for other relevant Publications, and authors were contacted if necessary. Results 23 randomised controlled trials were reviewed; two reported details of an economic evaluation. Eight trials reported effects in favour of stage based interventions, three trials showed mixed results, mid 12 trials found no statistically significant differences between a stage based intervention and a non-stage based intervention or no intervention. Eleven trials compared a stage based intervention with a non-stage based intervention, and one reported statistically significant effects in favour of the stage based intervention. Two studies reported mixed effects, and eight trials reported no statistically significant differences between groups. The methodological quality of the trials was mixed, and few reported any., validation of the instrument used to assess participants' stage of change. Overall, the evidence suggests that stage based interventions are no more effective than non-stage based interventions or no intervention in changing smoking behaviour. Conclusions Limited evidence exists for the effectiveness of stage based interventions in changing smoking behaviour.	Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England; Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; Univ W England, Sch Counselling & Hlth Psychol, Bristol BS16 2JP, Avon, England; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland	University of York - UK; University of York - UK; University of West England; University of Aberdeen	Riemsma, RP (corresponding author), Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England.	rpr1@york.ac.uk	Riemsma, Rob/E-2319-2016; Stirk, Lisa/A-2463-2010	Riemsma, Rob/0000-0001-8892-0861; Bridle, Chris/0000-0003-3986-6680				Ashworth P., 1997, HLTH ED J, V56, P166; Berman B A, 1995, J Cancer Educ, V10, P91; Brown RA, 2000, AM J MANAG CARE, V6, P394; Bunton R, 2000, CRIT PUBLIC HEALTH, V10, P55, DOI DOI 10.1080/713658223; BUNTON R, 1999, STAGES CHANGE MODEL; Butler CC, 1999, BRIT J GEN PRACT, V49, P611; Cinciripini PM, 1998, ONCOLOGY-NY, V12, P249; Cornuz J, 2002, ANN INTERN MED, V136, P429, DOI 10.7326/0003-4819-136-6-200203190-00006; *DEP HLTH, 2002, DEP HLTH B; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; Dijkstra A, 1999, PREV MED, V28, P203, DOI 10.1006/pmed.1998.0407; Emmons KM, 2001, PEDIATRICS, V108, P18, DOI 10.1542/peds.108.1.18; Etter JF, 2001, ARCH INTERN MED, V161, P2596, DOI 10.1001/archinte.161.21.2596; GRITZ ER, 1993, CANCER EPIDEM BIOMAR, V2, P261; Lennox AS, 2001, BRIT MED J, V322, P1396, DOI 10.1136/bmj.322.7299.1396; Lennox AS, 1998, HLTH ED J, V57, P140; Morgan GD, 1996, PREV MED, V25, P346, DOI 10.1006/pmed.1996.0065; National Institute for Clinical Excellence, 2002, GUID US NIC REPL THE; *NHS CTR REV DISS, 2001, UND SYST REV RES EFF; *NHS CTR REV DISS, 1998, EFFECTIVENESS MATTER, V3, P1; Office for National Statistics, 2000, LIV BRIT RES 1998 GE; Pallonen UE, 1998, SUBST USE MISUSE, V33, P935, DOI 10.3109/10826089809056250; PALLONEN UE, 1994, PREV MED, V23, P507, DOI 10.1006/pmed.1994.1069; Pieterse ME, 2001, PREV MED, V32, P182, DOI 10.1006/pmed.2000.0791; Pletsch PK, 2002, NURS CLIN N AM, V37, P315, DOI 10.1016/S0029-6465(01)00011-1; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; PROCHASKA JO, 1988, J CONSULT CLIN PSYCH, V56, P520, DOI 10.1037/0022-006X.56.4.520; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Prochaska JO, 2001, PREV MED, V32, P23, DOI 10.1006/pmed.2000.0767; Prochaska JO, 2001, ADDICT BEHAV, V26, P583, DOI 10.1016/S0306-4603(00)00151-9; Reeve K, 2000, J Am Acad Nurse Pract, V12, P163, DOI 10.1111/j.1745-7599.2000.tb00179.x; Resnicow K, 1997, PREV MED, V26, P373, DOI 10.1006/pmed.1997.0157; Sinclair HK, 1999, INT J PHARM PRACT, V7, P107, DOI DOI 10.1111/j.2042-7174.1999.tb00957.x; Stotts AL, 2002, ADDICT BEHAV, V27, P275, DOI 10.1016/S0306-4603(01)00174-5; Sutton S, 2000, PSYCHOL HEALTH, V15, P163, DOI 10.1080/08870440008400298; SUTTON S, 2000, UNDERSTANDING CHANGI; Sutton S. R., 1997, CAMBRIDGE HDB PSYCHO; Tappin DM, 2000, HEALTH EDUC RES, V15, P491, DOI 10.1093/her/15.4.491; TAPPIN DM, 2000, AMBULATORY CHILD S1, V6, P34, DOI DOI 10.1046/J; Wang Wei-Dean, 1994, Journal of the Formosan Medical Association, V93, P752; WEST R, 2001, SMOKING CESSATION TR; WHITEHEAD M, 1997, HLTH ED J, V56, P111; Whitelaw S, 2000, HEALTH EDUC RES, V15, P707, DOI 10.1093/her/15.6.707; Woolacott N F, 2002, Health Technol Assess, V6, P1; 1998, SMOKING KILLS WHITE	45	152	153	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2003	326	7400					1175	1177		10.1136/bmj.326.7400.1175	http://dx.doi.org/10.1136/bmj.326.7400.1175			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	686FC	12775617	Green Published, Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000183309900019
J	Rossouw, M; Nel, HJ; Cooke, GS; van Helden, PD; Hoal, EG				Rossouw, M; Nel, HJ; Cooke, GS; van Helden, PD; Hoal, EG			Association between tuberculosis and a polymorphic NF kappa B binding site in the interferon gamma gene	LANCET			English	Article								Interferon gamma is believed to be crucial for host defence against many infections. To test the hypothesis that a polymorphism in the gene for interferon gamma (IFNG) is associated with susceptibility to tuberculosis, we did two independent investigations. In a case-control study of 313 tuberculosis cases, we noted a significant association between a polymorphism (+874A-->T) in IFNG and tuberculosis in a South African population (p=0.0055). This finding was replicated in a family-based study, in which the transmission disequilibrium test was used in 131 families (p=0.005). The transcription factor NFkappaB binds preferentially to the +874T allele, which is over-represented in controls. This preferential binding suggests that genetically determined variability in interferon gamma and expression might be important for the development of tuberculosis.	Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Fac Hlth Sci, Dept Med Biochem, ZA-7505 Tygerberg, South Africa; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England	Stellenbosch University; Stellenbosch University; University of Oxford; Wellcome Centre for Human Genetics	Hoal, EG (corresponding author), Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa.			Hoal, Eileen/0000-0002-6444-5688; Cooke, Graham/0000-0001-6475-5056				Bream JH, 2000, IMMUNOGENETICS, V51, P50, DOI 10.1007/s002510050008; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Hoal-van Helden EG, 1999, PEDIATR RES, V45, P459, DOI 10.1203/00006450-199904010-00002; Pravica V, 2000, HUM IMMUNOL, V61, P863, DOI 10.1016/S0198-8859(00)00167-1; Yamada H, 2001, INFECT IMMUN, V69, P7100, DOI 10.1128/IAI.69.11.7100-7105.2001	5	185	189	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1871	1872		10.1016/S0140-6736(03)13491-5	http://dx.doi.org/10.1016/S0140-6736(03)13491-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788577				2022-12-28	WOS:000183205800015
J	Behrens, S				Behrens, S			Periplasmic chaperones - Preservers of subunit folding energy for organelle assembly	CELL			English	Editorial Material							PILUS		Univ Gottingen, Inst Microbiol & Genet, Dept Mol Genet & Preparat Mol Biol, D-37077 Gottingen, Germany	University of Gottingen	Behrens, S (corresponding author), Univ Gottingen, Inst Microbiol & Genet, Dept Mol Genet & Preparat Mol Biol, Grisebachstr 8, D-37077 Gottingen, Germany.							Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; MacIntyre S, 2001, MOL MICROBIOL, V39, P12, DOI 10.1046/j.1365-2958.2001.02199.x; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; Thanassi DG, 1998, CURR OPIN MICROBIOL, V1, P223, DOI 10.1016/S1369-5274(98)80015-5; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9	8	8	9	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					556	557		10.1016/S0092-8674(03)00396-9	http://dx.doi.org/10.1016/S0092-8674(03)00396-9			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787495	Bronze			2022-12-28	WOS:000183397600004
J	Kang, RS; Daniels, CM; Francis, SA; Shih, SC; Salerno, WJ; Hicke, L; Radhakrishnan, I				Kang, RS; Daniels, CM; Francis, SA; Shih, SC; Salerno, WJ; Hicke, L; Radhakrishnan, I			Solution structure of a CUE-ubiquitin complex reveals a conserved mode of ubiquitin binding	CELL			English	Article							NMR-SPECTROSCOPY; INTERACTING MOTIF; UBA DOMAINS; MACROMOLECULAR STRUCTURE; PROTEIN; SURFACE; DEGRADATION; PATHWAY; RECOGNITION; ENDOCYTOSIS	Monoubiquitination serves as a regulatory signal in a variety of cellular processes. Monoubiquitin signals are transmitted by binding to a small but rapidly expanding class of ubiquitin binding motifs. Several of these motifs, including the CUE domain, also promote intramolecular monoubiquitination. The solution structure of a CUE domain of the yeast Cue2 protein in complex with ubiquitin reveals intermolecular interactions involving conserved hydrophobic surfaces, including the Leu8-IIe44-Val70 patch on ubiquitin. The contact surface extends beyond this patch and encompasses Lys48, a site of polyubiquitin chain formation. This suggests an occlusion mechanism for inhibiting polyubiquitin chain formation during monoubiquitin signaling. The CUE domain shares a similar overall architecture with the UBA domain, which also contains a conserved hydrophobic patch. Comparative modeling suggests that the UBA domain interacts analogously with ubiquitin. The structure of the CUE-ubiquitin complex may thus serve as a paradigm for ubiquitin recognition and signaling by ubiquitin binding proteins.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Radhakrishnan, I (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.		Radhakrishnan, Ishwar/AHA-7392-2022; Radhakrishnan, Ishwar/R-8442-2018	Radhakrishnan, Ishwar/0000-0002-0195-9710; Radhakrishnan, Ishwar/0000-0002-0195-9710				BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1994, METHOD ENZYMOL, V239, P79; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1997, MACROMOLECULAR CRYST, P493; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee AL, 1999, J BIOMOL NMR, V13, P101, DOI 10.1023/A:1008304220445; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Stols L, 2002, PROTEIN EXPRES PURIF, V25, P8, DOI 10.1006/prep.2001.1603; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	52	188	191	1	16	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					621	630		10.1016/S0092-8674(03)00362-3	http://dx.doi.org/10.1016/S0092-8674(03)00362-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787503	Bronze			2022-12-28	WOS:000183397600012
J	Karamysheva, Z; Wang, LB; Shrode, T; Bednenko, J; Hurley, LA; Shippen, DE				Karamysheva, Z; Wang, LB; Shrode, T; Bednenko, J; Hurley, LA; Shippen, DE			Developmentally programmed gene elimination in Euplotes crassus facilitates a switch in the telomerase catalytic subunit	CELL			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; CILIATED PROTOZOA; DNA; RNA; OCTOCARINATUS; MACRONUCLEAR; REPLICATION; CONTAINS; ELEMENTS; TEMPLATE	The primary function of telomerase is to maintain preexisting telomere tracts. In the ciliate Euplotes crassus, however, telomerase RNP structure and substrate recognition are altered during macronuclear development to facilitate de novo telomere addition. We found that E. crassus harbors three TERT genes encoding the telomerase catalytic subunit that not only vary in their nucleotide and predicted protein sequences, but also in their expression profiles. Expression of EcTERT-1 and -3 correlates with the requirement for telomere maintenance, while that of EcTERT-2 correlates with de novo telomere synthesis. All three genes appear to require ribosomal frameshifting for expression of catalytically active protein. The transcriptionally active form of EcTERT-2 exists only transiently in mated cells and is absent from the vegetative macronucleus. Thus, telomerase expression in Euplotes is controlled by unique regulatory mechanisms that culminate in a developmental switch to a different catalytic subunit with properties suited to de novo telomere addition.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Shippen, DE (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.			Bednenko, Janna/0000-0001-9220-3531	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049157, R01GM049157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aigner S, 2000, EMBO J, V19, P6230, DOI 10.1093/emboj/19.22.6230; Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Bednenko J, 1997, EMBO J, V16, P2507, DOI 10.1093/emboj/16.9.2507; Bednenko J, 1998, NUCLEIC ACIDS RES, V26, P3998, DOI 10.1093/nar/26.17.3998; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; Doak TG, 2003, EUKARYOT CELL, V2, P95, DOI 10.1128/EC.2.1.95-102.2003; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Fan QC, 1996, MOL CELL BIOL, V16, P1267; Farabaugh PJ, 1996, ANNU REV GENET, V30, P507, DOI 10.1146/annurev.genet.30.1.507; FRELS JS, 1995, MOL CELL BIOL, V15, P6488; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; Greene EC, 1998, GENE DEV, V12, P2921, DOI 10.1101/gad.12.18.2921; HARPER DS, 1989, P NATL ACAD SCI USA, V86, P3252, DOI 10.1073/pnas.86.9.3252; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Jacobs ME, 2003, EUKARYOT CELL, V2, P103, DOI 10.1128/EC.2.1.103-114.2003; Jacobs ME, 1996, J EUKARYOT MICROBIOL, V43, P442, DOI 10.1111/j.1550-7408.1996.tb04503.x; Jahn CL, 2002, ANNU REV MICROBIOL, V56, P489, DOI 10.1146/annurev.micro.56.012302.160916; JAHN CL, 1993, GENE, V133, P71, DOI 10.1016/0378-1119(93)90226-S; JARACZEWSKI JW, 1993, GENE DEV, V7, P95, DOI 10.1101/gad.7.1.95; Kelleher C, 2002, TRENDS BIOCHEM SCI, V27, P572, DOI 10.1016/S0968-0004(02)02206-5; Klobutcher LA, 2002, CELL, V111, P763, DOI 10.1016/S0092-8674(02)01138-8; KLOBUTCHER LA, 1993, GENE DEV, V7, P84, DOI 10.1101/gad.7.1.84; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Metz AM, 2001, BIOTECHNOL APPL BIOC, V34, P47, DOI 10.1042/BA20010021; Miller MC, 2000, EMBO J, V19, P4412, DOI 10.1093/emboj/19.16.4412; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; PRICE CM, 1994, J EUKARYOT MICROBIOL, V41, P267, DOI 10.1111/j.1550-7408.1994.tb01507.x; Ray S, 2002, MOL CELL BIOL, V22, P5859, DOI 10.1128/MCB.22.16.5859-5868.2002; ROTH M, 1985, CELL, V41, P411, DOI 10.1016/S0092-8674(85)80014-3; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Tan M, 2001, J EUKARYOT MICROBIOL, V48, P575, DOI 10.1111/j.1550-7408.2001.tb00193.x; Tan M, 2001, J EUKARYOT MICROBIOL, V48, P80, DOI 10.1111/j.1550-7408.2001.tb00418.x; VERMEESCH JR, 1994, MOL CELL BIOL, V14, P554, DOI 10.1128/MCB.14.1.554; WANG L, 2002, NUCLEIC ACIDS RES, V30, P1	43	39	42	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					565	576		10.1016/S0092-8674(03)00363-5	http://dx.doi.org/10.1016/S0092-8674(03)00363-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787498	Bronze			2022-12-28	WOS:000183397600007
J	Mourier, T; Jeffares, DC				Mourier, T; Jeffares, DC			Eukaryotic intron loss	SCIENCE			English	Article							PSEUDOGENES; GENES		Univ Copenhagen, Inst Zool, Dept Evolutionary Biol, DK-2100 Copenhagen, Denmark	University of Copenhagen	Mourier, T (corresponding author), Univ Copenhagen, Inst Zool, Dept Evolutionary Biol, Univ Pk 15, DK-2100 Copenhagen, Denmark.		Mourier, Tobias/C-1164-2015; Jeffares, Daniel/N-2632-2018	Mourier, Tobias/0000-0003-2727-1903; Jeffares, Daniel/0000-0001-7320-0706				Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Derr LK, 1998, GENETICS, V148, P937; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; GIROUX MJ, 1994, P NATL ACAD SCI USA, V91, P12150, DOI 10.1073/pnas.91.25.12150; GLOCKNER G, COMMUNICATION; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; Sakurai A, 2002, GENE, V300, P89, DOI 10.1016/S0378-1119(02)01035-1; SCHANDORFF S, 2000, THESIS U COPENHAGEN; Simpson AGB, 2002, NATURE, V419, P270, DOI 10.1038/419270a; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215	14	164	174	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1393	1393		10.1126/science.1080559	http://dx.doi.org/10.1126/science.1080559			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775832				2022-12-28	WOS:000183181800034
J	Thornton, G				Thornton, G			Watching nanoparticles grow	SCIENCE			English	Editorial Material							X-RAY-DIFFRACTION; ART.; NANOCRYSTALS; MICROSCOPY; ATOM		Univ Manchester, Nanosci Res Ctr, Manchester M13 9PL, Lancs, England; Univ Manchester, Dept Chem, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester	Thornton, G (corresponding author), Univ Manchester, Nanosci Res Ctr, Manchester M13 9PL, Lancs, England.							Baldelli S, 2000, J CHEM PHYS, V113, P5432, DOI 10.1063/1.1290024; Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671; Binns C, 2001, SURF SCI REP, V44, P1, DOI 10.1016/S0167-5729(01)00015-2; Hansen PL, 2002, SCIENCE, V295, P2053, DOI 10.1126/science.1069325; Huynh WU, 2002, SCIENCE, V295, P2425, DOI 10.1126/science.1069156; Manoharan HC, 2000, NATURE, V403, P512, DOI 10.1038/35000508; Miao J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.155502; Miao JW, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.088303; Murray PW, 1997, SURF SCI, V380, pL455, DOI 10.1016/S0039-6028(97)00009-5; Renaud G, 2003, SCIENCE, V300, P1416, DOI 10.1126/science.1082146; Robinson IK, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.195505; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Wallis TM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.236802; Weyland M, 2002, TOP CATAL, V21, P175, DOI 10.1023/A:1021385427655	14	21	25	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1378	1379		10.1126/science.1085838	http://dx.doi.org/10.1126/science.1085838			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775827				2022-12-28	WOS:000183181800029
J	Newman, JRS; Keating, AE				Newman, JRS; Keating, AE			Comprehensive identification of human bZIP interactions with coiled-coil arrays	SCIENCE			English	Article							DNA-BINDING; TRANSCRIPTION FACTORS; SPECIFICITY; PROTEINS; FOS; JUN; COMPLEXES; PROTEOME; DOMAINS; FAMILY	In eukaryotes, the combinatorial association of sequence-specific DNA binding proteins is essential for transcription. We have used protein arrays to test 49(2) pairings of a nearly complete set of coiled-coil strands from human basic-region leucine zipper ( bZIP) transcription factors. We find considerable partnering selectivity despite the bZIPs' homologous sequences. The interaction data are of high quality, as assessed by their reproducibility, reciprocity, and agreement with previous observations. Biophysical studies in solution support the relative binding strengths observed with the arrays. New associations provide insights into the circadian clock and the unfolded protein response.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Keating, AE (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	keating@mit.edu		Keating, Amy/0000-0003-4074-8980				BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GREENBURY CL, 1965, IMMUNOLOGY, V8, P420; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HURST HC, 1995, PROTEIN PROFILE, V2, P105; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; Kohler JJ, 2001, BIOCHEMISTRY-US, V40, P130, DOI 10.1021/bi001881p; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; MacBeath G, 2000, SCIENCE, V289, P1760; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; Moll JR, 2000, J BIOL CHEM, V275, P34826, DOI 10.1074/jbc.M004545200; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Podust LM, 2001, J BIOL CHEM, V276, P505, DOI 10.1074/jbc.M005594200; PTASHNE M, 1987, GENETIC SWITCH GENE; SINGH M, 2001, P 5 ANN INT C COMP M, P279; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wolberger C, 1999, ANNU REV BIOPH BIOM, V28, P29, DOI 10.1146/annurev.biophys.28.1.29; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	33	370	386	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2097	2101		10.1126/science.1084648	http://dx.doi.org/10.1126/science.1084648			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12805554				2022-12-28	WOS:000183774900048
J	Sisk, JE; Whang, W; Butler, JC; Sneller, VP; Whitney, CG				Sisk, JE; Whang, W; Butler, JC; Sneller, VP; Whitney, CG			Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race	ANNALS OF INTERNAL MEDICINE			English	Article							REVACCINATION; MORTALITY; HEALTH	Background: Guidelines are increasingly recommending preventive services starting at 50 years of age, and policymakers are considering such a recommendation for pneumococcal polysaccharide vaccination. The finding that pneumococcal vaccination is cost-saving for people 65 years of age or older raises the question of the vaccination's implications for other older adults, especially black people, whose disease incidence exceeds that of nonblack people, and those with high-risk conditions. Objective: To assess the implications of vaccinating black and nonblack people 50 through 64 years of age against invasive pneumococcal disease. Design: Cost-effectiveness analysis. Data Sources: Published literature for vaccination effectiveness and cost estimates; data on disease incidence and case-fatality rates from the Centers for Disease Control and Prevention. Target Population: Hypothetical cohort 50 through 64 years of age with the 1995 U.S. age distribution. Time Horizon: Lifetime. Perspective: Societal. Intervention: Pneumococcal polysaccharide vaccination compared with no vaccination. Outcome Measures: Incremental medical costs and health effects, in quality-adjusted life-years per vaccinee. Results of Base-Case Analysis: vaccination saved medical costs and improved health among high-risk black people ($27.55 savings per vaccinee) and nonblack people ($5.92 savings per vaccinee), excluding survivors' future costs. For low-risk black and nonblack people and the overall general population, vaccination cost $2477, $8195, and $3434, respectively, to gain 1 year of healthy life. Results of Sensitivity Analysis: Excluding survivors' future costs, in the general immunocompetent population, cost per quality-adjusted life-year in global worst-case results ranged from $21 513 for black people to $68 871 for nonblack people; in the high-risk population, cost ranged from $11 548 for black people to $39 000 for nonblack people. In the global best case, vaccination was cost-saving for black and nonblack people in the general immunocompetent and high-risk populations, excluding survivors' future costs. The cost-effectiveness range was narrower in probabilistic sensitivity analyses, with 95% probabilistic intervals ranging from cost-saving to $1594 for black people and from cost-saving to $12 273 for nonblack people in the general immunocompetent population. Costs per quality-adjusted life-year for low-risk people with case-fatality rates from 1998 were $2477 for black people and $8195 for nonblack people, excluding survivors' medical costs. Conclusions: These results support the current recommendation to vaccinate high-risk people and provide useful information for considering extending the recommendation to the general population 50 through 64 years of age. Lack of evidence about the effectiveness of revaccination for people 65 years of age or older, when disease risks are higher, argues for further research to guide vaccination policy.	CUNY Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA; Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Ctr Dis Control & Prevent, Anchorage, AK USA; Ctr Dis Control & Prevent, Atlanta, GA USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University; Harvard University; Massachusetts General Hospital; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Sisk, JE (corresponding author), CUNY Mt Sinai Sch Med, Dept Hlth Policy, Room 2-34,1425 Madison Ave, New York, NY 10029 USA.	jane.sisk@mssm.edu	Whang, William/AAE-3853-2019					*AG HLTH CAR POL R, 1997, DAT 1987 NMES HOUS S; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; BORGONO JM, 1978, P SOC EXP BIOL MED, V157, P148, DOI 10.3181/00379727-157-40010; Breiman RF, 2000, ARCH INTERN MED, V160, P2633, DOI 10.1001/archinte.160.17.2633; *CDCP, 2001, HLTH PEOPL 2010, V1, P14; CHIANG CL, 1991, ANNU REV PUBL HEALTH, V12, P281, DOI 10.1146/annurev.pu.12.050191.001433; ERICKSON P, 1995, HLTH PEOPLE 2000; Feikin DR, 2000, AM J PUBLIC HEALTH, V90, P223, DOI 10.2105/AJPH.90.2.223; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Gold MR, 1996, COST EFFECTIVENESS H; Jackson L, 1999, JAMA-J AM MED ASSOC, V281, P243, DOI 10.1001/jama.281.3.243; LASCHOBER MA, 1997, HLTH HLTH CARE MEDIC; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAVE JR, 1994, MED CARE, V32, pJS77; MUFSON MA, 1991, VACCINE, V9, P403, DOI 10.1016/0264-410X(91)90126-Q; Nichol KL, 1997, AM J INFECT CONTROL, V25, P223, DOI 10.1016/S0196-6553(97)90008-0; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Singleton J A, 2000, MMWR CDC Surveill Summ, V49, P39; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; TORRANCE GT, 1995, 7 CDCP NAT CTR HLTH; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WAGNER JL, 1996, PREVENTION EARLY DET; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WINTER WP, 1986, HEMOGLOBIN VARIANTS; 2001, MMWR MORB MORTAL WKL, V50, P532; 1997, MMWR MORB MORTAL WKL, V46, P913	30	103	105	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2003	138	12					960	968		10.7326/0003-4819-138-12-200306170-00007	http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YM	12809452				2022-12-28	WOS:000183578100003
J	Alexander, M				Alexander, M			'The focus is on patients' clinical needs and distress'	BRITISH MEDICAL JOURNAL			English	Article									Assoc Community Hlth Councils England & Wales, London N5 1PB, England		Alexander, M (corresponding author), Assoc Community Hlth Councils England & Wales, Earlsmead House, London N5 1PB, England.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1332	1333		10.1136/bmj.326.7402.1332	http://dx.doi.org/10.1136/bmj.326.7402.1332			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805193	Green Published			2022-12-28	WOS:000183626500058
J	Bowling, JCR; Dowd, PM				Bowling, JCR; Dowd, PM			Raynaud's disease	LANCET			English	Editorial Material									Middlesex Hosp, Dept Dermatol, London W1N 8AA, England	University of London; University College London	Dowd, PM (corresponding author), Middlesex Hosp, Dept Dermatol, Mortimer St, London W1N 8AA, England.							BUNKER CB, 1993, LANCET, V342, P80, DOI 10.1016/0140-6736(93)91286-U; Coleiro B, 2001, RHEUMATOLOGY, V40, P1038, DOI 10.1093/rheumatology/40.9.1038; DOWD P, 1995, LANCET, V346, P283, DOI 10.1016/S0140-6736(95)92169-9; DOWD PM, 1982, BRIT J DERMATOL, V106, P81, DOI 10.1111/j.1365-2133.1982.tb00905.x; DOWD PM, 1986, BRIT J DERMATOL, V114, P527, DOI 10.1111/j.1365-2133.1986.tb04059.x; DOWD PM, 1998, TXB DERMATOLOGY, V3, P957; JACKSON R, ARCH DERMATOL, V119, P263; POPE J, 2000, COCHRANE DATABASE SY, V1, DOI UNSP CD000953; RAYNAUD M, 1967, JAMA-J AM MED ASSOC, V200, P985; Raynaud M., 1862, LOCAL ASPHYXIA SYMME; RAYNAUD M, 1881, PROGR MED PAR, V9, P552	11	32	34	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2078	2080		10.1016/S0140-6736(03)13646-X	http://dx.doi.org/10.1016/S0140-6736(03)13646-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814733				2022-12-28	WOS:000183488900028
J	Dindo, D; Muller, MK; Weber, M; Clavien, PA				Dindo, D; Muller, MK; Weber, M; Clavien, PA			Obesity in general elective surgery	LANCET			English	Article							BODY-MASS INDEX; QUALITY-OF-LIFE; CARDIAC-SURGERY; MORBID-OBESITY; RISK-FACTORS; MORTALITY; OUTCOMES; CHOLECYSTECTOMY; COMPLICATIONS; OPERATIONS	Background Obese patients are generally believed to be at a higher risk for surgery than those who are not obese, although convincing data are lacking. Methods We prospectively investigated a cohort of 6336 patients undergoing general elective surgery at our institution to assess whether obesity affects the outcome of surgery. Exclusion criteria were emergency, vascular, thoracic, and bariatric operations; transplantation procedures; patients under immunosuppression; and operations done under local anaesthesia. Postoperative morbidity was analysed for nonobese and obese patients (body-mass index <30 kg/m(2) vs &GE;30 kg/m(2)). Obesity was further stratified into mild obesity (30.0-34.9 kg/m(2)) and severe obesity (&GE;35 kg/m(2)). Risk factors were analysed with univariate and multivariate models. Findings The cohort consisted of 6336 patients, of whom 808 (13%) were obese, 569 (9%) were mildly obese, and 239 (4%) had severe obesity. The morbidity rates in patients who were obese compared with those who were not were much the same (122 [15.1%] of 808 vs 901 [16.3%] of 5528; p=0.26), with the exception of an increased incidence of wound infections after open surgery in patients who were obese (17 [4%] of 431 vs 92 [3%] of 3555, p=0.03). Incidence of complications did not differ between patients who were mildly obese (91 [16.0%] of 569), severely obese (36 [15.1%] of 239), and non-obese (901 [16.3%] of 5528; p=0.19). In multivariate regression analyses, obesity was not a risk factor for development of postoperative complications. Of note, the additional medical resource use as estimated by a new classification of complications showed no differences between patients who were and were not obese. Interpretation Obesity alone is not a risk factor for postoperative complications. The regressive attitude towards general surgery in obese patients is no longer justified.	Univ Zurich Hosp, Dept Visceral Surg & Transplantat, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Clavien, PA (corresponding author), Univ Zurich Hosp, Dept Visceral Surg & Transplantat, Ramistr 100, CH-8091 Zurich, Switzerland.							Allison DB, 1999, OBES RES, V7, P342, DOI 10.1002/j.1550-8528.1999.tb00417.x; Benoist S, 2000, AM J SURG, V179, P275, DOI 10.1016/S0002-9610(00)00337-8; Berkalp B, 1995, INT J CARDIOL, V52, P23, DOI 10.1016/0167-5273(95)02431-U; Brandt M, 2001, EUR J CARDIO-THORAC, V19, P662, DOI 10.1016/S1010-7940(01)00647-9; CHAPMAN GW, 1988, J NATL MED ASSOC, V80, P417; CLAVIEN PA, 1992, SURGERY, V111, P518; DeMaria J, 2002, ANN SURG, V235, P640, DOI 10.1097/00000658-200205000-00005; Engelman DT, 1999, J THORAC CARDIOV SUR, V118, P866, DOI 10.1016/S0022-5223(99)70056-5; Fazeli-Matin S, 1999, J UROLOGY, V162, P665, DOI 10.1097/00005392-199909010-00005; Flordal PA, 1996, EUR J SURG, V162, P783; Klotz HP, 1996, BRIT J SURG, V83, P1788, DOI 10.1002/bjs.1800831240; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Livingston EH, 2002, OBES RES, V10, P824, DOI 10.1038/oby.2002.111; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Moulton MJ, 1996, CIRCULATION, V94, P87; Nair S, 2002, HEPATOLOGY, V35, P105, DOI 10.1053/jhep.2002.30318; Nguyen NT, 2001, ANN SURG, V234, P279, DOI 10.1097/00000658-200109000-00002; PASULKA PS, 1986, ANN INTERN MED, V104, P540, DOI 10.7326/0003-4819-104-4-540; PEMBERTON LB, 1971, AM J SURG, V121, P87, DOI 10.1016/0002-9610(71)90081-X; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; POSTLETH.RW, 1972, ARCH SURG-CHICAGO, V105, P438; Schauer PR, 2001, SURG CLIN N AM, V81, P1145, DOI 10.1016/S0039-6109(05)70189-4; Schutz Y, 2002, INT J OBESITY, V26, pS3, DOI 10.1038/sj.ijo.0802122; SHAPIRO M, 1982, NEW ENGL J MED, V307, P1661, DOI 10.1056/NEJM198212303072701; Spicer DDM, 2001, INT ORTHOP, V25, P286, DOI 10.1007/s002640100265; TANAKA S, 1993, INT J OBESITY, V17, P631; WELCH CE, 1986, ANN SURG, V204, P454, DOI 10.1097/00000658-198610000-00014; Westling A, 2002, WORLD J SURG, V26, P470, DOI 10.1007/s00268-001-0251-9; World Health Organization, 1997, OB PREV MAN GLOB EP	30	453	467	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2032	2035		10.1016/S0140-6736(03)13640-9	http://dx.doi.org/10.1016/S0140-6736(03)13640-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814714				2022-12-28	WOS:000183488900010
J	Benton, MJ; Ayala, FJ				Benton, MJ; Ayala, FJ			Dating the tree of life	SCIENCE			English	Editorial Material							DIVERGENCE TIMES; MOLECULAR EVIDENCE; FOSSIL RECORD; ORIGIN; BIRDS; PHYLOGENY; SEQUENCES; SYSTEMATICS; EVOLUTION; PATTERNS	The relative merits of molecular and paleontological dates of major branching points in the tree of life are currently debated. In some cases, molecular date estimates are up to twice as old as paleontological dates. However, although it is true that paleontological dates are often too young (missing fossils), molecular dates are often too old (statistical bias). Intense study of the dating of major splits in the tree of mammals has shown rapprochement as fossil dates become older and molecular dates become younger.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA	University of Bristol; University of California System; University of California Irvine	Benton, MJ (corresponding author), Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England.	Mike.Benton@bris.ac.uk	Benton, Michael J/A-5639-2008	Benton, Michael J/0000-0002-4323-1824				Adoutte A, 1998, MOL PHYLOGENET EVOL, V9, P331, DOI 10.1006/mpev.1998.0547; Arnason U, 2002, P NATL ACAD SCI USA, V99, P8151, DOI 10.1073/pnas.102164299; Arnason U, 1996, J MOL EVOL, V43, P650, DOI 10.1007/BF02202113; AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Benton Michael J., 1996, Historical Biology, V12, P111; Benton MJ, 1998, MOL PHYLOGENET EVOL, V9, P398, DOI 10.1006/mpev.1998.0492; Benton MJ, 2000, NATURE, V403, P534, DOI 10.1038/35000558; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; BENTON MJ, TELLING EVOLUTIONARY; Bromham L, 1998, P NATL ACAD SCI USA, V95, P12386, DOI 10.1073/pnas.95.21.12386; Bromham LD, 2000, P ROY SOC B-BIOL SCI, V267, P1041, DOI 10.1098/rspb.2000.1108; Cooper A, 1998, TRENDS ECOL EVOL, V13, P151, DOI 10.1016/S0169-5347(97)01277-9; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; DARWIN C, 1959, ORIGN SPECIES MEANS; DONOGHUE PJ, IN PRESS TELLING EVO; Dyke GJ, 2001, GEOL J, V36, P305; Easteal S, 1999, BIOESSAYS, V21, P1052, DOI 10.1002/(SICI)1521-1878(199912)22:1<1052::AID-BIES9>3.0.CO;2-6; Easteal S., 1995, MAMMALIAN MOL CLOCK; Eizirik E, 2001, J HERED, V92, P212, DOI 10.1093/jhered/92.2.212; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; Gaunt MW, 2002, MOL BIOL EVOL, V19, P748, DOI 10.1093/oxfordjournals.molbev.a004133; GRAUR D, 1993, TRENDS ECOL EVOL, V8, P141, DOI 10.1016/0169-5347(93)90027-M; GRAYBEAL A, 1994, SYST BIOL, V43, P174, DOI 10.2307/2413460; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; Hudson RR, 2002, EVOLUTION, V56, P1557, DOI 10.1554/0014-3820(2002)056[1557:MCOTGS]2.0.CO;2; Janke A, 1997, P NATL ACAD SCI USA, V94, P1276, DOI 10.1073/pnas.94.4.1276; Ji Q, 2002, NATURE, V416, P816, DOI 10.1038/416816a; Kenrick P, 1999, NATURE, V402, P358, DOI 10.1038/46437; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lee MSY, 1999, J MOL EVOL, V49, P385, DOI 10.1007/PL00006562; Lynch M, 1999, EVOLUTION, V53, P319, DOI [10.2307/2640769, 10.1111/j.1558-5646.1999.tb03768.x]; Naylor GJP, 1998, SYST BIOL, V47, P61, DOI 10.1080/106351598261030; Nei M, 2001, P NATL ACAD SCI USA, V98, P2497, DOI 10.1073/pnas.051611498; Nikoh N, 1997, J MOL EVOL, V45, P97, DOI 10.1007/PL00006208; NORELL MA, 1992, SCIENCE, V255, P1690, DOI 10.1126/science.255.5052.1690; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Patterson C., 1987, MOL MORPHOLOGY EVOLU; Peters SE, 2002, NATURE, V416, P420, DOI 10.1038/416420a; Purvis A, 2000, NATURE, V405, P212, DOI 10.1038/35012221; RAUP DM, 1972, SCIENCE, V177, P1065, DOI 10.1126/science.177.4054.1065; Rodriguez-Trelles F, 2002, P NATL ACAD SCI USA, V99, P8112, DOI 10.1073/pnas.122231299; RODRIGUEZTRELLE.F, IN PRESS TELLING EVO; Sanderson MJ, 2002, MOL BIOL EVOL, V19, P101, DOI 10.1093/oxfordjournals.molbev.a003974; Sanderson MJ, 2001, AM J BOT, V88, P1499, DOI 10.2307/3558458; Schutze J, 1999, P ROY SOC B-BIOL SCI, V266, P63, DOI 10.1098/rspb.1999.0605; Smith AB, 2002, ANNU REV EARTH PL SC, V30, P65, DOI 10.1146/annurev.earth.30.091201.140057; Smith AB, 2001, PHILOS T R SOC B, V356, P351, DOI 10.1098/rstb.2000.0768; Soltis PS, 2002, P NATL ACAD SCI USA, V99, P4430, DOI 10.1073/pnas.032087199; van Tuinen M, 2001, MOL BIOL EVOL, V18, P206, DOI 10.1093/oxfordjournals.molbev.a003794; Waddell PJ, 1999, SYST BIOL, V48, P119; Wang DYC, 1999, P ROY SOC B-BIOL SCI, V266, P163, DOI 10.1098/rspb.1999.0617; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; Xun G, 1998, J MOL EVOL, V47, P369, DOI 10.1007/PL00013150; [No title captured]	57	192	204	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1698	1700		10.1126/science.1077795	http://dx.doi.org/10.1126/science.1077795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805535				2022-12-28	WOS:000183459700036
J	Daniel, RA; Errington, J				Daniel, RA; Errington, J			Control of cell morphogenesis in bacteria: Two distinct ways to make a rod-shaped cell	CELL			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; PEPTIDOGLYCAN SYNTHESIS; MUREIN SACCULUS; STRESS-BEARING; DIVISION SITE; WALL MATERIAL; GROWTH; PROTEIN; CYTOSKELETON	Cell shape in most eubacteria is maintained by a tough external peptidoglycan cell wall. Recently, cell shape determining proteins of the MreB family were shown to form helical, actin-like cables in the cell. We used a fluorescent derivative of the antibiotic vancomycin as a probe for nascent peptidoglycan synthesis in unfixed cells of various Gram-positive bacteria. In the rod-shaped bacterium B. subtilis, synthesis of the cylindrical part of the cell wall occurs in a helical pattern governed by an MreB homolog, Mbl. However, a few rod-shaped bacteria have no MreB system. Here, a rod-like shape can be achieved by a completely different mechanism based on use of polar growth zones derived from the division machinery. These results provide insights into the diverse molecular strategies used by bacteria to control their cellular morphology, as well as suggesting ways in which these strategies may impact on growth rates and cell envelope structure.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Errington, J (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		Errington, Jeff/G-1832-2011	Errington, Jeff/0000-0002-6977-9388; Daniel, Richard/0000-0002-6483-5897				ABHAYAWARDHANE Y, 1995, J BACTERIOL, V177, P765, DOI 10.1128/jb.177.3.765-773.1995; Archibald A. R., 1993, P381; BURMAN LG, 1983, J BACTERIOL, V155, P983, DOI 10.1128/JB.155.3.983-988.1983; Carballido-Lopez R, 2003, DEV CELL, V4, P19, DOI 10.1016/S1534-5807(02)00403-3; Chatterjee D, 1997, CURR OPIN CHEM BIOL, V1, P579, DOI 10.1016/S1367-5931(97)80055-5; CLARKESTURMAN AJ, 1989, J GEN MICROBIOL, V135, P657; Daniel RA, 2000, MOL MICROBIOL, V35, P299, DOI 10.1046/j.1365-2958.2000.01724.x; DANIEL RA, 1993, J GEN MICROBIOL, V139, P361, DOI 10.1099/00221287-139-2-361; DePedro MA, 1997, J BACTERIOL, V179, P2823, DOI 10.1128/jb.179.9.2823-2834.1997; DOYLE RJ, 1988, MICROBIOL REV, V52, P554, DOI 10.1128/MMBR.52.4.554-567.1988; Errington J, 2003, NAT CELL BIOL, V5, P175, DOI 10.1038/ncb0303-175; Ge M, 1999, SCIENCE, V284, P507, DOI 10.1126/science.284.5413.507; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; GRAY DI, 1990, J GEN MICROBIOL, V136, P1077, DOI 10.1099/00221287-136-6-1077; Harry EJ, 1997, MOL MICROBIOL, V25, P275, DOI 10.1046/j.1365-2958.1997.4581822.x; HENRIQUES AO, 1992, BIOCHIMIE, V74, P735, DOI 10.1016/0300-9084(92)90146-6; Hoch J.A., 2001, BACILLUS SUBTILIS IT, P21, DOI 10.1128/9781555817992.ch4; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; KOCH AL, 1988, MICROBIOL REV, V52, P337, DOI 10.1128/MMBR.52.3.337-353.1988; KOCH AL, 1990, ARCH MICROBIOL, V153, P569, DOI 10.1007/BF00245266; Koch AL, 2000, APPL ENVIRON MICROB, V66, P3657, DOI 10.1128/AEM.66.9.3657-3663.2000; Marston AL, 1998, GENE DEV, V12, P3419, DOI 10.1101/gad.12.21.3419; MENDELSON NH, 1976, P NATL ACAD SCI USA, V73, P1740, DOI 10.1073/pnas.73.5.1740; MERAD T, 1989, J GEN MICROBIOL, V135, P645; MICHAUD C, 1990, EUR J BIOCHEM, V194, P853, DOI 10.1111/j.1432-1033.1990.tb19479.x; MOBLEY HLT, 1984, J BACTERIOL, V158, P169, DOI 10.1128/JB.158.1.169-179.1984; PARTRIDGE SR, 1993, MOL MICROBIOL, V8, P945, DOI 10.1111/j.1365-2958.1993.tb01639.x; POOLEY HM, 1976, J BACTERIOL, V125, P1127, DOI 10.1128/JB.125.3.1127-1138.1976; POOLEY HM, 1976, J BACTERIOL, V125, P1139, DOI 10.1128/JB.125.3.1139-1147.1976; Prescott L.M., 1999, MICROBIOLOGY; REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563; SCHLAEPPI JM, 1982, J BACTERIOL, V149, P329, DOI 10.1128/JB.149.1.329-337.1982; Shapiro L, 2000, CELL, V100, P89, DOI 10.1016/S0092-8674(00)81686-4; Sharpe ME, 1998, J BACTERIOL, V180, P547, DOI 10.1128/JB.180.3.547-555.1998; SHELDRICK GM, 1978, NATURE, V271, P223, DOI 10.1038/271223a0; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; Trachtenberg S, 1998, J STRUCT BIOL, V124, P244, DOI 10.1006/jsbi.1998.4063; UMEDA A, 1983, MICROBIOL IMMUNOL, V27, P663, DOI 10.1111/j.1348-0421.1983.tb00629.x; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; VUORIO R, 1992, J BACTERIOL, V174, P7090, DOI 10.1128/jb.174.22.7090-7097.1992; WIENTJES FB, 1989, J BACTERIOL, V171, P3412, DOI 10.1128/jb.171.6.3412-3419.1989; WOLDRINGH CL, 1987, J GEN MICROBIOL, V133, P575	43	579	595	2	68	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 13	2003	113	6					767	776		10.1016/S0092-8674(03)00421-5	http://dx.doi.org/10.1016/S0092-8674(03)00421-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809607	Bronze			2022-12-28	WOS:000183514400011
J	Sharma, J; Dragoi, V; Tenenbaum, JB; Miller, EK; Sur, M				Sharma, J; Dragoi, V; Tenenbaum, JB; Miller, EK; Sur, M			V1 neurons signal acquisition of an internal representation of stimulus location	SCIENCE			English	Article							PRIMARY VISUAL-CORTEX; NEURAL BASIS; PARIETAL CORTEX; EYE-MOVEMENTS; ATTENTION; MONKEY; SACCADES; RESPONSES; DECISION; POSITION	A fundamental aspect of visuomotor behavior is deciding where to look or move next. Under certain conditions, the brain constructs an internal representation of stimulus location on the basis of previous knowledge and uses it to move the eyes or to make other movements. Neuronal responses in primary visual cortex were modulated when such an internal representation was acquired: Responses to a stimulus were affected progressively by sequential presentation of the stimulus at one location but not when the location was varied randomly. Responses of individual neurons were spatially tuned for gaze direction and tracked the Bayesian probability of stimulus appearance. We propose that the representation arises in a distributed cortical network and is associated with systematic changes in response selectivity and dynamics at the earliest stages of cortical visual processing.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA; MIT, RIKEN MIT Neurosci Ctr, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); RIKEN	Sharma, J (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.	jeetu@mit.edu; msur@ai.mit.edu	Miller, Earl K./AAE-8187-2019	Miller, Earl K./0000-0002-0582-6958				ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; ANDERSEN RA, 1997, ANNU REV NEUROSCI, V12, P377; Ben Hamed S, 2002, EXP BRAIN RES, V142, P512, DOI 10.1007/s00221-001-0954-z; CARPENTER RHS, 1995, NATURE, V377, P59, DOI 10.1038/377059a0; COLBY CL, 1995, CEREB CORTEX, V5, P470, DOI 10.1093/cercor/5.5.470; Dragoi V, 2002, NAT NEUROSCI, V5, P883, DOI 10.1038/nn900; EDWARDS AWF, 1972, LIKELIHOOD; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Gaymard B, 1998, EXP BRAIN RES, V123, P159, DOI 10.1007/s002210050557; Gilbert CD, 2001, NEURON, V31, P681, DOI 10.1016/S0896-6273(01)00424-X; Glimcher PW, 2001, TRENDS NEUROSCI, V24, P654, DOI 10.1016/S0166-2236(00)01932-9; Goldberg ME, 2002, ANN NY ACAD SCI, V956, P205, DOI 10.1111/j.1749-6632.2002.tb02820.x; Kowler E, 1990, Rev Oculomot Res, V4, P1; Krauzlis RJ, 1999, TRENDS NEUROSCI, V22, P544, DOI 10.1016/S0166-2236(99)01464-2; LAL R, 1989, SCIENCE, V243, P93, DOI 10.1126/science.2911723; LUCE RD, 1986, RESPONSE TIMES THEIR, P253; Lyon DC, 2002, NEURON, V33, P453, DOI 10.1016/S0896-6273(02)00580-9; Nakamura K, 2002, P NATL ACAD SCI USA, V99, P4026, DOI 10.1073/pnas.052379899; Posner MI, 1999, P NATL ACAD SCI USA, V96, P2585, DOI 10.1073/pnas.96.6.2585; Ress D, 2003, NAT NEUROSCI, V6, P414, DOI 10.1038/nn1024; Roelfsema PR, 1998, NATURE, V395, P376, DOI 10.1038/26475; Rosenbluth D, 2002, NEURON, V33, P143, DOI 10.1016/S0896-6273(01)00559-1; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; Schall JD, 2001, NAT REV NEUROSCI, V2, P33, DOI 10.1038/35049054; Schiller PH, 2001, PROG BRAIN RES, V134, P127; Schlag J, 1998, J NEUROPHYSIOL, V79, P64, DOI 10.1152/jn.1998.79.1.64; Schoups A, 2001, NATURE, V412, P549, DOI 10.1038/35087601; Shadlen MN, 2001, J NEUROPHYSIOL, V86, P1916, DOI 10.1152/jn.2001.86.4.1916; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; SOMERS DC, 1995, J NEUROSCI, V15, P5448; Sommer MA, 2002, SCIENCE, V296, P1480, DOI 10.1126/science.1069590; Tootell RBH, 2000, NAT NEUROSCI, V3, P206, DOI 10.1038/72904; TOYAMA K, 1984, J NEUROPHYSIOL, V51, P649, DOI 10.1152/jn.1984.51.4.649; Trotter Y, 1999, NATURE, V398, P239, DOI 10.1038/18444; WEYAND TG, 1993, J NEUROPHYSIOL, V69, P2258, DOI 10.1152/jn.1993.69.6.2258	35	42	44	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1758	1763		10.1126/science.1081721	http://dx.doi.org/10.1126/science.1081721			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805552	Green Submitted			2022-12-28	WOS:000183459700055
J	Tamimi, RM; Lagiou, P; Mucci, LA; Hsieh, CC; Adami, HO; Trichopoulos, D				Tamimi, RM; Lagiou, P; Mucci, LA; Hsieh, CC; Adami, HO; Trichopoulos, D			Average energy intake among pregnant women carrying a boy compared with a girl	BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE		Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece; Univ Massachusetts, Ctr Canc, Worcester, MA 01655 USA; Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden	Harvard University; Harvard T.H. Chan School of Public Health; Athens Medical School; National & Kapodistrian University of Athens; University of Massachusetts System; University of Massachusetts Worcester; Karolinska Institutet	Trichopoulos, D (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 665 Huntington Ave, Boston, MA 02115 USA.				NCI NIH HHS [CA54220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Lipworth L, 1999, BRIT J CANCER, V79, P7, DOI 10.1038/sj.bjc.6690003; ROMIEU I, 1990, AM J EPIDEMIOL, V131, P864, DOI 10.1093/oxfordjournals.aje.a115577; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YEN SSC, 1999, REPROD ENDOCRINOLOGY	5	106	107	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1245	1246		10.1136/bmj.326.7401.1245	http://dx.doi.org/10.1136/bmj.326.7401.1245			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791740	Green Published, Bronze			2022-12-28	WOS:000183480700017
J	Engel, S; Martinez, H; Shamoon, H; Engel, H; Dahms, W; Mayer, L; Pendegras, S; Zegarra, H; Miller, D; Singerman, L; Smith-Brewer, S; Genuth, S; Brillon, D; Lackaye, M; Heinemann, M; Reppuci, V; Lee, T; Whitehouse, F; Kruger, D; Galpern, A; Carey, JD; Bergenstal, R; Johnson, M; Kendall, D; Spencer, M; Noller, D; Morgan, K; Etzwiler, D; Jacobson, A; Golden, E; Sharuk, G; Arrigg, P; Baeser, R; Ganda, O; Rosenzweig, J; Wolpert, H; Economides, P; Handy, O; Rand, L; Nathan, D; Fritz, S; Godine, J; McKitrick, C; Lou, P; Service, FJ; Ziegler, G; Pach, J; Lindsey, J; Colwell, J; Wood, D; Mayfield, R; Hermayer, K; Szpiech, M; Lyons, T; Parker, J; Farr, A; Elsing, S; Thompson, T; Selby, J; Bracey, M; Molitch, M; Schaefer, B; Jampol, L; Weinberg, D; Lyon, A; Strugula, Z; Shankle, J; Astlesford, P; Kolterman, O; Lorenzi, G; Goldbaum, M; Sivitz, W; Bayless, M; Zeither, R; Weingeist, T; Stone, E; Boidt, HC; Gehres, K; Russell, S; Counts, D; Kowarski, A; Ostrowski, D; Donner, T; Steidl, S; Jones, B; Herman, W; Greene, D; Martin, C; Stevens, MJ; Vine, AK; Elner, S; Bantle, J; Rogness, B; Olsen, T; Steuer, E; Goldstein, D; Hitt, S; Giangiacomo, J; Hainsworth, D; Schade, D; Burge, M; Canady, J; Schluter, M; Das, A; Hornbeck, D; Schwartz, S; Bourne, PA; Maschak-Carey, BJ; Baker, L; Braunstein, S; Brucker, A; Orchard, T; Silvers, N; Songer, T; Doft, B; Olson, S; Bergren, RL; Lobes, L; Fineman, M; Drash, A; Malone, J; Vaccaro-Kish, J; Berger, C; Gstalder, R; Pavan, PR; Morrison, A; Dagogo-Jack, S; Schussler, S; Kitabchi, A; Lambeth, H; Murphy, MB; Moser, S; Meyer, D; Iannacone, A; Bryer-Ash, M; Raskin, P; Strowig, S; Edwards, A; Alappatt, J; Wilson, C; Park, S; He, Y; Zinman, B; Barnie, A; MacLean, S; Devenyi, R; Mandelcorn, M; Brent, M; Palmer, J; Catton, S; Kinyoun, J; Van Ottingham, L; Ginsberg, J; Dupre, J; Harth, J; Canny, C; Nicolle, D; May, M; Lorenz, R; Lipps, J; Survant, L; Feman, S; Tawansy, K; Agarwal, A; Adkins, T; White, N; Santiago, J; Levandoski, L; Boniuk, I; Grand, G; Thomas, M; Burgess, D; Joseph, D; Blinder, K; Shah, G; Tamborlane, W; Gatcomb, P; Stoessel, K; Taylor, K; Dahms, B; Trail, R; Quin, J; Lachin, J; Cleary, P; Kenny, D; Backlund, J; Diminick, L; Determan, A; Klump, K; Hawkins, M; Cowie, C; Fradkin, J; Siebert, C; Eastman, R; Davis, M; Hubbard, L; Geithman, P; Kastorff, L; Neider, M; Badal, D; Esser, B; Miner, K; Wabers, H; Glander, K; Joyce, J; Robinson, N; Hurtenbach, C; Hannon, C; Steffes, M; Bucksa, J; Chavers, B; O'Leary, D; Funk, L; Polak, J; Crow, R; O'Donnell, C; Gloeb, B; Thomas, S; Detrano, R; Wong, N; Fox, M; Kim, L; Oudiz, R; Weir, G; Clark, C; D'Agostino, R; Espeland, M; Klein, B; Manolio, T; Rand, L; Singer, D; Stern, M; Garvey, WT; Lyons, TJ; Jenkins, A; Klein, R; Lopes-Virella, M; Virella, G; Jaffa, AA; Zheng, D; Lackland, D; McGee, D; Mayfield, RK; Brabham, M; Boright, A; Paterson, A; Scherer, S; Zinman, B; Brunzell, J; Hokanson, J; Marcovina, S; Purnell, J; Sibley, S; Deeb, S; Edwards, K; Nathan, D				Engel, S; Martinez, H; Shamoon, H; Engel, H; Dahms, W; Mayer, L; Pendegras, S; Zegarra, H; Miller, D; Singerman, L; Smith-Brewer, S; Genuth, S; Brillon, D; Lackaye, M; Heinemann, M; Reppuci, V; Lee, T; Whitehouse, F; Kruger, D; Galpern, A; Carey, JD; Bergenstal, R; Johnson, M; Kendall, D; Spencer, M; Noller, D; Morgan, K; Etzwiler, D; Jacobson, A; Golden, E; Sharuk, G; Arrigg, P; Baeser, R; Ganda, O; Rosenzweig, J; Wolpert, H; Economides, P; Handy, O; Rand, L; Nathan, D; Fritz, S; Godine, J; McKitrick, C; Lou, P; Service, FJ; Ziegler, G; Pach, J; Lindsey, J; Colwell, J; Wood, D; Mayfield, R; Hermayer, K; Szpiech, M; Lyons, T; Parker, J; Farr, A; Elsing, S; Thompson, T; Selby, J; Bracey, M; Molitch, M; Schaefer, B; Jampol, L; Weinberg, D; Lyon, A; Strugula, Z; Shankle, J; Astlesford, P; Kolterman, O; Lorenzi, G; Goldbaum, M; Sivitz, W; Bayless, M; Zeither, R; Weingeist, T; Stone, E; Boidt, HC; Gehres, K; Russell, S; Counts, D; Kowarski, A; Ostrowski, D; Donner, T; Steidl, S; Jones, B; Herman, W; Greene, D; Martin, C; Stevens, MJ; Vine, AK; Elner, S; Bantle, J; Rogness, B; Olsen, T; Steuer, E; Goldstein, D; Hitt, S; Giangiacomo, J; Hainsworth, D; Schade, D; Burge, M; Canady, J; Schluter, M; Das, A; Hornbeck, D; Schwartz, S; Bourne, PA; Maschak-Carey, BJ; Baker, L; Braunstein, S; Brucker, A; Orchard, T; Silvers, N; Songer, T; Doft, B; Olson, S; Bergren, RL; Lobes, L; Fineman, M; Drash, A; Malone, J; Vaccaro-Kish, J; Berger, C; Gstalder, R; Pavan, PR; Morrison, A; Dagogo-Jack, S; Schussler, S; Kitabchi, A; Lambeth, H; Murphy, MB; Moser, S; Meyer, D; Iannacone, A; Bryer-Ash, M; Raskin, P; Strowig, S; Edwards, A; Alappatt, J; Wilson, C; Park, S; He, Y; Zinman, B; Barnie, A; MacLean, S; Devenyi, R; Mandelcorn, M; Brent, M; Palmer, J; Catton, S; Kinyoun, J; Van Ottingham, L; Ginsberg, J; Dupre, J; Harth, J; Canny, C; Nicolle, D; May, M; Lorenz, R; Lipps, J; Survant, L; Feman, S; Tawansy, K; Agarwal, A; Adkins, T; White, N; Santiago, J; Levandoski, L; Boniuk, I; Grand, G; Thomas, M; Burgess, D; Joseph, D; Blinder, K; Shah, G; Tamborlane, W; Gatcomb, P; Stoessel, K; Taylor, K; Dahms, B; Trail, R; Quin, J; Lachin, J; Cleary, P; Kenny, D; Backlund, J; Diminick, L; Determan, A; Klump, K; Hawkins, M; Cowie, C; Fradkin, J; Siebert, C; Eastman, R; Davis, M; Hubbard, L; Geithman, P; Kastorff, L; Neider, M; Badal, D; Esser, B; Miner, K; Wabers, H; Glander, K; Joyce, J; Robinson, N; Hurtenbach, C; Hannon, C; Steffes, M; Bucksa, J; Chavers, B; O'Leary, D; Funk, L; Polak, J; Crow, R; O'Donnell, C; Gloeb, B; Thomas, S; Detrano, R; Wong, N; Fox, M; Kim, L; Oudiz, R; Weir, G; Clark, C; D'Agostino, R; Espeland, M; Klein, B; Manolio, T; Rand, L; Singer, D; Stern, M; Garvey, WT; Lyons, TJ; Jenkins, A; Klein, R; Lopes-Virella, M; Virella, G; Jaffa, AA; Zheng, D; Lackland, D; McGee, D; Mayfield, RK; Brabham, M; Boright, A; Paterson, A; Scherer, S; Zinman, B; Brunzell, J; Hokanson, J; Marcovina, S; Purnell, J; Sibley, S; Deeb, S; Edwards, K; Nathan, D		Diabet Control Complications Trial	Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY-ARTERY-DISEASE; WALL THICKNESS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS RISK; INSULIN; COMPLICATIONS; ULTRASOUND; STROKE	BACKGROUND: Cardiovascular disease causes severe morbidity and mortality in type 1 diabetes, although the specific risk factors and whether chronic hyperglycemia has a role are unknown. We examined the progression of carotid intima-media thickness, a measure of atherosclerosis, in a population with type 1 diabetes. METHODS: As part of the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the long-term follow-up of the Diabetes Control and Complications Trial (DCCT), 1229 patients with type 1 diabetes underwent B-mode ultrasonography of the internal and common carotid arteries in 1994-1996 and again in 1998-2000. We assessed the intima-media thickness in 611 subjects who had been randomly assigned to receive conventional diabetes treatment during the DCCT and in 618 who had been assigned to receive intensive diabetes treatment. RESULTS: At year 1 of the EDIC study, the carotid intima-media thickness was similar to that in an age- and sex-matched nondiabetic population. After six years, the intima-media thickness was significantly greater in the diabetic patients than in the controls. The mean progression of the intima-media thickness was significantly less in the group that had received intensive therapy during the DCCT than in the group that had received conventional therapy (progression of the intima-media thickness of the common carotid artery, 0.032 vs. 0.046 mm; P=0.01; and progression of the combined intima-media thickness of the common and internal carotid arteries, -0.155 vs. 0.007; P=0.02) after adjustment for other risk factors. Progression of carotid intima-media thickness was associated with age, and the EDIC base-line systolic blood pressure, smoking, the ratio of low-density lipoprotein to high-density lipoprotein cholesterol, and urinary albumin excretion rate and with the mean glycosylated hemoglobin value during the mean duration (6.5 years) of the DCCT. CONCLUSIONS: Intensive therapy during the DCCT resulted in decreased progression of intima-media thickness six years after the end of the trial.	DCCT EDIC Res Grp, Bethesda, MD 20892 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Cornell Univ, Med Ctr, Ithaca, NY 14853 USA; Henry Ford Hlth Syst, Detroit, MI USA; Int Diabet Ctr, Minneapolis, MN USA; Joslin Diabet Ctr, Boston, MA 02215 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Med Univ S Carolina, Mol Risk Factors Program Project, Charleston, SC 29425 USA; Northwestern Univ, Evanston, IL 60208 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Iowa, Iowa City, IA 52242 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Univ Missouri, Columbia, MO 65211 USA; Univ New Mexico, Albuquerque, NM 87131 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA; Univ S Florida, Tampa, FL 33620 USA; Univ Tennessee, Knoxville, TN 37996 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Univ Toronto, Toronto, ON, Canada; Univ Western Ontario, London, ON N6A 3K7, Canada; Vanderbilt Univ, Nashville, TN USA; Washington Univ, St Louis, MO USA; Yale Univ, Sch Med, New Haven, CT 06520 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; George Washington Univ, Ctr Biostat, Washington, DC 20052 USA; NIDDKD, Program Off, Bethesda, MD 20892 USA; Univ Wisconsin, Cent Fundus Photog Reading Ctr, Madison, WI 53706 USA; Univ Minnesota, Cent Biochem Lab, Minneapolis, MN 55455 USA; Tufts Univ New England Med Ctr, Cent Carotid Ultrasound Unit, Boston, MA 02111 USA; Univ Minnesota, Cent Electrocardiog Reading Unit, Minneapolis, MN 55455 USA; Harbor UCLA Res & Educ Int, Comp Tomog Reading Ctr, Torrance, CA USA; Hosp Sick Children, Genet Studies Grp, Toronto, ON M5G 1X8, Canada; Univ Washington, Lipoprot Distribut Obes Grp, Seattle, WA 98195 USA	Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University; Cornell University; Henry Ford Health System; Henry Ford Hospital; International Diabetes Center; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Massachusetts General Hospital; Mayo Clinic; Medical University of South Carolina; Northwestern University; University of California System; University of California San Diego; University of Iowa; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities; University of Missouri System; University of Missouri Columbia; University of New Mexico; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of South Florida; University of Tennessee System; University of Tennessee Knoxville; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Toronto; Western University (University of Western Ontario); Vanderbilt University; Washington University (WUSTL); Yale University; Case Western Reserve University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System; University of Wisconsin Madison; University of Minnesota System; University of Minnesota Twin Cities; Tufts Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Washington; University of Washington Seattle	Engel, S (corresponding author), DCCT EDIC Res Grp, Box NDIC DCCT, Bethesda, MD 20892 USA.	dnathan@partners.org	Goldbaum, Michael/AAG-4258-2020; Paterson, Andrew D/A-4088-2011; Hramiak, Irene/G-3305-2011; Paterson, Andrew/AAQ-7511-2020; Zinman, Bernard/E-7266-2013; ginsberg, jeffrey s/ABC-1065-2020	Goldbaum, Michael/0000-0002-7721-2736; Paterson, Andrew D/0000-0002-9169-118X; Paterson, Andrew/0000-0002-9169-118X; Lachin, John/0000-0001-9838-2841; orchard, trevor/0000-0001-9552-3215	NIDDK NIH HHS [N01 DK062204-007, N01 DK062204-A] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK062204] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; BarrettConnor E, 1997, DIABETES CARE, V20, P1620, DOI 10.2337/diacare.20.10.1620; Bonora E, 1997, DIABETES CARE, V20, P627, DOI 10.2337/diacare.20.4.627; Bonora E, 2000, DIABETOLOGIA, V43, P156, DOI 10.1007/s001250050024; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; BURKE GL, 1995, STROKE, V26, P386, DOI 10.1161/01.STR.26.3.386; Chambless LE, 2000, AM J EPIDEMIOL, V151, P478; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; DONAHUE RP, 1992, DIABETES CARE, V15, P1141, DOI 10.2337/diacare.15.9.1141; DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; Draper N.R., 1998, APPL REGRESSION ANAL, P79; EDIC Res Grp, 1999, DIABETES, V48, P383; FOLSOM AR, 1994, STROKE, V25, P66, DOI 10.1161/01.STR.25.1.66; Genuth S, 1999, DIABETES CARE, V22, P99; Giannattasio C, 2001, DIABETOLOGIA, V44, P203, DOI 10.1007/s001250051600; GOLDSTEIN DE, 1987, CLIN CHEM, V33, P2267; Haffner SM, 2000, AM J CARDIOL, V85, P1395, DOI 10.1016/S0002-9149(00)00784-0; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; JensenUrstad KJ, 1996, DIABETES, V45, P1253, DOI 10.2337/diabetes.45.9.1253; KAWAMORI R, 1992, DIABETES CARE, V15, P1290, DOI 10.2337/diacare.15.10.1290; KLEIN R, 1995, ARCH INTERN MED, V155, P745, DOI 10.1001/archinte.155.7.745; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; Lachin J. M., 2000, WILEY SER PROB STAT; Lyons Timothy J., 1993, P169; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; MASER RE, 1991, ARTERIOSCLER THROMB, V11, P958, DOI 10.1161/01.ATV.11.4.958; Nathan DM, 1997, LANCET S1, V350, pSI4, DOI DOI 10.1016/S0140-6736(97)90021-0; NETER J, 1996, APPL LINEAR STAT MET; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; OLeary DH, 1996, STROKE, V27, P224, DOI 10.1161/01.STR.27.2.224; PUJIA A, 1994, DIABETES CARE, V17, P1330, DOI 10.2337/diacare.17.11.1330; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; SAS Institute, 1990, SAS STAT US GUID VER; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shannon H, 2000, NEW ENGL J MED, V342, P381; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *UK PROSP DIAB STU, 1998, LANCET, V352, P1557; Vlassara H, 1996, DIABETES, V45, pS65, DOI 10.2337/diab.45.3.S65; Wagenknecht LE, 1998, DIABETES CARE, V21, P1812, DOI 10.2337/diacare.21.11.1812; Wingard DL., 1995, DIABETES AM, P429; WOFFORD JL, 1991, ARTERIOSCLER THROMB, V11, P1786, DOI 10.1161/01.ATV.11.6.1786; YAMASAKI Y, 1994, DIABETES, V43, P634, DOI 10.2337/diabetes.43.5.634	47	327	331	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2294	2303						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788993				2022-12-28	WOS:000183296300004
J	Stearns, V; Beebe, KL; Iyengar, M; Dube, E				Stearns, V; Beebe, KL; Iyengar, M; Dube, E			Paroxetine controlled release in the treatment of menopausal hot flashes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; TAMOXIFEN; SEROTONIN; PREVENTION; EFFICACY; LIFE; RAT	Context Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective. Objective To evaluate a selective serotonin reuptake inhibitor (paroxetine controlled release [CR]) in treating the vasomotor symptoms displayed by a general cross-section of menopausal women. Design and Setting Randomized; double-blind, placebo-controlled, parallel group study conducted across 17 US sites, including urban, suburban, and rural clinics. Patients A total of 165 menopausal women aged 18 years or older experiencing at least 2 to 3 daily hot flashes and must have discontinued any hormone replacement therapy for at least 6 weeks. Women were excluded if they had any signs of active cancer or were undergoing chemotherapy or radiation therapy. Intervention After a 1-week placebo run-in phase, study participants were randomized to receive placebo or receive 12.5 mg/d or 25.0 mg/d of paroxetine CR (in a 1:1:1 ratio) for 6 weeks. Main Outcome Measures Mean change from baseline to week 6 in the daily hot flash composite score (frequency x severity). Results Fifty-six participants were randomly assigned to receive placebo and 51 to receive 12.5 mg/d and 58 to receive 25.0 mg/d of paroxetine CR. The mean reductions in the hot flash frequency composite score from baseline to week 6 were statistically significantly greater for those receiving paroxetine CR than for those receiving placebo. By week 6, the mean daily hot flash frequency went from 7.1 to 3.8 (mean reduction, 3.3) for those in the 12.5-mg/d and from 6.4 to 3.2 (mean reduction, 3.2) for those in the 25-mg/d paroxetine CR groups and from 6.6 to 4.8 (mean reduction, 1.8) for those in the placebo group. Mean placebo-adjusted reduction in hot flash composite scores were -4.7 (95% confidence interval,-8.1 to -1.3; P=.007) comparing 12.5-mg/d paroxetine CR with placebo; and -3.6 (95% confidence interval, -6.8 to -0.4; P=.03) comparing 25.0-mg/d paroxetine CR with placebo. This corresponded to median reductions of 62.2% for those in the 12.5-mg/d and 64.6% for those in the 25.0-mg/d paroxetine CR groups compared with 37.8% for those in the placebo group. Conclusion Paroxetine CR may be an effective and acceptable alternative to hormone replacement and other therapies in treating menopausal hot flash symptoms.	Univ Michigan, Ctr Comprehens Canc, Breast Oncol Program, Ann Arbor, MI 48109 USA; GlaxoSmithKline, Philadelphia, PA USA	University of Michigan System; University of Michigan; GlaxoSmithKline	Stearns, V (corresponding author), Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg,Room 1M53,1650 Or, Baltimore, MD 21231 USA.	vstearn1@jhmi.edu						Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Fallowfield L, 2001, J CLIN ONCOL, V19, P1885, DOI 10.1200/JCO.2001.19.7.1885; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Gold EB, 2000, AM J EPIDEMIOL, V152, P463, DOI 10.1093/aje/152.5.463; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; Golden RN, 2002, J CLIN PSYCHIAT, V63, P577, DOI 10.4088/JCP.v63n0707; GUDELSKY GA, 1986, NEUROPHARMACOLOGY, V25, P1307, DOI 10.1016/0028-3908(86)90101-2; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; KRONENBERG F, 1994, EXP GERONTOL, V29, P319, DOI 10.1016/0531-5565(94)90012-4; Lin MT, 1998, AM J PHYSIOL-REG I, V274, pR1260, DOI 10.1152/ajpregu.1998.274.5.R1260; Lopez JF, 1999, BIOL PSYCHIAT, V46, P1461, DOI 10.1016/S0006-3223(99)00266-8; Loprinzi CL, 2002, J CLIN ONCOL, V20, P1578, DOI 10.1200/JCO.20.6.1578; Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MYERS RD, 1981, J PHYSIOLOGY PARIS, V77, P505; *N AM MEN SOC, AM REP NAMS ADV PAN; Oerther S, 2000, NEUROREPORT, V11, P3949, DOI 10.1097/00001756-200012180-00009; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rubinow DR, 1998, BIOL PSYCHIAT, V44, P839, DOI 10.1016/S0006-3223(98)00162-0; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280; Stearns V, 2000, ANN ONCOL, V11, P17, DOI 10.1023/A:1008382706068; Stearns V, 2002, LANCET, V360, P1851, DOI 10.1016/S0140-6736(02)11774-0; *US BUR CENS, 2001, RES POP EST US AG SE	26	347	367	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2827	2834		10.1001/jama.289.21.2827	http://dx.doi.org/10.1001/jama.289.21.2827			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KH	12783913				2022-12-28	WOS:000183205500031
J	Wang, TJ; Levy, D; Benjamin, EJ; Vasan, RS				Wang, TJ; Levy, D; Benjamin, EJ; Vasan, RS			The epidemiology of "asymptomatic" left ventricular systolic dysfunction: Implications for screening	ANNALS OF INTERNAL MEDICINE			English	Review							BRAIN NATRIURETIC PEPTIDE; CONGESTIVE-HEART-FAILURE; FAMILIAL DILATED CARDIOMYOPATHY; CONVERTING ENZYME-INHIBITORS; MYOCARDIAL-INFARCTION; DIASTOLIC DYSFUNCTION; GENERAL-PRACTICE; BETA-BLOCKERS; PROGNOSTIC IMPLICATIONS; RETROSPECTIVE ANALYSIS	Congestive heart failure is a progressive disorder that is frequently preceded by asymptomatic left ventricular systolic dysfunction. We reviewed the epidemiology, diagnosis, and natural history of asymptomatic left ventricular systolic dysfunction and evaluated community-wide screening for this condition as a potential strategy to reduce the incidence of heart failure. Asymptomatic left ventricular systolic dysfunction has an estimated prevalence of 3% to 6%, and is at least as common in the community as systolic heart failure. Because it often occurs in the absence of known cardiovascular disease, this condition may go unrecognized and undertreated. In randomized trials, individuals with asymptomatic left ventricular systolic dysfunction have high rates of incident heart failure and death. However, little is known about the prognosis of individuals with this condition in the community, who have a substantially lower prevalence of myocardial infarction, have milder degrees of systolic dysfunction, and are older than patients enrolled in clinical trials. Current evidence is inadequate to support community-wide screening for asymptomatic left ventricular systolic dysfunction, either with echocardiography or with assays for natriuretic peptides. Given the increasing prevalence of heart failure, additional studies are needed to develop effective strategies to detect and optimally manage individuals with asymptomatic left ventricular dysfunction in the community.	Framingham Heart Dis Epidemiol Study, NHLBI, Framingham, MA 01702 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston Med Ctr, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; NHLBI, Bethesda, MD USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vasan, RS (corresponding author), Framingham Heart Dis Epidemiol Study, NHLBI, 73 Mt Wayne Ave,Suite 2, Framingham, MA 01702 USA.	vasan@fram.nhlbi.nih.gov	Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Ramachandran, Vasan/Y-2527-2019; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Benjamin, Emelia/0000-0003-4076-2336	NHLBI NIH HHS [1U01-HL-66582, N01-HC-25195, K24 HL-04334-01A1] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004334, U01HL066582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnlov J, 2000, J INTERN MED, V247, P699, DOI 10.1046/j.1365-2796.2000.00688.x; Aronow WS, 2001, AM J CARDIOL, V88, P1298, DOI 10.1016/S0002-9149(01)02092-6; Aurigemma GP, 2001, J AM COLL CARDIOL, V37, P1042, DOI 10.1016/S0735-1097(01)01110-X; Baig MK, 1998, J AM COLL CARDIOL, V31, P195, DOI 10.1016/S0735-1097(97)00433-6; BOYKO EJ, 1994, MED DECIS MAKING, V14, P175, DOI 10.1177/0272989X9401400210; CADMAN D, 1984, JAMA-J AM MED ASSOC, V251, P1580, DOI 10.1001/jama.251.12.1580; Cogswell ME, 1999, AM J PREV MED, V16, P134, DOI 10.1016/S0749-3797(98)00141-X; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Davidson NC, 1996, AM J CARDIOL, V77, P828, DOI 10.1016/S0002-9149(97)89176-X; Davie AP, 1996, BRIT MED J, V312, P222; Davies MK, 2001, LANCET, V358, P439, DOI 10.1016/S0140-6736(01)05620-3; Devereux RB, 2001, AM HEART J, V141, P439, DOI 10.1067/mhj.2001.113223; Devereux RB, 2001, HYPERTENSION, V38, P417, DOI 10.1161/01.HYP.38.3.417; Doughty RN, 1997, J AM COLL CARDIOL, V29, P1060, DOI 10.1016/S0735-1097(97)00012-0; Dries DL, 2000, J AM COLL CARDIOL, V35, P681, DOI 10.1016/S0735-1097(99)00608-7; Dries DL, 1998, J AM COLL CARDIOL, V32, P695, DOI 10.1016/S0735-1097(98)00297-6; Dries DL, 2001, J AM COLL CARDIOL, V38, P421, DOI 10.1016/S0735-1097(01)01408-5; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Friedl W, 1996, HEART, V76, P129, DOI 10.1136/hrt.76.2.129; Giannuzzi P, 1996, J AM COLL CARDIOL, V28, P383, DOI 10.1016/0735-1097(96)00163-5; Gottdiener JS, 2002, ANN INTERN MED, V137, P631, DOI 10.7326/0003-4819-137-8-200210150-00006; Hedberg P, 2001, EUR HEART J, V22, P676, DOI 10.1053/euhj.2000.2284; HERNANDEZ M, 1995, AM HEART J, V129, P492, DOI 10.1016/0002-8703(95)90274-0; Hetmanski DJ, 2000, HEART, V84, P440, DOI 10.1136/heart.84.4.440; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; Kelly R, 1999, QJM-INT J MED, V92, P295, DOI 10.1093/qjmed/92.6.295; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Kober L, 2000, LANCET, V356, P2052, DOI 10.1016/S0140-6736(00)03402-4; Krishnaswamy P, 2001, AM J MED, V111, P274, DOI 10.1016/S0002-9343(01)00841-5; Kupari M, 1997, J INTERN MED, V241, P387, DOI 10.1046/j.1365-2796.1997.129150000.x; Landray MJ, 2000, BRIT MED J, V320, P985, DOI 10.1136/bmj.320.7240.985; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; LERMAN A, 1993, LANCET, V341, P1105, DOI 10.1016/0140-6736(93)93125-K; LESTUZZI C, 1991, INT J CARDIOL, V33, P225, DOI 10.1016/0167-5273(91)90351-O; Luchner A, 2000, J HYPERTENS, V18, P1121, DOI 10.1097/00004872-200018080-00018; MacLellan WR, 2000, CURR OPIN CARDIOL, V15, P128, DOI 10.1097/00001573-200005000-00002; Mann DL, 1999, CIRCULATION, V100, P999, DOI 10.1161/01.CIR.100.9.999; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; McDonagh TA, 2002, HEART, V88, P12; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; McDonagh TA, 2001, HEART, V86, P21, DOI 10.1136/heart.86.1.21; McMurray JV, 1998, EUR HEART J, V19, P842, DOI 10.1093/eurheartj/19.6.842; Morgan S, 1999, BRIT MED J, V318, P368, DOI 10.1136/bmj.318.7180.368; Mosterd A, 1999, EUR HEART J, V20, P447, DOI 10.1053/euhj.1998.1239; Muders F, 1997, AM HEART J, V134, P442, DOI 10.1016/S0002-8703(97)70079-6; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Nicol RL, 2000, ANNU REV GENOM HUM G, V1, P179, DOI 10.1146/annurev.genom.1.1.179; Nielsen OW, 2001, HEART, V86, P172, DOI 10.1136/heart.86.2.172; Nielsen OW, 2000, BRIT MED J, V320, P220, DOI 10.1136/bmj.320.7229.220; Nielsen OW, 2003, J AM COLL CARDIOL, V41, P113, DOI 10.1016/S0735-1097(02)02625-6; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; REDFIELD MM, 1994, AM J CARDIOL, V74, P737, DOI 10.1016/0002-9149(94)90323-9; Redfield MM, 2001, J AM COLL CARDIOL, V37, p145A; REDFIELD MM, 1993, J AM COLL CARDIOL, V22, P1921, DOI 10.1016/0735-1097(93)90780-5; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; RIHAL CS, 1995, AM J CARDIOL, V75, P220, DOI 10.1016/0002-9149(95)80023-L; Schunkert H, 1998, LANCET, V351, P372, DOI 10.1016/S0140-6736(05)78298-2; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; SHARPE N, 1990, EUR HEART J, V11, P147, DOI 10.1093/eurheartj/11.suppl_B.147; Smith H, 2000, BMJ-BRIT MED J, V320, P906, DOI 10.1136/bmj.320.7239.906; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; Struthers AD, 2002, LANCET, V359, P1430, DOI 10.1016/S0140-6736(02)08358-7; Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981; Talwar S, 2002, CLIN SCI, V102, P9, DOI 10.1042/CS20010105; Towbin J. A., 2001, Current Molecular Medicine (Hilversum), V1, P81, DOI 10.2174/1566524013364077; Tsutamoto T, 1999, EUR HEART J, V20, P1799, DOI 10.1053/euhj.1999.1746; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Vantrimpont P, 1997, J AM COLL CARDIOL, V29, P229, DOI 10.1016/S0735-1097(96)00489-5; Vasan RS, 2000, AM HEART J, V139, P412, DOI 10.1016/S0002-8703(00)90084-X; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; Vasan RS, 2002, JAMA-J AM MED ASSOC, V288, P1252, DOI 10.1001/jama.288.10.1252; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988; Yamamoto K, 2000, J CARD FAIL, V6, P194, DOI 10.1054/jcaf.2000.9676; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zile MR, 2002, CIRCULATION, V105, P1387, DOI 10.1161/hc1102.105289	82	156	160	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					907	916		10.7326/0003-4819-138-11-200306030-00012	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779301				2022-12-28	WOS:000183296400006
J	O'Toole, L; Grech, ED				O'Toole, L; Grech, ED			ABC of interventional cardiology - Chronic stable angina: treatment options	BRITISH MEDICAL JOURNAL			English	Review							SURGERY		Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Winnipeg, MB, Canada	University of Sheffield; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	O'Toole, L (corresponding author), Royal Hallamshire Hosp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.							Kim MC, 2002, J AM COLL CARDIOL, V39, P923, DOI 10.1016/S0735-1097(02)01716-3; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; RACO DL, 2002, PRACTICAL INTERVENTI, P263; *SCOTT INT GUID NE, 1998, SIGN PUBL, V32; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	7	4	5	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2003	326	7400					1185	1188		10.1136/bmj.326.7400.1185	http://dx.doi.org/10.1136/bmj.326.7400.1185			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775620	Green Published			2022-12-28	WOS:000183309900022
J	Cristofari, G; Lingner, J				Cristofari, G; Lingner, J			Fingering the ends: How to make new telomeres	CELL			English	Editorial Material							REVERSE-TRANSCRIPTASE; COMPLEXES; SUBUNIT		Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Cristofari, G (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Cristofari, Gael/A-2831-2011	Cristofari, Gael/0000-0001-5620-3091; Lingner, Joachim/0000-0002-2853-5803				GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; Greene EC, 1998, GENE DEV, V12, P2921, DOI 10.1101/gad.12.18.2921; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Jahn CL, 2002, ANNU REV MICROBIOL, V56, P489, DOI 10.1146/annurev.micro.56.012302.160916; Karamysheva Z, 2003, CELL, V113, P565, DOI 10.1016/S0092-8674(03)00363-5; Kelleher C, 2002, TRENDS BIOCHEM SCI, V27, P572, DOI 10.1016/S0968-0004(02)02206-5; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4	8	6	7	1	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					552	554		10.1016/S0092-8674(03)00397-0	http://dx.doi.org/10.1016/S0092-8674(03)00397-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787493	Bronze			2022-12-28	WOS:000183397600002
J	Demaine, LJ; Fellmeth, AX				Demaine, LJ; Fellmeth, AX			Natural substances and patentable inventions	SCIENCE			English	Editorial Material									RAND Corp, Santa Monica, CA 90401 USA	RAND Corporation	Demaine, LJ (corresponding author), RAND Corp, Santa Monica, CA 90401 USA.							ALBERTSSCHONBERG G, 1980, Patent No. 4231938; Demaine LT, 2002, STANFORD LAW REV, V55, P303, DOI 10.2307/1229595; Enserink M, 2000, SCIENCE, V287, P1196, DOI 10.1126/science.287.5456.1196; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; *NIH, 1998, REP WORK GROUP RES T; 1977, Patent No. 4001395; 2001, FED REG, V66, P1092; 2002, Patent No. 6355246; 1977, Patent No. 4059437; 1993, Patent No. 5204057; 1995, Patent No. 5426248	11	12	13	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1375	1376		10.1126/science.1083367	http://dx.doi.org/10.1126/science.1083367			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775825				2022-12-28	WOS:000183181800027
J	Tilmann, F; Ni, J; Hearn, T; Ma, YS; Rapine, R; Kind, R; Mechie, J; Saul, J; Haines, S; Klemperer, S; Brown, L; Pananont, P; Ross, A; Nelson, KD; Guo, J; Zhao, W				Tilmann, F; Ni, J; Hearn, T; Ma, YS; Rapine, R; Kind, R; Mechie, J; Saul, J; Haines, S; Klemperer, S; Brown, L; Pananont, P; Ross, A; Nelson, KD; Guo, J; Zhao, W		IDEPTH III Seismic Team	Seismic imaging of the downwelling Indian lithosphere beneath central Tibet	SCIENCE			English	Article							UPPER-MANTLE; VELOCITY ZONE; PARTIAL MELT; PLATEAU; EVOLUTION; TOMOGRAPHY; SYSTEM; MODEL; CRUST	A tomographic image of the upper mantle beneath central Tibet from INDEPTH data has revealed a subvertical high-velocity zone from similar to 100- to similar to 400-kilometers depth, located approximately south of the Bangong-Nujiang Suture. We interpret this zone to be downwelling Indian mantle lithosphere. This additional lithosphere would account for the total amount of shortening in the Himalayas and Tibet. A consequence of this downwelling would be a deficit of asthenosphere, which should be balanced by an upwelling counterflow, and thus could explain the presence of warm mantle beneath north-central Tibet.	New Mexico State Univ, Dept Phys, Las Cruces, NM 88003 USA	New Mexico State University	Tilmann, F (corresponding author), Univ Cambridge, Dept Earth Sci, Cambridge CB3 0EZ, England.	tilmann@esc.cam.ac.uk	Klemperer, Simon L/A-5919-2012; Tilmann, Frederik J/E-4293-2012	Tilmann, Frederik J/0000-0002-7439-8782; Pananont, Passakorn/0000-0001-9365-5046; Klemperer, Simon/0000-0001-7050-1829				ALLEGRE CJ, 1984, NATURE, V307, P17, DOI 10.1038/307017a0; BARAZANGI M, 1982, GEOLOGY, V10, P179, DOI 10.1130/0091-7613(1982)10<179:VAPCOP>2.0.CO;2; BIRD P, 1978, J GEOPHYS RES, V83, P4975, DOI 10.1029/JB083iB10p04975; BRANDON C, 1986, J GEOPHYS RES-SOLID, V91, P6547, DOI 10.1029/JB091iB06p06547; Chemenda AI, 2000, EARTH PLANET SC LETT, V174, P397, DOI 10.1016/S0012-821X(99)00277-0; Chen WP, 1998, GEOPHYS J INT, V135, P93, DOI 10.1046/j.1365-246X.1998.00611.x; Conrad CP, 2000, GEOPHYS J INT, V143, P52, DOI 10.1046/j.1365-246x.2000.00214.x; Curtis A, 1997, J GEOPHYS RES-SOL EA, V102, P11789, DOI 10.1029/96JB03182; DeCelles PG, 2002, TECTONICS, V21, DOI 10.1029/2001TC001322; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Huang WC, 2000, J GEOPHYS RES-SOL EA, V105, P27979, DOI 10.1029/2000JB900339; Johnson MRW, 2002, EARTH-SCI REV, V59, P101, DOI 10.1016/S0012-8252(02)00071-5; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; Kind R, 2002, SCIENCE, V298, P1219, DOI 10.1126/science.1078115; Marotta AM, 1999, GEOPHYS J INT, V139, P98, DOI 10.1046/j.1365-246X.1999.00922.x; MCNAMARA DE, 1994, J GEOPHYS RES-SOL EA, V99, P13655, DOI 10.1029/93JB03406; McNamara DE, 1997, J GEOPHYS RES-SOL EA, V102, P493, DOI 10.1029/96JB02112; POWELL CMA, 1973, EARTH PLANET SC LETT, V20, P1, DOI 10.1016/0012-821X(73)90134-9; Rapine R, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000445; Rodgers AJ, 1998, J GEOPHYS RES-SOL EA, V103, P7137, DOI 10.1029/97JB03535; SATO H, 1989, J GEOPHYS RES-SOLID, V94, P5689, DOI 10.1029/JB094iB05p05689; Tapponnier P, 2001, SCIENCE, V294, P1671, DOI 10.1126/science.105978; TURNER S, 1993, NATURE, V364, P50, DOI 10.1038/364050a0; Wang Q, 2001, SCIENCE, V294, P574, DOI 10.1126/science.1063647; Wittlinger G, 1996, EARTH PLANET SC LETT, V139, P263, DOI 10.1016/0012-821X(95)00235-5; Yin A, 2000, ANNU REV EARTH PL SC, V28, P211, DOI 10.1146/annurev.earth.28.1.211; Zhou R, 1996, GEOPHYS RES LETT, V23, P25, DOI 10.1029/95GL03607	27	301	343	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1424	1427		10.1126/science.1082777	http://dx.doi.org/10.1126/science.1082777			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775838				2022-12-28	WOS:000183181800043
J	Baverstock, K				Baverstock, K			The 2003 NRPB report on UK nuclear-test veterans	LANCET			English	Editorial Material									Univ Kuopio, Fac Nat Sci & Environm Sci, FIN-70211 Kuopio, Finland	University of Eastern Finland	Baverstock, K (corresponding author), Univ Kuopio, Fac Nat Sci & Environm Sci, FIN-70211 Kuopio, Finland.							Muirhead CR, 2003, OCCUP ENVIRON MED, V60, P165, DOI 10.1136/oem.60.3.165; MUIRHEAD CR, MORTALITY CANC INCID; *NAS, 2003, REV DOS REC PROGR DE; ROFF RS, 2003, UNDERASCERTAINMENT M; THAUL S, 2003, 5 SERIES STUDY MORTA; Thorne MC, 2003, J RADIOL PROT, V23, P29, DOI 10.1088/0952-4746/23/1/302	6	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1759	1760		10.1016/S0140-6736(03)13447-2	http://dx.doi.org/10.1016/S0140-6736(03)13447-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781532				2022-12-28	WOS:000183074800005
J	Dispenzieri, A; Kyle, RA; Gertz, MA; Therneau, TM; Miller, WL; Chandrasekaran, K; McConnell, JP; Burritt, MF; Jaffe, AS				Dispenzieri, A; Kyle, RA; Gertz, MA; Therneau, TM; Miller, WL; Chandrasekaran, K; McConnell, JP; Burritt, MF; Jaffe, AS			Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins	LANCET			English	Article								Patients with primary systemic amyloidosis that affects the heart have a poor outlook. Cardiac troponins T and I (cTnT, cTnI) are highly specific and sensitive biomarkers of myocardial injury. Values of these troponins provide quantitative information about the disease. We retrospectively assessed 261 patients newly diagnosed as having primary systemic amyloidosis. Median survival for patients with detectable cTnT and cTnI (6 and 8 months, respectively), was worse than that for those with undetectable values (22 and 21 months, respectively). Median and 25th and, 75th percentile values for cTnT were 0.024 mug/l., less than 0.01 mug/L, and 0.084 mug/L, and for cTnI were 0.1 mug/L, 0.05 mug/L, and 0.24 mug/L, respectively. After multivariate analysis, cTnT proved a better predictor of survival than cTnI.	Mayo Clin, Div Haematol & Internal Med, Rochester, MN 55905 USA; Mayo Clin, Div Biostat, Rochester, MN 55905 USA; Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin, Div Internal Med, Rochester, MN 55905 USA; Mayo Clin, Div Lab Genet, Rochester, MN 55905 USA; Mayo Clin, Div Clin Biochem & Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Dispenzieri, A (corresponding author), Mayo Clin, Div Haematol & Internal Med, Rochester, MN 55905 USA.		Gertz, Morie/K-2873-2019	Dispenzieri, Angela/0000-0001-8780-9512	NATIONAL CANCER INSTITUTE [R21CA091561, P01CA062242] Funding Source: NIH RePORTER; NCI NIH HHS [CA 91561, CA 62242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apple FS, 2002, AM HEART J, V144, P981, DOI 10.1067/mhj.2002.124048; CUETOGARCIA L, 1985, J AM COLL CARDIOL, V6, P737, DOI 10.1016/S0735-1097(85)80475-7; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; KYLE RA, 1986, BLOOD, V68, P220; Miller WL, 2001, AM J CARDIOL, V88, P813, DOI 10.1016/S0002-9149(01)01877-X	5	216	233	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1787	1789		10.1016/S0140-6736(03)13396-X	http://dx.doi.org/10.1016/S0140-6736(03)13396-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781539				2022-12-28	WOS:000183074800012
J	Runciman, WB; Merry, AF; Tito, F				Runciman, WB; Merry, AF; Tito, F			Error, blame, and the law in health care - An antipodean perspective	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE EVENTS; SAFETY	Patients are frequently harmed by problems arising from the health care process itself. Addressing these problems requires understanding the role of errors, violations, and system failures in their genesis. Problem-solving is inhibited by a tendency to blame those involved, often inappropriately. This has been aggravated by the need to attribute blame before compensation can be obtained through tort and the human failing of attributing blame simply because there has been a serious outcome. Blaming and punishing for errors that are made by well-intentioned people working in the health care system drives the problem of iatrogenic harm underground and alienates people who are best placed to prevent such problems from recurring. on the other hand, failure to assign blame when it is due is also undesirable and erodes trust in the medical profession. Understanding the distinction between blameworthy behavior and inevitable human errors and appreciating the systemic factors that underlie most failures in complex systems are essential for the response to a harmed patient to be informed, fair, and effective in improving safety. It is important to meet society's needs to blame and exact retribution when appropriate. However, this should not be a prerequisite for compensation, which should be appropriately structured, fair, timely, and, ideally, properly funded as an intrinsic part of health care and social security systems.	Univ Adelaide, Adelaide, SA, Australia; Australian Patient Safety Fdn, Adelaide, SA, Australia; Univ Auckland, Auckland 1, New Zealand	University of Adelaide; University of Auckland	Runciman, WB (corresponding author), Royal Adelaide Hosp, Dept Anaesthesia & Intens Care, N Terrace, Adelaide, SA 5000, Australia.		Runciman, William B/F-3202-2013	Runciman, William B/0000-0001-8489-0693; Merry, Alan/0000-0001-7100-009X				*AUSTR COUNC SAF Q, 2002, SAF ACT IMPR PAT SAF; Bagian J P, 2001, Jt Comm J Qual Improv, V27, P522; Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; *CAN MED PROT ASS, 1998, P TORT REF C TOR ONT; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; Davis P. LYR, 2001, ADVERSE EVENTS NZ PU; Donaldson L., 2005, ORG MEMORY REPORT EX; FLEMING JG, 1983, LAW TORTS, P6; HUBBARD C, 2000, MCGILL J MED, V5, P111; Institute of Medicine, 2001, CROSSING QUALITY CHA; IPP DA, 2002, 1 COMM AUSTR; KENNEDY I, 2001, 5207I CM STAT OFF; Kohn KT, 2000, ERR IS HUMAN BUILDIN; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Merry A., 2001, ERRORS MED LAW; MERRY AF, 1995, NEW ZEAL MED J, V108, P185; Merry AF, 2001, ANESTH ANALG, V93, P385, DOI 10.1097/00000539-200108000-00030; *NAT AUD OFF, 2001, 403 HC STAT OFF; PATERSON R, 2002, PATIENTS RIGHTS NZ L; Reason J., 1990, HUMAN ERROR; Runciman B, 2001, BRIT MED J, V323, P298, DOI 10.1136/bmj.323.7308.298; RUNCIMAN WB, 1993, ANAESTH INTENS CARE, V21, P506, DOI 10.1177/0310057X9302100506; Runciman WB, 2002, QUAL SAF HEALTH CARE, V11, P224, DOI 10.1136/qhc.11.3.224; Runciman WB, 2001, IATROGENIC INJURY AU; SAVILL R, 1995, DAILY TELEGRAPH, P3; Schioler T, 2001, Ugeskr Laeger, V163, P5370; *SCOTT PARL, 2001, 0180 RN SCOTT PARL; Studdert DM, 2000, MED CARE, V38, P250, DOI 10.1097/00005650-200003000-00002; Studdert DM, 2001, JAMA-J AM MED ASSOC, V286, P217, DOI 10.1001/jama.286.2.217; Studdert DM, 1997, LAW CONTEMP PROBL, V60, pA1; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; VINCENT C, 2001, CLIN RISK MANAGEMENT; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x	33	78	79	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2003	138	12					974	979		10.7326/0003-4819-138-12-200306170-00009	http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690YM	12809454				2022-12-28	WOS:000183578100005
J	Elf, J; Nilsson, D; Tenson, T; Ehrenberg, M				Elf, J; Nilsson, D; Tenson, T; Ehrenberg, M			Selective charging of tRNA isoacceptors explains patterns of codon usage	SCIENCE			English	Article							TRANSFER-RNA ABUNDANCE; ESCHERICHIA-COLI; SEQUENCE; TRANSLATION; ADAPTATION; ACCURACY; PPGPP	We modeled how the charged levels of different transfer RNAs (tRNAs) that carry the same amino acid ( isoacceptors) respond when this amino acid becomes growth-limiting. The charged levels will approach zero for some isoacceptors (such as tRNA(2)(Leu)) and remain high for others (such as tRNA(4)(Leu)), as determined by the concentrations of isoacceptors and how often their codons occur in protein synthesis. The theory accounts for ( synonymous) codons for the same amino acid that are used in ribosome-mediated transcriptional attenuation, the choices of synonymous codons in trans-translating transfer-messenger RNA, and the overrepresentation of rare codons in messenger RNAs for amino acid biosynthetic enzymes.	Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden; Univ Tartu, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia	Uppsala University; Karolinska Institutet; University of Tartu	Ehrenberg, M (corresponding author), Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.	ehrenberg@xray.bmc.uu.se	Nilsson, Daniel/B-8365-2009; Tenson, Tanel/I-6431-2015	Nilsson, Daniel/0000-0001-5831-385X; Tenson, Tanel/0000-0002-0260-3601; elf, johan/0000-0001-5522-1810				Barak Z, 1996, J MOL BIOL, V256, P676, DOI 10.1006/jmbi.1996.0117; BJORK GR, 1996, CELLULAR MOL BIOL, P861; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOCK A, 1966, J BACTERIOL, V92, P1076; BULMER M, 1987, NATURE, V325, P728, DOI 10.1038/325728a0; CASHEL M, 1996, CELLULAR MOL BIOL, P1458; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; EHRENBERG M, 1984, Q REV BIOPHYS, V17, P45, DOI 10.1017/S0033583500005254; EHRENBERG M, UNPUB; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LANDICK R, 1987, CELLULAR MOL BIOL, P1276; MORRIS DW, 1965, J BACTERIOL, V90, P1624, DOI 10.1128/JB.90.6.1624-1631.1965; Nakamura Y, 1996, NUCLEIC ACIDS RES, V24, P214, DOI 10.1093/nar/24.1.214; NEIDHARDT FC, 1996, CELLULAR MOL BIOL; OFARRELL PH, 1978, CELL, V14, P545, DOI 10.1016/0092-8674(78)90241-6; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Rodnina MV, 2001, ANNU REV BIOCHEM, V70, P415, DOI 10.1146/annurev.biochem.70.1.415; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Sorensen MA, 2001, J MOL BIOL, V307, P785, DOI 10.1006/jmbi.2001.4525; Withey JH, 2002, CURR OPIN MICROBIOL, V5, P154, DOI 10.1016/S1369-5274(02)00299-0; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; YEGIAN CD, 1969, J MOL BIOL, V39, P45, DOI 10.1016/0022-2836(69)90332-5	27	182	187	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1718	1722		10.1126/science.1083811	http://dx.doi.org/10.1126/science.1083811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805541				2022-12-28	WOS:000183459700043
J	Inguscio, M				Inguscio, M			How to freeze out collisions	SCIENCE			English	Editorial Material							FERMI		Univ Florence, LENS, Dept Phys, I-50019 Florence, Italy; Univ Florence, INFM, I-50019 Florence, Italy	University of Florence; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Florence	Inguscio, M (corresponding author), Univ Florence, LENS, Dept Phys, I-50019 Florence, Italy.	inguscio@lens.unifi.it		Inguscio, Massimo/0000-0001-8152-8103				FANO U, 1935, NUOVO CIMENTO, V12, P156; Fermi E, 1925, NATURE, V115, P764, DOI 10.1038/115764b0; FESHBACH H, 1958, ANN PHYS-NEW YORK, V5, P357, DOI 10.1016/0003-4916(58)90007-1; Gorlitz A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.090401; Gupta S, 2003, SCIENCE, V300, P1723, DOI 10.1126/science.1085335; Harber DM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.053616; Inguscio M., 1999, P INT SCH PHYS E FER; Killian TC, 1998, PHYS REV LETT, V81, P3807, DOI 10.1103/PhysRevLett.81.3807; KOKKELMANS S, 2003, 34 DAMOP C 20 24 MAY; O'Hara KM, 2002, SCIENCE, V298, P2179, DOI 10.1126/science.1079107; Pitaevskii L, 2002, SCIENCE, V298, P2144, DOI 10.1126/science.1080087; Simoni A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.163202	12	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1671	+		10.1126/science.1085845	http://dx.doi.org/10.1126/science.1085845			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805526				2022-12-28	WOS:000183459700027
J	White, WB				White, WB			Ambulatory blood-pressure monitoring in clinical practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Connecticut, Sch Med, Div Hypertens & Clin Pharmacol, Farmington, CT 06032 USA	University of Connecticut	White, WB (corresponding author), Univ Connecticut, Sch Med, Div Hypertens & Clin Pharmacol, Farmington, CT 06032 USA.							GRIN JM, 1993, ANN INTERN MED, V118, P833, DOI 10.7326/0003-4819-118-11-199306010-00001	1	73	75	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2377	2378		10.1056/NEJMp030057	http://dx.doi.org/10.1056/NEJMp030057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802022				2022-12-28	WOS:000183428900002
J	Gosden, R; Trasler, J; Lucifero, D; Faddy, M				Gosden, R; Trasler, J; Lucifero, D; Faddy, M			Rare congenital disorders, imprinted genes, and assisted reproductive technology	LANCET			English	Review							INTRACYTOPLASMIC SPERM INJECTION; IN-VITRO FERTILIZATION; INFANTS BORN; IVF; EXPRESSION; CULTURE; EMBRYOS; MALFORMATIONS; DEFECTS; RISK	Context During the past two decades, assisted reproductive technologies (ARTs) have revolutionised the treatment of infertility. ARTs now account for between 1% and 3% of annual births in many western countries and in-vitro fertilisation (IVF) services are growing worldwide. In general, the incidence of abnormalities at birth is reassuringly low and children develop normally. Nevertheless, it is important to monitor the safety of ARTs as clinical protocols evolve and new technologies emerge. Starting point Three recent studies all report an unexpectedly high incidence of Beckwith-Wiedemann, syndrome (BWS) in children conceived with ARTs. Six of 149 cases were reported from a British BWS registry. (J Med Genet 2003; 40: 62-64); the same numbers were recorded in a French registry (Am Hum Genet 2003; 72: 1338-41), and a further seven children have been reported in the USA (Am J Hum Genet 2003; 72: 156-60). These frequencies are extraordinarily high for such a rare congenital condition and such findings are reminiscent of reports of sporadic cases of the imprinting disorder. Angelman syndrome which has also been linked with ARTs. Where next? Continuing surveillance of children conceived with ARTs is needed, including monitoring birth defects, development, and cancer. Studies will need to be prospective and multicentre, and should include molecular characterisation of epigenetic abnormalities, including the methylation status of imprinting control region within imprinted gene clusters.	Eastern Virginia Med Sch, Jones Inst Reprod Med, Norfolk, VA 23507 USA; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada; Univ Birmingham, Sch Math & Stat, Birmingham B15 2TT, W Midlands, England	Eastern Virginia Medical School; McGill University; McGill University; McGill University; University of Birmingham	Gosden, R (corresponding author), Eastern Virginia Med Sch, Jones Inst Reprod Med, Norfolk, VA 23507 USA.							BenEzra D, 2003, LANCET, V361, P273, DOI 10.1016/S0140-6736(03)12364-1; Boerrigter PJ, 2002, HUM REPROD, V17, P2027, DOI 10.1093/humrep/17.8.2027; Bonduelle M, 2002, HUM REPROD, V17, P671, DOI 10.1093/humrep/17.3.671; Cox GF, 2002, AM J HUM GENET, V71, P162, DOI 10.1086/341096; DeBaun MR, 2003, AM J HUM GENET, V72, P156, DOI 10.1086/346031; Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526; Ericson A, 2001, HUM REPROD, V16, P504, DOI 10.1093/humrep/16.3.504; Evers JLH, 2002, LANCET, V360, P151, DOI 10.1016/S0140-6736(02)09417-5; Gardner DK, 1998, HUM REPROD, V13, P3434, DOI 10.1093/humrep/13.12.3434; Gicquel C, 2003, AM J HUM GENET, V72, P1338, DOI 10.1086/374824; Hansen M, 2002, NEW ENGL J MED, V346, P725, DOI 10.1056/NEJMoa010035; Khosla S, 2001, BIOL REPROD, V64, P918, DOI 10.1095/biolreprod64.3.918; Koudstaal J, 2000, HUM REPROD, V15, P1819, DOI 10.1093/humrep/15.8.1819; Maher ER, 2003, J MED GENET, V40, P62, DOI 10.1136/jmg.40.1.62; Moll AC, 2003, LANCET, V361, P309, DOI 10.1016/S0140-6736(03)12332-X; Olivennes F, 2001, HUM REPROD, V16, P1588, DOI 10.1093/humrep/16.8.1588; Orstavik KH, 2003, AM J HUM GENET, V72, P218, DOI 10.1086/346030; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Salpekar A, 2001, MOL HUM REPROD, V7, P839, DOI 10.1093/molehr/7.9.839; Schieve LA, 2002, NEW ENGL J MED, V346, P731, DOI 10.1056/NEJMoa010806; Sutcliffe AG, 1995, HUM REPROD, V10, P3332, DOI 10.1093/oxfordjournals.humrep.a135915; Weksberg R, 2002, HUM MOL GENET, V11, P1317, DOI 10.1093/hmg/11.11.1317; Young D, 2000, BIRTH-ISS PERINAT C, V27, P153, DOI 10.1046/j.1523-536x.2000.00153.x	23	250	258	0	33	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1975	1977		10.1016/S0140-6736(03)13592-1	http://dx.doi.org/10.1016/S0140-6736(03)13592-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801753				2022-12-28	WOS:000183359700024
J	Bjedov, I; Tenaillon, O; Gerard, B; Souza, V; Denamur, E; Radman, M; Taddei, F; Matic, I				Bjedov, I; Tenaillon, O; Gerard, B; Souza, V; Denamur, E; Radman, M; Taddei, F; Matic, I			Stress-induced mutagenesis in bacteria	SCIENCE			English	Article							STATIONARY-PHASE MUTATION; DNA-POLYMERASE-II; ESCHERICHIA-COLI; ADAPTIVE MUTATION; MISMATCH REPAIR; GENE-EXPRESSION; POPULATIONS; MUTATORS; RPOS; RECOMBINATION	The evolutionary significance of stress-induced mutagenesis was evaluated by studying mutagenesis in aging colonies ( MAC) of Escherichia coli natural isolates. A large fraction of isolates exhibited a strong MAC, and the high MAC variability reflected the diversity of selective pressures in ecological niches. MAC depends on starvation, oxygen, and RpoS and adenosine 3',5'-monophosphate regulons; thus it may be a by-product of genetic strategies for improving survival under stress. MAC could also be selected through beneficial mutations that it generates, as shown by computer modeling and the patterns of stress-inducible and constitutive mutagenesis. We suggest that irrespective of the causes of their emergence, stress-induced mutations participate in adaptive evolution.	Univ Paris 05, Fac Med Necker Enfants Malad, INSERM, U571, F-75730 Paris 15, France; Univ Paris 07, Fac Med Xavier Bichat, INSERM, EO339, F-75870 Paris, France; Univ Nacl Autonoma Mexico, Inst Ecol, Dept Ecol Evolut, Mexico City 04510, DF, Mexico	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidad Nacional Autonoma de Mexico	Matic, I (corresponding author), Univ Paris 05, Fac Med Necker Enfants Malad, INSERM, U571, 156 Rue Vaugirard, F-75730 Paris 15, France.		Tenaillon, Olivier/L-9857-2017; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0003-0216-3148; Bjedov, Ivana/0000-0001-5894-6016; Radman, Miroslav/0000-0002-7034-4365; souza, valeria/0000-0002-2992-4229; Tenaillon, Olivier/0000-0002-3796-1601; Taddei, Francois/0000-0002-7894-0647				Bregeon D, 1999, J GENET, V78, P21, DOI 10.1007/BF02994699; Bridges BA, 1998, MUTAT RES-DNA REPAIR, V408, P1, DOI 10.1016/S0921-8777(98)00008-1; Chicurel M, 2001, SCIENCE, V292, P1824, DOI 10.1126/science.292.5523.1824; Courcelle J, 2001, GENETICS, V158, P41; CUPPLES CG, 1990, GENETICS, V125, P275; Denamur E, 2002, J BACTERIOL, V184, P605, DOI 10.1128/JB.184.2.605-609.2002; Denamur E, 2000, CELL, V103, P711, DOI 10.1016/S0092-8674(00)00175-6; Duriez P, 2001, MICROBIOL-SGM, V147, P1671, DOI 10.1099/00221287-147-6-1671; ESCARCELLER M, 1994, J BACTERIOL, V176, P6221, DOI 10.1128/jb.176.20.6221-6228.1994; Foster PL, 1999, ANNU REV GENET, V33, P57, DOI 10.1146/annurev.genet.33.1.57; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Giraud A, 2001, CURR OPIN MICROBIOL, V4, P582, DOI 10.1016/S1369-5274(00)00254-X; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; Harris RS, 1997, GENE DEV, V11, P2426, DOI 10.1101/gad.11.18.2426; Hengge-Aronis R, 2002, MICROBIOL MOL BIOL R, V66, P373, DOI 10.1128/MMBR.66.3.373-395.2002; Holliday R, 1995, UNDERSTANDING AGING; Karunakaran P, 2000, J BACTERIOL, V182, P3331, DOI 10.1128/JB.182.12.3331-3335.2000; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LENSKI RE, 1995, SCIENCE, V269, P285, DOI 10.1126/science.7618089; Matic I, 1997, SCIENCE, V277, P1833, DOI 10.1126/science.277.5333.1833; McKenzie GJ, 2000, P NATL ACAD SCI USA, V97, P6646, DOI 10.1073/pnas.120161797; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Miller JH, 1998, MUTAT RES-DNA REPAIR, V409, P99, DOI 10.1016/S0921-8777(98)00049-4; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; PETERS AC, 1987, J GEN MICROBIOL, V133, P1257; Runyen-Janecky LJ, 1999, INFECT IMMUN, V67, P1415, DOI 10.1128/IAI.67.3.1415-1423.1999; Saier MH, 1996, ESCHERICHIA COLI SAL, V1, P1325; Saumaa S, 2002, J BACTERIOL, V184, P6957, DOI 10.1128/JB.184.24.6957-6965.2002; SEDGWICK SG, 1985, P NATL ACAD SCI USA, V82, P4172, DOI 10.1073/pnas.82.12.4172; Sommer SS, 2001, MUTAT RES-DNA REPAIR, V487, P1, DOI 10.1016/S0921-8777(01)00108-2; STEELE DF, 1992, GENETICS, V132, P9; Taddei F, 1997, MOL GEN GENET, V256, P277, DOI 10.1007/s004380050570; TADDEI F, 1995, P NATL ACAD SCI USA, V92, P11736, DOI 10.1073/pnas.92.25.11736; Tenaillon O, 2000, P NATL ACAD SCI USA, V97, P10465, DOI 10.1073/pnas.180063397; Tenaillon O, 1999, GENETICS, V152, P485; Tenaillon O, 2001, RES MICROBIOL, V152, P11, DOI 10.1016/S0923-2508(00)01163-3; TESSMAN I, 1994, GENETICS, V136, P439; Tsui HCT, 1997, J BACTERIOL, V179, P7476, DOI 10.1128/jb.179.23.7476-7487.1997	38	404	416	5	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1404	1409		10.1126/science.1082240	http://dx.doi.org/10.1126/science.1082240			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775833				2022-12-28	WOS:000183181800037
J	Hjorth, J; Sollerman, J; Moller, P; Fynbo, JPU; Woosley, SE; Kouveliotou, C; Tanvir, NR; Greiner, J; Andersen, MI; Castro-Tirado, AJ; Ceron, JMC; Fruchter, AS; Gorosabel, J; Jakobsson, P; Kaper, L; Klose, S; Masetti, N; Pedersen, H; Pedersen, K; Pian, E; Palazzi, E; Rhoads, JE; Rol, E; van den Heuvel, EPJ; Vreeswijk, PM; Watson, D; Wijers, RAMJ				Hjorth, J; Sollerman, J; Moller, P; Fynbo, JPU; Woosley, SE; Kouveliotou, C; Tanvir, NR; Greiner, J; Andersen, MI; Castro-Tirado, AJ; Ceron, JMC; Fruchter, AS; Gorosabel, J; Jakobsson, P; Kaper, L; Klose, S; Masetti, N; Pedersen, H; Pedersen, K; Pian, E; Palazzi, E; Rhoads, JE; Rol, E; van den Heuvel, EPJ; Vreeswijk, PM; Watson, D; Wijers, RAMJ			A very energetic supernova associated with the gamma-ray burst of 29 March 2003	NATURE			English	Article							HUBBLE-SPACE-TELESCOPE; OPTICAL AFTERGLOW; EMISSION	Over the past five years evidence has mounted that long-duration (>2 s) gamma-ray bursts (GRBs)-the most luminous of all astronomical explosions-signal the collapse of massive stars in our Universe. This evidence was originally based on the probable association of one unusual GRB with a supernova(1), but now includes the association of GRBs with regions of massive star formation in distant galaxies(2,3), the appearance of supernova-like 'bumps' in the optical afterglow light curves of several bursts(4-6) and lines of freshly synthesized elements in the spectra of a few X-ray afterglows(7). These observations support, but do not yet conclusively demonstrate, the idea that long-duration GRBs are associated with the deaths of massive stars, presumably arising from core collapse. Here we report evidence that a very energetic supernova (a hypernova) was temporally and spatially coincident with a GRB at redshift z=0.1685. The timing of the supernova indicates that it exploded within a few days of the GRB, strongly suggesting that core-collapse events can give rise to GRBs, thereby favouring the 'collapsar' model(8,9).	Univ Copenhagen, NBIfAFG, Astron Observ, DK-2100 Copenhagen O, Denmark; Stockholm Observ, Dept Astron, S-10691 Stockholm, Sweden; European So Observ, D-85748 Garching, Germany; Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark; Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA; NSSTC, Huntsville, AL 35805 USA; Univ Hertfordshire, Dept Phys Sci, Hatfield AL10 9AB, Herts, England; Max Planck Inst Extraterr Phys, D-85741 Garching, Germany; Inst Astrophys, D-14482 Potsdam, Germany; CSIC, Inst Astrofis Andalucia, E-18080 Granada, Spain; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Thuringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany; CNR, Ist Astrofis Spaziale & Fis Cosm, Sez Bologna, I-40129 Bologna, Italy; Osserv Astron Trieste, INAF, I-34131 Trieste, Italy; European So Observ, Santiago 19, Chile	University of Copenhagen; Stockholm University; European Southern Observatory; Aarhus University; University of California System; University of California Santa Cruz; University of Hertfordshire; Max Planck Society; Leibniz Institut fur Astrophysik Potsdam (AIP); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); Space Telescope Science Institute; University of Amsterdam; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); European Southern Observatory	Hjorth, J (corresponding author), Univ Copenhagen, NBIfAFG, Astron Observ, Juliane Maries Vej, DK-2100 Copenhagen O, Denmark.	jens@astro.ku.dk	Fynbo, Johan P. U./L-8496-2014; van den Heuvel, Edward P.J./C-1262-2018; Watson, Darach/E-4521-2015; Jakobsson, Pall/L-9950-2015; Andersen, Michael/H-6403-2018; Hjorth, Jens/M-5787-2014; Palazzi, Eliana/N-4746-2015	Fynbo, Johan P. U./0000-0002-8149-8298; Watson, Darach/0000-0002-4465-8264; Jakobsson, Pall/0000-0002-9404-5650; Hjorth, Jens/0000-0002-4571-2306; Castro-Tirado, A. J./0000-0003-2999-3563				BLAKE C, 2003, 2011 GCN; Bloom JS, 1999, NATURE, V401, P453, DOI 10.1038/46744; Castro-Tirado AJ, 1999, ASTRON ASTROPHYS SUP, V138, P449, DOI 10.1051/aas:1999303; Fruchter AS, 1999, ASTROPHYS J, V519, pL13, DOI 10.1086/312094; Fynbo JU, 2000, ASTROPHYS J, V542, pL89, DOI 10.1086/312942; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; GARNAVICH P, 2003, 8114 IAU; Garnavich PM, 2003, ASTROPHYS J, V582, P924, DOI 10.1086/344785; Granot J, 2002, ASTROPHYS J, V570, pL61, DOI 10.1086/340991; GREINER J, 2003, 2020 GCN; Iwamoto K, 1998, NATURE, V395, P672, DOI 10.1038/27155; Kennicutt RC, 1998, ANNU REV ASTRON ASTR, V36, P189, DOI 10.1146/annurev.astro.36.1.189; Kulkarni SR, 1998, NATURE, V395, P663, DOI 10.1038/27139; Lee H, 2003, ASTRON ASTROPHYS, V401, P141, DOI 10.1051/0004-6361:20030101; Leonard DC, 2002, PUBL ASTRON SOC PAC, V114, P1333, DOI 10.1086/345092; MacFadyen AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790; Paczynski B, 1998, ASTROPHYS J, V494, pL45, DOI 10.1086/311148; Patat F, 2001, ASTROPHYS J, V555, P900, DOI 10.1086/321526; Price PA, 2003, NATURE, V423, P844, DOI 10.1038/nature01734; Reeves JN, 2002, NATURE, V416, P512, DOI 10.1038/416512a; Schlegel DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772; SOLLERMAN J, 2000, APJ, V537, P127; STANEK KZ, IN PRESS ASTROPHYS J; TORII K, 2003, 1986 GCN; VANDERSPEK R, 2003, 1997 GCN; Vietri M, 1999, ASTROPHYS J, V527, pL43, DOI 10.1086/312386; Wheeler JC, 2000, ASTROPHYS J, V537, P810, DOI 10.1086/309055; WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359; Woosley SE, 1999, ASTROPHYS J, V516, P788, DOI 10.1086/307131; ZHARIKOV S, 2003, 2022 GCN	30	1158	1165	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					847	850		10.1038/nature01750	http://dx.doi.org/10.1038/nature01750			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815425	Green Submitted			2022-12-28	WOS:000183585300039
J	Bolton, P; Bass, J; Neugebauer, R; Verdeli, H; Clougherty, KF; Wickramaratne, P; Speelman, L; Ndogoni, L; Weissman, M				Bolton, P; Bass, J; Neugebauer, R; Verdeli, H; Clougherty, KF; Wickramaratne, P; Speelman, L; Ndogoni, L; Weissman, M			Group interpersonal psychotherapy for depression in rural Uganda - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISABILITY	Context Despite the importance of mental illness in Africa, few controlled intervention trials related to this problem have been published. Objectives To test the efficacy of group interpersonal psychotherapy in alleviating, depression and dysfunction and to evaluate the feasibility of conducting controlled trials in Africa. Design, Setting, and Participants For this cluster randomized, controlled clinical trial (February-June 2002), 30 villages in the Masaka and Rakai districts of rural Uganda were selected using a random procedure; 15 were then randomly assigned for studying men and 15 for women. In each village, adult men or women believed by themselves and other villagers to have depressionlike illness were interviewed using a locally adapted Hopkins Symptom Checklist and an instrument assessing function. Based on these interviews, lists were created for each village totaling 341 men and women who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for major depression or subsyndromal depression. Interviewers revisited them in order of decreasing symptom severity until they had 8 to 12 persons per village, totaling 284. Of these, 248 agreed to be in the trial and 9 refused; the remainder died or relocated. A total of 108 men and 116 women completed the study and were reinterviewed. Intervention Eight of the 15 male villages and 7 of the 15 female villages were randomly assigned to the intervention arm and the remainder to the control arm. The intervention villages received group interpersonal psychotherapy for depression as weekly 90-minute sessions for 16 weeks. Main Outcome Measures Depression and dysfunction severity scores on scales adapted and validated for local use; proportion of persons meeting DSM-IV major depression diagnostic criteria. Results Mean reduction in depression severity was 17.47 points for intervention groups and 3.55 points for controls (P<.001). Mean reduction in dysfunction was 8.08 and 3.76 points, respectively (P<.001). After intervention, 6.5% and 54.7% of the intervention and control groups, respectively, met the criteria for major depression (P<.001) compared with 86% and 94%, respectively, prior to intervention (P=.04). The odds of postintervention depression among controls was 17.31 (95% confidence interval, 7.63-39.27) compared with the odds among intervention groups, Results from intention-to-treat analyses remained statistically significant. Conclusions Group interpersonal psychotherapy was highly efficacious in reducing depression and dysfunction. A clinical trial proved feasible in the local setting. Both findings should encourage similar trials in similar settings in Africa and beyond.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Int Emergency Disaster & Refugee Studies, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; New York State Psychiat Inst & Hosp, Epidemiol Dev Brain Disorders Dept, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Int Program Refugee Trauma, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Div Clin & Genet Epidemiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, Fac Med, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; World Vis Int, Washington, DC USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; New York State Psychiatry Institute; New York State Psychiatry Institute; New York State Psychiatry Institute; Columbia University; Columbia University; Columbia University	Bolton, P (corresponding author), 159 Tilden Rd, Scituate, MA 02066 USA.			Bass, Judith/0000-0002-5192-628X; Weissman, Myrna/0000-0003-3490-3075				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bolton P, 2002, SOC PSYCH PSYCH EPID, V37, P537, DOI 10.1007/s00127-002-0580-5; Bolton P, 2002, J NERV MENT DIS, V190, P631, DOI 10.1097/00005053-200209000-00009; Bolton P, 2001, J NERV MENT DIS, V189, P238, DOI 10.1097/00005053-200104000-00005; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Diggle PJ, 1994, ANAL LONGITUDINAL DA; EKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; Mollica RF, 1999, JAMA-J AM MED ASSOC, V282, P433, DOI 10.1001/jama.282.5.433; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Omar RZ, 2000, STAT MED, V19, P2675, DOI 10.1002/1097-0258(20001015)19:19<2675::AID-SIM556>3.3.CO;2-1; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; VERDELI H, IN PRESS WORLD PSYCH; WEISSMAN MM, 2000, COMPREHENSIVE GUIDE; *WHO, 2001, MENT HLTH NEW UND NE	14	406	408	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3117	3124		10.1001/jama.289.23.3117	http://dx.doi.org/10.1001/jama.289.23.3117			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690QM	12813117	Bronze			2022-12-28	WOS:000183560400026
J	Kruip, MJHA; Leclercq, MGL; van der Heul, C; Prins, MH; Buller, HR				Kruip, MJHA; Leclercq, MGL; van der Heul, C; Prins, MH; Buller, HR			Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies - A systematic review	ANNALS OF INTERNAL MEDICINE			English	Article							VENTILATION-PERFUSION SCINTIGRAPHY; D-DIMER ASSAY; SPIRAL COMPUTED-TOMOGRAPHY; DEEP VENOUS THROMBOSIS; LUNG-SCAN; HELICAL CT; ANTICOAGULANT-THERAPY; NONINVASIVE DIAGNOSIS; LOW-PROBABILITY; WORK-UP	Background: Pulmonary embolism is a common clinical disorder that is associated with high morbidity and mortality if untreated. It is important to confirm or rule out the diagnosis in patients with clinical suspicion of the disease. Purpose: To evaluate various diagnostic strategies for excluding pulmonary embolism. Data Sources: MEDLINE (1966 to February 2003), EMBASE, and DARE; study investigators; and reference lists. Study, Selection: Prospective clinical outcome studies. Data Extraction: The researchers recorded the frequency of symptomatic venous thromboembolism over 3 months of follow-up in patients in whom pulmonary embolism had been excluded according to various strategies. Strategies were divided into three categories according to the number of rounds of diagnostic tests needed to exclude pulmonary embolism. Data Synthesis: 25 studies involving more than 7000 patients were included. In all referred patients, two strategies-normal results on pulmonary angiography or lung scintigraphy and normal D-dimer levels combined with low clinical probability-safely excluded pulmonary embolism (failure rates less than or equal to 3%). In the second round of diagnostic tests, in patients who had had a nondiagnostic lung scan, both pulmonary angiography and serial leg testing for venous thrombosis were accurate and safe. When D-dimer testing combined with clinical probability was inconclusive, a normal perfusion lung scan safely excluded pulmonary embolism. Accumulating evidence shows that normal results on spiral computed tomography may also safely exclude the disease. Conclusions: Many diagnostic strategies to exclude pulmonary embolism have been evaluated in consecutive patients. Interest is likely to increase in a simple, fast strategy, starting with a normal perfusion lung scan or a combination of normal D-dimer levels and low clinical probability. After the initial round of testing, a reliable diagnostic method, such as angiography or lung scintigraphy, is warranted.	St Elizabeth Hosp, Dept Internal Med, NL-5000 LC Tilburg, Netherlands; Spectrum Twente, Enschede, Netherlands; Univ Maastricht, Maastricht, Netherlands; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	Elisabeth-TweeSteden Ziekenhuis (ETZ); Medical Spectrum Twente; Maastricht University; University of Amsterdam; Academic Medical Center Amsterdam	Kruip, MJHA (corresponding author), St Elizabeth Hosp, Dept Internal Med, Postbus 90151, NL-5000 LC Tilburg, Netherlands.	evert.janssen@zonnet.nl						ANDERSON DR, 2001, THROMB HAEMOST S, V7, pOC156; Barghouth G, 2000, EUR J NUCL MED, V27, P1280, DOI 10.1007/s002590000284; BARRITT DW, 1960, LANCET, V1, P1309; BARRO C, 2001, THROMB HAEMOST S, V7, pP718; BERNIER M, 2001, THROMB HAEMOST S, V7, pP754; BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; Burkill GJC, 2002, CLIN RADIOL, V57, P41, DOI 10.1053/crad.2001.0740; CHEELY R, 1981, AM J MED, V70, P17, DOI 10.1016/0002-9343(81)90406-X; Cross JJL, 1998, CLIN RADIOL, V53, P177, DOI 10.1016/S0009-9260(98)80097-4; de Groot MR, 1999, THROMB HAEMOSTASIS, V82, P1588; deMoerloose P, 1996, THROMB HAEMOSTASIS, V75, P11; Douketis JD, 2000, ARCH INTERN MED, V160, P3431, DOI 10.1001/archinte.160.22.3431; Drucker EA, 1998, RADIOLOGY, V209, P235, DOI 10.1148/radiology.209.1.9769837; ELBATARNY HS, 2001, THROMB HAEMOST S, V7, pP738; Ferretti GR, 1997, RADIOLOGY, V205, P453, DOI 10.1148/radiology.205.2.9356628; FISCHER KC, 1979, EUR J NUCL MED, V4, P49; Garg K, 1998, RADIOLOGY, V208, P201, DOI 10.1148/radiology.208.1.9646814; Ghaye B, 2000, JBR-BTR, V83, P271; GINSBERG JS, 1993, CHEST, V104, P1679, DOI 10.1378/chest.104.6.1679; Goodman LR, 2000, RADIOLOGY, V215, P535, DOI 10.1148/radiology.215.2.r00ma23535; GOODMAN LR, 1995, AM J ROENTGENOL, V164, P1369, DOI 10.2214/ajr.164.6.7754875; GRAY HW, 1990, Q J MED, V77, P1135, DOI 10.1093/qjmed/77.2.1135; Gupta A, 1999, RADIOLOGY, V210, P353, DOI 10.1148/radiology.210.2.r99fe53353; HENRY JW, 1995, CHEST, V107, P1375, DOI 10.1378/chest.107.5.1375; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1989, ARCH INTERN MED, V149, P2549, DOI 10.1001/archinte.149.11.2549; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; Janssen MCH, 1998, SEMIN THROMB HEMOST, V24, P393, DOI 10.1055/s-2007-996028; KAHN D, 1989, ARCH INTERN MED, V149, P377, DOI 10.1001/archinte.149.2.377; Kearon C, 1998, ANN INTERN MED, V129, P1044, DOI 10.7326/0003-4819-129-12-199812150-00009; Kim KI, 1999, RADIOLOGY, V210, P693, DOI 10.1148/radiology.210.3.r99mr01693; KIPPER MS, 1982, CHEST, V82, P411, DOI 10.1378/chest.82.4.411; Kline JA, 2002, ANN EMERG MED, V39, P144, DOI 10.1067/mem.2002.121398; Kline JA, 2001, JAMA-J AM MED ASSOC, V285, P761, DOI 10.1001/jama.285.6.761; Knecht MF, 1997, THROMB RES, V88, P413, DOI 10.1016/S0049-3848(97)00276-4; Kruip MJHA, 2002, ARCH INTERN MED, V162, P1631, DOI 10.1001/archinte.162.14.1631; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; Leclercq MGL, 2003, THROMB HAEMOSTASIS, V89, P97; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; Lomis NNT, 1999, J VASC INTERV RADIOL, V10, P707, DOI 10.1016/S1051-0443(99)70104-1; Lorut C, 2000, AM J RESP CRIT CARE, V162, P1413, DOI 10.1164/ajrccm.162.4.9909109; Mathis G, 1999, ULTRASCHALL MED, V20, P54, DOI 10.1055/s-1999-14234; Mayo JR, 1997, RADIOLOGY, V205, P447, DOI 10.1148/radiology.205.2.9356627; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; McAlister FA, 1999, ANN INTERN MED, V131, P947, DOI 10.7326/0003-4819-131-12-199912210-00007; MCBRIDE K, 1986, ARCH SURG-CHICAGO, V121, P754; MCNEIL BJ, 1976, J NUCL MED, V17, P613; Meaney JFM, 1997, NEW ENGL J MED, V336, P1422, DOI 10.1056/NEJM199705153362004; Miniati M, 2001, AM J MED, V110, P528, DOI 10.1016/S0002-9343(01)00693-3; Miniati M, 1996, AM J RESP CRIT CARE, V154, P1387, DOI 10.1164/ajrccm.154.5.8912753; Miron MJ, 1999, EUR RESPIR J, V13, P1365, DOI 10.1183/09031936.99.13613719; Musset D, 2002, LANCET, V360, P1914, DOI 10.1016/S0140-6736(02)11914-3; NOVELLINE RA, 1978, RADIOLOGY, V126, P561, DOI 10.1148/126.3.561; Oser RF, 1996, RADIOLOGY, V199, P31, DOI 10.1148/radiology.199.1.8633168; Ost D, 2001, AM J MED, V110, P16, DOI 10.1016/S0002-9343(00)00641-0; PALUD L, 2001, THROMB HAEMOST S, V7; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; Perrier A, 2001, SEMIN THROMB HEMOST, V27, P25, DOI 10.1055/s-2001-12844; Perrier A, 2001, ANN INTERN MED, V135, P88, DOI 10.7326/0003-4819-135-2-200107170-00008; Pinede L, 2000, BLOOD COAGUL FIBRIN, V11, P701, DOI 10.1097/00001721-200012000-00002; *PROSP INV STUD AC, 1995, CHEST, V107, pS33; Pruszczyk P, 1997, CHEST, V112, P722, DOI 10.1378/chest.112.3.722; Qanadli SD, 2000, RADIOLOGY, V217, P447, DOI 10.1148/radiology.217.2.r00nv01447; RemyJardin M, 1996, RADIOLOGY, V200, P699, DOI 10.1148/radiology.200.3.8756918; Rodger MA, 2001, CHEST, V120, P115, DOI 10.1378/chest.120.1.115; Schoepf UJ, 2002, RADIOLOGY, V222, P483, DOI 10.1148/radiol.2222001802; SIRAGUSA S, 2001, THROMB HAEMOST S, V7, pP1425; SPIES WG, 1986, RADIOLOGY, V159, P383, DOI 10.1148/radiology.159.2.3961170; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; STEIN PD, 1993, CHEST, V103, P1553, DOI 10.1378/chest.103.5.1553; TEIGEN CL, 1995, RADIOLOGY, V194, P313, DOI 10.1148/radiology.194.2.7824704; TEIGEN CL, 1993, RADIOLOGY, V188, P839, DOI 10.1148/radiology.188.3.8351359; TENWOLDE M, 2001, THROMB HAEMOST S, V7, pOC153; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; VANBEEK EJR, 1995, CHEST, V108, P170, DOI 10.1378/chest.108.1.170; vanBeek EJR, 1997, ARCH INTERN MED, V157, P2593, DOI 10.1001/archinte.157.22.2593; vanBeek EJR, 1996, EUR RADIOL, V6, P415, DOI 10.1007/BF00182453; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VANROOIJ WJJ, 1995, RADIOLOGY, V195, P793, DOI 10.1148/radiology.195.3.7754012; vanRossum AB, 1996, THORAX, V51, P23, DOI 10.1136/thx.51.1.23; vanRossum AB, 1996, RADIOLOGY, V201, P467, DOI 10.1148/radiology.201.2.8888242; VANSTRIJEN MJL, 2001, THROMB HAEMOSTASIS, V7, pOC154; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wallis JW, 2000, THROMB HAEMOSTASIS, V84, P925; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010; WORSLEY DF, 1994, ARCH INTERN MED, V154, P2737, DOI 10.1001/archinte.1994.00420230134016	90	141	144	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2003	138	12					941	951		10.7326/0003-4819-138-12-200306170-00005	http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YM	12809450				2022-12-28	WOS:000183578100001
J	McKee, RA; Walker, FJ; Nardelli, MB; Shelton, WA; Stocks, GM				McKee, RA; Walker, FJ; Nardelli, MB; Shelton, WA; Stocks, GM			The interface phase and the Schottky barrier for a crystalline dielectric on silicon	SCIENCE			English	Article							METAL-SEMICONDUCTOR INTERFACES; BAND OFFSETS; GAP STATES; HETEROJUNCTION; HEIGHTS; GROWTH; OXIDES; MODEL	The barrier height for electron exchange at a dielectric-semiconductor interface has long been interpreted in terms of Schottky's theory with modi. cations from gap states induced in the semiconductor by the bulk termination. Rather, we show with the structure specifics of heteroepitaxy that the electrostatic boundary conditions can be set in a distinct interface phase that acts as a "Coulomb buffer." This Coulomb buffer is tunable and will functionalize the barrier-height concept itself.	Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA; Univ Tennessee, Knoxville, TN 37996 USA; N Carolina State Univ, Raleigh, NC 27695 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; University of North Carolina; North Carolina State University	McKee, RA (corresponding author), Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA.	mckeera@ornl.gov	Stocks, George Malcollm/Q-1251-2016; Nardelli, Marco Buongiorno/AAO-8938-2020; Nardelli, Marco Buongiorno/C-9089-2009	Stocks, George Malcollm/0000-0002-9013-260X; Nardelli, Marco Buongiorno/0000-0003-0793-5055; Walker, Frederick/0000-0002-8094-249X				ANDERSON RL, 1962, SOLID STATE ELECTRON, V5, P341, DOI 10.1016/0038-1101(62)90115-6; BALDERESCHI A, 1988, PHYS REV LETT, V61, P734, DOI 10.1103/PhysRevLett.61.734; BARONI S, PLANE WAVE SELF CONS; Demkov AA, 1999, PHYS REV LETT, V83, P2038, DOI 10.1103/PhysRevLett.83.2038; Franciosi A, 1996, SURF SCI REP, V25, P1, DOI 10.1016/0167-5729(95)00008-9; FRENSLEY WR, 1977, PHYS REV B, V16, P2642, DOI 10.1103/PhysRevB.16.2642; Ghosez P, 2000, APPL PHYS LETT, V76, P2767, DOI 10.1063/1.126469; HARRISON WA, 1986, J VAC SCI TECHNOL B, V4, P1068, DOI 10.1116/1.583544; HARRISON WA, 1978, PHYS REV B, V18, P4402, DOI 10.1103/PhysRevB.18.4402; KRAUT EA, 1980, PHYS REV LETT, V44, P1623; Leonard F, 2000, PHYS REV LETT, V84, P4693, DOI 10.1103/PhysRevLett.84.4693; LOUIE SG, 1976, PHYS REV B, V13, P2461, DOI 10.1103/PhysRevB.13.2461; MCKEE RA, 1994, PHYS REV LETT, V72, P2741, DOI 10.1103/PhysRevLett.72.2741; MCKEE RA, 1993, APPL PHYS LETT, V63, P2818, DOI 10.1063/1.110297; McKee RA, 1998, PHYS REV LETT, V81, P3014, DOI 10.1103/PhysRevLett.81.3014; McKee RA, 2001, SCIENCE, V293, P468, DOI 10.1126/science.293.5529.468; Monch W, 1998, APPL PHYS LETT, V72, P1899, DOI 10.1063/1.121220; Monch W, 2001, SEMICONDUCTOR SURFAC; Mott NF, 1938, P CAMB PHILOS SOC, V34, P568, DOI 10.1017/S0305004100020570; PERESSI M, 1991, PHYS REV B, V43, P7347, DOI 10.1103/PhysRevB.43.7347; Robertson J, 2000, J VAC SCI TECHNOL B, V18, P1785, DOI 10.1116/1.591472; SCHOTTKY W, 1940, PHYS Z, V113, P367; Stoneham A.M., 2002, COMPILATION CRYSTAL; Sutton AP, 1995, INTERFACES CRYSTALLI, P349; TERSOFF J, 1984, PHYS REV LETT, V52, P465, DOI 10.1103/PhysRevLett.52.465; Tung RT, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.205310; Tung RT, 2001, MAT SCI ENG R, V35, P1, DOI 10.1016/S0927-796X(01)00037-7; Tung RT, 2000, PHYS REV LETT, V84, P6078, DOI 10.1103/PhysRevLett.84.6078	28	154	158	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1726	1730		10.1126/science.1083894	http://dx.doi.org/10.1126/science.1083894			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805542				2022-12-28	WOS:000183459700045
J	Kovalchuk, I; Kovalchuk, O; Kalck, V; Boyko, V; Filkowski, J; Heinlein, M; Hohn, B				Kovalchuk, I; Kovalchuk, O; Kalck, V; Boyko, V; Filkowski, J; Heinlein, M; Hohn, B			Pathogen-induced systemic plant signal triggers DNA rearrangements	NATURE			English	Article							TOBACCO MOSAIC-VIRUS; HOMOLOGOUS RECOMBINATION; TRANSPOSABLE ELEMENTS; MAIZE; ARABIDOPSIS; RESISTANCE; INFECTION; INDUCTION; RADIATION	Plant genome stability is known to be affected by various abiotic environmental conditions(1-7), but little is known about the effect of pathogens. For example, exposure of maize plants to barley stripe mosaic virus seems to activate transposable elements(8,9) and to cause mutations in the non-infected progeny of infected plants(10). The induction by barley stripe mosaic virus of an inherited effect may mean that the virus has a non-cell-autonomous influence on genome stability. Infection with Peronospora parasitica results in an increase in the frequency of somatic recombination in Arabidopsis thaliana(11); however, it is unclear whether effects on recombination require the presence of the pathogen or represent a systemic plant response. It is also not clear whether the changes in the frequency of somatic recombination can be inherited. Here we report a threefold increase in homologous recombination frequency in both infected and noninfected tissue of tobacco plants infected with either tobacco mosaic virus(12) or oilseed rape mosaic virus(13). These results indicate the existence of a systemic recombination signal that also results in an increased frequency of meiotic and/or inherited late somatic recombination.	Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada; Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland	University of Lethbridge; Friedrich Miescher Institute for Biomedical Research	Kovalchuk, I (corresponding author), Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.							Aguilar I, 1996, PLANT MOL BIOL, V30, P191, DOI 10.1007/BF00017814; Boyko V, 2000, NAT CELL BIOL, V2, P826, DOI 10.1038/35041072; BRAKKE MK, 1984, ANNU REV PHYTOPATHOL, V22, P77, DOI 10.1146/annurev.py.22.090184.000453; BURK L. G., 1964, TOBACCO SCI, V8, P101; DELLAPORTA SL, 1984, COLD SPRING HARB SYM, V49, P321, DOI 10.1101/SQB.1984.049.01.038; Dempsey DA, 1999, CRIT REV PLANT SCI, V18, P547, DOI 10.1080/07352689991309397; Dong XN, 2001, CURR OPIN PLANT BIOL, V4, P309, DOI 10.1016/S1369-5266(00)00178-3; Gorbunova V, 2000, PLANT J, V24, P601, DOI 10.1046/j.1365-313x.2000.00905.x; Harrison BD, 1999, PHILOS T ROY SOC B, V354, P521, DOI 10.1098/rstb.1999.0403; JOHNS MA, 1985, EMBO J, V4, P1093, DOI 10.1002/j.1460-2075.1985.tb03745.x; Karpinski S, 1999, SCIENCE, V284, P654, DOI 10.1126/science.284.5414.654; Kovalchuk I, 1998, NAT BIOTECHNOL, V16, P1054, DOI 10.1038/3505; Kumar A, 1999, ANNU REV GENET, V33, P479, DOI 10.1146/annurev.genet.33.1.479; Lucht JM, 2002, NAT GENET, V30, P311, DOI 10.1038/ng846; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PUCHTA H, 1995, PLANT J, V7, P203, DOI 10.1046/j.1365-313X.1995.7020203.x; Ries G, 2000, P NATL ACAD SCI USA, V97, P13425, DOI 10.1073/pnas.230251897; Ries G, 2000, NATURE, V406, P98, DOI 10.1038/35017595; Shalev G, 1999, P NATL ACAD SCI USA, V96, P7398, DOI 10.1073/pnas.96.13.7398; WALBOT V, 1992, MOL GEN GENET, V234, P353, DOI 10.1007/BF00538694; Walbot V, 1999, NATURE, V397, P398, DOI 10.1038/17043; Waterhouse PM, 2001, TRENDS PLANT SCI, V6, P297, DOI 10.1016/S1360-1385(01)01989-6; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	23	209	227	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					760	762		10.1038/nature01683	http://dx.doi.org/10.1038/nature01683			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802336				2022-12-28	WOS:000183443400045
J	Yamauchi, T; Kamon, J; Ito, Y; Tsuchida, A; Yokomizo, T; Kita, S; Sugiyama, T; Miyagishi, M; Hara, K; Tsunoda, M; Murakami, K; Ohteki, T; Uchida, S; Takekawa, S; Waki, H; Tsuno, NH; Shibata, Y; Terauchi, Y; Froguel, P; Tobe, K; Koyasu, S; Taira, K; Kitamura, T; Shimizu, T; Nagai, R; Kadowaki, T				Yamauchi, T; Kamon, J; Ito, Y; Tsuchida, A; Yokomizo, T; Kita, S; Sugiyama, T; Miyagishi, M; Hara, K; Tsunoda, M; Murakami, K; Ohteki, T; Uchida, S; Takekawa, S; Waki, H; Tsuno, NH; Shibata, Y; Terauchi, Y; Froguel, P; Tobe, K; Koyasu, S; Taira, K; Kitamura, T; Shimizu, T; Nagai, R; Kadowaki, T			Cloning of adiponectin receptors that mediate antidiabetic metabolic effects	NATURE			English	Article							ACTIVATED PROTEIN-KINASE; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; EXPRESSION; EFFICIENT; ADIPOSE; OBESITY; MICE	Adiponectin (also known as 30-kDa adipocyte complement-related protein; Acrp30)(1-4) is a hormone secreted by adipocytes that acts as an antidiabetic(5-12) and anti-atherogenic(8,12,13) adipokine. Levels of adiponectin in the blood are decreased under conditions of obesity, insulin resistance and type 2 diabetes(2). Administration of adiponectin causes glucose-lowering effects and ameliorates insulin resistance in mice(5-7). Conversely, adiponectin-deficient mice exhibit insulin resistance and diabetes(8,9). This insulin-sensitizing effect of adiponectin seems to be mediated by an increase in fatty-acid oxidation through activation of AMP kinase(10,11) and PPAR-alpha(5,6,12). Here we report the cloning of complementary DNAs encoding adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2) by expression cloning(14-16). AdipoR1 is abundantly expressed in skeletal muscle, whereas AdipoR2 is predominantly expressed in the liver. These two adiponectin receptors are predicted to contain seven transmembrane domains, but to be structurally and functionally distinct from G-protein-coupled receptors(17-19). Expression of AdipoR1/R2 or suppression of AdipoR1/R2 expression by small-interfering RNA 20 supports our conclusion that they serve as receptors for globular and full-length adiponectin, and that they mediate increased AMP kinase(10,11) and PPAR-alpha ligand activities(12), as well as fatty-acid oxidation and glucose uptake by adiponectin.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Nissan Chem Ind Co Ltd, Biol Res Labs, Saitama 3490294, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan; JST, PRESTO, Kawaguchi, Japan; Univ Tokyo, Inst Med Sci, Div Hematopoiet Factors, Tokyo 1088639, Japan; Univ Tokyo, Sch English, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Natl Inst AIST, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 1608582, Japan; Univ Tokyo, Grad Sch Med, Dept Transfus Med, Tokyo 1138655, Japan; Inst Pasteur, CNRS, Inst Biol, UPRES A8090, F-59000 Lille, France	University of Tokyo; Japan Science & Technology Agency (JST); Nissan Chemical Corporation; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Keio University; University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan.		FROGUEL, Philippe/O-6799-2017; Koyasu, Shigeo/J-5583-2015; Adiels, Martin/C-9278-2011; Miyagishi, Makoto/L-8174-2016; Terauchi, Yasuo/AAO-4347-2020; Yokomizo, Takehiko/P-5673-2016; Waki, Hironori/AAE-3942-2020; sheng, jian/E-9474-2012	FROGUEL, Philippe/0000-0003-2972-0784; Koyasu, Shigeo/0000-0001-9585-3038; Miyagishi, Makoto/0000-0001-7654-3616; Yokomizo, Takehiko/0000-0002-5219-1553; Waki, Hironori/0000-0002-5302-9793; 	Medical Research Council [G0000477] Funding Source: Medline; MRC [G0000477] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Karpichev IV, 2002, J BIOL CHEM, V277, P19609, DOI 10.1074/jbc.M202045200; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Michael I, 1998, EUR MASS SPECTROM, V4, P1; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P802; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	27	2426	2699	5	187	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					762	769		10.1038/nature01705	http://dx.doi.org/10.1038/nature01705			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802337				2022-12-28	WOS:000183443400046
J	Riddler, SA; Smit, E; Cole, SR; Li, R; Chmiel, JS; Dobs, A; Palella, F; Visscher, B; Evans, R; Kingsley, LA				Riddler, SA; Smit, E; Cole, SR; Li, R; Chmiel, JS; Dobs, A; Palella, F; Visscher, B; Evans, R; Kingsley, LA			Impact of HIV infection and HAART on serum lipids in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	10th Conference on Retroviruses and Opportunistic Infections	FEB 10-14, 2003	BOSTON, MA				INSULIN-RESISTANCE; PROTEASE; HYPERLIPIDEMIA; THERAPY; LIPODYSTROPHY; LIPOPROTEINS	Context Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values. Objective To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation. Design, Setting, and Participants The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002. Main Outcome Measures Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit. Results Among the 50 men, notable declines in mean serum TC (-30 mg/dL [-0.78 mmol/L]) HDL-C (-12 mg/dL [-0.31 mmol/L]), and LDL-C values (-22 mg/dL [-0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], -1 to 41) and -1 mg/dL <LF>(-0.03 mmol/L) (95% Cl, -25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL). Conclusions Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.	Univ Pittsburgh, Pittsburgh, PA USA; SUNY Buffalo, Buffalo, NY 14260 USA; Johns Hopkins Univ, Baltimore, MD USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Calif Los Angeles, Los Angeles, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Johns Hopkins University; Northwestern University; University of California System; University of California Los Angeles	Riddler, SA (corresponding author), 613 Falk Bldg,3601 5th Ave, Pittsburgh, PA 15213 USA.	riddler@msx.dept-med.pitt.edu		Kingsley, Lawrence/0000-0002-7000-8556	NIAID NIH HHS [U01 AI 35041, U01 AI 46383, P01 AI 43664, U01-AI-35039] Funding Source: Medline; NIDCR NIH HHS [DE 15166] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035041, P01AI043664, U01AI046383, U01AI035039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE015166] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; Berthold HK, 1999, J INTERN MED, V246, P567, DOI 10.1046/j.1365-2796.1999.00615.x; Bonnet F, 2000, J ACQ IMMUN DEF SYND, V25, P199, DOI 10.1097/00126334-200010010-00017; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Dong KL, 1999, J ACQ IMMUN DEF SYND, V21, P107; FRIISMOLLER F, 2003, 10 C RETR OPP INF FE; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; Henry K, 1998, LANCET, V352, P1031, DOI 10.1016/S0140-6736(98)00022-1; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700; Rifai N, 1998, CLIN CHEM, V44, P1242; Roberts AD, 1999, CLIN INFECT DIS, V29, P441, DOI 10.1086/520231; SHORPOSNER G, 1993, AM J MED, V94, P515, DOI 10.1016/0002-9343(93)90087-6; STASZEWSKI S, 2003, 10 C RETR OPP INF FE; *US DEP HHS, 1996, 3RD NAT HLTH NUTR EX; WARNICK GR, 1978, J LIPID RES, V19, P65	25	435	447	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					2978	2982		10.1001/jama.289.22.2978	http://dx.doi.org/10.1001/jama.289.22.2978			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	687XZ	12799406	Green Published, Bronze			2022-12-28	WOS:000183403400021
J	Barton, GM; Medzhitov, R				Barton, GM; Medzhitov, R			Toll-like receptor signaling pathways	SCIENCE			English	Editorial Material							TIRAP	Members of the Toll-like receptor (TLR) family recognize conserved microbial structures, such as bacterial lipopolysaccharide and viral double-stranded RNA, and activate signaling pathways that result in immune responses against microbial infections. All TLRs activate MyD88-dependent pathways to induce a core set of stereotyped responses, such as inflammation. However, individual TLRs can also induce immune responses that are tailored to a given microbial infection. Thus, these receptors are involved in both innate and adaptive immune responses. The mechanisms and components of these varied responses are only partly understood. Given the importance of TLRs in host defense, dissection of the pathways they activate has become an important emerging research focus. TLRs and their pathways are numerous; Science's Signal Transduction Knowledge Environment's TLR Connections Map provides an immediate, clear overview of the known components and relations of this complex system.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 300 Cedar St,CAB S660, New Haven, CT 06520 USA.			Barton, Gregory/0000-0002-3793-0100				BARTON G, 2003, SCI STKE; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668	9	1019	1083	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1524	1525		10.1126/science.1085536	http://dx.doi.org/10.1126/science.1085536			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791976				2022-12-28	WOS:000183333100036
J	Anest, V; Hanson, JL; Cogswell, PC; Steinbrecher, KA; Strahl, BD; Baldwin, AS				Anest, V; Hanson, JL; Cogswell, PC; Steinbrecher, KA; Strahl, BD; Baldwin, AS			A nucleosomal function for I kappa B kinase-alpha in NF-kappa B-dependent gene expression	NATURE			English	Article							HISTONE H3; NEMO/IKK-GAMMA; IKK-ALPHA; PHOSPHORYLATION; ACETYLATION; INDUCTION; ACTIVATION; PATHWAY; BETA	NF-kappaB is a principal transcriptional regulator of diverse cytokine-mediated processes and is tightly controlled by the IkappaB kinase complex (IKK-alpha/beta/gamma). IKK-beta and IKK-gamma are critical for cytokine-induced NF-kappaB function, whereas IKK-alpha is thought to be involved in other regulatory pathways(1-4). However, recent data suggest a role for IKK-alpha in NF-kappaB-dependent gene expression in response to cytokine treatment(1,5-7). Here we demonstrate nuclear accumulation of IKK-alpha after cytokine exposure, suggesting a nuclear function for this protein. Consistent with this, chromatin immunoprecipitation (ChIP) assays reveal that IKK-alpha was recruited to the promoter regions of NF-kappaB-regulated genes on stimulation with tumour-necrosis factor-alpha. Notably, NF-kappaB-regulated gene expression is suppressed by the loss of IKK-alpha and this correlates with a complete loss of gene-specific phosphorylation of histone H3 on serine 10, a modification previously associated with positive gene expression. Furthermore, we show that IKK-alpha can directly phosphorylate histone H3 in vitro, suggesting a new substrate for this kinase. We propose that IKK-alpha is an essential regulator of NF-kappaB-dependent gene expression through control of promoter-associated histone phosphorylation after cytokine exposure. These findings provide additional insight into the role of the IKK complex in NF-kappaB-regulated gene expression.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.		Strahl, Brian/C-7601-2012	Strahl, Brian/0000-0002-4947-6259				Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	22	454	476	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					659	663		10.1038/nature01648	http://dx.doi.org/10.1038/nature01648			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789343	Green Submitted			2022-12-28	WOS:000183301200045
J	Sanchez-Lavega, A; Perez-Hoyos, S; Rojas, JF; Hueso, R; French, RG				Sanchez-Lavega, A; Perez-Hoyos, S; Rojas, JF; Hueso, R; French, RG			A strong decrease in Saturn's equatorial jet at cloud level	NATURE			English	Article							ZONAL WINDS; ATMOSPHERIC DYNAMICS; OUTER PLANETS; TROPOSPHERE; DISTURBANCE; CONVECTION; STABILITY; MODEL; WAVE	The atmospheres of the giant planets Jupiter and Saturn have a puzzling system of zonal (east-west) winds alternating in latitude, with the broad and intense equatorial jets on Saturn having been observed previously to reach a velocity of about 470 m s(-1) at cloud level(1). Globally, the location and intensity of Jupiter's jets are stable in time to within about ten per cent(2,3), but little is known about the stability of Saturn's jet system. The long-term behaviour of these winds is an important discriminator between models for giant-planet circulations(4-9). Here we report that Saturn's winds show a large drop in the velocity of the equatorial jet of about 200 m s(-1) from 1996 to 2002. By contrast, the other measured jets (primarily in the southern hemisphere) appear stable when compared to the Voyager wind profile of 1980-81.	Univ Basque Country, Escuela Super Ingn, Dept Fis Aplicada 1, Bilbao 48013, Spain; Univ Basque Country, EUITI, Dept Fis Aplicada 1, Bilbao 48013, Spain; Wellesley Coll, Dept Astron, Wellesley, MA 02481 USA	University of Basque Country; University of Basque Country; Wellesley College	Sanchez-Lavega, A (corresponding author), Univ Basque Country, Escuela Super Ingn, Dept Fis Aplicada 1, Alameda Urquijo S-N, Bilbao 48013, Spain.	wupsalaa@bi.ehu.es	Sanchez-Lavega, Agustin/Z-3639-2019; Palenzuela, Jose Felix Rojas/H-2782-2015; Hueso, Ricardo/Z-3277-2019; Perez-Hoyos, Santiago/L-7543-2014	Palenzuela, Jose Felix Rojas/0000-0002-1102-5612; Hueso, Ricardo/0000-0003-0169-123X; Perez-Hoyos, Santiago/0000-0002-2587-4682; Sanchez-Lavega, Agustin/0000-0001-7355-1522; Sanchez-Lavega, Agustin/0000-0001-7234-7634				Acarreta JR, 1999, ICARUS, V137, P24, DOI 10.1006/icar.1998.6034; BARNET CD, 1992, ICARUS, V100, P499, DOI 10.1016/0019-1035(92)90113-L; BARNET CD, 1992, ICARUS, V98, P94, DOI 10.1016/0019-1035(92)90210-X; BEEBE RF, 1992, ICARUS, V95, P163, DOI 10.1016/0019-1035(92)90035-6; BUSSE FH, 1976, ICARUS, V29, P255, DOI 10.1016/0019-1035(76)90053-1; Cho JYK, 1996, SCIENCE, V273, P335, DOI 10.1126/science.273.5273.335; Garcia-Melendo E, 2001, ICARUS, V152, P316, DOI 10.1006/icar.2001.6646; INGERSOLL AP, 1982, ICARUS, V52, P62, DOI 10.1016/0019-1035(82)90169-5; INGERSOLL AP, 1990, SCIENCE, V248, P308, DOI 10.1126/science.248.4953.308; INGERSOLL AP, 1984, SATURN, P195; KARKOSCHKA E, 1992, ICARUS, V97, P161, DOI 10.1016/0019-1035(92)90125-Q; LINDAL GF, 1985, ASTRON J, V90, P1136, DOI 10.1086/113820; Porco CC, 2003, SCIENCE, V299, P1541, DOI 10.1126/science.1079462; Sanchez-Lavega A, 1999, PLANET SPACE SCI, V47, P1277, DOI 10.1016/S0032-0633(99)00050-1; SANCHEZ-LAVEGA A, 1982, ICARUS, V49, P1, DOI 10.1016/0019-1035(82)90052-5; Sanchez-Lavega A, 2000, ICARUS, V147, P405, DOI 10.1006/icar.2000.6449; Sanchez-Lavega A, 2002, ICARUS, V158, P272, DOI 10.1006/icar.2002.6864; Sanchez-Lavega A, 2002, ICARUS, V160, P216, DOI 10.1006/icar.2002.6947; SANCHEZLAVEGA A, 1993, J GEOPHYS RES-PLANET, V98, P18857, DOI 10.1029/93JE01777; SanchezLavega A, 1996, SCIENCE, V271, P631, DOI 10.1126/science.271.5249.631; SANCHEZLAVEGA A, 1991, NATURE, V353, P397, DOI 10.1038/353397a0; TOMASKO MG, 1994, SATURN, P150; WILLIAMS GP, 1985, ADV GEOPHYS, V28, P381; Yano JI, 2003, NATURE, V421, P36, DOI 10.1038/421036a; Zhang KK, 2000, SCIENCE, V290, P1944, DOI 10.1126/science.290.5498.1944	26	65	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2003	423	6940					623	625		10.1038/nature01653	http://dx.doi.org/10.1038/nature01653			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789333	Bronze			2022-12-28	WOS:000183301200035
J	Holmes, KV; Enjuanes, L				Holmes, KV; Enjuanes, L			The SARS coronavirus: A postgenomic era	SCIENCE			English	Editorial Material							REVERSE GENETICS; VIRUS GENOME; CDNA		Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Madrid, Spain	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Holmes, KV (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, 4200 E 9th Ave, Denver, CO 80262 USA.	kathryn.holmes@UCHSC.edu; L.Enjuanes@cnb.uam.es	Enjuanes, Luis/F-7845-2016	Enjuanes, Luis/0000-0002-0854-0226				Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516; ANAND K, 2003, SCIENCE         0513, DOI DOI 10.1126/SCIENCE.1085658; Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001; Enjuanes L, 2001, J BIOTECHNOL, V88, P183, DOI 10.1016/S0168-1656(01)00281-4; Lai M.M.C., 2001, FIELDS VIROLOGY, P1163; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Masters PS, 1999, ADV VIRUS RES, V53, P245, DOI 10.1016/S0065-3527(08)60351-6; Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; RUAN YJ, 2003, LANCET, V361; Sola I, 2003, J VIROL, V77, P4357, DOI 10.1128/JVI.77.7.4357-4369.2003; Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273; Yount B, 2002, J VIROL, V76, P11065, DOI 10.1128/JVI.76.21.11065-11078.2002	13	98	114	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1377	1378		10.1126/science.1086418	http://dx.doi.org/10.1126/science.1086418			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775826				2022-12-28	WOS:000183181800028
J	Mandal, M; Boese, B; Barrick, JE; Winkler, WC; Breaker, RR				Mandal, M; Boese, B; Barrick, JE; Winkler, WC; Breaker, RR			Riboswitches control fundamental biochemical pathways in Bacillus subtilis and other bacteria	CELL			English	Article							GENE-EXPRESSION; SMALL MOLECULES; MESSENGER-RNA; BINDING; OPERON; TRANSCRIPTION; BIOSYNTHESIS; ATTENUATION; METABOLISM; PROTEIN	Riboswitches are metabolite binding domains within certain messenger RNAs that serve as precision sensors for their corresponding targets. Allosteric rearrangement of mRNA structure is mediated by ligand binding, and this results in modulation of gene expression. We have identified a class of riboswitches that selectively recognizes guanine and becomes saturated at concentrations as low as 5 nM. In Bacillus subtilis, this mRNA motif is located on at least five separate transcriptional units that together encode 17 genes that are mostly involved in purine transport and purine nucleotide biosynthesis. Our findings provide further examples of mRNAs that sense metabolites and that control gene expression without the need for protein factors. Furthermore, it is now apparent that riboswitches contribute to the regulation of numerous fundamental metabolic pathways in certain bacteria.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Chem Engn, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Breaker, RR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.		Barrick, Jeffrey/A-3046-2012; Breaker, Ronald/E-9679-2010	Barrick, Jeffrey/0000-0003-0888-7358; Breaker, Ronald/0000-0002-2165-536X	NIGMS NIH HHS [GM 559343] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auger S, 2002, MICROBIOL-SGM, V148, P507, DOI 10.1099/00221287-148-2-507; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; Christiansen LC, 1997, J BACTERIOL, V179, P2540, DOI 10.1128/jb.179.8.2540-2550.1997; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; Epshtein V, 2003, P NATL ACAD SCI USA, V100, P5052, DOI 10.1073/pnas.0531307100; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gold L, 1997, P NATL ACAD SCI USA, V94, P59, DOI 10.1073/pnas.94.1.59; Grundy FJ, 1998, MOL MICROBIOL, V30, P737, DOI 10.1046/j.1365-2958.1998.01105.x; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820; Jadhav VR, 2002, BIOCHIMIE, V84, P877, DOI 10.1016/S0300-9084(02)01404-9; Jeffares DC, 1998, J MOL EVOL, V46, P18, DOI 10.1007/PL00006280; Kiga D, 1998, NUCLEIC ACIDS RES, V26, P1755, DOI 10.1093/nar/26.7.1755; Matthews KS, 1998, PROG NUCLEIC ACID RE, V58, P127; MCCONNELL TS, 1993, P NATL ACAD SCI USA, V90, P8362, DOI 10.1073/pnas.90.18.8362; McDaniel BAM, 2003, P NATL ACAD SCI USA, V100, P3083, DOI 10.1073/pnas.0630422100; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; MOSZER I, 1995, MICROBIOL-SGM, V141, P261, DOI 10.1099/13500872-141-2-261; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; PTASHNE M, 2002, GENES SIGNALS; Rodionov DA, 2002, J BIOL CHEM, V277, P48949, DOI 10.1074/jbc.M208965200; Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723; Shu D, 2003, J BIOL CHEM, V278, P7119, DOI 10.1074/jbc.M209895200; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584; Stormo GD, 2001, P NATL ACAD SCI USA, V98, P9465, DOI 10.1073/pnas.181334498; Sudarsan N, 2003, RNA, V9, P644, DOI 10.1261/rna.5090103; Switzer R.L., 2002, BACILLUS SUBTILIS IT, P255; Switzer RL, 1999, PROG NUCLEIC ACID RE, V62, P329; Vitreschak AG, 2002, NUCLEIC ACIDS RES, V30, P3141, DOI 10.1093/nar/gkf433; WENG ML, 1995, P NATL ACAD SCI USA, V92, P7455, DOI 10.1073/pnas.92.16.7455; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899	35	536	577	1	82	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					577	586		10.1016/S0092-8674(03)00391-X	http://dx.doi.org/10.1016/S0092-8674(03)00391-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787499	Bronze			2022-12-28	WOS:000183397600008
J	Hack, M				Hack, M			Uses of error - Continuity of neonatal care	LANCET			English	Editorial Material									Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Hack, M (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, 11,100 Euclid Ave, Cleveland, OH 44106 USA.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1809	1809		10.1016/S0140-6736(03)13406-X	http://dx.doi.org/10.1016/S0140-6736(03)13406-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781552				2022-12-28	WOS:000183074800022
J	Wong, RSM; Wu, A; To, KF; Lee, N; Lam, CWK; Wong, CK; Chan, PKS; Ng, MHL; Yu, LM; Hui, DS; Tam, JS; Cheng, G; Sung, JJY				Wong, RSM; Wu, A; To, KF; Lee, N; Lam, CWK; Wong, CK; Chan, PKS; Ng, MHL; Yu, LM; Hui, DS; Tam, JS; Cheng, G; Sung, JJY			Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article							CYTOMEGALOVIRUS-INDUCED THROMBOCYTOPENIA; IMMUNODEFICIENCY-VIRUS INFECTION; IMMUNOCOMPETENT ADULT; MEGAKARYOCYTES	Objectives To evaluate the haematological findings of patients with severe acute respiratory syndrome (SARS). Design Analysis of the demographic, clinical, and laboratory characteristics of patients with SARS. Setting Prince of Wales Hospital, Hong Kong. Subjects All patients with a diagnosis of SARS between 11 March and 29 March 2003 who had no pre-existing haematological disorders. Main outcome measures Clinical end points included the need for intensive care and death. Univariate and multivariate analyses were performed to examine factors associated with adverse outcome. Results 64 male and 93 female patients were included in this study. The most common findings included lymphopenia in 153 (98%) of the 157 patients, neutrophilia in 129 (82% thrombocytopenia in 87 patients (55%), followed by thrombocytosis in 77 (49%), and isolated prolonged activated partial thromboplastin time in 96 patients (63%). The haemoglobin count dropped by more than 20 g/l from baseline in 95 (61%) patients. Four patients (2.5%) developed disseminated intravascular coagulation. Lymphopenia was shown in haemato-lymphoid organs at postmortem examination. Multivariate analysis showed that advanced age and a high concentration of lactate dehydrogenase at presentation were independent predictors of an adverse outcome. Subsets of peripheral blood lymphocytes were analysed in 31 patients. The counts of CD4 positive and CD8 positive T cells fell early in the course of illness. Low counts of CD4 and CD8 cells at presentation were associated with adverse outcomes. Conclusions Abnormal haematological variables were common among patients with SARS. Lymphopenia and the depletion of T lymphocyte subsets may be associated with disease activity.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Ctr Clin Trials & Epidemiol Res, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Sung, JJY (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.		Sung, Joseph J. Y./R-3203-2018; Chan, Paul KS/J-9360-2013; Wong, Raymond S. M./H-9644-2016; Wong, CK/H-3256-2016; Hui, David Shu-Cheong/O-2754-2015; Lee, Nelson/B-6418-2008	Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Paul KS/0000-0002-6360-4608; Wong, Raymond S. M./0000-0002-9011-4268; Wong, CK/0000-0002-5637-8331; Hui, David Shu-Cheong/0000-0003-4382-2445; Lee, Nelson/0000-0002-0783-6607; Yu, Ly-Mee/0000-0003-0331-7364				[Anonymous], 2003, MMWR MORB MORTAL WKL, V52, P226; BALLEM PJ, 1992, NEW ENGL J MED, V327, P1779, DOI 10.1056/NEJM199212173272503; CHESNEY PJ, 1978, J PEDIATR-US, V92, P957, DOI 10.1016/S0022-3476(78)80375-8; EISENBERG MJ, 1993, WESTERN J MED, V158, P525; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; MAURY CPJ, 1990, J INTERN MED, V227, P253, DOI 10.1111/j.1365-2796.1990.tb00154.x; MCCROMICK JB, 1986, NEW ENGL J MED, V314, P20; NINOMIYA N, 1977, HELV PAEDIATR ACTA, V32, P87; OSKI FA, 1966, NEW ENGL J MED, V275, P352, DOI 10.1056/NEJM196608182750703; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; ROBERTS RB, 1987, CLIN PHARMACOL THER, V42, P365, DOI 10.1038/clpt.1987.165; VANCAMPEN H, 1989, J GEN VIROL, V70, P467, DOI 10.1099/0022-1317-70-2-467; vanSpronsen DJ, 1996, BRIT J HAEMATOL, V92, P218; ZUCKERFRANKLIN D, 1994, SEMIN HEMATOL, V31, P329	16	397	430	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1358	1362		10.1136/bmj.326.7403.1358	http://dx.doi.org/10.1136/bmj.326.7403.1358			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816821	Bronze, Green Published			2022-12-28	WOS:000183756400017
J	Ost, D; Fein, AM; Feinsilver, SH				Ost, D; Fein, AM; Feinsilver, SH			The solitary pulmonary nodule	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THORACIC NEEDLE-BIOPSY; LUNG-CANCER; FDG-PET; CT; MALIGNANCY; MANAGEMENT; TOMOGRAPHY; MODEL; PROBABILITY; EXPERIENCE		N Shore Univ Hosp, Ctr Pulm & Crit Care Med, Manhasset, NY 11030 USA; NYU, Sch Med, New York, NY USA; SUNY Stony Brook, Stony Brook, NY 11794 USA	Northwell Health; North Shore University Hospital; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ost, D (corresponding author), N Shore Univ Hosp, Ctr Pulm & Crit Care Med, 300 Community Dr, Manhasset, NY 11030 USA.	dost@nshs.edu	Feinsilver, Steven H/AAD-6827-2022; Ost, David E./AAT-9505-2021	Ost, David E./0000-0001-6351-5552; Feinsilver, Steven/0000-0001-7193-4167				Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Berger WG, 2001, AM J ROENTGENOL, V176, P201, DOI 10.2214/ajr.176.1.1760201; BERQUIST TH, 1980, MAYO CLIN PROC, V55, P475; CONCES DJ, 1987, CHEST, V91, P813, DOI 10.1378/chest.91.6.813; CORTESE DA, 1981, CHEST, V79, P610, DOI 10.1378/chest.79.5.610; CUMMINGS SR, 1986, AM REV RESPIR DIS, V134, P449; Diederich S, 2000, CANCER, V89, P2483, DOI 10.1002/1097-0142(20001201)89:11+<2483::AID-CNCR27>3.0.CO;2-1; Erasmus JJ, 1998, AM J ROENTGENOL, V170, P1369, DOI 10.2214/ajr.170.5.9574618; FEIN AM, 1998, FISHMANS PULMONARY D, V110, P1727; Gambhir SS, 1998, J CLIN ONCOL, V16, P2113, DOI 10.1200/JCO.1998.16.6.2113; Gould MK, 2001, JAMA-J AM MED ASSOC, V285, P914, DOI 10.1001/jama.285.7.914; GUPTA NC, 1992, RADIOLOGY, V184, P441, DOI 10.1148/radiology.184.2.1620844; Henschke C I, 2000, Radiology, V215 Suppl, P607; HENSCHKE CI, 1987, J COMPUT ASSIST TOMO, V11, P432, DOI 10.1097/00004728-198705000-00012; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Higashi K, 1998, J NUCL MED, V39, P1016; HIGGINS GA, 1975, ARCH SURG-CHICAGO, V110, P570; HOLIN SM, 1959, AM REV TUBERC PULM, V79, P427; HUSTON J, 1987, RADIOLOGY, V163, P481, DOI 10.1148/radiology.163.2.3562830; KHOURI NF, 1987, CHEST, V91, P128, DOI 10.1378/chest.91.1.128; Marshall D, 2001, EUR J CANCER, V37, P1759, DOI 10.1016/S0959-8049(01)00205-2; MARTINI N, 1980, J THORAC CARDIOV SUR, V80, P390; Ost D, 2000, AM J RESP CRIT CARE, V162, P782, DOI 10.1164/ajrccm.162.3.9812152; RAY JF, 1976, CHEST, V70, P332, DOI 10.1378/chest.70.3.332; Schmid RA, 1998, AM J RESP CRIT CARE, V157, pA256; SIEGELMAN SS, 1986, RADIOLOGY, V160, P307, DOI 10.1148/radiology.160.2.3726105; STEELE JD, 1963, J THORAC CARDIOV SUR, V46, P21, DOI 10.1016/S0022-5223(19)33683-9; Swensen SJ, 1999, MAYO CLIN PROC, V74, P319, DOI 10.4065/74.4.319; Swensen SJ, 2002, AM J RESP CRIT CARE, V165, P508, DOI 10.1164/ajrccm.165.4.2107006; Swensen SJ, 1997, ARCH INTERN MED, V157, P849, DOI 10.1001/archinte.157.8.849; SWENSEN SJ, 1990, MAYO CLIN PROC, V65, P173, DOI 10.1016/S0025-6196(12)65012-5; Vansteenkiste JF, 1997, CHEST, V112, P1480, DOI 10.1378/chest.112.6.1480; Yankelevitz DF, 1997, AM J ROENTGENOL, V168, P325, DOI 10.2214/ajr.168.2.9016198; Yankelevitz DF, 1999, RADIOLOGY, V212, P561, DOI 10.1148/radiology.212.2.r99au33561; ZERHOUNI EA, 1986, RADIOLOGY, V160, P319, DOI 10.1148/radiology.160.2.3726107; Zhang MM, 1997, RADIOLOGY, V205, P471, DOI 10.1148/radiology.205.2.9356631	36	401	450	2	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2535	2542		10.1056/NEJMcp012290	http://dx.doi.org/10.1056/NEJMcp012290			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815140				2022-12-28	WOS:000183577200009
J	Stollewerk, A; Schoppmeier, M; Damen, WGM				Stollewerk, A; Schoppmeier, M; Damen, WGM			Involvement of Notch and Delta genes in spider segmentation	NATURE			English	Article							SIGNALING PATHWAY; CUPIENNIUS-SALEI; EXPRESSION; OSCILLATOR; SOMITE; HAIRY; PATTERN; FRINGE; HER1	It is currently debated whether segmentation in different animal phyla has a common origin and shares a common genetic mechanism(1,2). The apparent use of different genetic networks in arthropods and vertebrates has become a strong argument against a common origin of segmentation. Our knowledge of arthropod segmentation is based mainly on the insect Drosophila, in which a hierarchical cascade of transcription factors controls segmentation(3,4). The function of some of these genes seems to be conserved among arthropods, including spiders(5,6), but not vertebrates(1,6-8). The Notch pathway has a key role in vertebrate segmentation (somitogenesis) but is not involved in Drosophila body segmentation(1,7,9). Here we show that Notch and Delta genes are involved in segmentation of another arthropod, the spider Cupiennius salei. Expression patterns of Notch and Delta, coupled with RNA interference experiments, identify many similarities between spider segmentation and vertebrate somitogenesis. Our data indicate that formation of the segments in arthropods and vertebrates may have shared a genetic programme in a common ancestor and that parts of this programme have been lost in particular descendant lineages.	Univ Cologne, Inst Genet Evolutionary Genet, D-50931 Cologne, Germany	University of Cologne	Damen, WGM (corresponding author), Univ Cologne, Inst Genet Evolutionary Genet, Weyertal 121, D-50931 Cologne, Germany.	damen@uni-koeln.de						Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Anderson D. T., 1973, EMBRYOLOGY PHYLOGENY, P365, DOI [10.1016/B978-0-08-017069-5.50014-7, DOI 10.1016/B978-0-08-017069-5.50014-7]; Baonza A, 2001, DEVELOPMENT, V128, P3889; Bessho Y, 2001, GENE DEV, V15, P2642, DOI 10.1101/gad.930601; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Dale JK, 2003, NATURE, V421, P275, DOI 10.1038/nature01244; Damen WGM, 2000, P NATL ACAD SCI USA, V97, P4515, DOI 10.1073/pnas.97.9.4515; Damen WGM, 2002, DEVELOPMENT, V129, P1239; Davis G.K., 1999, TRENDS GENET, V9, pM68; Davis GK, 2002, ANNU REV ENTOMOL, V47, P669, DOI 10.1146/annurev.ento.47.091201.145251; de Celis JF, 1998, DEVELOPMENT, V125, P4617; Dearden P, 2000, DEV GENES EVOL, V210, P329, DOI 10.1007/s004270000072; DeRobertis EM, 1997, NATURE, V387, P25, DOI 10.1038/387025a0; Holley SA, 2000, GENE DEV, V14, P1678; Holley SA, 2002, DEVELOPMENT, V129, P1175; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; Jouve C, 2000, DEVELOPMENT, V127, P1421; Oates AC, 2002, DEVELOPMENT, V129, P2929; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Pankratz Michael J., 1993, P467; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; Pourquie O, 1999, CURR OPIN GENET DEV, V9, P559, DOI 10.1016/S0959-437X(99)00011-8; Saga Y, 2001, NAT REV GENET, V2, P835, DOI 10.1038/35098552; Schoppmeier M, 2001, DEV GENES EVOL, V211, P76, DOI 10.1007/s004270000121; Seitz K. H., 1966, Zoologische Jahrbuecher (Anatomie), V83, P327; STJOHNSTON D, 1992, CELL, V68, P201; Stollewerk A, 2002, DEVELOPMENT, V129, P5339, DOI 10.1242/dev.00109; Wiellette EL, 1999, DEVELOPMENT, V126, P1985	30	174	184	1	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					863	865		10.1038/nature01682	http://dx.doi.org/10.1038/nature01682			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815430				2022-12-28	WOS:000183585300044
J	Novelli, W				Novelli, W			Lefter from America	BRITISH MEDICAL JOURNAL			English	Article									AARP, Washington, DC 20049 USA	American Association of Retired Persons (AARP)	Novelli, W (corresponding author), AARP, Washington, DC 20049 USA.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1301	1301		10.1136/bmj.326.7402.1301	http://dx.doi.org/10.1136/bmj.326.7402.1301			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805162	Green Published			2022-12-28	WOS:000183626500026
J	Reddy, MM; Quinton, PM				Reddy, MM; Quinton, PM			Control of dynamic CFTR selectivity by glutamate and ATP in epithelial cells	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT HCO3 TRANSPORT; CYSTIC-FIBROSIS; CHLORIDE CONDUCTANCE; CHANNEL; RECEPTORS; DELTA-F508; ACTIVATION; MUTATIONS; BINDING	Cystic fibrosis is caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel(1). Phosphorylation and ATP hydrolysis are generally believed to be indispensable for activating CFTR2. Here we report phosphorylation- and ATP-independent activation of CFTR by cytoplasmic glutamate that exclusively elicits Cl-, but not HCO3-, conductance in the human sweat duct. We also report that the anion selectivity of glutamate-activated CFTR is not intrinsically fixed, but can undergo a dynamic shift to conduct HCO3- by a process involving ATP hydrolysis. Duct cells from patients with DeltaF508 mutant CFTR showed no glutamate/ATP activated Cl- or HCO3- conductance. In contrast, duct cells from heterozygous patients with R117H/DeltaF508 mutant CFTR also lost most of the Cl- conductance, yet retained significant HCO3- conductance. Hence, not only does glutamate control neuronal ion channels, as is well known, but it can also regulate anion conductance and selectivity of CFTR in native epithelial cells. The loss of this uniquely regulated HCO3- conductance is most probably responsible for the more severe forms of cystic fibrosis pathology.	Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of California System; University of California San Diego; University of California System; University of California Riverside	Reddy, MM (corresponding author), Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA.							ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; Cavalheiro EA, 2001, P NATL ACAD SCI USA, V98, P5947, DOI 10.1073/pnas.121179198; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DalL'Asta V, 1999, AM J PHYSIOL-CELL PH, V276, pC865, DOI 10.1152/ajpcell.1999.276.4.C865; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Duan SM, 2000, J NEUROPHYSIOL, V83, P31, DOI 10.1152/jn.2000.83.1.31; Durie PR, 1999, CYSTIC FIBROSIS IN ADULTS, P261; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; LEW TS, 1991, PEDIATR PULM, V6, P251; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Linsdell P, 1998, J GEN PHYSIOL, V111, P601, DOI 10.1085/jgp.111.4.601; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1999, PHYSIOL REV, V79, P3; RAJ D, 2001, AM J PHYSIOL-RENAL, V280, pF214; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Reddy MM, 2001, AM J PHYSIOL-CELL PH, V280, pC604, DOI 10.1152/ajpcell.2001.280.3.C604; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; RIORDAN JR, 1989, SCIENCE, V245, P1066; Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; Sohma Y, 2000, J MEMBRANE BIOL, V176, P77, DOI 10.1007/s002320001077; Welbourne T, 2001, AM J PHYSIOL-CELL PH, V280, pC1151, DOI 10.1152/ajpcell.2001.280.5.C1151; WOLLHEIM C, 2002, DIABETOLOGIA, V43, P265	30	88	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					756	760		10.1038/nature01694	http://dx.doi.org/10.1038/nature01694			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802335				2022-12-28	WOS:000183443400044
J	Gu, LH				Gu, LH			Comment on "Climate and management contributions to recent trends in US agricultural yields"	SCIENCE			English	Editorial Material									Oak Ridge Natl Lab, Div Environm Sci, Oak Ridge, TN 37830 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory	Gu, LH (corresponding author), Oak Ridge Natl Lab, Div Environm Sci, Oak Ridge, TN 37830 USA.		Gu, Lianhong/H-8241-2014	Gu, Lianhong/0000-0001-5756-8738				Lobell DB, 2003, SCIENCE, V299, P1032, DOI 10.1126/science.1077838	1	11	15	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791966				2022-12-28	WOS:000183333100024
J	Roland, ME; Havlir, DV				Roland, ME; Havlir, DV			Responding to organ failure in HIV-infected patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth program,AIDS Div, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Roland, ME (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth program,AIDS Div, San Francisco, CA 94143 USA.							Roland ME, 2003, TRANSPLANTATION, V75, P425, DOI 10.1097/01.TP.0000046943.35335.18	1	33	33	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2279	2281		10.1056/NEJMp030074	http://dx.doi.org/10.1056/NEJMp030074			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788990				2022-12-28	WOS:000183296300001
J	Watkins, C; Moore, L; Harvey, I; Carthy, P; Robinson, E; Brawn, R				Watkins, C; Moore, L; Harvey, I; Carthy, P; Robinson, E; Brawn, R			Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Backwell & Nailsea Med Grp, Bristol BS48 3HA, Avon, England; Cardiff Univ, Sch Social Sci, Cardiff CF10 3WT, S Glam, Wales; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Salisbury NHS Hlth Care Trust, Res & Dev Support Unit, Salisbury SP2 8BJ, Wilts, England; Bloomsbury Surg, London WC1N 1PB, England; Grad Sch Educ, Bristol BS8 1JA, Avon, England	Cardiff University; University of East Anglia; University of Bristol	Watkins, C (corresponding author), Backwell & Nailsea Med Grp, Bristol BS48 3HA, Avon, England.			Moore, Laurence/0000-0003-2182-823X				*AUD COMM, 1996, PRESCR MOV MOR RAT P, P9; Little P, 1997, BRIT MED J, V315, P350; LLOYD DCEF, 1995, BRIT MED J, V310, P165, DOI 10.1136/bmj.310.6973.165; MARSHALL T, 1997, BANDOLIER, V44, P1; WATKINS C, IN PRESS QUALITY SAF	5	60	65	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2003	326	7400					1178	1179		10.1136/bmj.326.7400.1178	http://dx.doi.org/10.1136/bmj.326.7400.1178			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775618	Green Published, Bronze			2022-12-28	WOS:000183309900020
J	Parry, G; Tucker, J; Tarnow-Mordi, W				Parry, G; Tucker, J; Tarnow-Mordi, W		UK Neonatal Staffing Study Collabo	CRIB II: an update of the clinical risk index for babies score	LANCET			English	Article								The clinical risk index for babies (CRIB) score is a risk-adjustment instrument widely used in neonatal intensive care. Its appropriateness with contemporary data has been questioned. We have examined these questions, developed a new five-item CRIB II score with data from a UK-wide sample of infants admitted to neonatal intensive care in 1998-99, and shown how mortality after neonatal intensive care has fallen in the past 12 years. CRIB II provides a recalibrated and simplified scoring system that avoids the potential problems of early treatment bias. A valid and simple method of risk-adjustment for neonatal intensive care is important to ensure accurate assessment of quality of care. Such assessments should be done in tandem with national audit systems for neonatal intensive care, incorporating measures of morbidity as well as mortality.	Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England; Univ Aberdeen, Dept Obstet & Gynaecol, Dugland Baird Ctr Res Womens Hlth, Aberdeen, Scotland; Univ Sydney, Westmead & Childrens Hosp Westmead, Sydney, NSW 2006, Australia	University of Sheffield; University of Aberdeen; University of Sydney	Parry, G (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Regent Court,30 Regent St, Sheffield S1 4DA, S Yorkshire, England.		Parry, Gareth/CAF-6975-2022					COCKBURN F, 1993, LANCET, V342, P193; Draper ES, 1999, BRIT MED J, V319, P1093, DOI 10.1136/bmj.319.7217.1093; Halm EA, 2001, NEW ENGL J MED, V345, P692, DOI 10.1056/NEJM200108303450911; Richardson DK, 1998, PEDIATRICS, V102, P893, DOI 10.1542/peds.102.4.893; Tucker J, 2002, LANCET, V359, P99	5	315	328	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1789	1791		10.1016/S0140-6736(03)13397-1	http://dx.doi.org/10.1016/S0140-6736(03)13397-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781540				2022-12-28	WOS:000183074800013
J	Insel, TR; Charney, DS				Insel, TR; Charney, DS			Research on major depression - Strategies and priorities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DISORDERS; MOOD; PREVENTION; DISCOVERY; SUICIDE; IMPACT		NIMH, Mood & Anxiety Disorders Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Insel, TR (corresponding author), NIMH, Mood & Anxiety Disorders Res Program, 6001 Execut Blvd,Room 8235, Bethesda, MD 20892 USA.							Cizza G, 2001, TRENDS ENDOCRIN MET, V12, P198, DOI 10.1016/S1043-2760(01)00407-6; Cloninger CR, 2002, P NATL ACAD SCI USA, V99, P13365, DOI 10.1073/pnas.222532599; Conwell Y, 2001, SUICIDE LIFE-THREAT, V31, P32, DOI 10.1521/suli.31.1.5.32.24221; CooperPatrick L, 1997, J GEN INTERN MED, V12, P431, DOI 10.1046/j.1525-1497.1997.00075.x; Craddock N, 1999, J MED GENET, V36, P585, DOI 10.1136/jmg.36.8.585; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; Goldsmith SK, 2002, RED SUIC NAT IMP, P33; Hawton K, 1999, BRIT J PSYCHIAT, V175, P271, DOI 10.1192/bjp.175.3.271; Hollon SD, 2002, BIOL PSYCHIAT, V52, P610, DOI 10.1016/S0006-3223(02)01384-7; Jiang W, 2002, CNS DRUGS, V16, P111, DOI 10.2165/00023210-200216020-00004; Krishnan KRR, 2002, BIOL PSYCHIAT, V52, P559, DOI 10.1016/S0006-3223(02)01472-5; Lustman PJ, 2002, J PSYCHOSOM RES, V53, P917, DOI 10.1016/S0022-3999(02)00416-6; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; *MNAT I MENT HLTH, 2003, REAL MEN REAL DEPR; National Institute of Mental Health, 2003, BREAK GROUND BREAK S; Tamminga CA, 2002, BIOL PSYCHIAT, V52, P589, DOI 10.1016/S0006-3223(02)01470-1; WHO, 2001, WORLD HLTH REPORT 20; World Health Organization (WHO), 2002, WHO INN CAR CHRON CO, P99; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	20	74	81	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3167	3168		10.1001/jama.289.23.3167	http://dx.doi.org/10.1001/jama.289.23.3167			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690QM	12813123				2022-12-28	WOS:000183560400032
J	Baldwin, E				Baldwin, E			Time for a fresh look at complementary medicine	BRITISH MEDICAL JOURNAL			English	Article									House Lords, London SW1A 0PW, England		Baldwin, E (corresponding author), House Lords, London SW1A 0PW, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1322	1322		10.1136/bmj.326.7402.1322	http://dx.doi.org/10.1136/bmj.326.7402.1322			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805177	Green Published			2022-12-28	WOS:000183626500041
J	Bastian, H				Bastian, H			Just how demanding can we get before we blow it?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cochrane Collaborat Consumer, Burwood, Vic 3125, Australia		Bastian, H (corresponding author), Cochrane Collaborat Consumer, POB 96, Burwood, Vic 3125, Australia.			Bastian, Hilda/0000-0001-8544-7386					0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1277	1277		10.1136/bmj.326.7402.1277	http://dx.doi.org/10.1136/bmj.326.7402.1277			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805127	Green Published			2022-12-28	WOS:000183626500003
J	Gold, ER				Gold, ER			SARS genome patent: symptom or disease?	LANCET			English	Editorial Material									McGill Univ, Fac Law, Ctr Intellectual Property Policy, Montreal, PQ H3A 1W9, Canada	McGill University	Gold, ER (corresponding author), McGill Univ, Fac Law, Ctr Intellectual Property Policy, Montreal, PQ H3A 1W9, Canada.	Richard.Gold2@McGill.ca		Gold, E. Richard/0000-0002-3789-9238				BRICKLEY P, 2003, SCIENTIST       0509; Cho MK, 2003, J MOL DIAGN, V5, P3, DOI 10.1016/S1525-1578(10)60444-8; Gold ER, 2002, NAT GENET, V30, P359, DOI 10.1038/ng0402-359; Gold ER, 2002, LANCET, V359, P2268, DOI 10.1016/S0140-6736(02)09298-X; GOLD ER, 2002, DEBATING BIOTECHNOLO, P163; Gold ER, 1999, COMMERCIALIZATION GE, P63; Gold R, 2002, CAN MED ASSOC J, V167, P256; Merz JF, 2002, NATURE, V415, P577, DOI 10.1038/415577a; *MIN HLTH LONG TER, 2002, GEN TEST GEN PAT CHA; *ORG EC COOP DEV, 2002, GEN INV INT PROP RIT	10	14	14	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2002	2003		10.1016/S0140-6736(03)13674-4	http://dx.doi.org/10.1016/S0140-6736(03)13674-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814707	Green Published, hybrid			2022-12-28	WOS:000183488900004
J	Wu, XL; Li, Y; Crise, B; Burgess, SM				Wu, XL; Li, Y; Crise, B; Burgess, SM			Transcription start regions in the human genome are favored targets for MLV integration	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; RETROVIRAL INTEGRATION; GENE-THERAPY; DIRECTS INTEGRATION; DNA; MINICHROMOSOMES; ISLANDS; SITES	Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus-1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units ( either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important rami. cations for gene therapy and may aid in our understanding of the factors directing the integration process.	NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Science Applications International Corporation (SAIC)	Burgess, SM (corresponding author), NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.	burgess@mail.nih.gov	Wilson, Matthew H/K-3193-2013	Burgess, Shawn/0000-0003-1147-0596	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000183] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BUSHMAN FD, 1994, P NATL ACAD SCI USA, V91, P9233, DOI 10.1073/pnas.91.20.9233; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Check E, 2002, NATURE, V420, P116, DOI 10.1038/420116a; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Kaiser J, 2003, SCIENCE, V299, P495, DOI 10.1126/science.299.5606.495; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; Pruitt KD, 2000, TRENDS GENET, V16, P44, DOI 10.1016/S0168-9525(99)01882-X; PRUSS D, 1994, J BIOL CHEM, V269, P25031; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, P NATL ACAD SCI USA, V89, P9237, DOI 10.1073/pnas.89.19.9237; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; SCATCHERI P, COMMUNICATION; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Weidhaas JB, 2000, J VIROL, V74, P8382, DOI 10.1128/JVI.74.18.8382-8389.2000	18	1033	1101	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1749	1751		10.1126/science.1083413	http://dx.doi.org/10.1126/science.1083413			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805549				2022-12-28	WOS:000183459700052
J	Gallin, JI; Alling, DW; Malech, HL; Wesley, R; Koziol, D; Marciano, B; Eisenstein, EM; Turner, ML; DeCarlo, ES; Starling, JM; Holland, SM				Gallin, JI; Alling, DW; Malech, HL; Wesley, R; Koziol, D; Marciano, B; Eisenstein, EM; Turner, ML; DeCarlo, ES; Starling, JM; Holland, SM			Itraconazole to prevent fungal infections in chronic granulomatous disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVASIVE PULMONARY ASPERGILLOSIS; NEUTROPENIC PATIENTS; PHARMACOKINETICS; TRIMETHOPRIM; PROPHYLAXIS; THERAPY	Background: Chronic granulomatous disease is a rare disorder in which the phagocytes fail to produce hydrogen peroxide. The patients are predisposed to bacterial and fungal infections. Prophylactic antibiotics and interferon gamma have reduced bacterial infections, but there is also the danger of life-threatening fungal infections. We assessed the efficacy of itraconazole as prophylaxis against serious fungal infections in chronic granulomatous disease. Methods: Thirty-nine patients at least 5 years old (6 female and 33 male; mean age, 14.9 years) were enrolled in a randomized, double-blind, placebo-controlled study. After the initially assigned treatment, each patient alternated between itraconazole and placebo annually. Patients 13 years of age or older and all patients weighing at least 50 kg received a single dose of 200 mg of itraconazole per day; those less than 13 years old or weighing less than 50 kg received a single dose of 100 mg per day. The primary end point was severe fungal infection, as determined by histologic results or culture. Results: One patient (who had not been compliant with the treatment) had a serious fungal infection while receiving itraconazole, as compared with seven who had a serious fungal infection while receiving placebo (P=0.10). No patient receiving itraconazole but five patients receiving placebo had a superficial fungal infection. No serious toxic effects were noted, although one patient had a rash and another had elevated results on liver-function tests; both of these effects resolved with the discontinuation of itraconazole. Conclusions: Itraconazole prophylaxis appears to be an effective and well-tolerated treatment that reduces the frequency of fungal infections in chronic granulomatous disease, but monitoring for long-term toxic effects is warranted.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gallin, JI (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 2C128, Bethesda, MD 20892 USA.			Malech, Harry/0000-0001-5874-5775	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000155, Z01AI000645, ZIAAI000645, Z01AI000646, Z01AI000155, ZIAAI000646] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad SR, 2001, LANCET, V357, P1766, DOI 10.1016/S0140-6736(00)04891-1; Caillot D, 2001, CLIN INFECT DIS, V33, pE83, DOI 10.1086/323020; Chariyalertsak S, 2002, CLIN INFECT DIS, V34, P277, DOI 10.1086/338154; COHEN MS, 1981, AM J MED, V71, P59, DOI 10.1016/0002-9343(81)90259-X; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GALLIN JI, 1983, ANN INTERN MED, V99, P657, DOI 10.7326/0003-4819-99-5-657; Gupta AK, 1998, INT J DERMATOL, V37, P303, DOI 10.1046/j.1365-4362.1998.00360.x; HARDIN TC, 1988, ANTIMICROB AGENTS CH, V32, P1310, DOI 10.1128/AAC.32.9.1310; HEYKANTS J, 1989, MYCOSES, V32, P67, DOI 10.1111/j.1439-0507.1989.tb02296.x; Lamy T, 1998, LEUKEMIA LYMPHOMA, V30, P163, DOI 10.3109/10428199809050939; Lekstrom-Himes JA, 2000, NEW ENGL J MED, V343, P1703, DOI 10.1056/NEJM200012073432307; MARGOLIS DM, 1990, J INFECT DIS, V162, P723, DOI 10.1093/infdis/162.3.723; Myoken Y, 2002, J PERIODONTOL, V73, P33, DOI 10.1902/jop.2002.73.1.33; Smith D E, 2001, HIV Med, V2, P78, DOI 10.1046/j.1468-1293.2001.00060.x; VANCAUTEREN H, 1987, REV INFECT DIS, V9, pS43; VANPEER A, 1989, EUR J CLIN PHARMACOL, V36, P423, DOI 10.1007/BF00558308; WEENING RS, 1983, J PEDIATR-US, V103, P127, DOI 10.1016/S0022-3476(83)80798-7; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	20	237	252	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2416	2422		10.1056/NEJMoa021931	http://dx.doi.org/10.1056/NEJMoa021931			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802027				2022-12-28	WOS:000183428900007
J	de Silva, HA; Fonseka, MMD; Pathmeswaran, A; Alahakone, DGS; Ratnatilake, GA; Gunatilake, SB; Ranasinha, CD; Lalloo, DG; Aronson, JK; de Silva, HJ				de Silva, HA; Fonseka, MMD; Pathmeswaran, A; Alahakone, DGS; Ratnatilake, GA; Gunatilake, SB; Ranasinha, CD; Lalloo, DG; Aronson, JK; de Silva, HJ			Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial	LANCET			English	Article							THEVETIA-PERUVIANA; SRI-LANKA; DIGOXIN; RAT	Background Deliberate self-poisoning with yellow oleander seeds is common in Sri Lanka and is associated with severe cardiac toxicity and a mortality rate of about 10%. Specialised treatment with antidigoxin Fab fragments and temporary cardiac pacing is expensive and not widely available. Multiple-dose activated charcoal binds cardiac glycosides in the gut lumen and promotes their elimination. We aimed to assess the efficacy of multiple-dose activated charcoal in the treatment of patients with yellow-oleander poisoning. Methods On admission, participants received one dose of activated charcoal and were then randomly assigned either 50 g of activated charcoal every 6 h for 3 days or sterile water as placebo. A standard treatment protocol was used in all patients. We monitored cardiac rhythm and did 12-lead electocardiographs as needed. Death was the primary endpoint, and secondary endpoints were life-threatening cardiac arrhythmias, dose of atropine used, need for cardiac pacing, admission to intensive care, and number of days in hospital. Analysis was by intention to treat. Findings 201 patients received multiple-dose activated charcoal and 200 placebo. There were fewer deaths in the treatment group (five [2.5%] vs 16 [8%]; percentage difference 5.5%; 95% Cl 0.6-10.3; p=0.025), and we noted difference in favour of the treatment group for all secondary endpoints, apart from number of days in hospital. The drug was safe and well tolerated. Interpretation Multiple-dose activated charcoal is effective in reducing deaths and life-threatening cardiac arrhythmias after yellow oleander poisoning and should be considered in all patients.	Univ Kelaniya, Fac Med, Dept Pharmacol, Ragama, Sri Lanka; Teaching Hosp, Kurunegala, Sri Lanka; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Oxford, Dept Clin Pharmacol, Oxford, England	University Kelaniya; Liverpool School of Tropical Medicine; University of Liverpool; University of Oxford	de Silva, HA (corresponding author), Univ Kelaniya, Fac Med, Dept Pharmacol, POB 6, Ragama, Sri Lanka.	asita@mfac.kln.ac.lk	Pathmeswaran, Arunasalam/H-5650-2019	Pathmeswaran, Arunasalam/0000-0003-4065-2639; Lalloo, David/0000-0001-7680-2200				Am Acad Clin Toxicology, 1999, J TOXICOL-CLIN TOXIC, V37, P731; CALDWELL JH, 1980, N-S ARCH PHARMACOL, V312, P271, DOI 10.1007/BF00499157; CHYKA PA, 1995, ANN EMERG MED, V25, P356, DOI 10.1016/S0196-0644(95)70295-4; Eddleston M, 1999, TROP MED INT HEALTH, V4, P266, DOI 10.1046/j.1365-3156.1999.00397.x; Eddleston M, 2000, LANCET, V355, P967, DOI 10.1016/S0140-6736(00)90014-X; Eddleston M, 1998, BRIT MED J, V317, P133, DOI 10.1136/bmj.317.7151.133; Eddleston M, 2000, HEART, V83, P301, DOI 10.1136/heart.83.3.301; Fonseka MMD, 2002, HUM EXP TOXICOL, V21, P293, DOI 10.1191/0960327102ht257oa; IBANEZ C, 1995, INT J CARDIOL, V48, P27, DOI 10.1016/0167-5273(94)02212-2; LALONDE RL, 1985, CLIN PHARMACOL THER, V37, P367, DOI 10.1038/clpt.1985.55; Langford SD, 1996, TOXICOLOGY, V109, P1, DOI 10.1016/0300-483X(95)03296-R; Pearn J., 1989, TOXIC PLANTS ANIMALS, P37; Stephens RH, 2001, J PHARMACOL EXP THER, V296, P584	13	69	71	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1935	1938		10.1016/S0140-6736(03)13581-7	http://dx.doi.org/10.1016/S0140-6736(03)13581-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801736				2022-12-28	WOS:000183359700008
J	Fenton, KA; Ison, C; Johnson, AP; Rudd, E; Soltani, M; Martin, I; Nichols, T; Livermore, DM				Fenton, KA; Ison, C; Johnson, AP; Rudd, E; Soltani, M; Martin, I; Nichols, T; Livermore, DM		GRASP Collaboration	Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002	LANCET			English	Article								The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) monitors trends in antimicrobial resistance in consecutive gonococcal isolates from 26 genitourinary medicine clinics in England and Wales. In 2002, 2204 gonococcal isolates were tested, and the overall prevalence of ciprofloxacin resistance (minimum Inhibitory concentration greater than or equal to1 mg/L) was 9.8%, compared with 3.1% in 2001 and 2.1% in 2000. Between 2001 and 2002, prevalence of ciprofloxacin resistance increased two to three-fold, irrespective of recent sexual contact overseas, sex, or residence within or outside of London. These findings suggest that national and local treatment guidelines need to be reviewed urgently.	Hlth Protect Agcy, HIV STI Div, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; Hlth Protect Agcy, Cent Publ Hlth Lab, London NW9 5EQ, England; UCL Royal Free & UCL Med Sch, Ctr Infect Dis Epidemiol, Dept Primary Care, London, England; UCL Royal Free & UCL Med Sch, Ctr Infect Dis Epidemiol, Dept Populat Sci, London, England; UCL Royal Free & UCL Med Sch, Ctr Infect Dis Epidemiol, Dept Sexually Transmitted Dis, London, England; Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Microbiol, London, England	Health Protection Agency; Health Protection Agency; Public Health England; University of London; University College London; University of London; University College London; University of London; University College London; Imperial College London	Fenton, KA (corresponding author), Hlth Protect Agcy, HIV STI Div, Ctr Communicable Dis Surveillance, 61 Colindale Ave, London NW9 5EQ, England.	kevin.fenton@hpa.org.uk	Johnson, Alan P/F-4420-2014					*CDC, 2002, SEX TRANSM DIS SURV; *CLIN EFF GROUP AS, 2001 NAT GUID MAN GO; *GRASP STEER GROUP, 2002, GON RES ANT SURV PRO; HARDIH J, SMALL SAMPLE ADJUSTM; Ross JDC, 2002, INT J STD AIDS, V13, P499, DOI 10.1258/09564620260079671	5	75	78	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1867	1869		10.1016/S0140-6736(03)13489-7	http://dx.doi.org/10.1016/S0140-6736(03)13489-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788575				2022-12-28	WOS:000183205800013
J	Kryukov, GV; Castellano, S; Novoselov, SV; Lobanov, AV; Zehtab, O; Guigo, R; Gladyshev, VN				Kryukov, GV; Castellano, S; Novoselov, SV; Lobanov, AV; Zehtab, O; Guigo, R; Gladyshev, VN			Characterization of mammalian selenoproteomes	SCIENCE			English	Article							RNA STRUCTURAL MOTIF; SELENOCYSTEINE INSERTION; CONTAINING PROTEINS; MESSENGER-RNAS; HUMAN GENOME; IN-SILICO; SELENIUM; IDENTIFICATION; SEQUENCE; TRANSLATION	In the genetic code, UGA serves as a stop signal and a selenocysteine codon, but no computational methods for identifying its coding function are available. Consequently, most selenoprotein genes are misannotated. We identified selenoprotein genes in sequenced mammalian genomes by methods that rely on identification of selenocysteine insertion RNA structures, the coding potential of UGA codons, and the presence of cysteine-containing homologs. The human selenoproteome consists of 25 selenoproteins.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Pompeu Fabra, Ctr Regulacio Genom, Inst Municipal Invest Med, Grp Recerca Informat Biomed, Barcelona 08003, Catalonia, Spain	University of Nebraska System; University of Nebraska Lincoln; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	; Castellano, Sergi/A-7437-2016	Novoselov, Sergey/0000-0003-0104-6492; Castellano, Sergi/0000-0002-5819-4210; Gladyshev, Vadim/0000-0002-0372-7016; Kryukov, Gregory/0000-0002-6131-9483	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61603] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behne D, 1996, BIOL TRACE ELEM RES, V55, P99, DOI 10.1007/BF02784172; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Bock A, 2000, Biofactors, V11, P77; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Castellano S, 2001, EMBO REP, V2, P697, DOI 10.1093/embo-reports/kve151; Cataldo L, 1996, MOL REPROD DEV, V45, P320, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;320::AID-MRD9&gt;3.0.CO;2-U; Combs GF, 2001, BIOFACTORS, V14, P153, DOI 10.1002/biof.5520140120; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Kent WJ, 2001, GENOME RES, V11, P1541, DOI 10.1101/gr.183201; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kryukov GV, 2002, METHOD ENZYMOL, V347, P84; KRYUKOV GV, UNPUB; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Martin-Romero FJ, 2001, J BIOL CHEM, V276, P29798, DOI 10.1074/jbc.M100422200; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Walczak R, 1996, RNA, V2, P367	27	1690	1799	15	235	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1439	1443		10.1126/science.1083516	http://dx.doi.org/10.1126/science.1083516			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775843	Green Submitted			2022-12-28	WOS:000183181800048
J	Dillingham, MS; Spies, M; Kowalczykowski, SC				Dillingham, MS; Spies, M; Kowalczykowski, SC			RecBCD enzyme is a bipolar DNA helicase	NATURE			English	Article							SINGLE-STRANDED-DNA; RECOMBINATION HOTSPOT-CHI; ESCHERICHIA-COLI; NUCLEASE ACTIVITY; ATP HYDROLYSIS; PCRA HELICASE; STEP-SIZE; PROTEIN; TRANSLOCATION; SEQUENCE	Escherichia coli RecBCD is a heterotrimeric helicase/nuclease that catalyses a complex reaction in which double-strand breaks in DNA are processed for repair by homologous recombination(1). For some time it has been clear that the RecB subunit possesses a 3'-->5' DNA helicase activity(2-4), which was thought to drive DNA translocation and unwinding in the RecBCD holoenzyme. Here we show that purified RecD protein is also a DNA helicase, but one that possesses a 5'-->3' polarity. We also show that the RecB and RecD helicases are both active in intact RecBCD, because the enzyme remains capable of processive DNA unwinding when either of these subunits is inactivated by mutation. These findings point to a bipolar translocation model for RecBCD in which the two DNA helicases are complementary, travelling with opposite polarities, but in the same direction, on each strand of the antiparallel DNA duplex. This bipolar motor organization helps to explain various biochemical properties of RecBCD, notably its exceptionally high speed and processivity, and offers a mechanistic insight into aspects of RecBCD function.	Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu		Spies, Maria/0000-0002-7375-8037; Dillingham, Mark/0000-0002-4612-7141				Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Arnold DA, 1998, J BIOL CHEM, V273, P16476, DOI 10.1074/jbc.273.26.16476; ARNOLD DA, 1999, ENCY LIFE SCI; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; Bianco PR, 2000, NATURE, V405, P368, DOI 10.1038/35012652; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; Chen HW, 1997, J BIOL CHEM, V272, P10072; Chen HW, 1998, J MOL BIOL, V278, P89, DOI 10.1006/jmbi.1998.1694; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; HSIEH S, 1992, NUCLEIC ACIDS RES, V20, P5647, DOI 10.1093/nar/20.21.5647; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; KORANGY F, 1992, J BIOL CHEM, V267, P1727; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Phillips RJ, 1997, MOL GEN GENET, V254, P319, DOI 10.1007/PL00008605; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 2003, NATURE; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Yu M, 1998, P NATL ACAD SCI USA, V95, P981, DOI 10.1073/pnas.95.3.981; Zhang XJJ, 1999, NUCLEIC ACIDS RES, V27, P4200, DOI 10.1093/nar/27.21.4200	30	162	171	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					893	897		10.1038/nature01673	http://dx.doi.org/10.1038/nature01673			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815438				2022-12-28	WOS:000183585300052
J	Koh, D; Cook, GJR; Husband, JE				Koh, D; Cook, GJR; Husband, JE			New horizons in oncologic imaging	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Royal Marsden Hosp, Acad Dept Radiol, Sutton, Surrey, England	Royal Marsden NHS Foundation Trust	Koh, D (corresponding author), Royal Marsden Hosp, Acad Dept Radiol, Sutton, Surrey, England.			Koh, Dow-Mu/0000-0001-7654-8011; Cook, Gary/0000-0002-8732-8134					0	24	26	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2487	2488		10.1056/NEJMp030048	http://dx.doi.org/10.1056/NEJMp030048			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815132				2022-12-28	WOS:000183577200001
J	Rozen, S; Skaletsky, H; Marszalek, JD; Minx, PJ; Cordum, HS; Waterston, RH; Wilson, RK; Page, DC				Rozen, S; Skaletsky, H; Marszalek, JD; Minx, PJ; Cordum, HS; Waterston, RH; Wilson, RK; Page, DC			Abundant gene conversion between arms of palindromes in human and ape Y chromosomes	NATURE			English	Article							HUMAN-POPULATIONS; EVOLUTION; DAZ; REARRANGEMENTS; DUPLICATION; HOMINIDS; FAMILY; REGION	Eight palindromes comprise one-quarter of the euchromatic DNA of the male-specific region of the human Y chromosome, the MSY1. They contain many testis-specific genes and typically exhibit 99.97% intra-palindromic (arm-to-arm) sequence identity(1). This high degree of identity could be interpreted as evidence that the palindromes arose through duplication events that occurred about 100,000 years ago. Using comparative sequencing in great apes, we demonstrate here that at least six of these MSY palindromes predate the divergence of the human and chimpanzee lineages, which occurred about 5 million years ago. The arms of these palindromes must have subsequently engaged in gene conversion, driving the paired arms to evolve in concert. Indeed, analysis of MSY palindrome sequence variation in existing human populations provides evidence of recurrent arm-to-arm gene conversion in our species. We conclude that during recent evolution, an average of approximately 600 nucleotides per newborn male have undergone Y-Y gene conversion, which has had an important role in the evolution of multi-copy testis gene families in the MSY.	MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL)	Page, DC (corresponding author), MIT, Whitehead Inst Biomed Res, Howard Hughes Med Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	page_admin@wi.mit.edu	Wilson, Richard K./AAF-4139-2019; Rozen, Steven G./J-5939-2013	Wilson, Richard K./0000-0002-1992-1358; Rozen, Steven G./0000-0002-4288-0056				Agulnik AI, 1998, HUM MOL GENET, V7, P1371, DOI 10.1093/hmg/7.9.1371; Aradhya S, 2001, HUM MOL GENET, V10, P2557, DOI 10.1093/hmg/10.22.2557; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bohossian HB, 2000, NATURE, V406, P622, DOI 10.1038/35020557; CASANOVA M, 1985, SCIENCE, V230, P1403, DOI 10.1126/science.2999986; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; DEEB SS, 1994, P NATL ACAD SCI USA, V91, P7262, DOI 10.1073/pnas.91.15.7262; Fujiyama A, 2002, SCIENCE, V295, P131, DOI 10.1126/science.1065199; Glaser B, 1998, MAMM GENOME, V9, P226, DOI 10.1007/s003359900730; JACKSON JA, 1981, NATURE, V292, P306, DOI 10.1038/292306a0; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Kawaguchi TK, 2001, NAT GENET, V29, P279, DOI 10.1038/ng757; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Makova KD, 2002, NATURE, V416, P624, DOI 10.1038/416624a; MURTI JR, 1992, MOL CELL BIOL, V12, P2545, DOI 10.1128/MCB.12.6.2545; OHTA T, 1982, P NATL ACAD SCI-BIOL, V79, P3251, DOI 10.1073/pnas.79.10.3251; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Rochette CF, 2001, HUM GENET, V108, P255, DOI 10.1007/s004390100473; Saxena R, 2000, GENOMICS, V67, P256, DOI 10.1006/geno.2000.6260; Shen PD, 2000, P NATL ACAD SCI USA, V97, P7354, DOI 10.1073/pnas.97.13.7354; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Small K, 1997, NAT GENET, V16, P96, DOI 10.1038/ng0597-96; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; Zhou YH, 1996, MOL BIOL EVOL, V13, P780, DOI 10.1093/oxfordjournals.molbev.a025638	28	412	442	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					873	876		10.1038/nature01723	http://dx.doi.org/10.1038/nature01723			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815433				2022-12-28	WOS:000183585300047
J	Center, C; Davis, M; Detre, T; Ford, DE; Hansbrough, W; Hendin, H; Laszlo, J; Litts, DA; Mann, J; Mansky, PA; Michels, R; Miles, SH; Proujansky, R; Reynolds, CF; Silverman, MM				Center, C; Davis, M; Detre, T; Ford, DE; Hansbrough, W; Hendin, H; Laszlo, J; Litts, DA; Mann, J; Mansky, PA; Michels, R; Miles, SH; Proujansky, R; Reynolds, CF; Silverman, MM			Confronting depression and suicide in physicians - A consensus statement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-LICENSURE-APPLICATIONS; MENTAL-HEALTH-SERVICES; GENERAL-PRACTITIONERS; CARE; MORTALITY; DOCTORS; PREVENTION; STUDENTS; DISORDERS; SPECIALTY	Objective To encourage treatment of depression and prevention of suicide in physicians by calling for a shift in professional attitudes and institutional policies to support physicians seeking help. Participants An American Foundation for Suicide Prevention planning group invited 15 experts on the subject to evaluate the state of knowledge about physician depression and suicide and barriers to treatment. The group assembled for a workshop held October 6-7, 2002, in Philadelphia, Pa. Evidence The planning group worked with each participant on a preworkshop literature review in an assigned area. Abstracts of presentations and key publications were distributed to participants before the workshop. After workshop presentations, participants were assigned to 1, of 2 breakout groups: (1) physicians in their role as patients and (2) medical institutions and professional organizations. The groups-identified areas that required further research, barriers to treatment, and recommendations for reform. Consensus Process This consensus statement emerged from a plenary session during which each work group presented its recommendations. The consensus statement was circulated to and approved by all participants. Conclusions The culture of medicine accords low priority to physician mental health despite evidence of untreated mood disorders and an increased burden of suicide. Barriers to physicians' seeking help are often punitive, including discrimination in medical licensing, hospital privileges, and professional advancement. This consensus statement recommends transforming professional attitudes and changing institutional policies to encourage physicians to seek help. As barriers are removed and physicians confront depression and suicidality in their peers, they are more likely to recognize and treat these conditions in patients, including colleagues and medical students.	Univ Calif San Francisco, Hastings Coll Law, San Francisco, CA 94102 USA; Univ Calif San Francisco, Employment Law Ctr, San Francisco, CA USA; George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC USA; Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA; Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Hlth Policy & Management, Baltimore, MD USA; Univ Calif San Diego, Med Ctr, Dept Educ Res & Dev, San Diego, CA 92103 USA; New York Med Coll, Dept Psychiat, New York, NY USA; Amer Canc Soc, Atlanta, GA 30329 USA; Off US Surg Gen, Washington, DC USA; Columbia Univ, Med Ctr, Dept Psychiat, New York, NY USA; Med Soc State New York, Comm Phys Hlth, Albany, NY USA; Albany Med Coll Union Univ, Albany Coll, Dept Psychopharmacol, Albany, NY 12208 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Payne Whitney Clin, New York, NY USA; Univ Minnesota, Sch Med, Dept Med & Geriatr, Minneapolis, MN 55455 USA; Alfred I duPont Hosp Children, Wilmington, DE USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA; Natl Suicide Prevent Resource Ctr, Newton, MA USA; Univ Chicago, Sch Med, Dept Psychiat, Chicago, IL 60637 USA; Amer Fdn Suicide Prevent, New York, NY 10005 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; George Washington University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California San Diego; New York Medical College; American Cancer Society; Columbia University; Albany Medical College; Cornell University; University of Minnesota System; University of Minnesota Twin Cities; Nemours Alfred I. duPont Hospital for Children; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; University of Chicago	Hendin, H (corresponding author), Amer Fdn Suicide Prevent, 120 Wall St, New York, NY 10005 USA.	hhendin@afsp.org						*AMA COUNC SCI AFF, 1986, CONN MED, V50, P37; American Psychiatric Association, 1984, AM J PSYCHIAT, V141, P331; Appleby L, 1996, BRIT J PSYCHIAT, V168, P330, DOI 10.1192/bjp.168.3.330; Berg AO, 2002, ANN INTERN MED, V136, P760, DOI 10.7326/0003-4819-136-10-200205210-00012; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Bucknill JC, 1858, MANUAL PSYCHOL MED; Carpenter LM, 1997, OCCUP ENVIRON MED, V54, P388, DOI 10.1136/oem.54.6.388; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P656; Centers for Disease Control and Prevention (CDC), 1999, MMWR-MORBID MORTAL W, V48, P1053; CUMMINGS KM, 1987, AM J PREV MED, V3, P69; Fawcett J, 1991, Psychiatr Med, V9, P299; Ford DE, 1998, ARCH INTERN MED, V158, P1422, DOI 10.1001/archinte.158.13.1422; Frank E, 1999, AM J PSYCHIAT, V156, P1887; Frank E, 2000, AM J PREV MED, V19, P155, DOI 10.1016/S0749-3797(00)00201-4; FRANK E, 1995, PREV MED, V24, P543, DOI 10.1006/pmed.1995.1086; Givens JL, 2002, ACAD MED, V77, P918, DOI 10.1097/00001888-200209000-00024; Goldsmith S.K., 2002, REDUCING SUICIDE NAT; Gross CP, 2000, ARCH INTERN MED, V160, P3209, DOI 10.1001/archinte.160.21.3209; Hansen TE, 1998, PSYCHIATR SERV, V49, P202, DOI 10.1176/ps.49.2.202; Hawton K, 2001, J EPIDEMIOL COMMUN H, V55, P296, DOI 10.1136/jech.55.5.296; HBOLMES VF, 1990, SUICIDE LIFE CYCLE R, P599; ISOMETSA ET, 1995, AM J PSYCHIAT, V152, P919; Kaiser Family Foundation, 2002, NAT SURV PHYS 3; LEVINE RE, 2000, HOSP PHYS, V36, P67; Levine RE, 2000, HOSP PHYS, V36, P86; Lindeman S, 1996, BRIT J PSYCHIAT, V168, P274, DOI 10.1192/bjp.168.3.274; Lindeman S, 1998, ARCH SUICIDE RES, V4, P135, DOI 10.1023/A:1009663803540; LINN LS, 1985, JAMA-J AM MED ASSOC, V254, P2775, DOI 10.1001/jama.254.19.2775; Luoma JB, 2002, AM J PSYCHIAT, V159, P909, DOI 10.1176/appi.ajp.159.6.909; Maltsberger JT, 2003, SUICIDE LIFE-THREAT, V33, P111, DOI 10.1521/suli.33.2.111.22778; Mann JJ, 2002, ANN INTERN MED, V136, P302, DOI 10.7326/0003-4819-136-4-200202190-00010; Mansky PA, 1996, PSYCHIATR SERV, V47, P465; MATTHEWS K, 1994, BRIT J GEN PRACT, V44, P345; Miles SH, 1998, JAMA-J AM MED ASSOC, V280, P865, DOI 10.1001/jama.280.10.865; NELSON DE, 1994, JAMA-J AM MED ASSOC, V271, P1273, DOI 10.1001/jama.271.16.1273; Office of the Surgeon General, 2019, SURG GEN ADV MAR US; OPPENHEIMER K, 1987, J MED EDUC, V62, P504; *PHS, 2001, NAT STRAT SUIC PREV; Pirkis J, 1998, BRIT J PSYCHIAT, V173, P462, DOI 10.1192/bjp.173.6.462; PLAUT SM, 1993, ACAD MED, V68, P360, DOI 10.1097/00001888-199305000-00019; Roberts LW, 1996, ACAD MED, V71, P1225, DOI 10.1097/00001888-199611000-00019; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P83, DOI 10.1111/j.1600-0447.1992.tb01448.x; Sansome RA, 1999, ARCH FAM MED, V8, P448, DOI 10.1001/archfami.8.5.448; Shaffer D, 1999, J CLIN PSYCHIAT, V60, P70; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; SILVERMAN M, 2000, HDB PHYSICIAN HLTH E; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; Simon GE, 2001, J OCCUP ENVIRON MED, V43, P2, DOI 10.1097/00043764-200101000-00002; Torre DM, 2000, J GEN INTERN MED, V15, P150; VAILLANT GE, 1972, NEW ENGL J MED, V287, P372, DOI 10.1056/NEJM197208242870802; WELLS KB, 1984, JAMA-J AM MED ASSOC, V252, P2846, DOI 10.1001/jama.252.20.2846; WHO, 2002, WORLD HLTH REP 2001; Williams JW, 1999, ARCH FAM MED, V8, P58, DOI 10.1001/archfami.8.1.58; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55; ZOCCOLILLO M, 1986, J AFFECT DISORDERS, V11, P91, DOI 10.1016/0165-0327(86)90065-0	56	397	405	1	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3161	3166		10.1001/jama.289.23.3161	http://dx.doi.org/10.1001/jama.289.23.3161			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690QM	12813122				2022-12-28	WOS:000183560400031
J	Powsner, S; Spitzer, R				Powsner, S; Spitzer, R			Sex, lies, and medical compliance	LANCET			English	Editorial Material							PATIENT NONCOMPLIANCE; PAPER		Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Surg Emergency Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Med Informat, New Haven, CT 06520 USA; Conexions Ltd, Highland Pk, IL USA	Yale University; Yale University; Yale University	Powsner, S (corresponding author), Yale Univ, Sch Med, Dept Psychiat, 333 Cedar St, New Haven, CT 06520 USA.	seth.powsner@yale.edu						Adam D, 2003, NATURE, V421, P775, DOI 10.1038/421775a; [Anonymous], 2003, BBC NEWS 0523; Bok S, 1978, LYING MORAL CHOICE P; CARVEL J, 2003, GUARDIAN        0524; DIDLAKE RH, 1988, TRANSPLANT P, V20, P63; Eichenwald K, 1999, NY TIMES, pA16; EICHENWALD K, 1997, NY TIMES        1221; Eichenwald Kurt, 1999, N Y Times Web, pA16; Ferner RE, 2000, LANCET, V355, P947, DOI 10.1016/S0140-6736(00)99025-1; Kastrissios H, 1996, CLIN PHARMACOL THER, V59, P577, DOI 10.1016/S0009-9236(96)90186-1; Kohn LT., 2000, ERR IS HUMAN BUILDIN; LOWRY F, 1994, CAN MED ASSOC J, V151, P835; Parson T., 1951, SOCIAL SYSTEM; Safer DJ, 2002, J NERV MENT DIS, V190, P583, DOI 10.1097/00005053-200209000-00002; Sibbald B, 2000, CAN MED ASSOC J, V163, P591; Simmons MS, 2000, CHEST, V118, P290, DOI 10.1378/chest.118.2.290; Stone AA, 2003, CONTROL CLIN TRIALS, V24, P182, DOI 10.1016/S0197-2456(02)00320-3; VINCENT P, 1971, NURS RES, V20, P509; Weiss RB, 2000, LANCET, V355, P999, DOI 10.1016/S0140-6736(00)90024-2; 1994, LANCET, V343, P1443	20	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2003	2004		10.1016/S0140-6736(03)13675-6	http://dx.doi.org/10.1016/S0140-6736(03)13675-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814708				2022-12-28	WOS:000183488900005
J	Kraus, WL; Lis, JT				Kraus, WL; Lis, JT			PARP goes transcription	CELL			English	Review							POLY(ADP-RIBOSE) POLYMERASE BINDS; GENE-EXPRESSION; DEPENDENT TRANSCRIPTION; CHROMATIN STRUCTURE; COACTIVATOR; PROMOTER; NUCLEOSOME		Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University; Cornell University	Lis, JT (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.				NIDDK NIH HHS [R01 DK069710] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069710] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; Alvarez-Gonzalez R, 1999, MOL CELL BIOCHEM, V193, P19, DOI 10.1023/A:1006979220009; AME JC, 2000, DNA DAMAGE STRESS SI, P1; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; Griesenbeck J, 1999, FEBS LETT, V443, P20, DOI 10.1016/S0014-5793(98)01671-8; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; Kraus WL, 2002, EUR J BIOCHEM, V269, P2275, DOI 10.1046/j.1432-1033.2002.02889.x; Kun E, 2002, J BIOL CHEM, V277, P39066, DOI 10.1074/jbc.C200410200; Lee D, 2002, ONCOGENE, V21, P5877, DOI 10.1038/sj.onc.1205723; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; MALIK N, 1984, BIOCHEMISTRY-US, V23, P3721, DOI 10.1021/bi00311a023; MATHIS G, 1987, BIOCHEM BIOPH RES CO, V143, P1049, DOI 10.1016/0006-291X(87)90358-5; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; REALINI CA, 1992, J BIOL CHEM, V267, P18858; Rolli V., 2000, DNA DAMAGE STRESS SI, P35; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; VAQUERO A, 2003, SCI SAGE KE     0409; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	35	446	457	1	18	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 13	2003	113	6					677	683		10.1016/S0092-8674(03)00433-1	http://dx.doi.org/10.1016/S0092-8674(03)00433-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809599	Bronze			2022-12-28	WOS:000183514400003
J	Itoh, S; Yurimoto, H				Itoh, S; Yurimoto, H			Contemporaneous formation of chondrules and refractory inclusions in the early Solar System	NATURE			English	Article							ALUMINUM-RICH INCLUSIONS; CRYSTALLIZATION SEQUENCES; OXYGEN ISOTOPES; ALLENDE; NEBULA; CHONDRITES; METEORITES; MELILITE; ORIGIN; RAYS	Chondrules and calcium-aluminium-rich inclusions (CAIs) are preserved materials from the early history of the Solar System, where they resulted from thermal processing of pre-existing solids during various flash heating episodes which lasted for several million years(1). CAIs are believed to have formed about two million years before the chondrules(2-5). Here we report the discovery of a chondrule fragment embedded in a CAI. The chondrule's composition is poor in O-16, while the CAI has a O-16-poor melilite (Ca, Mg, Al-Silicate) core surrounded by a O-16-rich igneous mantle. These observations, when combined with the previously reported CAI-bearing chondrules(6-9),strongly suggest that the formation of chondrules and CAIs overlapped in time and space, and that there were large fluctuations in the oxygen isotopic compositions in the solar nebula probably synchronizing astrophysical pulses.	Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, Tokyo 1528551, Japan	Tokyo Institute of Technology	Yurimoto, H (corresponding author), Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, Tokyo 1528551, Japan.		Yurimoto, Hisayoshi/S-9938-2018	Yurimoto, Hisayoshi/0000-0003-0702-0533; Itoh, Shoichi/0000-0001-9431-0525				Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; BISCHOFF A, 1984, GEOCHIM COSMOCHIM AC, V48, P693, DOI 10.1016/0016-7037(84)90096-6; CAMERON AGW, 1995, METEORITICS, V30, P133, DOI 10.1111/j.1945-5100.1995.tb01110.x; CHEN JH, 1976, GEOCHIM COSMOCHIM AC, V40, P635, DOI 10.1016/0016-7037(76)90109-5; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; Gounelle M, 2001, ASTROPHYS J, V548, P1051, DOI 10.1086/319019; Hewins R., 1996, CHONDRULES PROTOPLAN, P55; ITOH S, 2000, LUNAR PLANET SCI, V31, P1323; ITOH S, IN PRESS GEOCHIM COS; Jones RH, 2000, METEORIT PLANET SCI, V35, P849, DOI 10.1111/j.1945-5100.2000.tb01468.x; Kojima T., 1995, PROC NIPR S ANTARCT, V8, P79; Krot AN, 2002, SCIENCE, V295, P1051, DOI 10.1126/science.1068200; Krot AN, 2001, METEORIT PLANET SCI, V36, P1189, DOI 10.1111/j.1945-5100.2001.tb01954.x; Krot AN, 1999, METEORIT PLANET SCI, V34, pA68; LASAGA AC, 1983, KINETICS EQUILIBRIUM, P81; MacPherson G.J., 1988, METEORITES EARLY SOL, P746; Maruyama S, 1999, EARTH PLANET SC LETT, V169, P165, DOI 10.1016/S0012-821X(99)00075-8; Noguchi T., 1989, P NIPR S ANT MET, V2, P169; Russell SS, 1996, SCIENCE, V273, P757, DOI 10.1126/science.273.5276.757; Shu FH, 1997, SCIENCE, V277, P1475, DOI 10.1126/science.277.5331.1475; Shu FH, 2001, ASTROPHYS J, V548, P1029, DOI 10.1086/319018; Srinivasan G, 1998, METEORIT PLANET SCI, V33, pA148; STOLPER E, 1986, GEOCHIM COSMOCHIM AC, V50, P1785, DOI 10.1016/0016-7037(86)90139-0; STOLPER E, 1982, GEOCHIM COSMOCHIM AC, V46, P2159, DOI 10.1016/0016-7037(82)90192-2; TATSUMOTO M, 1976, GEOCHIM COSMOCHIM AC, V40, P617, DOI 10.1016/0016-7037(76)90108-3; Wasson JT, 2000, METEORIT PLANET SCI, V35, pA166; Wasson JT, 2001, GEOCHIM COSMOCHIM AC, V65, P4539, DOI 10.1016/S0016-7037(01)00738-4; Yurimoto H, 1998, SCIENCE, V282, P1874, DOI 10.1126/science.282.5395.1874; YURIMOTO H, 1989, GEOCHIM COSMOCHIM AC, V53, P2387, DOI 10.1016/0016-7037(89)90360-8; YURIMOTO H, 2001, METEORIT PLANET SCI, V36, pA230	30	95	96	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					728	731		10.1038/nature01699	http://dx.doi.org/10.1038/nature01699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802328				2022-12-28	WOS:000183443400037
J	Andersen, JH; Thomsen, JF; Overgaard, E; Lassen, CF; Brandt, LPA; Vilstrup, I; Kryger, AI; Mikkelsen, S				Andersen, JH; Thomsen, JF; Overgaard, E; Lassen, CF; Brandt, LPA; Vilstrup, I; Kryger, AI; Mikkelsen, S			Computer use and carpal tunnel syndrome - A 1-year follow-up study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MUSCULOSKELETAL DISORDERS; GENERAL-POPULATION; RISK-FACTORS; WORK; PREVALENCE; SYMPTOMS	Context Computer use is increasingly common among many working populations, and concern exists about possible adverse effects of computer use, such as carpal tunnel syndrome (CTS). Objectives To estimate the prevalence and incidence of possible CTS and to evaluate the contribution of use of mouse devices and keyboards to the risk of possible CTS. Design and Setting A 1-year follow-up study with questionnaires conducted in 2000 and 2001 at 3500 workplaces in Denmark, followed on each of the 2 occasions by a clinical interview on symptom distribution and frequency. Participants The questionnaire was sent to 9480 members of a trade union, with an initial response rate of 73% (n=6943), and 82% (n=5658) at follow-up. Main Outcome Measures At baseline, there were 3 outcome measures: tingling/numbness in the right hand once a week or more as reported in the questionnaire; tingling, numbness, and pain in the median nerve in the right hand confirmed by clinical interview; and tingling, numbness, and pain in the median nerve in the right hand at night confirmed by clinical interview. At 1 year of follow-up the main outcome of interest was onset of symptoms among participants who had no or minor symptoms at baseline. Results The overall self-reported prevalence of tingling/numbness in the right hand at baseline was 10.9%. The interview confirmed that prevalence of tingling/numbness in the median nerve was 4.8%, of which about one third, corresponding to a prevalence of 1.4%, experienced symptoms at night. Onset of new symptoms in the 1-year follow-up was 5.5%. In the cross-sectional comparisons and in the follow-up analyses, there was an association between use of a mouse device for more than 20 h/wk and risk of possible CTS but no statistically significant association with keyboard use. Conclusions The occurrence of possible CTS in the right hand was low. The study emphasizes that computer use does riot pose a severe occupational hazard for developing symptoms of CTS.	Herning Hosp, Dept Occupat Med, DK-7400 Herning, Denmark; Copenhagen Univ Hosp, Dept Occupat Med, Glostrup, Denmark; Odense Univ Hosp, Dept Occupat & Environm Med, DK-5000 Odense, Denmark	Aarhus University; University of Copenhagen; University of Southern Denmark; Odense University Hospital	Andersen, JH (corresponding author), Herning Hosp, Dept Occupat Med, DK-7400 Herning, Denmark.	hecjha@ringamt.dk	Andersen, Johan Hviid/AAI-2086-2019	Andersen, Johan Hviid/0000-0003-1638-8276				Abbas M A, 1998, Int J Occup Environ Health, V4, P160; Atcheson SG, 1998, ARCH INTERN MED, V158, P1506, DOI 10.1001/archinte.158.14.1506; Atroshi I, 1999, JAMA-J AM MED ASSOC, V282, P153, DOI 10.1001/jama.282.2.153; BERNARD B, 1994, SCAND J WORK ENV HEA, V20, P417, DOI 10.5271/sjweh.1379; DEKROM MCTFM, 1992, J CLIN EPIDEMIOL, V45, P373, DOI 10.1016/0895-4356(92)90038-O; DEMBE A, 1996, OCCUPATION DIS SOCIA; Frost P, 1998, SCAND J WORK ENV HEA, V24, P285, DOI 10.5271/sjweh.322; Gerr F, 2002, AM J IND MED, V41, P221, DOI 10.1002/ajim.10066; HALES TR, 1994, ERGONOMICS, V37, P1603, DOI 10.1080/00140139408964940; Kristensen TS, 2002, SCAND J PUBLIC HEALT, V30, P41, DOI 10.1177/14034948020300032401; National Research Council Institute of Medicine, 2001, MUSC DIS WORKPL LOW; Nordstrom DL, 1998, EPIDEMIOLOGY, V9, P342, DOI 10.1097/00001648-199805000-00021; Palmer KT, 2001, OCCUP MED-OXFORD, V51, P392, DOI 10.1093/occmed/51.6.392; Rossignol M, 1997, OCCUP ENVIRON MED, V54, P519, DOI 10.1136/oem.54.7.519; STEVENS JC, 1988, NEUROLOGY, V38, P134, DOI 10.1212/WNL.38.1.134; Stevens JC, 2001, NEUROLOGY, V56, P1568; Thomsen JF, 2002, AM J IND MED, V42, P344, DOI 10.1002/ajim.10115; Tittiranonda P, 1999, OCCUP MED, V14, P17	18	146	147	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					2963	2969		10.1001/jama.289.22.2963	http://dx.doi.org/10.1001/jama.289.22.2963			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687XZ	12799404	Bronze			2022-12-28	WOS:000183403400019
J	Gambacorti-Passerini, C; Tornaghi, L; Cavagnini, F; Rossi, P; Pecori-Giraldi, F; Mariani, L; Cambiaghi, N; Pogliani, E; Corneo, G; Gnessi, L				Gambacorti-Passerini, C; Tornaghi, L; Cavagnini, F; Rossi, P; Pecori-Giraldi, F; Mariani, L; Cambiaghi, N; Pogliani, E; Corneo, G; Gnessi, L			Gynaecomastia in men with chronic myeloid leukaemia after imatinib	LANCET			English	Article							STEM-CELL FACTOR; GROWTH	cKit and platelet-derived growth-factor receptor (PDGFR) are receptor tyrosine kinases expressed in the testis, are involved in testosterone production, and are inhibited by imatinib. We measured hormone concentrations in 38 men receiving imatinib for chronic myeloid leukaemia at baseline and during treatment. Mean follow-up was 23-6 months (SD 7.5). We noted seven cases of gynaecomastia (18%, 95% CI 6-30%). A comparison of hormone concentrations in 21 patients before and during treatment showed that patients who developed gynaecomastia had a reduction in free testosterone concentrations of 29.53 pmol/L (95% Cl 11.63-47.43), while patients who did not had a decrease of 6.36 pmol/L (-1.02 to 13.74). In most men with chronic myeloid leukaemia studied here, imatinib was associated with a reduction in the production of testicular hormones and in some, with the development of gynaecomastia.	Ist Nazl Tumori, I-20133 Milan, Italy; Univ Milano Bicocca, Monza, Italy; Univ Milan, Ist Auxol Italiano, Milan, Italy; Univ Roma Tor Vergata, Rome, Italy; Univ Roma La Sapienza, Rome, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milano-Bicocca; IRCCS Istituto Auxologico Italiano; University of Milan; University of Rome Tor Vergata; Sapienza University Rome	Gambacorti-Passerini, C (corresponding author), Ist Nazl Tumori, Via Venezian 1, I-20133 Milan, Italy.		Rossi, Pellegrino/AAA-7072-2019; Giraldi, Francesca Pecori/F-5081-2011; Mariani, Luigi/AAB-9464-2019; Gnessi, Lucio/K-8025-2016; Mariani, Luigi/C-2580-2017	Giraldi, Francesca Pecori/0000-0001-6065-7803; Gnessi, Lucio/0000-0001-8217-2372; Mariani, Luigi/0000-0001-6208-4084; GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X; ROSSI, PELLEGRINO/0000-0003-4796-327X				Basciani S, 2002, J CLIN ENDOCR METAB, V87, P2310, DOI 10.1210/jc.87.5.2310; Griffin J, 2001, SEMIN ONCOL, V28, P3, DOI 10.1016/S0093-7754(01)90097-1; Huang CTF, 2001, BIOL REPROD, V64, P451, DOI 10.1095/biolreprod64.2.451; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Sette C, 2000, INT J DEV BIOL, V44, P599	5	72	76	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1954	1956		10.1016/S0140-6736(03)13554-4	http://dx.doi.org/10.1016/S0140-6736(03)13554-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801741	Green Submitted			2022-12-28	WOS:000183359700013
J	Du, KY; Herzig, S; Kulkarni, RN; Montminy, M				Du, KY; Herzig, S; Kulkarni, RN; Montminy, M			TRB3: A tribbles homolog that inhibits Akt/PKB activation by insulin in liver	SCIENCE			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; NEGATIVE REGULATOR; DROSOPHILA; MORPHOGENESIS; INACTIVATION; GLUCOSE; CELLS; PKB; RESISTANCE	Insulin resistance is a major hallmark in the development of type II diabetes, which is characterized by the failure of insulin to promote glucose uptake in muscle and to suppress glucose production in liver. The serine-threonine kinase Akt (PKB) is a principal target of insulin signaling that inhibits hepatic glucose output when glucose is available from food. Here we show that TRB3, a mammalian homolog of Drosophila tribbles, functions as a negative modulator of Akt. TRB3 expression is induced in liver under fasting conditions, and TRB3 disrupts insulin signaling by binding directly to Akt and blocking activation of the kinase. Amounts of TRB3 RNA and protein were increased in livers of db/db diabetic mice compared with those in wild-type mice. Hepatic overexpression of TRB3 in amounts comparable to those in db/db mice promoted hyperglycemia and glucose intolerance. Our results suggest that, by interfering with Akt activation, TRB3 contributes to insulin resistance in individuals with susceptibility to type II diabetes.	Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Salk Institute; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Herzig, Stephan/0000-0003-3950-3652				Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Buren J, 2002, EUR J ENDOCRINOL, V146, P419, DOI 10.1530/eje.0.1460419; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dirlewanger M, 2000, CLIN NUTR, V19, P29, DOI 10.1054/clnu.1999.0064; DU K, UNPUB; GANNON MC, 1984, J NUTR, V114, P2147, DOI 10.1093/jn/114.11.2147; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; Paez-Espinosa EV, 1999, MOL CELL ENDOCRINOL, V156, P121, DOI 10.1016/S0303-7207(99)00137-9; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; RAO RH, 1995, METABOLISM, V44, P817, DOI 10.1016/0026-0495(95)90199-X; Rorth P, 2000, MOL CELL, V6, P23; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150	24	688	723	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1574	1577		10.1126/science.1079817	http://dx.doi.org/10.1126/science.1079817			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791994				2022-12-28	WOS:000183333100056
J	Pardo, M; Nurse, P				Pardo, M; Nurse, P			Equatorial retention of the contractile actin ring by microtubules during cytokinesis	SCIENCE			English	Article							FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CELL-DIVISION; SPINDLE FORMATION; F-ACTIN; GENE; CHECKPOINT; CYCLE; EUKARYOTES; PLACEMENT	In most eukaryotes cytokinesis is brought about by a contractile actin ring located at the division plane. Here, in fission yeast the actin ring was found to be required to generate late-mitotic microtubular structures located at the division plane, and these in turn maintained the medial position of the actin ring. When these microtubular structures were disrupted, the actin ring migrated away from the cell middle in a membrane traffic-dependent manner, resulting in asymmetrical cell divisions that led to genomic instability. We propose that these microtubular structures contribute to a checkpoint control that retains the equatorial position of the ring when progression through cytokinesis is delayed.	Canc Res UK London Res Inst, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Pardo, M (corresponding author), Canc Res UK London Res Inst, Cell Cycle Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Pardo, Mercedes/0000-0002-3477-9695				Arai R, 2002, J CELL SCI, V115, P887; Ayscough K, 1998, METHOD ENZYMOL, V298, P18, DOI 10.1016/S0076-6879(98)98004-1; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Balasubramanian MK, 2000, J CELL SCI, V113, P1503; Chang F, 1996, J CELL SCI, V109, P131; Ding DQ, 1998, J CELL SCI, V111, P701; DRABIKOWSKI W, 1973, BIOCHIM BIOPHYS ACTA, V291, P61, DOI 10.1016/0005-2736(73)90060-6; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Finger FP, 2002, CELL, V108, P727, DOI 10.1016/S0092-8674(02)00668-2; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Gatti M, 2000, MICROSC RES TECHNIQ, V49, P202, DOI 10.1002/(SICI)1097-0029(20000415)49:2<202::AID-JEMT13>3.0.CO;2-8; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Guertin DA, 2002, MICROBIOL MOL BIOL R, V66, P155, DOI 10.1128/MMBR.66.2.155-178.2002; Hagan IM, 1998, J CELL SCI, V111, P1603; Heitz MJ, 2001, J CELL SCI, V114, P4521; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; Le Goff X, 1999, MOL GEN GENET, V262, P163; Liu JH, 1999, GENETICS, V153, P1193; Liu JH, 2000, J CELL SCI, V113, P1223; MARKS J, 1985, EUR J CELL BIOL, V39, P27; Paoletti A, 2000, MOL BIOL CELL, V11, P2757, DOI 10.1091/mbc.11.8.2757; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sohrmann M, 1996, GENE DEV, V10, P2707, DOI 10.1101/gad.10.21.2707; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; TURI TG, 1994, J BIOL CHEM, V269, P24229; Vardy L, 2000, EMBO J, V19, P6098, DOI 10.1093/emboj/19.22.6098; Wachtler V, 2003, J CELL SCI, V116, P867, DOI 10.1242/jcs.00299; West RR, 1998, MOL BIOL CELL, V9, P2839, DOI 10.1091/mbc.9.10.2839	31	62	62	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1569	1574		10.1126/science.1084671	http://dx.doi.org/10.1126/science.1084671			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791993				2022-12-28	WOS:000183333100055
J	Mello, MM; Studdert, DM; Brennan, TA				Mello, MM; Studdert, DM; Brennan, TA			The new medical malpractice crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CLAIMS		Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Mello, MM (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537; Mello, Michelle/0000-0003-2877-4270				DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; SLOAN FA, 1985, J HEALTH POLIT POLIC, V9, P629, DOI 10.1215/03616878-9-4-629; SLOAN FA, 1989, J HEALTH POLIT POLIC, V14, P663, DOI 10.1215/03616878-14-4-663; ZUCKERMAN S, 1990, INQUIRY, V27, P162	4	146	148	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2281	2284		10.1056/NEJMp030064	http://dx.doi.org/10.1056/NEJMp030064			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	686AA	12788991				2022-12-28	WOS:000183296300002
J	Shen, Y; Knoll, AH; Walter, MR				Shen, Y; Knoll, AH; Walter, MR			Evidence for low sulphate and anoxia in a mid-Proterozoic marine basin	NATURE			English	Article							PROTEROZOIC OCEAN CHEMISTRY; VELKERRI FORMATION; BELT SUPERGROUP; MCARTHUR BASIN; SULFUR-ISOTOPE; EVOLUTION; IRON; GEOCHEMISTRY; CONSTRAINTS; SEDIMENTS	Many independent lines of evidence document a large increase in the Earth's surface oxidation state 2,400 to 2,200 million years ago(1-4), and a second biospheric oxygenation 800 to 580 million years ago, just before large animals appear in the fossil record(5,6). Such a two-staged oxidation implies a unique ocean chemistry for much of the Proterozoic eon, which would have been neither completely anoxic and iron-rich as hypothesized for Archaean seas, nor fully oxic as supposed for most of the Phanerozoic eon(7). The redox chemistry of Proterozoic oceans has important implications for evolution(8), but empirical constraints on competing environmental models are scarce. Here we present an analysis of the iron chemistry of shales deposited in the marine Roper Basin, Australia, between about 1,500 and 1,400 million years ago, which record deep-water anoxia beneath oxidized surface water. The sulphur isotopic compositions of pyrites in the shales show strong variations along a palaeodepth gradient, indicating low sulphate concentrations in mid-Proterozoic oceans. Our data help to integrate a growing body of evidence favouring a long-lived intermediate state of the oceans, generated by the early Proterozoic oxygen revolution and terminated by the environmental transformation late in the Proterozoic eon.	Harvard Univ, Bot Museum, Cambridge, MA 02138 USA; Macquarie Univ, Australian Ctr Astrobiol, N Ryde, NSW 2109, Australia	Harvard University; Macquarie University	Shen, Y (corresponding author), Harvard Univ, Bot Museum, 26 Oxford St, Cambridge, MA 02138 USA.	yshen@oeb.harvard.edu	Shen, Yanan/L-3724-2018	Shen, Yanan/0000-0001-8343-6763				Abbott ST, 2000, AUST J EARTH SCI, V47, P637, DOI 10.1046/j.1440-0952.2000.00795.x; Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; BAKER PA, 1981, SCIENCE, V213, P214, DOI 10.1126/science.213.4504.214; Canfield DE, 1999, AM J SCI, V299, P697, DOI 10.2475/ajs.299.7-9.697; Canfield DE, 2000, SCIENCE, V288, P658, DOI 10.1126/science.288.5466.658; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; DERRY LA, 1992, GEOCHIM COSMOCHIM AC, V56, P1317, DOI 10.1016/0016-7037(92)90064-P; DONNELLY TH, 1988, PRECAMBRIAN RES, V42, P165, DOI 10.1016/0301-9268(88)90015-0; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; GAUTIER DL, 1986, GEOLOGY, V14, P225, DOI 10.1130/0091-7613(1986)14<225:CSFTWI>2.0.CO;2; Hayes J.M., 1992, PROTEROZOIC BIOSPHER, P129; Holland H. D., 1994, EARLY LIFE EARTH, V84, P237; Hurtgen MT, 2002, EARTH PLANET SC LETT, V203, P413, DOI 10.1016/S0012-821X(02)00804-X; JACKSON MJ, 1991, PRECAMBRIAN RES, V54, P81, DOI 10.1016/0301-9268(91)90070-Q; Kah LC, 2001, PRECAMBRIAN RES, V111, P203, DOI 10.1016/S0301-9268(01)00161-9; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; LOGAN GA, 1995, NATURE, V376, P53, DOI 10.1038/376053a0; Lyons TW, 1997, GEOCHIM COSMOCHIM AC, V61, P3367, DOI 10.1016/S0016-7037(97)00174-9; Lyons TW, 2000, GEOCHIM COSMOCHIM AC, V64, P427, DOI 10.1016/S0016-7037(99)00323-3; MARAIS DJD, 1992, NATURE, V359, P605, DOI 10.1038/359605a0; MUIR MD, 1985, AUST J EARTH SCI, V32, P239, DOI 10.1080/08120098508729328; Pavlov AA, 2003, GEOLOGY, V31, P87, DOI 10.1130/0091-7613(2003)031<0087:MRPA>2.0.CO;2; Raiswell R, 1998, AM J SCI, V298, P219, DOI 10.2475/ajs.298.3.219; Raiswell R, 2001, J SEDIMENT RES, V71, P286, DOI 10.1306/070300710286; ROSS GM, 1995, PRECAMBRIAN RES, V73, P71, DOI 10.1016/0301-9268(94)00072-Y; Shen YN, 2002, AM J SCI, V302, P81, DOI 10.2475/ajs.302.2.81; STRAUSS H, 1990, GEOCHIM COSMOCHIM AC, V54, P197, DOI 10.1016/0016-7037(90)90207-2; Wijsman JWM, 2001, MAR CHEM, V74, P261, DOI 10.1016/S0304-4203(01)00019-6; ZABACK DA, 1993, GEOLOGY, V21, P141, DOI 10.1130/0091-7613(1993)021<0141:TAROSA>2.3.CO;2	30	213	233	4	68	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 5	2003	423	6940					632	635		10.1038/nature01651	http://dx.doi.org/10.1038/nature01651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789336				2022-12-28	WOS:000183301200038
J	Moynihan, R				Moynihan, R			Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement	BRITISH MEDICAL JOURNAL			English	Article											Moynihan, R (corresponding author), 1312 21st St NW, Washington, DC 20036 USA.		Moynihan, Ray/ABC-3010-2020					*ACCR COUNC CONT M, 2003, STAND ENS SEP PROM E; *AM MED STUD ASS, 2002, PHARMFR CAMP; *ASS AM MED COLL, 2001, PROT SUBJ PRES TRUST, P9; CHREN M, 1994, ARCH DERMATOL, V130, P132; Pharmaceutical Research and Manufacturers of America, 2002, PRINC COND CLIN TRIA; Rennie J, 1997, SCI AM, V277, P8, DOI 10.1038/scientificamerican1197-8; HLTH SKEPTICISM; NO FREE LUNCH	8	70	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2003	326	7400					1193	1196		10.1136/bmj.326.7400.1193	http://dx.doi.org/10.1136/bmj.326.7400.1193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775622	Green Published			2022-12-28	WOS:000183309900024
J	Donnelly, CA; Ghani, AC; Leung, GM; Hedley, AJ; Fraser, C; Riley, S; Abu-Raddad, LJ; Ho, LM; Thach, TQ; Chau, P; Chan, KP; Lam, TH; Tse, LY; Tsang, T; Liu, SH; Kong, JHB; Lau, EMC; Ferguson, NM; Anderson, RM				Donnelly, CA; Ghani, AC; Leung, GM; Hedley, AJ; Fraser, C; Riley, S; Abu-Raddad, LJ; Ho, LM; Thach, TQ; Chau, P; Chan, KP; Lam, TH; Tse, LY; Tsang, T; Liu, SH; Kong, JHB; Lau, EMC; Ferguson, NM; Anderson, RM			Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong	LANCET			English	Article								Background Health authorities worldwide, especially in the Asia Pacific region, are seeking effective public-health interventions in the continuing epidemic of severe acute respiratory syndrome (SARS). We assessed the epidemiology of SARS in Hong Kong. Methods We included 1425 cases reported up to April 28, 2003. An integrated database was constructed from several sources containing information on epidemiological, demographic, and clinical variables. We estimated the key epidemiological distributions: infection to onset, onset to admission, admission to death, and admission to discharge. We measured associations between the estimated case fatality rate and patients' age and the time from onset to admission. Findings After the initial phase of exponential growth, the rate of confirmed cases fell to less than 20 per day by April 28. Public-health interventions included encouragement to report to hospital rapidly after the onset of clinical symptoms, contact tracing for confirmed and suspected cases, and quarantining, monitoring, and restricting the travel of contacts. The mean incubation period of the disease is estimated to be 6.4 days (95% CI 5.2-7.7). The mean time from onset of clinical symptoms to admission to hospital varied between 3 and 5 days, with longer times earlier in the epidemic. The estimated case fatality rate was 13.2% (9.8-16.8) for patients younger than 60 years and 43.3% (35.2-52.4) for patients aged 60 years or older assuming a parametric gamma distribution. A non-parametric method yielded estimates of 6.8% (4.0-9.6) and 55.0% (45.3-64.7), respectively. Case clusters have played an important part in the course of the epidemic. Interpretation Patients' age was strongly associated with outcome. The time between onset of symptoms and admission to hospital did not alter outcome, but shorter intervals will be important to the wider population by restricting the infectious period before patients are placed in quarantine.	Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England; Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China; Dept Hlth, Hong Kong, Hong Kong, Peoples R China; Hong Kong Hosp Author, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Community & Family Med, Hong Kong, Hong Kong, Peoples R China	Imperial College London; University of Hong Kong; Chinese University of Hong Kong	Donnelly, CA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Chan, King Pan/C-4523-2009; Hedley, Anthony/C-4305-2009; Hedley, Anthony J/A-9113-2013; Abu-Raddad, Laith J/AAY-1441-2020; Fraser, Christophe/A-8109-2008; Ferguson, Neil/B-8578-2008; Leung, Gabriel Matthew/C-4336-2009; Lam, Tai Hing/C-4317-2009; Thach, Thuan-Quoc/C-4416-2009; Ghani, Azra/B-8560-2009	Abu-Raddad, Laith J/0000-0003-0790-0506; Fraser, Christophe/0000-0003-2399-9657; Ferguson, Neil/0000-0002-1154-8093; Thach, Thuan-Quoc/0000-0003-3404-3888; Leung, Gabriel/0000-0002-2503-6283; Riley, Steven/0000-0001-7904-4804; Donnelly, Christl/0000-0002-0195-2463; Anderson, Roy/0000-0002-9528-3175; Ghani, Azra/0000-0002-0007-4910; ho, lm/0000-0002-2709-927X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], COM NUMB REP PROB CA; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; TSANG KW, CLUSTER CASES SEVERE; *WHO, COR SEEN HUM CAUS SA	4	612	664	1	77	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1761	1766		10.1016/S0140-6736(03)13410-1	http://dx.doi.org/10.1016/S0140-6736(03)13410-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781533	Green Published, Bronze			2022-12-28	WOS:000183074800006
J	Ashraf, H				Ashraf, H			UK ethicists say GM foods could help poor - Group back the controversial crops as government warily tests public opinion	LANCET			English	News Item																			0	2	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2051	2051						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814720				2022-12-28	WOS:000183488900016
J	Fleitmann, D; Burns, SJ; Mudelsee, M; Neff, U; Kramers, J; Mangini, A; Matter, A				Fleitmann, D; Burns, SJ; Mudelsee, M; Neff, U; Kramers, J; Mangini, A; Matter, A			Holocene forcing of the Indian monsoon recorded in a stalagmite from Southern Oman	SCIENCE			English	Article							ARABIAN SEA; CLIMATE; EVENTS; INSTABILITY; VARIABILITY; DESERT	A high-resolution oxygen-isotope record from a thorium-uranium-dated stalagmite from southern Oman re. ects variations in the amount of monsoon precipitation for the periods from 10.3 to 2.7 and 1.4 to 0.4 thousand years before the present (ky B.P.). Between 10.3 and 8 ky B. P., decadal to centennial variations in monsoon precipitation are in phase with temperature fluctuations recorded in Greenland ice cores, indicating that early Holocene monsoon intensity is largely controlled by glacial boundary conditions. After similar to8 ky B. P., monsoon precipitation decreases gradually in response to changing Northern Hemisphere summer solar insolation, with decadal to multidecadal variations in monsoon precipitation being linked to solar activity.	Univ Bern, Inst Geol Sci, CH-3012 Bern, Switzerland; Univ Massachusetts, Dept Geosci, Morrill Sci Ctr, Amherst, MA 01003 USA; Univ Leipzig, Inst Meteorol, D-04103 Leipzig, Germany; Heidelberg Acad Sci, D-69120 Heidelberg, Germany	University of Bern; University of Massachusetts System; University of Massachusetts Amherst; Leipzig University	Fleitmann, D (corresponding author), Univ Bern, Inst Geol Sci, CH-3012 Bern, Switzerland.	dominik.fleitmann@geo.unibe.ch	Burns, Stephen/H-9419-2013; Mudelsee, Manfred/C-6063-2018	Mudelsee, Manfred/0000-0002-2364-9561				Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Altabet MA, 2002, NATURE, V415, P159, DOI 10.1038/415159a; Beer J, 2000, QUATERNARY SCI REV, V19, P403, DOI 10.1016/S0277-3791(99)00072-4; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; Burns SJ, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001281; Burns SJ, 2001, GEOLOGY, V29, P623, DOI 10.1130/0091-7613(2001)029<0623:SEFOFC>2.0.CO;2; Cheng H, 2000, CHEM GEOL, V169, P17, DOI 10.1016/S0009-2541(99)00157-6; CLARK ID, 1987, USE STABLE ISOTOPES, P167; Claussen M, 1999, GEOPHYS RES LETT, V26, P2037, DOI 10.1029/1999GL900494; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; deMenocal P, 2000, QUATERNARY SCI REV, V19, P347, DOI 10.1016/S0277-3791(99)00081-5; Enzel Y, 1999, SCIENCE, V284, P125, DOI 10.1126/science.284.5411.125; FLEITMANN D, 1999, EOS S, V80; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; GASSE F, 1994, EARTH PLANET SC LETT, V126, P435, DOI 10.1016/0012-821X(94)90123-6; Gupta AK, 2003, NATURE, V421, P354, DOI 10.1038/nature01340; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; IVANOVICH M, 1993, URANIUM SERIES DISEQ; MCCLURE HA, 1976, NATURE, V263, P755, DOI 10.1038/263755a0; Mudelsee M, 2000, COMPUT GEOSCI, V26, P293, DOI 10.1016/S0098-3004(99)00141-7; Neff U, 2001, NATURE, V411, P290, DOI 10.1038/35077048; Overpeck J, 1996, CLIM DYNAM, V12, P213, DOI 10.1007/BF00211619; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; PRELL WL, 1987, J GEOPHYS RES-ATMOS, V92, P8411, DOI 10.1029/JD092iD07p08411; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; SIROCKO F, 1993, NATURE, V364, P322, DOI 10.1038/364322a0; SIROCKO F, 1991, QUATERNARY RES, V36, P72, DOI 10.1016/0033-5894(91)90018-Z; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Stuiver M., 1993, HOLOCENE, V3, P289, DOI DOI 10.1177/095968369300300401; THOMPSON LG, 1989, SCIENCE, V246, P474, DOI 10.1126/science.246.4929.474	32	1145	1305	9	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1737	1739		10.1126/science.1083130	http://dx.doi.org/10.1126/science.1083130			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805545				2022-12-28	WOS:000183459700048
J	van Montfort, RLM; Congreve, M; Tisi, D; Carr, R; Jhoti, H				van Montfort, RLM; Congreve, M; Tisi, D; Carr, R; Jhoti, H			Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B	NATURE			English	Article							REVERSIBLE INACTIVATION; SUBSTRATE-SPECIFICITY; INSULIN SENSITIVITY; HYDROGEN-PEROXIDE; ENZYME CATALYSIS; INTERMEDIATE; ROLES	Protein tyrosine phosphatases regulate signal transduction pathways involving tyrosine phosphorylation(1) and have been implicated in the development of cancer, diabetes, rheumatoid arthritis and hypertension(2). Increasing evidence suggests that the cellular redox state is involved in regulating tyrosine phosphatase activity through the reversible oxidization of the catalytic cysteine to sulphenic acid (Cys-SOH)(3-6). But how further oxidation to the irreversible sulphinic (Cys-SO2H) and sulphonic (Cys-SO3H) forms is prevented remains unclear. Here we report the crystal structures of the regulatory sulphenic and irreversible sulphinic and sulphonic acids of protein tyrosine phosphatase 1B (PTP1B), an important enzyme in the negative regulation of the insulin receptor(7,8) and a therapeutic target in type II diabetes and obesity(9). We also identify a sulphenyl-amide species that is formed through oxidation of its catalytic cysteine. Formation of the sulphenyl-amide causes large changes in the PTP1B active site, which are reversible by reduction with the cellular reducing agent glutathione. The sulphenyl-amide is a protective intermediate in the oxidative inhibition of PTP1B. In addition, it may facilitate reactivation of PTP1B by biological thiols and signal a unique state of the protein.	Astex Technol Ltd, Cambridge CB4 0QA, England		Jhoti, H (corresponding author), Astex Technol Ltd, 436 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0QA, England.	h.jhoti@astex-technology.com	van Montfort, Rob/D-3248-2009					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barford D, 1995, CURR OPIN STRUC BIOL, V5, P728, DOI 10.1016/0959-440X(95)80004-2; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Goldstein Barry J., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P265, DOI 10.2174/1568008013341163; HARTSHORN MJ, IN PRESS J COMPUT AI; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Scapin G, 2001, PROTEIN SCI, V10, P1596, DOI 10.1110/ps.11001; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	23	493	506	3	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					773	777		10.1038/nature01681	http://dx.doi.org/10.1038/nature01681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802339				2022-12-28	WOS:000183443400048
J	Wikelski, M; Tarlow, EM; Raim, A; Diehl, RH; Larkin, RP; Visser, GH				Wikelski, M; Tarlow, EM; Raim, A; Diehl, RH; Larkin, RP; Visser, GH			Costs of migration in free-flying songbirds	NATURE			English	Article							BIRD MIGRATION		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Univ Illinois, Dept Anim Biol, Urbana, IL 61801 USA; Illinois Nat Hist Survey, Champaign, IL 61820 USA; Univ Groningen, Ctr Isotope Res, NL-9747 AG Groningen, Netherlands; Univ Groningen, Zool Lab, NL-9750 AA Haren, Netherlands	Princeton University; University of Illinois System; University of Illinois Urbana-Champaign; Illinois Natural History Survey; University of Groningen; University of Groningen	Wikelski, M (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.							Alerstam T, 1998, J AVIAN BIOL, V29, P343, DOI 10.2307/3677155; BENNETT PM, 1987, J ZOOL, V213, P327, DOI 10.1111/j.1469-7998.1987.tb03708.x; COCHRAN WW, 1987, ANIM BEHAV, V35, P927, DOI 10.1016/S0003-3472(87)80132-X; Cochran WW, 1972, ANIMAL ORIENTATION N, P39; Faaborg John, 1995, P357; GRABER RR, 1971, BIOL NOTES ILLINOIS, V75; Hedenstrom A, 1997, J THEOR BIOL, V189, P227, DOI 10.1006/jtbi.1997.0505; Klaassen M, 1996, J EXP BIOL, V199, P57; MASMAN D, 1987, AUK, V104, P603, DOI 10.1093/auk/104.4.603; Pennycuick CJ, 1998, J THEOR BIOL, V191, P47, DOI 10.1006/jtbi.1997.0572; RICHARDSON WJ, 1978, OIKOS, V30, P224, DOI 10.2307/3543482; Speakman JR, 1997, DOUBLY LABELED WATER; [No title captured]	13	317	328	0	118	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					704	704		10.1038/423704a	http://dx.doi.org/10.1038/423704a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802324	Bronze			2022-12-28	WOS:000183443400032
J	Basnyat, B; Murdoch, DR				Basnyat, B; Murdoch, DR			High-altitude illness	LANCET			English	Review							ACUTE MOUNTAIN-SICKNESS; ENDOTHELIAL GROWTH-FACTOR; HYPOXIC VENTILATORY RESPONSE; INHALED NITRIC-OXIDE; PULMONARY-EDEMA; CEREBRAL EDEMA; BRONCHOALVEOLAR LAVAGE; SIMULATED DESCENT; MODERATE ALTITUDE; CONTROLLED TRIAL	High-altitude illness is the collective term for acute mountain sickness (AMS), high-altitude cerebral oedema (HACE), and high-altitude pulmonary oedema (HAPE). The pathophysiology of these syndromes is not completely understood, although studies have substantially contributed to the current understanding of several areas. These areas include the role and potential mechanisms of brain swelling in AMS and HACE, mechanisms accounting for exaggerated pulmonary hypertension in HAPE, and the role of inflammation and alveolar-fluid clearance in HAPE. Only limited information is available about the genetic basis of high-altitude illness, and no clear associations between gene polymorphisms and susceptibility have been discovered. Gradual ascent will always be the best strategy for preventing high-altitude illness, although chemoprophylaxis may be useful in some situations. Despite investigation of other agents, acetazolamide remains the preferred drug for preventing AMS. The next few years are likely to see many advances in the understanding of the causes and management of high-altitude illness.	Nepal Int Clin, Kathmandu, Nepal; Himalayan Rescue Assoc, Kathmandu, Nepal; Tribhuvan Univ, Inst Med, Kathmandu, Nepal; Good Samaritan Reg Med Ctr, Dept Med Educ, Phoenix, AZ USA; Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand; Canterbury Hlth Labs, Christchurch, New Zealand	Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Otago; Canterbury Health Laboratories	Basnyat, B (corresponding author), Nepal Int Clin, Lal Durbar,GPO Box 3596, Kathmandu, Nepal.	rishibas@wlink.com.np	Murdoch, David/A-2012-2009					Anand IS, 1998, CIRCULATION, V98, P2441, DOI 10.1161/01.CIR.98.22.2441; Bailey DM, 2001, HIGH ALT MED BIOL, V2, P21, DOI 10.1089/152702901750067882; BARTSCH P, 1994, LANCET, V344, P1445, DOI 10.1016/S0140-6736(94)90617-3; Bartsch P, 2000, CHEST, V117, P1393, DOI 10.1378/chest.117.5.1393; BARTSCH P, 1989, J APPL PHYSIOL, V66, P2136, DOI 10.1152/jappl.1989.66.5.2136; BARTSCH P, 1991, J APPL PHYSIOL, V71, P136; BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805; BARTSCH P, 1993, BRIT MED J, V306, P1098, DOI 10.1136/bmj.306.6885.1098; Bartsch P., 2001, HIGH ALTITUDE EXPLOR, P731; BARTSCH P, 2002, HIGH ALT MED BIOL, V3, P105; Basnyat B, 2000, High Alt Med Biol, V1, P167; Basnyat B, 2003, HIGH ALT MED BIOL, V4, P45, DOI 10.1089/152702903321488979; Basnyat B, 2002, J TRAVEL MED, V9, P105, DOI 10.2310/7060.2002.21973; Basnyat B, 1997, WILD ENVIRON MED, V8, P78, DOI 10.1580/1080-6032(1997)008[0078:MPOPAT]2.3.CO;2; Basnyat B, 2000, WILD ENVIRON MED, V11, P89, DOI 10.1580/1080-6032(2000)011[0089:DAAPAE]2.3.CO;2; Bernhard WN, 1998, AVIAT SPACE ENVIR MD, V69, P883; BERTHIAUME Y, 1988, J APPL PHYSIOL, V65, P585, DOI 10.1152/jappl.1988.65.2.585; BERTHIAUME Y, 1987, J CLIN INVEST, V79, P335, DOI 10.1172/JCI112817; BIRCHER HP, 1994, J WILDERNESS MED, V5, P302, DOI 10.1580/0953-9859-5.3.302; BROOME JR, 1994, AVIAT SPACE ENVIR MD, V65, P19; BURTSCHER M, 1995, LANCET, V346, P254, DOI 10.1016/S0140-6736(95)91303-3; Burtscher M, 1998, BRIT MED J, V316, P1057; Busch T, 2001, AM J RESP CRIT CARE, V163, P368, DOI 10.1164/ajrccm.163.2.2001134; Cremona G, 2002, LANCET, V359, P303, DOI 10.1016/S0140-6736(02)07496-2; Cumbo TA, 2002, AVIAT SPACE ENVIR MD, V73, P898; Davis PR, 2002, HIGH ALT MED BIOL, V3, P101; Dehnert C, 2002, MED SCI SPORT EXER, V34, P1928, DOI 10.1097/00005768-200212000-00011; Dehnert C, 2002, HIGH ALT MED BIOL, V3, P100; del Rio MS, 1999, ADV EXP MED BIOL, V474, P145; Droma Y, 2002, CIRCULATION, V106, P826, DOI 10.1161/01.CIR.0000024409.30143.70; Dumont L, 2000, BRIT MED J, V321, P267, DOI 10.1136/bmj.321.7256.267; Duplain H, 1999, CIRCULATION, V99, P1713, DOI 10.1161/01.CIR.99.13.1713; Duplain H, 2000, AM J RESP CRIT CARE, V162, P221, DOI 10.1164/ajrccm.162.1.9908039; Durmowicz AG, 1997, J PEDIATR-US, V130, P838, DOI 10.1016/S0022-3476(97)80033-9; Eichenberger U, 1996, AM J RESP CRIT CARE, V154, P1748, DOI 10.1164/ajrccm.154.6.8970365; Eldridge MW, 1996, J APPL PHYSIOL, V81, P911, DOI 10.1152/jappl.1996.81.2.911; ELLSWORTH AJ, 1991, WESTERN J MED, V154, P289; Fallon MB, 1998, AM J PHYSIOL-LUNG C, V275, pL283, DOI 10.1152/ajplung.1998.275.2.L283; FERRAZZINI G, 1987, BRIT MED J, V294, P1380, DOI 10.1136/bmj.294.6584.1380; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FORWAND SA, 1968, NEW ENGL J MED, V279, P839, DOI 10.1056/NEJM196810172791601; Gabri AL, 2003, CHEST, V123, P49, DOI 10.1378/chest.123.1.49; Ge RL, 1997, CHEST, V111, P58, DOI 10.1378/chest.111.1.58; Gertsch JH, 2002, HIGH ALT MED BIOL, V3, P29, DOI 10.1089/152702902753639522; Grissom CK, 1997, CHEST, V112, P1572, DOI 10.1378/chest.112.6.1572; GRISSOM CK, 1992, ANN INTERN MED, V116, P461, DOI 10.7326/0003-4819-116-6-461; Hackett P H, 2000, High Alt Med Biol, V1, P337, DOI 10.1089/15270290050502417; HACKETT PH, 1982, RESPIRATION, V43, P321, DOI 10.1159/000194501; HACKETT PH, 1979, AM J MED, V67, P214, DOI 10.1016/0002-9343(79)90393-0; HACKETT PH, 1980, NEW ENGL J MED, V302, P1070, DOI 10.1056/NEJM198005083021907; HACKETT PH, 1976, LANCET, V2, P1149; HACKETT PH, 1988, AVIAT SPACE ENVIR MD, V59, P950; HACKETT PH, 1992, INT J SPORTS MED, V13, pS68, DOI 10.1055/s-2007-1024599; Hackett PH, 1998, JAMA-J AM MED ASSOC, V280, P1920, DOI 10.1001/jama.280.22.1920; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; Hackett PH, 1999, ADV EXP MED BIOL, V474, P23; Hackett PH, 1999, WILD ENVIRON MED, V10, P97, DOI 10.1580/1080-6032(1999)010[0097:TCEOHA]2.3.CO;2; Hanaoka M, 1998, CIRCULATION, V97, P1124, DOI 10.1161/01.CIR.97.12.1124; HOHENHAUS E, 1995, EUR RESPIR J, V8, P1825, DOI 10.1183/09031936.95.08111825; HONIGMAN B, 1993, ANN INTERN MED, V118, P587, DOI 10.7326/0003-4819-118-8-199304150-00003; Hopkins SR, 1997, AM J RESP CRIT CARE, V155, P1090, DOI 10.1164/ajrccm.155.3.9116992; HOUSTON CS, 1975, LANCET, V2, P758; Hultgren HN, 1996, ANNU REV MED, V47, P267; HULTGREN HN, 1971, CIRCULATION, V44, P759, DOI 10.1161/01.CIR.44.5.759; ICENOGLE M, 1999, ADV EXPT MED BIOL, V474, P392; Jerome EH, 1996, NEW ENGL J MED, V334, P662, DOI 10.1056/NEJM199603073341013; JOHNSON TS, 1984, NEW ENGL J MED, V310, P683, DOI 10.1056/NEJM198403153101103; KASIC JF, 1991, ANN EMERG MED, V20, P1109, DOI 10.1016/S0196-0644(05)81385-X; KAYSER B, 1991, J WILDERNESS MED, V2, P110, DOI 10.1580/0953-9859-2.2.110; KELLER HR, 1995, BMJ-BRIT MED J, V310, P1232, DOI 10.1136/bmj.310.6989.1232; KILGORE D, 1999, ADV EXPT MED BIOL, V474, P396; KING AB, 1972, AEROSPACE MED, V43, P419; Kleger GR, 1996, J APPL PHYSIOL, V81, P1917, DOI 10.1152/jappl.1996.81.5.1917; Klekamp JG, 1997, PEDIATR RES, V42, P744, DOI 10.1203/00006450-199712000-00005; KRASNEY J, 1997, HYPOXIA WOMEN ALTITU, P254; Kubo K, 1998, RESP PHYSIOL, V111, P301, DOI 10.1016/S0034-5687(98)00006-1; Kubo K, 1996, THORAX, V51, P739, DOI 10.1136/thx.51.7.739; Leadbetter G, 2001, HIGH ALT MED BIOL, V2, P110; LEVINE BD, 1989, NEW ENGL J MED, V321, P1707, DOI 10.1056/NEJM198912213212504; Levine BD, 1999, ADV EXP MED BIOL, V474, P319; Maggiorini M, 2001, CIRCULATION, V103, P2078; Maloney J, 2000, CHEST, V118, P47, DOI 10.1378/chest.118.1.47; MATSUZAWA Y, 1994, J WILDERNESS MED, V5, P269, DOI 10.1580/0953-9859-5.3.269; Matsuzawa Y, 1992, HIGH ALTITUDE MED, P300; MAYHAN WG, 1986, CIRC RES, V59, P216, DOI 10.1161/01.RES.59.2.216; MCKECHNIE JK, 1979, S AFR MED J, V56, P261; MILLEDGE JS, 1991, EUR RESPIR J, V4, P1000; MOORE LG, 1986, J APPL PHYSIOL, V60, P1407, DOI 10.1152/jappl.1986.60.4.1407; Morocz IA, 2001, EXP NEUROL, V168, P96, DOI 10.1006/exnr.2000.7596; Murdoch, 1995, J Travel Med, V2, P255, DOI 10.1111/j.1708-8305.1995.tb00671.x; MURDOCH DR, 1995, AVIAT SPACE ENVIR MD, V66, P148; Murdoch DR, 1998, NEW ZEAL MED J, V111, P168; MURDOCH DR, 1999, NEWSLETTERS INT SOC, V9, P3; Naeije R, 1996, CHEST, V110, P286, DOI 10.1378/chest.110.1.286; OELZ O, 1989, LANCET, V2, P1241; Pollard AJ, 2001, HIGH ALT MED BIOL, V2, P389, DOI 10.1089/15270290152608561; REEVES JT, 1993, HYPOXIA AND MOLECULAR MEDICINE, P275; RIED LD, 1994, J WILDERNESS MED, V5, P34; ROACH RC, 1995, WESTERN J MED, V162, P32; Roach RC, 2001, J EXP BIOL, V204, P3161; Roach RC, 2000, J APPL PHYSIOL, V88, P581, DOI 10.1152/jappl.2000.88.2.581; Roncin JP, 1996, AVIAT SPACE ENVIR MD, V67, P445; ROSS RT, 1985, LANCET, V1, P990; Sartori C, 2001, ADV EXP MED BIOL, V502, P315; Sartori C, 2002, NEW ENGL J MED, V346, P1631, DOI 10.1056/NEJMoa013183; Sartori C, 1999, CIRCULATION, V99, P2665, DOI 10.1161/01.CIR.99.20.2665; Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; SCHOENE RB, 1986, JAMA-J AM MED ASSOC, V256, P63, DOI 10.1001/jama.256.1.63; SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605; SCHOENE RB, 2001, HIGH ALTITUDE EXPLOR, P777; SEVERINGHAUS JW, 1995, J APPL PHYSIOL, V79, P375, DOI 10.1152/jappl.1995.79.2.375; SHLIM DR, 1991, ANN EMERG MED, V20, P315, DOI 10.1016/S0196-0644(05)80948-5; Silber E, 2003, NEUROLOGY, V60, P1167, DOI 10.1212/01.WNL.0000055876.26737.B9; SINGH I, 1969, NEW ENGL J MED, V280, P175, DOI 10.1056/NEJM196901232800402; SUTTON JR, 1976, AVIAT SPACE ENVIR MD, V47, P1032; Swenson ER, 2002, JAMA-J AM MED ASSOC, V287, P2228, DOI 10.1001/jama.287.17.2228; SWENSON ER, 1997, HYPOXIA WOMEN ALTITU, P272; TSUKIMOTO K, 1991, J APPL PHYSIOL, V71, P573, DOI 10.1152/jappl.1991.71.2.573; TSUKIMOTO K, 1994, J APPL PHYSIOL, V76, P321, DOI 10.1152/jappl.1994.76.1.321; Utiger D, 1999, ADV EXP MED BIOL, V474, P435; VANN R, 2003, HIGH ALT MED BIOL, V3, P451; VOCK P, 1991, CHEST, V100, P1306, DOI 10.1378/chest.100.5.1306; Walter R, 2001, EUR J APPL PHYSIOL, V85, P113, DOI 10.1007/s004210100419; WEST JB, 1995, EUR RESPIR J, V8, P523; WEST JB, 1992, INT J SPORTS MED, V13, pS54, DOI 10.1055/s-2007-1024594; *WHO, 1996, WORLD HLTH STAT ANN; Woods DR, 2001, HIGH ALT MED BIOL, V2, P201, DOI 10.1089/152702901750265305; Xu FP, 1998, J APPL PHYSIOL, V85, P53, DOI 10.1152/jappl.1998.85.1.53; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZAVASKY D, 1995, WILD ENVIRON MED, V6, P229; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	133	344	370	6	82	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1967	1974		10.1016/S0140-6736(03)13591-X	http://dx.doi.org/10.1016/S0140-6736(03)13591-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801752				2022-12-28	WOS:000183359700023
J	Hansen, L				Hansen, L			Commentary: We need to determine who benefits most from flu treatments	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Edinburgh, Edinburgh EH9 1QH, Midlothian, Scotland	University of Edinburgh	Hansen, L (corresponding author), Univ Edinburgh, Edinburgh EH9 1QH, Midlothian, Scotland.							*ADV COMM IMM PRAC, 2002, MMWR, V51; *APPR COMM NAT I C, 2003, FULL GUID US ZAN OS; Peters PH, 2001, J AM GERIATR SOC, V49, P1025, DOI 10.1046/j.1532-5415.2001.49204.x	3	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1239	1240		10.1136/bmj.326.7401.1239	http://dx.doi.org/10.1136/bmj.326.7401.1239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791736	Green Published			2022-12-28	WOS:000183480700013
J	Tian, PF; Keusters, D; Suzaki, Y; Warren, WS				Tian, PF; Keusters, D; Suzaki, Y; Warren, WS			Femtosecond phase-coherent two-dimensional spectroscopy	SCIENCE			English	Article							PEPTIDES; SEQUENCES; DYNAMICS; ECHO	Femtosecond phase-coherent two-dimensional (2D) spectroscopy has been experimentally demonstrated as the direct optical analog of 2D nuclear magnetic resonance. An acousto-optic pulse shaper created a collinear three-pulse sequence with well-controlled and variable interpulse delays and phases, which interacted with a model atomic system of rubidium vapor. The desired nonlinear polarization was selected by phase cycling (coadding experimental results obtained with different interpulse phases). This method may enhance our ability to probe the femtosecond structural dynamics of macromolecules.	Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA; Princeton Univ, Ctr Ultrafast Laser Applicat, Dept Chem, Princeton, NJ 08544 USA; Kagawa Univ, Fac Engn, Dept Adv Mat Sci, Kagawa 7610396, Japan	Princeton University; Princeton University; Kagawa University	Tian, PF (corresponding author), Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA.							Asplund MC, 2000, P NATL ACAD SCI USA, V97, P8219, DOI 10.1073/pnas.140227997; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; de Boeij WP, 1998, CHEM PHYS, V233, P287, DOI 10.1016/S0301-0104(98)00084-6; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; Ge NH, 2002, PHYSCHEMCOMM, V5, P17, DOI 10.1039/b109935c; Golonzka O, 2001, PHYS REV LETT, V86, P2154, DOI 10.1103/PhysRevLett.86.2154; Hamm P, 1998, J PHYS CHEM B, V102, P6123, DOI 10.1021/jp9813286; Hybl JD, 2001, J CHEM PHYS, V115, P6606, DOI 10.1063/1.1398579; Keusters D, 2001, SPRINGER SERIES CHEM, V66, P165; Keusters D, 1999, J PHYS CHEM A, V103, P10369, DOI 10.1021/jp99235b; KHALIL M, IN PRESS J PHYS CH A; Merchant KA, 2001, PHYS REV LETT, V86, P3899, DOI 10.1103/PhysRevLett.86.3899; Mukamel S, 2000, ANNU REV PHYS CHEM, V51, P691, DOI 10.1146/annurev.physchem.51.1.691; Mukamel S., 1995, PRINCIPLES NONLINEAR, V1st; SCHERER NF, 1991, J CHEM PHYS, V95, P1487, DOI 10.1063/1.461064; Scheurer C, 2001, J CHEM PHYS, V115, P4989, DOI 10.1063/1.1391266; TAN HS, UNPUB; TAN HW, COMMUNICATION, P37401; WARREN WS, 1981, J CHEM PHYS, V75, P5956, DOI 10.1063/1.442051; Weiner AM, 2000, REV SCI INSTRUM, V71, P1929, DOI 10.1063/1.1150614; Woutersen S, 2002, J PHYS-CONDENS MAT, V14, pR1035, DOI 10.1088/0953-8984/14/39/202; Woutersen S, 2001, P NATL ACAD SCI USA, V98, P11254, DOI 10.1073/pnas.201169498; Yang WG, 1998, OPT LETT, V23, P1843, DOI 10.1364/OL.23.001843; Zanni MT, 2001, P NATL ACAD SCI USA, V98, P11265, DOI 10.1073/pnas.201412998; 2001, CHEM PHYS, V266, P135	25	373	391	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1553	1555		10.1126/science.1083433	http://dx.doi.org/10.1126/science.1083433			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791987	Green Submitted			2022-12-28	WOS:000183333100049
J	Wirth, S; Yanike, M; Frank, LM; Smith, AC; Brown, EN; Suzuki, WA				Wirth, S; Yanike, M; Frank, LM; Smith, AC; Brown, EN; Suzuki, WA			Single neurons in the monkey hippocampus and learning of new associations	SCIENCE			English	Article							CONDITIONAL OCULOMOTOR ASSOCIATIONS; SUPPLEMENTARY EYE FIELD; PERIRHINAL NEURONS; CORTEX; MEMORY; ACQUISITION; RESPONSES; TASK	The medial temporal lobe is crucial for the ability to learn and retain new declarative memories. This form of memory includes the ability to quickly establish novel associations between unrelated items. To better understand the patterns of neural activity during associative memory formation, we recorded the activity of hippocampal neurons of macaque monkeys as they learned new associations. Hippocampal neurons signaled learning by changing their stimulus-selective response properties. This change in the pattern of selective neural activity occurred before, at the same time as, or after learning, which suggests that these neurons are involved in the initial formation of new associative memories.	NYU, Ctr Neural Sci, New York, NY 10003 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Anesthesia & Crit Care, Harvard MIT Div Hlth Sci & Technol, Boston, MA 02114 USA	New York University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Suzuki, WA (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.		Wirth, Sylvia/M-4752-2017	Wirth, Sylvia/0000-0001-7002-329X; Frank, Loren/0000-0002-1752-5677				Asaad WF, 1998, NEURON, V21, P1399, DOI 10.1016/S0896-6273(00)80658-3; BERGER TW, 1976, SCIENCE, V192, P483, DOI 10.1126/science.1257783; CAHUSAC PMB, 1993, HIPPOCAMPUS, V3, P29, DOI 10.1002/hipo.450030104; CHEN LL, 1995, J NEUROPHYSIOL, V73, P1122, DOI 10.1152/jn.1995.73.3.1122; CHEN LL, 1995, J NEUROPHYSIOL, V73, P1101, DOI 10.1152/jn.1995.73.3.1101; Erickson CA, 1999, J NEUROSCI, V19, P10404; Erickson CA, 2000, NAT NEUROSCI, V3, P1143, DOI 10.1038/80664; Frank LM, 2001, J NEUROPHYSIOL, V86, P2029, DOI 10.1152/jn.2001.86.4.2029; Fyhn M, 2002, NEURON, V35, P555, DOI 10.1016/S0896-6273(02)00784-5; McEchron MD, 1999, HIPPOCAMPUS, V9, P385, DOI 10.1002/(SICI)1098-1063(1999)9:4<385::AID-HIPO5>3.0.CO;2-K; Messinger A, 2001, P NATL ACAD SCI USA, V98, P12239, DOI 10.1073/pnas.211431098; MITZ AR, 1991, J NEUROSCI, V11, P1855; Moody SL, 1998, J NEUROSCI, V18, P399; Naya Y, 2001, SCIENCE, V291, P661, DOI 10.1126/science.291.5504.661; Repa JC, 2001, NAT NEUROSCI, V4, P724, DOI 10.1038/89512; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Squire LR, 1996, P NATL ACAD SCI USA, V93, P13515, DOI 10.1073/pnas.93.24.13515	18	251	255	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1578	1581		10.1126/science.1084324	http://dx.doi.org/10.1126/science.1084324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791995				2022-12-28	WOS:000183333100057
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Serv Task Force	Screening for dementia: Recommendation and rationale	ANNALS OF INTERNAL MEDICINE			English	Article								This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for dementia and the supporting scientific evidence and updates the 1996 recommendations on this topic. The complete USPSTF recommendation and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and the National Guideline Clearinghouse (www.guideline.gov) and in print by subscribing to the Guide to Clinical Preventive Services, Third Edition: Periodic Updates. The cost of this subscription is $60, and it can be ordered through the Agency for Healthcare Research and Quality (AHRQ) Publications Clearinghouse (call 1-800-358-9295 or e-mail ahrqpubs@ahrq.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned. The summary of the evidence is also available in print through the AHRQ Publications Clearinghouse.	US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA	Agency for Healthcare Research & Quality	Berg, AO (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							*AM MED ASS, 2003, PRACT GUID PRIM CAR; *CAN TASK FORC PER, 1994, CAN GUID CLIN PREV H, P902; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; SantaCruz KS, 2001, AM FAM PHYSICIAN, V63, P703	4	36	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					925	926		10.7326/0003-4819-138-11-200306030-00014	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779303				2022-12-28	WOS:000183296400008
J	Lexchin, J; Bero, LA; Djulbegovic, B; Clark, O				Lexchin, J; Bero, LA; Djulbegovic, B; Clark, O			Pharmaceutical industry sponsorship and research outcome and quality: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; REGISTER RANDOMIZED TRIALS; CLINICAL-TRIALS; PUBLICATION BIAS; ECONOMIC-ANALYSES; RHEUMATOID-ARTHRITIS; CONSORT STATEMENT; METAANALYSIS; EFFICACY; TIME	Objective To investigate whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support. Methods Medline (January 1966 to December 2002) and Embase (January 1980 to December 2002) searches were supplemented with material identified in the references and in the authors' personal files. Data were independently abstracted by three of the authors and disagreements were resolved by consensus. Results 30 studies were included. Research funded by drug companies was less likely to be published than research funded by other sources. Studies sponsored by pharmaceutical companies were more likely to have outcomes favouring the sponsor than were studies with other sponsors (odds ratio 4.05; 95% confidence interval 2.98 to 5.51; 18 comparisons). None of the 13 studies that analysed methods reported that studies funded by industry was of poorer quality. Conclusion Systematic bias favours products which are made by the company funding the research. Explanations include the selection of an inappropriate comparator to the product being investigated and publication bias.	York Univ, Sch Hlth Policy & Management, N York, ON M3J 1P3, Canada; Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94118 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94118 USA; Univ S Florida, Interdisciplinary Oncol Program, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Inst Radium Campinas, BR-13075460 Campinas, SP, Brazil	York University - Canada; University of California System; University of California San Francisco; University of California System; University of California San Francisco; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Lexchin, J (corresponding author), York Univ, Sch Hlth Policy & Management, N York, ON M3J 1P3, Canada.	joel.lexchin@utoronto.ca	Djulbegovic, Benjamin/I-3661-2012	Djulbegovic, Benjamin/0000-0003-0671-1447; Bero, Lisa/0000-0003-1893-6651				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; ANDERSON JJ, 1991, ARTHRITIS RHEUM-US, V34, P1304, DOI 10.1002/art.1780341015; Anis AH, 2000, PHARMACOECONOMICS, V18, P55, DOI 10.2165/00019053-200018010-00006; Azimi NA, 1998, J GEN INTERN MED, V13, P664, DOI 10.1046/j.1525-1497.1998.00201.x; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Berlin JA, 1999, JAMA-J AM MED ASSOC, V282, P1083, DOI 10.1001/jama.282.11.1083; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Chard JA, 2000, ANN RHEUM DIS, V59, P414, DOI 10.1136/ard.59.6.414; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; CLIFFORD TJ, FUNDING SOURCE TRIAL; Davidoff F, 2001, NEW ENGL J MED, V345, P825, DOI 10.1056/NEJMed20010093; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Dieppe P, 1999, LANCET, V353, P1626, DOI 10.1016/S0140-6736(05)75755-X; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Djulbegovic B, 2001, Curr Oncol Rep, V3, P389, DOI 10.1007/s11912-001-0024-5; Djulbegovic B, 1999, BLOOD, V94, p399A; Dorman PJ, 1999, STROKE, V30, P1995, DOI 10.1161/01.STR.30.10.1995; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Freemantle N, 2000, BRIT J PSYCHIAT, V177, P292, DOI 10.1192/bjp.177.4.292; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; HENNCKENS CH, 1987, EPIDEMIOLOGY MED; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Hill SR, 2000, JAMA-J AM MED ASSOC, V283, P2116, DOI 10.1001/jama.283.16.2116; Horton R, 1999, LANCET, V354, P1138, DOI 10.1016/S0140-6736(99)00328-1; Horton R, 1999, BRIT MED J, V319, P865, DOI 10.1136/bmj.319.7214.865; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Johansen HK, 1999, JAMA-J AM MED ASSOC, V282, P1752, DOI 10.1001/jama.282.18.1752; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kamal-Bahl S, 2002, ARCH PEDIAT ADOL MED, V156, P1034, DOI 10.1001/archpedi.156.10.1034; Kemmeren JM, 2001, BMJ, V323, P1; Kjaergard LL, 1999, HEPATOLOGY, V30, P1134, DOI 10.1002/hep.510300510; Knox KS, 2000, ANN ONCOL, V11, P1591, DOI 10.1023/A:1008309817708; Koepp R, 1999, JAMA-J AM MED ASSOC, V281, P2287, DOI 10.1001/jama.281.24.2287; Liebeskind DS, 1999, STROKE, V30, P268; Mandelkern M, 1999, J CLIN PSYCHIAT, V60, P122, DOI 10.4088/JCP.v60n0210a; MASSIE BM, 1993, NEW ENGL J MED, V328, P1196; MASSIE BM, 1984, CIRCULATION, V70, P390; Matthews JNS, 1999, BRIT MED J, V318, P1762, DOI 10.1136/bmj.318.7200.1762a; McCarthy M, 2000, LANCET, V356, P1659, DOI 10.1016/S0140-6736(00)03166-4; MEINERT CL, 1988, CONTROL CLIN TRIALS, V9, P1, DOI 10.1016/0197-2456(88)90002-5; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Moher D., 1999, HEALTH TECHNOL ASSES, V3, pi, DOI [DOI 10.3310/HTA3120, 10.3310/hta3120]; Nathan DG, 1999, LANCET, V353, P771, DOI 10.1016/S0140-6736(99)00072-0; Neumann PJ, 2000, HEALTH AFFAIR, V19, P92, DOI 10.1377/hlthaff.19.2.92; *PHARM RES MAN AM, 2003, 2001 IND PROF; Qizilbash N, 1999, JAMA-J AM MED ASSOC, V281, P2287; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Sacristan JA, 1997, PHARMACOECONOMICS, V11, P289; Safer DJ, 2002, J NERV MENT DIS, V190, P583, DOI 10.1097/00005053-200209000-00002; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Tallon D, 2000, LANCET, V355, P2037, DOI 10.1016/S0140-6736(00)02351-5; Thomas PS, 2002, LANCET, V359, P351, DOI 10.1016/S0140-6736(02)07506-2; Vandenbroucke JP, 2000, BRIT MED J, V320, P381; Wahlbeck K, 1999, BRIT MED J, V318, P465; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W; Yaphe J, 2001, FAM PRACT, V18, P565, DOI 10.1093/fampra/18.6.565	66	1430	1473	5	103	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2003	326	7400					1167	1170B		10.1136/bmj.326.7400.1167	http://dx.doi.org/10.1136/bmj.326.7400.1167			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	686FC	12775614	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000183309900014
J	Valentino, R; Hilbert, G; Vargas, F; Gruson, D				Valentino, R; Hilbert, G; Vargas, F; Gruson, D			Computed tomographic scan of massive cerebral air embolism	LANCET			English	Editorial Material									Serv Reanimat Med B, F-33076 Bordeaux, France		Valentino, R (corresponding author), Serv Reanimat Med B, F-33076 Bordeaux, France.		Formisano, Pietro/J-4237-2018						0	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1848	1848		10.1016/S0140-6736(03)13502-7	http://dx.doi.org/10.1016/S0140-6736(03)13502-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788570				2022-12-28	WOS:000183205800008
J	Hudson, BG; Tryggvason, K; Sundaramoorthy, M; Neilson, EG				Hudson, BG; Tryggvason, K; Sundaramoorthy, M; Neilson, EG			Alport's syndrome, Goodpasture's syndrome, and type IV collagen	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GLOMERULAR-BASEMENT-MEMBRANE; NONCOLLAGENOUS NC1 DOMAIN; NAIL-PATELLA SYNDROME; ANTI-GBM NEPHRITIS; ALPHA-3(IV) COLLAGEN; MOLECULAR-BASIS; CRESCENTIC GLOMERULONEPHRITIS; DIFFUSE LEIOMYOMATOSIS; EXTRACELLULAR-MATRIX; FAMILIAL HEMATURIA		Vanderbilt Univ, Med Ctr, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden	Vanderbilt University; Vanderbilt University; Vanderbilt University; Karolinska Institutet	Neilson, EG (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Med, D-3100 MCN, Nashville, TN 37232 USA.	eric.neilson@vanderbilt.edu	Wilson, Matthew H/K-3193-2013	Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [DK-62524, DK-55926, DK-53763, DK-46282, DK-18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055926, P01DK053763, R01DK018381, R01DK046282, R37DK018381, R01DK062524] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler Liora, 2002, BMC Nephrol, V3, P2, DOI 10.1186/1471-2369-3-2; ALMKUIST RD, 1981, CLIN IMMUNOL IMMUNOP, V18, P54, DOI 10.1016/0090-1229(81)90007-6; Alport AC, 1927, BMJ-BRIT MED J, V1927, P504, DOI 10.1136/bmj.1.3454.504; ANTIGNAC C, 1992, KIDNEY INT, V42, P1178, DOI 10.1038/ki.1992.402; Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Badenas C, 2002, J AM SOC NEPHROL, V13, P1248, DOI 10.1681/ASN.V1351248; BARICOS WH, 1991, ARCH BIOCHEM BIOPHYS, V288, P468, DOI 10.1016/0003-9861(91)90222-5; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BOLTON WK, 1995, KIDNEY INT, V47, P404, DOI 10.1038/ki.1995.53; Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; BOSCH X, 1991, CLIN NEPHROL, V36, P107; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; Buzza M, 2001, KIDNEY INT, V59, P1670, DOI 10.1046/j.1523-1755.2001.0590051670.x; Byrne MC, 2002, AM J KIDNEY DIS, V39, P769, DOI 10.1053/ajkd.2002.31997; Colville DJ, 1997, OPHTHALMIC GENET, V18, P161, DOI 10.3109/13816819709041431; Cosgrove D, 1998, HEARING RES, V121, P84, DOI 10.1016/S0378-5955(98)00069-0; Dagher H, 2001, AM J KIDNEY DIS, V38, P1217, DOI 10.1053/ajkd.2001.29217; David M, 2001, J BIOL CHEM, V276, P6370, DOI 10.1074/jbc.M008956200; Davies JA, 1997, BIOESSAYS, V19, P699, DOI 10.1002/bies.950190810; DERRY CJ, 1995, CLIN EXP IMMUNOL, V100, P262; DISCHE FE, 1990, J CLIN PATHOL, V43, P457, DOI 10.1136/jcp.43.6.457; DONAGHY M, 1983, LANCET, V2, P1390; Fowler SJ, 2000, J BIOL CHEM, V275, P39589, DOI 10.1074/jbc.M005871200; GOODPASTURE EW, 1919, US NAVAL MED B, V13, P177; Gross O, 2002, NEPHROL DIAL TRANSPL, V17, P1218, DOI 10.1093/ndt/17.7.1218; Grunfeld JP, 2000, RENAL FAILURE, V22, P759, DOI 10.1081/JDI-100101961; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Gunnarsson A, 2000, J BIOL CHEM, V275, P30844, DOI 10.1074/jbc.M004717200; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, AM J RESP CELL MOL, V5, P107, DOI 10.1165/ajrcmb/5.2.107; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; Hamano Y, 2002, J BIOL CHEM, V277, P31154, DOI 10.1074/jbc.M204806200; Harvey SJ, 1998, KIDNEY INT, V54, P1857, DOI 10.1046/j.1523-1755.1998.00188.x; HASSTEDT SJ, 1986, AM J HUM GENET, V38, P940; Heikkila P, 2001, GENE THER, V8, P882, DOI 10.1038/sj.gt.3301342; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Holdsworth SR, 1999, KIDNEY INT, V55, P1198, DOI 10.1046/j.1523-1755.1999.00369.x; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; Huang T, 2000, INT J DEV NEUROSCI, V18, P259, DOI 10.1016/S0736-5748(99)00094-5; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Isbel NM, 2001, KIDNEY INT, V60, P614, DOI 10.1046/j.1523-1755.2001.060002614.x; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Jais JP, 2000, J AM SOC NEPHROL, V11, P649, DOI 10.1681/ASN.V114649; Kalluri R, 1998, CONNECT TISSUE RES, V37, P143, DOI 10.3109/03008209809028906; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 1996, P ASSOC AM PHYSICIAN, V108, P134; Kalluri R, 1996, ANN INTERN MED, V124, P651, DOI 10.7326/0003-4819-124-7-199604010-00005; Kalluri R, 2000, TRANSPLANTATION, V69, P679, DOI 10.1097/00007890-200002270-00038; Kalluri R, 1997, J CLIN INVEST, V100, P2263, DOI 10.1172/JCI119764; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; Kalluri R, 1997, J AM SOC NEPHROL, V8, P1795; Kalluri R, 2000, J BIOL CHEM, V275, P20027, DOI 10.1074/jbc.M904549199; Kashtan C E, 1996, Contrib Nephrol, V117, P142; Kashtan CE, 1995, PEDIATR NEPHROL, V9, P679, DOI 10.1007/BF00868709; Kashtan CE, 2001, CONTRIB NEPHROL, V136, P79; KEFALIDES NA, 1966, BIOCHEM BIOPH RES CO, V22, P26, DOI 10.1016/0006-291X(66)90597-3; KIM KH, 1995, J AM SOC NEPHROL, V5, P1659; Kitching AR, 1999, EUR J IMMUNOL, V29, P1; Kitching AR, 2002, J AM SOC NEPHROL, V13, P350, DOI 10.1681/ASN.V132350; Kluth DC, 1999, J AM SOC NEPHROL, V10, P2446; Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455; LANGEVELD JPM, 1991, J BIOL CHEM, V266, P2622; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269; Lemmink HH, 1996, J CLIN INVEST, V98, P1114, DOI 10.1172/JCI118893; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Levy JB, 2001, ANN INTERN MED, V134, P1033, DOI 10.7326/0003-4819-134-11-200106050-00009; LOCKWOOD CM, 1980, ANNU REV MED, V31, P167, DOI 10.1146/annurev.me.31.020180.001123; Longo I, 2002, KIDNEY INT, V61, P1947, DOI 10.1046/j.1523-1755.2002.00379.x; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; Martin P, 1998, J AM SOC NEPHROL, V9, P2291; MCCOY RC, 1982, KIDNEY INT, V21, P642, DOI 10.1038/ki.1982.72; McIntosh I, 1998, AM J HUM GENET, V63, P1651, DOI 10.1086/302165; Meyers KEC, 1998, KIDNEY INT, V53, P402, DOI 10.1046/j.1523-1755.1998.00827.x; Meyers KEC, 2002, KIDNEY INT, V61, P1666, DOI 10.1046/j.1523-1755.2002.00312.x; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Miner JH, 2002, J CLIN INVEST, V109, P1065, DOI 10.1172/JCi200213954; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; Morello R, 2001, NAT GENET, V27, P205, DOI 10.1038/84853; MYERS JC, 1990, AM J HUM GENET, V46, P1024; NAYAK BR, 1991, J BIOL CHEM, V266, P13978; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; Netzer KO, 1998, NEPHROL DIAL TRANSPL, V13, P1346, DOI 10.1093/oxfordjournals.ndt.a027889; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; OOHASHI T, 1994, J BIOL CHEM, V269, P7520; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; Phelps RG, 1999, KIDNEY INT, V56, P1638, DOI 10.1046/j.1523-1755.1999.00720.x; Reddan JR, 1996, CELL MOL BIOL, V42, P209; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Remuzzi G, 1993, Curr Opin Nephrol Hypertens, V2, P465, DOI 10.1097/00041552-199305000-00015; Reynolds J, 2000, J CLIN INVEST, V105, P643, DOI 10.1172/JCI6710; RUMPELT HJ, 1987, PEDIATR NEPHROL, V1, P422, DOI 10.1007/BF00849248; Rutgers A, 2000, KIDNEY INT, V58, P115, DOI 10.1046/j.1523-1755.2000.00146.x; Sado Y, 1998, KIDNEY INT, V54, P311; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; Salama AD, 2002, AM J KIDNEY DIS, V39, P1162, DOI 10.1053/ajkd.2002.33385; Salama AD, 2001, J AM SOC NEPHROL, V12, P1908, DOI 10.1681/ASN.V1291908; SAUS J, 1988, J BIOL CHEM, V263, P13374; SAVAGE COS, 1986, BRIT MED J, V292, P301, DOI 10.1136/bmj.292.6516.301; Schock F, 2002, ANNU REV CELL DEV BI, V18, P463, DOI 10.1146/annurev.cellbio.18.022602.131838; Sheerin NS, 1997, CLIN EXP IMMUNOL, V110, P403, DOI 10.1046/j.1365-2249.1997.4261438.x; SOININEN R, 1987, FEBS LETT, V225, P188; Spear G S, 1974, Pathol Annu, V9, P93; Spear G S, 1973, Clin Nephrol, V1, P336; STANTON M. C., 1958, AUSTRALASEAN ANN MED, V7, P132; STEVENSON A, 1995, QJM-MON J ASSOC PHYS, V88, P23; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; Timoshanko JR, 2002, J IMMUNOL, V168, P4135, DOI 10.4049/jimmunol.168.8.4135; Timoshanko JR, 2001, J AM SOC NEPHROL, V12, P464, DOI 10.1681/ASN.V123464; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; Tipping PG, 1997, EUR J IMMUNOL, V27, P530, DOI 10.1002/eji.1830270226; TRYGGVASON K, 1980, BIOCHEMISTRY-US, V19, P1284, DOI 10.1021/bi00548a003; van Setten G, 2001, J CATARACT REFR SURG, V27, P1071, DOI 10.1016/S0886-3350(00)00836-1; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P3838, DOI 10.1073/pnas.81.12.3838; WILLIAMSON D, 1961, LANCET, V2, P1321; WILSON CB, 1973, KIDNEY INT, V3, P74, DOI 10.1038/ki.1973.14; Wong DC, 2001, KIDNEY INT, V60, P1777, DOI 10.1046/j.1523-1755.2001.00014.x; Wu J, 2002, J CLIN INVEST, V109, P517, DOI 10.1172/JCI200213876; Wu J, 2001, J IMMUNOL, V167, P2388, DOI 10.4049/jimmunol.167.4.2388; YOSHIOKA K, 1994, AM J PATHOL, V144, P986; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; Yurchenco PD, 2002, METHOD CELL BIOL, V69, P111, DOI 10.1016/S0091-679X(02)69010-7; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zeisberg M, 2002, AM J PATHOL, V160, P2001, DOI 10.1016/S0002-9440(10)61150-9; Zhang X, 1996, GENOMICS, V33, P473, DOI 10.1006/geno.1996.0222; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176; ZHOU J, 1994, J BIOL CHEM, V269, P13193; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	141	632	686	2	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2543	2556		10.1056/NEJMra022296	http://dx.doi.org/10.1056/NEJMra022296			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815141				2022-12-28	WOS:000183577200010
J	Zhong, WW; Feng, H; Santiago, FE; Kipreos, ET				Zhong, WW; Feng, H; Santiago, FE; Kipreos, ET			CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing	NATURE			English	Article							MITOTIC CHROMOSOME CONDENSATION; CAENORHABDITIS-ELEGANS; C-ELEGANS; CELL-CYCLE; S-PHASE; PROTEIN; CDT1; PROLIFERATION; INTERFERENCE; EXPRESSION	To maintain genome stability, DNA replication is strictly regulated to occur only once per cell cycle. In eukaryotes, the presence of 'licensing proteins' at replication origins during the G1 cell-cycle phase allows the formation of the pre-replicative complex(1). The removal of licensing proteins from chromatin during the S phase ensures that origins fire only once per cell cycle(1). Here we show that the CUL-4 ubiquitin ligase temporally restricts DNA-replication licensing in Caenorhabditis elegans. Inactivation of CUL-4 causes massive DNA re-replication, producing cells with up to 100C DNA content. The C. elegans orthologue of the replication-licensing factor Cdt1 (refs 2, 3) is required for DNA replication. C. elegans CDT-1 is present in G1-phase nuclei but disappears as cells enter S phase. In cells lacking CUL-4, CDT-1 levels fail to decrease during S phase and instead remain constant in the re-replicating cells. Removal of one genomic copy of cdt-1 suppresses the cul-4 re-replication phenotype. We propose that CUL-4 prevents aberrant re-initiation of DNA replication, at least in part, by facilitating the degradation of CDT-1.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Kipreos, ET (corresponding author), Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.		Feng, Hui/D-4423-2019; Santiago, Fernando Enrique/GLS-9127-2022; Feng, Hui/L-4343-2019	Feng, Hui/0000-0003-1318-821X; Santiago, Fernando/0000-0001-9514-3722				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Cimbora DM, 2001, CELL, V104, P643, DOI 10.1016/S0092-8674(01)00260-4; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hong Y, 1998, DEVELOPMENT, V125, P3585; Koppen M, 2001, NAT CELL BIOL, V3, P983, DOI 10.1038/ncb1101-983; Lorson MA, 2000, J CELL BIOL, V148, P73, DOI 10.1083/jcb.148.1.73; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; MILLER DM, 1995, CAENORHABDITIS ELEGA, P365; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Praitis V, 2001, GENETICS, V157, P1217; Seydoux G, 2001, INT REV CYTOL, V203, P139; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648	30	251	260	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					885	889		10.1038/nature01747	http://dx.doi.org/10.1038/nature01747			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815436				2022-12-28	WOS:000183585300050
J	Eaton, L				Eaton, L			Saddle up, partner	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ, London WC1H 9JR, England		Eaton, L (corresponding author), BMJ, London WC1H 9JR, England.	leaton@bmj.com							0	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2003	326	7402					1275	1275		10.1136/bmj.326.7402.1275	http://dx.doi.org/10.1136/bmj.326.7402.1275			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805125	Green Published			2022-12-28	WOS:000183626500001
J	Lonser, RR; Glenn, GM; Walther, M; Chew, EY; Libutti, SK; Linehan, WM; Oldfield, EH				Lonser, RR; Glenn, GM; Walther, M; Chew, EY; Libutti, SK; Linehan, WM; Oldfield, EH			von Hippel-Lindau disease	LANCET			English	Review							TUMOR-SUPPRESSOR GENE; CENTRAL-NERVOUS-SYSTEM; RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; SPORADIC CEREBELLAR HEMANGIOBLASTOMAS; ENDOLYMPHATIC SAC TUMORS; VHL GENE; PAPILLARY CYSTADENOMA; GERMLINE MUTATIONS; NEUROENDOCRINE TUMORS	von Hippel-Lindau disease is a heritable multisystem cancer syndrome that is associated with a germline mutation of the VHL tumour suppressor gene on the short arm of chromosome 3. This disorder is not rare (about one in 36 000 livebirths) and Is Inherited as a highly penetrant autosomal dominant trait (le, with a high individual risk of disease). Affected individuals are at risk of developing various benign and malignant tumours of the central nervous system, kidneys, adrenal glands, pancreas, and reproductive adnexal organs. Because of the complexities associated with management of the various types of tumours in this disease, treatment is multidisciplinary. We present an overview of the clinical aspects, management, and treatment options for von Hippel-Lindau disease.	NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA; NEI, Clin Trials Branch, NIH, Bethesda, MD 20892 USA; NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lonser, RR (corresponding author), NINDS, Surg Neurol Branch, NIH, Bldg 10,Room 5D37, Bethesda, MD 20892 USA.	lonserr@ninds.nih.gov			Intramural NIH HHS [Z99 EY999999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC006659, Z01SC010368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002855] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aiello LP, 2002, OPHTHALMOLOGY, V109, P1745, DOI 10.1016/S0161-6420(02)01159-4; Baghai M, 2002, ARCH SURG-CHICAGO, V137, P682, DOI 10.1001/archsurg.137.6.682; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BILLESBOLLE P, 1988, J UROLOGY, V139, P1062, DOI 10.1016/S0022-5347(17)42773-X; BINKOVITZ LA, 1990, AM J ROENTGENOL, V155, P501, DOI 10.2214/ajr.155.3.1974734; Bohling T, 1996, J NEUROPATH EXP NEUR, V55, P522; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Brieger J, 1999, J MOL MED-JMM, V77, P505, DOI 10.1007/s001099900022; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chakraborti PR, 1997, BRIT J NEUROSURG, V11, P110; Chan CC, 1999, ARCH OPHTHALMOL-CHIC, V117, P625; CHANDLER HC, 1994, NEUROSURGERY, V34, P353, DOI 10.1227/00006123-199402000-00021; Chang SD, 1998, NEUROSURGERY, V43, P28, DOI 10.1097/00006123-199807000-00018; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CHOYKE PL, 1992, AM J ROENTGENOL, V159, P1229, DOI 10.2214/ajr.159.6.1442389; Choyke PL, 1997, UROLOGY, V49, P926, DOI 10.1016/S0090-4295(97)00074-5; CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955; Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cybulski C, 2002, J MED GENET, V39, DOI 10.1136/jmg.39.7.e38; Dollfus H, 2002, INVEST OPHTH VIS SCI, V43, P3067; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Eisenhofer G, 1999, NEW ENGL J MED, V340, P1872, DOI 10.1056/NEJM199906173402404; ESCOUROLLE R, 1978, MANUAL NEUROPATHOLOG, P49; FILLINGKATZ MR, 1991, NEUROLOGY, V41, P41, DOI 10.1212/WNL.41.1.41; Friedrich CA, 1999, CANCER-AM CANCER SOC, V86, P2478, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5; FUNK KC, 1989, AM J ROENTGENOL, V153, P527, DOI 10.2214/ajr.153.3.527; GAFFEY MJ, 1994, AM J SURG PATHOL, V18, P1254, DOI 10.1097/00000478-199412000-00009; Gallou C, 1999, HUM MUTAT, V13, P464, DOI 10.1002/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A; GERSELL DJ, 1988, AM J SURG PATHOL, V12, P145, DOI 10.1097/00000478-198802000-00008; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GRUBER MB, 1980, UROLOGY, V16, P305, DOI 10.1016/0090-4295(80)90053-9; Hammel PR, 2000, GASTROENTEROLOGY, V119, P1087, DOI 10.1053/gast.2000.18143; Hes F, 2000, HUM GENET, V106, P425, DOI 10.1007/s004390000265; HOUGH DM, 1994, AM J ROENTGENOL, V162, P1091, DOI 10.2214/ajr.162.5.8165988; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; KANNO H, 1994, CANCER RES, V54, P4845; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee JY, 1998, CANCER RES, V58, P504; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Libutti SK, 1998, SURGERY, V124, P1153, DOI 10.1067/msy.1998.91823; Libutti SK, 2000, SURGERY, V128, P1022, DOI 10.1067/msy.2000.110239; Linehan W.M., 2002, GENETIC BASIS HUMAN; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; LINEHAN WM, 2001, METABOLIC MOL BASES, P907; Lissens P, 1995, Acta Urol Belg, V63, P109; Lonser RR, 2003, J NEUROSURG, V98, P106, DOI 10.3171/jns.2003.98.1.0106; Lubensky IA, 1998, AM J PATHOL, V153, P223, DOI 10.1016/S0002-9440(10)65563-0; Maddock IR, 1996, J MED GENET, V33, P120, DOI 10.1136/jmg.33.2.120; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Malis LI, 2002, J NEUROSURG, V97, P1, DOI 10.3171/spi.2002.97.1.0001; Manski TJ, 1997, JAMA-J AM MED ASSOC, V277, P1461, DOI 10.1001/jama.277.18.1461; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; NEUMANN HPH, 1992, J NEUROL NEUROSUR PS, V55, P898, DOI 10.1136/jnnp.55.10.898; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; NEUMANN HPH, 1991, GASTROENTEROLOGY, V101, P465, DOI 10.1016/0016-5085(91)90026-H; Niemela M, 1996, J NEUROSURG, V85, P591, DOI 10.3171/jns.1996.85.4.0591; Oberstrass J, 1996, J PATHOL, V179, P151, DOI 10.1002/(SICI)1096-9896(199606)179:2<151::AID-PATH556>3.0.CO;2-0; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; PAGE KA, 1993, SURG NEUROL, V40, P424, DOI 10.1016/0090-3019(93)90225-P; Patrice SJ, 1996, INT J RADIAT ONCOL, V35, P493; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pavlovich C P, 2001, Curr Urol Rep, V2, P19, DOI 10.1007/s11934-001-0021-0; Pavlovich CP, 2002, J UROLOGY, V167, P10, DOI 10.1016/S0022-5347(05)65371-2; POSTON CD, 1995, J UROLOGY, V153, P22, DOI 10.1097/00005392-199501000-00009; REIFENBERGER G, 1995, AM J PATHOL, V147, P245; Richard S, 1998, J INTERN MED, V243, P547; Richard S, 2000, NEUROSURG REV, V23, P1, DOI 10.1007/s101430050024; Seagroves T, 2002, CANCER CELL, V1, P211, DOI 10.1016/S1535-6108(02)00048-X; Sgambati MT, 2000, AM J HUM GENET, V66, P84, DOI 10.1086/302726; Shingleton WB, 2002, J UROLOGY, V167, P1268, DOI 10.1016/S0022-5347(05)65279-2; Shingleton WB, 2001, J UROLOGY, V165, P773, DOI 10.1016/S0022-5347(05)66523-8; Singh AD, 2002, OPHTHALMOLOGY, V109, P1799, DOI 10.1016/S0161-6420(02)01177-6; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; Tse JYM, 1997, AM J CLIN PATHOL, V107, P459; Vortmeyer AO, 1997, HUM PATHOL, V28, P540, DOI 10.1016/S0046-8177(97)90075-7; Walther MM, 1999, J UROLOGY, V161, P1475, DOI 10.1016/S0022-5347(05)68930-6; WALTHER MM, 1995, J UROLOGY, V154, P2010, DOI 10.1016/S0022-5347(01)66674-6; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; Wanebo JE, 2003, J NEUROSURG, V98, P82, DOI 10.3171/jns.2003.98.1.0082; Webster AR, 1999, ARCH OPHTHALMOL-CHIC, V117, P371, DOI 10.1001/archopht.117.3.371; Weil RJ, 2003, J NEUROSURG, V98, P95, DOI 10.3171/jns.2003.98.1.0095; Weise M, 2002, J CLIN ENDOCR METAB, V87, P1955, DOI 10.1210/jc.87.5.1955; WERNERT N, 1986, PATHOL RES PRACT, V181, P260, DOI 10.1016/S0344-0338(86)80022-X; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	98	953	994	1	52	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2059	2067		10.1016/S0140-6736(03)13643-4	http://dx.doi.org/10.1016/S0140-6736(03)13643-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814730				2022-12-28	WOS:000183488900025
J	Aleman, BMP; Raemaekers, JMM; Tirelli, U; Bortolus, R; van't Veer, MB; Lybeert, MLM; Keuning, JJ; Carde, P; Girinsky, T; van der Maazen, RWM; Tomsic, R; Vovk, M; van Hoof, A; Demeestere, G; Lugtenburg, PJ; Thomas, J; Schroyens, W; De Boeck, K; Baars, JW; Kluin-Nelemans, JC; Carrie, C; Aoudjhane, M; Bron, D; Eghbali, H; Smit, WGJM; Meerwaldt, JH; Hagenbeek, A; Pinna, A; Henry-Amar, M				Aleman, BMP; Raemaekers, JMM; Tirelli, U; Bortolus, R; van't Veer, MB; Lybeert, MLM; Keuning, JJ; Carde, P; Girinsky, T; van der Maazen, RWM; Tomsic, R; Vovk, M; van Hoof, A; Demeestere, G; Lugtenburg, PJ; Thomas, J; Schroyens, W; De Boeck, K; Baars, JW; Kluin-Nelemans, JC; Carrie, C; Aoudjhane, M; Bron, D; Eghbali, H; Smit, WGJM; Meerwaldt, JH; Hagenbeek, A; Pinna, A; Henry-Amar, M		European Org Res Treatment Canc Ly	Involved-field radiotherapy for advanced Hodgkin's lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DETUDES-DES-LYMPHOMES; LADULTE H89 TRIAL; 2ND MALIGNANCY; ALTERNATING CHEMOTHERAPY; ALKYLATING-AGENTS; COOPERATIVE GROUP; SALVAGE THERAPY; 6 CYCLES; DISEASE; RISK	Background: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. Methods: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP-ABV) to receive either no further treatment or involved-field radiotherapy. Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy to all initially involved extranodal sites. Patients in partial remission were treated with 30 Gy to nodal areas and 18 to 24 Gy to extranodal sites. Results: Of 739 patients, 421 had a complete remission; 161 of these patients were assigned to no further treatment, and 172 to involved-field radiotherapy. The median follow-up was 79 months. The five-year event-free survival rate was 84 percent in the group that did not receive radiotherapy and 79 percent in the group that received involved-field radiotherapy (P=0.35). The five-year overall survival rates were 91 and 85 percent, respectively (P=0.07). Among the 250 patients in partial remission after chemotherapy, the five-year event-free and overall survival rates were 79 and 87 percent, respectively. Conclusions: Involved-field radiotherapy did not improve the outcome in patients with advanced-stage Hodgkin's lymphoma who had a complete remission after MOPP-ABV chemotherapy. Radiotherapy may benefit patients with a partial response after chemotherapy.	Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands; Univ Med Ctr Nijmegen, Nijmegen, Netherlands; Natl Canc Inst, Aviano, Italy; Erasmus Univ, Med Ctr, Rotterdam, Netherlands; Catharina Hosp, Eindhoven, Netherlands; Maxima Med Ctr, Veldhoven, Netherlands; Inst Gustave Roussy, Villejuif, France; Inst Oncol, Ljubljana, Slovenia; Oncol Ctr Algemeen Ziekenhuis St Jan, Brugge, Belgium; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Univ Antwerp Hosp, Edegem, Belgium; Algemeen Zienkenhuis Middelheim, Antwerp, Belgium; Leiden Univ, Med Ctr, Leiden, Netherlands; Ctr Leon Berard, F-69373 Lyon, France; Hop St Antoine, F-75571 Paris, France; Inst Jules Bordet, B-1000 Brussels, Belgium; Inst Bergonie Bordeaux, Bordeaux, France; Radiotherapeut Inst Friesland, Leeuwarden, Netherlands; Med Spectrum Twente, Enschede, Netherlands; Univ Med Ctr Utrecht, Utrecht, Netherlands; Ctr Francois Baclesse, F-14021 Caen, France	Netherlands Cancer Institute; Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Catharina Hospital; Maxima Medical Center; UNICANCER; Gustave Roussy; Institute of Oncology - Slovenia; KU Leuven; University Hospital Leuven; University of Antwerp; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; UNICANCER; Centre Leon Berard; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut Jules Bordet; UNICANCER; Institut Bergonie; Medical Spectrum Twente; Utrecht University; Utrecht University Medical Center; UNICANCER; Centre Francois Baclesse	Aleman, BMP (corresponding author), Netherlands Canc Inst, Dept Radiotherapy, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		van der Maazen, R.W.M./L-4498-2015; Bortolus, Roberto/AAC-1859-2020; Kluin-Nelemans, Johanna C/F-8658-2018; shaoping, liang/I-3447-2012; Henry-Amar, Michel/S-9358-2019	Bortolus, Roberto/0000-0002-1268-4425; Kluin-Nelemans, Johanna C/0000-0003-2617-9427; Henry-Amar, Michel/0000-0002-9357-6476				CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Canellos GP, 2002, NEW ENGL J MED, V346, P1417, DOI 10.1056/NEJM200205023461821; Coleman M, 1998, INT J RADIAT ONCOL, V41, P639, DOI 10.1016/S0360-3016(98)00071-6; DEVITA VT, 1980, ANN INTERN MED, V92, P587, DOI 10.7326/0003-4819-92-5-587; Diehl V, 1998, J CLIN ONCOL, V16, P3810, DOI 10.1200/JCO.1998.16.12.3810; Diehl V, 1995, ANN ONCOL, V6, P901, DOI 10.1093/oxfordjournals.annonc.a059357; DIXON DO, 1987, J CLIN ONCOL, V5, P1670, DOI 10.1200/JCO.1987.5.10.1670; Duggan DB, 2003, J CLIN ONCOL, V21, P607, DOI 10.1200/JCO.2003.12.086; FABIAN CJ, 1994, ANN INTERN MED, V120, P903, DOI 10.7326/0003-4819-120-11-199406010-00002; Ferme C, 2000, BLOOD, V95, P2246; Ferme C, 2002, J CLIN ONCOL, V20, P467, DOI 10.1200/JCO.20.2.467; Glick JH, 1998, J CLIN ONCOL, V16, P19, DOI 10.1200/JCO.1998.16.1.19; Hancock, 1996, Semin Radiat Oncol, V6, P225, DOI 10.1016/S1053-4296(96)80018-X; Henry-Amar M, 1992, Ann Oncol, V3 Suppl 4, P117; HENRYAMAR M, 1990, INT J RADIAT ONCOL, V19, P1155, DOI 10.1016/0360-3016(90)90221-5; Horning SJ, 2000, J CLIN ONCOL, V18, P972, DOI 10.1200/JCO.2000.18.5.972; International Commission of Radiation Units and Measurements, 1978, 29 ICRU; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KLIMO P, 1985, J CLIN ONCOL, V3, P1174, DOI 10.1200/JCO.1985.3.9.1174; LEE CKK, 1980, CANCER-AM CANCER SOC, V46, P2403, DOI 10.1002/1097-0142(19801201)46:11<2403::AID-CNCR2820461116>3.0.CO;2-9; Loeffler M, 1998, J CLIN ONCOL, V16, P818, DOI 10.1200/JCO.1998.16.3.818; MAUCH PM, 1985, J CLIN ONCOL, V3, P501, DOI 10.1200/JCO.1985.3.4.501; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; Ng AK, 2002, J CLIN ONCOL, V20, P2101, DOI 10.1200/JCO.2002.08.021; PAVLOVSKY S, 1992, ANN ONCOL, V3, P533, DOI 10.1093/oxfordjournals.annonc.a058255; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; Raemaekers J, 1997, ANN ONCOL, V8, P111, DOI 10.1023/A:1008286824606; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; SOMERS R, 1994, J CLIN ONCOL, V12, P279, DOI 10.1200/JCO.1994.12.2.279; Statacorp, 2001, STAT STAT SOFTW REL; Sureda A, 2001, J CLIN ONCOL, V19, P1395, DOI 10.1200/JCO.2001.19.5.1395; Swerdlow AJ, 2000, J CLIN ONCOL, V18, P498, DOI 10.1200/JCO.2000.18.3.498; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; Swerdlow AJ, 1997, BRIT J CANCER, V75, P116, DOI 10.1038/bjc.1997.19; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; van Leeuwen FE, 2000, J CLIN ONCOL, V18, P487, DOI 10.1200/JCO.2000.18.3.487; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P1063, DOI 10.1200/JCO.1994.12.5.1063; WARTELLE M, 1983, P 2 INT WORKSH STAT; YAHALOM J, 1991, J CLIN ONCOL, V9, P2193, DOI 10.1200/JCO.1991.9.12.2193; Yuen AR, 1997, BLOOD, V89, P814, DOI 10.1182/blood.V89.3.814	40	212	224	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2396	2406		10.1056/NEJMoa022628	http://dx.doi.org/10.1056/NEJMoa022628			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802025	Green Published			2022-12-28	WOS:000183428900005
J	Dalton, AB; Collins, S; Munoz, E; Razal, JM; Ebron, VH; Ferraris, JP; Coleman, JN; Kim, BG; Baughman, RH				Dalton, AB; Collins, S; Munoz, E; Razal, JM; Ebron, VH; Ferraris, JP; Coleman, JN; Kim, BG; Baughman, RH			Super-tough carbon-nanotube fibres - These extraordinary composite fibres can be woven into electronic textiles.	NATURE			English	Article							SPIDER SILK; FIBERS; ROPES		Univ Texas, Dept Chem, Richardson, TX 75080 USA; Univ Texas, NanoTech Inst, Richardson, TX 75080 USA; Univ Dublin Trinity Coll, Dept Phys, Dublin 2, Ireland	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; Trinity College Dublin	Dalton, AB (corresponding author), Univ Texas, Dept Chem, Richardson, TX 75080 USA.		Coleman, Jonathan N/B-8403-2011; Dalton, Alan B/A-1643-2018; Baughman, Ray/A-8628-2018; Dalton, Alan/B-3739-2010; Razal, Joselito M/E-6741-2011; Razal, Joselito M/G-7597-2011; Dalton, Alan/AAI-3508-2020; Munoz, Edgar/M-1722-2014	Coleman, Jonathan N/0000-0001-9659-9721; Dalton, Alan B/0000-0001-8043-1377; Baughman, Ray/0000-0001-5845-5137; Dalton, Alan/0000-0001-8043-1377; Razal, Joselito M/0000-0002-9758-3702; Dalton, Alan/0000-0001-8043-1377; Munoz, Edgar/0000-0001-9309-2394				Chand S, 2000, J MATER SCI, V35, P1303, DOI 10.1023/A:1004780301489; Jiang KL, 2002, NATURE, V419, P801, DOI 10.1038/419801a; Kubik S, 2002, ANGEW CHEM INT EDIT, V41, P2721, DOI 10.1002/1521-3773(20020802)41:15&lt;2721::AID-ANIE2721&gt;3.0.CO;2-3; Lesuer DR, 1999, METALL MATER TRANS A, V30, P1559, DOI 10.1007/s11661-999-0093-x; Mamedov AA, 2002, NAT MATER, V1, P190, DOI 10.1038/nmat747; Nikolaev P, 1999, CHEM PHYS LETT, V313, P91, DOI 10.1016/S0009-2614(99)01029-5; Poulin P, 2002, CARBON, V40, P1741, DOI 10.1016/S0008-6223(02)00042-8; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331; Vigolo B, 2002, APPL PHYS LETT, V81, P1210, DOI 10.1063/1.1497706; Vollrath F, 2001, NATURE, V410, P541, DOI 10.1038/35069000; Walters DA, 1999, APPL PHYS LETT, V74, P3803, DOI 10.1063/1.124185; Yu MF, 2000, PHYS REV LETT, V84, P5552, DOI 10.1103/PhysRevLett.84.5552; Zhu HW, 2002, SCIENCE, V296, P884, DOI 10.1126/science.1066996	13	1303	1353	17	805	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					703	703		10.1038/423703a	http://dx.doi.org/10.1038/423703a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802323				2022-12-28	WOS:000183443400031
J	Lehmann, LE; Anupindi, S; Harris, NL				Lehmann, LE; Anupindi, S; Harris, NL			Case 18-2003: A 15-year-old girl with pain in the left leg and back, pruritus, and thoracic lymphadenopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NON-HODGKINS-LYMPHOMA; REED-STERNBERG CELLS; SOLITARY BONE-TUMOR; MEDICAL PROGRESS; DISEASE; CHILDHOOD; REPRESENT; EXPANSION		Childrens Hosp, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Lehmann, LE (corresponding author), Childrens Hosp, Dept Med, Boston, MA 02115 USA.							Armata J, 1999, MED PEDIATR ONCOL, V33, P382, DOI 10.1002/(SICI)1096-911X(199910)33:4<382::AID-MPO7>3.3.CO;2-Z; Chhieng DC, 2001, CANCER CYTOPATHOL, V93, P52, DOI 10.1002/1097-0142(20010225)93:1<52::AID-CNCR9007>3.0.CO;2-3; Dong HY, 2001, MODERN PATHOL, V14, P472, DOI 10.1038/modpathol.3880336; Filippa DA, 1996, BLOOD, V87, P2905, DOI 10.1182/blood.V87.7.2905.bloodjournal8772905; HADDY TB, 1988, BLOOD, V72, P1141; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Lones MA, 2000, J CLIN ONCOL, V18, P3845, DOI 10.1200/JCO.2000.18.22.3845; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Marafioti T, 1997, NEW ENGL J MED, V337, P453, DOI 10.1056/NEJM199708143370703; MAUCH PM, 1993, CANCER-AM CANCER SOC, V71, P2062, DOI 10.1002/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0; Mora J, 2000, CANCER, V88, P186, DOI 10.1002/(SICI)1097-0142(20000101)88:1<186::AID-CNCR26>3.0.CO;2-5; Ozdemirli M, 1998, AM J SURG PATHOL, V22, P795, DOI 10.1097/00000478-199807000-00002; Ozdemirli M, 1996, CANCER, V77, P79, DOI 10.1002/(SICI)1097-0142(19960101)77:1<79::AID-CNCR14>3.0.CO;2-5; Pulsoni A, 2002, AM J HEMATOL, V69, P67, DOI 10.1002/ajh.10008; Sandlund JT, 1996, NEW ENGL J MED, V334, P1238, DOI 10.1056/NEJM199605093341906; SMITH MA, 2002, PRINCIPLES PRACTICE, P1; STEIN H, 2001, WHO CLASSIFICATION T, P244; URBA WJ, 1992, NEW ENGL J MED, V326, P678, DOI 10.1056/NEJM199203053261006; Vietti TJ, 2002, PRINCIPLES PRACTICE, P149; Yuen RWS, 1996, ARCH PATHOL LAB MED, V120, P573; ZIEGLER JL, 1981, NEW ENGL J MED, V305, P735, DOI 10.1056/NEJM198109243051305	21	0	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2443	2451		10.1056/NEJMcpc030007	http://dx.doi.org/10.1056/NEJMcpc030007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802031				2022-12-28	WOS:000183428900011
J	Burgess, I				Burgess, I			Commentary: How to advise a patient when over the counter products have failed	BRITISH MEDICAL JOURNAL			English	Editorial Material									Insect Res & Dev Ltd, Cambridge CB1 5EL, England		Burgess, I (corresponding author), Insect Res & Dev Ltd, Cambridge CB1 5EL, England.		Burgess, Ian/E-4049-2016; Burgess, Ian/N-2977-2013	Burgess, Ian/0000-0001-9348-2915; Burgess, Ian/0000-0003-0747-3938					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1257	1257		10.1136/bmj.326.7401.1257	http://dx.doi.org/10.1136/bmj.326.7401.1257			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791745	Green Published			2022-12-28	WOS:000183480700022
J	Durbin, DR; Elliott, MR; Winston, FK				Durbin, DR; Elliott, MR; Winston, FK			Belt-positioning booster seats and reduction in risk of injury among children in vehicle crashes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESTRAINT; SAMPLE	Context Although more than a dozen states have ratified laws that require booster seats for children older than 4 years, most states continue to have child restraint laws that only cover children through age 4 years. Lack of booster seat effectiveness data may be a barrier to passage of stronger child restraint laws. Objectives To quantify the association of belt-positioning booster seats compared with seat belts alone and risk of injury among 4- to 7-year-old children and to assess patterns of injury among children in booster seats vs seat belts. Design, Setting, and Population Cross-sectional study of children aged 4 to 7 years in crashes of insured vehicles in 15 states, with data collected via insurance claims records and a telephone survey. A probability sample of 3616 crashes involving 4243 children, weighted to represent 56593 children in 48257 crashes was collected between December 1, 1998, and May 31, 2002. Main Outcome Measure Parent report of clinically significant injuries. Results Injuries occurred among 1.81% of all 4- to 7-year-olds, including 1.95% of those in seat belts and 0.77% of those in belt-positioning booster seats. The odds of injury, adjusting for child, driver, crash, and vehicle characteristics, were 59% lower for children aged 4 to 7 years in belt-positioning boosters than in seat belts (odds ratio, 0.41; 95% confidence interval, 0.20-0.86). Children in belt-positioning booster seats had no injuries to the abdomen, neck/spine/back, or lower extremities, while children in seat belts alone had injuries to all body regions. Conclusion Belt-positioning booster seats were associated with added safety benefits compared with seat belts to children through age 7 years, including reduction of injuries classically associated with improper seat belt fit in children.	Childrens Hosp Philadelphia, Dept Pediat, Div Emergency Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Durbin, DR (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Emergency Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.		Durbin, Dennis/AAD-7829-2022					*ADV HIGHW AUT SAF, STAT BOOST SEAT LAW; AGRAN PF, 1987, J TRAUMA, V27, P58, DOI 10.1097/00005373-198701000-00011; *AM AC PED, SEL US MOST APPR CAR; Arbogast KB, 2002, J TRAUMA, V52, P693, DOI 10.1097/00005373-200204000-00014; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Braver E R, 1998, Inj Prev, V4, P181; Davidson A.C., 1997, BOOTSTRAP METHODS TH; Durbin DR, 2001, PEDIATR EMERG CARE, V17, P474, DOI 10.1097/00006565-200112000-00021; Durbin DR, 1999, ARCH PEDIAT ADOL MED, V153, P404; Durbin DR, 2001, ACCIDENT ANAL PREV, V33, P407, DOI 10.1016/S0001-4575(00)00054-3; Durbin DR, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.6.e109; GARRETT J W, 1962, J Trauma, V2, P220, DOI 10.1097/00005373-196205000-00002; KLINICH K, 1994, STUDY OLDER CHILD RE; KORN EL, 1995, AM STAT, V49, P291, DOI 10.2307/2684203; KULOWSKI J, 1956, ARCH SURG-CHICAGO, V73, P970, DOI 10.1001/archsurg.1956.01280060070015; Miller Ted, 2002, Annu Proc Assoc Adv Automot Med, V46, P249; *NAT HIGHW TRAFF S, CHILD PASS SAF; National Center for Health Statistics. Centers for Disease Control and Prevention (CDC), CLIN GROWTH CHARTS; Simpson EM, 2002, PEDIATRICS, V110, P729, DOI 10.1542/peds.110.4.729; Webber K., 2000, UMTRI RES REV, V31, P1; WILLIAMS AF, 1977, ACCIDENT ANAL PREV, V9, P69, DOI 10.1016/0001-4575(77)90007-0; Winston FK, 2000, PEDIATRICS, V105, P1179, DOI 10.1542/peds.105.6.1179; WINSTON FK, 2000, DTNH2298C05142 NAT H	23	228	236	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2835	2840		10.1001/jama.289.21.2835	http://dx.doi.org/10.1001/jama.289.21.2835			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KH	12783914				2022-12-28	WOS:000183205500032
J	Jong, P; Yusuf, S; Rousseau, MF; Ahn, SA; Bangdiwala, SI				Jong, P; Yusuf, S; Rousseau, MF; Ahn, SA; Bangdiwala, SI			Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; NATIONAL-DEATH-INDEX; MORTALITY DATA-BASE; HEART-FAILURE; SURGERY	Background In the studies of left ventricular dysfunction (SOLVD), enalapril reduced mortality in patients with symptomatic but not asymptomatic left ventricular systolic dysfunction during the trial. We did a 12-year follow-up of SOLVD to establish if the mortality reduction with enalapril among patients with heart failure was sustained, and whether a subsequent reduction in mortality would emerge among those with asymptomatic ventricular dysfunction. Methods Of the 6797 patients previously enrolled in the SOLVD prevention and treatment trials, we ascertained the subsequent vital status of 5165 individuals who were alive when the trials had been completed. Follow-up was done through direct contacts in Belgium and linkages with national death registries and federal beneficiary or historic tax summary files in the USA and Canada. Findings Follow-up was 99.8% (6784/6797) complete. In the prevention trial, 50.9% (1074/2111) of the enalapril group had died compared with 56.4% (1195/2117) of the placebo group (generalised Wilcoxon p=0.001). In the treatment trial, 79.8% (1025/1285) of the enalapril group had died compared with 80.8% (1038/1284) of the placebo group (generalised Wilcoxon p=0.01). The reductions in cardiac deaths were significant and similar in both trials. When data for the prevention and treatment trials were combined, the hazard ratio for death was 0.90 for the enalapril group compared with the placebo group (95% Cl 0.84-0.95, generalised Wilcoxon p=0.0003). Enalapril extended median survival by 9.4 months in the combined trials (95% CI 2.8-16.5, p=0.004). Interpretation Treatment with enalapril for 3-4 years led to a sustained improvement in survival beyond the original trial period in patients with left ventricular systolic dysfunction, with an important increase in life expectancy.	McMaster Univ, Hamilton Gen Hosp, McMaster Clin, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; McMaster Univ, Hamilton Gen Hosp, Div Cardiol, Hamilton, ON L8L 2X2, Canada; Univ Catholique Louvain, Div Cardiol, B-1200 Brussels, Belgium; Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA	McMaster University; Population Health Research Institute; McMaster University; Universite Catholique Louvain; University of North Carolina; University of North Carolina Chapel Hill	Yusuf, S (corresponding author), McMaster Univ, Hamilton Gen Hosp, McMaster Clin, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.			Yusuf, Salim/0000-0003-4776-5601				AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS KB, 1985, CONTROL CLIN TRIALS, V6, P179, DOI 10.1016/0197-2456(85)90001-7; FAIR M, 1988, INFO0266 AT EN CONTR; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; ROGOT E, 1983, AM J PUBLIC HEALTH, V73, P1265, DOI 10.2105/AJPH.73.11.1265; SHANNON HS, 1989, CAN J PUBLIC HEALTH, V80, P54; Simonoff J.S., 1996, SMOOTING METHODS STA, V2nd; SMITH ME, 1982, CAN J PUBLIC HEALTH, V73, P39; Swedberg K, 1999, EUR HEART J, V20, P136, DOI 10.1053/euhj.1998.1098; Torp-Pedersen C, 1999, LANCET, V354, P9, DOI 10.1016/S0140-6736(98)09374-X; *US DEP HHS PHS CD, 1990, NAT DEATH IND US MAN; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; YUSUF S, 1990, AM J CARDIOL, V66, P315; Yusuf S., 1992, NEW ENGL J MED, V327, P685, DOI [DOI 10.1056/NEJM199209033271003, 10.1056/NEJM199209033271003.Erratumin]; 1990, AM J CARDIOL, V66, P1026	21	245	257	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1843	1848		10.1016/S0140-6736(03)13501-5	http://dx.doi.org/10.1016/S0140-6736(03)13501-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788569				2022-12-28	WOS:000183205800007
J	Ramachandran, GK; Hopson, TJ; Rawlett, AM; Nagahara, LA; Primak, A; Lindsay, SM				Ramachandran, GK; Hopson, TJ; Rawlett, AM; Nagahara, LA; Primak, A; Lindsay, SM			A bond-fluctuation mechanism for stochastic switching in wired molecules	SCIENCE			English	Article							THERMAL-DESORPTION SPECTROSCOPY; SELF-ASSEMBLED MONOLAYERS; ALKANETHIOL MONOLAYERS; EXCHANGE; SURFACE	Stochastic on-off conductivity switching observed in phenylene-ethynylene oligomers has been explained in terms of changes in ring conformations, or electron localization, or both. We report the observation of stochastic on-off switching in the simplest of wired molecules: octanedithiol, decanedithiol, and dodecanedithiol bonded on an Au(111) surface. Stochastic switching was observed even when a top gold contact was pressed on by a conducting atomic force microscope tip at constant force. The rate of switching increased substantially at 60 degreesC, a temperature at which these films are commonly annealed. Because such switching in alkanethiols is unlikely to be caused by internal molecular electronic changes and cannot be fully accounted for by breaking of the top contact, we argue that the cause is the well-known mobility of molecules tethered to gold via a thiol linkage.	Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Azbiodesign Inst, Tempe, AZ 85287 USA; Motorola Labs, Phys Sci Res Labs, Tempe, AZ 85284 USA; USA, Res Lab, Aberdeen Proving Ground, MD 21005 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Legend Holdings; Lenovo; United States Department of Defense; US Army Research, Development & Engineering Command (RDECOM); US Army Research Laboratory (ARL)	Ramachandran, GK (corresponding author), Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA.							Beardmore KM, 1998, CHEM PHYS LETT, V286, P40, DOI 10.1016/S0009-2614(97)01361-4; Bross AL, 1999, ABSTR PAP AM CHEM S, V218, pU156; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; COLLARD DM, 1991, LANGMUIR, V7, P1192, DOI 10.1021/la00054a029; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cui XD, 2002, NANOTECHNOLOGY, V13, P5, DOI 10.1088/0957-4484/13/1/302; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Cygan MT, 1998, J AM CHEM SOC, V120, P2721, DOI 10.1021/ja973448h; Di Ventra M, 2001, PHYS REV LETT, V86, P288, DOI 10.1103/PhysRevLett.86.288; Donhauser ZJ, 2001, SCIENCE, V292, P2303, DOI 10.1126/science.1060294; Donhauser ZJ, 2002, JPN J APPL PHYS 1, V41, P4871, DOI 10.1143/JJAP.41.4871; DUBOIS LH, 1992, ANNU REV PHYS CHEM, V43, P437, DOI 10.1146/annurev.pc.43.100192.002253; Kajikawa K, 1997, JPN J APPL PHYS 2, V36, pL1116, DOI 10.1143/JJAP.36.L1116; KOPRNILOVITCH PE, 2001, PHYS REV B, V64; Nishida N, 1997, JPN J APPL PHYS 1, V36, P2379, DOI 10.1143/JJAP.36.2379; Nishida N, 1996, JPN J APPL PHYS 1, V35, P5866, DOI 10.1143/JJAP.35.5866; Rawlett AM, 2002, APPL PHYS LETT, V81, P3043, DOI 10.1063/1.1512815; Schlenoff JB, 1995, J AM CHEM SOC, V117, P12528, DOI 10.1021/ja00155a016; Seminario JM, 2002, J AM CHEM SOC, V124, P10266, DOI 10.1021/ja0176090; Solak AO, 2002, ELECTROCHEM SOLID ST, V5, pE43, DOI 10.1149/1.1490716; Ulman A, 1996, CHEM REV, V96, P1533, DOI 10.1021/cr9502357; Weare WW, 2000, J AM CHEM SOC, V122, P12890, DOI 10.1021/ja002673n; Wold DJ, 2001, J AM CHEM SOC, V123, P5549, DOI 10.1021/ja0101532; Xiao XD, 2001, SURF SCI, V472, P41, DOI 10.1016/S0039-6028(00)00920-1	24	386	398	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1413	1416		10.1126/science.1083825	http://dx.doi.org/10.1126/science.1083825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775835				2022-12-28	WOS:000183181800039
J	Renaud, G; Lazzari, R; Revenant, C; Barbier, A; Noblet, M; Ulrich, O; Leroy, F; Jupille, J; Borensztein, Y; Henry, CR; Deville, JP; Scheurer, F; Mane-Mane, J; Fruchart, O				Renaud, G; Lazzari, R; Revenant, C; Barbier, A; Noblet, M; Ulrich, O; Leroy, F; Jupille, J; Borensztein, Y; Henry, CR; Deville, JP; Scheurer, F; Mane-Mane, J; Fruchart, O			Real-time monitoring of growing nanoparticles	SCIENCE			English	Article							X-RAY-SCATTERING; AU(111) SURFACE; GROWTH; SHAPE; CLUSTERS; FILMS	One challenge in the production of nanometer-sized objects with given properties is to control their growth at a macroscopic scale in situ and in real time. A dedicated ultrahigh-vacuum grazing-incidence small-angle x-ray scattering setup has been developed, yielding high sensitivity and dynamics. Its capabilities to derive the average particle shape and size and the film growth mode and ordering and to probe both surfaces and buried interfaces are illustrated for two prototypical cases: the model catalyst Pd/MgO(100) and the self-organized Co/Au(111) system. A wide range of technologically important systems can potentially be investigated in various gaseous environments.	Commissariat Energie Atom, Serv Phys Mat & Microstruct, Dept Rech Fondamentale Mat Condensee, F-38054 Grenoble 09, France; Univ Paris 06, Phys Solides Grp, F-75251 Paris 05, France; Univ Paris 07, Phys Solides Grp, F-75251 Paris 05, France; CNRS, Lab Opt Solide, F-75252 Paris 05, France; CNRS, Ctr Rech Mecanismes Croissance Cristalline, F-13288 Marseille 09, France; Univ Strasbourg, CNRS, Unite Mixte REch 7504, Inst Phys & Chim Mat Strasbourg, F-67037 Strasbourg, France; CNRS, Lab Louis Neel, F-38042 Grenoble 9, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Renaud, G (corresponding author), Commissariat Energie Atom, Serv Phys Mat & Microstruct, Dept Rech Fondamentale Mat Condensee, F-38054 Grenoble 09, France.	grenaud@cea.fr	Leroy, Frederic/K-2785-2015; Barbier, Antoine/I-1802-2019; Fruchart, Olivier/N-4829-2018; Renaud, Gilles/C-2073-2017; Borensztein, Yves/AAK-6343-2021	Leroy, Frederic/0000-0001-8731-9572; Fruchart, Olivier/0000-0001-7717-5229; Borensztein, Yves/0000-0002-1570-732X; Barbier, Antoine/0000-0002-1032-299X; Revenant, Christine/0000-0003-0847-8351				BARTH JV, 1990, PHYS REV B, V42, P9307, DOI 10.1103/PhysRevB.42.9307; BEYSENS D, 1986, PHYS REV LETT, V57, P1433, DOI 10.1103/PhysRevLett.57.1433; Corno J, 1997, J MAGN MAGN MATER, V174, pL10, DOI 10.1016/S0304-8853(97)00469-1; Graoui H, 1998, SURF SCI, V417, P350, DOI 10.1016/S0039-6028(98)00688-8; Haas G, 2000, PHYS REV B, V61, P11105, DOI 10.1103/PhysRevB.61.11105; Hansen PL, 2002, SCIENCE, V295, P2053, DOI 10.1126/science.1069325; Henry CR, 1998, SURF SCI REP, V31, P235; KAISHEW R, 1952, THESIS, P81; KASHCHIEV D, 1978, THIN SOLID FILMS, V55, P399, DOI 10.1016/0040-6090(78)90157-8; Lazzari R, 2002, J APPL CRYSTALLOGR, V35, P406, DOI 10.1107/S0021889802006088; LEVINE JR, 1989, J APPL CRYSTALLOGR, V22, P528, DOI 10.1107/S002188988900717X; LIU CL, 1991, SURF SCI, V253, P334, DOI 10.1016/0039-6028(91)90604-Q; MOODIE AF, 1977, PHILOS MAG, V35, P201, DOI 10.1080/14786437708235983; Rauscher M, 1999, J APPL PHYS, V86, P6763, DOI 10.1063/1.371724; SANDY AR, 1991, PHYS REV B, V43, P4667, DOI 10.1103/PhysRevB.43.4667; Schmidbauer M, 1998, PHYS REV B, V58, P10523, DOI 10.1103/PhysRevB.58.10523; SHI AC, 1987, PHYS REV B, V36, P9068, DOI 10.1103/PhysRevB.36.9068; Stangl J, 1999, APPL PHYS LETT, V74, P3785, DOI 10.1063/1.124179; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; VIOVY JL, 1988, PHYS REV A, V37, P4965, DOI 10.1103/PhysRevA.37.4965; VOIGTLANDER B, 1991, PHYS REV B, V44, P10354, DOI 10.1103/PhysRevB.44.10354; Wulff G, 1901, Z KRYSTALLOGR MINERA, V34, P449, DOI 10.1524/zkri.1901.34.1.449; ZUNGER A, 1998, MAT RES SOC B, V23	23	320	323	3	143	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1416	1419		10.1126/science.1082146	http://dx.doi.org/10.1126/science.1082146			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775836				2022-12-28	WOS:000183181800040
J	Crampton, JS; Beu, AG; Cooper, RA; Jones, CM; Marshall, B; Maxwell, PA				Crampton, JS; Beu, AG; Cooper, RA; Jones, CM; Marshall, B; Maxwell, PA			Estimating the rock volume bias in paleobiodiversity studies	SCIENCE			English	Article							FOSSIL RECORD; BIODIVERSITY; EXTINCTION; DIVERSITY	To interpret changes in biodiversity through geological time, it is necessary first to correct for biases in sampling effort related to variations in the exposure of rocks and recovery of fossils with age. Data from New Zealand indicate that outcrop area is likely to be a reliable proxy of rock volume in both stable cratonic regions, where the paleobiodiversity record is strongly correlated with relative sea level, and on tectonically active margins. In contrast, another potential proxy, the number of rock formations, is a poor predictor of outcrop area or sampling effort in the New Zealand case.	Inst Geol & Nucl Sci, Lower Hutt, New Zealand; Museum New Zealand Te Papa Tongarewa, Wellington, New Zealand	GNS Science - New Zealand	Crampton, JS (corresponding author), Inst Geol & Nucl Sci, POB 30-368, Lower Hutt, New Zealand.	j.crampton@gns.cri.nz	Crampton, James/G-1381-2012; Jones, Craig/C-9693-2011	Crampton, James/0000-0003-3270-9981; Jones, Craig/0000-0002-1495-9293				Alroy J, 2001, P NATL ACAD SCI USA, V98, P6261, DOI 10.1073/pnas.111144698; CARTER RM, 1991, SPEC PUBL INT ASS SE, V12, P41; COOPER RA, IN PRESS I GEOLOGICA; Edbrooke PR., 1999, I GEOLOGICAL NUCL SC, V1; Jackson JBC, 2001, SCIENCE, V293, P2401, DOI 10.1126/science.1063789; Miller AI, 2000, PALEOBIOLOGY, V26, P53, DOI 10.1666/0094-8373(2000)26[53:CAPGD]2.0.CO;2; Peters SE, 2002, NATURE, V416, P420, DOI 10.1038/416420a; Peters SE, 2001, PALEOBIOLOGY, V27, P583, DOI 10.1666/0094-8373(2001)027<0583:BITPAR>2.0.CO;2; RAUP D M, 1976, Paleobiology, V2, P289; SEPKOSKI JJ, 1981, NATURE, V293, P435, DOI 10.1038/293435a0; Smith AB, 2001, PALEOBIOLOGY, V27, P241, DOI 10.1666/0094-8373(2001)027<0241:SLCARR>2.0.CO;2; Smith AB, 2001, PHILOS T R SOC B, V356, P351, DOI 10.1098/rstb.2000.0768; Wignall PB, 1999, J GEOL SOC LONDON, V156, P453, DOI 10.1144/gsjgs.156.3.0453	13	132	134	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	2003	301	5631					358	360		10.1126/science.1085075	http://dx.doi.org/10.1126/science.1085075			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	702CG	12805555				2022-12-28	WOS:000184207300041
J	Cliften, P; Sudarsanam, P; Desikan, A; Fulton, L; Fulton, B; Majors, J; Waterston, R; Cohen, BA; Johnston, M				Cliften, P; Sudarsanam, P; Desikan, A; Fulton, L; Fulton, B; Majors, J; Waterston, R; Cohen, BA; Johnston, M			Finding functional features in Saccharomyces genomes by phylogenetic footprinting	SCIENCE			English	Article							REGULATORY NETWORKS; CELL-CYCLE; BUDDING YEAST; DNA-SEQUENCE; CEREVISIAE; EXPRESSION; ALIGNMENT; ELEMENTS; GENES; RESPONSES	The sifting and winnowing of DNA sequence that occur during evolution cause nonfunctional sequences to diverge, leaving phylogenetic footprints of functional sequence elements in comparisons of genome sequences. We searched for such footprints among the genome sequences of six Saccharomyces species and identified potentially functional sequences. Comparison of these sequences allowed us to revise the catalog of yeast genes and identify sequence motifs that may be targets of transcriptional regulatory proteins. Some of these conserved sequence motifs reside upstream of genes with similar functional annotations or similar expression patterns or those bound by the same transcription factor and are thus good candidates for functional regulatory sequences.	Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Johnston, M (corresponding author), Washington Univ, Sch Med, Dept Genet, 660 S Euclid Ave, St Louis, MO 63110 USA.	mj@genetics.wustl.edu	Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063803] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063803, R01 GM63803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bailey T L, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P21; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Fischer G, 2000, NATURE, V405, P451, DOI 10.1038/35013058; Gasch AP, 2001, MOL BIOL CELL, V12, P2987, DOI 10.1091/mbc.12.10.2987; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; LANDER E S, 1988, Genomics, V2, P231; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Llorente B, 2000, FEBS LETT, V487, P101, DOI 10.1016/S0014-5793(00)02289-4; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; Moller K, 2002, BIOTECHNOL BIOENG, V77, P186, DOI 10.1002/bit.10122; Petersen RF, 1999, INT J SYST BACTERIOL, V49, P1925, DOI 10.1099/00207713-49-4-1925; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Rajewsky N, 2002, GENOME RES, V12, P298, DOI 10.1101/gr.207502. Article published online before print in January 2002; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vilardell J, 1997, MOL CELL BIOL, V17, P1959, DOI 10.1128/MCB.17.4.1959	34	671	734	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					71	76		10.1126/science.1084337	http://dx.doi.org/10.1126/science.1084337			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12775844				2022-12-28	WOS:000183914700033
J	Taylor, AF; Smith, GR				Taylor, AF; Smith, GR			RecBCD enzyme is a DNA helicase with fast and slow motors of opposite polarity	NATURE			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; ATP-BINDING; HOMOLOGOUS RECOMBINATION; PURIFIED SUBUNITS; RECD SUBUNIT; TRANSLOCATION; SEQUENCE; PROTEIN; CHI	Helicases are molecular motors that move along and unwind double-stranded nucleic acids(1). RecBCD enzyme is a complex helicase and nuclease, essential for the major pathway of homologous recombination and DNA repair in Escherichia coli(2). It has sets of helicase motifs(1) in both RecB and RecD, two of its three subunits. This rapid, highly processive enzyme unwinds DNA in an unusual manner: the 5'-ended strand forms a long single-stranded tail, whereas the 3'-ended strand forms an ever-growing single-stranded loop and short single-stranded tail. Here we show by electron microscopy of individual molecules that RecD is a fast helicase acting on the 5'-ended strand and RecB is a slow helicase acting on the 3'-ended strand on which the single-stranded loop accumulates. Mutational inactivation of the helicase domain in RecB or in RecD, or removal of the RecD subunit, altered the rates of unwinding or the types of structure produced, or both. This dual-helicase mechanism explains how the looped recombination intermediates are generated and may serve as a general model for highly processive travelling machines with two active motors, such as other helicases and kinesins.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Smith, GR (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.			Smith, Gerald/0000-0002-8747-1352				Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; Chen HW, 1997, J BIOL CHEM, V272, P10072; Chen HW, 1998, J MOL BIOL, V278, P89, DOI 10.1006/jmbi.1998.1694; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; GEORGE JW, 1994, J MOL BIOL, V229, P67; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; HSIEH S, 1992, NUCLEIC ACIDS RES, V20, P5647, DOI 10.1093/nar/20.21.5647; KORANGY F, 1994, BIOCHEMISTRY-US, V33, P9552, DOI 10.1021/bi00198a022; KORANGY F, 1992, J BIOL CHEM, V267, P1733; LEE MS, 1990, J BIOL CHEM, V265, P17078; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MASTERSON C, 1992, J BIOL CHEM, V267, P13564; Phillips RJ, 1997, MOL GEN GENET, V254, P319, DOI 10.1007/PL00008605; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Smith GR, 2001, ANNU REV GENET, V35, P243, DOI 10.1146/annurev.genet.35.102401.090509; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1995, J BIOL CHEM, V270, P24451, DOI 10.1074/jbc.270.41.24451; Tomishige M, 2002, SCIENCE, V297, P2263, DOI 10.1126/science.1073386; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Yu M, 1998, J MOL BIOL, V283, P797, DOI 10.1006/jmbi.1998.2127	30	158	167	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					889	893		10.1038/nature01674	http://dx.doi.org/10.1038/nature01674			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815437				2022-12-28	WOS:000183585300051
J	Berman, B				Berman, B			Integrative approaches to pain management: how to get the best of both worlds	BRITISH MEDICAL JOURNAL			English	Article									Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Berman, B (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.				NCCIH NIH HHS [N0 5-P50-AT00084-02] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P50AT000084] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)			0	9	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1320	+		10.1136/bmj.326.7402.1320-a	http://dx.doi.org/10.1136/bmj.326.7402.1320-a			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805175	Green Published			2022-12-28	WOS:000183626500040
J	Donaldson, L				Donaldson, L			Expert patients usher in a new era of opportunity for the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material									Dept Hlth, London SW1A 2NS, England		Donaldson, L (corresponding author), Dept Hlth, London SW1A 2NS, England.								0	94	94	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1279	1279		10.1136/bmj.326.7402.1279	http://dx.doi.org/10.1136/bmj.326.7402.1279			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805129	Green Published			2022-12-28	WOS:000183626500005
J	Shi, YG; Massague, J				Shi, YG; Massague, J			Mechanisms of TGF-beta signaling from cell membrane to the nucleus	CELL			English	Review							ANAPHASE-PROMOTING COMPLEX; UBIQUITIN LIGASE COMPLEX; CRYSTAL-STRUCTURE; SMAD PROTEINS; DNA-BINDING; DEPENDENT DEGRADATION; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; I RECEPTOR; LOCALIZATION SIGNAL		Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA	Princeton University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Shi, YG (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu; j-massague@ski.mskcc.org		Massague, Joan/0000-0001-9324-8408; Shi, Yigong/0000-0003-2030-168X	NATIONAL CANCER INSTITUTE [R37CA034610, R01CA082171] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA34610, R01-CA82171] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bitzer M, 2000, GENE DEV, V14, P187; Boesen CC, 2002, STRUCTURE, V10, P913, DOI 10.1016/S0969-2126(02)00780-3; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; CHAI J, 2003, IN PRESS J BIOL CHEM; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; De Caestecker M, 2001, RESPIR RES, V2, P193; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gong YQ, 1999, NAT GENET, V21, P302, DOI 10.1038/6821; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Greenspan S, 1999, INT REV PSYCHIATR, V11, P6, DOI 10.1080/09540269974474; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Grimm OH, 2002, NAT CELL BIOL, V4, P519, DOI 10.1038/ncb812; Grishin NV, 2001, J MOL BIOL, V307, P31, DOI 10.1006/jmbi.2000.4486; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Harland RM, 2001, NATURE, V410, P423, DOI 10.1038/35068657; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hoodless PA, 1999, DEV BIOL, V207, P364, DOI 10.1006/dbio.1998.9168; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marchuk D A, 1998, Curr Opin Hematol, V5, P332, DOI 10.1097/00062752-199809000-00005; Marlow MS, 2003, J MOL BIOL, V326, P989, DOI 10.1016/S0022-2836(03)00023-8; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Nishihara A, 2002, MOL BIOL CELL, V13, P3055, DOI 10.1091/mbc.E02-02-0063; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Patterson GI, 2000, TRENDS GENET, V16, P27, DOI 10.1016/S0168-9525(99)01916-2; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qin BY, 2001, MOL CELL, V8, P1303, DOI 10.1016/S1097-2765(01)00417-8; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; ROSA FM, 2002, SCI STKE, pPE47; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	140	4525	4850	25	847	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2003	113	6					685	700		10.1016/S0092-8674(03)00432-X	http://dx.doi.org/10.1016/S0092-8674(03)00432-X			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809600	Bronze			2022-12-28	WOS:000183514400004
J	Trono, D				Trono, D			Picking the right spot	SCIENCE			English	Editorial Material							NUCLEAR-LOCALIZATION; HUMAN GENOME; STIMULATION; INTEGRATION; EXPRESSION; PROTEIN		Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland	University of Geneva	Trono, D (corresponding author), Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland.	didier.trono@medecine.unige.ch						BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Cherry SR, 2000, MOL CELL BIOL, V20, P7419, DOI 10.1128/MCB.20.20.7419-7426.2000; COFFIN J, 2000, RETROVIRUSES; Fassati A, 1999, J VIROL, V73, P8919, DOI 10.1128/JVI.73.11.8919-8925.1999; FISCHER A, COMMUNICATION; Greber UF, 2003, TRAFFIC, V4, P136, DOI 10.1034/j.1600-0854.2003.00114.x; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Li L, 2000, J VIROL, V74, P10965, DOI 10.1128/JVI.74.23.10965-10974.2000; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Lin CW, 2003, J VIROL, V77, P5030, DOI 10.1128/JVI.77.8.5030-5036.2003; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413	15	27	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1670	1671		10.1126/science.1086238	http://dx.doi.org/10.1126/science.1086238			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805525				2022-12-28	WOS:000183459700026
J	Hayes, EB; Piesman, J				Hayes, EB; Piesman, J			Current concepts - How can we prevent Lyme disease?	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IXODES-SCAPULARIS ACARI; DEER-TICK BITES; DAMMINI ACARI; IXODIDAE NYMPHS; SOUTHEASTERN CONNECTICUT; ANTIBIOTIC-TREATMENT; REDUCED ABUNDANCE; RESIDENTIAL AREA; NEW-YORK; RISK		Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA	Centers for Disease Control & Prevention - USA	Piesman, J (corresponding author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, POB 2087,Rampart Rd, Ft Collins, CO 80522 USA.	jfp2@cdc.gov						*ADV COMM IMM PRAC, 1999, MMWR-MORBID MORTAL W, V48, P833; AGRE F, 1993, AM J DIS CHILD, V147, P945, DOI 10.1001/archpedi.1993.02160330035013; Allan SA, 1998, MED VET ENTOMOL, V12, P141, DOI 10.1046/j.1365-2915.1998.00080.x; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; CDC, 1999, MMWR-MORBID MORTAL W, V48, P1; Costello C M, 1989, Conn Med, V53, P338; Crippa M, 2002, VECTOR-BORNE ZOONOT, V2, P3, DOI 10.1089/153036602760260724; CURRAN KL, 1993, J MED ENTOMOL, V30, P107, DOI 10.1093/jmedent/30.1.107; DANIELS TJ, 1995, J MED ENTOMOL, V32, P5, DOI 10.1093/jmedent/32.1.5; DANIELS TJ, 1991, J MED ENTOMOL, V28, P537, DOI 10.1093/jmedent/28.4.537; DEBLINGER RD, 1991, J MED ENTOMOL, V28, P708, DOI 10.1093/jmedent/28.5.708; DELBINGER RD, 1993, J MED ENTOMOL, V30, P144; Gresikova M, 1997, ACTA VIROL, V41, P115; HASSLER D, 1990, INFECTION, V18, P16, DOI 10.1007/BF01644175; Hayes E B, 1999, J Public Health Manag Pract, V5, P84; Herrington JE, 1997, AM J PUBLIC HEALTH, V87, P2035, DOI 10.2105/AJPH.87.12.2035; Kahl O, 1998, ZBL BAKT-INT J MED M, V287, P41; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Lathrop SL, 2002, VACCINE, V20, P1603, DOI 10.1016/S0264-410X(01)00500-X; LEY C, 1995, AM J EPIDEMIOL, V142, pS39, DOI 10.1093/aje/142.Supplement_9.S39; Logigian EL, 1999, J INFECT DIS, V180, P377, DOI 10.1086/314860; MALOUIN R, IN PRESS AM J EPIDEM; MAUPIN GO, 1991, AM J EPIDEMIOL, V133, P1105, DOI 10.1093/oxfordjournals.aje.a115823; Meltzer MI, 1999, EMERG INFECT DIS, V5, P321, DOI 10.3201/eid0503.990302; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; Nadelman RB, 2001, NEW ENGL J MED, V345, P79, DOI 10.1056/NEJM200107123450201; O'Connell S, 1998, ZBL BAKT-INT J MED M, V287, P229, DOI 10.1016/S0934-8840(98)80124-2; Orloski K A, 2000, MMWR CDC Surveill Summ, V49, P1; Orloski KA, 1998, AM J EPIDEMIOL, V147, P391; Panella NA, 1997, J MED ENTOMOL, V34, P340, DOI 10.1093/jmedent/34.3.340; Parola P, 2001, CLIN INFECT DIS, V33, P749; PATRICAN LA, 1995, J MED ENTOMOL, V32, P859, DOI 10.1093/jmedent/32.6.859; PFISTER HW, 1991, J INFECT DIS, V163, P311, DOI 10.1093/infdis/163.2.311; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; Poland GA, 2001, MAYO CLIN PROC, V76, P713, DOI 10.4065/76.7.713; Pound JM, 2000, J MED ENTOMOL, V37, P588, DOI 10.1603/0022-2585-37.4.588; Rothermel H, 2001, PEDIATRICS, V108, P477, DOI 10.1542/peds.108.2.477; SCHULZE TL, 1995, J MED ENTOMOL, V32, P730, DOI 10.1093/jmedent/32.5.730; Schulze TL, 2001, J ECON ENTOMOL, V94, P123, DOI 10.1603/0022-0493-94.1.123; Schulze TL, 2001, J MED ENTOMOL, V38, P344, DOI 10.1603/0022-2585-38.2.344; Shapiro ED, 2001, NEW ENGL J MED, V345, P133, DOI 10.1056/NEJM200107123450210; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; STAFFORD KC, 1991, J MED ENTOMOL, V28, P32, DOI 10.1093/jmedent/28.1.32; Stafford KC, 1998, J MED ENTOMOL, V35, P510, DOI 10.1093/jmedent/35.4.510; STAFFORD KC, 1993, J MED ENTOMOL, V30, P762, DOI 10.1093/jmedent/30.4.762; STAFFORD KC, 1992, J MED ENTOMOL, V29, P717, DOI 10.1093/jmedent/29.4.717; Stafford KC, 1996, J MED ENTOMOL, V33, P183, DOI 10.1093/jmedent/33.1.183; Steere AC, 1998, NEW ENGL J MED, V339, P1638; Steere AC, 2001, J AUTOIMMUN, V16, P263, DOI 10.1006/jaut.2000.0495; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1994, ARTHRITIS RHEUM-US, V37, P878, DOI 10.1002/art.1780370616; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; WILSON ML, 1986, J ECON ENTOMOL, V79, P693, DOI 10.1093/jee/79.3.693; WILSON ML, 1988, J MED ENTOMOL, V25, P224, DOI 10.1093/jmedent/25.4.224; Wormser GP, 2000, CLIN INFECT DIS, V31, pS1, DOI 10.1086/314053; Wormser GP, 1997, NEW ENGL J MED, V336, P1107; Zhioua E, 1997, J PARASITOL, V83, P815, DOI 10.2307/3284273; ZHIOUA E, 1995, J MED ENTOMOL, V32, P900, DOI 10.1093/jmedent/32.6.900; 2001, MMWR MORB MORTAL WKL, V50, P92	61	159	168	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2424	2430		10.1056/NEJMra021397	http://dx.doi.org/10.1056/NEJMra021397			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802029				2022-12-28	WOS:000183428900009
J	Stewart, KS; Steinweg, DL				Stewart, KS; Steinweg, DL			Lymphoma-associated "ivory rib''	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Virginia, Roanoke, VA 24033 USA	University of Virginia	Stewart, KS (corresponding author), Univ Virginia, Roanoke, VA 24033 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2423	2423		10.1056/NEJMicm020406	http://dx.doi.org/10.1056/NEJMicm020406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802028				2022-12-28	WOS:000183428900008
J	Alijani, A; Hanna, GB; Ziyaie, D; Burns, SL; Campbell, KL; McMurdo, MET; Cuschieri, A				Alijani, A; Hanna, GB; Ziyaie, D; Burns, SL; Campbell, KL; McMurdo, MET; Cuschieri, A			Instrument for objective assessment of appropriateness of surgical bed occupancy: validation study	BRITISH MEDICAL JOURNAL			English	Article									Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Ninewells Hosp & Med Sch, Dept Med, Dundee, Scotland	University of Dundee; University of Dundee	Cuschieri, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.		Cuschieri, Alfred/A-7634-2013; Cuschieri, Alfred/O-4092-2019	Cuschieri, Alfred/0000-0003-0764-5947				Department of Health, 2000, SHAP FUT NHS LONG TE; Kalant N, 2000, CAN MED ASSOC J, V162, P1809; Lorenzo S, 1999, INT J QUAL HEALTH C, V11, P419, DOI 10.1093/intqhc/11.5.419	3	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1243	1244		10.1136/bmj.326.7401.1243	http://dx.doi.org/10.1136/bmj.326.7401.1243			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791738	Bronze, Green Published			2022-12-28	WOS:000183480700015
J	Chin-Dusting, JPF; Dart, AM				Chin-Dusting, JPF; Dart, AM			Age and the treatment gap in the use of statins	LANCET			English	Editorial Material							DISEASE; INTERVENTION; THERAPY		Baker Heart Res Inst, Alfred & Baker Med Unit, Melbourne, Vic 3004, Australia; Alfred Hosp, Melbourne, Vic 3004, Australia	Baker Heart and Diabetes Institute; Florey Institute of Neuroscience & Mental Health	Chin-Dusting, JPF (corresponding author), Baker Heart Res Inst, Alfred & Baker Med Unit, Wynn Domain, Melbourne, Vic 3004, Australia.	j.chin@alfred.org.au	Dart, Anthony M/E-7461-2010	Dart, Anthony M/0000-0003-1360-3778				*AM HEART ASS, 2003, CHOL LOW DRUGS; Bartlett C, 2003, HEART, V89, P327, DOI 10.1136/heart.89.3.327; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DeWilde S, 2003, HEART, V89, P417, DOI 10.1136/heart.89.4.417; Hilleman DE, 2001, PHARMACOTHERAPY, V21, P1415, DOI 10.1592/phco.21.17.1415.34422; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Julian DG, 1997, EUR HEART J, V18, P394; *NAT HEART FDN AUS, 2003, RED RISK HEART DIS G; *NAT SERV FRAM COR, 1998, EM FIND REP; PEDERSEN TR, 1994, LANCET, V344, P1383; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; VALE MJ, IN PRESS ARCH INTERN; WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9	14	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2003	361	9373					1925	1926		10.1016/S0140-6736(03)13601-X	http://dx.doi.org/10.1016/S0140-6736(03)13601-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801733				2022-12-28	WOS:000183359700005
J	Song, BS; Noda, S; Asano, T				Song, BS; Noda, S; Asano, T			Photonic devices based on in-plane hetero photonic crystals	SCIENCE			English	Article							NEAR-INFRARED WAVELENGTHS; EMISSION; DEFECT		Kyoto Univ, Dept Elect Sci & Engn, Kyoto 6068501, Japan	Kyoto University	Noda, S (corresponding author), Kyoto Univ, Dept Elect Sci & Engn, Kyoto 6068501, Japan.							Chutinan A, 2001, APPL PHYS LETT, V79, P2690, DOI 10.1063/1.1413720; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; Krauss TF, 1996, NATURE, V383, P699, DOI 10.1038/383699a0; Noda S, 2000, NATURE, V407, P608, DOI 10.1038/35036532; Noda S, 2000, SCIENCE, V289, P604, DOI 10.1126/science.289.5479.604; Seassal C, 2002, IEEE J QUANTUM ELECT, V38, P811, DOI 10.1109/JQE.2002.1017591; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059	7	282	306	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1537	1537		10.1126/science.1083066	http://dx.doi.org/10.1126/science.1083066			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791984				2022-12-28	WOS:000183333100044
J	Yao, MC; Fuller, P; Xi, XH				Yao, MC; Fuller, P; Xi, XH			Programmed DNA deletion as an RNA-guided system of genome defense	SCIENCE			English	Article							TETRAHYMENA-THERMOPHILA; DEVELOPMENTAL EXCISION; PARAMECIUM-TETRAURELIA; HISTONE H3; GENE; METHYLATION; REARRANGEMENTS; ELIMINATION; EXPRESSION; SEQUENCES	Genomewide DNA rearrangements occur in many eukaryotes during development, but their functions and mechanisms are poorly understood. Previous studies have implicated a sequence-recognition mechanism based on RNA-mediated interactions between nuclei in ciliated protozoa. In this study, we found that the process recognized and deleted a foreign gene integrated in a Tetrahymena chromosome, suggesting an unusual mechanism of genome surveillance. We further found that injection of double-stranded RNA into the cell at specific developmental stages triggers efficient deletion of the targeted genomic regions. Together the results indicate an RNA-based mechanism that directs genomewide DNA rearrangements and serves to disable invading genetic agents.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Yao, MC (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026210] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM26210] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aufsatz W, 2002, EMBO J, V21, P6832, DOI 10.1093/emboj/cdf663; CASSIDYHANLEY D, 1994, GENETICS, V137, P95; Chalker DL, 1996, MOL CELL BIOL, V16, P3658; Chalker DL, 2001, GENE DEV, V15, P1287, DOI 10.1101/gad.884601; CHALKER DL, UNPUB; COYNE R, UNPUB; Coyne RS, 1999, MOL CELL, V4, P865, DOI 10.1016/S1097-2765(00)80396-2; Duharcourt S, 1998, MOL CELL BIOL, V18, P7075, DOI 10.1128/MCB.18.12.7075; DUHARCOURT S, 1995, GENE DEV, V9, P2065, DOI 10.1101/gad.9.16.2065; Duharcourt S, 2002, EUKARYOT CELL, V1, P293, DOI 10.1128/EC.1.2.293-303.2002; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; MARCZYNSKI GT, 1985, NUCLEIC ACIDS RES, V13, P8487, DOI 10.1093/nar/13.23.8487; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; Matzke MA, 1996, TRENDS PLANT SCI, V1, P382, DOI 10.1016/S1360-1385(96)80313-X; MCGRATH KE, 1994, CELL MOTIL CYTOSKEL, V27, P272, DOI 10.1002/cm.970270308; Meyer E, 1996, CELL, V87, P9, DOI 10.1016/S0092-8674(00)81317-3; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Taverna SD, 2002, CELL, V110, P701, DOI 10.1016/S0092-8674(02)00941-8; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wassenegger M, 2000, PLANT MOL BIOL, V43, P203, DOI 10.1023/A:1006479327881; YAO MC, UNPUB; Yao MC, 2002, MOBILE DNA, P730; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	27	154	159	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1581	1584		10.1126/science.1084737	http://dx.doi.org/10.1126/science.1084737			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791996				2022-12-28	WOS:000183333100058
J	Harborne, L; Fleming, R; Lyall, H; Norman, J; Sattar, N				Harborne, L; Fleming, R; Lyall, H; Norman, J; Sattar, N			Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome	LANCET			English	Review							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ORAL HYPOGLYCEMIC AGENTS; HORMONE-BINDING GLOBULIN; INSULIN-RESISTANCE; OBESE WOMEN; NORMAL MENSES; METABOLIC PROFILES; INDUCED OVULATION; THERAPY IMPROVES; DOUBLE-BLIND	Use of metformin in polycystic ovary syndrome (PCOS) is becoming increasingly accepted and widespread, but clinical practice is ahead of the evidence. Although a wide range of benefits in metabolic, reproductive, and clinical measures have been reported from non-randomised trials with metformin, close inspection of results from the adequately controlled studies shows that the benefits are modest. Our aim in this descriptive review is not to define practice guidelines but to improve clinicians' knowledge of the available published clinical evidence, concentrating on the few randomised controlled trials. We also highlight other issues, including hirsutism, acne, pregnancy, and neonatal outcome, that require more attention before clinical recommendations for the use of metformin in PCOS can be formalised. The potentially greater benefits achievable by lifestyle changes alone are also emphasised. We hope that the review will lead to more judicious use of metformin in PCOS and a more structured approach to research.	Glasgow Royal Infirm Univ NHS Trust, Dept Pathol Biochem, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland	University of Glasgow	Sattar, N (corresponding author), Glasgow Royal Infirm Univ NHS Trust, Dept Pathol Biochem, Glasgow G31 2ER, Lanark, Scotland.	nsattar@clinmed.gla.ac.uk	Norman, Jane/B-2347-2010					Acbay O, 1996, FERTIL STERIL, V65, P946, DOI 10.1016/S0015-0282(16)58266-1; Azziz R, 2001, J CLIN ENDOCR METAB, V86, P1626, DOI 10.1210/jc.86.4.1626; BURGHEN GA, 1980, J CLIN ENDOCR METAB, V50, P113, DOI 10.1210/jcem-50-1-113; CASMIRRI F, 1997, INT J OBESITY S, V21, pS61; Cataldo NA, 2001, FERTIL STERIL, V76, P1057, DOI 10.1016/S0015-0282(01)02843-6; CHANG RJ, 1983, J CLIN ENDOCR METAB, V57, P356, DOI 10.1210/jcem-57-2-356; Clark AM, 1998, HUM REPROD, V13, P1502, DOI 10.1093/humrep/13.6.1502; COETZEE EJ, 1979, DIABETOLOGIA, V16, P241, DOI 10.1007/BF01221950; CRAVE JC, 1995, J CLIN ENDOCR METAB, V80, P2057, DOI 10.1210/jc.80.7.2057; De Leo V, 1999, FERTIL STERIL, V72, P282, DOI 10.1016/S0015-0282(99)00208-3; DENNO KM, 1994, TERATOLOGY, V49, P260, DOI 10.1002/tera.1420490405; Diamanti-Kandarakis E, 1998, EUR J ENDOCRINOL, V138, P269, DOI 10.1530/eje.0.1380269; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; Dunaif A, 2001, ANNU REV MED, V52, P401, DOI 10.1146/annurev.med.52.1.401; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P524, DOI 10.1210/jc.82.2.524; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Fleming R, 2002, J CLIN ENDOCR METAB, V87, P569, DOI 10.1210/jc.87.2.569; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Freeman DJ, 2002, DIABETES, V51, P1596, DOI 10.2337/diabetes.51.5.1596; Glueck CJ, 1999, METABOLISM, V48, P511, DOI 10.1016/S0026-0495(99)90113-0; Glueck CJ, 2001, FERTIL STERIL, V75, P46, DOI 10.1016/S0015-0282(00)01666-6; Glueck CJ, 2001, J ADOLESCENT HEALTH, V29, P160, DOI 10.1016/S1054-139X(01)00202-6; Hasegawa I, 1999, FERTIL STERIL, V71, P323, DOI 10.1016/S0015-0282(98)00454-3; Heard MJ, 2002, FERTIL STERIL, V77, P669, DOI 10.1016/S0015-0282(01)03266-6; Hellmuth E, 2000, DIABETIC MED, V17, P507, DOI 10.1046/j.1464-5491.2000.00314.x; Jakubowicz DJ, 2002, J CLIN ENDOCR METAB, V87, P524, DOI 10.1210/jc.87.2.524; Katsuki A, 1996, J CLIN ENDOCR METAB, V81, P2515, DOI 10.1210/jc.81.7.2515; Kelly CCJ, 2001, J CLIN ENDOCR METAB, V86, P2453, DOI 10.1210/jc.86.6.2453; Kelly CJG, 2002, EUR J ENDOCRINOL, V147, P217, DOI 10.1530/eje.0.1470217; Kelly CJG, 2002, J CLIN ENDOCR METAB, V87, P3287, DOI 10.1210/jc.87.7.3287; KIDDY DS, 1992, CLIN ENDOCRINOL, V36, P105, DOI 10.1111/j.1365-2265.1992.tb02909.x; Kim LH, 2000, FERTIL STERIL, V73, P1097, DOI 10.1016/S0015-0282(00)00540-9; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kocak M, 2002, FERTIL STERIL, V77, P101, DOI 10.1016/S0015-0282(01)02941-7; Kolodziejczyk B, 2000, FERTIL STERIL, V73, P1149, DOI 10.1016/S0015-0282(00)00501-X; KORYTKOWSKI MT, 1995, J CLIN ENDOCR METAB, V80, P3327, DOI 10.1210/jc.80.11.3327; la Marca A, 1999, FERTIL STERIL, V72, P985, DOI 10.1016/S0015-0282(99)00407-0; Mehnert H, 2001, EXP CLIN ENDOCR DIAB, V109, pS259, DOI 10.1055/s-2001-18587; Mitwally MFM, 1999, HUM REPROD, V14, P2700, DOI 10.1093/humrep/14.11.2700; Moghetti P, 2000, J CLIN ENDOCR METAB, V85, P139, DOI 10.1210/jc.85.1.139; Morin-Papunen LC, 1998, FERTIL STERIL, V69, P691, DOI 10.1016/S0015-0282(98)00011-9; Morin-Papunen LC, 2000, J CLIN ENDOCR METAB, V85, P3161, DOI 10.1210/jc.85.9.3161; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603; Nestler JE, 1999, NEW ENGL J MED, V340, P1314, DOI 10.1056/NEJM199904293401703; Nestler JE, 1997, J CLIN ENDOCR METAB, V82, P4075, DOI 10.1210/jc.82.12.4075; Nestler JE, 2002, FERTIL STERIL, V77, P209, DOI 10.1016/S0015-0282(01)02963-6; Ng EHY, 2001, HUM REPROD, V16, P1625, DOI 10.1093/humrep/16.8.1625; Norman RJ, 1998, REPROD FERT DEVELOP, V10, P55, DOI 10.1071/R98010; Pasquali R, 2000, J CLIN ENDOCR METAB, V85, P2767, DOI 10.1210/jc.85.8.2767; Pirwany IR, 1999, HUM REPROD, V14, P2963, DOI 10.1093/humrep/14.12.2963; Sattar N, 1998, LANCET, V351, P305, DOI 10.1016/S0140-6736(05)78345-8; Solomon CG, 2002, J CLIN ENDOCR METAB, V87, P2013, DOI 10.1210/jc.87.5.2013; Solomon CG, 2001, JAMA-J AM MED ASSOC, V286, P2421, DOI 10.1001/jama.286.19.2421; Stadtmauer LA, 2001, FERTIL STERIL, V75, P505, DOI 10.1016/S0015-0282(00)01766-0; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; VANDERSPUY ZM, 1996, HUM REPROD, V11, P167; Velazquez E, 1997, OBSTET GYNECOL, V90, P392; Velazquez EM, 1997, METABOLISM, V46, P454, DOI 10.1016/S0026-0495(97)90066-4; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; Wild RA, 2002, AM J OBSTET GYNECOL, V186, P35, DOI 10.1067/mob.2002.119180; Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI200114178; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	65	163	168	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	2003	361	9372					1894	1901		10.1016/S0140-6736(03)13493-9	http://dx.doi.org/10.1016/S0140-6736(03)13493-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788588				2022-12-28	WOS:000183205800025
J	Ordovas, J; Pittas, A; Greenberg, AS				Ordovas, J; Pittas, A; Greenberg, AS			Might the diabetic environment in utero, lead to type 2 diabetes?	LANCET			English	Editorial Material							HYPOTHESIS; BURDEN		Tufts Univ, Nutr & Genom Lab, Boston, MA 02111 USA; Tufts Univ, Obes & Metab Lab, Jean Mayer USDA Human Nutr Res, Ctr Aging, Boston, MA 02111 USA	Tufts University; Tufts University; United States Department of Agriculture (USDA)	Greenberg, AS (corresponding author), Tufts Univ, Nutr & Genom Lab, Boston, MA 02111 USA.		Ordovas, Jose/B-8727-2013	Ordovas, Jose/0000-0002-7581-5680				Amos A.F., 1997, DIABET MED S5, V14, P1; Bagust A, 2002, DIABETIC MED, V19, P1, DOI 10.1046/j.1464-5491.19.s4.2.x; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Klupa T, 2002, DIABETES CARE, V25, P2292, DOI 10.2337/diacare.25.12.2292; Neel JV, 1998, PERSPECT BIOL MED, V42, P44; Stride A, 2002, DIABETES CARE, V25, P2287, DOI 10.2337/diacare.25.12.2287	7	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1839	1840		10.1016/S0140-6736(03)13537-4	http://dx.doi.org/10.1016/S0140-6736(03)13537-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788565				2022-12-28	WOS:000183205800003
J	Spencer, RMC; Zelaznik, HN; Diedrichsen, J; Ivry, RB				Spencer, RMC; Zelaznik, HN; Diedrichsen, J; Ivry, RB			Disrupted timing of discontinuous but not continuous movements by cerebellar lesions	SCIENCE			English	Article							DRAWING MOVEMENTS; DISSOCIATION; PERCEPTION; HUMANS; FMRI	Patients with cerebellar damage are known to exhibit deficits in the temporal control of movements. We report that these deficits are restricted to discontinuous movements. Cerebellar patients exhibited no deficit in temporal variability when producing continuous, rhythmic movements. We hypothesize that the temporal properties of continuous movements are emergent and reflect the operation of other control parameters not associated with the cerebellum. In contrast, discontinuous movements require an explicit representation of the temporal goal, a function of the cerebellum. The requirement for explicit temporal representation provides a parsimonious account of cerebellar involvement in a range of tasks.	Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; Purdue Univ, Dept Hlth & Kinesiol, Integrat Program Neurosci, W Lafayette, IN 47907 USA	University of California System; University of California Berkeley; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Spencer, RMC (corresponding author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall 1650, Berkeley, CA 94720 USA.	rspencer@socrates.berkeley.edu	Diedrichsen, Jörn/AAQ-2242-2020; Diedrichsen, Jörn/A-7789-2010	Diedrichsen, Jörn/0000-0003-0264-8532; Diedrichsen, Jörn/0000-0003-0264-8532; Spencer, Rebecca/0000-0002-8674-2384; zelaznik, howard/0000-0003-0071-2377	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS017778, R29NS030256, P01NS017778, P01NS040813, R01NS030256] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30256, NS17778, NS40813] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann H, 1997, BRAIN LANG, V60, P323, DOI 10.1006/brln.1997.1826; Ackermann H, 2001, NEUROREPORT, V12, P4087, DOI 10.1097/00001756-200112210-00045; Bastian AJ, 1996, J NEUROPHYSIOL, V76, P492, DOI 10.1152/jn.1996.76.1.492; Burdet E, 2001, NATURE, V414, P446, DOI 10.1038/35106566; DAUM I, 1993, BEHAV NEUROSCI, V107, P748, DOI 10.1037/0735-7044.107.5.748; HOGAN N, 1987, TRENDS NEUROSCI, V10, P170, DOI 10.1016/0166-2236(87)90043-9; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; HORE J, 1991, J NEUROPHYSIOL, V65, P563, DOI 10.1152/jn.1991.65.3.563; IVRY R, 1993, ANN NY ACAD SCI, V682, P214, DOI 10.1111/j.1749-6632.1993.tb22970.x; IVRY R, 1997, INT REV NEUROBIOL, V41, P556; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; IVRY RB, 1988, EXP BRAIN RES, V73, P167, DOI 10.1007/BF00279670; IVRY RB, 1993, ATTENTION PERFORM, V14, P771; JACIKSON J, 1991, NATO ADV STUDY I SER, V62, P169; JUEPTNER M, 1995, NEUROLOGY, V45, P1540, DOI 10.1212/WNL.45.8.1540; Kawashima R, 2000, J NEUROPHYSIOL, V83, P1079, DOI 10.1152/jn.2000.83.2.1079; Kennerley SW, 2002, NAT NEUROSCI, V5, P376, DOI 10.1038/nn822; KILLEEN PR, 1987, PSYCHOL REV, V94, P455, DOI 10.1037/0033-295X.94.4.455; Mangels JA, 1998, COGNITIVE BRAIN RES, V7, P15, DOI 10.1016/S0926-6410(98)00005-6; Mussa-Ivaldi FA, 2000, BIOMECHANICS AND NEURAL CONTROL OF POSTURE AND MOVEMENT, P325; Robertson SD, 1999, J EXP PSYCHOL HUMAN, V25, P1316, DOI 10.1037/0096-1523.25.5.1316; Timmann D, 2000, EXP BRAIN RES, V130, P441, DOI 10.1007/s002219900277; TOPKA H, 1993, BRAIN, V116, P961, DOI 10.1093/brain/116.4.961; Turvey M., 1977, PERCEIVING ACTING KN, P211; van Beers RJ, 2002, PHILOS T R SOC B, V357, P1137, DOI 10.1098/rstb.2002.1101; VORBERG D, 1996, HDB PERCEPTION ACTIO, V2, P1581; WoodruffPak DS, 1996, NEUROPSYCHOLOGY, V10, P443; Zelaznik HN, 2000, J MOTOR BEHAV, V32, P193, DOI 10.1080/00222890009601370; Zelaznik HN, 2002, J EXP PSYCHOL HUMAN, V28, P575, DOI 10.1037//0096-1523.28.3.575	29	351	357	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2003	300	5624					1437	1439		10.1126/science.1083661	http://dx.doi.org/10.1126/science.1083661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	683ZW	12775842				2022-12-28	WOS:000183181800047
J	Bauer, DC; Ettinger, B; Nevitt, MC; Stone, KL				Bauer, DC; Ettinger, B; Nevitt, MC; Stone, KL		Study Osteoporotic Fractures Res G	Risk for fracture in women with low serum levels of thyroid-stimulating hormone	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MINERAL DENSITY; THYROXINE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; OLDER WOMEN; SUBCLINICAL HYPERTHYROIDISM; VERTEBRAL FRACTURES; HYPOTHYROID PATIENTS; HIP FRACTURE; TSH ASSAYS; THYROTROPIN	Background: Biochemical evidence of hyperthyroidism may be associated with low bone mass, particularly in older postmenopausal women, but no prospective studies of thyroid function and subsequent fracture risk have been done. Objective: To examine the association between low levels of thyroid-stimulating hormone (TSH) and fracture in older women. Design: Prospective cohort study with case-cohort sampling. Setting: Four clinical centers in the United States. Patients: 686 women older than 65 years of age from a cohort of 9704 women recruited from population-based listings between 1986 and 1988, Measurements: Baseline assessment of calcaneal bone mass, spine radiography, and history of thyroid disease. Spine radiography was repeated after a mean follow-up of 3.7 years; nonspine fractures were centrally adjudicated, Thyroid-stimulating hormone was measured in sera obtained at baseline from 148 women with new hip fractures, 149 women with new vertebral fractures, and a subsample of 398 women randomly selected from the cohort. Results: After adjustment for age, history of previous hyperthyroidism, self-rated health, and use of estrogen and thyroid hormone, women with a low TSH level (less than or equal to0.1 mU/L) had a threefold increased risk for hip fracture (relative hazard, 3.6 [95% CI, 1.0 to 12.9]) and a fourfold increased risk for vertebral fracture (odds ratio, 4.5 [CI, 1.3 to 15.6]) compared with women who had normal TSH levels (0.5 to 5.5 mU/L), After adjustment for TSH level, a history of hyperthyroidism was associated with a twofold increase in hip fracture (relative hazard, 2.2 [CI, 1.0 to 4.4]), but use of thyroid hormone itself was not associated with increased risk for hip fracture (relative hazard, 0.5 [CI, 0.2 to 1.3]). Conclusions: Women older than 65 years of age who have low serum TSH levels, indicating physiologic hyperthyroidism, are at increased risk for new hip and vertebral fractures. Use of thyroid hormone itself does not increase risk for fracture if TSH levels are normal.	Univ Calif San Francisco, San Francisco, CA 94105 USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Minnesota, Minneapolis, MN USA; Kaiser Permanente Med Care Program, Oakland, CA 94611 USA	University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities; Kaiser Permanente	Bauer, DC (corresponding author), Univ Calif San Francisco, 74 New Montgomery,Suite 600, San Francisco, CA 94105 USA.				NIA NIH HHS [K08 AG00629] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000629] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; AUWERX J, 1986, Q J MED, V60, P737; BARAN DT, 1994, THYROID, V4, P143, DOI 10.1089/thy.1994.4.143; Barlow WE, 1999, J CLIN EPIDEMIOL, V52, P1165, DOI 10.1016/S0895-4356(99)00102-X; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; Bauer DC, 1997, J CLIN ENDOCR METAB, V82, P2931, DOI 10.1210/jc.82.9.2931; BAUER DC, 1993, P 4 INT S OST CONS D, P170; BAYER MF, 1991, MED CLIN N AM, V75, P1; BAYLEY TA, 1980, J CLIN ENDOCR METAB, V50, P916, DOI 10.1210/jcem-50-5-916; BLACK DM, 1995, J BONE MINER RES, V10, P890; COMPSTON JE, 1993, CLIN ENDOCRINOL, V39, P519, DOI 10.1111/j.1365-2265.1993.tb02402.x; Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1996, J BONE MINER RES  S1, V11, pS128; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; FRANKLYN JA, 1993, CLIN ENDOCRINOL, V38, P453, DOI 10.1111/j.1365-2265.1993.tb00339.x; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; FRASER SA, 1971, LANCET, V1, P981; GAM AN, 1991, J ENDOCRINOL INVEST, V14, P451, DOI 10.1007/BF03346838; Garnero P, 1996, J BONE MINER RES, V11, P1531; Genant HK, 1996, J BONE MINER RES, V11, P984; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; GRUND FM, 1989, ARCH INTERN MED, V149, P921, DOI 10.1001/archinte.149.4.921; Hallengren B, 1999, J INTERN MED, V246, P139, DOI 10.1046/j.1365-2796.1999.00497.x; HARVEY RD, 1991, J CLIN ENDOCR METAB, V72, P1189, DOI 10.1210/jcem-72-6-1189; Helfand M, 1998, ANN INTERN MED, V129, P144, DOI 10.7326/0003-4819-129-2-199807150-00020; KASHIWAI T, 1991, SCAND J CLIN LAB INV, V51, P417, DOI 10.3109/00365519109091635; KIEL DP, 1995, J BONE MINER RES, V10, pS189; KRAKAUER JC, 1992, ARCH INTERN MED, V152, P360, DOI 10.1001/archinte.152.2.360; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem-70-3-766; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; LEHMKE J, 1992, CLIN ENDOCRINOL, V36, P511, DOI 10.1111/j.1365-2265.1992.tb02254.x; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003-4819-128-10-199805150-00001; Orwoll ES, 1996, ANN INTERN MED, V124, P187, DOI 10.7326/0003-4819-124-2-199601150-00001; PRENTICE RL, 1986, BIOMETRICS, V42, P301, DOI 10.2307/2531051; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; ROSS DS, 1994, THYROID, V4, P319, DOI 10.1089/thy.1994.4.319; ROSS DS, 1991, J CLIN ENDOCR METAB, V72, P507, DOI 10.1210/jcem-72-2-507; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SAWIN CT, 1989, JAMA-J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SAWIN CT, 1995, CLIN GERIATR MED, V11, P231, DOI 10.1016/S0749-0690(18)30293-3; Seppel T, 1996, J CLIN ENDOCR METAB, V81, P1663, DOI 10.1210/jc.81.4.1663; SOLOMON BL, 1993, THYROID, V3, P17, DOI 10.1089/thy.1993.3.17; Spencer CA, 1996, CLIN CHEM, V42, P140; SPENCER CA, 1993, J CLIN ENDOCR METAB, V76, P494, DOI 10.1210/jc.76.2.494; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; von Recklinghausen F., 1891, FESTSCHRIFT R VIRCHO; WARTOFSKY L, 1995, ARCH INTERN MED, V155, P1130, DOI 10.1001/archinte.155.11.1130; WEJDA B, 1995, J INTERN MED, V237, P241, DOI 10.1111/j.1365-2796.1995.tb01172.x	52	315	341	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 3	2001	134	7					561	568		10.7326/0003-4819-134-7-200104030-00009	http://dx.doi.org/10.7326/0003-4819-134-7-200104030-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	419CF	12803168	Green Submitted			2022-12-28	WOS:000167931200003
J	Lardinois, D; Weder, W; Hany, TF; Kamel, EM; Korom, S; Seifert, B; von Schulthess, GK; Steinert, HC				Lardinois, D; Weder, W; Hany, TF; Kamel, EM; Korom, S; Seifert, B; von Schulthess, GK; Steinert, HC			Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CT IMAGE FUSION; WHOLE-BODY PET; FDG-PET; METASTASES; MANAGEMENT; SYSTEM; IMPACT	BACKGROUND: <LF>We compared the diagnostic accuracy of integrated positron-emission tomography (PET) and computed tomography (CT) with that of CT alone, that of PET alone, and that of conventional visual correlation of PET and CT in determining the stage of disease in non-small-cell lung cancer. METHODS: In a prospective study, integrated PET-CT was performed in 50 patients with proven or suspected non-small-cell lung cancer. CT and PET alone, visually correlated PET and CT, and integrated PET-CT were evaluated separately, and a tumor-node-metastasis (TNM) stage was assigned on the basis of image analysis. Nodal stations were identified according to the mapping system of the American Thoracic Society. The standard of reference was histopathological assessment of tumor stage and node stage. Extrathoracic metastases were confirmed histopathologically or by at least one other imaging method. A paired sign test was used to compare integrated PET-CT with the other imaging methods. RESULTS: Integrated PET-CT provided additional information in 20 of 49 patients (41 percent), beyond that provided by conventional visual correlation of PET and CT. Integrated PET-CT had better diagnostic accuracy than the other imaging methods. Tumor staging was significantly more accurate with integrated PET-CT than with CT alone (P=0.001), PET alone (P<0.001), or visual correlation of PET and CT (P=0.013); node staging was also significantly more accurate with integrated PET-CT than with PET alone (P=0.013). In metastasis staging, integrated PET-CT increased the diagnostic certainty in two of eight patients. CONCLUSIONS: Integrated PET-CT improves the diagnostic accuracy of the staging of non-small-cell lung cancer.	Univ Zurich Hosp, Div Nucl Med, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Div Thorac Surg, CH-8091 Zurich, Switzerland; Univ Zurich, Dept Biostat, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich	Steinert, HC (corresponding author), Univ Zurich Hosp, Div Nucl Med, Ramistr 100, CH-8091 Zurich, Switzerland.			Seifert, Burkhardt/0000-0002-5829-2478; Hany, Thomas Frank/0000-0001-9341-3936				Belley G, 2000, RADIOLOGY, V217, P361; Beyer T, 2000, J NUCL MED, V41, P1369; Burger C, 2002, EUR J NUCL MED MOL I, V29, P922, DOI 10.1007/s00259-002-0796-3; Cook GJR, 1999, EUR J NUCL MED, V26, P1363, DOI 10.1007/s002590050597; Dietlein M, 2000, EUR J NUCL MED, V27, P1598, DOI 10.1007/s002590000376; Dwamena BA, 1999, RADIOLOGY, V213, P530, DOI 10.1148/radiology.213.2.r99nv46530; Engel H, 1996, J NUCL MED, V37, P441; Goerres GW, 2002, EUR J NUCL MED MOL I, V29, P351, DOI 10.1007/s00259-001-0710-4; Gupta NC, 1999, ANN SURG, V229, P286, DOI 10.1097/00000658-199902000-00018; Hany TF, 2002, RADIOLOGY, V225, P575, DOI 10.1148/radiol.2252011568; Hellwig D, 2001, Pneumologie, V55, P367, DOI 10.1055/s-2001-16201; Kalff V, 2001, J CLIN ONCOL, V19, P111, DOI 10.1200/JCO.2001.19.1.111; Kamel E, 2002, EUR J NUCL MED MOL I, V29, P346, DOI 10.1007/s00259-001-0698-9; Kamel EM, 2002, RADIOLOGY, V224, P153, DOI 10.1148/radiol.2241011254; Kernstine KH, 2002, ANN THORAC SURG, V73, P394, DOI 10.1016/S0003-4975(01)03432-4; Kluetz P G., 2000, Clin Positron Imaging, V3, P223, DOI 10.1016/S1095-0397(01)00055-3; Magnani P, 1999, J CARDIOVASC SURG, V40, P741; Marom EM, 1999, RADIOLOGY, V212, P803, DOI 10.1148/radiology.212.3.r99se21803; Martini N, 1995, Chest Surg Clin N Am, V5, P189; Mountain CF, 1997, CHEST, V111, P1718, DOI 10.1378/chest.111.6.1718; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; RENDINA EA, 1987, J THORAC CARDIOV SUR, V94, P57; Seltzer MA, 2002, J NUCL MED, V43, P752; Steinert HC, 1997, RADIOLOGY, V202, P441, DOI 10.1148/radiology.202.2.9015071; Strauss LG, 1996, EUR J NUCL MED, V23, P1409, DOI 10.1007/BF01367602; TISI GM, 1983, AM REV RESPIR DIS, V127, P659, DOI 10.1164/arrd.1983.127.5.659; van Tinteren H, 2002, LANCET, V359, P1388, DOI 10.1016/S0140-6736(02)08352-6; Vansteenkiste JF, 1998, EUR J NUCL MED, V25, P1495, DOI 10.1007/s002590050327; WAHL RL, 1994, RADIOLOGY, V191, P371, DOI 10.1148/radiology.191.2.8153308; Weder W, 1998, ANN THORAC SURG, V66, P886, DOI 10.1016/S0003-4975(98)00675-4	30	1054	1112	0	80	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2500	2507		10.1056/NEJMoa022136	http://dx.doi.org/10.1056/NEJMoa022136			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815135	Green Accepted			2022-12-28	WOS:000183577200004
J	Sakai, T; Larsen, M; Yamada, KM				Sakai, T; Larsen, M; Yamada, KM			Fibronectin requirement in branching morphogenesis	NATURE			English	Article							CELL-MATRIX ADHESIONS; SALIVARY-GLAND; SUBMANDIBULAR-GLAND; EPITHELIUM; CADHERIN; SURFACE; LUNG	Many organs, including salivary glands, lung and kidney, are formed during embryonic development by epithelial branching. In branching morphogenesis, repetitive epithelial cleft and bud formation create the complex three-dimensional branching structures characteristic of many organs(1-3). Although the mechanisms are poorly understood, one might involve the site-specific accumulation of some regulatory protein. Here we show that the extracellular matrix protein fibronectin(4,5) is essential for cleft formation during the initiation of epithelial branching. Fibronectin messenger RNA and fibrils appeared transiently and focally in forming cleft regions of submandibular salivary-gland epithelia, accompanied by an adjacent loss of cadherin localization. Decreasing the fibronectin concentration by using small interfering RNA and inhibition by anti-fibronectin or anti-integrin antibodies blocked cleft formation and branching. Exogenous fibronectin accelerated cleft formation and branching. Similar effects of fibronectin suppression and augmentation were observed in developing lung and kidney. Mechanistic studies revealed that fibrillar fibronectin can induce cell-matrix adhesions on cultured human salivary epithelial cells with a local loss of cadherins at cell-cell junctions. Thus, fibronectin expression is required for cleft formation in branching morphogenesis associated with the conversion of cell-cell adhesions to cell-matrix adhesions.	Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, KM (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA.		Sakai, Takayoshi/L-1456-2019	Sakai, Takayoshi/0000-0003-4348-4896; Larsen, Melinda/0000-0002-5026-2012; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERNFIELD MR, 1972, J CELL BIOL, V52, P674, DOI 10.1083/jcb.52.3.674; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Davies JA, 2002, BIOESSAYS, V24, P937, DOI 10.1002/bies.10161; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; GILBERT SF, 1997, DEV BIOL, P683; GROBSTEIN C, 1953, NATURE, V172, P869, DOI 10.1038/172869a0; GROBSTEIN C, 1965, SCIENCE, V150, P626, DOI 10.1126/science.150.3696.626; HARDMAN P, 1992, ANAT REC, V234, P452, DOI 10.1002/ar.1092340315; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; Hoffman MP, 2002, DEVELOPMENT, V129, P5767, DOI 10.1242/dev.00172; Hogan BLM, 1998, CURR OPIN GENET DEV, V8, P481, DOI 10.1016/S0959-437X(98)80121-4; Hynes RO, 1990, FIBRONECTINS; Jiang ST, 2000, KIDNEY INT, V57, P1860, DOI 10.1046/j.1523-1755.2000.00035.x; KADOYA Y, 1995, J CELL BIOL, V129, P521, DOI 10.1083/jcb.129.2.521; Kashimata M, 2000, DEV BIOL, V220, P183, DOI 10.1006/dbio.2000.9639; Levenberg S, 1998, J CELL SCI, V111, P347; Menko AS, 2002, DEV DYNAM, V224, P321, DOI 10.1002/dvdy.10111; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Mosher DF, 1989, FIBRONECTIN; NAKANISHI Y, 1986, DEV BIOL, V113, P201, DOI 10.1016/0012-1606(86)90122-3; NAKANISHI Y, 1988, DEVELOPMENT, V104, P51; NOGAWA H, 1991, DEVELOPMENT, V112, P855; Roman J, 1997, EXP LUNG RES, V23, P147, DOI 10.3109/01902149709074027; SAKAI T, 2002, CURRENT PROTOCOLS CE; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; SPOONER BS, 1972, DEV BIOL, V27, P38, DOI 10.1016/0012-1606(72)90111-X; Spooner BS, 1986, DEV BIOL COMPREHENSI, V3, P225; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; YAMADA KM, 1978, NATURE, V275, P179, DOI 10.1038/275179a0	30	387	394	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					876	881		10.1038/nature01712	http://dx.doi.org/10.1038/nature01712			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815434				2022-12-28	WOS:000183585300048
J	Whitney, D; Westwood, DA; Goodale, MA				Whitney, D; Westwood, DA; Goodale, MA			The influence of visual motion on fast reaching movements to a stationary object	NATURE			English	Article							PERCEIVED POSITION; SPACE; PERCEPTION; TARGET; HAND; DISPLACEMENT; INFORMATION; LOCATION; SYSTEMS; VISION	One of the most important functions of vision is to direct actions to objects(1). However, every time that vision is used to guide an action, retinal motion signals are produced by the movement of the eye and head as the person looks at the object or by the motion of other objects in the scene. To reach for the object accurately, the visuomotor system must separate information about the position of the stationary target from background retinal motion signals-a long-standing problem that is poorly understood(2-7). Here we show that the visuomotor system does not distinguish between these two information sources: when observers made fast reaching movements to a briefly presented stationary target, their hand shifted in a direction consistent with the motion of a distant and unrelated stimulus, a result contrary to most other findings(8,9). This can be seen early in the hand's trajectory (similar to120 ms) and occurs continuously from programming of the movement through to its execution. The visuomotor system might make use of the motion signals arising from eye and head movements to update the positions of targets rapidly and redirect the hand to compensate for body movements.	Univ Western Ontario, Dept Psychol, CIHR Grp Act & Percept, London, ON N6A 5C2, Canada; Dalhousie Univ, Sch Hlth & Human Performance, Halifax, NS B3H 3J5, Canada	Western University (University of Western Ontario); Dalhousie University	Whitney, D (corresponding author), Univ Western Ontario, Dept Psychol, CIHR Grp Act & Percept, London, ON N6A 5C2, Canada.		Goodale, Melvyn A/M-5907-2013	Goodale, Melvyn A/0000-0001-6748-0561; Westwood, David/0000-0003-3317-0447	NATIONAL EYE INSTITUTE [F32EY013899] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY013899-03, F32 EY013899, F32 EY013899-02, F32 EY013899-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMS RA, 1990, PERCEPT PSYCHOPHYS, V47, P349, DOI 10.3758/BF03210875; Andersen RA, 1997, ANNU REV NEUROSCI, V20, P303, DOI 10.1146/annurev.neuro.20.1.303; [Anonymous], EYE MOVEMENTS THEIR; BACON JH, 1982, PERCEPT PSYCHOPHYS, V32, P353, DOI 10.3758/BF03206241; Berry MJ, 1999, NATURE, V398, P334, DOI 10.1038/18678; BLOUIN J, 1995, NEUROREPORT, V6, P1165, DOI 10.1097/00001756-199505300-00023; Brenner E, 1997, J MOTOR BEHAV, V29, P297, DOI 10.1080/00222899709600017; BRIDGEMAN B, 1979, J EXP PSYCHOL HUMAN, V5, P692, DOI 10.1037/0096-1523.5.4.692; Bridgeman B, 1997, PERCEPT PSYCHOPHYS, V59, P456, DOI 10.3758/BF03211912; Buneo CA, 2002, NATURE, V416, P632, DOI 10.1038/416632a; Desmurget M, 2000, TRENDS COGN SCI, V4, P423, DOI 10.1016/S1364-6613(00)01537-0; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; GOODALE MA, 1986, NATURE, V320, P748, DOI 10.1038/320748a0; Hayes A, 2000, P ROY SOC B-BIOL SCI, V267, P1341, DOI 10.1098/rspb.2000.1148; Henriques DYP, 1998, J NEUROSCI, V18, P1583; Jeannerod M., 1988, NEURAL BEHAV ORG GOA; LEPECQ JC, 1993, PERCEPTION, V22, P49, DOI 10.1068/p220049; MASSON G, 1995, VISION RES, V35, P837, DOI 10.1016/0042-6989(94)00185-O; Nishida S, 1999, NATURE, V397, P610, DOI 10.1038/17600; PAULIGNAN Y, 1990, EXP BRAIN RES, V79, P431, DOI 10.1007/BF00608255; PELISSON D, 1986, EXP BRAIN RES, V62, P303; PRABLANC C, 1992, J NEUROPHYSIOL, V67, P455, DOI 10.1152/jn.1992.67.2.455; RAMACHANDRAN VS, 1990, PERCEPTION, V19, P611, DOI 10.1068/p190611; Sheth BR, 2000, PERCEPTION, V29, P1279, DOI 10.1068/p3114; SMEETS JBJ, 1995, J EXP PSYCHOL HUMAN, V21, P19, DOI 10.1037/0096-1523.21.1.19; Snowden RJ, 1998, CURR BIOL, V8, P1343, DOI 10.1016/S0960-9822(07)00567-2; Whitaker D, 1999, VISION RES, V39, P2999, DOI 10.1016/S0042-6989(99)00010-3; Whitney D, 2000, NAT NEUROSCI, V3, P954, DOI 10.1038/78878; WONG E, 1981, ACTA PSYCHOL, V48, P123, DOI 10.1016/0001-6918(81)90054-8; Yamagishi N, 2001, P ROY SOC B-BIOL SCI, V268, P973, DOI 10.1098/rspb.2001.1603	30	93	93	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					869	873		10.1038/nature01693	http://dx.doi.org/10.1038/nature01693			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	691BQ	12815432	Green Accepted			2022-12-28	WOS:000183585300046
J	Ambros, V				Ambros, V			MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing	CELL			English	Review							CAENORHABDITIS-ELEGANS; REGULATORY RNA; DROSOPHILA; EXPRESSION; ENCODES; LIN-14		Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA	Dartmouth College	Ambros, V (corresponding author), Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA.							Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; CARRINGTON J, 2003, IN PRESS SCIENCE; Fay DS, 1999, DEV BIOL, V205, P240, DOI 10.1006/dbio.1998.9096; Hipfner DR, 2002, GENETICS, V161, P1527; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	20	1020	1128	0	59	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 13	2003	113	6					673	676		10.1016/S0092-8674(03)00428-8	http://dx.doi.org/10.1016/S0092-8674(03)00428-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809598	Bronze			2022-12-28	WOS:000183514400002
J	Dai, DX; Wang, CC; Harich, SA; Wang, XY; Yang, XM; Chao, SD; Skodje, RT				Dai, DX; Wang, CC; Harich, SA; Wang, XY; Yang, XM; Chao, SD; Skodje, RT			Interference of quantized transition-state pathways in the H+D2 -> D+HD chemical reaction	SCIENCE			English	Article							CROSS-SECTIONS; SPECTRAL QUANTIZATION; SCATTERING; RESONANCE; DYNAMICS; THRESHOLDS; H+D-2; H+H2	The collision-energy dependence of the state-resolved differential cross section at a specific backward-scattering angle for the reaction H + D-2 --> D + HD is measured with the D-atom Rydberg "tagging" time-of-flight technique. The reaction was modeled theoretically with converged quantum scattering calculations that provided physical interpretation of the observations. Oscillations in the differential cross sections in the backward-scattering direction are clearly observed and are attributed to the transition-state structures that originate from the interferences of different quantized transition-state pathways.	Chinese Acad Sci, Dalian Inst Chem Phys, State Key Lab Mol React Dynam, Dalian, Peoples R China; Acad Sinica, Inst Atom & Mol Sci, Taipei, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 10764, Taiwan; Natl Tsing Hua Univ, Dept Chem, Hsinchu, Taiwan; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Academia Sinica - Taiwan; National Taiwan University; National Tsing Hua University; University of Colorado System; University of Colorado Boulder	Yang, XM (corresponding author), Chinese Acad Sci, Dalian Inst Chem Phys, State Key Lab Mol React Dynam, Dalian, Peoples R China.	xmyang@po.iams.sinica.edu.tw; skodje@spot.colorado.edu	Yang, Xueming/C-8764-2013					Allison TC, 2000, CHEM PHYS LETT, V327, P439, DOI 10.1016/S0009-2614(00)00885-X; Althorpe SC, 2002, NATURE, V416, P67, DOI 10.1038/416067a; Boothroyd AI, 1996, J CHEM PHYS, V104, P7139, DOI 10.1063/1.471430; Chao SD, 2002, J CHEM PHYS, V117, P8341, DOI 10.1063/1.1504083; Chao SD, 2001, CHEM PHYS LETT, V336, P364, DOI 10.1016/S0009-2614(01)00105-1; Chatfield DC, 2000, J CHEM PHYS, V112, P8387, DOI 10.1063/1.481443; CHILD MS, 1996, MOL COLLISION THEORY, P161; DMELLO M, 1991, J CHEM PHYS, V94, P5985, DOI 10.1063/1.460432; Fernandez-Alonso F, 2000, ANGEW CHEM INT EDIT, V39, P2748, DOI 10.1002/1521-3773(20000804)39:15<2748::AID-ANIE2748>3.3.CO;2-#; Gezelter JD, 1996, J CHEM PHYS, V104, P3546, DOI 10.1063/1.471059; Harich SA, 2002, NATURE, V419, P281, DOI 10.1038/nature01068; Kendrick BK, 2001, J CHEM PHYS, V114, P8796, DOI 10.1063/1.1367377; KIM SK, 1995, J CHEM PHYS, V102, P3202, DOI 10.1063/1.468631; KITSOPOULOS TN, 1993, SCIENCE, V260, P1605, DOI 10.1126/science.260.5114.1605; LAUNAY JM, 1989, CHEM PHYS LETT, V163, P178, DOI 10.1016/0009-2614(89)80031-4; Liu KP, 2001, ANNU REV PHYS CHEM, V52, P139, DOI 10.1146/annurev.physchem.52.1.139; MILLER WH, 1990, ANNU REV PHYS CHEM, V41, P245; NEUMARK DM, 1984, PHYS REV LETT, V53, P226, DOI 10.1103/PhysRevLett.53.226; PACK RT, 1987, J CHEM PHYS, V87, P3888, DOI 10.1063/1.452944; SADEGHI R, 1995, J CHEM PHYS, V102, P193, DOI 10.1063/1.469391; SCHATZ GC, 1988, CHEM PHYS LETT, V150, P92, DOI 10.1016/0009-2614(88)80402-0; Schnieder L, 1997, J CHEM PHYS, V107, P6175, DOI 10.1063/1.474283; SCHNIEDER L, 1995, SCIENCE, V260, P1605; SKODJE RT, 1994, J CHEM PHYS, V101, P1725, DOI 10.1063/1.467728; Skodje RT, 2000, PHYS REV LETT, V85, P1206, DOI 10.1103/PhysRevLett.85.1206; Skouteris D, 2000, COMPUT PHYS COMMUN, V133, P128, DOI 10.1016/S0010-4655(00)00167-3; Sukiasyan S, 2001, J PHYS CHEM A, V105, P2604, DOI 10.1021/jp003767m; WU YSM, 1995, CHEM PHYS LETT, V235, P105, DOI 10.1016/0009-2614(95)00069-G	28	120	125	9	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1730	1734		10.1126/science.1084041	http://dx.doi.org/10.1126/science.1084041			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805543				2022-12-28	WOS:000183459700046
J	Ellwood, BB; Benoist, SL; El Hassani, A; Wheeler, C; Crick, RE				Ellwood, BB; Benoist, SL; El Hassani, A; Wheeler, C; Crick, RE			Impact ejecta layer from the mid-Devonian: Possible connection to global mass extinctions	SCIENCE			English	Article							MAGNETOSUSCEPTIBILITY EVENT; CYCLOSTRATIGRAPHY MSEC; ANTI-ATLAS; BOUNDARY; MOROCCO; MOUNDS; ROCKS	We have found evidence for a bolide impacting Earth in the mid-Devonian (similar to380 million years ago), including high concentrations of shocked quartz, Ni, Cr, As, V, and Co anomalies; a large negative carbon isotope shift (-9 per mil); and microspherules and microcrysts at Jebel Mech Irdane in the Anti Atlas desert near Rissani, Morocco. This impact is important because it is coincident with a major global extinction event (Kacak/otomari event), suggesting a possible cause-and-effect relation between the impact and the extinction. The result may represent the extinction of as many as 40% of all living marine animal genera.	Louisiana State Univ, Dept Geol & Geophys, Baton Rouge, LA 70803 USA; Inst Sci, Dept Geol, Rabat, Morocco; Univ Texas, Dept Geol, Arlington, TX 76019 USA	Louisiana State University System; Louisiana State University; Mohammed V University in Rabat; University of Texas System; University of Texas Arlington	Ellwood, BB (corresponding author), Louisiana State Univ, Dept Geol & Geophys, E235 Howe Russell Geosci Complex, Baton Rouge, LA 70803 USA.			EL HASSANI, Ahmed/0000-0002-2272-817X				Crick RE, 1997, EPISODES, V20, P167, DOI 10.18814/epiiugs/1997/v20i3/004; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Ellwood BB, 2003, EARTH PLANET SC LETT, V206, P529, DOI 10.1016/S0012-821X(02)01124-X; Ellwood BB, 2000, GEOLOGY, V28, P1135, DOI 10.1130/0091-7613(2000)028<1135:MEACMA>2.3.CO;2; Ellwood BB, 1999, AAPG BULL, V83, P1119; FRENCH BM, 1998, LUNAR PLANET I CONTR, V954; GRIEVE RAF, 1988, CAN J EARTH SCI, V25, P1530, DOI 10.1139/e88-144; HLADIL J, 2002, CORAL RES B, V7, P65; HOUSE MR, 1985, NATURE, V313, P17, DOI 10.1038/313017a0; HSU KJ, 1985, NATURE, V316, P809, DOI 10.1038/316809a0; IRWIN H, 1977, NATURE, V269, P209, DOI 10.1038/269209a0; JOHNSON JG, 1985, GEOL SOC AM BULL, V96, P567, DOI 10.1130/0016-7606(1985)96<567:DEFIE>2.0.CO;2; Kaufmann B, 1997, J SEDIMENT RES, V67, P945; KUMP LR, 1991, GEOLOGY, V19, P299, DOI 10.1130/0091-7613(1991)019<0299:ICIESO>2.3.CO;2; KVENVOLDEN KA, 1993, REV GEOPHYS, V31, P173, DOI 10.1029/93RG00268; Salvador A, 1994, INT STRATIGRAPHIC GU; SMIT J, 1997, MICROPALEONTOLOGY, V29, P65; SMIT J, 1982, CRETACEOUS RES, V3, P307, DOI DOI 10.1016/0195-6671(82)90031-3; SPEKOSKI JJ, 1996, GLOBAL EVENTS EVENT, P35; TALENT JA, 1993, PALAEOGEOGR PALAEOCL, V104, P139, DOI 10.1016/0031-0182(93)90126-4; Walliser OH, 1995, EPISODES, V18, P107, DOI 10.18814/epiiugs/1995/v18i3/002; Wendt J, 1997, J SEDIMENT RES, V67, P424	22	39	42	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1734	1737		10.1126/science.1081544	http://dx.doi.org/10.1126/science.1081544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805544				2022-12-28	WOS:000183459700047
J	Zhao, J; Kilman, VL; Keegan, KP; Peng, Y; Emery, P; Rosbash, M; Allada, R				Zhao, J; Kilman, VL; Keegan, KP; Peng, Y; Emery, P; Rosbash, M; Allada, R			Drosophila clock can generate ectopic circadian clocks	CELL			English	Article							PER-TIM COMPLEX; MUSHROOM BODIES; TIMELESS GENES; EXPRESSION; TRANSCRIPTION; RHYTHMS; PROTEIN; VRILLE; FLIES; PHOTORECEPTORS	Circadian rhythms of behavior, physiology, and gene expression are present in diverse tissues and organisms. The function of the transcriptional activator, Clock, is necessary in both Drosophila and mammals for the expression of many core clock components. We demonstrate in Drosophila that Clock misexpression in naive brain regions induces circadian gene expression. This includes major components of the pacemaker program, as Clock also activates the rhythmic expression of cryptochrome, a gene that CLOCK normally represses. Moreover, this ectopic clock expression has potent effects on behavior, radically altering locomotor activity patterns. We propose that Clock is uniquely able to induce and organize the core elements of interdependent feedback loops necessary for circadian rhythms.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Brandeis Univ, Howard Hughes Med Inst, Dept Biol, Waltham, MA 02454 USA	Northwestern University; Brandeis University; Howard Hughes Medical Institute	Allada, R (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, 2153 Sheridan Rd, Evanston, IL 60208 USA.							Allada R, 2001, ANNU REV NEUROSCI, V24, P1091, DOI 10.1146/annurev.neuro.24.1.1091; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 2000, J NEUROSCI, V20, P1746; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; Bonini NM, 1997, DEVELOPMENT, V124, P4819; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cyran SA, 2003, CELL, V112, P329, DOI 10.1016/S0092-8674(03)00074-6; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Emery P, 2000, NEURON, V26, P493, DOI 10.1016/S0896-6273(00)81181-2; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Glossop NRJ, 2003, NEURON, V37, P249, DOI 10.1016/S0896-6273(03)00002-3; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Helfrich-Forster C, 2000, J NEUROSCI, V20, P3339, DOI 10.1523/JNEUROSCI.20-09-03339.2000; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; Joiner MLA, 1999, LEARN MEMORY, V6, P177; Kaneko M, 2000, J COMP NEUROL, V422, P66, DOI 10.1002/(SICI)1096-9861(20000619)422:1<66::AID-CNE5>3.0.CO;2-2; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kaneko M, 1998, CURR OPIN NEUROBIOL, V8, P652, DOI 10.1016/S0959-4388(98)80095-0; Kim EY, 2002, NEURON, V34, P69, DOI 10.1016/S0896-6273(02)00639-6; Lee C, 1999, MOL CELL BIOL, V19, P5316; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Martin JR, 1999, J COMP PHYSIOL A, V185, P277, DOI 10.1007/s003590050387; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; Moreau-Fauvarque C, 1998, MECH DEVELOP, V78, P47, DOI 10.1016/S0925-4773(98)00147-6; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; YANG MY, 1995, NEURON, V15, P45	36	102	103	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 13	2003	113	6					755	766		10.1016/S0092-8674(03)00400-8	http://dx.doi.org/10.1016/S0092-8674(03)00400-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809606	Bronze			2022-12-28	WOS:000183514400010
J	Clement, DL; De Buyzere, ML; De Bacquer, DA; de Leeuw, PW; Duprez, DA; Fagard, RH; Gheeraert, PJ; Missault, LH; Braun, JJ; Six, RO; Van Der Niepen, P; O'Brien, E				Clement, DL; De Buyzere, ML; De Bacquer, DA; de Leeuw, PW; Duprez, DA; Fagard, RH; Gheeraert, PJ; Missault, LH; Braun, JJ; Six, RO; Van Der Niepen, P; O'Brien, E		Off versus Ambulatory Pressure Stu	Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR RISK; OLDER PATIENTS; PREDICTION; EVENTS	Background: It is uncertain whether ambulatory blood-pressure measurements recorded for 24 hours in patients with treated hypertension predict cardiovascular events independently of blood-pressure measurements obtained in the physician's office and other cardiovascular risk factors. Methods: We assessed the association between base-line ambulatory blood pressures in treated patients and subsequent cardiovascular events among 1963 patients with a median follow-up of 5 years (range, 1 to 66 months). Results: We documented new cardiovascular events in 157 patients. In a Cox proportional-hazards model with adjustment for age, sex, smoking status, presence or absence of diabetes mellitus, serum cholesterol concentration, body-mass index, use or nonuse of lipid-lowering drugs, and presence or absence of a history of cardiovascular events, as well as blood pressure measured at the physician's office, higher mean values for 24-hour ambulatory systolic and diastolic blood pressure were independent risk factors for new cardiovascular events. The adjusted relative risk of cardiovascular events associated with a 1-SD increment in blood pressure was 1.34 (95 percent confidence interval, 1.11 to 1.62) for 24-hour ambulatory systolic blood pressure, 1.30 (95 percent confidence interval, 1.08 to 1.58) for ambulatory systolic blood pressure during the daytime, and 1.27 (95 percent confidence interval, 1.07 to 1.57) for ambulatory systolic blood pressure during the nighttime. For ambulatory diastolic blood pressure, the corresponding relative risks of cardiovascular events associated with a 1-SD increment were 1.21 (95 percent confidence interval, 1.01 to 1.46), 1.24 (95 percent confidence interval, 1.03 to 1.49), and 1.18 (95 percent confidence interval, 0.98 to 1.40). Conclusions: In patients with treated hypertension, a higher ambulatory systolic or diastolic blood pressure predicts cardiovascular events even after adjustment for classic risk factors including office measurements of blood pressure.	Univ Ghent, Dept Cardiovasc Dis, B-9000 Ghent, Belgium; Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium; Univ Hosp Maastricht, Dept Med, Maastricht, Netherlands; Univ Minnesota, Div Cardiovasc, Minneapolis, MN 55455 USA; Univ Louvain, Hypertens & Cardiovasc Rehabil Unit, Louvain, Belgium; Algemeen Ziekenhuis St Jan, Dept Cardiol, Brugge, Belgium; Vlietland Hosp, Dept Internal Med, Schiedam, Netherlands; Free Univ Brussels, Dept Internal Med & Hypertens, Brussels, Belgium; Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland; Beaumont Hosp, Arterial Dis Assessment Prevent & Treatment Ctr, Dublin 9, Ireland	Ghent University; Ghent University; Maastricht University; Maastricht University Medical Centre (MUMC); University of Minnesota System; University of Minnesota Twin Cities; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Clement, DL (corresponding author), Ghent Univ Hosp, Dept Cardiol & Angiol, De Pintelaan 185, B-9000 Ghent, Belgium.	denis.clement@skynet.be	de Leeuw, Peter W./J-4552-2016; De Bacquer, Dirk/HGU-3191-2022	de Leeuw, Peter W./0000-0002-4949-5812; De Bacquer, Dirk/0000-0002-3202-7238; Van der Niepen, Patricia/0000-0002-6401-1580				Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; De Henauw S, 1998, J HYPERTENS, V16, P277; Fagard R, 1996, J HYPERTENS, V14, P557, DOI 10.1097/00004872-199605000-00003; Fagard RH, 1997, HYPERTENSION, V29, P22, DOI 10.1161/01.HYP.29.1.22; Kario K, 2001, HYPERTENSION, V38, P852, DOI 10.1161/hy1001.092640; Khattar RS, 1999, CIRCULATION, V100, P1760; Mancia G, 2002, ARCH INTERN MED, V162, P582, DOI 10.1001/archinte.162.5.582; Nakano S, 1998, DIABETES, V47, P1501, DOI 10.2337/diabetes.47.9.1501; OBRIEN E, 1988, LANCET, V2, P397; Ohkubo T, 1997, J HYPERTENS, V15, P357, DOI 10.1097/00004872-199715040-00006; Ohkubo T, 1998, HYPERTENSION, V32, P255, DOI 10.1161/01.HYP.32.2.255; Ohkubo T, 2002, J HYPERTENS, V20, P2183, DOI 10.1097/00004872-200211000-00017; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PERLOFF D, 1989, J HYPERTENS       S3, V7, P3; PICKERING TG, 1995, AM J HYPERTENS, V8, P681, DOI 10.1016/0895-7061(95)00212-8; Redon J, 1998, HYPERTENSION, V31, P712, DOI 10.1161/01.HYP.31.2.712; Sander D, 2000, CIRCULATION, V102, P1536, DOI 10.1161/01.CIR.102.13.1536; Staessen JA, 1997, JAMA-J AM MED ASSOC, V278, P1065, DOI 10.1001/jama.278.13.1065; Staessen JA, 1999, JAMA-J AM MED ASSOC, V282, P539, DOI 10.1001/jama.282.6.539; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; VERDECCHIA P, 1995, HYPERTENSION, V25, P462; Verdecchia P, 2002, J AM COLL CARDIOL, V39, P878, DOI 10.1016/S0735-1097(01)01827-7; Verdecchia P, 1998, HYPERTENSION, V32, P983, DOI 10.1161/01.HYP.32.6.983; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; Verdecchia P, 1996, BLOOD PRESS MONIT S, V1, pS81; Yamamoto Y, 1998, STROKE, V29, P570, DOI 10.1161/01.STR.29.3.570; ZWEIKER R, 1994, ACTA MED AUST, V21, P86	28	833	864	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2407	2415		10.1056/NEJMoa022273	http://dx.doi.org/10.1056/NEJMoa022273			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802026				2022-12-28	WOS:000183428900006
J	DeVita, VT				DeVita, VT			Hodgkin's disease - Clinical trials and travails	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA; Yale New Haven Med Ctr, New Haven, CT 06504 USA	Yale University; Yale University	DeVita, VT (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, 333 Cedar St, New Haven, CT 06510 USA.								0	24	24	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2375	2376		10.1056/NEJMp030049	http://dx.doi.org/10.1056/NEJMp030049			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802021				2022-12-28	WOS:000183428900001
J	Atkinson, MR; Savageau, MA; Myers, JT; Ninfa, AJ				Atkinson, MR; Savageau, MA; Myers, JT; Ninfa, AJ			Development of genetic circuitry exhibiting toggle switch or oscillatory behavior in Escherichia coli	CELL			English	Article							GLUTAMINE-SYNTHETASE; NITROGEN STARVATION; GLNA PROMOTER; EXPRESSION; OPERON; CYANOBACTERIA; TRANSCRIPTION; RHYTHMS; PROTEIN; PRODUCT	Analysis of the system design principles of signaling systems requires model systems where all components and regulatory interactions are known. Components of the Lac and Ntr systems were used to construct genetic circuits that display toggle switch or oscillatory behavior. Both devices contain an "activator module" consisting of a modified glnA promoter with lac operators, driving the expression of the activator, NRI. Since NRI activates the glnA promoter, this creates an autoactivated circuit repressible by Lacl. The oscillator contains a "repressor module" consisting of the NRI-activated glnK promoter driving Lacl expression. This circuitry produced synchronous damped oscillations in turbidostat cultures, with periods much longer than the cell cycle. For the toggle switch, Lacl was provided constitutively; the level of active repressor was controlled by using a lacY mutant and varying the concentration of IPTG. This circuitry provided nearly discontinuous expression of activator.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ninfa, AJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [R01-GM63642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson MR, 2002, MOL MICROBIOL, V46, P1247, DOI 10.1046/j.1365-2958.2002.03211.x; Atkinson MR, 2002, J BACTERIOL, V184, P5358, DOI 10.1128/JB.184.19.5358-5363.2002; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; Beckwith J, 1987, ESCHERICHIA COLI SAL, P1444; Blauwkamp TA, 2002, MOL MICROBIOL, V46, P203, DOI 10.1046/j.1365-2958.2002.03153.x; CHEN YM, 1982, J BACTERIOL, V150, P214, DOI 10.1128/JB.150.1.214-220.1982; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mori T, 1996, P NATL ACAD SCI USA, V93, P10183, DOI 10.1073/pnas.93.19.10183; Ninfa AJ, 2000, CURR TOP CELL REGUL, V36, P31; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; ROTHSTEIN DM, 1980, P NATL ACAD SCI-BIOL, V77, P7372, DOI 10.1073/pnas.77.12.7372; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU MA, 1975, NATURE, V258, P208, DOI 10.1038/258208a0; Savageau MA, 2002, MATH BIOSCI, V180, P237, DOI 10.1016/S0025-5564(02)00113-X; Silhavy T. J., 1984, EXPT GENE FUSIONS, P107; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504	25	513	527	5	81	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					597	607		10.1016/S0092-8674(03)00346-5	http://dx.doi.org/10.1016/S0092-8674(03)00346-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787501	Bronze			2022-12-28	WOS:000183397600010
J	Tanaka, EM				Tanaka, EM			Regeneration: If they can do it, why can't we?	CELL			English	Review							NEWT; CELLS; DEDIFFERENTIATION; EXPRESSION		Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Max Planck Society	Tanaka, EM (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	tanaka@mpi-cbg.de		Tanaka, Elly/0000-0003-4240-2158				Brockes JR, 2002, NAT REV MOL CELL BIO, V3, P566, DOI 10.1038/nrm881; Cebria F, 2002, NATURE, V419, P620, DOI 10.1038/nature01042; da Silva SM, 2002, DEV CELL, V3, P547, DOI 10.1016/S1534-5807(02)00288-5; Echeverri K, 2001, DEV BIOL, V236, P151, DOI 10.1006/dbio.2001.0312; Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6; GARDINER DM, 1995, DEVELOPMENT, V121, P1731; Goss RJ., 1969, PRINCIPLES REGENERAT; KODAMA R, 1995, SEMIN CELL BIOL, V6, P143, DOI 10.1006/scel.1995.0020; LO DC, 1993, P NATL ACAD SCI USA, V90, P7230, DOI 10.1073/pnas.90.15.7230; McGann CJ, 2001, P NATL ACAD SCI USA, V98, P13699, DOI 10.1073/pnas.221297398; MEINHARDT M, 1982, MODELS BIOL PATTERN; MESCHER AL, 1976, J EXP ZOOL, V195, P117, DOI 10.1002/jez.1401950111; Newmark PA, 2002, NAT REV GENET, V3, P210, DOI 10.1038/nrg759; Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Simon A, 2002, EXP CELL RES, V281, P101, DOI 10.1006/excr.2002.5650; Stocum DL, 1996, INT J DEV BIOL, V40, P773; Tosh D, 2002, NAT REV MOL CELL BIO, V3, P187, DOI 10.1038/nrm761; Yokoyama H, 2000, DEV BIOL, V219, P18, DOI 10.1006/dbio.1999.9587	19	93	96	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2003	113	5					559	562		10.1016/S0092-8674(03)00395-7	http://dx.doi.org/10.1016/S0092-8674(03)00395-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787496	Bronze			2022-12-28	WOS:000183397600005
J	Ruan, YJ; Wei, CL; Ee, LA; Vega, VB; Thoreau, H; Yun, STS; Chia, JM; Ng, P; Chiu, KP; Lim, L; Tao, Z; Peng, CK; Ean, LOL; Lee, NM; Sin, LY; Ng, LFP; Chee, RE; Stanton, LW; Long, PM; Liu, ET				Ruan, YJ; Wei, CL; Ee, LA; Vega, VB; Thoreau, H; Yun, STS; Chia, JM; Ng, P; Chiu, KP; Lim, L; Tao, Z; Peng, CK; Ean, LOL; Lee, NM; Sin, LY; Ng, LFP; Chee, RE; Stanton, LW; Long, PM; Liu, ET			Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection	LANCET			English	Article							TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; MOUSE HEPATITIS-VIRUS; BRONCHITIS VIRUS; SPIKE PROTEIN; RECOMBINATION; DETERMINANT; EVOLUTION	Background The cause of severe acute respiratory syndrome (SARS) has been identified as a new coronavirus. Whole genome sequence analysis of various isolates might provide an indication of potential strain differences of this new virus. Moreover, mutation analysis will help to develop effective vaccines. Methods We sequenced the entire SARS viral genome of cultured isolates from the index case (SIN2500) presenting in Singapore, from three primary contacts (SIN2774, SIN2748, and SIN2677), and one secondary contact (SIN2679). These sequences were compared with the isolates from Canada (TOR2), Hong Kong (CUHK-W1 and HKU39849), Hanoi (URBANI), Guangzhou (GZ01), and Beijing (BJ01, BJ02, BJ03, BJ04). Findings We identified 129 sequence variations among the 14 isolates, with 16 recurrent variant sequences. Common variant sequences at four loci define two distinct genotypes of the SARS virus. One genotype was linked with infections originating in Hotel M in Hong Kong, the second contained isolates from Hong Kong, Guangzhou, and Beijing with no association with Hotel M (p<0.0001). Moreover, other common sequence variants further distinguished the geographical origins of the isolates, especially between Singapore and Beijing. Interpretation Despite the recent onset of the SARS epidemic, genetic signatures are emerging that partition the worldwide SARS viral isolates into groups on the basis of contact source history and geography. These signatures can be used to trace sources of infection. In addition, a common variant associated with a non-conservative aminoacid change in the S1 region of the spike protein, suggests that immunological pressures might be starting to influence the evolution of the SARS virus in human populations.	Genome Inst Singapore, Singapore, Singapore; Singapore Gen Hosp, Dept Pathol, Virol Sect, Singapore 0316, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 117548, Singapore; Natl Univ Singapore, Electron Microscopy Unit, Singapore 117548, Singapore; Tan Tock Seng Hosp, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Singapore General Hospital; National University of Singapore; National University of Singapore; Tan Tock Seng Hospital	Liu, ET (corresponding author), 1 Sci Pk Rd 05-01,Singapore Sci Pk 2, Singapore 117528, Singapore.	gisliue@nus.edu.sg	Liu, Edison/C-4141-2008; Chia, Jer-Ming/C-9992-2012	Ng, Lisa/0000-0003-4071-5222; THOREAU, HERVE/0000-0001-6643-167X				Bergmann CC, 1996, J GEN VIROL, V77, P315, DOI 10.1099/0022-1317-77-2-315; Bush RM, 2000, P NATL ACAD SCI USA, V97, P6974, DOI 10.1073/pnas.97.13.6974; CALLENBAUT P, 1998, J GEN VIROL, V77, P309; DROSTEN C, 2003, N ENGL J MED    0410, DOI DOI 10.1026/NEJMOA030781; *GISH W, WU BLAST 1996 2003; Gomez N, 1998, VIROLOGY, V249, P352, DOI 10.1006/viro.1998.9315; HOMBERGER FR, 1994, VIRUS RES, V31, P49; Jackwood M W, 1995, Adv Exp Med Biol, V380, P213; KSIAZEK TG, 2003, N ENGL J MED    0410, DOI DOI 10.1056/NEJMOA030747; Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000; Lee CW, 2001, VIRUS RES, V80, P33, DOI 10.1016/S0168-1702(01)00345-8; MARRA MA, 2003, GENOME SEQUENCE SARS; Ndifuna A, 1998, J VIROL METHODS, V70, P37, DOI 10.1016/S0166-0934(97)00170-5; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Phillips JJ, 1999, J VIROL, V73, P7752, DOI 10.1128/JVI.73.9.7752-7760.1999; Rowe CL, 1997, J VIROL, V71, P6183, DOI 10.1128/JVI.71.8.6183-6190.1997; Sanchez CM, 1999, J VIROL, V73, P7607; Swofford D.L., 2003, PAUP VERSION 40 B10; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; *US CDC WHO, 2003, MMWR-MORBID MORTAL W, V52, P269; *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81; World Health Organization, CUM NUMB REP PROB CA	22	329	437	1	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2003	361	9371					1779	1785		10.1016/S0140-6736(03)13414-9	http://dx.doi.org/10.1016/S0140-6736(03)13414-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781537	hybrid, Green Published			2022-12-28	WOS:000183074800010
J	Abbott, A				Abbott, A			British panel bans use of antidepressant to treat children	NATURE			English	News Item																			0	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					792	792		10.1038/423792a	http://dx.doi.org/10.1038/423792a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815392	Bronze			2022-12-28	WOS:000183585300009
J	Bremner, JD; Vythilingam, M; Ng, CK; Vermetten, E; Nazeer, A; Oren, DA; Berman, RM; Charney, DS				Bremner, JD; Vythilingam, M; Ng, CK; Vermetten, E; Nazeer, A; Oren, DA; Berman, RM; Charney, DS			Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms - Implications for the neural circuitry of depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CEREBRAL BLOOD-FLOW; ANTIDEPRESSANT-INDUCED REMISSION; ADRENERGIC-RECEPTOR BINDING; SUBGENUAL PREFRONTAL CORTEX; RECURRENT MAJOR DEPRESSION; TRYPTOPHAN-DEPLETION; LOCUS-COERULEUS; SUICIDE VICTIMS; GERIATRIC DEPRESSION; HIPPOCAMPAL VOLUME	Context We previously used positron emission tomography (PET) measurement of brain metabolism with (18)fluorodeoxyglucose to show that patients receiving selective serotonin reuptake inhibitors (SSRIs) who have a tryptophan depletion-induced return of depressive symptoms have an acute decrease in metabolism in orbitofrontal cortex, dorsolateral prefrontal cortex, and thalamus. Many patients with depression in remission while taking norepinephrine reuptake inhibitors (NRIs) (but not SSRIs) experience a return of depressive symptoms with depletion of norepinephrine and dopamine using alpha-methylparatyrosine (AMPT). Objective To assess brain metabolic correlates of AMPT administration in patients with depression in remission while receiving NRIs. Design, Setting, and Participants Randomized, controlled, double-blind trial in which 18 patients recruited in 1997-2000 from the general community who had depression in remission while taking NRIs had PET imaging in a psychiatric research unit following AMPT and placebo administration. Interventions After initial medication with desipramine and follow-up until response, patients underwent active AMPT (five 1-g doses administered orally over 28 hours) and placebo (diphenhydramine hydrochloride, five 50- mg doses administered similarly) catecholamine depletion challenges in randomized order of assignment, after which PET imaging was performed on day 3 of each condition. Both study conditions were performed 1 week apart. Main Outcome Measures Regional brain metabolism rates in patients with and without AMPT-induced return of depressive symptoms. Results AMPT-induced return of depressive symptoms was experienced by 11 of the 18 patients and led to decreased brain metabolism in a number of cortical areas, with the greatest magnitude of effects in orbitofrontal (P=.002) and dorsolateral prefrontal (P=.03) cortex and thalamus (P=.006). Increased resting metabolism in prefrontal and limbic areas predicted vulnerability to return of depressive symptoms. Conclusions Different neurochemical systems that mediate depression may have effects on a common brain circuitry. Baseline metabolism in successfully treated depressed patients may predict vulnerability to future episodes of depression.	Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Behav Sci, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Emory Ctr Positron Emiss Tomog, Atlanta, GA 30322 USA; Atlanta Vet Affairs Med Ctr, Decatur, GA USA; NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA; Univ Louisville, Dept Radiol, Louisville, KY 40292 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA	Emory University; Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Louisville; Yale University	Bremner, JD (corresponding author), Emory Univ Hosp, PET Ctr Nucl Med, 1256 Briarcliff Rd, Atlanta, GA 30306 USA.	jdbremn@emory.edu	Vermetten, Eric/B-1335-2008; Bremner, James D/B-1632-2013	Vermetten, Eric/0000-0003-0579-4404; Bremner, James Douglas/0000-0003-1633-6433; Nazeer, Ahsan/0000-0002-3189-3724	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056120] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH056120, 1R01MH56120, R01 MH056120-12] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAHAM WC, 1979, BRAIN RES, V172, P387, DOI 10.1016/0006-8993(79)90552-3; ARANGO V, 1990, ARCH GEN PSYCHIAT, V47, P1038; ASBERG M, 1976, SCIENCE, V191, P478; Ashtari M, 1999, PSYCHOL MED, V29, P629, DOI 10.1017/S0033291799008405; BATES D, 1977, BRAIN RES, V136, P431, DOI 10.1016/0006-8993(77)90068-3; BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243; BENCH CJ, 1992, PSYCHOL MED, V22, P607, DOI 10.1017/S003329170003806X; Berman RM, 1999, ARCH GEN PSYCHIAT, V56, P395, DOI 10.1001/archpsyc.56.5.395; BIVER F, 1994, BIOL PSYCHIAT, V36, P381, DOI 10.1016/0006-3223(94)91213-0; Bremner J Douglas, 1998, Clin Positron Imaging, V1, P145, DOI 10.1016/S1095-0397(98)00015-6; Bremner J Douglas, 2002, CNS Spectr, V7, P129; Bremner JD, 2002, BIOL PSYCHIAT, V51, P273, DOI 10.1016/S0006-3223(01)01336-1; Bremner JD, 1997, ARCH GEN PSYCHIAT, V54, P364; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; BRODIE HKH, 1971, CLIN PHARMACOL THER, V12, P218; Brody AL, 2001, ARCH GEN PSYCHIAT, V58, P631, DOI 10.1001/archpsyc.58.7.631; BROWNELL GL, 1983, J COMPUT ASSIST TOMO, V7, P919, DOI 10.1097/00004728-198310000-00038; CHARNEY DS, 1982, ARCH GEN PSYCHIAT, V39, P290; CHARNEY DS, 1981, ARCH GEN PSYCHIAT, V38, P1160; DELATORRE JC, 1977, ACTA NEUROL SCAND, V56, P104; DELGADO PL, 1993, PSYCHOPHARMACOL BULL, V29, P389; DELGADO PL, 1990, ARCH GEN PSYCHIAT, V47, P411; DELGADO PL, 1994, ARCH GEN PSYCHIAT, V51, P865; DELGADO PL, 1989, LIFE SCI, V45, P2323, DOI 10.1016/0024-3205(89)90114-8; Delgado PL, 2000, J CLIN PSYCHIAT, V61, P6; Delgado PL, 1999, BIOL PSYCHIAT, V46, P212, DOI 10.1016/S0006-3223(99)00014-1; Delgado PL, 2000, J CLIN PSYCHIAT, V61, P5; Drevets WC, 2002, PHARMACOL BIOCHEM BE, V71, P431, DOI 10.1016/S0091-3057(01)00687-6; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; EBERT D, 1991, PSYCHIAT RES-NEUROIM, V40, P247, DOI 10.1016/0925-4927(91)90016-J; ENGELMAN K, 1968, J CLIN INVEST, V47, P577, DOI 10.1172/JCI105754; Ferrier I N, 1986, Ann N Y Acad Sci, V487, P128, DOI 10.1111/j.1749-6632.1986.tb27893.x; First M.B., 2016, STRUCTURED CLIN INTE; George MS, 1997, J NEUROPSYCH CLIN N, V9, P55; George MS, 1994, DEPRESSION, V2, P59, DOI [DOI 10.1002/DEPR.3050020202, 10.1002/depr.3050020202]; GOADSBY PJ, 1989, BRAIN RES, V476, P71, DOI 10.1016/0006-8993(89)91537-0; GOLDEN RN, 1990, PSYCHIAT RES, V31, P39, DOI 10.1016/0165-1781(90)90107-G; GOLDEN RN, 1988, ARCH GEN PSYCHIAT, V45, P150; GOODWIN FK, 1971, SEMIN PSYCHIAT, V3, P435; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Heninger GR, 1996, PHARMACOPSYCHIATRY, V29, P2, DOI 10.1055/s-2007-979535; HENINGER GR, 1984, ARCH GEN PSYCHIAT, V41, P398; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; JONES JS, 1990, AM J PSYCHIAT, V147, P1225; KATAYAMA Y, 1981, BRAIN RES, V216, P173, DOI 10.1016/0006-8993(81)91285-3; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Klimek V, 1997, J NEUROSCI, V17, P8451; KRISHNAN KRR, 1991, J NEUROPSYCH CLIN N, V3, P387; Lai TJ, 2000, BIOL PSYCHIAT, V48, P971, DOI 10.1016/S0006-3223(00)01042-8; LOWTHER S, 1994, BRAIN RES, V642, P281, DOI 10.1016/0006-8993(94)90932-6; MANN JJ, 1992, BIOL PSYCHIAT, V32, P243; Mann JJ, 1996, AM J PSYCHIAT, V153, P174; MANN JJ, 1986, ARCH GEN PSYCHIAT, V43, P954; MANN JJ, 1989, BRIT J PSYCHIAT, V155, P7, DOI 10.1192/S000712500029171X; MARTINOT JL, 1990, AM J PSYCHIAT, V147, P1313; MATUSSEK N, 1980, PSYCHIAT RES, V2, P25, DOI 10.1016/0165-1781(80)90004-9; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; MAYBERG HS, 1990, ANN NEUROL, V28, P57, DOI 10.1002/ana.410280111; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Mayberg HS, 2000, BIOL PSYCHIAT, V48, P830, DOI 10.1016/S0006-3223(00)01036-2; Mayberg HS, 1997, NEUROREPORT, V8, P1057, DOI 10.1097/00001756-199703030-00048; MAYBERG HS, 1994, J NUCL MED, V35, P929; MAYBERG HS, 1993, J AFFECT DISORDERS, V29, P245; MCCANN UD, 1995, NEUROPSYCHOPHARMACOL, V13, P41, DOI 10.1038/sj.npp.1380274; MCCULLOCH J, 1979, NEUROLOGY, V29, P201, DOI 10.1212/WNL.29.2.201; MENDELS J, 1974, ARCH GEN PSYCHIAT, V30, P447; Mervaala E, 2000, PSYCHOL MED, V30, P117, DOI 10.1017/S0033291799001567; Miller HL, 1996, ARCH GEN PSYCHIAT, V53, P117; Miller HL, 1996, NEUROPSYCHOPHARMACOL, V14, P151, DOI 10.1016/0893-133X(95)00072-L; Moreno FA, 1999, BIOL PSYCHIAT, V46, P498, DOI 10.1016/S0006-3223(99)00095-5; Moreno FA, 2000, BIOL PSYCHIAT, V48, P327, DOI 10.1016/S0006-3223(00)00893-3; MUHLBAUER HD, 1985, J NEURAL TRANSM, V61, P81, DOI 10.1007/BF01253053; MULLANI NA, 1990, J NUCL MED, V31, P610; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Ongur D, 1998, P NATL ACAD SCI USA, V95, P13290, DOI 10.1073/pnas.95.22.13290; ORDWAY GA, 1994, J NEUROCHEM, V62, P680; Pantel J, 1997, J AFFECT DISORDERS, V42, P69, DOI 10.1016/S0165-0327(96)00105-X; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; RING HA, 1994, BRIT J PSYCHIAT, V165, P333, DOI 10.1192/bjp.165.3.333; RISCH SC, 1992, J CLIN PSYCHIAT, V53, P3; ROBB RA, 1989, COMPUT MED IMAG GRAP, V13, P433, DOI 10.1016/0895-6111(89)90285-1; Salomon RM, 1997, BIOL PSYCHIAT, V41, P58, DOI 10.1016/0006-3223(95)00670-2; SAVAKI HE, 1982, BRAIN RES, V234, P65, DOI 10.1016/0006-8993(82)90473-5; SAVAKI HE, 1984, BRAIN RES, V292, P239, DOI 10.1016/0006-8993(84)90760-1; SCHWARTZ WJ, 1978, NEUROSCI LETT, V7, P141, DOI 10.1016/0304-3940(78)90158-1; Shah PJ, 1998, BRIT J PSYCHIAT, V172, P527, DOI 10.1192/bjp.172.6.527; Sheline YI, 2000, BIOL PSYCHIAT, V48, P791, DOI 10.1016/S0006-3223(00)00994-X; Sheline YI, 2001, BIOL PSYCHIAT, V50, P651, DOI 10.1016/S0006-3223(01)01263-X; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Sheline YI, 1999, J NEUROSCI, V19, P5034; SIEVER IJ, 1982, PSYCHOPHARMACOL B, V18, P118; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Spillmann MK, 2001, PSYCHOPHARMACOLOGY, V155, P123, DOI 10.1007/s002130000669; STANLEY M, 1983, LANCET, V1, P214; Steffens DC, 2000, BIOL PSYCHIAT, V48, P301, DOI 10.1016/S0006-3223(00)00829-5; Steffens DC, 1998, BIOL PSYCHIAT, V43, P705, DOI 10.1016/S0006-3223(98)00084-5; Vakili K, 2000, BIOL PSYCHIAT, V47, P1087, DOI 10.1016/S0006-3223(99)00296-6; van Elst LT, 1999, BIOL PSYCHIAT, V46, P1614, DOI 10.1016/S0006-3223(99)00212-7; YOUNG SN, 1989, PSYCHOPHARMACOLOGY, V98, P508, DOI 10.1007/BF00441950; ZUBAL IG, 1993, J NUCL MED, V34, pP187	101	97	98	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3125	3134		10.1001/jama.289.23.3125	http://dx.doi.org/10.1001/jama.289.23.3125			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690QM	12813118	Bronze, Green Accepted			2022-12-28	WOS:000183560400027
J	Coulter, A				Coulter, A			Killing the goose that laid the golden egg?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Picker Inst Europe, Oxford OX1 1RX, England		Coulter, A (corresponding author), Picker Inst Europe, Oxford OX1 1RX, England.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375					0	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1280	1280		10.1136/bmj.326.7402.1280	http://dx.doi.org/10.1136/bmj.326.7402.1280			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805130	Green Published			2022-12-28	WOS:000183626500006
J	Holdaas, H; Fellstrom, B; Jardine, AG; Holme, I; Nyberg, G; Fauchald, P; Gronhagen-Riska, C; Madsen, S; Neumayer, HH; Cole, E; Maes, B; Ambuhl, P; Olsson, AG; Hartmann, A; Solbu, DO; Pedersen, TR				Holdaas, H; Fellstrom, B; Jardine, AG; Holme, I; Nyberg, G; Fauchald, P; Gronhagen-Riska, C; Madsen, S; Neumayer, HH; Cole, E; Maes, B; Ambuhl, P; Olsson, AG; Hartmann, A; Solbu, DO; Pedersen, TR		ALERT Study Investigators	Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; LONG-TERM GRAFT; PATIENT SURVIVAL; CORONARY EVENTS; CHOLESTEROL; PREVENTION; RISK; PRAVASTATIN; AVERAGE; IMPACT	Background Renal transplant recipients are at increased risk of premature cardiovascular disease. Although statins reduce cardiovascular risk in the general population, their efficacy and safety in renal transplant recipients have not been established. We investigated the effects of fluvastatin on cardiac and renal endpoints in this population. Methods We did a multicentre, randomised, double-blind, placebo-controlled trial in 2102 renal transplant recipients with total cholesterol 4.0-9.0 mmol/L. We randomly assigned patients fluvastatin (n=1050) or placebo (n=1052) and follow up was for 5-6 years. The primary endpoint was the occurrence of a major adverse cardiac event, defined as cardiac death, nonfatal myocardial infarction (MI), or coronary intervention procedure. Secondary endpoints were individual cardiac events, combined cardiac death or non-fatal MI, cerebrovascular events, non-cardiovascular death, all-cause mortality, and graft loss or doubling of serum creatinine. Analysis was by intention to treat. Findings After a mean follow-up of 5.1 years, fluvastatin lowered LDL cholesterol concentrations by 32%. Risk reduction with fluvastatin for the primary endpoint (risk ratio 0.83 [95% Cl 0.64-1.06], p=0.139) was not significant, although there were fewer cardiac deaths or non-fatal MI (70 vs 104, 0.65 [0.48-0.88] p=0.005) in the fluvastatin group than in the placebo group. Coronary intervention procedures and other secondary endpoints did not differ significantly between groups. Interpretation Although cardiac deaths and non-fatal MI seemed to be reduced, fluvastatin did not generally reduce rates of coronary intervention procedures or mortality. Overall effects of fluvastatin were similar to those of statins in other populations.	Natl Hosp Norway, N-0072 Oslo, Norway; Univ Hosp, Uppsala, Sweden; Univ Glasgow, Glasgow, Lanark, Scotland; Ullevaal Univ Hosp, Prevent Med Clin, Oslo, Norway; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; Univ Hosp, Helsinki, Finland; Skejby Hosp, Aarhus, Denmark; Univ Klinikum Charite, Berlin, Germany; Toronto Gen Hosp, Toronto, ON, Canada; Univ Hosp, Louvain, Belgium; Univ Hosp, Zurich, Switzerland; Univ Hosp, Linkoping, Sweden; Novartis Norge AS, Oslo, Norway	University of Oslo; National Hospital Norway; Uppsala University; Uppsala University Hospital; University of Glasgow; University of Oslo; Sahlgrenska University Hospital; University of Helsinki; Helsinki University Central Hospital; Aarhus University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Zurich; University Zurich Hospital; Novartis	Holdaas, H (corresponding author), Natl Hosp Norway, Sognsvannsvn 20, N-0072 Oslo, Norway.	hallvard.holdaas@rikshospitalet.no	Jardine, Alan/L-5770-2019	Jardine, Alan/0000-0001-5815-9370				*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; Baigent C, 2000, LANCET, V356, P147, DOI 10.1016/S0140-6736(00)02456-9; Ballantyne CM, 2003, ARCH INTERN MED, V163, P553, DOI 10.1001/archinte.163.5.553; Bumgardner GL, 1995, TRANSPLANTATION, V60, P1418, DOI 10.1097/00007890-199560120-00008; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cosio FG, 2002, AM J KIDNEY DIS, V40, P638, DOI 10.1053/ajkd.2002.34927; DIMENY E, 1995, EUR J CLIN INVEST, V25, P574, DOI 10.1111/j.1365-2362.1995.tb01748.x; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Gould AL, 1998, CIRCULATION, V97, P946; Holdaas H, 2001, J CARDIOVASC RISK, V8, P63, DOI 10.1097/00043798-200104000-00002; Jardine A, 1999, J CLIN PHARM THER, V24, P397, DOI 10.1046/j.1365-2710.1999.00252.x; Kasiske BL, 2000, J AM SOC NEPHROL, V11, P1735, DOI 10.1681/ASN.V1191735; Kyllonen L, 2000, Transpl Int, V13 Suppl 1, pS394, DOI 10.1007/s001470050369; Larsson O, 1987, Nephrol Dial Transplant, V2, P109; LINDHOLM A, 1995, TRANSPLANTATION, V60, P451, DOI 10.1097/00007890-199509000-00008; Patel R, 1997, CLIN MICROBIOL REV, V10, P86, DOI 10.1128/CMR.10.1.86; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3; Roodnat JI, 2000, TRANSPLANTATION, V69, P1704; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tonelli M, 2003, ANN INTERN MED, V138, P98, DOI 10.7326/0003-4819-138-2-200301210-00010; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Woo YM, 2002, J NEPHROL, V15, P380; Wood D, 1998, EUR HEART J, V19, P1434	29	683	711	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2024	2031		10.1016/S0140-6736(03)13638-0	http://dx.doi.org/10.1016/S0140-6736(03)13638-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814712				2022-12-28	WOS:000183488900009
J	Vivekananthan, DP; Penn, MS; Sapp, SK; Hsu, A; Topol, EJ				Vivekananthan, DP; Penn, MS; Sapp, SK; Hsu, A; Topol, EJ			Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials	LANCET			English	Article							CORONARY-HEART-DISEASE; BETA-CAROTENE; ALPHA-TOCOPHEROL; E CONSUMPTION; FATTY STREAK; BASAL-CELL; ATHEROSCLEROSIS; SUPPLEMENTATION; CANCER; RISK	Introduction Oxidised LDL is thought to play an important part in the pathogenesis of atherosclerosis. Observational studies have associated alpha tocopherol (vitamin E), beta carotene, or both, with reductions in cardiovascular events, but not clinical trials. We did a meta-analysis to assess the effect of these compounds on long-term cardiovascular mortality and morbidity. Methods We analysed seven randomised trials of vitamin E treatment and, separately, eight of beta carotene treatment; all trials included 1000 or more patients. The dose range for vitamin E was 50-800 IU, and for beta carotene was 15-50 mg. Follow-up ranged from 1.4 to 12.0 years. Findings The vitamin E trials involved a total of 81788 patients and the beta carotene trials 138 113 in the all-cause mortality analyses. Vitamin E did not provide benefit in mortality compared with control treatment (11.3 vs 11.1%, odds ratio 1.02 [95% Cl 0.98-1.06] p=0.42) or significantly decrease risk of cardiovascular death (6.0 vs 6.0%, p=0.86) or cerebrovascular accident (3.6 vs 3.5%, p=0.31). P carotene led to a small but significant increase in all-cause mortality (7.4 vs 7.0%, 1.07 [1.02-1.11] p=0.003) and with a slight increase in cardiovascular death (3.4 vs 3.1%, 1.1 [1.03-1.17] p=0.003). No significant heterogeneity was noted for any analysis. Interpretation The lack of a salutary effect was seen consistently for various doses of vitamins in diverse populations. Our results, combined with the lack of mechanistic data for efficacy of vitamin E, do not support the routine use of vitamin E.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Penn, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	pennm@ccf.org		Topol, Eric/0000-0002-1478-4729				Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Crawford RS, 1998, ARTERIOSCL THROM VAS, V18, P1506, DOI 10.1161/01.ATV.18.9.1506; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Fang JC, 2002, LANCET, V359, P1108, DOI 10.1016/S0140-6736(02)08154-0; Fletcher RH, 2002, JAMA-J AM MED ASSOC, V287, P3127, DOI 10.1001/jama.287.23.3127; Green A, 1999, LANCET, V354, P723, DOI 10.1016/S0140-6736(98)12168-2; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Hoppe PP, 2000, EUR J NUTR, V39, P183, DOI 10.1007/s003940070010; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Losonczy KG, 1996, AM J CLIN NUTR, V64, P190, DOI 10.1093/ajcn/64.2.190; Meagher EA, 2001, JAMA-J AM MED ASSOC, V285, P1178, DOI 10.1001/jama.285.9.1178; Mehta J, 1997, AM J CARDIOL, V79, P1558, DOI 10.1016/S0002-9149(97)00196-3; Monsen ER, 2000, J AM DIET ASSOC, V100, P637, DOI 10.1016/S0002-8223(00)00189-9; MORRIS DL, 1994, JAMA-J AM MED ASSOC, V272, P1439, DOI 10.1001/jama.272.18.1439; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PARKER RA, 1995, ARTERIOSCL THROM VAS, V15, P349, DOI 10.1161/01.ATV.15.3.349; PRASAD K, 1993, AM HEART J, V125, P958, DOI 10.1016/0002-8703(93)90102-F; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; Redlich CA, 1999, ATHEROSCLEROSIS, V143, P427, DOI 10.1016/S0021-9150(98)00303-7; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Thomas SR, 2001, ARTERIOSCL THROM VAS, V21, P585, DOI 10.1161/01.ATV.21.4.585; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Wang HD, 1999, J NEUROSCI RES, V57, P1; Wang XD, 1999, J NATL CANCER I, V91, P60, DOI 10.1093/jnci/91.1.60; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Willett WC, 2001, NEW ENGL J MED, V345, P1819, DOI 10.1056/NEJMcp010710; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	44	779	824	1	59	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2017	2023		10.1016/S0140-6736(03)13637-9	http://dx.doi.org/10.1016/S0140-6736(03)13637-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814711				2022-12-28	WOS:000183488900008
J	Lackner, KS				Lackner, KS			A guide to CO2 sequestration	SCIENCE			English	Editorial Material							CARBON; ENERGY		Columbia Univ, Dept Earth & Environm Engn, New York, NY 10027 USA	Columbia University	Lackner, KS (corresponding author), Columbia Univ, Dept Earth & Environm Engn, New York, NY 10027 USA.	kl2010@columbia.edu						CHADWICK RA, 2002, 6 INT C GREENH GAS T; Herzog H, 2000, SCI AM, V282, P72, DOI 10.1038/scientificamerican0200-72; Herzog HJ, 1996, ANNU REV ENERG ENV, V21, P145, DOI 10.1146/annurev.energy.21.1.145; Hoffert MI, 2002, SCIENCE, V298, P981, DOI 10.1126/science.1072357; Holloway S, 2001, ANNU REV ENERG ENV, V26, P145, DOI 10.1146/annurev.energy.26.1.145; Lackner KS, 2002, ANNU REV ENERG ENV, V27, P193, DOI 10.1146/annurev.energy.27.122001.083433; Lackner KS, 1999, P 24 ANN TECHN C COA; Rogner HH, 1997, ANNU REV ENERG ENV, V22, P217, DOI 10.1146/annurev.energy.22.1.217; YEGULALP TM, 2001, INT J SURF MIN RECLA, V15, P52, DOI DOI 10.1076/ijsm.15.1.52.3423; ZEMAN FS, 2003, 2 ANN C CARB SEQ AL	10	809	847	11	228	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1677	1678		10.1126/science.1079033	http://dx.doi.org/10.1126/science.1079033			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805529				2022-12-28	WOS:000183459700030
J	Meis, PJ; Klebanoff, M; Thom, E; Dombrowski, MP; Sibai, B; Moawad, AH; Spong, CY; Hauth, JC; Miodovnik, M; Varner, MW; Leveno, KJ; Caritis, SN; Iams, JD; Wapner, RJ; Conway, D; O'Sullivan, MJ; Carpenter, M; Mercer, B; Ramin, SM; Thorp, JM; Peaceman, AM				Meis, PJ; Klebanoff, M; Thom, E; Dombrowski, MP; Sibai, B; Moawad, AH; Spong, CY; Hauth, JC; Miodovnik, M; Varner, MW; Leveno, KJ; Caritis, SN; Iams, JD; Wapner, RJ; Conway, D; O'Sullivan, MJ; Carpenter, M; Mercer, B; Ramin, SM; Thorp, JM; Peaceman, AM		Natl Inst Child Hlth Human Dev Mat	Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; PREMATURE LABOR; HABITUAL ABORTION; BIRTH PREVENTION; CLINICAL-TRIALS; RISK-FACTORS; PROGESTERONE; PREGNANCY; WOMEN; PREDICTION	Background: Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk of preterm delivery. Methods: We conducted a double-blind, placebo-controlled trial involving pregnant women with a documented history of spontaneous preterm delivery. Women were enrolled at 19 clinical centers at 16 to 20 weeks of gestation and randomly assigned by a central data center, in a 2:1 ratio, to receive either weekly injections of 250 mg of 17P or weekly injections of an inert oil placebo; injections were continued until delivery or to 36 weeks of gestation. The primary outcome was preterm delivery before 37 weeks of gestation. Analysis was performed according to the intention-to-treat principle. Results: Base-line characteristics of the 310 women in the progesterone group and the 153 women in the placebo group were similar. Treatment with 17P significantly reduced the risk of delivery at less than 37 weeks of gestation (incidence, 36.3 percent in the progesterone group vs. 54.9 percent in the placebo group; relative risk, 0.66 [95 percent confidence interval, 0.54 to 0.81]), delivery at less than 35 weeks of gestation (incidence, 20.6 percent vs. 30.7 percent; relative risk, 0.67 [95 percent confidence interval, 0.48 to 0.93]), and delivery at less than 32 weeks of gestation (11.4 percent vs. 19.6 percent; relative risk, 0.58 [95 percent confidence interval, 0.37 to 0.91]). Infants of women treated with 17P had significantly lower rates of necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen. Conclusions: Weekly injections of 17P resulted in a substantial reduction in the rate of recurrent preterm delivery among women who were at particularly high risk for preterm delivery and reduced the likelihood of several complications in their infants.	Wake Forest Univ, Dept Obstet & Gynecol, Winston Salem, NC 27157 USA; NICHHD, Bethesda, MD 20892 USA; George Washington Univ, Dept Biostat, Rockville, MD USA; Wayne State Univ, Detroit, MI USA; Univ Tennessee, Memphis, TN USA; Univ Chicago, Chicago, IL 60637 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Cincinnati, Cincinnati, OH USA; Columbia Univ, New York, NY USA; Univ Utah, Salt Lake City, UT USA; Univ Texas San Antonio, SW Med Ctr, Dallas, TX USA; Univ Pittsburgh, Pittsburgh, PA USA; Ohio State Univ, Columbus, OH 43210 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Univ Texas San Antonio, San Antonio, TX 78285 USA; Univ Miami, Miami, FL 33152 USA; Brown Univ, Providence, RI 02912 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Texas San Antonio, Houston, TX USA; Univ N Carolina, Chapel Hill, NC USA; Northwestern Univ, Chicago, IL 60611 USA	Wake Forest University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); George Washington University; Wayne State University; University of Tennessee System; University of Tennessee Health Science Center; University of Chicago; University of Alabama System; University of Alabama Birmingham; University System of Ohio; University of Cincinnati; Columbia University; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas at San Antonio (UTSA); University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; Ohio State University; Jefferson University; University of Texas System; University of Texas at San Antonio (UTSA); University of Miami; Brown University; Case Western Reserve University; University of Texas System; University of Texas at San Antonio (UTSA); University of North Carolina; University of North Carolina Chapel Hill; Northwestern University	Meis, PJ (corresponding author), Wake Forest Univ, Dept Obstet & Gynecol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	pmeis@wfubmc.edu	/AAO-2076-2020; Varner, Michael/K-9890-2013	Peaceman, Alan/0000-0002-4515-4850; caritis, steve/0000-0002-2169-0712; Varner, Michael/0000-0001-9455-3973	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD034116, UG1HD034116, UG1HD040512, U10HD027915, U10HD040544, U10HD040560, U10HD036801, U10HD034208, UG1HD040560, UG1HD027915, U10HD027917, UG1HD034208, UG1HD040544, U10HD027869, U10HD021410, U10HD040500, UG1HD027869, UG1HD040500, U10HD040512] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD021414, U10HD027861, U10HD034136, U01HD036801, U10HD034122, U10HD034210, U10HD021414, U01HD021410, U10HD027860, U10HD027905] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-000080] Funding Source: Medline; NICHD NIH HHS [HD40544, HD27917, HD27861, HD40512, HD34116, HD40500, HD36801, HD27869, HD27860, HD21414, HD34210, HD27905, HD34208, HD34136, HD21410, HD34122, HD27915, HD40560] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHALLIS JRG, 1971, NATURE, V229, P208, DOI 10.1038/229208a0; CREASY RK, 1993, AM J OBSTET GYNECOL, V168, P1223, DOI 10.1016/0002-9378(93)90373-Q; da Fonseca EB, 2003, AM J OBSTET GYNECOL, V188, P419, DOI 10.1067/mob.2003.41; FRYDMAN R, 1992, OBSTET GYNECOL, V80, P972; FUCHS F, 1960, AM J OBSTET GYNECOL, V79, P172, DOI 10.1016/0002-9378(60)90381-1; GARFIELD RE, 1980, AM J PHYSIOL, V238, P81; Goldenberg RL, 1998, AM J PUBLIC HEALTH, V88, P233, DOI 10.2105/AJPH.88.2.233; GOLDSTEIN P, 1989, BRIT J OBSTET GYNAEC, V96, P265, DOI 10.1111/j.1471-0528.1989.tb02385.x; GOLDZIEHER JW, 1964, JAMA-J AM MED ASSOC, V188, P651; HARTIKAINENSORRI AL, 1980, OBSTET GYNECOL, V56, P692; HAUTH JC, 1983, AM J OBSTET GYNECOL, V146, P187, DOI 10.1016/0002-9378(83)91051-7; Hauth JC, 1998, PRENAT NEONAT MED, V3, P86; HOBEL CJ, 1994, AM J OBSTET GYNECOL, V170, P54; Iams JD, 1998, AM J OBSTET GYNECOL, V178, P1035, DOI 10.1016/S0002-9378(98)70544-7; Iams JD, 2002, NEW ENGL J MED, V346, P250, DOI 10.1056/NEJMoa002868; JOHNSON JWC, 1975, NEW ENGL J MED, V293, P675, DOI 10.1056/NEJM197510022931401; KEIRSE MJNC, 1990, BRIT J OBSTET GYNAEC, V97, P149, DOI 10.1111/j.1471-0528.1990.tb01740.x; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEVINE L, 1964, W J SURG OBSTET GYNE, V72, P3036; Mattison DR, 2001, PAEDIATR PERINAT EP, V15, P7, DOI 10.1046/j.1365-3016.2001.00004.x; MITCHELL B, 1982, J CLIN ENDOCR METAB, V55, P1237, DOI 10.1210/jcem-55-6-1237; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; PAPIERNIK E, 1970, SERIE, V4, P65; RAMANWILMS L, 1995, OBSTET GYNECOL, V85, P141, DOI 10.1016/0029-7844(94)00341-A; SCHARDEIN JL, 1980, TERATOLOGY, V22, P251, DOI 10.1002/tera.1420220302; SIITERI PK, 1981, FETAL ENDOCRINOLOGY, P1; SONDERGAARD F, 1985, CONTRACEPT FERTIL S, V13, P1227; SWYER GIM, 1953, BMJ-BRIT MED J, V1, P1073, DOI 10.1136/bmj.1.4819.1073; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; WEI LJ, 1989, CONTROL CLIN TRIALS, V10, pA126; YEMINI M, 1985, AM J OBSTET GYNECOL, V151, P574, DOI 10.1016/0002-9378(85)90141-3	31	1073	1106	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2379	2385		10.1056/NEJMoa035140	http://dx.doi.org/10.1056/NEJMoa035140			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802023				2022-12-28	WOS:000183428900003
J	Bower, P; Byford, S; Barber, J; Beecham, J; Simpson, S; Friedli, K; Corney, R; King, M; Harvey, I				Bower, P; Byford, S; Barber, J; Beecham, J; Simpson, S; Friedli, K; Corney, R; King, M; Harvey, I			Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; NEED	Objective To assess the feasibility of overcoming sample size limitations in economic analyses of clinical trials through meta-analysis of data on individual patients from multiple trials. Design Meta-analysis of individual patient data from trials of counselling in primary care compared with usual care by a general practitioner. Setting Primary care. Patients People with mental health problems. Main outcome measures Direct treatment costs, depressive symptoms, and cost effectiveness. Results Meta-analysis of individual patient data proved feasible. The results showed that the previous analyses of individual trials were underpowered to provide useful conclusions about the cost comparisons. The results are sensitive to assumptions made about the costs of sessions with a counsellor and the management of patients by a general practitioner. Conclusions Meta-analysis of individual patient data may assist in overcoming sample size limitations in economic analyses. Although feasible, such analysis has shortcomings that may limit the validity of the results. The relative costs and benefits of this method, as opposed to further collection of primary data, are as yet unclear.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Inst Psychiat, David Goldberg Ctr, Ctr Econ Mental Hlth, London SE5 8AF, England; UCL Hosp NHS Trust, Res & Dev Directorate, London NW1 2LT, England; Unic Cardiff, Ctr Occupat Psychol, Cardiff CF10 3YG, S Glam, Wales; Univ Hertfordshire, Fac Hlth & Human Sci, Ctr Res Primary & Community Care, Hatfield AL10 9AB, Herts, England; Univ Greenwich, London SE9 2UG, England; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England	University of Manchester; University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Cardiff University; University of Hertfordshire; University of Greenwich; University of East Anglia; University of London; University College London	Bower, P (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	peter.bower@man.ac.uk	Beecham, Jennifer K/E-7836-2010; Byford, Sarah/D-1699-2010; Friedli, Karin/A-4219-2009; King, Michael B/D-7477-2011; Simpson, Sharon A/B-5109-2009; Bower, Peter/A-1508-2011	Beecham, Jennifer K/0000-0001-5147-3383; Byford, Sarah/0000-0001-7084-1495; King, Michael B/0000-0003-4715-7171; Bower, Peter/0000-0001-9558-3349; Barber, Julie/0000-0001-5762-762X				Briggs A, 2000, BRIT MED J, V321, P1362, DOI 10.1136/bmj.321.7273.1362; Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766; Efron B., 1994, MONOGRAPHS STAT APPL; Friedli K, 2000, BRIT J GEN PRACT, V50, P276; Gotzsche PC, 2000, BRIT MED J, V321, P585, DOI 10.1136/bmj.321.7261.585; Harvey I, 1998, BRIT J GEN PRACT, V48, P1043; Johnston K, 1999, HLTH TECHNOL ASSESS, V3; KALTENTHALER E, 2002, HLTH TECHNOL ASSESS, V6; KING M, 2000, HLTH TECHNOL ASSESS, V4; LAVE J, 1999, COST EFFECTIVENESS P, P75; McGuire A, 2001, EC EVALUATION HLTH C, P172; SIMPSON S, 2000, HLTH TECHNOL ASSESS, V4; SPEIRS R, 1995, BRIT J GEN PRACT, V45, P31; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Sutton A, 1998, HLTH TECHNOL ASSESS, V2; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505	16	33	33	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1247	1250		10.1136/bmj.326.7401.1247	http://dx.doi.org/10.1136/bmj.326.7401.1247			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791741	Green Accepted, Green Submitted, Green Published, Bronze			2022-12-28	WOS:000183480700018
J	Nash, B				Nash, B			Extracts from "best treatments" - Treating head lice	BRITISH MEDICAL JOURNAL			English	Review									BMJ Publishing Grp, London WC1H 9JR, England	BMJ Publishing Group Ltd	Nash, B (corresponding author), BMJ Publishing Grp, London WC1H 9JR, England.							Meinking TL, 2002, J PEDIATR-US, V141, P665, DOI 10.1067/mpd.2002.129031	1	28	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1256	1257		10.1136/bmj.326.7401.1256	http://dx.doi.org/10.1136/bmj.326.7401.1256			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791744	Green Published			2022-12-28	WOS:000183480700021
J	Van Gelder, RN; Herzog, ED; Schwartz, WJ; Taghert, PH				Van Gelder, RN; Herzog, ED; Schwartz, WJ; Taghert, PH			Circadian rhythms: In the loop at last	SCIENCE			English	Editorial Material							CLOCK; DROSOPHILA; GENE; NEURONS; CYANOBACTERIA; EXPRESSION; TIMELESS; LIMB	The basic molecular mechanisms underlying circadian oscillators follow the same general plan across the phylogenetic spectrum: oscillating feedback loops in which clock gene products negatively regulate their own expression. The circadian clocks of animals involve at least two interacting feedback loops. This Viewpoint compares and contrasts the circadian clocks of mammals and of Drosophila, emphasizing how different players are used to create the same basic script. Both the general script and the specific details of the murine and Drosophila circadian pathways are available at Science's Signal Transduction Knowledge Environment Connections Maps.	Washington Univ, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Dept Biol, St Louis, MO 63110 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Massachusetts System; University of Massachusetts Worcester	Van Gelder, RN (corresponding author), Washington Univ, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.		Van Gelder, Russell/ABB-4225-2021	Van Gelder, Russell/0000-0001-5368-3659; Herzog, Erik/0000-0001-7209-5174				Akten B, 2003, NAT NEUROSCI, V6, P251, DOI 10.1038/nn1007; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Cyran SA, 2003, CELL, V112, P329, DOI 10.1016/S0092-8674(03)00074-6; Dardente H, 2002, CELL TISSUE RES, V310, P85, DOI 10.1007/s00441-002-0609-9; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Glossop NRJ, 2003, NEURON, V37, P249, DOI 10.1016/S0896-6273(03)00002-3; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; HERZOG ED, 2003, J NEUROPHYSIOL; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Jackson FR, 2001, DEV CELL, V1, P730, DOI 10.1016/S1534-5807(01)00100-9; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Loros JJ, 2001, ANNU REV PHYSIOL, V63, P757, DOI 10.1146/annurev.physiol.63.1.757; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Stanewsky R, 2003, J NEUROBIOL, V54, P111, DOI 10.1002/neu.10164; Tischkau SA, 2003, J BIOL CHEM, V278, P718, DOI 10.1074/jbc.M209241200; VANGELDER RN, 2003, SCI STKE; Yanovsky MJ, 2001, CURR OPIN PLANT BIOL, V4, P429, DOI 10.1016/S1369-5266(00)00196-5	28	46	47	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1534	1535		10.1126/science.1085446	http://dx.doi.org/10.1126/science.1085446			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791982				2022-12-28	WOS:000183333100042
J	Cubukcu, E; Aydin, K; Ozbay, E; Foteinopoulou, S; Soukoulis, CM				Cubukcu, E; Aydin, K; Ozbay, E; Foteinopoulou, S; Soukoulis, CM			Negative refraction by photonic crystals	NATURE			English	Article									Bilkent Univ, Dept Phys, TR-06533 Bilkent, Ankara, Turkey; Iowa State Univ, Ames Lab, US Dept Energy, Ames, IA 50011 USA; Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA; Univ Crete, Res Ctr Crete, Iraklion 71100, Crete, Greece; Univ Crete, Dept Mat Sci & Technol, Iraklion 71100, Crete, Greece	Ihsan Dogramaci Bilkent University; Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University; University of Crete; University of Crete	Cubukcu, E (corresponding author), Bilkent Univ, Dept Phys, TR-06533 Bilkent, Ankara, Turkey.	cubukcu@fen.bllkent.edu.tr	Ozbay, Ekmel/B-9495-2008; Aydin, Koray/D-5100-2009; Soukoulis, Costas M./A-5295-2008; Cubukcu, Ertugrul/F-4807-2010; Cubukcu, Ertugrul/D-5007-2012; Foteinopoulou, Stavroula/I-3900-2019; Aydin, Koray/G-2537-2011	Aydin, Koray/0000-0002-3268-2216; Foteinopoulou, Stavroula/0000-0003-4405-5209; 				Bayindir M, 2002, APPL PHYS LETT, V81, P120, DOI 10.1063/1.1492009; Foteinopoulou S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.107402; Kong JA, 2002, APPL PHYS LETT, V80, P2084, DOI 10.1063/1.1462865; Luo C, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.201104; Notomi M, 2000, PHYS REV B, V62, P10696, DOI 10.1103/PhysRevB.62.10696; Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847	7	609	642	3	187	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					604	605		10.1038/423604b	http://dx.doi.org/10.1038/423604b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789328	Bronze			2022-12-28	WOS:000183301200029
J	Sharp, D				Sharp, D			Celebrating Everest	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							BASNYAT B, 2003, HIGH ALTITUDE CEREBR; GILLMAN P, 2003, TIMES S         0514, P22; HUHN E, 2003, EVEREST CLIN TENDS I; Hunt John, 1953, ASCENT EVEREST; PUGH G, 1953, ASCENT EVEREST; SHLIM DR, 1992, INT J SPORTS MED, V13, pS74, DOI 10.1055/s-2007-1024601; Ward MP, 2003, HIGH ALT MED BIOL, V4, P27, DOI 10.1089/152702903321488951; 1989, LANCET, P73; 2003, TIMES S         0514, P47	9	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1842	1842		10.1016/S0140-6736(03)13540-4	http://dx.doi.org/10.1016/S0140-6736(03)13540-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788568				2022-12-28	WOS:000183205800006
J	Torsvik, TH				Torsvik, TH			The Rodinia jigsaw puzzle	SCIENCE			English	Editorial Material							BREAK-UP; LAURENTIA; COLLISION; SUPERCONTINENT; PALEOMAGNETISM; HYPOTHESIS; CONNECTION; AUSTRALIA; BALTICA; MA		Geol Survey Norway, Geodynam Ctr, N-7491 Trondheim, Norway	Geological Survey of Norway								DALZIEL IWD, 1991, GEOLOGY, V19, P598, DOI 10.1130/0091-7613(1991)019<0598:PMOLAE>2.3.CO;2; Dalziel IWD, 1997, GEOL SOC AM BULL, V109, P16, DOI 10.1130/0016-7606(1997)109<0016:ONPGAT>2.3.CO;2; DEWEY JF, 1973, J GEOL, V81, P683, DOI 10.1086/627920; GURNIS M, 1988, NATURE, V332, P695, DOI 10.1038/332695a0; Hartz EH, 2002, GEOLOGY, V30, P255, DOI 10.1130/0091-7613(2002)030<0255:BUDANP>2.0.CO;2; HOFFMAN PF, 1991, SCIENCE, V252, P1409, DOI 10.1126/science.252.5011.1409; Meert JG, 2003, TECTONOPHYSICS, V362, P1, DOI 10.1016/S0040-1951(02)00629-7; Meert JG, 2001, PRECAMBRIAN RES, V110, P1, DOI 10.1016/S0301-9268(01)00177-2; MOORES EM, 1991, GEOLOGY, V19, P425, DOI 10.1130/0091-7613(1991)019<0425:SUSEAS>2.3.CO;2; POWELL CM, 1993, GEOLOGY, V21, P889, DOI 10.1130/0091-7613(1993)021<0889:PCOTOT>2.3.CO;2; Tohver E, 2002, EARTH PLANET SC LETT, V199, P185, DOI 10.1016/S0012-821X(02)00561-7; Torsvik TH, 1996, EARTH-SCI REV, V40, P229, DOI 10.1016/0012-8252(96)00008-6; Torsvik TH, 2001, PRECAMBRIAN RES, V108, P319, DOI 10.1016/S0301-9268(01)00139-5; Weil AB, 1998, EARTH PLANET SC LETT, V154, P13, DOI 10.1016/S0012-821X(97)00127-1; Wingate MTD, 2000, PRECAMBRIAN RES, V100, P335, DOI 10.1016/S0301-9268(99)00080-7	15	227	251	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1379	1381		10.1126/science.1083469	http://dx.doi.org/10.1126/science.1083469			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775828				2022-12-28	WOS:000183181800030
J	Ohtake, F; Takeyama, K; Matsumoto, T; Kitagawa, H; Yamamoto, Y; Nohara, K; Tohyama, C; Krust, A; Mimura, J; Chambon, P; Yanagisawa, J; Fujii-Kuriyama, Y; Kato, S				Ohtake, F; Takeyama, K; Matsumoto, T; Kitagawa, H; Yamamoto, Y; Nohara, K; Tohyama, C; Krust, A; Mimura, J; Chambon, P; Yanagisawa, J; Fujii-Kuriyama, Y; Kato, S			Modulation of oestrogen receptor signalling by association with the activated dioxin receptor	NATURE			English	Article							ESTROGEN-RECEPTOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; TRANSCRIPTION FACTOR; GENE-EXPRESSION; C-FOS; NUCLEAR RECEPTORS; AH RECEPTOR; ENDOMETRIOSIS; ALPHA; INHIBITION	Environmental contaminants affect a wide variety of biological events in many species. Dioxins are typical environmental contaminants that exert adverse oestrogen-related effects(1). Although their anti-oestrogenic actions(2,3) are well described, dioxins can also induce endometriosis(4-7) and oestrogen-dependent tumours(8,9), implying possible oestrogenic effects. However, the molecular mechanism underlying oestrogen-related actions of dioxins remains largely unknown. A heterodimer of the dioxin receptor (AhR) and Arnt, which are basic helix-loop-helix/PAS-family transcription factors, mediates most of the toxic effects of dioxins(10,11). Here we show that the agonist-activated AhR/Arnt heterodimer directly associates with oestrogen receptors ER-alpha and ER-beta. This association results in the recruitment of unliganded ER and the co-activator p300 to oestrogen-responsive gene promoters, leading to activation of transcription and oestrogenic effects. The function of liganded ER is attenuated. Oestrogenic actions of AhR agonists were detected in wild-type ovariectomized mouse uteri, but were absent in AhR(-/-) or ER-alpha(-/-) ovariectomized mice. Our findings suggest a novel mechanism by which ER-mediated oestrogen signalling is modulated by a co-regulatory-like function of activated AhR/Arnt, giving rise to adverse oestrogen-related actions of dioxin-type environmental contaminants.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol, SORST, Kawaguchi, Saitama 3320012, Japan; Taiho Pharmaceut Co Ltd, Canc Res Lab, Hanno Res Ctr, Hanno, Saitama 3578527, Japan; Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan; Japan Sci & Technol, CREST, Kawaguchi, Saitama 3320012, Japan; Univ Strasbourg 1, Coll France, CNRS,INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France; Univ Tsukuba, TARA Ctr, Tsukuba, Ibaraki 3058577, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Taiho Pharmaceutical; National Institute for Environmental Studies - Japan; Japan Science & Technology Agency (JST); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Tsukuba	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Mimura, Junsei/E-7893-2013; Tohyama, Chiharu/AAI-5598-2020	Tohyama, Chiharu/0000-0003-1061-6872				ASTROFF B, 1991, TOXICOL LETT, V56, P305, DOI 10.1016/0378-4274(91)90159-4; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Bock K W, 1994, Rev Physiol Biochem Pharmacol, V125, P1, DOI 10.1007/BFb0030908; Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623; Cummings AM, 1996, TOXICOL APPL PHARM, V138, P131, DOI 10.1006/taap.1996.0106; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Davis BJ, 2000, CANCER RES, V60, P5414; Dupont S, 2000, DEVELOPMENT, V127, P4277; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; GIBBONS A, 1993, SCIENCE, V262, P1373, DOI 10.1126/science.8248776; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; Kuchenhoff A, 1999, FERTIL STERIL, V71, P354, DOI 10.1016/S0015-0282(98)00437-3; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mayani A, 1997, HUM REPROD, V12, P373, DOI 10.1093/humrep/12.2.373; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Sogawa K, 1997, J BIOCHEM, V122, P1075; Tian Y, 1998, J STEROID BIOCHEM, V67, P17, DOI 10.1016/S0960-0760(98)00067-3; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1	30	593	631	2	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					545	550		10.1038/nature01606	http://dx.doi.org/10.1038/nature01606			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12774124				2022-12-28	WOS:000183162900045
J	Woods, GL; White, KL; Vanderwall, DK; Li, GP; Aston, KI; Bunch, TD; Meerdo, LN; Pate, BJ				Woods, GL; White, KL; Vanderwall, DK; Li, GP; Aston, KI; Bunch, TD; Meerdo, LN; Pate, BJ			A mule cloned from fetal cells by nuclear transfer	SCIENCE			English	Article									Univ Idaho, Dept Vet & Anim Sci, NW Equine Reprod Lab, Moscow, ID 83844 USA; Utah State Univ, Ctr Dev & Mol Biol, Ctr Biotechnol, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA	Idaho; University of Idaho; Utah System of Higher Education; Utah State University	Woods, GL (corresponding author), Univ Idaho, Dept Vet & Anim Sci, NW Equine Reprod Lab, Moscow, ID 83844 USA.		Migliaccio, Kati/AAC-8451-2020					ALLEN WR, 1993, EQUINE REPROD, pCH63; Hinrichs K, 1998, THERIOGENOLOGY, V49, P13, DOI 10.1016/S0093-691X(97)00398-1; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; WOODS G, UNPUB; Woods GL, 2002, THERIOGENOLOGY, V58, P779	5	214	266	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1063	1063		10.1126/science.1086743	http://dx.doi.org/10.1126/science.1086743			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12775846				2022-12-28	WOS:000184872400030
J	Rainer, TH; Cameron, PA; Smit, D; Ong, KL; Hung, ANW; Nin, DCP; Ahuja, AT; Si, LCY; Sung, JJY				Rainer, TH; Cameron, PA; Smit, D; Ong, KL; Hung, ANW; Nin, DCP; Ahuja, AT; Si, LCY; Sung, JJY			Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the clinical and radiological features of severe acute respiratory syndrome (SARS) and to evaluate the accuracy of the World Health Organization's guidelines on defining cases of SARS. Design Prospective observational study. Setting A newly set up SARS screening clinic in the emergency department of a university hospital in Hong Kong's New Territories. Participants 556 hospital staff, patients, and relatives who attended the screening clinic and who had had contact with someone with SARS. Main outcome measure Number of confirmed cases of SARS. Results Of the 556 people, 141 were admitted to hospital, and 97 had confirmed SARS. Fever, chills, malaise, myalgia, rigor, loss of appetite, vomiting, diarrhoea, and neck pain but not respiratory tract symptoms were significantly more common among the 97 patients than among the other patients. The overall accuracy of the WHO guidelines for identifying suspected SARS was 83% and their negative predictive value was 86% (95% confidence interval 83% to 89%). They had a sensitivity of 26% (17% to 36%) and a specificity of 96% (93% to 97%). Conclusions Current WHO guidelines for diagnosing suspected SARS may not be sufficiently sensitive in assessing patients before admission to hospital. Daily follow up, evaluation of non-respiratory, systemic symptoms, and chest radiography would be better screening tools.	Chinese Univ Hong Kong, Accid & Emergency Med Acad Unit, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Rainer, TH (corresponding author), Prince Wales Hosp, Dept Emergency Med, Shatin, Hong Kong, Peoples R China.		Ahuja, Anil T/H-4031-2017; Rainer, Timothy/I-2591-2013; Sung, Joseph J. Y./R-3203-2018	Ahuja, Anil T/0000-0002-0726-5402; Rainer, Timothy/0000-0003-3355-3237; Sung, Joseph J. Y./0000-0003-3125-5199; Cameron, Peter/0000-0002-1443-557X				[Anonymous], 2003, Wkly Epidemiol Rec, V78, P97; Chan-Yeung M, 2003, BRIT MED J, V326, P850, DOI 10.1136/bmj.326.7394.850; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Ho W, 2003, LANCET, V361, P1313, DOI 10.1016/S0140-6736(03)13085-1; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; *WHO, 2003, CUM NUMB REP CAS SAR; *WHO, CAS DEF SURV SEV AC	13	92	95	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1354	1358		10.1136/bmj.326.7403.1354	http://dx.doi.org/10.1136/bmj.326.7403.1354			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816820	Bronze, Green Published			2022-12-28	WOS:000183756400016
J	Reinertsen, JL				Reinertsen, JL			Zen and the art of physician autonomy maintenance	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CLINICAL-PRACTICE GUIDELINES; PRIMARY-CARE; QUALITY; MANAGEMENT; LITIGATION; MEDICINE	The miracles of scientific medicine propelled physicians to an unparalleled level of clinical autonomy during the 20th century. During the past 20 years, physician autonomy has been declining, in part because the public has become aware that physicians are not consistently applying all of the science they know. One of medicine's most cherished professional values, individual clinical autonomy, is an important cause of the sometimes suboptimal performance in the timely and consistent application of clinical science; thus, it contributes to the decline in overall professional autonomy. This paper calls for physicians to practice the science of medicine as a profession so that society will allow physicians to continue practicing the art of medicine as individual professionals. In a Zen-like paradox, physicians must give up autonomy in order to regain it.	Inst Healthcare Improvement, Boston, MA USA	Institute for Healthcare Improvement	Reinertsen, JL (corresponding author), 375 E Aspen Meadow Lane, Alta, WY 83414 USA.	reinertsen@att.net						Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Cook D, 2000, CRIT CARE MED, V28, P3547, DOI 10.1097/00003246-200010000-00034; Davidoff F, 1998, ANN INTERN MED, V128, P572, DOI 10.7326/0003-4819-128-7-199804010-00011; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Davis RM, 1999, BRIT MED J, V318, P1090, DOI 10.1136/bmj.318.7191.1090; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; EAST TD, 1992, CHEST, V101, P697, DOI 10.1378/chest.101.3.697; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; GOSFIELD A, 2001, HLTH LAW HDB, P285; GOSFIELD A, 1998, QUALITY CLIN CULTURE; HYAMS AL, 1995, ANN INTERN MED, V122, P450, DOI 10.7326/0003-4819-122-6-199503150-00008; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Jacobson PD, 2000, JAMA-J AM MED ASSOC, V283, P921, DOI 10.1001/jama.283.7.921; James BC, 2001, NEW ENGL J MED, V345, P991, DOI 10.1056/NEJM200109273451311; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Kassirer JP, 2001, ANN INTERN MED, V134, P587, DOI 10.7326/0003-4819-134-7-200104030-00012; Lin CT, 2001, ARCH INTERN MED, V161, P1437, DOI 10.1001/archinte.161.11.1437; Little P, 2001, BMJ-BRIT MED J, V322, P468, DOI 10.1136/bmj.322.7284.468; McNeil BJ, 2001, NEW ENGL J MED, V345, P1612, DOI 10.1056/NEJMsa011810; Mechanic D, 2000, HEALTH AFFAIR, V19, P100, DOI 10.1377/hlthaff.19.5.100; Morris AH, 2000, ANN INTERN MED, V132, P373, DOI 10.7326/0003-4819-132-5-200003070-00007; Pont EA, 2000, CAMB Q HEALTHC ETHIC, V9, P98, DOI 10.1017/S0963180100001109; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; Shekelle PG, 2001, JAMA-J AM MED ASSOC, V286, P1461, DOI 10.1001/jama.286.12.1461; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; STARR PAUL, 1982, SOCIAL TRANSFORMATIO, P3; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WOLFF JA, 1991, PEDIATR HEMAT ONCOL, V8, P89	31	35	35	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2003	138	12					992	995		10.7326/0003-4819-138-12-200306170-00011	http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YM	12809456				2022-12-28	WOS:000183578100007
J	Rose, D				Rose, D			'Having a diagnosis is a qualification for the job'	BRITISH MEDICAL JOURNAL			English	Article									Inst Psychiat, London SE5 8AF, England	University of London; King's College London	Rose, D (corresponding author), Inst Psychiat, London SE5 8AF, England.		Rose, Diana S/D-1387-2010; Rose, Diana/HGE-8574-2022	Rose, Diana S/0000-0002-6393-6389; 					0	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1331	1331		10.1136/bmj.326.7402.1331	http://dx.doi.org/10.1136/bmj.326.7402.1331			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805192	Green Published			2022-12-28	WOS:000183626500057
J	Schmidt, R; Enzinger, C; Ropele, S; Schmidt, H; Fazekas, F				Schmidt, R; Enzinger, C; Ropele, S; Schmidt, H; Fazekas, F			Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study	LANCET			English	Article							HYPERINTENSITIES; MRI	More than half of all elderly people have some degree of cerebral white matter lesions. However, the rate of progression of these lesions is uncertain. We aimed to assess the progression of lesions in community-dwelling volunteers aged 50-75 years without neuropsychiatric disease. We used MRI to grade and measure the total volume of white matter lesions in 296 volunteers at baseline, 3 years, and 6 years. 58 participants with no lesions and 123 with punctate abnormalities at baseline had a low tendency for lesion progression, whereas 14 participants with early confluent and nine with confluent lesions underwent median increases of 2.7 cm(3) (IQR 0.5-5.9) and 9.3 cm(3) (7.1-21.0), respectively, in lesion volume at 6 years. Lesion grade at baseline was the only significant predictor of lesion progression (p<0.0001). Punctate white matter lesions are not progressive and are thus benign, whereas early confluent and confluent white matter abnormalities are progressive, and thus malignant.	Karl Franzens Univ Graz, Dept Neurol, A-8036 Graz, Austria; Karl Franzens Univ Graz, MRI Ctr, A-8036 Graz, Austria; Karl Franzens Univ Graz, Inst Med Biochem & Med Mol Biol, A-8036 Graz, Austria	University of Graz; University of Graz; University of Graz	Schmidt, R (corresponding author), Karl Franzens Univ Graz, Dept Neurol, A-8036 Graz, Austria.							FAZEKAS F, 1993, NEUROLOGY, V43, P1683, DOI 10.1212/WNL.43.9.1683; Schmidt R, 1999, NEUROLOGY, V53, P132, DOI 10.1212/WNL.53.1.132; van Gijn J, 2000, LANCET, V356, P612, DOI 10.1016/S0140-6736(00)02599-X; Veldink JH, 1998, NEUROLOGY, V51, P319, DOI 10.1212/WNL.51.1.319; Whitman GT, 2001, NEUROLOGY, V57, P990, DOI 10.1212/WNL.57.6.990	5	225	234	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2046	2048		10.1016/S0140-6736(03)13616-1	http://dx.doi.org/10.1016/S0140-6736(03)13616-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814718				2022-12-28	WOS:000183488900014
J	Stryer, D; Clancy, C				Stryer, D; Clancy, C			Boosting performance measure for measure	BRITISH MEDICAL JOURNAL			English	Editorial Material									US Dept HHS, Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, Rockville, MD 20850 USA	Agency for Healthcare Research & Quality	Stryer, D (corresponding author), US Dept HHS, Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, Rockville, MD 20850 USA.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1278	1278		10.1136/bmj.326.7402.1278	http://dx.doi.org/10.1136/bmj.326.7402.1278			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805128	Green Published			2022-12-28	WOS:000183626500004
J	Walsh, P				Walsh, P			'We must accept that health care is a risky business'	BRITISH MEDICAL JOURNAL			English	Article									Act Victims Med Accid, London CR0 1YB, England		Walsh, P (corresponding author), Act Victims Med Accid, London CR0 1YB, England.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1333	1334		10.1136/bmj.326.7402.1333	http://dx.doi.org/10.1136/bmj.326.7402.1333			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805194	Green Published			2022-12-28	WOS:000183626500059
J	Wandinger, KP; Lunemann, JD; Wengert, O; Bellmann-Strobl, J; Aktas, O; Weber, A; Grundstrom, E; Ehrlich, S; Wernecke, KD; Volk, HD; Zipp, F				Wandinger, KP; Lunemann, JD; Wengert, O; Bellmann-Strobl, J; Aktas, O; Weber, A; Grundstrom, E; Ehrlich, S; Wernecke, KD; Volk, HD; Zipp, F			TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis	LANCET			English	Article							BLOOD MONONUCLEAR-CELLS; HUMAN T-CELLS; I INTERFERONS; MS PATIENTS; GUIDELINES; LYMPHOCYTE; MECHANISM; LINES	Background Many patients with multiple sclerosis do not respond to interferon beta, which is widely used as an immunomodulatory treatment in this disease. We aimed to assess the functional relevance of tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), which is upregulated on incubation with interferon beta, for clinical treatment response. Methods We quantified gene expression longitudinally by realtime-PCR of the peripheral immune cells of 82 patients with multiple sclerosis. In a first cohort of 62 patients, 20 were classified as first-year responders since they did not have relapses during treatment with interferon beta la; 19 were classified as first-year non-responders; and 23 developed neutralising antibodies to interferon beta. A second cohort, also characterised by MRI, consisted of 11 patients on interferon beta la and nine patients who,were not treated. Concentrations of soluble TRAIL were determined by ELISA in serum samples of nine non-treated patients, 49 patients before treatment (29 responders, 20 non-responders), as well as longitudinally in a subset of 23 patients. Findings In both patient cohorts, drug-responders could be distinguished from non-responders by early and sustained induction of TRAIL (p<0.0001, each). In the presence of neutralising antibodies, initial upregulation of TRAIL expression was subsequently abrogated. Raised concentrations of soluble TRAIL in patients' serum samples before the start of treatment allowed prediction of the treatment response in the first year (ROC analysis with area under the curve 0.879 [0.785-0.974]). Interpretation Our data suggest that TRAIL expression is a candidate for pretreatment assessment and might thus be used as a prognostic marker of treatment response to interferon beta in multiple sclerosis. Furthermore, our observations have implications for the development of future immunoregulatory strategies in multiple sclerosis therapy.	Charite Univ Hosp, Neurosci Res Ctr, Inst Neuroimmunol, NWFZ 2680, D-10117 Berlin, Germany; Charite Univ Hosp, Dept Neurol, D-10117 Berlin, Germany; Charite Univ Hosp, Inst Med Biometry, D-10117 Berlin, Germany; Charite Univ Hosp, Inst Med Immunol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Zipp, F (corresponding author), Charite Univ Hosp, Neurosci Res Ctr, Inst Neuroimmunol, NWFZ 2680, Schumannstr 20-21, D-10117 Berlin, Germany.		Zipp, Frauke/C-9968-2015; Ehrlich, Stefan/ABB-4650-2020; Aktas, Orhan/B-7623-2009; Lunemann, Jan D/G-8729-2011; volk, hans-dieter/AAV-8053-2021	Zipp, Frauke/0000-0002-1231-1928; Ehrlich, Stefan/0000-0003-2132-4445; Aktas, Orhan/0000-0002-2020-9210; Lunemann, Jan D/0000-0002-3007-708X; volk, hans-dieter/0000-0002-7743-6668; Bellmann-Strobl, Judith/0000-0003-2615-1643				Brunner E, 2002, NONPARAMETRIC ANAL L; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Deisenhammer F, 1999, NEUROLOGY, V52, P1239, DOI 10.1212/WNL.52.6.1239; Duquette P, 1996, NEUROLOGY, V47, P889; Ebers G, 1999, NEUROLOGY, V53, P679; Francis G, 2001, NEUROLOGY, V56, P1628; Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; Hilliard B, 2001, J IMMUNOL, V166, P1314, DOI 10.4049/jimmunol.166.2.1314; Huang WX, 2000, NEUROLOGY, V55, P928, DOI 10.1212/WNL.55.7.928; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kracke A, 2000, NEUROLOGY, V54, P193, DOI 10.1212/WNL.54.1.193; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lunemann JD, 2002, J IMMUNOL, V168, P4881, DOI 10.4049/jimmunol.168.10.4881; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; Markovic-Plese S, 2001, J CLIN INVEST, V108, P1185, DOI 10.1172/JCI12516; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; STONE LA, 1995, ANN NEUROL, V37, P611, DOI 10.1002/ana.410370511; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wandinger KP, 2001, ANN NEUROL, V50, P349, DOI 10.1002/ana.1096; Wandinger KP, 1997, J NEUROL SCI, V149, P87, DOI 10.1016/S0022-510X(97)05383-5; Wang X, 2000, J IMMUNOL, V165, P548, DOI 10.4049/jimmunol.165.1.548; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	30	173	186	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2036	2043		10.1016/S0140-6736(03)13641-0	http://dx.doi.org/10.1016/S0140-6736(03)13641-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814715				2022-12-28	WOS:000183488900011
J	Baldauf, SL				Baldauf, SL			The deep roots of eukaryotes	SCIENCE			English	Editorial Material							OSTREOCOCCUS-TAURI CHLOROPHYTA; UNIVERSAL TREE; DIVERSITY; EVOLUTION; GENOME; SEQUENCES; PLASTIDS; ANCIENT; ORIGIN	Most cultivated and characterized eukaryotes can be confidently assigned to one of eight major groups. After a few false starts, we are beginning to resolve relationships among these major groups as well. However, recent developments are radically revising this picture again, particularly (i) the discovery of the likely antiquity and taxonomic diversity of ultrasmall eukaryotes, and (ii) a fundamental rethinking of the position of the root. Together these data suggest major gaps in our understanding simply of what eukaryotes are or, when it comes to the tree, even which end is up.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of York - UK	Baldauf, SL (corresponding author), Univ York, Dept Biol, Box 373, York YO10 5YW, N Yorkshire, England.	slb14@york.ac.uk		Baldauf, Sandra/0000-0003-4485-6671				Amaral Zettler Linda A., 2002, Nature (London), V417, P137, DOI 10.1038/417137a; AMARALZETTLER LA, 2001, J EUKARYOT MICROBIOL, V48, P293; Archibald JM, 2002, TRENDS GENET, V18, P577, DOI 10.1016/S0168-9525(02)02777-4; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; Courties C, 1998, J PHYCOL, V34, P844, DOI 10.1046/j.1529-8817.1998.340844.x; Dawson SC, 2002, P NATL ACAD SCI USA, V99, P8324, DOI 10.1073/pnas.062169599; DeLong EE, 2001, SYST BIOL, V50, P470, DOI 10.1080/106351501750435040; Derelle E, 2002, J PHYCOL, V38, P1150, DOI 10.1046/j.1529-8817.2002.02021.x; Dyall SD, 2000, CURR OPIN MICROBIOL, V3, P404, DOI 10.1016/S1369-5274(00)00112-0; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Gribaldo S, 2002, THEOR POPUL BIOL, V61, P391, DOI 10.1006/tpbi.2002.1593; Hausmann K., 1996, PROTOZOOLOGY; Hilario E, 1998, J MOL EVOL, V46, P703, DOI 10.1007/PL00006351; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; Keeling PJ, 1996, EMBO J, V15, P2285, DOI 10.1002/j.1460-2075.1996.tb00581.x; Klobutcher LA, 2002, CELL, V111, P763, DOI 10.1016/S0092-8674(02)01138-8; LEE JJ, 2000, ILLUTRATED GUIDE PRO; Lopez-Garcia P, 2001, NATURE, V409, P603, DOI 10.1038/35054537; Lopez-Garcia P, 2002, MOL BIOL EVOL, V19, P118, DOI 10.1093/oxfordjournals.molbev.a003976; Massana R, 2002, APPL ENVIRON MICROB, V68, P4554, DOI 10.1128/AEM.68.9.4554-4558.2002; Moon-van der Staay SY, 2001, NATURE, V409, P607, DOI 10.1038/35054541; Moreira D, 2002, TRENDS MICROBIOL, V10, P31, DOI 10.1016/S0966-842X(01)02257-0; PATTERSON DJ, 2000, FLAGELLATES UNITY DI, P269; Prescott DM, 2000, NAT REV GENET, V1, P191, DOI 10.1038/35042057; RIZZO PJ, 1977, SCIENCE, V198, P1258, DOI 10.1126/science.563104; Simpson AGB, 2002, CURR BIOL, V12, pR691, DOI 10.1016/S0960-9822(02)01207-1; SOGIN ML, 1993, NATURE, V362, P795, DOI 10.1038/362795a0; Stechmann A, 2002, SCIENCE, V297, P89, DOI 10.1126/science.1071196; Williams BAP, 2002, NATURE, V418, P865, DOI 10.1038/nature00949; YANAI I, 2002, CURR BIOL, V3, P24; Yoon HS, 2002, P NATL ACAD SCI USA, V99, P11724, DOI 10.1073/pnas.172234799	34	572	613	3	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1703	1706		10.1126/science.1085544	http://dx.doi.org/10.1126/science.1085544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805537				2022-12-28	WOS:000183459700038
J	Nosengo, N				Nosengo, N			Pollution fears put work at neutrino laboratory on hold	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					675	675		10.1038/423675b	http://dx.doi.org/10.1038/423675b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802302	Bronze			2022-12-28	WOS:000183443400012
J	Turekian, KK				Turekian, KK			Harmon Craig (1926-2003) - Obituary	NATURE			English	Biographical-Item									Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	Yale University	Turekian, KK (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.								0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					701	701		10.1038/423701a	http://dx.doi.org/10.1038/423701a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802321	Bronze			2022-12-28	WOS:000183443400030
J	McIntyre, LA; Fergusson, DA; Hebert, PC; Moher, D; Hutchison, JS				McIntyre, LA; Fergusson, DA; Hebert, PC; Moher, D; Hutchison, JS			Prolonged therapeutic hypothermia after traumatic brain injury in adults - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MILD HYPOTHERMIA; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; TRIALS; TEMPERATURE; BARBITURATE; EXPERIENCE; EFFICACY; QUALITY	Context The benefits of therapeutic hypothermia as a treatment for traumatic brain injury (TBI) remain unclear. Objective To explore the effects of depth, duration, and rate of rewarming after discontinuation of hypothermia on mortality and neurologic outcome in adults after TBI. Data Sources An electronic search of MEDLINE (OVID), EMBASE, Current Contents, the Cochrane library and a hand search of key journals were performed. Corresponding authors of identified studies were contacted for additional unpublished or ongoing clinical trials. Study Selection All randomized controlled trials of therapeutic hypothermia for at least 24 hours vs normothermia in adults with TBI. Data Extraction Demographic and clinical data, hypothermia interventions and cointerventions, mortality and neurologic outcomes, and methodological quality were abstracted by 2 independent reviewers. Data Synthesis Twelve trials met eligibility criteria and were included in the analysis. We also performed subanalyses by different hypothermia interventions (ie, depth, duration, and rapidity of rewarming after hypothermia) and methodological quality. Therapeutic hypothermia was associated with a 19% reduction in the risk of death (95% confidence interval [CI], 0.69-0.96) and a 22% reduction in the risk of poor neurologic outcome (95% CI, 0.63-0.98) compared with normothermia. Hypothermia longer than 48 hours was associated with a reduction in the risks of death and of poor neurologic outcome (relative risk [RR], 0.70; 95% CI, 0.56-0.87 and RR, 0.65; 95% CI, 0.48-0.89, respectively) compared with normothermia. Hypothermia to a target temperature between 32degreesC and 33degreesC, a duration of 24 hours, and rewarming within 24 hours were all associated with reduced risks of poor neurologic outcome compared with normothermia. Assessment of methodological quality did not reveal evidence of bias. Conclusions Therapeutic hypothermia may reduce the risks of mortality and poor neurologic outcome in adults with TBI. Outcomes were influenced, however, by depth and duration of hypothermia as well as rate of rewarming (less than or equal to24 hours) after discontinuation of hypothermia. Nonetheless, the evidence is not yet sufficient to recommend routine use of therapeutic hypothermia for TBI outside of research settings.	Univ Ottawa, Ottawa Hosp, Dept Med, Div Intens Care, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ctr Transfus Res, Clin Epidemiol Program, Hlth Res Inst, Ottawa, ON, Canada; Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, Ottawa, ON, Canada; Univ Ottawa, Dept Pediat, Ottawa, ON, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Univ Toronto, Hosp Sick Children, Dept Crit Care, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	McIntyre, LA (corresponding author), Univ Ottawa, Ottawa Hosp, Dept Med, Div Intens Care, Gen Campus, 501 Smyth Rd,Box 201, Ottawa, ON K1H 8L6, Canada.	lmcintyre@ottawahospital.on.ca	McIntyre, Lauralyn/AAR-7710-2021	McIntyre, Lauralyn/0000-0001-7421-1407; Fergusson, Dean/0000-0002-3389-2485; Moher, David/0000-0003-2434-4206				Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Bernard S, 1996, ANAESTH INTENS CARE, V24, P382, DOI 10.1177/0310057X9602400315; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; *COCHR LIB, 2002, COCHR CONTR TRIALS R; DRAKE CG, 1962, CAN MED ASSOC J, V87, P887; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; Gadkary CS, 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001048; Ginsberg MD, 2002, CRIT CARE MED, V30, P935, DOI 10.1097/00003246-200204000-00040; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; Hedges LV, 2002, STAT METHODS METAANA; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Heyland DK, 2001, JAMA-J AM MED ASSOC, V286, P944, DOI 10.1001/jama.286.8.944; Hirayama TKY, 1994, INTRACRANIAL PRESSUR, VIX, P233; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Mouritzen CV, 1966, J THORAC CARDIOVASC, V51, P579; Nakamura T, 1998, ACT NEUR S, V71, P85; Nara I, 1998, ACT NEUR S, V71, P22; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schwab S, 1998, STROKE, V29, P305; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHEN JH, 2000, HEIBEL MED J, V6, P498; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vespa PM, 2001, CRIT CARE MED, V29, P2224; Yan Y, 2001, Chin J Traumatol, V4, P8; Zhang K, 2000, INNER MONGOLIA MED J, V32, P4	58	239	248	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					2992	2999		10.1001/jama.289.22.2992	http://dx.doi.org/10.1001/jama.289.22.2992			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687XZ	12799408				2022-12-28	WOS:000183403400023
J	Jonas, DM				Jonas, DM			Optical analogs of 2D NMR	SCIENCE			English	Editorial Material							SPECTROSCOPY		Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Jonas, DM (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Jonas, David M/A-7491-2008	Jonas, David M/0000-0002-1085-8161				AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; Demirdoven N, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.237401; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; Hybl JD, 1998, CHEM PHYS LETT, V297, P307, DOI 10.1016/S0009-2614(98)01140-3; Jonas DM, 2003, ANNU REV PHYS CHEM, V54, P425, DOI 10.1146/annurev.physchem.54.011002.103907; Jones DJ, 2000, SCIENCE, V288, P635, DOI 10.1126/science.288.5466.635; Lepetit L, 1996, OPT LETT, V21, P564, DOI 10.1364/OL.21.000564; Mukamel S, 2000, ANNU REV PHYS CHEM, V51, P691, DOI 10.1146/annurev.physchem.51.1.691; Tian PF, 2003, SCIENCE, V300, P1553, DOI 10.1126/science.1083433; Trebino R, 1997, REV SCI INSTRUM, V68, P3277, DOI 10.1063/1.1148286; Weiner AM, 2000, REV SCI INSTRUM, V71, P1929, DOI 10.1063/1.1150614; Wright JC, 2002, INT REV PHYS CHEM, V21, P185, DOI 10.1080/01442350210124506; Zanni MT, 2001, P NATL ACAD SCI USA, V98, P11265, DOI 10.1073/pnas.201412998; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645; Zilian A, 1996, MOL PHYS, V87, P1261, DOI 10.1080/00268979650026794	15	47	49	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1515	1517		10.1126/science.1085687	http://dx.doi.org/10.1126/science.1085687			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791972				2022-12-28	WOS:000183333100032
J	Zazula, GD; Froese, DG; Schweger, CE; Mathewes, RW; Beaudoin, AB; Telka, AM; Harington, CR; Westgate, JA				Zazula, GD; Froese, DG; Schweger, CE; Mathewes, RW; Beaudoin, AB; Telka, AM; Harington, CR; Westgate, JA			Ice-age steppe vegetation in east Beringia - Tiny plant fossils indicate how this frozen region once sustained huge herds of mammals	NATURE			English	Article							ALASKA; TUNDRA		Simon Fraser Univ, Dept Biol Sci, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Dept Earth Sci, Burnaby, BC V5A 1S6, Canada; Prov Museum Alberta, Edmonton, AB T5N 0M6, Canada; Univ Alberta, Dept Anthropol, Edmonton, AB T6G 2H4, Canada; PALEOTEC Serv, W Ottawa, ON K1R 5K2, Canada; Canadian Museum Nat, Ottawa, ON K1P 6P4, Canada; Univ Toronto, Dept Geol, Toronto, ON M5S 3B1, Canada	Simon Fraser University; Simon Fraser University; University of Alberta; University of Toronto	Zazula, GD (corresponding author), Simon Fraser Univ, Dept Biol Sci, Burnaby, BC V5A 1S6, Canada.		Beaudoin, Alwynne B./H-3873-2011; Froese, Duane G/B-6038-2009	Beaudoin, Alwynne B./0000-0002-8895-4567; MATHEWES, ROLF/0000-0001-7637-199X				ANDERSON PM, 1994, QUATERNARY SCI REV, V13, P71, DOI 10.1016/0277-3791(94)90125-2; Birks HH, 2000, J BIOGEOGR, V27, P31, DOI 10.1046/j.1365-2699.2000.00375.x; CWYNAR LC, 1980, SCIENCE, V208, P1375, DOI 10.1126/science.208.4450.1375; EDWARDS ME, 1989, ARCTIC ALPINE RES, V21, P296, DOI 10.2307/1551569; Elias SA, 1996, NATURE, V382, P60, DOI 10.1038/382060a0; Froese D, 2002, QUATERNARY SCI REV, V21, P2137, DOI 10.1016/S0277-3791(02)00038-0; Goetcheus VG, 2001, QUATERNARY SCI REV, V20, P135, DOI 10.1016/S0277-3791(00)00127-X; Guthrie R.D., 1990, FROZEN FAUNA MAMMOTH; Harington C.R., 1996, Current Research in the Pleistocene, V13, P105; Vetter MA, 2000, ARCTIC, V53, P165	10	77	79	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					603	603		10.1038/423603a	http://dx.doi.org/10.1038/423603a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789326	Bronze			2022-12-28	WOS:000183301200027
J	Keenan, SP; Sinuff, T; Cook, DJ; Hill, NS				Keenan, SP; Sinuff, T; Cook, DJ; Hill, NS			Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE RESPIRATORY-FAILURE; STANDARD MEDICAL THERAPY; NASAL MASK VENTILATION; MECHANICAL VENTILATION; FACE MASK; METAANALYSIS; MORTALITY; SUPPORT; TRIAL; COPD	Background: Over the past decade, noninvasive positive-pressure ventilation (NPPV) in the setting of acute exacerbations of chronic obstructive pulmonary disease (COPD) has increased in popularity. Although several trials have been published on the relative effectiveness of this treatment, apparent inconsistencies in study results remain. Purpose: To assess the effect of NPPV on rate of endotracheal intubation, length of hospital stay, and in-hospital mortality rate in patients with an acute exacerbation of COPD and to determine the effect of exacerbation severity on these outcomes. Data Sources: MEDLINE (1966 to 2002) and EMBASE (1990 to 2002). Additional data sources included the Cochrane Library, personal files, abstract proceedings, reference lists of selected articles, and expert contact. There were no language restrictions. Study Selection: The researchers selected randomized, controlled trials that 1) examined patients with acute exacerbation of COPD; 2) compared noninvasive ventilation and standard therapy with standard therapy alone; and 3) included need for endotracheal intubation, length of hospital stay, or hospital survival as an outcome. Data Extraction: Methodologic quality and results were abstracted independently and in duplicate. Data Synthesis: The addition of NPPV to standard care in patients with an acute exacerbation of COPD decreased the rate of endotracheal intubation (risk reduction, 28% [95% CI, 15% to 40%]), length of hospital stay (absolute reduction, 4.57 days [CI, 2.30 to 6.83 days]), and in-hospital mortality rate (risk reduction, 10% [CI, 5% to 15%]). However, subgroup analysis showed that these beneficial effects occurred only in patients with severe exacerbations, not in those with milder exacerbations. Conclusions: Patients with severe exacerbations of COPD benefit from the addition of NPPV to standard therapy. However, NPPV has not been shown to benefit hospitalized patients with milder COPD exacerbations.	Royal Columbian Hosp, New Westminster, BC, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; McMaster Fac Sci, Hamilton, ON, Canada; Tufts Univ New England Med Ctr, Boston, MA USA	University of British Columbia; St. Paul's Hospital; University of Saskatchewan; McMaster University; Tufts Medical Center	Keenan, SP (corresponding author), Suite 103,250 Keary St, New Westminster, BC V3L 5E7, Canada.	Sean_Keenan@telus.net						AbouShala N, 1996, CRIT CARE MED, V24, P705, DOI 10.1097/00003246-199604000-00025; Ambrosino N, 1996, EUR RESPIR J, V9, P795, DOI 10.1183/09031936.96.09040795; Ambrosino N, 1993, Monaldi Arch Chest Dis, V48, P144; Angus RM, 1996, THORAX, V51, P1048, DOI 10.1136/thx.51.10.1048; Antonelli M, 2000, CRIT CARE, V4, P15, DOI 10.1186/cc645; Avdeev S N, 1998, Anesteziol Reanimatol, P45; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; Bardi G, 2000, EUR RESPIR J, V15, P98, DOI 10.1034/j.1399-3003.2000.15a18.x; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Clark HE, 1997, LUNG, V175, P143, DOI 10.1007/PL00007562; Confalonieri M, 1999, AM J RESP CRIT CARE, V160, P1585, DOI 10.1164/ajrccm.160.5.9903015; Daskalopoulou E, 1993, CHEST, V103, p271S; Dikensoy O, 2002, INT J CLIN PRACT, V56, P85; ELLIOTT MW, 1990, BRIT MED J, V300, P358, DOI 10.1136/bmj.300.6721.358; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; HILL NS, 1993, AM REV RESPIR DIS, V147, P1050, DOI 10.1164/ajrccm/147.4.1050; HOO GWS, 1994, CRIT CARE MED, V22, P1253, DOI 10.1097/00003246-199408000-00009; Jasmer RM, 1997, CHEST, V111, P1672, DOI 10.1378/chest.111.6.1672; Keenan SP, 2000, CRIT CARE MED, V28, P2094, DOI 10.1097/00003246-200006000-00072; Keenan SP, 1998, CRIT CARE CLIN, V14, P359, DOI 10.1016/S0749-0704(05)70005-1; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; Keenan SP, 2001, AM J RESP CRIT CARE, V163, pA250; Khilnani G.C., 2002, AM J RESP CRIT CARE, V165, pA387; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; MARINO W, 1991, CHEST, V99, P681, DOI 10.1378/chest.99.3.681; Martin TJ, 2000, AM J RESP CRIT CARE, V161, P807, DOI 10.1164/ajrccm.161.3.9808143; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; Meduri GU, 1997, CRIT CARE MED, V25, P1631, DOI 10.1097/00003246-199710000-00008; Meduri GU, 1996, CLIN CHEST MED, V17, P513, DOI 10.1016/S0272-5231(05)70330-0; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; Mehta S, 2001, AM J RESP CRIT CARE, V163, P540, DOI 10.1164/ajrccm.163.2.9906116; Mehta S, 1996, Respir Care Clin N Am, V2, P267; MEYER TJ, 1994, ANN INTERN MED, V120, P760, DOI 10.7326/0003-4819-120-9-199405010-00008; Nicholson D, 1998, Curr Opin Pulm Med, V4, P66, DOI 10.1097/00063198-199803000-00003; Pang D, 1998, CHEST, V114, P1185, DOI 10.1378/chest.114.4.1185; Peter JV, 2002, CRIT CARE MED, V30, P555, DOI 10.1097/00003246-200203000-00010; Plant PK, 2001, THORAX, V56, P708, DOI 10.1136/thorax.56.9.708; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Porta R, 2000, Monaldi Arch Chest Dis, V55, P509; SERVERA E, 1995, CHEST, V108, P1572, DOI 10.1378/chest.108.6.1572; SERVILLO G, 1994, INTENS CARE MED, V50, pS54; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8	46	256	282	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					861	870		10.7326/0003-4819-138-11-200306030-00007	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779296				2022-12-28	WOS:000183296400001
J	Arlt, W; Allolio, B				Arlt, W; Allolio, B			Adrenal insufficiency	LANCET			English	Review							GLUCOCORTICOID REPLACEMENT THERAPY; DAILY CORTISOL PRODUCTION; BONE-MINERAL DENSITY; ADRENOCORTICOTROPIN STIMULATION TEST; CORTICOTROPIN-RELEASING-HORMONE; INSULIN-INDUCED HYPOGLYCEMIA; AUTOIMMUNE ADDISONS-DISEASE; STEROID-PRODUCING CELLS; KEARNS-SAYRE-SYNDROME; DOSE METYRAPONE TEST	Adrenal insufficiency is caused by either primary adrenal failure (mostly due to autoimmune adrenalitis) or by hypothalamic-pituitary impairment of the corticotropic axis (predominantly due to pituitary disease). It is a rare disease, but is life threatening when overlooked. Main presenting symptoms such as fatigue, anorexia, and weight loss are nonspecific, thus diagnosis is often delayed. The diagnostic work-up is well established but some pitfalls remain, particularly in the identification of secondary adrenal insufficiency. Despite optimised life-saving glucocorticoid-replacement and mineralocorticoid-replacement therapy, health-related quality of life in adrenal insufficiency is more severely impaired than previously thought. Dehydroeplandrosterone-replacement therapy has been introduced that could help to restore quality of life. Monitoring of glucocorticoid-replacement quality is hampered by lack of objective methods of assessment, and is therefore largely based on clinical grounds. Thus, long-term management of patients with adrenal insufficiency remains a challenge, requiring an experienced specialist. However, all doctors should know how to diagnose and manage suspected acute adrenal failure.	Univ Wurzburg, Dept Med, Endocrine & Diabet Unit, D-97080 Wurzburg, Germany; Univ Birmingham, Div Med Sci, Birmingham, W Midlands, England	University of Wurzburg; University of Birmingham	Allolio, B (corresponding author), Univ Wurzburg, Dept Med, Endocrine & Diabet Unit, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	allolio_b@klinik.uni.wuerzburg.de	Arlt, Wiebke/B-6310-2009	Arlt, Wiebke/0000-0001-5106-9719				Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; ALLOLIO B, 1990, CLIN ENDOCRINOL, V33, P279, DOI 10.1111/j.1365-2265.1990.tb00492.x; ALLOLIO B, 1983, LANCET, V2, P626; Allolio B, 2002, TRENDS ENDOCRIN MET, V13, P288, DOI 10.1016/S1043-2760(02)00617-3; ALLOLIO B, 1994, CLIN ENDOCRINOL, V40, P769, DOI 10.1111/j.1365-2265.1994.tb02511.x; Allolio B, 1985, AKT ENDOKR STOFFW, V6, P35; ALSHOUMER KAS, 1995, CLIN ENDOCRINOL, V42, P85, DOI 10.1111/j.1365-2265.1995.tb02602.x; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Arlt W, 1999, NEW ENGL J MED, V341, P1013, DOI 10.1056/NEJM199909303411401; Auchus RJ, 1997, CLIN ENDOCRINOL, V46, P21, DOI 10.1046/j.1365-2265.1997.d01-1748.x; BARBATO AL, 1977, ACTA ENDOCRINOL-COP, V84, P600, DOI 10.1530/acta.0.0840600; Bates AS, 1996, J CLIN ENDOCR METAB, V81, P1169, DOI 10.1210/jc.81.3.1169; Beishuizen A, 2001, BEST PRACT RES CL EN, V15, P513, DOI 10.1053/beem.2001.0167; Betterle C, 1999, J CLIN ENDOCR METAB, V84, P618, DOI 10.1210/jc.84.2.618; Betterle C, 2002, ENDOCR REV, V23, P327, DOI 10.1210/er.23.3.327; Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; BRAATVEDT GD, 1990, BRIT MED J, V301, P1312, DOI 10.1136/bmj.301.6764.1312; Braatvedt GD, 1999, OSTEOPOROSIS INT, V10, P435, DOI 10.1007/s001980050251; Brandon DD, 1999, STEROIDS, V64, P372, DOI 10.1016/S0039-128X(98)00112-3; BRIEGEL J, 1992, INTENS CARE MED, V18, P318, DOI 10.1007/BF01706486; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; BURCH WM, 1982, JAMA-J AM MED ASSOC, V247, P2002, DOI 10.1001/jama.247.14.2002; Clark PM, 1998, CLIN ENDOCRINOL, V49, P287; Courtney CH, 2000, CLIN ENDOCRINOL, V53, P309; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; De Vroede M, 1998, ARCH DIS CHILD, V78, P544, DOI 10.1136/adc.78.6.544; DICKSTEIN G, 1986, ACTA ENDOCRINOL-COP, V112, P28, DOI 10.1530/acta.0.1120028; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; DIEDERICH S, 1994, DEUT MED WOCHENSCHR, V119, P595, DOI 10.1055/s-2008-1058735; Donner H, 1997, J CLIN ENDOCR METAB, V82, P4130, DOI 10.1210/jc.82.12.4130; DRUCKER D, 1986, CRIT CARE MED, V14, P789, DOI 10.1097/00003246-198609000-00006; ESTEBAN NV, 1991, J CLIN ENDOCR METAB, V72, P39, DOI 10.1210/jcem-72-1-39; Fallo F, 1999, EUR J ENDOCRINOL, V140, P425, DOI 10.1530/eje.0.1400425; FALLO F, 1994, AM J HYPERTENS, V7, P1105, DOI 10.1093/ajh/7.12.1105; FEEK CM, 1981, CLIN ENDOCRINOL, V14, P451, DOI 10.1111/j.1365-2265.1981.tb00634.x; FEEK CM, 1981, CLIN ENDOCRINOL, V15, P75, DOI 10.1111/j.1365-2265.1981.tb02750.x; FIAD TM, 1994, CLIN ENDOCRINOL, V40, P603, DOI 10.1111/j.1365-2265.1994.tb03011.x; FINDLING JW, 1994, J CLIN ENDOCR METAB, V79, P1091, DOI 10.1210/jc.79.4.1091; FINDLING JW, 1987, J CLIN ENDOCR METAB, V64, P592, DOI 10.1210/jcem-64-3-592; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; Flemming TG, 1999, J INTERN MED, V246, P497, DOI 10.1046/j.1365-2796.1999.00538.x; FLORKOWSKI CM, 1994, NEW ZEAL MED J, V107, P52; FRANCKE U, 1987, AM J HUM GENET, V40, P212; Glowniak JV, 1997, SURGERY, V121, P123, DOI 10.1016/S0039-6060(97)90280-4; GRINSPOON SK, 1994, J CLIN ENDOCR METAB, V79, P923, DOI 10.1210/jc.79.4.923; GROVES RW, 1988, J ROY SOC MED, V81, P514, DOI 10.1177/014107688808100906; HAGG E, 1987, CLIN ENDOCRINOL, V26, P221, DOI 10.1111/j.1365-2265.1987.tb00780.x; Handschug K, 2001, HUM MOL GENET, V10, P283, DOI 10.1093/hmg/10.3.283; Hangaard J, 1996, J CLIN ENDOCR METAB, V81, P2502, DOI 10.1210/jc.81.7.2502; HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x; Henzen C, 2000, LANCET, V355, P542, DOI 10.1016/S0140-6736(99)06290-X; Howlett TA, 1997, CLIN ENDOCRINOL, V46, P263, DOI 10.1046/j.1365-2265.1997.1340955.x; Hunt PJ, 2000, J CLIN ENDOCR METAB, V85, P4650, DOI 10.1210/jc.85.12.4650; Inder WJ, 2002, J CLIN ENDOCR METAB, V87, P2745, DOI 10.1210/jc.87.6.2745; Johannsson G, 2002, J CLIN ENDOCR METAB, V87, P2046, DOI 10.1210/jc.87.5.2046; JURNEY TH, 1987, CHEST, V92, P292, DOI 10.1378/chest.92.2.292; Kannisto S, 2000, J CLIN ENDOCR METAB, V85, P652, DOI 10.1210/jc.85.2.652; Kasperlik-Zaluska AA, 1998, CLIN ENDOCRINOL, V49, P779, DOI 10.1046/j.1365-2265.1998.00611.x; Kawashima A, 1998, RADIOGRAPHICS, V18, P393, DOI 10.1148/radiographics.18.2.9536486; KEHLET H, 1976, CLIN ENDOCRINOL, V5, P37, DOI 10.1111/j.1365-2265.1976.tb01937.x; Kemp EH, 1998, CLIN ENDOCRINOL, V49, P609; KERRIGAN JR, 1993, J CLIN ENDOCR METAB, V76, P1505, DOI 10.1210/jc.76.6.1505; Knapen MH, 1993, ADDISON PATIENTS NET; KONG MF, 1994, CLIN ENDOCRINOL, V41, P757, DOI 10.1111/j.1365-2265.1994.tb02790.x; Kraan GPB, 1998, J CLIN ENDOCR METAB, V83, P1247, DOI 10.1210/jc.83.4.1247; Krasner AS, 1999, JAMA-J AM MED ASSOC, V282, P671, DOI 10.1001/jama.282.7.671; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Lam KY, 2001, CLIN ENDOCRINOL, V54, P633, DOI 10.1046/j.1365-2265.2001.01266.x; Lamberts SWJ, 1997, NEW ENGL J MED, V337, P1285, DOI 10.1056/NEJM199710303371807; LANDON J, 1966, J CLIN INVEST, V45, P437, DOI 10.1172/JCI105358; Lange M, 2002, EUR J ENDOCRINOL, V147, P41, DOI 10.1530/eje.0.1470041; Laureti S, 1999, J CLIN ENDOCR METAB, V84, P1762, DOI 10.1210/jc.84.5.1762; LEBRETHON MC, 1994, J CLIN INVEST, V93, P1828, DOI 10.1172/JCI117168; LEDINGHAM IM, 1983, LANCET, V1, P1270; Lindholm J, 2001, CLIN ENDOCRINOL, V54, P283, DOI 10.1046/j.1365-2265.2001.01163.x; LINDHOLM J, 1987, CLIN ENDOCRINOL, V26, P53, DOI 10.1111/j.1365-2265.1987.tb03638.x; Lovas K, 2002, CLIN ENDOCRINOL, V56, P581, DOI 10.1046/j.1365-2265.2002.01466.x; Lovas K, 2002, CLIN ENDOCRINOL, V56, P787, DOI 10.1046/j.1365-2265.2002.t01-1-01552.x; Lutz A, 2000, EUR J ENDOCRINOL, V143, P91, DOI 10.1530/eje.0.1430091; MAISEY DN, 1974, LANCET, V2, P896; MASON AS, 1968, LANCET, V2, P744; Mayenknecht J, 1998, J CLIN ENDOCR METAB, V83, P1558, DOI 10.1210/jc.83.5.1558; Monson JP, 1997, CLIN ENDOCRINOL, V46, P269, DOI 10.1046/j.1365-2265.1997.87897.x; Moser HW, 1997, BRAIN, V120, P1485, DOI 10.1093/brain/120.8.1485; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; Murphy H, 1998, J CLIN ENDOCR METAB, V83, P712; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; NELSON JC, 1978, AM J MED SCI, V275, P165, DOI 10.1097/00000441-197803000-00006; NERUP J, 1974, ACTA ENDOCRINOL-COP, V76, P127, DOI 10.1530/acta.0.0760127; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; Nilsson B, 2000, J CLIN ENDOCR METAB, V85, P1420, DOI 10.1210/jc.85.4.1420; NUSSEY SS, 1993, CLIN ENDOCRINOL, V39, P381, DOI 10.1111/j.1365-2265.1993.tb02381.x; OELKERS W, 1989, NEW ENGL J MED, V321, P492, DOI 10.1056/NEJM198908243210802; OELKERS W, 1992, J CLIN ENDOCR METAB, V75, P259, DOI 10.1210/jc.75.1.259; Oelkers W, 1998, EUR J ENDOCRINOL, V139, P567, DOI 10.1530/eje.0.1390567; Peacey SR, 1997, CLIN ENDOCRINOL, V46, P255, DOI 10.1046/j.1365-2265.1997.780907.x; POWRIE JK, 1995, CLIN ENDOCRINOL, V42, P315, DOI 10.1111/j.1365-2265.1995.tb01881.x; Randeva HS, 1999, CLIN ENDOCRINOL, V51, P181, DOI 10.1046/j.1365-2265.1999.00754.x; Regal M, 2001, CLIN ENDOCRINOL, V55, P735, DOI 10.1046/j.1365-2265.2001.01406.x; REINCKE M, 1993, J CLIN ENDOCR METAB, V77, P151, DOI 10.1210/jc.77.1.151; RHEAUME E, 1992, NAT GENET, V1, P239, DOI 10.1038/ng0792-239; RIEDEL M, 1993, EXP CLIN ENDOCRINOL, V101, P106, DOI 10.1055/s-0029-1211215; ROBINSON BG, 1987, CLIN ENDOCRINOL, V27, P437, DOI 10.1111/j.1365-2265.1987.tb01171.x; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; ROTHWELL PM, 1991, LANCET, V337, P582, DOI 10.1016/0140-6736(91)91641-7; SALEM M, 1994, ANN SURG, V219, P416, DOI 10.1097/00000658-199404000-00013; Satta MA, 2000, CLIN ENDOCRINOL, V52, P123; SAWCZUK IS, 1986, UROL RADIOL, V8, P44, DOI 10.1007/BF02924072; SCHULTE HM, 1987, CLIN ENDOCRINOL, V27, P655, DOI 10.1111/j.1365-2265.1987.tb02948.x; SCOTT RS, 1978, CLIN ENDOCRINOL, V9, P571, DOI 10.1111/j.1365-2265.1978.tb01516.x; Soule S, 1999, CLIN ENDOCRINOL, V50, P115, DOI 10.1046/j.1365-2265.1999.00625.x; STEIN CA, 1986, ANN INTERN MED, V104, P286, DOI 10.7326/0003-4819-104-2-286_2; STEWART PM, 1988, LANCET, V1, P1208; Stewart PM, 1998, CLIN ENDOCRINOL, V48, P124, DOI 10.1046/j.1365-2265.1998.0429d.x; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; Tajima T, 2001, J CLIN ENDOCR METAB, V86, P3820, DOI 10.1210/jc.86.8.3820; Thaler LM, 1998, J CLIN ENDOCR METAB, V83, P2726, DOI 10.1210/jc.83.8.2726; Thomas PQ, 2001, HUM MOL GENET, V10, P39, DOI 10.1093/hmg/10.1.39; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; TORDJMAN K, 1995, J CLIN ENDOCR METAB, V80, P1301, DOI 10.1210/jc.80.4.1301; Tordjman K, 2000, CLIN ENDOCRINOL, V52, P633, DOI 10.1046/j.1365-2265.2000.00984.x; TSATSOULIS A, 1988, CLIN ENDOCRINOL, V28, P225, DOI 10.1111/j.1365-2265.1988.tb03659.x; TSIGOS C, 1993, J CLIN INVEST, V92, P2458, DOI 10.1172/JCI116853; Tuchelt H, 2000, CLIN ENDOCRINOL, V53, P301, DOI 10.1046/j.1365-2265.2000.01089.x; Tullio-Pelet A, 2000, NAT GENET, V26, P332, DOI 10.1038/81642; VASIKARAN SD, 1994, CLIN ENDOCRINOL, V41, P261, DOI 10.1111/j.1365-2265.1994.tb02540.x; Vilain E, 1999, J CLIN ENDOCR METAB, V84, P4335, DOI 10.1210/jc.84.12.4335; Wassif CA, 1998, AM J HUM GENET, V63, P55, DOI 10.1086/301936; WATTS NB, 1988, JAMA-J AM MED ASSOC, V259, P708, DOI 10.1001/jama.259.5.708; WEBER A, 1994, HUM MOL GENET, V3, P585, DOI 10.1093/hmg/3.4.585; WEETMAN AP, 1995, BAILLIERE CLIN ENDOC, V9, P157, DOI 10.1016/S0950-351X(95)80899-X; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; WHITE PC, 1991, J CLIN INVEST, V87, P1664, DOI 10.1172/JCI115182; Wichers M, 1999, CLIN ENDOCRINOL, V50, P759, DOI 10.1046/j.1365-2265.1999.00723.x; Willis AC, 1997, POSTGRAD MED J, V73, P286, DOI 10.1136/pgmj.73.859.286; WINQVIST O, 1992, LANCET, V339, P1559, DOI 10.1016/0140-6736(92)91829-W; WOOD JB, 1965, LANCET, V1, P243; Wu W, 1998, NAT GENET, V18, P147, DOI 10.1038/ng0298-147; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zelissen P, 1994, ADDISON PATIENTS NET; ZELISSEN PMJ, 1994, ANN INTERN MED, V120, P207, DOI 10.7326/0003-4819-120-3-199402010-00005	146	605	633	0	53	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	2003	361	9372					1881	1893		10.1016/S0140-6736(03)13492-7	http://dx.doi.org/10.1016/S0140-6736(03)13492-7			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788587				2022-12-28	WOS:000183205800024
J	Lima, CD				Lima, CD			CUE'd up for monoubiquitin	CELL			English	Editorial Material							UBIQUITIN; DEGRADATION		Cornell Univ, Weill Med Coll, Dept Biochem, Struct Biol Program, New York, NY 10021 USA	Cornell University	Lima, CD (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, Struct Biol Program, New York, NY 10021 USA.			Lima, Christopher/0000-0002-9163-6092				Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140	11	4	4	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 30	2003	113	5					554	556		10.1016/S0092-8674(03)00398-2	http://dx.doi.org/10.1016/S0092-8674(03)00398-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787494	Bronze			2022-12-28	WOS:000183397600003
J	Watmough, SA; Dillon, PJ				Watmough, SA; Dillon, PJ			Ecology - Mycorrhizal weathering in base-poor forests	NATURE			English	Editorial Material							NORTHERN HARDWOOD FOREST; UNITED-STATES; CALCIUM; ECOSYSTEMS; CANADA; LAKE		Trent Univ, Environm & Resource Studies Dept, Peterborough, ON K9J 7B8, Canada	Trent University	Watmough, SA (corresponding author), Trent Univ, Environm & Resource Studies Dept, Peterborough, ON K9J 7B8, Canada.							Blum JD, 2002, NATURE, V417, P729, DOI 10.1038/nature00793; Duchesne L, 2001, CAN J FOREST RES, V31, P333, DOI 10.1139/cjfr-31-2-333; FEDERER CA, 1989, ENVIRON MANAGE, V13, P593, DOI 10.1007/BF01874965; Johnson CE, 2000, ECOSYSTEMS, V3, P159, DOI 10.1007/s100210000017; Jongmans AG, 1997, NATURE, V389, P682, DOI 10.1038/39493; KIRKWOOD DE, 1991, GEOCHIM COSMOCHIM AC, V55, P1295, DOI 10.1016/0016-7037(91)90308-R; Lawrence GB, 1997, BIOGEOCHEMISTRY, V38, P19, DOI 10.1023/A:1005790130253; Likens GE, 1998, BIOGEOCHEMISTRY, V41, P89, DOI 10.1023/A:1005984620681; Likens GE, 1996, SCIENCE, V272, P244, DOI 10.1126/science.272.5259.244; Poszwa A, 2000, PLANT SOIL, V225, P299, DOI 10.1023/A:1026570812307; Sverdrup H, 1998, FOREST ECOL MANAG, V110, P221, DOI 10.1016/S0378-1127(98)00283-7; van Breemen N, 2000, BIOGEOCHEMISTRY, V49, P53, DOI 10.1023/A:1006256231670; Watmough SA, 2003, FOREST ECOL MANAG, V177, P155, DOI 10.1016/S0378-1127(02)00320-1	13	13	13	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					823	824		10.1038/423823b	http://dx.doi.org/10.1038/423823b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815420				2022-12-28	WOS:000183585300033
J	Wilson, JF				Wilson, JF			Physicians contribute professional expertise worldwide	ANNALS OF INTERNAL MEDICINE			English	Article													Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2003	138	12					1013	1016		10.7326/0003-4819-138-12-200306170-00032	http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00032			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YM	12809476				2022-12-28	WOS:000183578100025
J	Garlick, W				Garlick, W			Head to head - Should drug companies be allowed to talk directly to patients? No	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1302	1303		10.1136/bmj.326.7402.1302-a	http://dx.doi.org/10.1136/bmj.326.7402.1302-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805164	Green Published			2022-12-28	WOS:000183626500028
J	Bignami, GF; Caraveo, PA; De Luca, A; Mereghetti, S				Bignami, GF; Caraveo, PA; De Luca, A; Mereghetti, S			The magnetic field of an isolated neutron star from X-ray cyclotron absorption lines	NATURE			English	Article							SUPERNOVA REMNANT PKS-1209-51/52; PHOTON IMAGING CAMERA; XMM-NEWTON; FEATURES; SPECTRUM; PULSAR; 1E-1207.4-5209; SCATTERING; DISCOVERY	Isolated neutron stars are highly magnetized, fast-rotating objects that form as an end point of stellar evolution. They are directly observable in X-ray emission, because of their high surface temperatures. Features in their X-ray spectra could in principle reveal the presence of atmospheres(1), or be used to estimate the strength of their magnetic fields through the cyclotron process(2), as is done for X-ray binaries(3,4). Almost all isolated neutron star spectra observed so far appear as featureless thermal continua(5,6). The only exception is 1E1207.4-5209 (refs 7-9), where two deep absorption features have been detected(10,11), but with insufficient definition to permit unambiguous interpretation. Here we report a long X-ray observation of the same object in which the star's spectrum shows three distinct features, regularly spaced at 0.7, 1.4 and 2.1 keV, plus a fourth feature of lower significance, at 2.8 keV. These features vary in phase with the star's rotation. The logical interpretation is that they are features from resonant cyclotron absorption, which allows us to calculate a magnetic field strength of 8 X 10(10) G, assuming the absorption arises from electrons.	Ctr Etud Spatiale Rayonnements, CNRS, UPS, F-31028 Toulouse 4, France; Univ Pavia, Dipartimento Fis Nucl & Teor, I-27100 Pavia, Italy; Ist Astrofis Spaziale & Fis Cosm, Sez Milano G Occhialini, I-20133 Milan, Italy; Univ Milano Bicocca, Dipartimento Fis, I-20126 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Pavia; Istituto Nazionale Astrofisica (INAF); University of Milano-Bicocca	Bignami, GF (corresponding author), Ctr Etud Spatiale Rayonnements, CNRS, UPS, 9 Ave Colonel Roche, F-31028 Toulouse 4, France.		Caraveo, Patrizia/AAL-5708-2020	Caraveo, Patrizia/0000-0003-2478-8018; De Luca, Andrea/0000-0001-6739-687X; Bignami, Giovanni/0000-0001-9582-2450				BECKER W, 2002, XRAY OBSERVATIONS NE, P64; BIGNAMI GF, 1992, ASTROPHYS J, V389, pL67, DOI 10.1086/186350; Bignami GF, 1996, ASTROPHYS J, V456, pL111, DOI 10.1086/309876; CAMILO F, IN PRESS ASP C SER; Caraveo PA, 1996, ASTRON ASTROPHYS REV, V7, P209, DOI 10.1007/s001590050004; den Herder JW, 2001, ASTRON ASTROPHYS, V365, pL7, DOI 10.1051/0004-6361:20000058; Freeman PE, 1999, ASTROPHYS J, V524, P772, DOI 10.1086/307818; Giacani EB, 2000, ASTRON J, V119, P281, DOI 10.1086/301173; Hailey CJ, 2002, ASTROPHYS J, V578, pL133, DOI 10.1086/344716; Isenberg M, 1998, ASTROPHYS J, V505, P688, DOI 10.1086/306171; KIRSCH M, 2002, XMMSOCCALTN0018 NEWT; LAMB DQ, 1990, ASTROPHYS J, V363, P670, DOI 10.1086/169375; Mereghetti S, 2002, ASTROPHYS J, V581, P1280, DOI 10.1086/344435; MESZAROS P, 1985, ASTROPHYS J, V298, P147, DOI 10.1086/163594; Miller JM, 2003, ASTROPHYS J, V583, pL99, DOI 10.1086/368105; MORI K, UNPUB ASTROPHYS J; NAGASE F, 1991, ASTROPHYS J, V375, pL49, DOI 10.1086/186085; Pavlov GG, 2002, ASTROPHYS J, V569, pL95, DOI 10.1086/340640; PAVLOV GG, 2002, THERMAL RAD NEUTRON, P273; Sanwal D, 2002, ASTROPHYS J, V574, pL61, DOI 10.1086/342368; Struder L, 2001, ASTRON ASTROPHYS, V365, pL18, DOI 10.1051/0004-6361:20000066; TRUMPER J, 1978, ASTROPHYS J LETT, V219, P105; Turner MJL, 2001, ASTRON ASTROPHYS, V365, pL27, DOI 10.1051/0004-6361:20000087; VOGES W, 1982, ASTROPHYS J, V263, P803, DOI 10.1086/160550; WEATHON WA, 1979, NATURE, V282, P240; Xu RX, 2003, CHINESE PHYS LETT, V20, P314, DOI 10.1088/0256-307X/20/2/343; Zane S, 2001, ASTROPHYS J, V560, P384, DOI 10.1086/322360; Zavlin VE, 1996, ASTRON ASTROPHYS, V315, P141; Zavlin VE, 2000, ASTROPHYS J, V540, pL25, DOI 10.1086/312866; ZAVLIN VE, 2002, MODELING NEUTRON STA, P263	30	143	148	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2003	423	6941					725	727		10.1038/nature01703	http://dx.doi.org/10.1038/nature01703			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802327				2022-12-28	WOS:000183443400036
J	Clark, JD; Beyene, Y; WoldeGabriel, G; Hart, WK; Renne, PR; Gilbert, H; Defleur, A; Suwa, G; Katoh, S; Ludwig, KR; Boisserie, JR; Asfaw, B; White, TD				Clark, JD; Beyene, Y; WoldeGabriel, G; Hart, WK; Renne, PR; Gilbert, H; Defleur, A; Suwa, G; Katoh, S; Ludwig, KR; Boisserie, JR; Asfaw, B; White, TD			Stratigraphic, chronological and behavioural contexts of Pleistocene Homo sapiens from Middle Awash, Ethiopia	NATURE			English	Article							HOMINID	Clarifying the geographic, environmental and behavioural contexts in which the emergence of anatomically modern Homo sapiens occurred has proved difficult, particularly because Africa lacked adequate geochronological, palaeontological and archaeological evidence. The discovery of anatomically modern Homo sapiens fossils at Herto, Ethiopia(1), changes this. Here we report on stratigraphically associated Late Middle Pleistocene artefacts and fossils from fluvial and lake margin sandstones of the Upper Herto Member of the Bouri Formation, Middle Awash, Afar Rift, Ethiopia. The fossils and artefacts are dated between 160,000 and 154,000 years ago by precise age determinations using the 40Ar/39Ar method. The archaeological assemblages contain elements of both Acheulean and Middle Stone Age technocomplexes. Associated faunal remains indicate repeated, systematic butchery of hippopotamus carcasses. Contemporary adult and juvenile Homo sapiens fossil crania manifest bone modifications indicative of deliberate mortuary practices.	Univ Calif Berkeley, Museum Vertebrate Zool, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Museum Vertebrate Zool, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Anthropol, Berkeley, CA 94720 USA; Author Res & Conservat Cultural Heritage, Dept Anthropol & Archaeol, Addis Ababa, Ethiopia; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Miami Univ, Dept Geol, Oxford, OH 45056 USA; Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Fac Med, Lab Anthropol, CNRS, UMR 6569, F-13916 Marseille 20, France; Univ Tokyo, Univ Museum, Bunkyo Ku, Tokyo 1130033, Japan; Hyogo Museum Nat & Human Act, Sanda 6691546, Japan; Univ Poitiers, CNRS, UMR 6046, Poitiers, France; Rift Valley Res Serv, Addis Ababa, Ethiopia	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Los Alamos National Laboratory; University System of Ohio; Miami University; Berkeley Geochronolgy Center; University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	White, TD (corresponding author), Univ Calif Berkeley, Museum Vertebrate Zool, Dept Integrat Biol, Berkeley, CA 94720 USA.	timwhite@socrates.berkeley.edu		Renne, Paul/0000-0003-1769-5235				Asfaw B, 1999, SCIENCE, V284, P629, DOI 10.1126/science.284.5414.629; Asfaw B, 2002, NATURE, V416, P317, DOI 10.1038/416317a; Chavaillon J., 1979, Quaternaria, V21, P87; CLARK JD, 1999, HOMINID EVOLUTION LI, P277; Clarke Julia A., 2001, American Museum Novitates, P1; DEHEINZELIN J, 2000, ACHEULEAN PLIOPLEIST, V104; HOURS F, 1976, P PAN C PREH QUAT ST, P99; Howell FC, 1999, J ANTHROPOL RES, V55, P191, DOI 10.1086/jar.55.2.3631209; Katoh S., 1996, P GEN M ASS JPN GEOG, V49, P208; Pickering TR, 2000, AM J PHYS ANTHROPOL, V111, P579, DOI 10.1002/(SICI)1096-8644(200004)111:4<579::AID-AJPA12>3.0.CO;2-Y; Stringer CB, 2001, GEOL SOC SPEC PUBL, V190, P265, DOI 10.1144/GSL.SP.2001.190.01.18; Tryon CA, 2002, J HUM EVOL, V42, P211, DOI 10.1006/jhev.2001.0513; White T.D., 1992, PREHISTORIC CANNIBAL; White TD, 2003, NATURE, V423, P742, DOI 10.1038/nature01669; WHITE TD, 1991, CURR ANTHROPOL, V32, P118, DOI 10.1086/203931; WHITE TD, 2000, AM J PHYS ANTHROPOL, V69, P503	16	237	249	0	45	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					747	752		10.1038/nature01670	http://dx.doi.org/10.1038/nature01670			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	688PA	12802333				2022-12-28	WOS:000183443400042
J	Goldman, DP; Berry, SH; McCabe, MS; Kilgore, ML; Potosky, AL; Schoenbaum, ML; Schonlau, M; Weeks, JC; Kaplan, R; Escarce, JJ				Goldman, DP; Berry, SH; McCabe, MS; Kilgore, ML; Potosky, AL; Schoenbaum, ML; Schonlau, M; Weeks, JC; Kaplan, R; Escarce, JJ			Incremental treatment costs in National Cancer Institute-sponsored clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; MEDICAL ONCOLOGISTS; BARRIERS; CARE; CHEMOTHERAPY; MULTICENTER; KNOWLEDGE; ATTITUDES	Context Concern about additional costs for direct patient care impedes efforts to enroll patients in clinical trials. But generalizable evidence substantiating these concerns is lacking. Objective To assess the additional cost of treating cancer patients in the National Cancer Institute (NCI)-sponsored clinical trials in the United States across a range of trial phases, treatment modalities, and patient care settings. Design Retrospective cost study using a multistage, stratified, random sample of patients enrolled in 1 of 35 active phase 3 trials or phase 1 or any phase 2 trials between October 1, 1998, and December 31, 1999. Unadjusted and adjusted costs were compared and related to trial phase, institution type, and vital status. Setting and Participants A representative sample of 932 cancer patients enrolled in nonpediatric, NCI-sponsored clinical trials and 696 nonparticipants with a similar stage of disease not enrolled in a research protocol from 83 cancer clinical research institutions across the United States. Main Outcome Measures Direct treatment costs as measured using a combination of medical records, telephone survey, and Medicare claims data. Administrative and other research costs were excluded. Results The incremental costs of direct care in trials were modest. Over approximately a 2.5-year period, adjusted costs were 6.5% higher for trial participants than nonparticipants ($35418 vs $33248; P=.11). Cost differences for phase 3 studies were 3.5% (P=.22), lower than for phase 1 or 2 trials (12.8%; P=.20). Trial participants who died had higher costs than nonparticipants who died (17.9%; $39420 vs $33432, respectively; P=15). Conclusions Treatment costs for nonpediatric clinical trial participants are on average 6.5% higher than what they would be if patients did not enroll. This implies total incremental treatment costs for NCI-sponsored trials of $16 million in 1999. Incremental costs were higher for patients who died and who were in early phase studies although these findings deserve further scrutiny. Overall, the additional treatment costs of an open reimbursement policy for government-sponsored cancer clinical trials appear minimal.	RAND Corp, Hlth, Santa Monica, CA 90407 USA; RAND Corp, Stat, Santa Monica, CA 90407 USA; NCI, Off Educ & Special Initiat, Div Canc Control & Populat Sci, Washington, DC USA; NCI, Clin Invest Branch, Natl Canc Therapy Evaluat Program, Washington, DC USA; Univ Alabama, Dept Hlth Care Org & Policy, Birmingham, AL USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA	RAND Corporation; RAND Corporation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Goldman, DP (corresponding author), RAND Corp, Hlth, 1700 Main St, Santa Monica, CA 90407 USA.		Goldman, Dana P/E-7667-2013; Schoenbaum, Michael/GRR-3988-2022	Goldman, Dana P/0000-0001-8498-6396; Kaplan, Richard S./0000-0002-0189-8348				Aaron HJ., 2000, EXTENDING MEDICARE R; BENSON AB, 1991, J CLIN ONCOL, V9, P2067, DOI 10.1200/JCO.1991.9.11.2067; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; Brown ML, 2002, MED CARE, V40, P104; Brown ML, 1999, J NATL CANCER I, V91, P818, DOI 10.1093/jnci/91.10.818; Chirikos TN, 2001, MED CARE, V39, P373, DOI 10.1097/00005650-200104000-00008; Cochran W.G., 2007, SAMPLING TECHNIQUES; Fireman BH, 2000, J NATL CANCER I, V92, P136, DOI 10.1093/jnci/92.2.136; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FLEMING ID, 1994, CANCER, V74, P2662, DOI 10.1002/1097-0142(19941101)74:9+<2662::AID-CNCR2820741813>3.0.CO;2-3; GLICKSMAN AS, 1996, STRATEGIES EVALUATIN; Goldman DP, 2001, J CLIN ONCOL, V19, P105, DOI 10.1200/JCO.2001.19.1.105; GOLDMAN DP, 2000, RAND PUBLICATION; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; Lara PN, 2001, J CLIN ONCOL, V19, P1728, DOI 10.1200/JCO.2001.19.6.1728; Manning WG, 1998, J HEALTH ECON, V17, P283, DOI 10.1016/S0167-6296(98)00025-3; MANSOUR EG, 1994, CANCER, V74, P2672, DOI 10.1002/1097-0142(19941101)74:9+<2672::AID-CNCR2820741815>3.0.CO;2-X; Martin Joseph B, 2002, Trans Am Clin Climatol Assoc, V113, P227; Paller MS, 2002, ACAD MED, V77, P1201, DOI 10.1097/00001888-200212000-00008; Perez EA, 1998, J CLIN ONCOL, V16, P754, DOI 10.1200/JCO.1998.16.2.754; POTOSKY AL, 1993, MED CARE, V31, P732; QUIRK J, 2000, ANN M AM SOC CLIN ON; Roche K, 2002, J CLIN ONCOL, V20, P545, DOI 10.1200/JCO.20.2.545; SCHAIN WS, 1994, CANCER, V74, P2666, DOI 10.1002/1097-0142(19941101)74:9+<2666::AID-CNCR2820741814>3.0.CO;2-P; SCHOENBAUM M, 2001, HLTH SERV OUTCOMES R, V2, P67; Siminoff LA, 2000, MED CARE, V38, P696, DOI 10.1097/00005650-200007000-00002; Siminoff LA, 2000, J CLIN ONCOL, V18, P1203, DOI 10.1200/JCO.2000.18.6.1203; Simon MS, 1999, AM J CLIN ONCOL-CANC, V22, P42, DOI 10.1097/00000421-199902000-00011; STINSON TJ, 2000, ANN M AM SOC CLIN ON; US General Accounting Office, 1999, US GEN ACC OFF PUBL; Wagner JL, 1999, JNCI-J NATL CANCER I, V91, P847, DOI 10.1093/jnci/91.10.847; 2002, FED REG          DEC, V76, P236	34	56	56	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2003	289	22					2970	2977		10.1001/jama.289.22.2970	http://dx.doi.org/10.1001/jama.289.22.2970			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687XZ	12799405	Bronze			2022-12-28	WOS:000183403400020
J	Girardin, SE; Boneca, IG; Carneiro, LAM; Antignac, A; Jehanno, M; Viala, J; Tedin, K; Taha, MK; Labigne, A; Zahringer, U; Coyle, AJ; Bertin, J; Sansonetti, PJ; Philpott, DJ				Girardin, SE; Boneca, IG; Carneiro, LAM; Antignac, A; Jehanno, M; Viala, J; Tedin, K; Taha, MK; Labigne, A; Zahringer, U; Coyle, AJ; Bertin, J; Sansonetti, PJ; Philpott, DJ			Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan	SCIENCE			English	Article							NF-KAPPA-B; RECOGNITION PROTEIN; IMMUNE-RESPONSES; ESCHERICHIA-COLI; CROHNS-DISEASE; FAMILY MEMBER; DROSOPHILA; INNATE; TOLL; ACTIVATION	Although the role of Toll-like receptors in extracellular bacterial sensing has been investigated intensively, intracellular detection of bacteria through Nod molecules remains largely uncharacterized. Here, we show that human Nod1 specifically detects a unique diaminopimelate-containing N-acetylglucosamine-N-acetylmuramic acid (GlcNAc-MurNAc) tripeptide motif found in Gram-negative bacterial peptidoglycan, resulting in activation of the transcription factor NF-kappaB pathway. Moreover, we show that in epithelial cells (which represent the first line of defense against invasive pathogens), Nod1 is indispensable for intracellular Gram-negative bacterial sensing.	Inst Pasteur, Unite Neisseria, F-75724 Paris 15, France; Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France; Inst Pasteur, Grp Immunite Innee & Signalisat, F-75724 Paris 15, France; Free Univ Berlin, Inst Mikrobiol & Tierseuchen, D-10115 Berlin, Germany; Res Ctr Borstel, Div Immunochem, Ctr Med & Biosci, D-23845 Borstel, Germany; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Free University of Berlin; Forschungszentrum Borstel; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Philpott, DJ (corresponding author), Inst Pasteur, Unite Neisseria, 28 Rue Dr Roux, F-75724 Paris 15, France.		Boneca, Ivo G/H-1677-2014; Carneiro, Leticia/T-8978-2019	Boneca, Ivo G/0000-0001-8122-509X; Carneiro, Leticia/0000-0001-5870-8288; Tedin, Karsten/0000-0003-2109-0730				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Blackburn NT, 2001, J MOL EVOL, V52, P78, DOI 10.1007/s002390010136; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; Eckmann L, 2000, J BIOL CHEM, V275, P14084, DOI 10.1074/jbc.275.19.14084; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HOLTJE J, 1988, MICROBIOL MOL BIOL R, V62, P181; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; McLaughlan AM, 1998, MICROBIOL-SGM, V144, P1359, DOI 10.1099/00221287-144-5-1359; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; PEDRON T, UNPUB; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735	30	1156	1214	3	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1584	1587		10.1126/science.1084677	http://dx.doi.org/10.1126/science.1084677			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791997				2022-12-28	WOS:000183333100059
J	Paelinck, B; Dendale, PA				Paelinck, B; Dendale, PA			Cardiac tamponade in Dressler's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Antwerp Hosp, B-2650 Edegem, Belgium	University of Antwerp	Paelinck, B (corresponding author), Univ Antwerp Hosp, B-2650 Edegem, Belgium.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					E8	E8		10.1056/ENEJMicm020006	http://dx.doi.org/10.1056/ENEJMicm020006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12789012				2022-12-28	WOS:000183296300009
J	Wilcken, B; Wiley, V; Hammond, J; Carpenter, K				Wilcken, B; Wiley, V; Hammond, J; Carpenter, K			Screening newborns for inborn errors of metabolism by tandem mass spectrometry	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							A DEHYDROGENASE-DEFICIENCY; DRIED-BLOOD SPOTS; CYSTIC-FIBROSIS; DIAGNOSIS	BACKGROUND: The recent development of electrospray tandem mass spectrometry makes it possible to screen newborns for many rare inborn errors of metabolism, but the efficacy and outcomes of screening remain unknown. We examined the effect of the screening of newborns by tandem mass spectrometry on the rates of diagnosis of 31 disorders. METHODS: We compared the rates of detection of 31 inborn errors affecting the metabolism of the urea cycle, amino acids, and organic acids and fatty-acid oxidation among 362,000 newborns screened by tandem mass spectrometry over a four-year period (April 1998 through March 2002) with the rates in six preceding four-year birth cohorts in New South Wales and the Australian Capital Territory, Australia, where screening, diagnostic, and clinical services were centralized. RESULTS: The overall prevalence of disorders during the periods when clinical diagnosis was used did not vary between 1982 and 1998. In the cohort screened with tandem mass spectrometry, the prevalence of inborn errors, excluding phenylketonuria, was 15.7 per 100,000 births (95 percent confidence interval, 11.9 to 20.4), as compared with adjusted rates of 8.6 to 9.5 per 100,000 births in the four preceding four-year cohorts. Of the 57 cases diagnosed after the introduction of newborn screening, 15 were diagnosed clinically; 7 of the 15 newborns had a normal result on screening. The rate of detection was increased specifically for medium-chain acyl-coenzyme A dehydrogenase deficiency (P<0.001) and other disorders of fatty-acid oxidation (P=0.007), as compared with the 16-year period before the implementation of neonatal screening for these disorders. CONCLUSIONS: More cases of inborn errors of metabolism are diagnosed by screening with tandem mass spectrometry than are diagnosed clinically. It is not yet clear which patients with disorders diagnosed by such screening would have become symptomatic if screening had not been performed.	New S Wales Newborn Screening Programme, Sydney, NSW, Australia; New S Wales Biochem Genet Serv, Sydney, NSW, Australia; Childrens Hosp Westmead, Sydney, NSW, Australia; Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Wilcken, B (corresponding author), Childrens Hosp Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.	bridgetw@chw.edu.au						ALBERS S, 2001, PEDIATRICS, V107, P1417; Andresen B. S., 2000, Journal of Inherited Metabolic Disease, V23, P12; Carpenter K, 2001, ARCH DIS CHILD-FETAL, V85, pF105, DOI 10.1136/fn.85.2.F105; Chace DH, 2001, CLIN CHEM, V47, P2040; CHATFIELD S, 1991, ARCH DIS CHILD-FETAL, V66, P29, DOI 10.1136/adc.66.1_Spec_No.29; Dean A.G., 1994, EPI INFO VERSION 6 W; Farrell PM, 2001, PEDIATRICS, V107, P1, DOI 10.1542/peds.107.1.1; Gibson KM, 1998, J PEDIATR-US, V132, P519, DOI 10.1016/S0022-3476(98)70032-0; HEPTINSTALL LE, 1995, J INHERIT METAB DIS, V18, P638, DOI 10.1007/BF02436011; IAFOLLA AK, 1994, J PEDIATR-US, V124, P409, DOI 10.1016/S0022-3476(94)70363-9; LEES CM, 2000, COCHRANE DB SYST REV, V2; LEUNG KC, 1992, J PEDIATR-US, V121, P965, DOI 10.1016/S0022-3476(05)80353-1; Marshall E, 2002, SCIENCE, V295, P2370; Marshall E, 2001, SCIENCE, V294, P2272, DOI 10.1126/science.294.5550.2272; Peterschmitt MJ, 1999, NEW ENGL J MED, V341, P1572, DOI 10.1056/NEJM199911183412103; Pourfarzam M, 2001, LANCET, V358, P1063, DOI 10.1016/S0140-6736(01)06199-2; Ranieri E., 2000, Journal of Inherited Metabolic Disease, V23, P3; Rhead W. J., 2002, Journal of Inherited Metabolic Disease, V25, P4; Roscher A., 2000, Journal of Inherited Metabolic Disease, V23, P4; Schulze A, 2001, CLIN CHEM, V47, P1424; *US C OFF TECHN AS, 1988, PUBL US C; Wilcken B, 2001, J INHERIT METAB DIS, V24, P291, DOI 10.1023/A:1010387522195; Wilcken B, 2001, J PEDIATR-US, V138, P581, DOI 10.1067/mpd.2001.111813; Wilcken Bridget, 2000, Journal of Inherited Metabolic Disease, V23, P4; Wiley V, 1999, ACTA PAEDIATR, V88, P48, DOI 10.1080/080352599750029376; Wood JC, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e19; Zytkovicz TH, 2001, CLIN CHEM, V47, P1945	27	468	507	3	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2304	2312		10.1056/NEJMoa025225	http://dx.doi.org/10.1056/NEJMoa025225			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788994				2022-12-28	WOS:000183296300005
J	Smith, R				Smith, R			Medical journals and pharmaceutical companies: uneasy bedfellows	BRITISH MEDICAL JOURNAL			English	Article							QUALITY; TRIALS		BMJ, London WC1H 9JR, England		Smith, R (corresponding author), BMJ, London WC1H 9JR, England.			Smith, Richard/0000-0001-9634-2918				Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; Davidoff F, 2001, LANCET, V358, P854, DOI 10.1016/S0140-6736(01)06035-4; Egger M, 2001, BRIT MED J, V323, P1253, DOI 10.1136/bmj.323.7323.1253a; GOTTLIEB S, 2002, BRIT MED J, V325, P137; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Villanueva P, 2003, LANCET, V361, P27, DOI 10.1016/S0140-6736(03)12118-6; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912	8	85	94	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2003	326	7400					1202	1205		10.1136/bmj.326.7400.1202	http://dx.doi.org/10.1136/bmj.326.7400.1202			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775625	Green Published			2022-12-28	WOS:000183309900027
J	McKay, L; Clery, H; Carrick-Anderson, K; Hollis, S; Scott, G				McKay, L; Clery, H; Carrick-Anderson, K; Hollis, S; Scott, G			Genital Chlamydia trachomatis infection in a subgroup of young men in the UK	LANCET			English	Article							PREVALENCE	The frequency of genital Chlamydia trachomads infection in young men in the UK has been found to be consistently lower than that in young women, but studies In such populations might have been affected by selection bias. We tested 798 male military recruits for chlamydia as part of their routine medical examination at Glencorse barracks in Scotland. 78 (9.8%) men were infected with chlamydia; rates of infection were similar in all age-groups. 69 (88%) chlamydia-positive men were asymptomatic. This rate is higher than those usually cited, showing the importance of opportunistic testing for chlamydia in men as well as in women.	Royal Infirm, Dept Genitourinary Med, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh	Scott, G (corresponding author), Royal Infirm, Dept Genitourinary Med, Lauriston Pl, Edinburgh EH3 9YW, Midlothian, Scotland.							Fenton KA, 2001, LANCET, V358, P1851, DOI 10.1016/S0140-6736(01)06886-6; Pierpoint T, 2000, SEX TRANSM INFECT, V76, P273, DOI 10.1136/sti.76.4.273; Rogstad KE, 2001, SEX TRANSM INFECT, V77, P111, DOI 10.1136/sti.77.2.111; *UK DEP HLTH, 1998, SUMM CONCL CMOS EXP; Van der Pol B, 2000, J CLIN MICROBIOL, V38, P1105, DOI 10.1128/JCM.38.3.1105-1112.2000	5	27	27	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1792	1792		10.1016/S0140-6736(03)13398-3	http://dx.doi.org/10.1016/S0140-6736(03)13398-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781541				2022-12-28	WOS:000183074800014
J	van Santbrink, H; Hamer, PCD				van Santbrink, H; Hamer, PCD			Spinal AV malformation	LANCET			English	Editorial Material									Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	van Santbrink, H (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		De Witt Hamer, Philip/E-7630-2013	De Witt Hamer, Philip/0000-0003-2988-8544					0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1766	1766		10.1016/S0140-6736(03)13411-3	http://dx.doi.org/10.1016/S0140-6736(03)13411-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781534				2022-12-28	WOS:000183074800007
J	Christensen, PR; Bandfield, JL; Bell, JF; Gorelick, N; Hamilton, VE; Ivanov, A; Jakosky, BM; Kieffer, HH; Lane, MD; Jakosky, BM; Kieffer, HH; Lane, MD; Malin, MC; McConnochie, T; McEwen, AS; McSween, HY; Mehall, GL; Moersch, JE; Nealson, KH; Rice, JW; Richardson, MI; Ruff, SW; Smith, MD; Titus, TN; Wyatt, MB				Christensen, PR; Bandfield, JL; Bell, JF; Gorelick, N; Hamilton, VE; Ivanov, A; Jakosky, BM; Kieffer, HH; Lane, MD; Jakosky, BM; Kieffer, HH; Lane, MD; Malin, MC; McConnochie, T; McEwen, AS; McSween, HY; Mehall, GL; Moersch, JE; Nealson, KH; Rice, JW; Richardson, MI; Ruff, SW; Smith, MD; Titus, TN; Wyatt, MB			Morphology and composition of the surface of Mars: Mars Odyssey THEMIS results	SCIENCE			English	Article							THERMAL INERTIA; MARTIAN SURFACE; WHITE ROCK; ORIGIN; SOIL	The Thermal Emission Imaging System (THEMIS) on Mars Odyssey has produced infrared to visible wavelength images of the martian surface that show lithologically distinct layers with variable thickness, implying temporal changes in the processes or environments during or after their formation. Kilometer-scale exposures of bedrockare observed; elsewhere airfall dust completely mantles the surface over thousands of square kilometers. Mars has compositional variations at 100-meter scales, for example, an exposure of olivine-rich basalt in the walls of Ganges Chasma. Thermally distinct ejecta facies occur around some craters with variations associated with crater age. Polar observations have identified temporal patches of water frost in the north polar cap. No thermal signatures associated with endogenic heat sources have been identified.	Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Colorado, LASP, Boulder, CO 80309 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Planetary Sci Inst, Phoenix, AZ 85032 USA; Malin Space Sci Syst, San Diego, CA 92191 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Univ Tennessee, Dept Geol Sci, Knoxville, TN 37996 USA; Univ So Calif, Los Angeles, CA 90089 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	Arizona State University; Arizona State University-Tempe; Cornell University; University of Hawaii System; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Colorado System; University of Colorado Boulder; United States Department of the Interior; United States Geological Survey; University of Arizona; University of Tennessee System; University of Tennessee Knoxville; University of Southern California; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Christensen, PR (corresponding author), Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA.	phil.christensen@asu.edu	Ivanov, Anton B/C-8944-2014; Smith, Michael/C-8875-2012; Moersch, Jeffrey E/F-7189-2010	Ivanov, Anton B/0000-0001-8376-8581; Moersch, Jeffrey E/0000-0003-3433-9419; Gorelick, Noel/0000-0002-5548-2436; Bandfield, Joshua/0000-0003-3571-3716; Richardson, Mark/0000-0001-9633-4141				ARVIDSON RE, IN PRESS J GEOPHYS R; Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; Bandfield JL, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2004JE002290; Bell JF, 2000, J GEOPHYS RES-PLANET, V105, P1721, DOI 10.1029/1999JE001060; Burr DM, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013345; CARR MH, 1977, J GEOPHYS RES, V91, P3533; Christensen, 1992, MARS, P686; Christensen PR, 2001, J GEOPHYS RES-PLANET, V106, P23873, DOI 10.1029/2000JE001415; Christensen PR, 2000, J GEOPHYS RES-PLANET, V105, P9609, DOI 10.1029/1999JE001127; CHRISTENSEN PR, 1986, ICARUS, V68, P217, DOI 10.1016/0019-1035(86)90020-5; CHRISTENSEN PR, IN PRESS SPACE SCI R; GILLESPIE AR, 1986, REMOTE SENS ENVIRON, V20, P209, DOI 10.1016/0034-4257(86)90044-1; Jakosky BM, 2000, J GEOPHYS RES-PLANET, V105, P9643, DOI 10.1029/1999JE001088; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; KIEFFER HH, 1976, SCIENCE, V194, P1344, DOI 10.1126/science.194.4271.1344; Lane MD, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001832; Malin MC, 2000, SCIENCE, V290, P1927, DOI 10.1126/science.290.5498.1927; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; McSween HY, 1999, J GEOPHYS RES-PLANET, V104, P8679, DOI 10.1029/98JE02551; Mellon MT, 2000, ICARUS, V148, P437, DOI 10.1006/icar.2000.6503; MOUGINISMARK P, 1979, J GEOPHYS RES, V84, P8011, DOI 10.1029/JB084iB14p08011; PALLUCONI FD, 1981, ICARUS, V45, P415, DOI 10.1016/0019-1035(81)90044-0; Presley MA, 1997, J GEOPHYS RES-PLANET, V102, P6551, DOI 10.1029/96JE03303; Ruff SW, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001580; Ruff SW, 2001, J GEOPHYS RES-PLANET, V106, P23921, DOI 10.1029/2000JE001329; Shorthill R. W., 1973, Moon, V7, P22, DOI 10.1007/BF00578805; Sullivan R, 2001, J GEOPHYS RES-PLANET, V106, P23607, DOI 10.1029/2000JE001296; Titus TN, 2003, SCIENCE, V299, P1048, DOI 10.1126/science.1080497; Treiman AH, 1997, J GEOPHYS RES-PLANET, V102, P9153, DOI 10.1029/96JE03884; WILLIAMS SH, 1994, GEOLOGY, V22, P107, DOI 10.1130/0091-7613(1994)022<0107:WRAEML>2.3.CO;2	30	285	288	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2056	2061		10.1126/science.1080885	http://dx.doi.org/10.1126/science.1080885			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12791998				2022-12-28	WOS:000183774900036
J	Brignall, H				Brignall, H			'You matter to the last moment of your life'	BRITISH MEDICAL JOURNAL			English	Article									St Anns Hospice, Manchester, Lancs, England		Brignall, H (corresponding author), St Anns Hospice, Manchester, Lancs, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1335	1335		10.1136/bmj.326.7402.1335	http://dx.doi.org/10.1136/bmj.326.7402.1335			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805195	Green Published			2022-12-28	WOS:000183626500060
J	Essex, C				Essex, C			'Copying letters to patients is coming to a clinic near you'	BRITISH MEDICAL JOURNAL			English	Article									Gulson Hosp, Child Dev Unit, Coventry, W Midlands, England		Essex, C (corresponding author), Gulson Hosp, Child Dev Unit, Coventry, W Midlands, England.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1330	1331		10.1136/bmj.326.7402.1330	http://dx.doi.org/10.1136/bmj.326.7402.1330			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805191	Green Published			2022-12-28	WOS:000183626500056
J	Fulton, JE; Delany, ME				Fulton, JE; Delany, ME			Poultry genetic resources - Operation rescue needed	SCIENCE			English	Editorial Material							FUTURE		Hy Line Int, Dallas Ctr, Dallas Ctr, IA 50063 USA; Univ Calif Davis, Dept Anim Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Fulton, JE (corresponding author), Hy Line Int, Dallas Ctr, Dallas Ctr, IA 50063 USA.	medelany@ucdavis.edu						ABPLANALP H, 1990, IMMUNOGENETICS, V31, P291, DOI 10.1007/BF02115002; AUSTIN LM, 1995, AM J PATHOL, V146, P1529; Bacon LD, 2000, POULTRY SCI, V79, P1082, DOI 10.1093/ps/79.8.1082; Beck MM, 1998, POULTRY SCI, V77, P226, DOI 10.1093/ps/77.2.226; BRILLARD JP, COMMUNICATION; Chalah T, 1999, CRYOBIOLOGY, V39, P185, DOI 10.1006/cryo.1999.2201; Chang Il-Kuk, 1998, Japanese Poultry Science, V35, P321; Cheng K. S., COMMUNICATION; CHENG KM, 2003, STRATEGIC OPERATIONA; COEHLO CND, 1991, DEVELOPMENT, V113, P1487; Delany ME, 1998, POULT AVIAN BIOL REV, V9, P25; DELANY ME, 2003, POULTRY GENETICS BRE; ERF GF, 2002, MODERN CONCEPTS IMMU, P316; *FAO UN, WORLD WATCH LIST DOM; FITE KV, 1989, CURR EYE RES, V8, P1039, DOI 10.3109/02713688908997396; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Li ZD, 2002, POULTRY SCI, V81, P1360, DOI 10.1093/ps/81.9.1360; PETITTE JN, 2003, POULTRY GENETICS BRE; PISENTI JM, 1999, AVIAN GENETIC RESOUR; Punnett R. C, 1923, HEREDITY POULTRY HEREDITY POULTRY; SOMES RG, 1988, B STORRS AGR EXPT ST, V476; Weigend S, 2002, WORLD POULTRY SCI J, V58, P411, DOI 10.1079/WPS20020031; Wentworth AL, 2000, AVIAN POULT BIOL REV, V11, P173	23	48	50	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1667	1668		10.1126/science.1085407	http://dx.doi.org/10.1126/science.1085407			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805523				2022-12-28	WOS:000183459700024
J	Simpson, GG; Dijkwel, PP; Quesada, V; Henderson, I; Dean, C				Simpson, GG; Dijkwel, PP; Quesada, V; Henderson, I; Dean, C			FY is an RNA 3 ' end-processing factor that interacts with FCA to control the Arabidopsis floral transition	CELL			English	Article							LATE-FLOWERING MUTANTS; DROSOPHILA-MELANOGASTER; REPEAT PROTEIN; DOMAIN; GENE; RECOGNITION; COMPLEX; TIME; MECHANISM; THALIANA	The nuclear RNA binding protein, FCA, promotes Arabidopsis reproductive development. FCA contains a WW protein interaction domain that is essential for FCA function. We have identified FY as a protein partner for this domain. FY belongs to a highly conserved group of eukaryotic proteins represented in Saccharomyces cerevisiae by the RNA 3' end-processing factor, Pfs2p. FY regulates RNA 3' end processing in Arabidopsis as evidenced through its role in FCA regulation. FCA expression is autoregulated through the use of different polyadenylation sites within the FCA pre-mRNA, and the FCA/FY interaction is required for efficient selection of the promoter-proximal polyadenylation site. The FCA/FY interaction is also required for the downregulation of the floral repressor FLC. We propose that FCA controls 3' end formation of specific transcripts and that in higher eukaryotes, proteins homologous to FY may have evolved as sites of association for regulators of RNA 3' end processing.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dean, C (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England.		Dijkwel, P/J-5515-2013	Dijkwel, P/0000-0002-1432-2209; quesada, victor/0000-0002-0965-8680; Henderson, Ian/0000-0001-5066-1489				Barabino SML, 1999, CELL, V99, P9, DOI 10.1016/S0092-8674(00)80057-4; Beaudoing E, 2001, GENOME RES, V11, P1520, DOI 10.1101/gr.190501; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Braun DM, 1997, PLANT J, V12, P83, DOI 10.1046/j.1365-313X.1997.12010083.x; Brogna S, 1997, EMBO J, V16, P2023, DOI 10.1093/emboj/16.8.2023; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Harlow E., 1988, ANTIBODIES LAB MANUA; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Ito S, 2001, BIOCHEM BIOPH RES CO, V280, P656, DOI 10.1006/bbrc.2000.4163; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; Juge F, 2000, RNA, V6, P1529, DOI 10.1017/S1355838200001266; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; KOORNNEEF M, 1994, PLANT J, V6, P911, DOI 10.1046/j.1365-313X.1994.6060911.x; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, GENETICS, V148, P885; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; Lorkovic ZJ, 2002, NUCLEIC ACIDS RES, V30, P623, DOI 10.1093/nar/30.3.623; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Macknight R, 2002, PLANT CELL, V14, P877, DOI 10.1105/tpc.010456; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Michaels SD, 2001, PLANT CELL, V13, P935, DOI 10.1105/tpc.13.4.935; MITCHELSON A, 1993, GENE DEV, V7, P241, DOI 10.1101/gad.7.2.241; Mouradov A, 2002, PLANT CELL, V14, pS111, DOI 10.1105/tpc.001362; Mylne J, 1998, PLANT MOL BIOL REP, V16, P257, DOI 10.1023/A:1007520410190; Ohnacker M, 2000, EMBO J, V19, P37, DOI 10.1093/emboj/19.1.37; Quesada V, 2003, EMBO J, V22, P3142, DOI 10.1093/emboj/cdg305; Schomburg FM, 2001, PLANT CELL, V13, P1427, DOI 10.1105/tpc.13.6.1427; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	39	308	343	3	51	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 13	2003	113	6					777	787		10.1016/S0092-8674(03)00425-2	http://dx.doi.org/10.1016/S0092-8674(03)00425-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	689VV	12809608	Bronze			2022-12-28	WOS:000183514400012
J	Wooster, R; Weber, BL				Wooster, R; Weber, BL			Breast and ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GENE-EXPRESSION PROFILES; BRCA2 MUTATION CARRIERS; SUSCEPTIBILITY GENE; PROPHYLACTIC OOPHORECTOMY; RISK; WOMEN; FAMILIES; LINKAGE; CANDIDATE; SURVIVAL		Wellcome Trust Sanger Inst, Cambridge, England; Univ Penn, Philadelphia, PA 19104 USA	Wellcome Trust Sanger Institute; University of Pennsylvania	Wooster, R (corresponding author), Wellcome Trust Sanger Inst, Cambridge, England.							Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armes JE, 1999, CANCER RES, V59, P2011; BARKARDOTTIR RB, 1995, ACTA ONCOL, V34, P657, DOI 10.3109/02841869509094044; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P952; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843; Figeys D, 1998, ELECTROPHORESIS, V19, P1811, DOI 10.1002/elps.1150191045; FORD D, 1995, AM J HUM GENET, V57, P1457; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; GARBER JE, 1991, CANCER RES, V51, P6094; Gayther SA, 1999, AM J HUM GENET, V65, P1021, DOI 10.1086/302583; Goode EL, 2002, CANCER RES, V62, P3052; Gudmundsson J, 1996, AM J HUM GENET, V58, P749; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; Kudoh K, 2000, CANCER RES, V60, P4161; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; Newman B, 1997, EPIDEMIOL REV, V19, P69, DOI 10.1093/oxfordjournals.epirev.a017948; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rahman N, 2000, ONCOGENE, V19, P4170, DOI 10.1038/sj.onc.1203735; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Sekine M, 2001, HUM MOL GENET, V10, P1421, DOI 10.1093/hmg/10.13.1421; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stoutjesdijk MJ, 2001, JNCI-J NATL CANCER I, V93, P1095, DOI 10.1093/jnci/93.14.1095; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Thompson D, 2002, P NATL ACAD SCI USA, V99, P827, DOI 10.1073/pnas.012584499; Tilanus-Linthorst M, 2002, INT J CANCER, V102, P665, DOI 10.1002/ijc.10838; Tilanus-Linthorst M, 2002, INT J CANCER, V102, P91, DOI 10.1002/ijc.10666; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Warner E, 2001, J CLIN ONCOL, V19, P3524, DOI 10.1200/JCO.2001.19.15.3524; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Wooster R, 1996, NATURE, V379, P749, DOI 10.1038/379749a0; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	58	406	438	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2339	2347		10.1056/NEJMra012284	http://dx.doi.org/10.1056/NEJMra012284			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788999				2022-12-28	WOS:000183296300011
J	Murkofsky, RL; Phillips, RS; McCarthy, EP; Davis, RB; Hamel, MB				Murkofsky, RL; Phillips, RS; McCarthy, EP; Davis, RB; Hamel, MB			Length of stay in home care before and after the 1997 Balanced Budget Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE PAYMENT; FOR-PROFIT; OWNERSHIP; QUALITY; FACILITIES; MORTALITY; SERVICES	Context Prior to 1997, home health agencies (HHAs) were reimbursed on a fee-for-service basis and had incentives to provide more services. The 1997 Balanced Budget Act (BBA) reduced payments for home care services to help control Medicare spending. Objective To examine the length of stay in home care before and after the 1997 BBA. Design and Setting Cross-sectional study of home care patients in the 1996 and 1998 National Home and Hospice Care Surveys, which surveyed 1053 HHAs in 1996 and 1088 HHAs in 1998. Patients Nationally representative random sample of home care patients with Medicare coverage in 1996 (4127 patients) and 1998 (4051 patients). Main Outcome Measure Length of stay in home care (based on the number of days a patient was enrolled in home care services). Results From 1996 to 1998, unadjusted median length of stay decreased by 16 days for all home care patients (60-44 days, P=.002). The decrease affected for-profit HHAs more than not-for-profit HHAs (111-55 days [51% decrease, P=.002] vs 46-36 days [22% decrease, P=.042]). In a Cox proportional hazards model of time to discharge from home care, post-BBA year (1,998) was associated with a shorter length of stay in home care (adjusted hazard ratio [aHR] for home care discharge, 1.39 [95% confidence interval {CI}, 1.19-1.61]), and for-profit status was associated with a longer length of stay in home care (aHR, 0.82 [95% CI, 0.71-0.94]) after adjusting for patient demographics, diagnoses, and functional status. Conclusion After the 1997 BBA, length of stay in home care decreased among Medicare patients, particularly among those receiving care from for-profit HHAs.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gerontol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Murkofsky, RL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gerontol, 1 Deaconess Rd,Palmer 119, Boston, MA 02215 USA.	rmurkofs@bidmc.harvard.edu			NIA NIH HHS [5K12AG00294] Funding Source: Medline; BHP HRSA HHS [5T32PE11001] Funding Source: Medline; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE011001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); BHP HRSA HHS; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FREEMAN L, 1995, MON LABOR REV, V118, P3; Furth SL, 1999, PEDIATRICS, V104, P519, DOI 10.1542/peds.104.3.519; Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; Harrington C, 2001, AM J PUBLIC HEALTH, V91, P1452, DOI 10.2105/AJPH.91.9.1452; Himmelstein DU, 1999, JAMA-J AM MED ASSOC, V282, P159, DOI 10.1001/jama.282.2.159; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kominski G F, 1993, Health Care Financ Rev, V15, P121; McCall N, 2003, HEALTH SERV RES, V38, P85, DOI 10.1111/1475-6773.00106; MENKE T, 1990, INQUIRY-J HEALTH CAR, V27, P114; MULLER A, 1993, MED CARE, V31, P296, DOI 10.1097/00005650-199304000-00002; MUSHLIN AI, 1988, MED CARE, V26, P1081, DOI 10.1097/00005650-198811000-00006; *NAT CTR HLTH STAT, 1998, NAT HOM HOSP CAR SUR; *NAT CTR HLTH STAT, 1996, NAT HOM HOSP CAR SUR; *NAT CTR HLTH STAT, 2002, NAT HOM HOSP CAR SUR; *NAT CTR HLTH STAT, NAT HLTH CAR SURV; SCHEFFLER RM, 1994, MED CARE, V32, P471, DOI 10.1097/00005650-199405000-00006; SCHLESINGER M, 1989, MED CARE, V27, P244, DOI 10.1097/00005650-198903000-00003; Schlesinger M, 1997, MED CARE, V35, P974, DOI 10.1097/00005650-199709000-00009; Shah BV, 1996, SUDAAN USERS MANUAL; Thomas EJ, 2000, J GEN INTERN MED, V15, P211, DOI 10.1046/j.1525-1497.2000.015004211.x; Tu HT, 2002, NEW ENGL J MED, V346, P1288, DOI 10.1056/NEJMsa011250; *US DEP HHS, 1995, OEI049300260 US DEP; *US DEP HHS, 1995, OEI049300262 US DEP; *US DEP HHS, 1997, PUBL US DEP HHS; *US DEP HHS, 2000, PUBL US DEP HHS; *US DEP HHS, 1999, OEI029900530 US DEP; *US GAO, 1997, GAOHEHS97139R US GAO; *US GAO, 1998, MED HOM HLTH BEN IMP; *US GAO, 1996, GAOHEHS9616 US GAO; *US GAO, 2000, GAOHEHS00176 US GAO; *US GAO, 1998, SUBC HLTH COMM WAYS, P1; Yuan Z, 2000, MED CARE, V38, P231, DOI 10.1097/00005650-200002000-00012; 2002, FED REG         0628, V67, P43616; 1995, FED REG         0810, V60, P40847	37	34	34	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2841	2848		10.1001/jama.289.21.2841	http://dx.doi.org/10.1001/jama.289.21.2841			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	684KH	12783915	Bronze			2022-12-28	WOS:000183205500033
J	Rott, KT; Agudelo, CA				Rott, KT; Agudelo, CA			Gout	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SERUM URIC-ACID; CARDIOVASCULAR-DISEASE; MANAGEMENT; RISK		Atlanta Vet Affairs Med Ctr, Div Rheumatol, Atlanta, GA 30033 USA; Emory Univ, Sch Med, Div Rheumatol & Immunol, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Agudelo, CA (corresponding author), Atlanta Vet Affairs Med Ctr, Div Rheumatol, 1670 Clairmont Rd NE, Atlanta, GA 30033 USA.							Agudelo CA, 1998, CLIN GERIATR MED, V14, P495; AGUDELO CA, 1979, ARTHRITIS RHEUM, V22, P559, DOI 10.1002/art.1780220521; Arai M, 2002, J GASTROEN HEPATOL, V17, P625, DOI 10.1046/j.1440-1746.2002.02692.x; Arromdee E, 2002, J RHEUMATOL, V29, P2403; Bomalaski JS, 2002, ARTHRITIS RHEUM-US, V46, pS141; Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; DIEPPE PA, 1991, ANN RHEUM DIS, V50, P263, DOI 10.1136/ard.50.4.263; DOHERTY M, 1986, CLIN RHEUM DIS, V12, P97; Emmerson BT, 1996, NEW ENGL J MED, V334, P445, DOI 10.1056/NEJM199602153340707; Fam AG, 1998, DRUG AGING, V13, P229, DOI 10.2165/00002512-199813030-00006; Fang J, 2000, JAMA-J AM MED ASSOC, V283, P2404, DOI 10.1001/jama.283.18.2404; GONZALEZ EB, 1994, DRUG AGING, V4, P128, DOI 10.2165/00002512-199404020-00005; Holland NW, 1996, J RHEUMATOL, V23, P690; JOHNSON R, 2002, AM COLL RHEUM 66 ANN; Mazzali M, 2001, HYPERTENSION, V38, P1101, DOI 10.1161/hy1101.092839; Pal B, 2000, CLIN RHEUMATOL, V19, P21, DOI 10.1007/s100670050005; TERBORG EJ, 1987, ANN RHEUM DIS, V46, P72, DOI 10.1136/ard.46.1.72; Tomita M, 2000, J Epidemiol, V10, P403; Verdecchia P, 2000, HYPERTENSION, V36, P1072, DOI 10.1161/01.HYP.36.6.1072; Weselman KO, 2001, B RHEUM DIS, V50, P1; Wortmann RL, 2002, CURR OPIN RHEUMATOL, V14, P281, DOI 10.1097/00002281-200205000-00015	21	111	122	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2003	289	21					2857	2860		10.1001/jama.289.21.2857	http://dx.doi.org/10.1001/jama.289.21.2857			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KH	12783917				2022-12-28	WOS:000183205500035
J	Templeton, A				Templeton, A			Varicocele and infertility	LANCET			English	Editorial Material							SPERMATIC VEIN LIGATION		Univ Aberdeen, Aberdeen Matern Hosp, Dept Obstet & Gynecol, Aberdeen AB9 2ZD, Scotland	University of Aberdeen	Templeton, A (corresponding author), Univ Aberdeen, Aberdeen Matern Hosp, Dept Obstet & Gynecol, Aberdeen AB9 2ZD, Scotland.							DUBIN L, 1988, PROGR INFERTILITY, P689; Grasso M, 2000, BJU INT, V85, P305, DOI 10.1046/j.1464-410x.2000.00437.x; MADGAR I, 1995, FERTIL STERIL, V63, P120, DOI 10.1016/S0015-0282(16)57306-3; MORDEL N, 1990, J REPROD MED, V35, P123; NILSSON S, 1979, BRIT J UROL, V51, P591, DOI 10.1111/j.1464-410X.1979.tb03609.x; *ROYAL COLL OBST G, 1998, MAN INF SEC CAR EV B; TULLOCH W S, 1951, Edinb Med J, V59, P29; Unal D, 2001, INT J UROL, V8, P227, DOI 10.1046/j.1442-2042.2001.00289.x	8	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1838	1839		10.1016/S0140-6736(03)13536-2	http://dx.doi.org/10.1016/S0140-6736(03)13536-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788564				2022-12-28	WOS:000183205800002
J	Bogaty, P; Brophy, J				Bogaty, P; Brophy, J			Increasing burden of treatment in the acute coronary syndromes: is it justified?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; CONSERVATIVE STRATEGIES; THROMBOLYSIS; MORTALITY; ASPIRIN		Univ Laval, Quebec Heart Inst, Quebec City, PQ, Canada; McGill Univ, Ctr Hlth, Montreal, PQ, Canada	Laval University; McGill University	Bogaty, P (corresponding author), Hop Laval, Quebec Heart Inst, 2725 Chemin St Foy, Ste Foy, PQ G1V 4G5, Canada.	Peter.Bogaty@med.ulaval.ca	brophy, james/H-6673-2019	brophy, james/0000-0001-8049-6875				ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boersma E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1; BRAUNWALD E, ACC AHA 2002 GUIDELI; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Franzosi MG, 1998, CIRCULATION, V97, P2202, DOI 10.1161/01.CIR.97.22.2202; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Heidenreich PA, 2001, J AM COLL CARDIOL, V38, P478, DOI 10.1016/S0735-1097(01)01388-2; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; Liem AH, 2002, EUR HEART J, V23, P1931, DOI 10.1053/euhj.2002.3291; McPherson K, 2001, QUAL HEALTH CARE, V10, pI61; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Simoons ML, 2001, LANCET, V357, P1915; Topol E, 1998, NEW ENGL J MED, V339, P436; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416; Wallentin L, 1999, LANCET, V354, P708; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2000, NEW ENGL J MED, V342, P145	26	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2003	361	9371					1813	1816		10.1016/S0140-6736(03)13407-1	http://dx.doi.org/10.1016/S0140-6736(03)13407-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781554				2022-12-28	WOS:000183074800024
J	Nicholls, JM; Poon, LLM; Lee, KC; Ng, WF; Lai, ST; Leung, CY; Chu, CM; Hui, PK; Mak, KL; Lim, W; Yan, KW; Chan, KH; Tsang, NC; Guan, Y; Yuen, KY; Peiris, JSM				Nicholls, JM; Poon, LLM; Lee, KC; Ng, WF; Lai, ST; Leung, CY; Chu, CM; Hui, PK; Mak, KL; Lim, W; Yan, KW; Chan, KH; Tsang, NC; Guan, Y; Yuen, KY; Peiris, JSM			Lung pathology of fatal severe acute respiratory syndrome	LANCET			English	Article							CLINICAL-FEATURES; HUMAN MACROPHAGES; CORONAVIRUS; PATHOGENICITY; AMPLIFICATION; PNEUMONIA; VIRUSES	Background Severe acute respiratory syndrome (SARS) is a novel infectious disease with global impact. A virus from the family Coronaviridae has been identified as the cause, but the pathogenesis is still unclear. Methods Post-mortem tissue samples from six patients who died from SARS in February and March, 2003, and an open lung biopsy from one of these patients were studied by histology and virology. Only one full autopsy was done. Evidence of infection with the SARS-associated coronavirus (SARS-CoV) and human metapneumovirus was sought by reverse-transcriptase PCR and serology. Pathological samples were examined by light and electron microscopy and immunohistochemistry. Findings All six patients had serological evidence of recent infection with SARS-CoV. Diffuse alveolar damage was common but not universal. Morphological changes identified were bronchial epithelial denudation, loss of cilia, and squamous metaplasia. Secondary bacterial pneumonia was present in one case. A giant-cell infiltrate was seen in four patients, with a pronounced increase in macrophages in the alveoli and the interstitium of the lung. Haemophagocytosis was present in two patients. The alveolar pneumocytes also showed cytomegaly with granular amphophilic cytoplasm. The patient for whom full autopsy was done had atrophy of the white pulp of the spleen. Electron microscopy revealed viral particles in the cytoplasm of epithelial cells corresponding to coronavirus. Interpretation SARS is associated with epithelial-cell proliferation and an increase in macrophages in the lung. The presence of haemophagocytosis supports the contention that cytokine dysregulation may account, at least partly, for the severity of the clinical disease. The case definition of SARS should acknowledge the range of lung pathology associated with this disease.	Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Pathol & Med, Kowloon, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China; United Christian Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China; United Christian Hosp, Dept Med, Kowloon, Hong Kong, Peoples R China; Kwong Wah Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China; Govt Virus Unit, Kowloon, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Microbiol, Kowloon, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; United Christian Hospital; United Christian Hospital; Kwong Wah Hospital	Peiris, JSM (corresponding author), Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.	malik@hkucc.hku.hk	Poon, Leo Lit Man/C-4382-2009; Yuen, Kwok Yung/C-4465-2009; Poon, Leo/AAP-6887-2020; Chan, Kwok Hung/ABD-5399-2021; Nicholls, John Malcolm/C-4375-2009	Poon, Leo Lit Man/0000-0002-9101-7953; Guan, Yi/0000-0001-6057-9243; Nicholls, John Malcolm/0000-0001-7217-7444; Yuen, Kwok-yung/0000-0002-2083-1552; Chu, Chung Ming/0000-0002-9959-1271	PHS HHS [A195357] Funding Source: Medline; Wellcome Trust Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome TrustEuropean Commission)		Bellingan GJ, 2002, THORAX, V57, P540, DOI 10.1136/thorax.57.6.540; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Collins AR, 1998, ADV EXP MED BIOL, V440, P635; Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002; Fisman DN, 2000, EMERG INFECT DIS, V6, P601, DOI 10.3201/eid0606.000608; Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000; Garantziotis S, 2001, CHEST, V119, P1277, DOI 10.1378/chest.119.4.1277; HALBUR PG, 1993, J VET DIAGN INVEST, V5, P184, DOI 10.1177/104063879300500207; Halbur PG, 2003, VET REC, V152, P358, DOI 10.1136/vr.152.12.358; HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606; Kim EA, 2002, RADIOGRAPHICS, V22, pS137, DOI 10.1148/radiographics.22.suppl_1.g02oc15s137; KSIAZEK TG, IN PRESS N ENGL J ME; Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291; LEE N, IN PRESS N ENGL MED; Mitchell S, 2003, J CLIN VIROL, V26, P331, DOI 10.1016/S1386-6532(02)00082-3; MYERS JL, 1994, PULMONARY PATHOLOGY, P57; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; PENSAERT MB, 1989, VIRUS INFECTIONS POR, P154; POUTANEN SM, IN PRESS N ENGL J ME; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; TSANG KW, IN PRESS N ENGL J ME; *WHO, CUM NUM REP CAS SEV; *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81; *WHO, CAS DEF SURV SEV AC; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	25	766	876	0	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2003	361	9371					1773	1778		10.1016/S0140-6736(03)13413-7	http://dx.doi.org/10.1016/S0140-6736(03)13413-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781536	Bronze, Green Published			2022-12-28	WOS:000183074800009
J	Yildiz, A; Forkey, JN; McKinney, SA; Ha, T; Goldman, YE; Selvin, PR				Yildiz, A; Forkey, JN; McKinney, SA; Ha, T; Goldman, YE; Selvin, PR			Myosin V walks hand-over-hand: Single fluorophore imaging with 1.5-nm localization	SCIENCE			English	Article							FLUORESCENT-PROBES; MOLECULES; MOTOR; ROTATION; MOVEMENT; TRACKING; ACTIN; RESOLUTION; MODEL	Myosin V is a dimeric molecular motor that moves processively on actin, with the center of mass moving similar to37 nanometers for each adenosine triphosphate hydrolyzed. We have labeled myosin V with a single fluorophore at different positions in the light-chain domain and measured the step size with a standard deviation of <1.5 nanometers, with 0.5-second temporal resolution, and observation times of minutes. The step size alternates between 37 + 2x nm and 37 - 2x, where x is the distance along the direction of motion between the dye and the midpoint between the two heads. These results strongly support a hand-over-hand model of motility, not an inchworm model.	Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Pennsylvania	Selvin, PR (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.	selvin@uiuc.edu	Ha, Taekjip/B-9506-2009; Yildiz, Ahmet/E-6167-2015	Ha, Taekjip/0000-0003-2195-6258; Yildiz, Ahmet/0000-0003-4792-174X; McKinney, Sean/0000-0002-9740-6247	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026846, R01AR044420, R29AR044420, R37AR026846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065367] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44420, AR26846] Funding Source: Medline; NIGMS NIH HHS [R01 GM065367, GM65367] Funding Source: Medline; PHPPO CDC HHS [PHS 5 T32 GM08276] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHPPO CDC HHS		Adachi K, 2000, P NATL ACAD SCI USA, V97, P7243, DOI 10.1073/pnas.120174297; Ali MY, 2002, NAT STRUCT BIOL, V9, P464, DOI 10.1038/nsb803; AXELROD D, 1989, METHOD CELL BIOL, V30, P245; Bartko AP, 1999, J PHYS CHEM B, V103, P3053, DOI 10.1021/jp9846330; BOBROFF N, 1986, REV SCI INSTRUM, V57, P1152, DOI 10.1063/1.1138619; Burgess S, 2002, J CELL BIOL, V159, P983, DOI 10.1083/jcb.200208172; Cheezum MK, 2001, BIOPHYS J, V81, P2378, DOI 10.1016/S0006-3495(01)75884-5; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Hua W, 2002, SCIENCE, V295, P844, DOI 10.1126/science.1063089; Kubitscheck U, 2000, BIOPHYS J, V78, P2170, DOI 10.1016/S0006-3495(00)76764-6; Lacoste TD, 2000, P NATL ACAD SCI USA, V97, P9461, DOI 10.1073/pnas.170286097; Mehta A, 2001, J CELL SCI, V114, P1981; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592	30	1426	1487	15	378	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2061	2065		10.1126/science.1084398	http://dx.doi.org/10.1126/science.1084398			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12791999				2022-12-28	WOS:000183774900037
J	Skaletsky, H; Kuroda-Kawaguchi, T; Minx, PJ; Cordum, HS; Hillier, L; Brown, LG; Repping, S; Pyntikova, T; Ali, J; Bieri, T; Chinwalla, A; Delehaunty, A; Delehaunty, K; Du, H; Fewell, G; Fulton, L; Fulton, R; Graves, T; Hou, SF; Latrielle, P; Leonard, S; Mardis, E; Maupin, R; McPherson, J; Miner, T; Nash, W; Nguyen, C; Ozersky, P; Pepin, K; Rock, S; Rohlfing, T; Scott, K; Schultz, B; Strong, C; Tin-Wollam, A; Yang, SP; Waterston, RH; Wilson, RK; Rozen, S; Page, DC				Skaletsky, H; Kuroda-Kawaguchi, T; Minx, PJ; Cordum, HS; Hillier, L; Brown, LG; Repping, S; Pyntikova, T; Ali, J; Bieri, T; Chinwalla, A; Delehaunty, A; Delehaunty, K; Du, H; Fewell, G; Fulton, L; Fulton, R; Graves, T; Hou, SF; Latrielle, P; Leonard, S; Mardis, E; Maupin, R; McPherson, J; Miner, T; Nash, W; Nguyen, C; Ozersky, P; Pepin, K; Rock, S; Rohlfing, T; Scott, K; Schultz, B; Strong, C; Tin-Wollam, A; Yang, SP; Waterston, RH; Wilson, RK; Rozen, S; Page, DC			The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes	NATURE			English	Article							HUMAN X-CHROMOSOME; HUMAN GENOME; SEX-CHROMOSOME; INTRACHROMOSOMAL RECOMBINATION; DROSOPHILA-MELANOGASTER; HUMAN CENTROMERE; GENE CONVERSION; TURNER SYNDROME; SHORT ARM; MAP	The male-specific region of the Y chromosome, the MSY, differentiates the sexes and comprises 95% of the chromosome's length. Here, we report that the MSY is a mosaic of heterochromatic sequences and three classes of euchromatic sequences: X-transposed, X-degenerate and ampliconic. These classes contain all 156 known transcription units, which include 78 protein-coding genes that collectively encode 27 distinct proteins. The X-transposed sequences exhibit 99% identity to the X chromosome. The X-degenerate sequences are remnants of ancient autosomes from which the modern X and Y chromosomes evolved. The ampliconic class includes large regions (about 30% of the MSY euchromatin) where sequence pairs show greater than 99.9% identity, which is maintained by frequent gene conversion (non-reciprocal transfer). The most prominent features here are eight massive palindromes, at least six of which contain testis genes.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, Ctr Reprod Med, NL-1105 AZ Amsterdam, Netherlands	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL); University of Amsterdam; Academic Medical Center Amsterdam	Page, DC (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	page_admin@wi.mit.edu	Wilson, Richard K./AAF-4139-2019; Mardis, Elaine/W-2202-2019; McPherson, John D/D-2633-2017; Rozen, Steven G./J-5939-2013	Wilson, Richard K./0000-0002-1992-1358; McPherson, John D/0000-0001-8049-9347; Chinwalla, Asif/0000-0001-7831-3996; Rozen, Steven G./0000-0002-4288-0056; Schultz, Brian/0000-0003-4964-976X; Repping, Sjoerd/0000-0002-6959-149X				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Blanco P, 2000, J MED GENET, V37, P752, DOI 10.1136/jmg.37.10.752; Carrel L, 1999, P NATL ACAD SCI USA, V96, P14440, DOI 10.1073/pnas.96.25.14440; Carvalho AB, 2001, P NATL ACAD SCI USA, V98, P13225, DOI 10.1073/pnas.231484998; Delbridge ML, 1999, NAT GENET, V22, P223, DOI 10.1038/10279; FERGUSON-SMITH M A, 1965, J Med Genet, V2, P142, DOI 10.1136/jmg.2.2.142; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FORD CE, 1959, LANCET, V1, P711; Graves JAM, 1992, CURR OPIN GENET DEV, V2, P890, DOI 10.1016/S0959-437X(05)80112-1; JACKSON JA, 1981, NATURE, V292, P306, DOI 10.1038/292306a0; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; Jegalian K, 1998, NATURE, V394, P776, DOI 10.1038/29522; Kamp C, 2000, HUM MOL GENET, V9, P2563, DOI 10.1093/hmg/9.17.2563; Kawaguchi TK, 2001, NAT GENET, V29, P279, DOI 10.1038/ng757; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; Lahn BT, 1999, NAT GENET, V21, P429, DOI 10.1038/7771; Lahn BT, 1999, SCIENCE, V286, P964, DOI 10.1126/science.286.5441.964; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mazeyrat S, 1999, NAT GENET, V22, P224, DOI 10.1038/10282; Mumm S, 1997, GENOME RES, V7, P307, DOI 10.1101/gr.7.4.307; Ohno S., 1967, SEX CHROMOSOMES SEX; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; Painter TS, 1921, SCIENCE, V53, P503, DOI 10.1126/science.53.1378.503; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; Repping S, 2002, AM J HUM GENET, V71, P906, DOI 10.1086/342928; Rozen S, 2003, NATURE, V423, P873, DOI 10.1038/nature01723; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Saxena R, 2000, GENOMICS, V67, P256, DOI 10.1006/geno.2000.6260; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; Schueler MG, 2001, SCIENCE, V294, P109, DOI 10.1126/science.1065042; Schweitzer F., 1998, ADV COMPLEX SYST, V1, P11, DOI DOI 10.1142/S021952599800003X; Shen PD, 2000, P NATL ACAD SCI USA, V97, P7354, DOI 10.1073/pnas.97.13.7354; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; STERN C, 1957, AM J HUM GENET, V9, P147; Sun C, 1999, NAT GENET, V23, P429, DOI 10.1038/70539; Sun C, 2000, HUM MOL GENET, V9, P2291, DOI 10.1093/oxfordjournals.hmg.a018920; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tilford CA, 2001, NATURE, V409, P943, DOI 10.1038/35057170; TYLERSMITH C, 1988, J MOL BIOL, V203, P837, DOI 10.1016/0022-2836(88)90110-6; TYLERSMITH C, 1993, NAT GENET, V5, P368, DOI 10.1038/ng1293-368; Underhill PA, 2000, NAT GENET, V26, P358, DOI 10.1038/81685; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vogt PH, 1997, CYTOGENET CELL GENET, V79, P2; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WATSON JM, 1991, P NATL ACAD SCI USA, V88, P11256, DOI 10.1073/pnas.88.24.11256; Yeh RF, 2001, GENOME RES, V11, P803, DOI 10.1101/gr.175701; Zhao S, 2000, GENOMICS, V63, P321, DOI 10.1006/geno.1999.6082; ZINN AR, 1993, TRENDS GENET, V9, P90, DOI 10.1016/0168-9525(93)90230-F	50	1436	1572	2	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					825	U2		10.1038/nature01722	http://dx.doi.org/10.1038/nature01722			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815422	Bronze			2022-12-28	WOS:000183585300035
J	Wolfe, LC; Harris, NL; Weinstein, HJ; Ferry, JA; Ebb, DH; Roberts, AE				Wolfe, LC; Harris, NL; Weinstein, HJ; Ferry, JA; Ebb, DH; Roberts, AE			A five-day-old girl with leukocytosis and a worsening rash from birth - Transient myeloproliferative disorder associated with mosaicism for trisomy 21	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONGENITAL LEUKEMOID REACTION; DOWN-SYNDROME; NORMAL NEWBORN; INFANT		Tufts New England Med Ctr, Floating Childrens Canc Ctr, Div Pediat Hematol Oncol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Pediat, Boston, MA 02111 USA; Massachusetts Gen Hosp Children, Div Pediat Hematol & Oncol, Boston, MA USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Floating Hospital For Children; Tufts Medical Center; Tufts University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wolfe, LC (corresponding author), Tufts New England Med Ctr, Floating Childrens Canc Ctr, Div Pediat Hematol Oncol, Boston, MA 02111 USA.							Al-Kasim F, 2002, J PEDIAT HEMATOL ONC, V24, P9, DOI 10.1097/00043426-200201000-00004; BRODEUR GM, 1980, BLOOD, V55, P691; HANNA MD, 1985, AM J PEDIAT HEMATOL, V7, P79; Holt SE, 2002, J PEDIAT HEMATOL ONC, V24, P14, DOI 10.1097/00043426-200201000-00005; HOMANS AC, 1993, AM J PEDIAT HEMATOL, V15, P392; JACOBS D, 1996, LAB TEST HDB, P153; JAFFE ES, 2001, PATHOLOGY GENETICS T, P101; Lerner LH, 1996, J AM ACAD DERMATOL, V35, P330, DOI 10.1016/S0190-9622(96)90662-3; LIN HP, 1980, AM J DIS CHILD, V134, P939, DOI 10.1001/archpedi.1980.02130220017005; Massey G, 2002, BLOOD, V100, p87A; MIYAUCHI J, 1992, BLOOD, V80, P1521; NATHAN DG, 1993, HEMATOLOGY INFANCY C, P1194; NATHAN DG, 1993, HEMATOLOGY INFANCY C; Nijhawan A, 2001, ARCH DERMATOL, V137, P760; OSKI FA, 1982, HEMATOLOGIC PROBLEMS, P215; RESNIK KS, 1993, ARCH DERMATOL, V129, P1301, DOI 10.1001/archderm.129.10.1301; RIDGWAY D, 1990, AM J DIS CHILD, V144, P1117, DOI 10.1001/archpedi.1990.02150340063024; SEIBEL NL, 1984, J PEDIATR-US, V104, P251, DOI 10.1016/S0022-3476(84)81006-9; Taub JW, 1999, BLOOD, V94, P1393; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEINBERG AG, 1982, AM J DIS CHILD, V136, P310, DOI 10.1001/archpedi.1982.03970400028007; WEINSTEIN HJ, 1978, CLIN HAEMATOL, V7, P147; WHITLEY RJ, 1995, INFECT DIS FETUS NEW, P354; Zipursky A, 1997, SEMIN PERINATOL, V21, P97, DOI 10.1016/S0146-0005(97)80025-0; Zipursky A, 1999, CLIN LAB MED, V19, P157; ZIPURSKY A, 1992, PEDIATR HEMAT ONCOL, V9, P139, DOI 10.3109/08880019209018329	26	12	13	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2003	348	25					2557	2566		10.1056/NEJMcpc030012	http://dx.doi.org/10.1056/NEJMcpc030012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YC	12815142				2022-12-28	WOS:000183577200011
J	Hammond, P				Hammond, P			The whole truth?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1340	1340		10.1136/bmj.326.7402.1340	http://dx.doi.org/10.1136/bmj.326.7402.1340			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805198	Green Published			2022-12-28	WOS:000183626500063
J	Wadsworth, P				Wadsworth, P			Persistence pays	SCIENCE			English	Editorial Material							MICROTUBULE RELEASE; DYNAMIC INSTABILITY		Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Wadsworth, P (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	patw@bio.umass.edu						Abal M, 2002, J CELL BIOL, V159, P731, DOI 10.1083/jcb.200207076; Dhonukshe P, 2003, PLANT CELL, V15, P597, DOI 10.1105/tpc.008961; HUSH JM, 1994, J CELL SCI, V107, P775; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Komarova YA, 2002, J CELL SCI, V115, P3527; Margolis RL, 1998, BIOESSAYS, V20, P830, DOI 10.1002/(SICI)1521-1878(199810)20:10<830::AID-BIES8>3.0.CO;2-N; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; Shaw SL, 2003, SCIENCE, V300, P1715, DOI 10.1126/science.1083529; Wang L, 2002, CURR BIOL, V12, P1496, DOI 10.1016/S0960-9822(02)01078-3; WatermanStorer CM, 1997, CURR BIOL, V7, pR369, DOI 10.1016/S0960-9822(06)00177-1; Yvon AMC, 2000, J CELL BIOL, V151, P1003, DOI 10.1083/jcb.151.5.1003	13	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1675	+		10.1126/science.1086055	http://dx.doi.org/10.1126/science.1086055			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805528				2022-12-28	WOS:000183459700029
J	Tsubuki, S; Takaki, Y; Saido, TC				Tsubuki, S; Takaki, Y; Saido, TC			Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of A beta to physiologically relevant proteolytic degradation	LANCET			English	Article							PROTEIN; DISEASE	The Dutch, Flemish, Italian, and Arctic mutations in the amyloid precursor protein (APP) gene encode changes within the sequence of the amyloid beta peptide (Abeta) and cause presenile cerebral amyloid angiopathy, cerebral parenchymal amyloidosis, or both. These disorders are caused by accumulation of Abeta, with no evidence of increased Abeta production. Our results showed that these mutations in Abeta make it resistant to proteolytic degradation by neprilysin, the peptidase with the most important role in catabolism of Abeta in the brain. These mutations in Abeta could thus be pathogenic not only by facilitating fibrillogenesis but also by extending the half-life of Abeta in the brain.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan	RIKEN	Saido, TC (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903				Kumar-Singh S, 2000, NEUROBIOL DIS, V7, P9, DOI 10.1006/nbdi.1999.0272; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; SAITO T, 2003, SCI SAAGE KE    0122; Walsh DM, 2001, BIOCHEM J, V355, P869, DOI 10.1042/bj3550869	5	115	126	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1957	1958		10.1016/S0140-6736(03)13555-6	http://dx.doi.org/10.1016/S0140-6736(03)13555-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801742				2022-12-28	WOS:000183359700014
J	Wang, HY; Malbon, CC				Wang, HY; Malbon, CC			Wnt signaling, Ca2+, and cyclic GMP: Visualizing frizzled functions	SCIENCE			English	Editorial Material							BETA-CATENIN; G-PROTEINS; XENOPUS; PATHWAY; KINASE; RECEPTOR; HOMOLOGS; FAMILY; CELLS	Wnts control the specification of cell fate, cell adhesion, migration, polarity, and proliferation. Their roles in development have been probed in fruit flies, nematodes, zebrafish, frogs, and mice. Some Wnts inhibit the degradation of beta-catenin, which can regulate transcription of specific genes. Other Wnts exert their influences in other ways, such as increasing intracellular concentrations of Ca2+ and decreasing intracellular concentrations of cyclic guanosine monophosphate (cGMP). Heterotrimeric guanine nucleotide-binding proteins (G proteins) and RGS proteins have been implicated in Wnt signaling. Wnt regulation of intracellular Ca2+ and cGMP levels requires the G protein transducin and a cGMP-specific phosphodiesterase, which are major elements in signaling of the visual pathway.	SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020					Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; IRVINE RF, 2002, SCI STKE; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuhl M, 2001, MECH DEVELOP, V106, P61, DOI 10.1016/S0925-4773(01)00416-6; Kume S, 2000, DEV BIOL, V226, P88, DOI 10.1006/dbio.2000.9849; Li H, 2002, BIOCHEM PHARMACOL, V64, P1325, DOI 10.1016/S0006-2952(02)01345-X; Li H, 2002, CANCER BIOL THER, V1, P621, DOI 10.4161/cbt.309; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; WANG HY, 2003, SCI STKE; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu CL, 2000, DEVELOPMENT, V127, P2773	22	115	119	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2003	300	5625					1529	1530		10.1126/science.1085259	http://dx.doi.org/10.1126/science.1085259			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791979				2022-12-28	WOS:000183333100039
J	Calabrese, LH; Albrecht, M; Young, J; McCarthy, P; Haug, M; Jarcho, J; Zackin, R				Calabrese, LH; Albrecht, M; Young, J; McCarthy, P; Haug, M; Jarcho, J; Zackin, R			Successful cardiac transplantation in an HIV-1-infected patient with advanced disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOLID-ORGAN TRANSPLANTATION; LIVER-TRANSPLANTATION; HEART-TRANSPLANTATION; HIV-INFECTION; BYPASS; DNA		Cleveland Clin Fdn, Dept Rheumatol & Immunol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pharm, Cleveland, OH 44195 USA; Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Calabrese, LH (corresponding author), Cleveland Clin Fdn, Dept Rheumatol & Immunol, 9500 Euclid Ave,Desk A-50, Cleveland, OH 44195 USA.	calabrl@ccf.org						ANTHUBER M, 1991, J HEART LUNG TRANSPL, V10, P611; Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501; Billingham M E, 1990, J Heart Transplant, V9, P587; Calabrese F, 1998, APMIS, V106, P470, DOI 10.1111/j.1699-0463.1998.tb01373.x; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Gow PJ, 2001, TRANSPLANTATION, V72, P177, DOI 10.1097/00007890-200107270-00001; Gow PJ, 2001, AIDS, V15, P291, DOI 10.1097/00002030-200101260-00029; Halpern SD, 2002, NEW ENGL J MED, V347, P284, DOI 10.1056/NEJMsb020632; Hennessy M, 2002, BRIT J CLIN PHARMACO, V53, P75, DOI 10.1046/j.0306-5251.2001.01516.x; Holmes RD, 2002, TRANSPLANTATION, V74, P367, DOI 10.1097/00007890-200208150-00013; JELLIFFE RW, 1993, THER DRUG MONIT, V15, P380, DOI 10.1097/00007691-199310000-00005; Kuo PC, 2001, TRANSPLANTATION, V71, P1689, DOI 10.1097/00007890-200106150-00033; OELLERICH M, 1995, THER DRUG MONIT, V17, P642, DOI 10.1097/00007691-199512000-00017; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Prachalias AA, 2001, TRANSPLANTATION, V72, P1684, DOI 10.1097/00007890-200111270-00020; PTACHCINSKI RJ, 1987, J CLIN PHARMACOL, V27, P243, DOI 10.1002/j.1552-4604.1987.tb02193.x; Ragni MV, 1999, BLOOD, V93, P1113, DOI 10.1182/blood.V93.3.1113.403a38e_1113_1115; Rinder CS, 1997, J LAB CLIN MED, V129, P592, DOI 10.1016/S0022-2143(97)90193-1; Rowe DT, 1997, J CLIN MICROBIOL, V35, P1612, DOI 10.1128/JCM.35.6.1612-1615.1997; Shaw LM, 1999, CLIN THER, V21, P1632, DOI 10.1016/S0149-2918(99)80044-7; Struber M, 1999, ANN THORAC SURG, V68, P1330, DOI 10.1016/S0003-4975(99)00729-8; TZAKIS AG, 1990, TRANSPLANTATION, V49, P354, DOI 10.1097/00007890-199002000-00025; White IE, 2000, J CLIN MICROBIOL, V38, P1992, DOI 10.1128/JCM.38.5.1992-1995.2000	23	77	79	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2323	2328		10.1056/NEJMoa022935	http://dx.doi.org/10.1056/NEJMoa022935			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788996				2022-12-28	WOS:000183296300007
J	Giles, J				Giles, J			UK universities face star treatment in funding revamp	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					574	574		10.1038/423574b	http://dx.doi.org/10.1038/423574b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789301	Bronze			2022-12-28	WOS:000183301200006
J	Chau, TTH; Thwaites, GE; Chuong, LV; Sinh, DX; Farrar, JJ				Chau, TTH; Thwaites, GE; Chuong, LV; Sinh, DX; Farrar, JJ			Headache and confusion: the dangers of a raw snail supper	LANCET			English	Article							ANGIOSTRONGYLUS-CANTONENSIS; EOSINOPHILIC MENINGITIS		Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Dis, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Thwaites, GE (corresponding author), Univ Oxford, Clin Res Unit, Hosp Trop Dis, 190 Ben Ham Tu,Quan 5, Ho Chi Minh City, Vietnam.	gthwaites@hcm.vnn.vn	Farrar, Jeremy J./HGA-7610-2022; Thwaites, Guy E/R-4993-2019	Thwaites, Guy E/0000-0002-2858-2087; Farrar, Jeremy/0000-0002-2700-623X				Chotmongkol V, 2000, CLIN INFECT DIS, V31, P660, DOI 10.1086/314036; Lo Re V, 2001, CLIN INFECT DIS, V33, pE112; NEW D, 1995, NEW ENGL J MED, V332, P1105, DOI 10.1056/NEJM199504203321619; Slom TJ, 2002, NEW ENGL J MED, V346, P668, DOI 10.1056/NEJMoa012462	4	21	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	2003	361	9372					1866	1866		10.1016/S0140-6736(03)13506-4	http://dx.doi.org/10.1016/S0140-6736(03)13506-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788574				2022-12-28	WOS:000183205800012
J	Jodar, L; LaForce, FM; Ceccarini, C; Aguado, T; Granoff, DM				Jodar, L; LaForce, FM; Ceccarini, C; Aguado, T; Granoff, DM			Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries	LANCET			English	Editorial Material									WHO, CH-1211 Geneva, Switzerland; Programme Appropriate Technol Hlth, Ferney Voltaire, France; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	World Health Organization; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Jodar, L (corresponding author), Int Vaccine Inst, Bldg 81,SNU Campus, Seoul 151600, South Korea.				NIAID NIH HHS [AI46464, R01 AI 45642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046464, R01AI045642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2; LEVINE MM, 1997, NEW GENERATION VACCI, P489; Ramsay ME, 2001, LANCET, V357, P195, DOI 10.1016/S0140-6736(00)03594-7; Sanchez JL, 1997, LANCET, V349, P1825, DOI 10.1016/S0140-6736(97)04486-3; Wenger J, 2001, VACCINE, V19, P1588, DOI 10.1016/S0264-410X(00)00356-X; *WHO, WHOV B0134; Wittet S, 2000, VACCINE, V19, P385, DOI 10.1016/S0264-410X(00)00196-1; 2002, WKLY EPIDEMIOL REC, V18, P152; 2001, WYETH ANN REPORTS; 1997, WKLY EPIDEMIOL REC, V72, P313; 2000, WYETH ANN REPORTS	11	72	73	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 31	2003	361	9372					1902	1904		10.1016/S0140-6736(03)13494-0	http://dx.doi.org/10.1016/S0140-6736(03)13494-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KL	12788589				2022-12-28	WOS:000183205800026
J	Wager, E				Wager, E			How to dance with porcupines: rules and guidelines on doctors' relations with drug companies	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-INDUSTRY RELATIONS; RESEARCHERS							Wager, Elizabeth/0000-0002-4202-7813				*AAMC TASK FORC FI, 2002, PROT SUBJ PRES TRUST; *AAMC TASK FORC FI, 2001, PROT SUBJ PRES TRUST; *ASS BRIT PHARM IN, CLIN TRIAL AGR PHARM; *ASS BRIT PHARM IN, GUID R D MAN NHS TRU; Cho MK, 2000, JAMA-J AM MED ASSOC, V284, P2203, DOI 10.1001/jama.284.17.2203; *COMM PUBL ETH, COPE REP 1999 GUID G; Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014; Coyle SL, 2002, ANN INTERN MED, V136, P403, DOI 10.7326/0003-4819-136-5-200203050-00015; Davidoff F, 2001, ANN INTERN MED, V135, P463, DOI 10.7326/0003-4819-135-6-200109180-00016; *ETH ISS COMM, 2000, INT J PHARM MED, V14, P163; Josefson D, 1998, BRIT MED J, V316, P493; KORENMAN SG, 2003, SCI EDITOR, V26, P42; Lewis S, 2001, CAN MED ASSOC J, V165, P783; *OFF INSP GEN, COMPL PROGR GUID PRO; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; Senn S, 2000, BMJ-BRIT MED J, V321, P1016; Simmonds H, 2002, BRIT MED J, V324, P850; Smith R, 2001, BRIT MED J, V323, P588, DOI 10.1136/bmj.323.7313.588; Spurgeon D, 2001, BRIT MED J, V323, P1085, DOI 10.1136/bmj.323.7321.1085; Wager E, 2003, CURR MED RES OPIN, V19, P149, DOI 10.1185/030079903125001767; WHITE LJ, 1990, ANN INTERN MED, V112, P624, DOI 10.7326/0003-4819-112-8-624; *WHO, WHO CRIT MED DRUG PR	22	38	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2003	326	7400					1196	1198		10.1136/bmj.326.7400.1196	http://dx.doi.org/10.1136/bmj.326.7400.1196			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775623	Green Published			2022-12-28	WOS:000183309900025
J	Mitsui, K; Tokuzawa, Y; Itoh, H; Segawa, K; Murakami, M; Takahashi, K; Maruyama, M; Maeda, M; Yamanaka, S				Mitsui, K; Tokuzawa, Y; Itoh, H; Segawa, K; Murakami, M; Takahashi, K; Maruyama, M; Maeda, M; Yamanaka, S			The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells	CELL			English	Article							EMBRYONIC STEM-CELLS; LEUKEMIA INHIBITORY FACTOR; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; SELF-RENEWAL; HUMAN BLASTOCYSTS; GENE; DIFFERENTIATION; EXPRESSION; STAT3	Embryonic stem (ES) cells derived from the inner cell mass (ICM) of blastocysts grow infinitely while maintaining pluripotency. Leukemia inhibitory factor (LIF) can maintain self-renewal of mouse ES cells through activation of Stat3. However, LIF/Stat3 is dispensable for maintenance of ICM and human ES cells, suggesting that the pathway is not fundamental for pluripotency. In search of a critical factor(s) that underlies pluripotency in both ICM and ES cells, we performed in silico differential display and identified several genes specifically expressed in mouse ES cells and preimplantation embryos. We found that one of them, encoding the homeoprotein Nanog, was capable of maintaining ES cell self-renewal independently of LIF/Stat3. nanog-deficient ICM failed to generate epiblast and only produced parietal endoderm-like cells. nanog-deficient ES cells lost pluripotency and differentiated into extraembryonic endoderm lineage. These data demonstrate that Nanog is a critical factor underlying pluripotency in both ICM and ES cells.	Nara Inst Sci & Technol, Lab Anim Mol Technol, Res & Educ Ctr Genet Informat, Nara 6300192, Japan; Osaka City Univ, Sch Med, Dept Anat 1, Osaka 5458585, Japan	Nara Institute of Science & Technology; Osaka Metropolitan University	Yamanaka, S (corresponding author), Nara Inst Sci & Technol, Lab Anim Mol Technol, Res & Educ Ctr Genet Informat, Nara 6300192, Japan.	shinyay@gtc.aist-nara-ac.jp	Takahashi, Kazutoshi/ABE-5504-2020; Mitsui, Kaoru/E-1464-2011	Takahashi, Kazutoshi/0000-0002-5329-8395; Mitsui, Kaoru/0000-0003-0534-9845				Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Berger CN, 1997, GROWTH FACTORS, V14, P145, DOI 10.3109/08977199709021517; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Colman A, 2001, EMBO REP, V2, P2, DOI 10.1093/embo-reports/kve017; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fan Y, 1999, DEV BIOL, V210, P481, DOI 10.1006/dbio.1999.9279; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; GASSMANN M, 1995, P NATL ACAD SCI USA, V92, P1292, DOI 10.1073/pnas.92.5.1292; Guo Y, 2002, P NATL ACAD SCI USA, V99, P3663, DOI 10.1073/pnas.062041099; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jackson M, 2002, J BIOL CHEM, V277, P38683, DOI 10.1074/jbc.M203459200; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lachmann P, 2001, EMBO REP, V2, P165, DOI 10.1093/embo-reports/kve053; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Mieth D, 2000, EMBO REP, V1, P4, DOI 10.1093/embo-reports/kvd020; Molkentin JD, 2000, DEV BIOL, V217, P301, DOI 10.1006/dbio.1999.9544; Morrison B, 1998, SWINE HEALTH PROD, V6, P4; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nichols J, 2001, DEVELOPMENT, V128, P2333; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; ROGERS MB, 1991, DEVELOPMENT, V113, P815; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; Smith A, 1998, CURR BIOL, V8, pR802, DOI 10.1016/S0960-9822(07)00504-0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Sun-Wada GH, 2000, J BIOCHEM-TOKYO, V127, P703, DOI 10.1093/oxfordjournals.jbchem.a022660; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Wang SH, 2003, GENE EXPR PATTERNS, V3, P99, DOI 10.1016/S1567-133X(03)00005-X; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yamanaka S, 2000, EMBO J, V19, P5533, DOI 10.1093/emboj/19.20.5533; Yamanaka S, 1998, GENOMICS, V54, P191, DOI 10.1006/geno.1998.5561; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	60	2382	2660	10	287	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2003	113	5					631	642		10.1016/S0092-8674(03)00393-3	http://dx.doi.org/10.1016/S0092-8674(03)00393-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	687VL	12787504	Bronze			2022-12-28	WOS:000183397600013
J	Rosenberg, SM; Hastings, PJ				Rosenberg, SM; Hastings, PJ			Modulating mutation rates in the wild	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; ADAPTIVE AMPLIFICATION; EVOLUTION; MUTATORS		Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Rosenberg, SM (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.			Rosenberg, Susan M./0000-0003-1444-473X				Bjedov I, 2003, SCIENCE, V300, P1404, DOI 10.1126/science.1082240; Bridges BA, 1997, NATURE, V387, P557, DOI 10.1038/42370; Harris RS, 1997, GENE DEV, V11, P2426, DOI 10.1101/gad.11.18.2426; Hastings PJ, 2000, CELL, V103, P723, DOI 10.1016/S0092-8674(00)00176-8; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LOMBARDO MP, UNPUB; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; Matic I, 1997, SCIENCE, V277, P1833, DOI 10.1126/science.277.5333.1833; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Rosenberg SM, 2001, NAT REV GENET, V2, P504, DOI 10.1038/35080556; Rosenberg SM, 1998, GENETICS, V148, P1559; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Taddei F, 1997, MOL GEN GENET, V256, P277, DOI 10.1007/s004380050570	13	35	40	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2003	300	5624					1382	1383		10.1126/science.1085691	http://dx.doi.org/10.1126/science.1085691			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683ZW	12775830				2022-12-28	WOS:000183181800032
J	Turner-Stokes, L				Turner-Stokes, L			Poststroke depression: getting the full picture	LANCET			English	Editorial Material							LESION LOCATION; STROKE PATIENTS; MOOD DISORDERS; BRAIN INJURY		Northwick Pk Hosp & Clin Res Ctr, Acad Dept Rehabil, Reg Rehabil Unit, Harrow HA1 3UJ, Middx, England; Univ London Kings Coll, Harrow HA1 3UJ, Middx, England	Imperial College London; University of London; King's College London	Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Acad Dept Rehabil, Reg Rehabil Unit, Harrow HA1 3UJ, Middx, England.		Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462				Aben I, 2003, J NEUROL NEUROSUR PS, V74, P581, DOI 10.1136/jnnp.74.5.581; ANDERSEN G, 1994, STROKE, V25, P1099, DOI 10.1161/01.STR.25.6.1099; Gainotti G, 1997, STROKE, V28, P2145, DOI 10.1161/01.STR.28.11.2145; Gordon A, 2001, HOSP PRACT, V36, P71, DOI 10.3810/hp.2001.03.232; Hassan N, 2002, CLIN REHABIL, V16, P534, DOI 10.1191/0269215502cr523oa; HERRMANN M, 1995, STROKE, V26, P850, DOI 10.1161/01.STR.26.5.850; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; ROBINS AH, 1976, J CHRON DIS, V29, P479, DOI 10.1016/0021-9681(76)90088-6; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; SHARPE M, 1990, PSYCHOL MED, V20, P815, DOI 10.1017/S0033291700036503; Singh A, 1998, CAN J PSYCHIAT, V43, P921, DOI 10.1177/070674379804300907; Staley JK, 1998, BIOL PSYCHIAT, V44, P534, DOI 10.1016/S0006-3223(98)00185-1; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STARKSTEIN SE, 1988, ARCH NEUROL-CHICAGO, V45, P725, DOI 10.1001/archneur.1988.00520310031013; Sutcliffe LM, 1998, CLIN REHABIL, V12, P506, DOI 10.1191/026921598672167702; Turner-Stokes L, 2003, CLIN REHABIL, V17, P150, DOI 10.1191/0269215503cr595oa	16	18	20	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1757	1758						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781530				2022-12-28	WOS:000183074800003
J	Fritsche, A; Schweitzer, MA; Haring, HU				Fritsche, A; Schweitzer, MA; Haring, HU		4001 Study Grp	Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							NPH INSULIN; MELLITUS; THERAPY; SULFONYLUREA; REGIMENS; NIDDM; HYPOGLYCEMIA; EFFICACY	Background: Patients with type 2 diabetes are often treated with oral antidiabetic agents plus a basal insulin. Objective: To investigate the efficacy and safety of glimepiride combined with either morning or bedtime insulin glargine or bedtime neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes. Design: open-label, randomized, controlled trial. Setting: 111 centers in 13 European countries. Patients: 695 patients with type 2 diabetes who were previously treated with oral antidiabetic agents. Intervention: Randomization to treatment with morning insulin glargine, bedtime NPH insulin, or bedtime insulin glargine for 24 weeks in addition to 3 mg of glimepiride. The insulin dose was titrated by using a predefined regimen to achieve fasting blood glucose levels of 5.56 mmol/L or lower (less than or equal to100 mg/dL). Measurements: Hemoglobin A(1c) values, blood glucose levels, insulin dose, and body weight. Results: Hemoglobin A(1c) levels improved by -1.24% (two-sided 90% CI, -1,10% to -1.38%) with morning insulin glargine, by -0.96% (CI, -0.81% to -1.10%) with bedtime insulin glargine, and by -0.84% (CI, -0.69% to -0.98%) with bedtime NPH insulin. Hemoglobin A(1c) improvement was more pronounced with morning insulin glargine than with NPH insulin (0.40% [CI, 0.23% to 0.58%]; P = 0.001) or bedtime insulin glargine (0.28% [CI, 0.11% to 0.46%]; P = 0.008). Baseline to end-point fasting blood glucose levels improved similarly in all three groups. Nocturnal hypoglycemia was less frequent with morning (39 of 236 patients [17%]) and bedtime insulin glargine (52 of 227 patients [23%]) than with bedtime NPH insulin (89 of 232 patients [38%]) (P < 0.001). Conclusion: The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine than with glimepiride in combination with bedtime NPH insulin in patients with type 2 diabetes. Morning insulin glargine provided better glycemic control than did bedtime insulin glargine or bedtime NPH insulin.	Univ Tubingen, Med Klin, Abt Endokrinol Stoffwechsel & Pathobiochem, D-72076 Tubingen, Germany; Aventis, Frankfurt, Germany	Eberhard Karls University of Tubingen	Haring, HU (corresponding author), Univ Tubingen, Med Klin, Abt Endokrinol Stoffwechsel & Pathobiochem, Otfried Muller Str 10, D-72076 Tubingen, Germany.	Hans-Ulrich.Haering@med.uni-tuebingen.de						[Anonymous], 1995, Diabetes, V44, P1249; Belfiglio M, 2001, DIABETES CARE, V24, P423, DOI 10.2337/diacare.24.3.423; Bolli GB, 1999, DIABETOLOGIA, V42, P1151, DOI 10.1007/s001250051286; de Sonnaville JJJ, 1998, DIABETES CARE, V21, P919, DOI 10.2337/diacare.21.6.919; Gerich JE, 2000, LANCET, V356, P1946, DOI 10.1016/S0140-6736(00)03303-1; Gillies PS, 2000, DRUGS, V59, P253, DOI 10.2165/00003495-200059020-00009; GROOP LC, 1992, DIABETES CARE, V15, P831, DOI 10.2337/diacare.15.7.831; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Holman R R, 1985, Diabet Med, V2, P45; Hunt LM, 1997, DIABETES CARE, V20, P292, DOI 10.2337/diacare.20.3.292; Kreider M, 1997, DIABETES NUTR METAB, V10, P82; NISKANEN L, 1992, DIABETES RES CLIN PR, V18, P185, DOI 10.1016/0168-8227(92)90144-G; Owens DR, 2001, LANCET, V358, P739, DOI 10.1016/S0140-6736(01)05842-1; PETERS AL, 1991, ANN INTERN MED, V115, P45, DOI 10.7326/0003-4819-115-1-45; Rosenstock J, 2001, DIABETES CARE, V24, P631, DOI 10.2337/diacare.24.4.631; SEIGLER DE, 1992, DIABETIC MED, V9, P826; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UK Prospective Diabetes Study Grp, 1999, DIABETES CARE, V22, P1125; Wolffenbuttel BHR, 1996, DIABETES CARE, V19, P1326, DOI 10.2337/diacare.19.12.1326; Wright A, 2002, DIABETES CARE, V25, P330, DOI 10.2337/diacare.25.2.330; Yki-Jarvinen H, 1999, ANN INTERN MED, V130, P389, DOI 10.7326/0003-4819-130-5-199903020-00002; Yki-Jarvinen H, 2000, DIABETES CARE, V23, P1130, DOI 10.2337/diacare.23.8.1130; Yki-Jarvinen H, 2001, DIABETES CARE, V24, P758, DOI 10.2337/diacare.24.4.758; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	26	267	277	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2003	138	12					952	959		10.7326/0003-4819-138-12-200306170-00006	http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YM	12809451				2022-12-28	WOS:000183578100002
J	Highland, KB; Strange, C; Heffner, JE				Highland, KB; Strange, C; Heffner, JE			Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease - A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article							DOUBLE-BLIND; BECLOMETHASONE; BUDESONIDE; MODERATE; TRIAL; MILD	Background: There is no consensus on the effectiveness of inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD). Purpose: To evaluate the long-term effects of inhaled corticosteroids on the rate of FEV1 decline in patients with COPD. Data Sources: MEDLINE, EMBASE, CISCOM, and AMED databases and the Cochrane Library (1966 to December 2002), reference lists from identified articles, and consultation with experts. Searches were not limited to the English language. Study Selection: Randomized, placebo-controlled trials that examined the rate of FEV1 decline as a primary outcome in patients with COPD. Data Extraction: Two reviewers independently extracted the data by using predetermined criteria. Data Synthesis: For the six studies that met the inclusion criteria, the summary estimate for the difference in FEV1 decline between the placebo and treatment groups was -5.0 +/- 3.2 mL/y (95% CI, -11.2 to 1.2 mL/y; P = 0.11). Conclusions: The use of inhaled corticosteroids was not associated with the rate of FEV1 decline in 3571 patients followed for 24 to 54 months.	Med Univ S Carolina, Div Pulmonary Crit Care Allergy & Clin Immunol, Charleston, SC 29425 USA	Medical University of South Carolina	Highland, KB (corresponding author), Med Univ S Carolina, Div Pulmonary Crit Care Allergy & Clin Immunol, 96 Jonathan Lucas St,Suite 812 CSB,POB 250623, Charleston, SC 29425 USA.	highlakb@musc.edu		Strange, Charlie/0000-0002-8109-8067				Abrams KR, 2000, METHODS METAANALYSIS; Altose MD, 2000, NEW ENGL J MED, V343, P1902; [Anonymous], 2000, WORLD HLTH REP; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Derenne JP, 1995, AM J RESP CRIT CARE, V151, pA463; Ferreira IM, 2001, AM J RESP CRIT CARE, V164, P1012, DOI 10.1164/ajrccm.164.6.2012139; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Renkema TEJ, 1996, CHEST, V109, P1156, DOI 10.1378/chest.109.5.1156; Rosner B., 2000, FUNDAMENTALS BIOSTAT; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sullivan SD, 2000, CHEST, V117, P5; van Grunsven PM, 1999, THORAX, V54, P7, DOI 10.1136/thx.54.1.7; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Weir DC, 1999, CLIN EXP ALLERGY, V29, P125, DOI 10.1046/j.1365-2222.1999.00021.x; YANG IA, 2003, COCHRANE LIB	16	99	100	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2003	138	12					969	973		10.7326/0003-4819-138-12-200306170-00008	http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690YM	12809453				2022-12-28	WOS:000183578100004
J	Collins, R; Armitage, J; Parish, S; Sleight, P; Peto, R				Collins, R; Armitage, J; Parish, S; Sleight, P; Peto, R		Heart Protection Study Collaborati	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial	LANCET			English	Article							REQUIRING PROLONGED OBSERVATION; MYOCARDIAL-INFARCTION; CORONARY EVENTS; RISK-FACTORS; MORTALITY; DISEASE; PRAVASTATIN; MELLITUS; AVERAGE; PREVENTION	Background Individuals with diabetes are at increased risk of cardiovascular morbidity and mortality, although typically their plasma concentrations of LDL cholesterol are similar to those in the general population. Previous evidence about the effects of lowering cholesterol in people with diabetes has been limited, and most diabetic patients do not currently receive cholesterol-lowering therapy despite their increased risk. Methods 5963 UK adults (aged 40-80 years) known to have diabetes, and an additional 14 573 with occlusive arterial disease (but no diagnosed diabetes), were randomly allocated to receive 40 mg simvastatin daily or matching placebo. Prespecified analyses in these prior disease subcategories, and other relevant subcategories, were of first major coronary event (ie, non-fatal myocardial infarction or coronary death) and of first major vascular event (ie, major coronary event, stroke or revascularisation). Analyses were also conducted of subsequent vascular events during the scheduled treatment period. Comparisons are of all simvastatin-allocated versus all placebo-allocated participants (ie, intention to treat), which yielded an average difference in LDL cholesterol of 1.0 mmol/L (39 mg/dL) during the 5-year treatment period. Findings Both among the participants who presented with diabetes and among those who did not, there were highly significant reductions of about a quarter in the first event rate for major coronary events, for strokes, and for revascularisations. For the first occurrence of any of these major vascular events among participants with diabetes, there was a definite 22% (95% Cl 13-30) reduction in the event rate (601 [20-2%) simvastatin-allocated vs 748 [25.1%] placebo-allocated, p<0.0001), which was similar to that among the other high-risk individuals studied. There were also highly significant reductions of 33% (95% Cl 17-46, p=0.0003) among the 2912 diabetic participants who did not have any diagnosed occlusive arterial disease at entry, and of 27% (95% Cl 13-40, p=0.0007) among the 2426 diabetic participants whose pretreatment LDL cholesterol concentration was below 3.0 mmol/L (116 mg/dL). The proportional reduction in risk was also about a quarter among various other subcategories of diabetic patient studied, including: those with different duration, type, or control of diabetes; those aged over 65 years at entry or with hypertension; and those with total cholesterol below 5.0 mmol/L (193 mg/dL). In addition, among participants who had a first major vascular event following randomisation, allocation to simvastatin reduced the rate of subsequent events during the scheduled treatment period. Interpretation The present study provides direct evidence that cholesterol-lowering therapy is beneficial for people with diabetes even if they do not already have manifest coronary disease or high cholesterol concentrations. Allocation to 40 mg simvastatin daily reduced the rate of first major vascular events by about a quarter in a wide range of diabetic patients studied. After making allowance for non-compliance, actual use of this statin regimen would probably reduce these rates by about a third. For example, among the type of diabetic patient studied without occlusive arterial disease, 5 years of treatment would be expected to prevent about 45 people per 1000 from having at least one major vascular event (and, among these 45 people, to prevent about 70 first or subsequent events during this treatment period). Statin therapy should now be considered routinely for all diabetic patients at sufficiently high risk of major vascular events, irrespective of their initial cholesterol concentrations.	Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Collins, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Harkness Bldg, Oxford OX2 6HE, England.	hps@ctsu.ox.ac.uk	Adiels, Martin/C-9278-2011; Lindley, Richard/B-8148-2013	Lindley, Richard/0000-0002-0104-5679; Mihaylova, Borislava/0000-0002-0951-1304				*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; American Diabetes Association,, 2003, DIABETES CARE S1, V26, ps83; American Diabetes Association, 2002, DIABETES CARE S1, V25, pS33, DOI DOI 10.2337/DIACARE.25.2007.S33; Arday DR, 2002, DIABETES CARE, V25, P2230, DOI 10.2337/diacare.25.12.2230; Armitage J, 2000, HEART, V84, P357, DOI 10.1136/heart.84.4.357; Campeau L, 1997, NEW ENGL J MED, V336, P153; Chen J., 1990, DIET LIFE STYLE MORT; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; *DEP HLTH, NAT SERV FRAM DIAB S; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Freeman DJ, 2001, CIRCULATION, V103, P357; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; HAMWI A, 1995, AM J CLIN PATHOL, V104, P89, DOI 10.1093/ajcp/104.1.89; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Manley SE, 1997, DIABETES CARE, V20, P1683; MCINTOSH A, CLIN GUIDELINES TYPE; Meade T, 1999, EUR HEART J, V20, P725; Neal B, 2000, LANCET, V356, P1955; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Prior M J, 1993, Ann Epidemiol, V3, P9; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Turner RC, 1998, BMJ-BRIT MED J, V316, P823, DOI 10.1136/bmj.316.7134.823; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wilson K, 2000, ARCH INTERN MED, V160, P939, DOI 10.1001/archinte.160.7.939; Yeo KR, 2002, HEART, V87, P423, DOI 10.1136/heart.87.5.423; Yusuf S, 2000, NEW ENGL J MED, V342, P145	46	2088	2162	0	63	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2005	2016						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814710				2022-12-28	WOS:000183488900007
J	Ghattas, H; Fulford, T; Prentice, A				Ghattas, H; Fulford, T; Prentice, A			Effect of moderate anaemia on later mortality in rural African children	LANCET			English	Article							ANEMIA	Severe anaemia in childhood is associated with increased mortality, although evidence relating moderate anaemia to child survival is scarce. We aimed to investigate this association. We did a case-control study of children with moderate anaemia, and compared haemoglobin concentrations measured up to a year before death for 403 children (age range 28 days to 15 years) with those from children who survived (matched for age and sex). Data were obtained from long-term health records (1950-97) of a rural Gambian research centre. Excluding an acute effect In this last week of life, no evidence was recorded of lower haemoglobin concentrations in the children who died than in survivors, or of any general or disease-specific effects of non-severe anaemia (70-110 g/L) on mortality.	St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England; MRC Labs, Banjul, Gambia; London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Publ Hlth Nutr Unit, London WC1B 3DP, England	St Georges University London; MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine	Ghattas, H (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, Cranmer Terrace, London SW17 0RE, England.		Prentice, Andrew/AAG-1961-2019; Ghattas, Hala/K-5661-2016					BATES CJ, 1994, EUR J CLIN NUTR, V48, P660; Brabin BJ, 2001, J NUTR, V131, p636S, DOI 10.1093/jn/131.2.636S; Gonzalez MA, 2000, B WORLD HEALTH ORGAN, V78, P97; SMITH AW, 1989, ANN TROP PAEDIATR, V2, P6; Stoltzfus RJ, 2001, J NUTR, V131, p697S, DOI 10.1093/jn/131.2.697S	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2048	2050		10.1016/S0140-6736(03)13617-3	http://dx.doi.org/10.1016/S0140-6736(03)13617-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814719				2022-12-28	WOS:000183488900015
J	Lindholm, LH				Lindholm, LH			Major benefits from cholesterol-lowering in patients with diabetes	LANCET			English	Editorial Material							INTERVENTION; TRIAL		Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden	Umea University	Lindholm, LH (corresponding author), Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.	larsh.lindholm@fammed.umu.se						*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; American Diabetes Association,, 2003, DIABETES CARE S1, V26, ps83; American Diabetes Association, 2002, DIABETES CARE S1, V25, pS33, DOI DOI 10.2337/DIACARE.25.2007.S33; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; McIntosh AHA, 2002, CLIN GUIDELINES EVID; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0	8	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2000	2001		10.1016/S0140-6736(03)13672-0	http://dx.doi.org/10.1016/S0140-6736(03)13672-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814705				2022-12-28	WOS:000183488900002
J	Mason, EE				Mason, EE			Surgery in the obese	LANCET			English	Editorial Material							BYPASS		Univ Iowa Hosp & Clin, Dept Surg, Iowa City, IA 52242 USA	University of Iowa	Mason, EE (corresponding author), Univ Iowa Hosp & Clin, Dept Surg, Iowa City, IA 52242 USA.	edward-mason@uiowa.edu						*AM SOC BAR SURG, 2001, RAT SURG TREATM MORB; Bhardwaj A, 2001, J NEUROSURG ANESTH, V13, P314, DOI 10.1097/00008506-200110000-00006; Cottam DR, 2003, ARCH SURG-CHICAGO, V138, P367, DOI 10.1001/archsurg.138.4.367; Davies KE, 2001, ANAESTHESIA, V56, P1112; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Kuduvalli M, 2002, EUR J CARDIO-THORAC, V22, P787, DOI 10.1016/S1010-7940(02)00448-7; MacDonald KG, 2003, ARCH SURG-CHICAGO, V138, P357, DOI 10.1001/archsurg.138.4.357; MASON EE, 1956, SURGERY, V39, P143; Mason EE, 2003, ARCH SURG-CHICAGO, V138, P361, DOI 10.1001/archsurg.138.4.361; MASON EE, 1967, SURG CLIN N AM, V47, P1345; Sjostrom L, 2000, ENDOCRINE, V13, P213, DOI 10.1385/ENDO:13:2:213; Telfeian AE, 2002, J NEUROSURG, V97, P20, DOI 10.3171/spi.2002.97.1.0020; Uva Miguel Sousa, 2002, Rev Port Cardiol, V21, P255	13	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2001	2002		10.1016/S0140-6736(03)13673-2	http://dx.doi.org/10.1016/S0140-6736(03)13673-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814706				2022-12-28	WOS:000183488900003
J	Salmeen, A; Andersen, JN; Myers, MP; Meng, TC; Hinks, JA; Tonks, NK; Barford, D				Salmeen, A; Andersen, JN; Myers, MP; Meng, TC; Hinks, JA; Tonks, NK; Barford, D			Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate	NATURE			English	Article							HYDROGEN-PEROXIDE; REVERSIBLE INACTIVATION; INSULIN SENSITIVITY; GENERATION; MECHANISM; KINASES	The second messenger hydrogen peroxide is required for optimal activation of numerous signal transduction pathways, particularly those mediated by protein tyrosine kinases(1-6). One mechanism by which hydrogen peroxide regulates cellular processes is the transient inhibition of protein tyrosine phosphatases through the reversible oxidization of their catalytic cysteine, which suppresses protein dephosphorylation(7-9). Here we describe a structural analysis of the redox-dependent regulation of protein tyrosine phosphatase 1B (PTP1B), which is reversibly inhibited by oxidation after cells are stimulated with insulin(8) and epidermal growth factor(9). The sulphenic acid intermediate produced in response to PTP1B oxidation is rapidly converted into a previously unknown sulphenyl-amide species, in which the sulphur atom of the catalytic cysteine is covalently linked to the main chain nitrogen of an adjacent residue. Oxidation of PTP1B to the sulphenyl-amide form is accompanied by large conformational changes in the catalytic site that inhibit substrate binding. We propose that this unusual protein modification both protects the active-site cysteine residue of PTP1B from irreversible oxidation to sulphonic acid and permits redox regulation of the enzyme by promoting its reversible reduction by thiols.	Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cold Spring Harbor Laboratory	Barford, D (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	david.barford@icr.ac.uk	Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021; Andersen, Jannik/0000-0003-4528-2120	NATIONAL CANCER INSTITUTE [R37CA053840] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Rao GN, 1996, ONCOGENE, V13, P713; Rhee S. G., 2000, SCI STKE, V53; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6	26	726	753	3	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					769	773		10.1038/nature01680	http://dx.doi.org/10.1038/nature01680			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802338				2022-12-28	WOS:000183443400047
J	Yip, L; Dart, RC				Yip, L; Dart, RC			A 20-hour treatment for acute acetaminophen overdose	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							N-ACETYLCYSTEINE; PARACETAMOL		Rocky Mt Poison & Drug Ctr, Denver, CO 80230 USA		Yip, L (corresponding author), Rocky Mt Poison & Drug Ctr, Denver, CO 80230 USA.			Dart, Richard/0000-0001-5989-9354				PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; PRESCOTT LF, 1977, LANCET, V2, P432	2	25	25	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2471	2472		10.1056/NEJM200306123482422	http://dx.doi.org/10.1056/NEJM200306123482422			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802041				2022-12-28	WOS:000183428900032
J	Moens, V; Baruch, G; Fearon, P				Moens, V; Baruch, G; Fearon, P			Opportunistic screening for Chlamydia at a community based contraceptive service for young people	BRITISH MEDICAL JOURNAL			English	Article								Problem The suspected high prevalence of Chlamydia infection that is undiagnosed and untreated among high risk women who attend a contraceptive service for young people. Design Cross sectional study from a community screening service. Background and setting An inner city contraceptive and psychotherapy service for young people aged 12-21 years. Key measure for improvement Prevalence of infection commensurate with or above findings from the national screening pilot (13.8% for > 16 year olds, 10.5% for 16-19 year olds, and 7.2% for 20 to 24 year olds). Strategies for change Offering testing (of a first catch urine sample) for Chlamydia to all young people using the contraceptive service who were not previously screened; launching a publicity campaign about the new service; training medical staff and reception staff to deliver the service to maximise take up of screening and of treatment by infected cases; and surveying results from testing to monitor significant patterns of infection requiring further action. Effects of change Percentage of clients with infection exceeded targets for each age group, 76% with a positive or equivocal result returned for treatment, 87% of those treated returned for a test of cure, and 99% of tests of cure were negative. Prevention work was initiated in a school with a particularly heavy concentration of infected clients. Lessons learnt A contraceptive service for young women is a highly acceptable location for effective Chlamydia screening.	Brandon Ctr Counselling & Psychotherapy Young Peo, London NW5 3LG, England; UCL, Subdept Clin Hlth Psychol, London WC1E 6BT, England	University of London; University College London	Baruch, G (corresponding author), Brandon Ctr Counselling & Psychotherapy Young Peo, London NW5 3LG, England.	G.Baruch@compuserve.com						BARUCH G., 2001, COMMUNITY BASED PSYC; *CAMD ISL HLTH AUT, 2001, PUBL HLTH REP HLTH I; *DEP HLTH, 2002, PIL STUD OPP SCREEN; Department of Health, 2001, NAT STRAT SEX HLTH H; DiClemente RJ, 2001, LANCET, V358, P1828, DOI 10.1016/S0140-6736(01)06878-7; Fenton KA, 2001, LANCET, V358, P1851, DOI 10.1016/S0140-6736(01)06886-6	6	15	15	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2003	326	7401					1252	1255		10.1136/bmj.326.7401.1252	http://dx.doi.org/10.1136/bmj.326.7401.1252			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689FJ	12791743	Green Published			2022-12-28	WOS:000183480700020
J	Petit, RJ; Aguinagalde, I; de Beaulieu, JL; Bittkau, C; Brewer, S; Cheddadi, R; Ennos, R; Fineschi, S; Grivet, D; Lascoux, M; Mohanty, A; Muller-Starck, GM; Demesure-Musch, B; Palme, A; Martin, JP; Rendell, S; Vendramin, GG				Petit, RJ; Aguinagalde, I; de Beaulieu, JL; Bittkau, C; Brewer, S; Cheddadi, R; Ennos, R; Fineschi, S; Grivet, D; Lascoux, M; Mohanty, A; Muller-Starck, GM; Demesure-Musch, B; Palme, A; Martin, JP; Rendell, S; Vendramin, GG			Glacial refugia: Hotspots but not melting pots of genetic diversity	SCIENCE			English	Article							POSTGLACIAL COLONIZATION ROUTES; SOUTHEASTERN EUROPE; CHLOROPLAST DNA; ICE AGES; DIFFERENTIATION; PHYLOGEOGRAPHY; CONSEQUENCES; POPULATIONS; FORESTS; PLANTS	Glacial refuge areas are expected to harbor a large fraction of the intraspecific biodiversity of the temperate biota. To test this hypothesis, we studied chloroplast DNA variation in 22 widespread European trees and shrubs sampled in the same forests. Most species had genetically divergent populations in Mediterranean regions, especially those with low seed dispersal abilities. However, the genetically most diverse populations were not located in the south but at intermediate latitudes, a likely consequence of the admixture of divergent lineages colonizing the continent from separate refugia.	INRA, UMR Biodivers Genes & Ecosyst, F-33612 Cestas, France; Univ Politecn Madrid, Escuela Tecn Super Ingn Agron, E-28040 Madrid, Spain; Fac Sci & Tech St Jerome, Inst Mediterraneen Ecol & Paleoecol, F-13397 Marseille, France; Tech Univ Munich, Fachgebiet Forstgenet, D-85354 Freising Weihenstephan, Germany; Univ Edinburgh, Inst Ecol & Resource Management, Edinburgh EH9 3JU, Midlothian, Scotland; CNR, Ist Biol Agroambientale & Forestale, I-05010 Porano, TR, Italy; Uppsala Univ, Dept Conservat Biol & Genet, Evolutionary Biol Ctr, S-75236 Uppsala, Sweden; Off Natl Forets, Dept Rech Tech Conservatoire Genet Arbres Foresti, F-45160 Ardon, France; CNR, Ist Genet Vegetale, Sez Firenze, I-50134 Florence, Italy	INRAE; Universidad Politecnica de Madrid; UDICE-French Research Universities; Aix-Marseille Universite; Technical University of Munich; University of Edinburgh; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Agroambientale e Forestale (IBAF-CNR); Uppsala University; Consiglio Nazionale delle Ricerche (CNR)	Petit, RJ (corresponding author), INRA, UMR Biodivers Genes & Ecosyst, F-33612 Cestas, France.	petit@pierroton.inra.fr	Grivet, Delphine/G-9708-2012; Vendramin, Giovanni G/K-9731-2014; Clemente, Juan Pedro Martín/F-3218-2016; Petit, Rémy/A-8842-2008; Fineschi, Silvia/ABF-9775-2020; Petit, Remy/AAD-9078-2019	Grivet, Delphine/0000-0001-8168-4456; Vendramin, Giovanni G/0000-0001-9921-7872; Clemente, Juan Pedro Martín/0000-0002-8180-5489; Petit, Rémy/0000-0002-4809-1453; MOHANTY, APARAJITA/0000-0001-7296-8940; FINESCHI, SILVIA/0000-0002-3583-6073; Brewer, Simon/0000-0002-6810-1911; Lascoux, Martin/0000-0003-1699-9042				Austerlitz F, 2000, GENETICS, V154, P1309; Bennett, 1997, EVOLUTION ECOLOGY PA; BENNETT KD, 1991, J BIOGEOGR, V18, P103, DOI 10.2307/2845248; Carcaillet C, 2001, QUATERNARY RES, V55, P385, DOI 10.1006/qres.2001.2226; Comps B, 2001, GENETICS, V157, P389; CWYNAR LC, 1987, AM NAT, V129, P463, DOI 10.1086/284651; Davis MB, 2001, SCIENCE, V292, P673, DOI 10.1126/science.292.5517.673; Dynesius M, 2000, P NATL ACAD SCI USA, V97, P9115, DOI 10.1073/pnas.97.16.9115; Grivet D, 2003, CONSERV GENET, V4, P47, DOI 10.1023/A:1021804009832; Grivet D, 2002, MOL ECOL, V11, P1351, DOI 10.1046/j.1365-294X.2002.01522.x; Hewitt G, 2000, NATURE, V405, P907, DOI 10.1038/35016000; Hewitt GM, 1999, BIOL J LINN SOC, V68, P87, DOI 10.1111/j.1095-8312.1999.tb01160.x; Hewitt GM, 1996, BIOL J LINN SOC, V58, P247, DOI 10.1111/j.1095-8312.1996.tb01434.x; Palme AE, 2003, MOL ECOL, V12, P201, DOI 10.1046/j.1365-294X.2003.01724.x; PALME AE, IN PRESS HEREDITY; PETIT RJ, 1993, HEREDITY, V71, P630, DOI 10.1038/hdy.1993.188; Petit RJ, 2002, FOREST ECOL MANAG, V156, P49, DOI 10.1016/S0378-1127(01)00634-X; Petit RJ, 1998, CONSERV BIOL, V12, P844, DOI 10.1046/j.1523-1739.1998.96489.x; Petit RJ, 2001, INTEGRATING ECOLOGY, P295; Pons O, 1996, GENETICS, V144, P1237; Rendell S, 2002, MOL ECOL, V11, P69, DOI 10.1046/j.0962-1083.2001.01413.x; Sanchezgoni MF, 2002, CLIM DYNAM, V19, P95, DOI 10.1007/s00382-001-0212-x; Taberlet P, 1998, MOL ECOL, V7, P453, DOI 10.1046/j.1365-294x.1998.00289.x; Willis KJ, 2002, SCIENCE, V295, P1245, DOI 10.1126/science.1067335; Willis KJ, 2000, QUATERNARY RES, V53, P203, DOI 10.1006/qres.1999.2119	25	1352	1408	5	305	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1563	1565		10.1126/science.1083264	http://dx.doi.org/10.1126/science.1083264			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791991				2022-12-28	WOS:000183333100053
J	Gandhi, SP; Stevens, CF				Gandhi, SP; Stevens, CF			Three modes of synaptic vesicular recycling revealed by single-vesicle imaging	NATURE			English	Article							RETINAL BIPOLAR CELLS; HIPPOCAMPAL SYNAPSES; NERVE-TERMINALS; MEMBRANE RETRIEVAL; CHROMAFFIN CELLS; ENDOCYTOSIS; EXOCYTOSIS; CALCIUM; FUSION; PH	Synapses recycle their spent vesicles in order to keep up with on-going neurotransmitter release. To investigate vesicle recycling in the small synapses of hippocampal neurons, we have used an optical recording method that permits us to resolve single-vesicle events. Here we show that an exocytic event can terminate with three modes of vesicle retrieval: a fast (400-860 ms) 'kiss-and-run' mode that has a selective fusion pore; a slow (8-21 s) 'compensatory' mode; and a 'stranded' mode of recycling, in which a vesicle is left on the cell surface until a nerve impulse triggers its retrieval. We have also observed that, in response to a nerve impulse, synapses with low release probability primarily use the kiss-and-run mode, whereas high release probability terminals predominantly use the compensatory mode of vesicle retrieval.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Neurosci Program, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; Salk Institute; Salk Institute; University of California System; University of California San Diego	Stevens, CF (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.							Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Beutner D, 2001, NEURON, V29, P681, DOI 10.1016/S0896-6273(01)00243-4; Cousin MA, 2000, J NEUROCHEM, V75, P1645, DOI 10.1046/j.1471-4159.2000.0751645.x; Engisch KL, 1998, J PHYSIOL-LONDON, V506, P591, DOI 10.1111/j.1469-7793.1998.591bv.x; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; Heidelberger R, 2002, J NEUROPHYSIOL, V88, P2509, DOI 10.1152/jn.00267.2002; Heidelberger R, 2001, J NEUROSCI, V21, P6467, DOI 10.1523/JNEUROSCI.21-17-06467.2001; Hsu SF, 1996, J PHYSIOL-LONDON, V494, P539, DOI 10.1113/jphysiol.1996.sp021512; Huang EP, 1997, J NEUROPHYSIOL, V78, P2870, DOI 10.1152/jn.1997.78.6.2870; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Murthy VN, 1999, NAT NEUROSCI, V2, P503, DOI 10.1038/9149; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Neale EA, 1999, J CELL BIOL, V147, P1249, DOI 10.1083/jcb.147.6.1249; Neves G, 2001, P NATL ACAD SCI USA, V98, P15282, DOI 10.1073/pnas.261311698; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Pyle JL, 2000, NEURON, V28, P221, DOI 10.1016/S0896-6273(00)00098-2; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199, DOI 10.1016/S0006-3495(00)76468-X; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Sun JY, 2002, NATURE, V417, P555, DOI 10.1038/417555a; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Wu MM, 2000, CHEM BIOL, V7, P197, DOI 10.1016/S1074-5521(00)00088-0; Zenisek D, 2002, NEURON, V35, P1085, DOI 10.1016/S0896-6273(02)00896-6	37	346	356	3	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					607	613		10.1038/nature01677	http://dx.doi.org/10.1038/nature01677			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789331				2022-12-28	WOS:000183301200032
J	Mizutani, A; Chahl, JS; Srinivasan, MV				Mizutani, A; Chahl, JS; Srinivasan, MV			Motion camouflage in dragonflies	NATURE			English	Article									Australian Natl Univ, Res Sch Biol Sci, Ctr Visual Sci, Canberra, ACT 2601, Australia; Def Sci & Technol Org, Weapons Syst Div, Edinburgh, SA 5111, Australia	Australian National University; Defence Science & Technology	Mizutani, A (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Ctr Visual Sci, POB 475, Canberra, ACT 2601, Australia.		Srinivasan, Mandyam V/G-5571-2010	Muthukumarasamy, Srinivasan/0000-0002-2948-6206; Chahl, Javaan/0000-0001-6496-0543				COLLETT TS, 1975, J COMP PHYSIOL, V99, P1, DOI 10.1007/BF01464710; CURLO E, 1976, ETHOLOGY PREDATION; SRINIVASAN MV, 1995, P ROY SOC B-BIOL SCI, V259, P19, DOI 10.1098/rspb.1995.0004; SRINIVASAN MV, 1903, VISUAL MOTION ITS RO, P139; TSAI RY, 1987, IEEE T ROBOTIC AUTOM, V3, P323, DOI 10.1109/JRA.1987.1087109; *US OFF NAV RES, INS VIS BAS SEEK CON	6	96	102	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					604	604		10.1038/423604a	http://dx.doi.org/10.1038/423604a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789327	Bronze			2022-12-28	WOS:000183301200028
J	Shlipak, MG				Shlipak, MG			Pharmacotherapy for heart failure in patients with renal insufficiency	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CONVERTING-ENZYME-INHIBITOR; LEFT-VENTRICULAR DYSFUNCTION; LIFE-THREATENING HYPERKALEMIA; GLOMERULAR-FILTRATION-RATE; RANDOMIZED-TRIAL; BETA-BLOCKERS; MYOCARDIAL-INFARCTION; SERUM CREATININE; ELDERLY-PATIENTS; COMBINED THERAPY	Clinical trials have demonstrated that angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and spironolactone improve survival in patients with heart failure. Because patients with heart failure and renal insufficiency have been underrepresented in these trials, little evidence is available to guide clinicians in the optimal management of patients with both conditions. Approximately one third to one half of patients with heart failure have renal insufficiency (estimated glomerular filtration rate [GFR] <60 mL/min per 1.73 m(2)), and renal insufficiency is among the strongest predictors of mortality in patients with heart failure. Evidence supports the use of ACE inhibitors to improve survival in patients with moderate renal insufficiency (GFR, 30 to 60 mL/min per 1.73 m(2)), but there is little evidence with which to weigh the risks and benefits in patients with more advanced renal dysfunction. beta-Blockers improve survival in patients with heart failure, and their beneficial effect is unlikely to differ according to renal function. Spironolactone improves outcomes in patients with advanced heart failure, but renal insufficiency appears to increase risk for hyperkalemia and limits the use of the drug in patients with severe renal insufficiency. Future clinical trials in heart failure should include a representative number of patients with renal insufficiency to improve the evidence base and outcomes in this vulnerable population.	Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Shlipak, MG (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.	shlip@itsa.ucsf.edu			NHLBI NIH HHS [R03 HL68099-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL068099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77; Adams KF, 1999, J CARD FAIL, V5, P357; Bakris GL, 2000, ARCH INTERN MED, V160, P685, DOI 10.1001/archinte.160.5.685; BALL SG, 1993, LANCET, V342, P821; Berry C, 2001, Heart, V85, pE8, DOI 10.1136/heart.85.4.e8; Blaustein DA, 2002, AM J CARDIOL, V90, P662, DOI 10.1016/S0002-9149(02)02580-8; Brophy JM, 2001, ANN INTERN MED, V134, P550, DOI 10.7326/0003-4819-134-7-200104030-00008; CLELAND JGF, 1995, BRIT HEART J, V74, P215; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CODY RJ, 1989, ARCH INTERN MED, V149, P1023, DOI 10.1001/archinte.149.5.1023; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; DAgati V, 1996, AM J KIDNEY DIS, V28, pS24, DOI 10.1016/S0272-6386(96)90565-X; DOHERTY JE, 1972, AM J CARDIOL, V29, P470, DOI 10.1016/0002-9149(72)90435-3; DOHERTY JE, 1985, CARDIOLOGY, V72, P225; Dries DL, 2000, J AM COLL CARDIOL, V35, P681, DOI 10.1016/S0735-1097(99)00608-7; DZAU VJ, 1984, NEW ENGL J MED, V310, P347, DOI 10.1056/NEJM198402093100603; Edep ME, 1997, J AM COLL CARDIOL, V30, P518, DOI 10.1016/S0735-1097(97)00176-9; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Feenstra J, 2002, ARCH INTERN MED, V162, P265, DOI 10.1001/archinte.162.3.265; Feenstra J, 1997, DRUG SAFETY, V17, P166, DOI 10.2165/00002018-199717030-00003; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Frances CD, 2000, ARCH INTERN MED, V160, P2645, DOI 10.1001/archinte.160.17.2645; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Georges B, 2000, LANCET, V355, P1369, DOI 10.1016/S0140-6736(05)72606-4; GOTTLIEB SS, 1992, AM HEART J, V124, P131, DOI 10.1016/0002-8703(92)90930-T; Hillege HL, 2000, CIRCULATION, V102, P203, DOI 10.1161/01.CIR.102.2.203; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; Knight EL, 1999, AM HEART J, V138, P849, DOI 10.1016/S0002-8703(99)70009-8; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Lechat P, 1999, LANCET, V353, P9; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; LJUNGMAN S, 1990, DRUGS, V39, P10, DOI 10.2165/00003495-199000394-00004; LJUNGMAN S, 1992, AM J CARDIOL, V70, P479, DOI 10.1016/0002-9149(92)91194-9; MacDowall P, 1998, LANCET, V352, P13, DOI 10.1016/S0140-6736(97)11060-1; MacMahon S, 1997, LANCET, V349, P375; Maggioni AP, 2002, J AM COLL CARDIOL, V40, P1414, DOI 10.1016/S0735-1097(02)02304-5; Massie BM, 2001, ARCH INTERN MED, V161, P165, DOI 10.1001/archinte.161.2.165; Metra M, 2000, CIRCULATION, V102, P546; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Obialo CI, 2002, AM J CARDIOL, V90, P663, DOI 10.1016/S0002-9149(02)02581-X; OKADA RD, 1978, CIRCULATION, V58, P1196, DOI 10.1161/01.CIR.58.6.1196; OLSEN SL, 1995, J AM COLL CARDIOL, V25, P1225, DOI 10.1016/0735-1097(95)00012-S; OSTER JR, 1992, ARCH INTERN MED, V152, P704, DOI 10.1001/archinte.152.4.704; PACKER M, 1987, ANN INTERN MED, V106, P346, DOI 10.7326/0003-4819-106-3-346; Packer M, 1999, CIRCULATION, V100, P2312, DOI 10.1161/01.CIR.100.23.2312; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Packer M, 1999, AM J CARDIOL, V83, p1A; Perry G, 1997, NEW ENGL J MED, V336, P525; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Philbin EF, 1998, CLIN CARDIOL, V21, P103, DOI 10.1002/clc.4960210208; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; POOLEWILSON PA, 1989, NEW ENGL J MED, V321, P476; RAMBAUSEK M, 1985, Blood Purification, V3, P4, DOI 10.1159/000169394; Rathore SS, 2002, NEW ENGL J MED, V347, P1403, DOI 10.1056/NEJMoa021266; Schepkens H, 2001, AM J MED, V110, P438, DOI 10.1016/S0002-9343(01)00642-8; Schoolwerth AC, 2001, CIRCULATION, V104, P1985, DOI 10.1161/hc4101.096153; Shlipak MG, 2001, AM J MED, V110, P425, DOI 10.1016/S0002-9343(01)00652-0; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWEDBERG K, 1991, Z KARDIOL, V80, P50; SWEDBERG K, 1990, AM J CARDIOL, V66, pD40, DOI 10.1016/0002-9149(90)90475-G; Teerlink JR, 1999, AM HEART J, V138, P193, DOI 10.1016/S0002-8703(99)70099-2; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; [No title captured]	69	126	144	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2003	138	11					917	924		10.7326/0003-4819-138-11-200306030-00013	http://dx.doi.org/10.7326/0003-4819-138-11-200306030-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AB	12779302				2022-12-28	WOS:000183296400007
J	Brown, EG; Tetro, JA				Brown, EG; Tetro, JA			Comparative analysis of the SARS coronavirus genome: a good start to a long journey	LANCET			English	Editorial Material							INFLUENZA; VIRULENCE; EVOLUTION		Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Brown, EG (corresponding author), Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada.			Tetro, Jason/0000-0001-8759-7281				Brown EG, 2001, P NATL ACAD SCI USA, V98, P6883, DOI 10.1073/pnas.111165798; Bush RM, 2000, P NATL ACAD SCI USA, V97, P6974, DOI 10.1073/pnas.97.13.6974; DROSTEN C, 2003, N ENGL J MED; Ewald PW, 1998, J URBAN HEALTH, V75, P480, DOI 10.1007/BF02427686; FIELDS BN, 1994, NATURE, V369, P95, DOI 10.1038/369095a0; Lai M.M.C., 2001, FIELDS VIROLOGY, P1163; Luk J, 2001, CLIN INFECT DIS, V33, P1375, DOI 10.1086/322662; MARRA MA, 2003, SCIENCE; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; ROTA PA, 2003, SCIENCE; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; *WHO, 2003, HOSP INF CONTR GUID	13	13	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1756	1757		10.1016/S0140-6736(03)13444-7	http://dx.doi.org/10.1016/S0140-6736(03)13444-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781529	Bronze, Green Published			2022-12-28	WOS:000183074800002
J	Mangeat, B; Turelli, P; Caron, G; Friedli, M; Perrin, L; Trono, D				Mangeat, B; Turelli, P; Caron, G; Friedli, M; Perrin, L; Trono, D			Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ARTHRITIS-ENCEPHALITIS VIRUS; G->A HYPERMUTATION; IN-VIVO; LENTIVIRAL VECTOR; DNA-SYNTHESIS; VIF PROTEIN; GENE; REPLICATION; SUBSTITUTIONS	Viral replication usually requires that innate intracellular lines of defence be overcome, a task usually accomplished by specialized viral gene products. The virion infectivity factor (Vif) protein of human immunodeficiency virus (HIV) is required during the late stages of viral production to counter the antiviral activity of APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; also known as CEM15), a protein expressed notably in human T lymphocytes(1-4). When produced in the presence of APOBEC3G, vif-defective virus is non-infectious. APOBEC3G is closely related to APOBEC1, the central component of an RNA-editing complex that deaminates a cytosine residue in apoB messenger RNA(5-7). APOBEC family members also have potent DNA mutator activity through dC deamination(8); however, whether the editing potential of APOBEC3G has any relevance to HIV inhibition is unknown. Here, we demonstrate that it does, as APOBEC3G exerts its antiviral effect during reverse transcription to trigger G-to-A hypermutation in the nascent retroviral DNA. We also find that APOBEC3G can act on a broad range of retroviruses in addition to HIV, suggesting that hypermutation by editing is a general innate defence mechanism against this important group of pathogens.	Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Med, CH-1211 Geneva, Switzerland; Univ Geneva, Frontiers Genet Res Program, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva; University of Geneva	Trono, D (corresponding author), Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland.			Mangeat, Bastien/0000-0003-2592-0236				BORMAN AM, 1995, VIROLOGY, V208, P601, DOI 10.1006/viro.1995.1191; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; CHARNIAUX-COTTON HELENE, 1962, GEN AND COMP ENDOCRINOL SUPPL, V1, P241, DOI 10.1016/0016-6480(62)90095-3; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gunther S, 1997, VIROLOGY, V235, P104, DOI 10.1006/viro.1997.8676; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; JAYANTA C, 2003, NATURE, V422, P726; JOHNSON PR, 1991, VIROLOGY, V185, P217, DOI 10.1016/0042-6822(91)90769-8; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mansky LM, 2000, J VIROL, V74, P9525, DOI 10.1128/JVI.74.20.9525-9531.2000; Mitrophanous KA, 1999, GENE THER, V6, P1808, DOI 10.1038/sj.gt.3301023; Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WAINHOBSON S, 1995, VIROLOGY, V209, P297, DOI 10.1006/viro.1995.1261; Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	28	1184	1232	2	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					99	103		10.1038/nature01709	http://dx.doi.org/10.1038/nature01709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12808466				2022-12-28	WOS:000183912800048
J	Zhang, H; Yang, B; Pomerantz, RJ; Zhang, CM; Arunachalam, SC; Gao, L				Zhang, H; Yang, B; Pomerantz, RJ; Zhang, CM; Arunachalam, SC; Gao, L			The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; B MESSENGER-RNA; TYPE-1 VIF PROTEIN; REVERSE TRANSCRIPTION; G->A HYPERMUTATION; NONPERMISSIVE CELLS; EDITING ENZYME; SOR GENE; INFECTION; REPLICATION	High mutation frequency during reverse transcription has a principal role in the genetic variation of primate lentiviral populations. It is the main driving force for the generation of drug resistance and the escape from immune surveillance. G to A hypermutation is one of the characteristics of primate lentiviruses, as well as other retroviruses, during replication in vivo and in cell culture(1-6). The molecular mechanisms of this process, however, remain to be clarified. Here, we demonstrate that CEM15 (also known as apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G; APOBEC3G)(7,8), an endogenous inhibitor of human immunodeficiency virus type 1 (HIV-1) replication, is a cytidine deaminase and is able to induce G to A hypermutation in newly synthesized viral DNA. This effect can be counteracted by the HIV-1 virion infectivity factor (Vif). It seems that this viral DNA mutator is a viral defence mechanism in host cells that may induce either lethal hypermutation or instability of the incoming nascent viral reverse transcripts, which could account for the Vif-defective phenotype. Importantly, the accumulation of CEM15-mediated non-lethal hypermutation in the replicating viral genome could potently contribute to the genetic variation of primate lentiviral populations.	Thomas Jefferson Univ, Dept Med, Div Infect Dis & Environm Med, Ctr Human Virol & Biodef,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA	Jefferson University	Zhang, H (corresponding author), Thomas Jefferson Univ, Dept Med, Div Infect Dis & Environm Med, Ctr Human Virol & Biodef,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA.		Yang, Bin/J-4044-2015; Yang, Bin/W-7014-2019	Yang, Bin/0000-0003-4110-1513; Yang, Bin/0000-0003-1180-6184	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047720] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI047720] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CATTANEO R, 1988, CELL, V55, P255, DOI 10.1016/0092-8674(88)90048-7; Chester A, 2000, BBA-GENE STRUCT EXPR, V1494, P1, DOI 10.1016/S0167-4781(00)00219-0; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; Dornadula G, 2000, J VIROL, V74, P2594, DOI 10.1128/JVI.74.6.2594-2602.2000; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FITZGIBBON JE, 1993, AIDS RES HUM RETROV, V9, P833, DOI 10.1089/aid.1993.9.833; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Janini M, 2001, J VIROL, V75, P7973, DOI 10.1128/JVI.75.17.7973-7986.2001; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kao S, 2003, J VIROL, V77, P1131, DOI 10.1128/JVI.77.2.1131-1140.2003; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; MARTINEZ MA, 1994, P NATL ACAD SCI USA, V91, P11787, DOI 10.1073/pnas.91.25.11787; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Vartanian JP, 1997, J MOL BIOL, V270, P139, DOI 10.1006/jmbi.1997.1104; Vartanian JP, 2002, J GEN VIROL, V83, P801, DOI 10.1099/0022-1317-83-4-801; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Zhang H, 2000, J VIROL, V74, P8252, DOI 10.1128/JVI.74.18.8252-8261.2000; ZHANG L, 1996, TERRA NOVA ABSTR S, V1, P70	30	879	905	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					94	98		10.1038/nature01707	http://dx.doi.org/10.1038/nature01707			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12808465	Green Accepted			2022-12-28	WOS:000183912800047
J	Kawasaki, H; Taira, K				Kawasaki, H; Taira, K			RETRACTED: Hes1 is a target of microRNA-23 during retinoic-acid-induced neuronal differentiation of NT2 cells (Retracted Article. See 426, pg 100, 2003)	NATURE			English	Article; Retracted Publication							RNA-INTERFERENCE; CAENORHABDITIS-ELEGANS; REGULATORY RNA; EXPRESSION; GENES; ROLES; IDENTIFICATION; MATURATION; CLEAVAGE; SEQUENCE	MicroRNAs (miRNAs) are phylogenetically widespread small RNAs of 18-25 nucleotides in length, and are found in animals and plants. These small RNAs can regulate gene expression at a translational level through interactions with their target messenger RNAs, and they have a role in the development of Caenorhabditis elegans and plants. Although more than two hundred miRNAs have been found in mammals, their mRNA targets remain to be identified. Here, we demonstrate that the expression of Hes1, basic helix-loop-helix transcriptional repressor, is regulated by miRNA-23 (miR-23) in NT2 cells. miR-23 is almost complementary to part of the coding region, just upstream of the termination codon, of Hes1 mRNA. Reduction in the level of miR-23 by small interfering RNAs resulted in the accumulation of Hes1, and hindered the retinoic-acid-induced neuronal differentiation of NT2 cells. Thus, our results indicate that miR-23 regulates the expression of Hes1 at the post-transcriptional level, and participates in retinoic-acid-induced neuronal differentiation of NT2 cells.	Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; AIST, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Kawasaki, H (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	kawasaki@chembio.t.u-tokyo.ac.jp; taria@chembio.t.u-tokyo.ac.jp						Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Cheung WMW, 2000, J NEUROCHEM, V75, P34, DOI 10.1046/j.1471-4159.2000.0750034.x; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; KURIE JM, 1993, DIFFERENTIATION, V54, P115; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	40	77	106	1	61	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 19	2003	423	6942					838	842		10.1038/nature01730	http://dx.doi.org/10.1038/nature01730			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12808467				2022-12-28	WOS:000183585300036
J	Siddall, M; Rohling, EJ; Almogi-Labin, A; Hemleben, C; Meischner, D; Schmelzer, I; Smeed, DA				Siddall, M; Rohling, EJ; Almogi-Labin, A; Hemleben, C; Meischner, D; Schmelzer, I; Smeed, DA			Sea-level fluctuations during the last glacial cycle	NATURE			English	Article							BAH AL MANDAB; RED-SEA; CLIMATE-CHANGE; GREENLAND; ISOTOPE; RECORDS; CORALS; AGES; FORAMINIFERA; TEMPERATURE	The last glacial cycle was characterized by substantial millennial-scale climate fluctuations(1-5), but the extent of any associated changes in global sea level (or, equivalently, ice volume) remains elusive. Highstands of sea level can be reconstructed from dated fossil coral reef terraces(6,7), and these data are complemented by a compilation of global sea-level estimates based on deep-sea oxygen isotope ratios at millennial-scale resolution(8) or higher(1). Records based on oxygen isotopes, however, contain uncertainties in the range of +/-30 m, or +/-1degreesC in deep sea temperature(9,10). Here we analyse oxygen isotope records from Red Sea sediment cores to reconstruct the history of water residence times in the Red Sea. We then use a hydraulic model of the water exchange between the Red Sea and the world ocean to derive the sill depth and hence global sea level-over the past 470,000 years (470 kyr). Our reconstruction is accurate to within +/-12 m, and gives a centennial-scale resolution from 70 to 25 kyr before present. We find that sea-level changes of up to 35 m, at rates of up to 2 cm yr(-1), occurred, coincident with abrupt changes in climate.	Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England; Geol Survey Israel, IL-95501 Jerusalem, Israel; Univ Tubingen, Dept Geol & Paleontol, D-7400 Tubingen, Germany; Univ Gottingen, Inst Geol & Palaeontol, Dept Sedimentary Geol, D-37073 Gottingen, Germany	NERC National Oceanography Centre; University of Southampton; Geological Survey Israel; Eberhard Karls University of Tubingen; University of Gottingen	Siddall, M (corresponding author), Southampton Oceanog Ctr, European Way, Southampton SO14 3ZH, Hants, England.		Smeed, David/B-4726-2012; Rohling, Eelco J/B-9736-2008	Smeed, David/0000-0003-1740-1778; Rohling, Eelco J/0000-0001-5349-2158; Almogi-Labin, Ahuva/0000-0002-4082-7120				Adkins JF, 2002, SCIENCE, V298, P1769, DOI 10.1126/science.1076252; Almogi-Labina A, 2000, MAR MICROPALEONTOL, V40, P295, DOI 10.1016/S0377-8398(00)00043-8; BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Chappell J, 2002, QUATERNARY SCI REV, V21, P1229, DOI 10.1016/S0277-3791(01)00141-X; Cutler KB, 2003, EARTH PLANET SC LETT, V206, P253, DOI 10.1016/S0012-821X(02)01107-X; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Edwards F.J., 1987, KEY ENV RED SEA, P45; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; Fairbanks RG, 1990, PALEOCEANOGRAPHY, V5, P937, DOI 10.1029/PA005i006p00937; Fenton M, 2000, MAR MICROPALEONTOL, V40, P277, DOI 10.1016/S0377-8398(00)00042-6; GALLUP CD, 1994, SCIENCE, V263, P796, DOI 10.1126/science.263.5148.796; GRIFFITHS RW, 1984, DEEP-SEA RES, V31, P245, DOI 10.1016/0198-0149(84)90104-3; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hemleben C, 1996, PALEOCEANOGRAPHY, V11, P147, DOI 10.1029/95PA03838; PIRAZZOLI PA, 1993, MAR GEOL, V109, P221, DOI 10.1016/0025-3227(93)90062-Z; Rohling EJ, 1998, NATURE, V394, P162, DOI 10.1038/28134; Rohling EJ, 1999, PALEOCEANOGRAPHY, V14, P706, DOI 10.1029/1999PA900042; SCHMELZER I, 1998, HIGH FREQUENCY EVENT; SHACKLETON NJ, 1987, QUATERNARY SCI REV, V6, P183, DOI 10.1016/0277-3791(87)90003-5; Shackleton NJ, 2000, PALEOCEANOGRAPHY, V15, P565, DOI 10.1029/2000PA000513; Siddall M, 2002, DEEP-SEA RES PT I, V49, P1551, DOI 10.1016/S0967-0637(02)00043-2; Smeed D, 1997, OCEANOL ACTA, V20, P773; Smeed DA, 2000, J PHYS OCEANOGR, V30, P2574, DOI 10.1175/1520-0485(2000)030<2574:HCOTLE>2.0.CO;2; Sofianos SS, 2002, DEEP-SEA RES PT II, V49, P1323, DOI 10.1016/S0967-0645(01)00164-3; Voelker AHL, 1998, RADIOCARBON, V40, P517; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9	29	1160	1205	5	324	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2003	423	6942					853	858		10.1038/nature01690	http://dx.doi.org/10.1038/nature01690			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691BQ	12815427				2022-12-28	WOS:000183585300041
J	Gilbody, S; Whitty, P; Grimshaw, J; Thomas, R				Gilbody, S; Whitty, P; Grimshaw, J; Thomas, R			Educational and organizational interventions to improve the management of depression in primary care - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIAL; DISSEMINATING QUALITY IMPROVEMENT; GENERAL-PRACTICE; PHYSICIAN EDUCATION; COST-EFFECTIVENESS; OLDER-PEOPLE; COLLABORATIVE MANAGEMENT; CHRONIC ILLNESS; PRACTICE NURSE; GUIDELINES	Context Depression is commonly encountered in primary care settings yet is often missed or suboptimally managed. A number of organizational and educational strategies to improve management of depression have been proposed. The clinical effectiveness and cost-effectiveness of these strategies have not yet been subjected to systematic review. Objective To systematically evaluate the effectiveness of organizational and educational interventions to improve the management of depression in primary care settings. Data Sources We searched electronic medical and psychological databases from inception to March 2003 (MEDLINE,,PsycLIT, EMBASE, CINAHL, Cochrane Controlled Trials Register, United Kingdom National Health Service Economic Evaluations Database, Cochrane Depression Anxiety and Neurosis Group register, and Cochrane Effective Professional and Organisational Change Group specialist register); conducted correspondence with authors; and used reference lists. Search terms were related to depression, primary care, and all guidelines and organizational and educational interventions. Study Selection We selected 36 studies, including 29 randomized controlled trials and nonrandomized controlled clinical trials, 5 controlled before-and-after studies, and 2 interrupted time-series studies. Outcomes relating to management and outcome of depression were sought. Data Extraction Methodological details and outcomes were extracted and checked by 2 reviewers. Summary relative risks were, where possible, calculated from original data and attempts were made to correct for unit of analysis error. Data Synthesis A narrative synthesis was conducted. Twenty-one studies with positive results were found. Strategies effective in improving patient outcome generally were those with complex interventions that incorporated clinician education, an enhanced role of the. nurse (nurse case management), and a greater degree of integration between primary and secondary care (consultation-liaison). Telephone medication counseling delivered by practice nurses or trained counselors was also effective. Simple guideline implementation and educational strategies were generally ineffective. Conclusions There is substantial potential to improve the management of depression in primary care. Commonly used guidelines and educational strategies are likely to be ineffective. The implementation of the findings from this research will require substantial investment in primary care services and a major shift in the organization and provision of care.	Univ Leeds, Acad Unit Psychiat & Behav Sci, Leeds LS2 9LT, W Yorkshire, England; Univ Newcastle Upon Tyne, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Ottawa, Inst Populat Hlth, Clin Epidemiol Program, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Cochrane Effect Profess & Org Change Grp, Ottawa, ON, Canada; Univ Ottawa, Ctr Best Practices, Ottawa, ON, Canada; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland	University of Leeds; Newcastle University - UK; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Aberdeen	Gilbody, S (corresponding author), Univ Leeds, Acad Unit Psychiat & Behav Sci, Leeds LS2 9LT, W Yorkshire, England.		Gilbody, Simon/AAY-3720-2021; Grimshaw, Jeremy/D-8726-2013; Gilbody, Simon/E-6543-2010	Gilbody, Simon/0000-0002-8236-6983; Grimshaw, Jeremy/0000-0001-8015-8243				*AG HEALTHC RES QU, 2002, CREEN DEPR SYST EV R; *AG HLTH CAR POL R, 2000, DEPR PRIM CAR DET DI; *AG HLTH CAR POL R, 1993, DEPR PRIM CAR; ANDERSEN SM, 1990, GEN HOSP PSYCHIAT, V12, P177, DOI 10.1016/0163-8343(90)90077-P; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Arthur AJ, 2002, BRIT J GEN PRACT, V52, P202; Baker R, 2001, BRIT J GEN PRACT, V51, P737; Bashir K, 2000, BRIT J GEN PRACT, V50, P626; Blanchard MR, 1999, INT J GERIATR PSYCH, V14, P733; BLANCHARD MR, 1995, INT J GERIATR PSYCH, V10, P289, DOI 10.1002/gps.930100405; Brook O, 2003, EUR NEUROPSYCHOPHARM, V13, P1, DOI 10.1016/S0924-977X(02)00074-3; Brown J B, 2000, Jt Comm J Qual Improv, V26, P39; Cabana MD, 2002, GEN HOSP PSYCHIAT, V24, P35, DOI 10.1016/S0163-8343(01)00169-4; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Coleman EA, 1999, J AM GERIATR SOC, V47, P775, DOI 10.1111/j.1532-5415.1999.tb03832.x; COOK TD, 1979, QUASI EXPT DESIGN AN; Eccles M, 2003, QUAL SAF HEALTH CARE, V12, P47, DOI 10.1136/qhc.12.1.47; Freemantle N, 2002, BRIT J GEN PRACT, V52, P290; Gerrity MS, 1999, J FAM PRACTICE, V48, P949; Gilbody SM, 2001, BRIT MED J, V322, P406, DOI 10.1136/bmj.322.7283.406; GILBODY SM, 2002, EFFECTIVE HLTH CARE, V7; Goldberg H I, 1998, Jt Comm J Qual Improv, V24, P130; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Katon W, 1997, GEN HOSP PSYCHIAT, V19, P169, DOI 10.1016/S0163-8343(97)00016-9; Katon W, 2001, ARCH GEN PSYCHIAT, V58, P241, DOI 10.1001/archpsyc.58.3.241; Katon W, 2001, GEN HOSP PSYCHIAT, V23, P138, DOI 10.1016/S0163-8343(01)00136-0; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katzelnick DJ, 2000, ARCH FAM MED, V9, P345, DOI 10.1001/archfami.9.4.345; Kendrick T, 2001, BRIT J GEN PRACT, V51, P911; Kessler D, 1999, BRIT MED J, V318, P436, DOI 10.1136/bmj.318.7181.436; Kiuttu J, 1999, NORD J PSYCHIAT, V53, P347, DOI 10.1080/080394899427818; Lin EHB, 1997, MED CARE, V35, P831, DOI 10.1097/00005650-199708000-00008; Lin EHB, 2000, ARCH FAM MED, V9, P1052, DOI 10.1001/archfami.9.10.1052; Lin EHB, 2001, J GEN INTERN MED, V16, P614, DOI 10.1046/j.1525-1497.2001.016009614.x; Lin EHB, 1999, AM J PSYCHIAT, V156, P643; Ludman E, 2000, INT J PSYCHIAT MED, V30, P229, DOI 10.2190/44LK-28E9-RRJ5-KQVW; Mann AH, 1998, BRIT J GEN PRACT, V48, P875; Mason J, 1999, HLTH TRENDS, V30, P120; Meredith LS, 2000, J GEN INTERN MED, V15, P868, DOI 10.1046/j.1525-1497.2000.91149.x; Moore AA, 1997, AM J MED, V102, P371, DOI 10.1016/S0002-9343(97)00089-2; Peveler R, 2001, BRIT MED BULL, V57, P193, DOI 10.1093/bmb/57.1.193; Peveler R, 1999, BRIT MED J, V319, P612, DOI 10.1136/bmj.319.7210.612; Priest RG, 1996, BRIT MED J, V313, P858; Rollman BL, 2001, ARCH INTERN MED, V161, P189, DOI 10.1001/archinte.161.2.189; Rost K, 2000, GEN HOSP PSYCHIAT, V22, P66, DOI 10.1016/S0163-8343(00)00059-1; Rost K, 2001, J GEN INTERN MED, V16, P143, DOI 10.1111/j.1525-1497.2001.00537.x; Rubenstein LV, 1999, HEALTH AFFAIR, V18, P89, DOI 10.1377/hlthaff.18.5.89; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P83, DOI 10.1111/j.1600-0447.1992.tb01448.x; Schoenbaum M, 2001, JAMA-J AM MED ASSOC, V286, P1325, DOI 10.1001/jama.286.11.1325; Shah Ajit, 1992, International Review of Psychiatry, V4, P243, DOI 10.3109/09540269209066324; Sherbourne CD, 2001, ARCH GEN PSYCHIAT, V58, P696, DOI 10.1001/archpsyc.58.7.696; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; Simon GE, 2002, MED CARE, V40, P941, DOI 10.1097/00005650-200210000-00011; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Smith JL, 2000, J RURAL HEALTH, V16, P313, DOI 10.1111/j.1748-0361.2000.tb00482.x; Solberg L I, 2001, Eff Clin Pract, V4, P239; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; THOMPSON C, 2000, LANCET, V355, P50; *UK NAT HLTH SERV, 1974, IMPL PRACT GUID; *UK NAT HLTH SERV, 1999, GETT EV INT PRACT; *UK NATL HLTH SERV, 2001, 4 CRD UK NATL HLTH S; *UK NT HLTH SERV C, 2001, 6 CRD UK NAT HLTH SE; Ukoumunne OC, 1999, HLTH TECHNOL ASSESS, V3; Unutzer J, 2001, ARCH GEN PSYCHIAT, V58, P935, DOI 10.1001/archpsyc.58.10.935; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; van Eijk MEC, 2001, BRIT MED J, V322, P654, DOI 10.1136/bmj.322.7287.654; Von Korff M, 1998, PSYCHOSOM MED, V60, P143, DOI 10.1097/00006842-199803000-00005; Von Korff M, 2001, BRIT MED J, V323, P948, DOI 10.1136/bmj.323.7319.948; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Wells KB, 1999, ARCH FAM MED, V8, P529, DOI 10.1001/archfami.8.6.529; WHO, 2001, WORLD HLTH REPORT 20; WILKINSON G, 1993, PSYCHOL MED, V23, P229, DOI 10.1017/S0033291700039027; Worrall G, 1999, CAN MED ASSOC J, V161, P37	78	539	554	4	73	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2003	289	23					3145	3151		10.1001/jama.289.23.3145	http://dx.doi.org/10.1001/jama.289.23.3145			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690QM	12813120				2022-12-28	WOS:000183560400029
J	Chan, WM; Li, EKM; Chan, AYK; Lam, DSC				Chan, WM; Li, EKM; Chan, AYK; Lam, DSC			Bilateral retinal detachment in a young woman	LANCET			English	Editorial Material							SYSTEMIC-LUPUS-ERYTHEMATOSUS; METHYLPREDNISOLONE; CYCLOPHOSPHAMIDE; CHOROIDOPATHY		Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Chan, WM (corresponding author), Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.		Lam, Dennis/AAL-1211-2020					Baca V, 1999, J RHEUMATOL, V26, P432; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; JABS DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P230; Khng CGYW, 2000, CLIN EXP OPHTHALMOL, V28, P309, DOI 10.1046/j.1442-9071.2000.00328.x; Nguyen QD, 2000, LUPUS, V9, P288, DOI 10.1191/096120300680199024	5	5	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 14	2003	361	9374					2044	2044		10.1016/S0140-6736(03)13642-2	http://dx.doi.org/10.1016/S0140-6736(03)13642-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814716				2022-12-28	WOS:000183488900012
J	Stokes, T; Dixon-Woods, M; Windridge, KC; McKinley, RK				Stokes, T; Dixon-Woods, M; Windridge, KC; McKinley, RK			Patients' accounts of being removed from their general practitioner's list: qualitative study	BRITISH MEDICAL JOURNAL			English	Article									Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of Leicester	Stokes, T (corresponding author), Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England.		Stokes, Tim/M-9420-2018; McKinley, Robert Kee/H-9211-2013	Stokes, Tim/0000-0002-1127-1952; McKinley, Robert Kee/0000-0002-3684-3435; Dixon-Woods, Mary/0000-0002-5915-0041				Allsop J, 1994, LAW POLICY, V16, P149; *ASS COMM HLTH COU, 1994, 19934 ACHCEW; Baruch G., 1981, SOCIOLOGY HLTH ILLNE, V3, P275, DOI DOI 10.1111/1467-9566.EP10486851; *DEP HLTH, 1989, TERMS SERV DOCT GEN; Department of Health, 1994, BEING HEARD REP REV; *GEN PRACT COMM BR, 1999, REM PAT GP LISTS; General Medical Council, 2001, GOOD MED PRACT; Goffman E., 1961, ASYLUMS; *HOUS COMM SEL COM, 2002, 5 HOUS COMM SEL COMM; HOWITT D, 1989, SOCIAL PSYCHOL CONFL; HYDEN LC, 1997, SOCIOL HLTH ILLN, V19, P148; Munro J, 1998, BRIT J GEN PRACT, V48, P1837; O'Reilly D, 1998, BRIT J GEN PRACT, V48, P1669; *ROYAL COLL GEN PR, 1997, REM PAT GPS LISTS GU; Stokes T, 1999, BRIT J GEN PRACT, V49, P144; STOKES TN, 2002, THESIS U LEICESTER L; STRONG PM, 1979, CEREMONIAL ORDER CLI; Yamey G, 1999, BRIT MED J, V319, P791, DOI 10.1136/bmj.319.7212.791	18	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1316	1319		10.1136/bmj.326.7402.1316	http://dx.doi.org/10.1136/bmj.326.7402.1316			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805172	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000183626500036
J	Vincent, JL				Vincent, JL			Nosocomial infections in adult intensive-care units	LANCET			English	Review							BLOOD-STREAM INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; URINARY-TRACT-INFECTIONS; CENTRAL VENOUS CATHETERS; CRITICALLY-ILL PATIENTS; RANDOMIZED CLINICAL-TRIAL; RISK-FACTORS; SECULAR TRENDS; SELECTIVE DECONTAMINATION; ANTIMICROBIAL RESISTANCE	Nosocomial infections affect about 30% of patients in intensive-care units and are associated with substantial morbidity and mortality. Several risk factors have been identified, including the use of catheters and other invasive equipment, and certain groups of patients-eg, those with trauma or burns-are recognised as being more susceptible to nosocomial infection than others. Awareness of these factors and adherence to simple preventive measures, such as adequate hand hygiene, can limit the burden of disease. Management of nosocomial infection relies on adequate and appropriate antibiotic therapy, which should be selected after discussion with infectious-disease specialists and adapted as microbiological data become available.	Free Univ Brussels, Erasme Hosp, Dept Intens Care, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vincent, JL (corresponding author), Free Univ Brussels, Erasme Hosp, Dept Intens Care, 808 Route Lennik, B-1070 Brussels, Belgium.	jlvincent@ulb.ac.be		Vincent, Jean-Louis/0000-0001-6011-6951				AERDTS SJA, 1993, BRIT MED J, V307, P525; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Appelgren P, 2001, ACTA ANAESTH SCAND, V45, P710, DOI 10.1034/j.1399-6576.2001.045006710.x; Archibald L, 1997, CLIN INFECT DIS, V24, P211, DOI 10.1093/clinids/24.2.211; Artigas AT, 2001, CRIT CARE MED, V29, P304, DOI 10.1097/00003246-200102000-00015; ASADULLAH K, 1995, CRIT CARE MED, V23, P1976, DOI 10.1097/00003246-199512000-00006; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; Bochicchio GV, 2001, J TRAUMA, V50, P612, DOI 10.1097/00005373-200104000-00004; Bologna RA, 1999, UROLOGY, V54, P982, DOI 10.1016/S0090-4295(99)00318-0; Bouza E, 2001, CLIN MICROBIOL INFEC, V7, P532, DOI 10.1046/j.1198-743x.2001.00324.x; Brossette SE, 2000, METHOD INFORM MED, V39, P303; COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; Cook D, 1997, CRIT CARE MED, V25, P1417, DOI 10.1097/00003246-199708000-00033; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Correa L, 2000, J HOSP INFECT, V46, P89, DOI 10.1053/jhin.2000.0803; Cunnion KM, 1996, AM J RESP CRIT CARE, V153, P158, DOI 10.1164/ajrccm.153.1.8542110; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; Dagan O, 1999, CRIT CARE MED, V27, P104, DOI 10.1097/00003246-199901000-00035; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; de Leon-Rosales SP, 2000, CRIT CARE MED, V28, P1316, DOI 10.1097/00003246-200005000-00010; DiGiovine B, 1999, AM J RESP CRIT CARE, V160, P976, DOI 10.1164/ajrccm.160.3.9808145; Dimick JB, 2001, ARCH SURG-CHICAGO, V136, P229, DOI 10.1001/archsurg.136.2.229; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; Ebner W, 2000, EUR J CLIN MICROBIOL, V19, P243, DOI 10.1007/s100960050470; Edgeworth JD, 1999, CRIT CARE MED, V27, P1421, DOI 10.1097/00003246-199908000-00002; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; Eggimann P, 2001, CHEST, V120, P2059, DOI 10.1378/chest.120.6.2059; Eggimann P, 2000, LANCET, V355, P1864, DOI 10.1016/S0140-6736(00)02291-1; Esparza J, 2001, INTENS CARE MED, V27, P660, DOI 10.1007/s001340100880; ESTES RJ, 1995, INTENS CARE MED, V21, P365, DOI 10.1007/BF01705418; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Ferrer M, 1999, ANN INTERN MED, V130, P991, DOI 10.7326/0003-4819-130-12-199906150-00007; Foca M, 2000, NEW ENGL J MED, V343, P695, DOI 10.1056/NEJM200009073431004; Fridkin SK, 1999, CLIN CHEST MED, V20, P303, DOI 10.1016/S0272-5231(05)70143-X; Fridkin SK, 1996, INFECT CONT HOSP EP, V17, P150; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Garnacho-Montero J, 2001, INTENS CARE MED, V27, P1288, DOI 10.1007/s001340101009; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gastmeier P, 2000, INFECT CONT HOSP EP, V21, P366, DOI 10.1086/501774; Gaynes RP, 1997, INFECT CONT HOSP EP, V18, P475; George DL, 1998, CLIN INFECT DIS, V27, P463, DOI 10.1086/514711; Girou E, 2000, JAMA-J AM MED ASSOC, V284, P2361, DOI 10.1001/jama.284.18.2361; Girou E, 1996, J HOSP INFECT, V34, P131, DOI 10.1016/S0195-6701(96)90138-3; Girou E, 1998, AM J RESP CRIT CARE, V157, P1151, DOI 10.1164/ajrccm.157.4.9701129; Gruson D, 2000, CRIT CARE MED, V28, P3155, DOI 10.1097/00003246-200009000-00005; HALEY RW, 1985, AM J EPIDEMIOL, V121, P182, DOI 10.1093/oxfordjournals.aje.a113990; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; Harnett SJ, 2001, J HOSP INFECT, V47, P301, DOI 10.1053/jhin.2001.0941; Holzapfel L, 1999, AM J RESP CRIT CARE, V159, P695, DOI 10.1164/ajrccm.159.3.9712076; House of Commons Committee of Public Accounts, MAN CONTR HOSP ACQ I; Hurr H, 1999, AM J INFECT CONTROL, V27, P79, DOI 10.1016/S0196-6553(99)70085-4; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; Ibrahim EH, 2001, CHEST, V120, P555, DOI 10.1378/chest.120.2.555; Johnson JR, 1999, ANTIMICROB AGENTS CH, V43, P2990, DOI 10.1128/AAC.43.12.2990; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; Karchmer TB, 2000, ARCH INTERN MED, V160, P3294, DOI 10.1001/archinte.160.21.3294; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046; Kollef MH, 1999, CHEST, V116, P1339, DOI 10.1378/chest.116.5.1339; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kropec A, 1996, INTENS CARE MED, V22, P1155, DOI 10.1007/BF01709329; Kunin CM, 2001, CHEST, V120, P10, DOI 10.1378/chest.120.1.10; L'heriteau F, 2002, INTENS CARE MED, V28, pS83; Lai KK, 2002, AM J INFECT CONTROL, V30, P221, DOI 10.1067/mic.2002.120128; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; Laupland KB, 2002, J CRIT CARE, V17, P50, DOI 10.1053/jcrc.2002.33029; Legras A, 1998, INTENS CARE MED, V24, P1040, DOI 10.1007/s001340050713; Leone M, 2001, CHEST, V120, P220, DOI 10.1378/chest.120.1.220; LIBERATI A, 2000, COCHRANE DB SYST REV, V4, P22; Livrelli V, 1996, J CLIN MICROBIOL, V34, P1963, DOI 10.1128/JCM.34.8.1963-1969.1996; Luzzati R, 2000, EUR J CLIN MICROBIOL, V19, P602, DOI 10.1007/s100960000325; Marco F, 1999, J CLIN MICROBIOL, V37, P2817, DOI 10.1128/JCM.37.9.2817-2828.1999; Markowicz P, 2000, AM J RESP CRIT CARE, V161, P1942, DOI 10.1164/ajrccm.161.6.9909122; Maury E, 2000, AM J RESP CRIT CARE, V162, P324, DOI 10.1164/ajrccm.162.1.9908118; Mayor S, 2000, BRIT MED J, V321, P1370, DOI 10.1136/bmj.321.7273.1370/a; McCusker ME, 2002, AM J INFECT CONTROL, V30, P139, DOI 10.1067/mic.2002.121662; McNeil SA, 2001, CLIN INFECT DIS, V32, P367, DOI 10.1086/318488; Napolitano LM, 1999, SURG CLIN N AM, V79, P1385, DOI 10.1016/S0039-6109(05)70084-0; NNIS System, 2001, AM J INFECT CONTROL, V29, P404, DOI 10.1067/mic.2001.119952; Nourdine K, 1999, INTENS CARE MED, V25, P567, DOI 10.1007/s001340050904; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Papia G, 1999, J TRAUMA, V47, P923, DOI 10.1097/00005373-199911000-00018; Peters M, 1999, BRIT MED J, V319, P609, DOI 10.1136/bmj.319.7210.609; Pfaller MA, 1998, J CLIN MICROBIOL, V36, P1886, DOI 10.1128/JCM.36.7.1886-1889.1998; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V30, P121, DOI 10.1016/S0732-8893(97)00192-2; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 1999, ARCH INTERN MED, V159, P821, DOI 10.1001/archinte.159.8.821; Pittet D, 2001, LANCET, P9; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Polderman KH, 2002, INTENS CARE MED, V28, P18, DOI 10.1007/s00134-001-1156-7; Pugach JL, 1999, J UROLOGY, V162, P883, DOI 10.1097/00005392-199909010-00084; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Raad I, 1998, LANCET, V351, P893, DOI 10.1016/S0140-6736(97)10006-X; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; Randolph AG, 1998, CRIT CARE MED, V26, P1452, DOI 10.1097/00003246-199808000-00038; Rangel-Frausto MS, 1999, CLIN INFECT DIS, V29, P253, DOI 10.1086/520194; Raymond DP, 2001, CRIT CARE MED, V29, P1101, DOI 10.1097/00003246-200106000-00001; Rebollo MH, 1996, J THORAC CARDIOV SUR, V112, P908, DOI 10.1016/S0022-5223(96)70090-9; Rello J, 2000, AM J RESP CRIT CARE, V162, P1027, DOI 10.1164/ajrccm.162.3.9911093; RELLO J, 1994, INTENS CARE MED, V20, P94, DOI 10.1007/BF01707661; Renaud B, 2001, AM J RESP CRIT CARE, V163, P1584, DOI 10.1164/ajrccm.163.7.9912080; Richards MJ, 1998, AM J CARDIOL, V82, P789, DOI 10.1016/S0002-9149(98)00450-0; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Riley TV, 1996, PATHOLOGY, V28, P359, DOI 10.1080/00313029600169354; Robert J, 2000, INFECT CONT HOSP EP, V21, P12, DOI 10.1086/501690; Roberts SA, 2001, J HOSP INFECT, V48, P228, DOI 10.1053/jhin.2001.0985; Rocco TR, 2000, ARCH SURG-CHICAGO, V135, P160, DOI 10.1001/archsurg.135.2.160; Rosenberg AL, 2000, CHEST, V118, P492, DOI 10.1378/chest.118.2.492; Rosser CJ, 1999, AM J SURG, V177, P287, DOI 10.1016/S0002-9610(99)00048-3; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; Salisbury DM, 1997, AM J INFECT CONTROL, V25, P24; Schinkel C, 1998, J TRAUMA, V44, P743, DOI 10.1097/00005373-199805000-00001; Sherertz RJ, 2000, ANN INTERN MED, V132, P641, DOI 10.7326/0003-4819-132-8-200004180-00007; Smulders K, 2002, CHEST, V121, P858, DOI 10.1378/chest.121.3.858; Soufir L, 1999, INFECT CONT HOSP EP, V20, P396, DOI 10.1086/501639; Spencer RC, 1996, EUR J CLIN MICROBIOL, V15, P281, DOI 10.1007/BF01695658; SPROAT LJ, 1994, J HOSP INFECT, V26, P137, DOI 10.1016/0195-6701(94)90057-4; Thibon P, 2000, J HOSP INFECT, V45, P117, DOI 10.1053/jhin.1999.0715; Timsit JF, 1996, JAMA-J AM MED ASSOC, V276, P1416, DOI 10.1001/jama.276.17.1416; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; van de Mortel T, 2000, Aust Crit Care, V13, P91, DOI 10.1016/S1036-7314(00)70630-8; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V282, P554, DOI 10.1001/jama.282.6.554; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Vincent JL, 1997, INTENS CARE MED, V23, P1181, DOI 10.1007/s001340050479; Voss A, 1997, INFECT CONT HOSP EP, V18, P205; Wallace WC, 1999, AM SURGEON, V65, P987; Wang JT, 2001, J HOSP INFECT, V47, P104, DOI 10.1053/jhin.2000.0878; Zedler S, 1999, CRIT CARE MED, V27, P66, DOI 10.1097/00003246-199901000-00028; 2000, MMWR MORB MORTAL WKL, V49, P149	139	421	449	3	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2003	361	9374					2068	2077		10.1016/S0140-6736(03)13644-6	http://dx.doi.org/10.1016/S0140-6736(03)13644-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	689JT	12814731				2022-12-28	WOS:000183488900026
J	Presgraves, DC; Balagopalan, L; Abmayr, SM; Orr, HA				Presgraves, DC; Balagopalan, L; Abmayr, SM; Orr, HA			Adaptive evolution drives divergence of a hybrid inviability gene between two species of Drosophila	NATURE			English	Article							NUCLEAR-PORE COMPLEX; POPULATION-GENETICS; NUCLEOPORIN; PROTEIN; NUP98; MELANOGASTER; HITCHHIKING; SITE; ARCHITECTURE; SPECIATION	Speciation-the splitting of one species into two-occurs by the evolution of any of several forms of reproductive isolation between taxa, including the intrinsic sterility and inviability of hybrids. Abundant evidence shows that these hybrid fitness problems are caused by incompatible interactions between loci: new alleles that become established in one species are sometimes functionally incompatible with alleles at interacting loci from another species. However, almost nothing is known about the genes involved in such hybrid incompatibilities or the evolutionary forces that drive their divergence. Here we identify a gene that causes epistatic inviability in hybrids between two fruitfly species, Drosophila melanogaster and D. simulans. Our population genetic analysis reveals that this gene-which encodes a nuclear pore protein-evolved by positive natural selection in both species' lineages. These results show that a lethal hybrid incompatibility has evolved as a by-product of adaptive protein evolution.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Rochester; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Presgraves, DC (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	dvnp@mail.rochester.edu						Andolfatto P, 2001, MOL BIOL EVOL, V18, P279, DOI 10.1093/oxfordjournals.molbev.a003804; Barbash DA, 2003, P NATL ACAD SCI USA, V100, P5302, DOI 10.1073/pnas.0836927100; Belgareh N, 2001, J CELL BIOL, V154, P1147, DOI 10.1083/jcb.200101081; BRAVERMAN JM, 1995, GENETICS, V140, P783, DOI 10.1093/genetics/140.2.783; Comeron JM, 1999, BIOINFORMATICS, V15, P763, DOI 10.1093/bioinformatics/15.9.763; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Davis AW, 1996, NATURE, V380, P157, DOI 10.1038/380157a0; Dobzhansky T., 1937; Emtage JLT, 1997, J CELL SCI, V110, P911; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Fay JC, 2000, GENETICS, V155, P1405; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Fontoura BMA, 2001, P NATL ACAD SCI USA, V98, P3208, DOI 10.1073/pnas.061014698; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; HEY J, 1993, MOL BIOL EVOL, V10, P804; KAPLAN NL, 1989, GENETICS, V123, P887; Keller CA, 1998, DEV BIOL, V202, P157, DOI 10.1006/dbio.1998.9009; KIMURA M, 1977, NATURE, V267, P275, DOI 10.1038/267275a0; LACHAISE D, 1986, EVOLUTION, V40, P262, DOI 10.1111/j.1558-5646.1986.tb00468.x; Lynch M, 2000, AM NAT, V156, P590, DOI 10.1086/316992; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MULLER H. J., 1942, GENETICS, V27, P157; Naveira HF, 1998, ENDLESS FORMS, P330; Orr HA, 2000, BIOESSAYS, V22, P1085, DOI 10.1002/1521-1878(200012)22:12&lt;1085::AID-BIES6&gt;3.0.CO;2-G; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Presgraves DC, 2003, GENETICS, V163, P955; ROSE MR, 1983, SCIENCE, V220, P157, DOI 10.1126/science.220.4593.157; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Sawamura K, 2000, P NATL ACAD SCI USA, V97, P2652, DOI 10.1073/pnas.050558597; Sturtevant AH, 1920, GENETICS, V5, P488; STURTEVANT AH, 1929, PUBL CARNEG I WASH, V399, P1; TAJIMA F, 1989, GENETICS, V123, P585; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Ting CT, 1998, SCIENCE, V282, P1501, DOI 10.1126/science.282.5393.1501; Turelli M, 2000, GENETICS, V154, P1663; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Wall JD, 2002, GENETICS, V162, P203; WATANABE TK, 1979, JPN J GENET, V54, P325, DOI 10.1266/jjg.54.325; Wilson A.S., 1976, MOL EVOLUTION, P225; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; Wu CI, 1998, ENDLESS FORMS, P339; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4	48	312	315	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					715	719		10.1038/nature01679	http://dx.doi.org/10.1038/nature01679			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802326				2022-12-28	WOS:000183443400034
J	White, TD; Asfaw, B; DeGusta, D; Gilbert, H; Richards, GD; Suwa, G; Howell, FC				White, TD; Asfaw, B; DeGusta, D; Gilbert, H; Richards, GD; Suwa, G; Howell, FC			Pleistocene Homo sapiens from Middle Awash, Ethiopia	NATURE			English	Article							EARLY HOMINID; AUSTRALOPITHECUS; ORIGINS; MAKA	The origin of anatomically modern Homo sapiens and the fate of Neanderthals have been fundamental questions in human evolutionary studies for over a century(1-4). A key barrier to the resolution of these questions has been the lack of substantial and accurately dated African hominid fossils from between 100,000 and 300,000 years ago(5). Here we describe fossilized hominid crania from Herto, Middle Awash, Ethiopia, that fill this gap and provide crucial evidence on the location, timing and contextual circumstances of the emergence of Homo sapiens. Radioisotopically dated to between 160,000 and 154,000 years ago(6), these new fossils predate classic Neanderthals and lack their derived features. The Herto hominids are morphologically and chronologically intermediate between archaic African fossils and later anatomically modern Late Pleistocene humans. They therefore represent the probable immediate ancestors of anatomically modern humans. Their anatomy and antiquity constitute strong evidence of modern-human emergence in Africa.	Univ Calif Berkeley, Museum Vertebrate Zool, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Museum Vertebrate Zool, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA; Rift Valley Res Serv, Addis Ababa, Ethiopia; Univ Tokyo, Univ Museum, Bunkyo Ku, Tokyo 1130033, Japan	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Tokyo	White, TD (corresponding author), Univ Calif Berkeley, Museum Vertebrate Zool, Dept Integrat Biol, Berkeley, CA 94720 USA.	timwhite@socrates.berkeley.edu						Arsuaga JL, 1997, J HUM EVOL, V33, P219, DOI 10.1006/jhev.1997.0133; Asfaw B, 1999, SCIENCE, V284, P629, DOI 10.1126/science.284.5414.629; Asfaw B, 2002, NATURE, V416, P317, DOI 10.1038/416317a; Brauer G., 2001, HUMANITY AFRICAN NAI, P191; Cann RL, 2001, SCIENCE, V291, P1742, DOI 10.1126/science.1058948; Clark JD, 2003, NATURE, V423, P747, DOI 10.1038/nature01670; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; Hawks JD, 2001, QUATERN INT, V75, P41, DOI 10.1016/S1040-6182(00)00076-8; Howell FC, 1999, J ANTHROPOL RES, V55, P191, DOI 10.1086/jar.55.2.3631209; Howells W. W., 1973, PAPERS PEABODY MUSEU, V67; Howells W. W., 1989, PAP PEABODY MUS, V79, P1; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Lieberman DE, 2002, P NATL ACAD SCI USA, V99, P1134, DOI 10.1073/pnas.022440799; Lovejoy CO, 2002, AM J PHYS ANTHROPOL, V119, P97, DOI 10.1002/ajpa.10111; MBUA EN, 2001, PATTERNS MIDDLE PLEI; Rightmire G.Ph., 2001, HUMANITY AFRICAN NAI, P231; SARICH VM, 1997, CONCEPTUAL ISSUES MO, P392; Stringer C, 2002, PHILOS T R SOC B, V357, P563, DOI 10.1098/rstb.2001.1057; Stringer CB, 2001, GEOL SOC SPEC PUBL, V190, P265, DOI 10.1144/GSL.SP.2001.190.01.18; Templeton AR, 2002, NATURE, V416, P45, DOI 10.1038/416045a; TILLIER AM, 1992, EVOLUTION DISPERSAL, P15; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0; Wolpoff M. H., 1997, CONCEPTUAL ISSUES MO, P28; Wolpoff MH, 2001, SCIENCE, V291, P293, DOI 10.1126/science.291.5502.293	26	561	600	1	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2003	423	6941					742	747		10.1038/nature01669	http://dx.doi.org/10.1038/nature01669			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688PA	12802332				2022-12-28	WOS:000183443400041
J	Reynolds, EH				Reynolds, EH			Brain and mind: a challenge for WHO	LANCET			English	Editorial Material							ILLNESS		Kings Coll London, Inst Epileptol, London SE5 9PJ, England	University of London; King's College London	Reynolds, EH (corresponding author), Kings Coll London, Inst Epileptol, Denmark Hill Campus, London SE5 9PJ, England.	reynolds@buckles.u-net.com						Baker M, 2001, BRIT MED J, V322, P937, DOI 10.1136/bmj.322.7291.937; Bogousslavsky J, 2003, LANCET NEUROL, V2, P212, DOI 10.1016/S1474-4422(03)00347-8; Crisp AH, 2000, BRIT J PSYCHIAT, V177, P4, DOI 10.1192/bjp.177.1.4; EISENBERG L, 1995, AM J PSYCHIAT, V152, P1563, DOI 10.1176/ajp.152.11.1563; Kendell RE, 2001, BRIT J PSYCHIAT, V178, P490, DOI 10.1192/bjp.178.6.490; Ramachandran VS, 2003, REITH LECT, V3; Reynolds E. H., 1989, BRIDGE NEUROLOGY PSY; REYNOLDS EH, 1990, BRIT J PSYCHIAT, V157, P481, DOI 10.1192/bjp.157.4.481; WHO, 2001, WORLD HLTH REPORT 20; 2002, ICD10 INT STAT CLASS	10	44	45	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1924	1925		10.1016/S0140-6736(03)13600-8	http://dx.doi.org/10.1016/S0140-6736(03)13600-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801732				2022-12-28	WOS:000183359700004
J	Broecker, WS				Broecker, WS			Does the trigger for abrupt climate change reside in the ocean or in the atmosphere?	SCIENCE			English	Review							LAURENTIDE ICE-SHEET; SANTA-BARBARA BASIN; YOUNGER DRYAS EVENT; LAST DEGLACIATION; NORTH-ATLANTIC; COLD REVERSAL; SOUTHERN ALPS; GREENLAND; ANTARCTICA; END	Two hypotheses have been put forward to explain the large and abrupt climate changes that punctuated glacial time. One attributes such changes to reorganizations of the ocean's thermohaline circulation and the other to changes in tropical atmosphere-ocean dynamics. In an attempt to distinguish between these hypotheses, two lines of evidence are examined. The first involves the timing of the freshwater injections to the northern Atlantic that have been suggested as triggers for the global impacts associated with the Younger Dryas and Heinrich events. The second has to do with evidence for precursory events associated with the Heinrich ice-rafted debris layers in the northern Atlantic and with the abrupt Dansgaard-Oeschger warmings recorded in the Santa Barbara Basin.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Broecker, WS (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, 61 Route 9W,POB 1000, Palisades, NY 10964 USA.	broecker@ldeo.columbia.edu						ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; Arz HW, 1998, QUATERNARY RES, V50, P157, DOI 10.1006/qres.1998.1992; Biscaye PE, 1997, J GEOPHYS RES-OCEANS, V102, P26765, DOI 10.1029/97JC01249; Blunier T, 1997, GEOPHYS RES LETT, V24, P2683, DOI 10.1029/97GL02658; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Broecker WS, 1988, PALEOCEANOGRAPHY, V3, P1, DOI 10.1029/PA003i001p00001; Broecker W.S., 1982, TRACERS SEA; Broecker WS, 2001, SCIENCE, V294, P2308, DOI 10.1126/science.1068389; BROECKER WS, 1989, NATURE, V341, P318, DOI 10.1038/341318a0; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; Brook EJ, 1999, GEOPH MONOG SERIES, V112, P165; Cacho I, 2001, PALEOCEANOGRAPHY, V16, P40, DOI 10.1029/2000PA000502; Cane M, 1999, GEOPH MONOG SERIES, V112, P373; Clapperton CM, 1997, QUATERNARY RES, V47, P13, DOI 10.1006/qres.1996.1861; Dallenbach A, 2000, GEOPHYS RES LETT, V27, P1005, DOI 10.1029/1999GL010873; DENTON GH, 1994, SCIENCE, V264, P1434, DOI 10.1126/science.264.5164.1434; GOSSE JC, 1995, GEOLOGY, V23, P877, DOI 10.1130/0091-7613(1995)023<0877:PCBMIW>2.3.CO;2; GRIMM EC, 1993, SCIENCE, V261, P198, DOI 10.1126/science.261.5118.198; Hajdas I, 1995, RADIOCARBON, V37, P149, DOI 10.1017/S0033822200030587; Hajdas I, 1998, GEOLOGY, V26, P1047, DOI 10.1130/0091-7613(1998)026<1047:CROKIA>2.3.CO;2; HEMMING SR, UNPUB; Hendy IL, 2000, PALEOCEANOGRAPHY, V15, P30, DOI 10.1029/1999PA000413; Hendy IL, 2002, QUATERNARY SCI REV, V21, P1167, DOI 10.1016/S0277-3791(01)00138-X; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; Ivy-Ochs S, 1999, GEOGR ANN A, V81A, P313, DOI 10.1111/1468-0459.00060; JOHNSON RG, 1995, PALAEOGEOGR PALAEOCL, V117, P123, DOI 10.1016/0031-0182(94)00120-W; JOUZEL J, 1995, CLIM DYNAM, V11, P151, DOI 10.1007/BF00223498; LEVERINGTON DW, 2000, QUATERNARY RES, P174; Licciardi JM, 1999, GEOPH MONOG SERIES, V112, P177; Litt T, 2003, QUATERNARY SCI REV, V22, P7, DOI 10.1016/S0277-3791(02)00180-4; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P775, DOI 10.1029/93PA02200; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P767, DOI 10.1029/93PA02201; MAYEWSKI PA, 1994, SCIENCE, V263, P1747, DOI 10.1126/science.263.5154.1747; Monnin E, 2001, SCIENCE, V291, P112, DOI 10.1126/science.291.5501.112; MORAN SR, 1973, N DAK GEOL SURV MISC, V53, P1; Morgan V, 2002, SCIENCE, V297, P1862, DOI 10.1126/science.1074257; MOTT RJ, 1986, NATURE, V323, P247, DOI 10.1038/323247a0; Muscheler R, 2000, NATURE, V408, P567, DOI 10.1038/35046041; Pailler D, 2002, PALAEOGEOGR PALAEOCL, V181, P431, DOI 10.1016/S0031-0182(01)00444-8; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; ROBERTS N, 1993, NATURE, V366, P146, DOI 10.1038/366146a0; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; Severinghaus JP, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000146; Steig EJ, 1998, SCIENCE, V282, P92, DOI 10.1126/science.282.5386.92; Teller JT, 2002, QUATERNARY SCI REV, V21, P879, DOI 10.1016/S0277-3791(01)00145-7; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618	47	211	239	2	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2003	300	5625					1519	1522		10.1126/science.1083797	http://dx.doi.org/10.1126/science.1083797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686QU	12791974				2022-12-28	WOS:000183333100034
J	Coursol, S; Fan, LM; Le Stunff, H; Spiegel, S; Gilroy, S; Assmann, SM				Coursol, S; Fan, LM; Le Stunff, H; Spiegel, S; Gilroy, S; Assmann, SM			Sphingolipid signalling in Arabidopsis guard cells involves heterotrimeric G proteins	NATURE			English	Article							SPHINGOSINE 1-PHOSPHATE; COUPLED RECEPTOR; KINASE; SPHINGOSINE-1-PHOSPHATE; PLANTS; THALIANA; CHANNELS; LYSOPHOSPHOLIPIDS; PROLIFERATION; ACTIVATION	In animals, the sphingolipid metabolite sphingosine-1-phosphate (S1P) functions as both an intracellular messenger and an extracellular ligand for G-protein-coupled receptors of the S1P receptor family, regulating diverse biological processes ranging from cell proliferation to apoptosis(1-3). Recently, it was discovered in plants that S1P is a signalling molecule involved in abscisic acid (ABA) regulation of guard cell turgor(4). Here we report that the enzyme responsible for S1P production, sphingosine kinase (SphK), is activated by ABA in Arabidopsis thaliana, and is involved in both ABA inhibition of stomatal opening and promotion of stomatal closure. Consistent with this observation, inhibition of SphK attenuates ABA regulation of guard cell inward K+ channels and slow anion channels, which are involved in the regulation of stomatal pore size. Surprisingly, S1P regulates stomatal apertures and guard cell ion channel activities in wild-type plants, but not in knockout lines of the sole prototypical heterotrimeric G-protein alpha-subunit gene, GPA1 (refs 5-8). Our results implicate heterotrimeric G proteins as downstream elements in the S1P signalling pathway that mediates ABA regulation of stomatal function, and suggest that the interplay between S1P and heterotrimeric G proteins represents an evolutionarily conserved signalling mechanism.	Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Virginia Commonwealth University	Assmann, SM (corresponding author), Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.		LE STUNFF, Hervé/AAA-6882-2019	Gilroy, Simon/0000-0001-9597-6839				Assmann SM, 2001, CURR OPIN PLANT BIOL, V4, P421, DOI 10.1016/S1369-5266(00)00195-3; Assmann SM, 2002, PLANT CELL, V14, pS355, DOI 10.1105/tpc.001792; Blatt MR, 2000, ANNU REV CELL DEV BI, V16, P221, DOI 10.1146/annurev.cellbio.16.1.221; Brownlee C, 2001, CURR BIOL, V11, pR535, DOI 10.1016/S0960-9822(01)00313-X; Cismowski MJ, 2001, LIFE SCI, V68, P2301, DOI 10.1016/S0024-3205(01)01019-0; Colucci G, 2002, P NATL ACAD SCI USA, V99, P4736, DOI 10.1073/pnas.072087699; Crowther GJ, 1997, ARCH BIOCHEM BIOPHYS, V337, P284, DOI 10.1006/abbi.1996.9799; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Himmel HM, 2000, MOL PHARMACOL, V58, P449, DOI 10.1124/mol.58.2.449; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Jones AM, 2002, CURR OPIN PLANT BIOL, V5, P402, DOI 10.1016/S1369-5266(02)00288-1; Josefsson LG, 1997, EUR J BIOCHEM, V249, P415, DOI 10.1111/j.1432-1033.1997.t01-1-00415.x; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Ng CKY, 2001, ANN BOT-LONDON, V88, P957, DOI 10.1006/anbo.2001.1543; Ng CKY, 2001, NATURE, V410, P596, DOI 10.1038/35069092; Nishiura H, 2000, BIOCHEM SOC T, V28, P747, DOI 10.1042/BST0280747; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Pandey S, 2002, NEW PHYTOL, V153, P517, DOI 10.1046/j.0028-646X.2001.00329.x; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Schilling T, 2002, NEUROSCIENCE, V109, P827, DOI 10.1016/S0306-4522(01)00534-6; Schroeder JI, 2001, NATURE, V410, P327, DOI 10.1038/35066500; Sperling P, 1998, J BIOL CHEM, V273, P28590, DOI 10.1074/jbc.273.44.28590; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046	29	264	288	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2003	423	6940					651	654		10.1038/nature01643	http://dx.doi.org/10.1038/nature01643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789341	Bronze			2022-12-28	WOS:000183301200043
J	Perkins, BA; Ficociello, LH; Silva, KH; Finkelstein, DM; Warram, JH; Krolewski, AS				Perkins, BA; Ficociello, LH; Silva, KH; Finkelstein, DM; Warram, JH; Krolewski, AS			Regression of microalbuminuria in type 1 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FILTRATION-RATE; NEPHROPATHY; RISK; PREVALENCE; ALBUMIN; COMPLICATIONS; PROTEINURIA; PROGRESSION; PREDICTORS; REMISSION	BACKGROUND: In the present study, we aimed to determine the frequency of a significant reduction in urinary albumin excretion and factors affecting such reduction in patients with type 1 diabetes and microalbuminuria. METHODS: The study included 386 patients with persistent microalbuminuria, indicated by repeated measurements of urinary albumin excretion (estimated on the basis of albumin-to-creatinine ratios) in the range of 30 to 299 microg per minute during an initial two-year evaluation period. Subsequent measurements during the next six years were grouped into two-year periods, averaged, and analyzed for regression of microalbuminuria, which was defined as a 50 percent reduction in urinary albumin excretion from one two-year period to the next. RESULTS: Regression of microalbuminuria was frequent, with a six-year cumulative incidence of 58 percent (95 percent confidence interval, 52 to 64 percent). The use of angiotensin-converting-enzyme inhibitors was not associated with the regression of microalbuminuria. However, microalbuminuria of short duration, salutary levels of glycosylated hemoglobin (less than 8 percent), low systolic blood pressure (less than 115 mm Hg), and low levels of both cholesterol and triglycerides (less than 198 mg per deciliter [5.12 mmol per liter] and 145 mg per deciliter [1.64 mmol per liter], respectively) were independently associated with the regression of microalbuminuria. Patients with salutary levels of all modifiable factors had a hazard ratio for regression of 3.0 (95 percent confidence interval, 1.5 to 6.0), as compared with patients with no salutary levels of any modifiable factor. CONCLUSIONS: Frequent regression of microalbuminuria in patients with type 1 diabetes indicates that elevated urinary albumin excretion does not imply inexorably progressive nephropathy. Identification of the multiple determinants of the regression of microalbuminuria has implications for current theories about the mechanisms of early diabetic nephropathy.	Joslin Diabet Ctr, Sect Genet & Epidemiol, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Krolewski, AS (corresponding author), Joslin Diabet Ctr, Sect Genet & Epidemiol, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	andrzej.krolewski@joslin.harvard.edu		Ficociello, Linda/0000-0003-3523-0028	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041526] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1999, Diabet Med, V16, P918; Caramori ML, 2000, DIABETES, V49, P1399, DOI 10.2337/diabetes.49.9.1399; Chaturvedi N, 2001, ANN INTERN MED, V134, P370, DOI 10.7326/0003-4819-134-5-200103060-00009; Chaturvedi N, 1996, BMJ-BRIT MED J, V312, P253; Chaturvedi N, 2001, KIDNEY INT, V60, P219, DOI 10.1046/j.1523-1755.2001.00789.x; CLOSE CF, 1995, BMJ-BRIT MED J, V311, P973; COONROD BA, 1993, DIABETES CARE, V16, P1376, DOI 10.2337/diacare.16.10.1376; COOPER ME, 1988, DIABETIC MED, V5, P361, DOI 10.1111/j.1464-5491.1988.tb01006.x; COOPER ME, 1988, DIABETIC MED, V5, P422; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; Ellis D, 1996, AM J KIDNEY DIS, V27, P809, DOI 10.1016/S0272-6386(96)90518-1; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; FORSBLOM CM, 1992, BRIT MED J, V305, P1051, DOI 10.1136/bmj.305.6861.1051; Gaede P, 1999, LANCET, V353, P617, DOI 10.1016/S0140-6736(98)07368-1; Garg AX, 2002, KIDNEY INT, V61, P2165, DOI 10.1046/j.1523-1755.2002.00356.x; Genuth S, 2002, JAMA-J AM MED ASSOC, V287, P2563; Hovind P, 2001, DIABETES CARE, V24, P1972, DOI 10.2337/diacare.24.11.1972; HUMES HD, 1989, AM J PHYSIOL, V256, pF688, DOI 10.1152/ajprenal.1989.256.4.F688; Kitamura M, 1999, KIDNEY INT, V55, P1639, DOI 10.1046/j.1523-1755.1999.00425.x; Krolewski AS, 1999, KIDNEY INT, V55, P1582, DOI 10.1046/j.1523-1755.1999.00371.x; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; MATHIESEN ER, 1995, DIABETIC MED, V12, P482, DOI 10.1111/j.1464-5491.1995.tb00528.x; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116; Osicka TM, 1997, CLIN SCI, V93, P65, DOI 10.1042/cs0930065; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; Raats CJI, 2000, KIDNEY INT, V57, P385, DOI 10.1046/j.1523-1755.2000.00858.x; Raptis AE, 2001, EXP CLIN ENDOCR DIAB, V109, pS424, DOI 10.1055/s-2001-18600; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; RUDBERG S, 1992, KIDNEY INT, V41, P822, DOI 10.1038/ki.1992.126; Schreiner G F, 1995, Curr Opin Nephrol Hypertens, V4, P369; Scott LJ, 2001, DIABETES, V50, P2842, DOI 10.2337/diabetes.50.12.2842; Stockand JD, 1997, AM J KIDNEY DIS, V29, P971, DOI 10.1016/S0272-6386(97)90476-5; VIBERTI GC, 1982, LANCET, V1, P1430; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; Warram JH, 2000, DIABETES, V49, P94, DOI 10.2337/diabetes.49.1.94; Warram JH, 1996, J AM SOC NEPHROL, V7, P930; Wilmer WA, 1999, AM J KIDNEY DIS, V34, P308, DOI 10.1016/S0272-6386(99)70360-4; Wong T, 1999, J Am Pharm Assoc (Wash), V39, P785; Zoja C, 1995, AM J KIDNEY DIS, V26, P934, DOI 10.1016/0272-6386(95)90058-6	42	552	581	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2285	2293		10.1056/NEJMoa021835	http://dx.doi.org/10.1056/NEJMoa021835			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788992				2022-12-28	WOS:000183296300003
J	Van de Walle, CG; Neugebauer, J				Van de Walle, CG; Neugebauer, J			Universal alignment of hydrogen levels in semiconductors, insulators and solutions	NATURE			English	Article							TRANSITION-METAL IMPURITIES; BAND LINEUPS; ENERGY; OFFSETS	Hydrogen strongly affects the electronic and structural properties of many materials. It can bind to defects or to other impurities, often eliminating their electrical activity: this effect of defect passivation is crucial to the performance of many photovoltaic and electronic devices(1,2). A fuller understanding of hydrogen in solids is required to support development of improved hydrogen-storage systems(3), proton-exchange membranes for fuel cells, and high-permittivity dielectrics for integrated circuits. In chemistry and in biological systems, there have also been many efforts to correlate proton affinity and deprotonation with host properties(4). Here we report a systematic theoretical study (based on ab initio methods) of hydrogen in a wide range of hosts, which reveals the existence of a universal alignment for the electronic transition level of hydrogen in semiconductors, insulators and even aqueous solutions. This alignment allows the prediction of the electrical activity of hydrogen in any host material once some basic information about the band structure of that host is known. We present a physical explanation that connects the behaviour of hydrogen to the line-up of electronic band structures at heterojunctions.	Xerox Corp, Palo Alto Res Ctr, Palo Alto, CA 94304 USA; Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany	Xerox; Max Planck Society; Fritz Haber Institute of the Max Planck Society	Van de Walle, CG (corresponding author), Xerox Corp, Palo Alto Res Ctr, 3333 Coyote Hill Rd, Palo Alto, CA 94304 USA.	vandewalle@parc.com	Neugebauer, Joerg/K-2041-2015; Van de Walle, Chris G/A-6623-2012	Neugebauer, Joerg/0000-0002-7903-2472; Van de Walle, Chris G/0000-0002-4212-5990				Blochl PE, 1999, PHYS REV LETT, V83, P372, DOI 10.1103/PhysRevLett.83.372; Bockstedte M, 1997, COMPUT PHYS COMMUN, V107, P187, DOI 10.1016/S0010-4655(97)00117-3; CALDAS MJ, 1984, APPL PHYS LETT, V45, P671, DOI 10.1063/1.95351; Franciosi A, 1996, SURF SCI REP, V25, P1, DOI 10.1016/0167-5729(95)00008-9; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Hofmann DM, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.045504; Janotti A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.086403; LEDEBO LA, 1982, J PHYS C SOLID STATE, V15, pL961, DOI 10.1088/0022-3719/15/27/003; Limpijumnong S, 2001, PHYS STATUS SOLIDI B, V228, P303, DOI 10.1002/1521-3951(200111)228:1<303::AID-PSSB303>3.0.CO;2-A; Look DC, 2002, APPL PHYS LETT, V80, P258, DOI 10.1063/1.1432742; LOUIE SG, 1982, PHYS REV B, V26, P1738, DOI 10.1103/PhysRevB.26.1738; Majewski JA, 1997, MATER RES SOC SYMP P, V449, P917; Mejias JA, 2000, J CHEM PHYS, V113, P7306, DOI 10.1063/1.1313793; MILLS BE, 1976, J AM CHEM SOC, V98, P2380, DOI 10.1021/ja00425a002; *NIST, 2003, NIST CHEM WEBB; Pankove J, 1991, SEMICONDUCTORS SEMIM, V34; Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634; TERSOFF J, 1987, PHYS REV LETT, V58, P2367, DOI 10.1103/PhysRevLett.58.2367; TERSOFF J, 1984, PHYS REV B, V30, P4874, DOI 10.1103/PhysRevB.30.4874; Tuttle BR, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.155324; Van de Walle CG, 2000, PHYS REV LETT, V85, P1012, DOI 10.1103/PhysRevLett.85.1012; Van de Walle CG, 1999, SEMICONDUCT SEMIMET, V57, P157; VAN DE WALLE CG, 1986, PHYS REV B, V34, P5621, DOI 10.1103/PhysRevB.34.5621; VAN DE WALLE CG, 1989, PHYS REV B, V39, P1871, DOI 10.1103/PhysRevB.39.1871; YU ET, 1992, SOLID STATE PHYS, V46, P1, DOI 10.1016/S0081-1947(08)60397-5	25	991	998	7	317	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2003	423	6940					626	628		10.1038/nature01665	http://dx.doi.org/10.1038/nature01665			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686BT	12789334				2022-12-28	WOS:000183301200036
J	Moynihan, R				Moynihan, R			Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHARMACEUTICAL-INDUSTRY; PHYSICIANS				Moynihan, R (corresponding author), 1312 21st St NW, Washington, DC 20036 USA.	raymond.moynihan@verizon.net	Moynihan, Ray/ABC-3010-2020					*AM MED ASS, 2001, ETH GUID GIFTS PHYS; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209; BRICHACEK A, 2001, PHARM EXECUTIVE  SEP; *CTR SCI PUBL INT, INT SCI DAT SCI NONP; Jackson T, 2001, BRIT MED J, V322, P1312, DOI 10.1136/bmj.322.7297.1312; KATZ D, 2003, IN PRESS AM J BIOETH; Lenzer J, 2002, BRIT MED J, V324, P723, DOI 10.1136/bmj.324.7339.723; Lexchin J, 1997, CAN FAM PHYSICIAN, V43, P941; LEXCHIN J, 1993, CAN MED ASSOC J, V149, P1401; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Moynihan R, 2003, BRIT MED J, V326, P9; *NAT I HLTH CAR MA, 20022 NAT I HLTH CAR; Relman AS, 2002, NEW REPUBLIC, V227, P27; Smith R, 2003, BRIT MED J, V326, P1202, DOI 10.1136/bmj.326.7400.1202; Steinman MA, 2001, AM J MED, V110, P551, DOI 10.1016/S0002-9343(01)00660-X; *TASK FORC FIN CON, 2001, PROT SUBJ PRES TRUST, P3; Turone F, 2003, BRIT MED J, V326, P413; *US GEN ACC OFF, 2002, PRESCR DRUGS FDA OV; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	22	135	142	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2003	326	7400					1189	1192		10.1136/bmj.326.7400.1189	http://dx.doi.org/10.1136/bmj.326.7400.1189			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686FC	12775621	Green Published			2022-12-28	WOS:000183309900023
J	Brugarolas, J; Clark, JW; Chabner, B				Brugarolas, J; Clark, JW; Chabner, B			Using "rationally designed drugs" rationally	LANCET			English	Editorial Material							CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; INHIBITOR; BCR/ABL; CELLS; MICE; INDUCTION		Dana Farber Canc Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital	Brugarolas, J (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.							Brugarolas J, 2001, LANCET, V357, P249, DOI 10.1016/S0140-6736(00)03608-4; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Demetri GD, 2002, EUR J CANCER, V38, pS52, DOI 10.1016/S0959-8049(02)80603-7; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Rothenberg ML, 2003, NAT REV CANCER, V3, P303, DOI 10.1038/nrc1047; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987	13	5	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1758	1759		10.1016/S0140-6736(03)13446-0	http://dx.doi.org/10.1016/S0140-6736(03)13446-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781531				2022-12-28	WOS:000183074800004
J	Peiris, JSM; Chu, CM; Cheng, VCC; Chan, KS; Hung, IFN; Poon, LLM; Law, KI; Tang, BSF; Hon, TYW; Chan, CS; Chan, KH; Ng, JSC; Zheng, BJ; Ng, WL; Lai, RWM; Guan, Y; Yuen, KY				Peiris, JSM; Chu, CM; Cheng, VCC; Chan, KS; Hung, IFN; Poon, LLM; Law, KI; Tang, BSF; Hon, TYW; Chan, CS; Chan, KH; Ng, JSC; Zheng, BJ; Ng, WL; Lai, RWM; Guan, Y; Yuen, KY		HKU UCH SARS Study Grp	Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study	LANCET			English	Article							VIRUS	Background We investigated the temporal progression of the clinical, radiological, and virological changes in a community outbreak of severe acute respiratory syndrome (SARS). Methods We followed up 75 patients for 3 weeks managed with a standard treatment protocol of ribavirin and corticosteroids, and assessed the, pattern of clinical disease, viral load, risk factors for poor clinical outcome, and the usefulness of virological diagnostic methods. Findings Fever and pneumonia initially improved but 64 (85%) patients developed recurrent fever after a mean of 8-9 (SD 3.1) days, 55 (73%) had watery diarrhoea after 7.5 (2.3) days, 60 (80%) had radiological worsening after 7.4 (2.2) days, and respiratory symptoms worsened in 34 (45%) after 8.6 (3.0) days. In 34 (45%) patients, improvement of initial pulmonary lesions was associated with appearance of new radiological lesions at other sites. Nine (12%) patients developed spontaneous pneumomediastinum and 15 (20%) developed acute respiratory distress syndrome (ARDS) in week 3. Quantitative reverse-transcriptase (RT) PCR of nasopharyngeal aspirates in 14 patients (four with ARDS) showed peak viral load at day 10, and at day 15 a load lower than at admission. Age and chronic hepatitis B virus infection treated with lamivudine were independent significant risk factors for progression to ARDS (p=0.001). SARS-associated coronavirus in faeces was seen on RT-PCR in 65 (97%) of 67 patients at day 14. The mean time to seroconversion was 20 days. Interpretation The consistent clinical progression, shifting radiological infiltrates, and an inverted V viral-load profile suggest that worsening in week 2 is unrelated to uncontrolled viral replication but may be related to immunopathological damage.	Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; United Christian Hosp, Dept Med Intens Care Radiol & Pathol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; United Christian Hospital	Yuen, KY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Chan, Chung Sing/C-4577-2009; Hung, Ivan FN/ABD-5916-2021; Poon, Leo/AAP-6887-2020; Poon, Leo Lit Man/C-4382-2009; Yuen, Kwok Yung/C-4465-2009; Peiris, Joseph Sriyal Malik/C-4380-2009	Hung, Ivan FN/0000-0002-1556-2538; Poon, Leo Lit Man/0000-0002-9101-7953; Guan, Yi/0000-0001-6057-9243; CHENG, Vincent Chi-Chung/0000-0003-1765-7706; Chu, Chung Ming/0000-0002-9959-1271; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Yuen, Kwok-yung/0000-0002-2083-1552	PHS HHS [A195357] Funding Source: Medline; Wellcome Trust Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome TrustEuropean Commission)		BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; *CDCP, SARS COR SEQ; *HA, HA GUID SEV AC RESP; Ho W, 2003, LANCET, V361, P1313, DOI 10.1016/S0140-6736(03)13085-1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KSIAZEK TG, NOVEL CORONAVIRUS AS; LEE N, MAJOR OUTBREAK SEVER; Majeski EI, 2003, AM J RESP CELL MOL, V28, P208, DOI 10.1165/rcmb.4891; Ning Q, 1998, J IMMUNOL, V160, P3487; OLLIFF JFC, 1989, CLIN RADIOL, V40, P463, DOI 10.1016/S0009-9260(89)80245-4; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; POON LLM, RAPID DIAGNOSIS CORO; POUTANEN SM, IDENTIFICATION SEVER; *SEV AC RESP SYNDR, MULT COUNTR OUTBR; TSANG KW, CLUSTER CASES SEVERE; TURNER RB, 1986, J INFECT DIS, V154, P443, DOI 10.1093/infdis/154.3.443; TUTOR JD, 1995, PEDIATR PULM, V19, P393, DOI 10.1002/ppul.1950190614; ATYPICAL PNEUMONIA	18	1638	1796	3	210	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 24	2003	361	9371					1767	1772		10.1016/S0140-6736(03)13412-5	http://dx.doi.org/10.1016/S0140-6736(03)13412-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	682CY	12781535	Green Published, Bronze			2022-12-28	WOS:000183074800008
J	Sidi, S; Friedrich, RW; Nicolson, T				Sidi, S; Friedrich, RW; Nicolson, T			NompC TRP channel required for vertebrate sensory hair cell mechanotransduction	SCIENCE			English	Article							MECHANOSENSORY TRANSDUCTION; DROSOPHILA; MUTANTS	The senses of hearing and balance in vertebrates rely on the sensory hair cells (HCs) of the inner ear. The central element of the HC's transduction apparatus is a mechanically gated ion channel of unknown identity. Here we report that the zebrafish ortholog of Drosophila no mechanoreceptor potential C (nompC), which encodes a transient receptor potential (TRP) channel, is critical for HC mechanotransduction. In zebrafish larvae, nompC is selectively expressed in sensory HCs. Morpholino-mediated removal of nompC function eliminated transduction-dependent endocytosis and electrical responses in HCs, resulting in larval deafness and imbalance. These observations indicate that nompC encodes a vertebrate HC mechanotransduction channel.	Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; Max Planck Inst Med Res, D-69120 Heidelberg, Germany	Max Planck Society; Max Planck Society	Nicolson, T (corresponding author), Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Portland, OR 97201 USA.			Friedrich, Rainer/0000-0001-9107-0482				ASSAD JA, 1991, NEURON, V7, P985, DOI 10.1016/0896-6273(91)90343-X; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Colbert HA, 1997, J NEUROSCI, V17, P8259; COREY DP, 1983, J NEUROSCI, V3, P962; COREY DP, 1983, J NEUROSCI, V3, P942; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; MONELL C, 2003, SCI STKE 2003; Nicolson T, 1998, NEURON, V20, P271, DOI 10.1016/S0896-6273(00)80455-9; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PICKLES JO, 1984, HEARING RES, V15, P103, DOI 10.1016/0378-5955(84)90041-8; Seiler C, 1999, J NEUROBIOL, V41, P424, DOI 10.1002/(SICI)1097-4695(19991115)41:3<424::AID-NEU10>3.0.CO;2-G; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Strassmaier M, 2002, CURR OPIN NEUROBIOL, V12, P380, DOI 10.1016/S0959-4388(02)00344-6; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229	19	228	249	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					96	99		10.1126/science.1084370	http://dx.doi.org/10.1126/science.1084370			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12805553				2022-12-28	WOS:000183914700041
J	Pietroni, P; Winkler, F; Graham, L				Pietroni, P; Winkler, F; Graham, L			Cultural revolution in care delivery	BRITISH MEDICAL JOURNAL			English	Article									St Charles Hosp, Reg Educ Support Unit, London W10 6DZ, England; St Charles Hosp, 4Ps Dev Ctr, London W10 6DZ, England	Imperial College London; Imperial College London	Winkler, F (corresponding author), St Charles Hosp, Reg Educ Support Unit, Courtfield House, London W10 6DZ, England.								0	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2003	326	7402					1304	1306		10.1136/bmj.326.7402.1304	http://dx.doi.org/10.1136/bmj.326.7402.1304			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691VK	12805165	Green Published			2022-12-28	WOS:000183626500029
J	Hu, C; Ahmed, M; Melia, TJ; Sollner, TH; Mayer, T; Rothman, JE				Hu, C; Ahmed, M; Melia, TJ; Sollner, TH; Mayer, T; Rothman, JE			Fusion of cells by flipped SNAREs	SCIENCE			English	Article							DEPENDENT MEMBRANE-FUSION; COMPLEX-FORMATION; 3-DIMENSIONAL STRUCTURE; EXOCYTOSIS; VESICLE; SPECIFICITY; REQUIRES; PROTEINS; SNAP-25; PATHWAY	The SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) hypothesis suggests that pairs of proteins known as vesicle (v-) SNAREs and target membrane (t-) SNAREs interact specifically to control and mediate intracellular membrane fusion events. Here, cells expressing the interacting domains of v- and t- SNAREs on the cell surface were found to fuse spontaneously, demonstrating that SNAREs are sufficient to fuse biological membranes.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave,Box 251, New York, NY 10021 USA.	j-rothman@ski.mskcc.org		Mayer, Thomas/0000-0001-6954-2287				Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; HU CY, UNPUB; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Paumet F, 2001, J CELL BIOL, V155, P961, DOI 10.1083/jcb.200104092; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Witze E, 2002, CURR BIOL, V12, pR467, DOI 10.1016/S0960-9822(02)00948-X	28	173	179	3	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2003	300	5626					1745	1749		10.1126/science.1084909	http://dx.doi.org/10.1126/science.1084909			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12805548				2022-12-28	WOS:000183459700051
J	Smith, IE; Dowsett, M				Smith, IE; Dowsett, M			Drug therapy: Aromatase inhibitors in breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FIRST-LINE THERAPY; PHASE-III TRIAL; 2ND-LINE HORMONAL TREATMENT; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; MEGESTROL-ACETATE; RANDOMIZED-TRIAL; DOUBLE-BLIND; ENDOCRINE THERAPY; REPLACEMENT THERAPY		Royal Marsden Hosp, Breast Unit, Fulham Rd, London SW3 6JJ, England; Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England; Inst Canc Res, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Smith, IE (corresponding author), Royal Marsden Hosp, Breast Unit, Fulham Rd, London SW3 6JJ, England.	ian.smith@rmh.nthames.nhs.uk						*ACOG COMM, 2000, TAM END CANC; Bajetta E, 2000, ANN ONCOL, V11, P1017, DOI 10.1023/A:1008388823113; Baum M, 2002, LANCET, V359, P2131; Baum M, 2001, BRIT J CANCER, V85, P317, DOI 10.1054/bjoc.2001.1925; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BERGH J, 1997, P AN M AM SOC CLIN, V16, pA155; Bhatnagar A, 1998, BREAST CANCER RES TR, V49, pS73; Bisagni G, 1996, ANN ONCOL, V7, P99; Boccardo F, 2001, J CLIN ONCOL, V19, P4209, DOI 10.1200/JCO.2001.19.22.4209; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; BRUNING PF, 1988, BRIT J CANCER, V58, P497, DOI 10.1038/bjc.1988.248; Buzdar A, 2001, J CLIN ONCOL, V19, P3357, DOI 10.1200/JCO.2001.19.14.3357; Buzdar A, 2001, CLIN CANCER RES, V7, P2620; Buzdar A, 1996, J CLIN ONCOL, V14, P2000, DOI 10.1200/JCO.1996.14.7.2000; Buzdar AU, 1996, CANCER, V77, P2503, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W; Buzdar AU, 1998, CANCER-AM CANCER SOC, V83, P1142, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7; BUZDAR AU, 1999, CANCER, V15, P1010; Carlini P, 2001, ANN ONCOL, V12, P1539, DOI 10.1023/A:1013180214359; Cheung KL, 2000, ENDOCR-RELAT CANCER, V7, P131, DOI 10.1677/erc.0.0070131; Clarke M, 1998, LANCET, V351, P1451; COOMBES RC, 1987, CANCER RES, V47, P2496; Costantino JP, 1997, J NATL CANCER I, V89, P776, DOI 10.1093/jnci/89.11.776; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Cuzick J, 2002, LANCET, V360, P817; DEFRIEND DJ, 1994, BRIT J CANCER, V70, P204, DOI 10.1038/bjc.1994.281; DIRIX L, 2001, P AN M AM SOC CLIN, V20, pA29; Dixon JM, 2001, AROMATASE INHIBITION AND BREAST CANCER, P103; Dombernowsky P, 1998, J CLIN ONCOL, V16, P453, DOI 10.1200/JCO.1998.16.2.453; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dowsett M, 1999, CLIN CANCER RES, V5, P2338; Eiermann W, 2001, ANN ONCOL, V12, P1527, DOI 10.1023/A:1013128213451; Elisaf MS, 2001, EUR J CANCER, V37, P1510, DOI 10.1016/S0959-8049(01)00155-1; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; EVANS CT, 1986, P NATL ACAD SCI USA, V83, P6387, DOI 10.1073/pnas.83.17.6387; Falkson CI, 1996, ANN ONCOL, V7, P465; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fodor J, 2002, LANCET, V360, P1520; FORREST APM, 1986, LANCET, V2, P840; GALE KE, 1994, CANCER, V73, P354, DOI 10.1002/1097-0142(19940115)73:2<354::AID-CNCR2820730220>3.0.CO;2-J; Geisler J, 1998, CLIN CANCER RES, V4, P2089; Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751; Gershanovich M, 1998, ANN ONCOL, V9, P639, DOI 10.1023/A:1008226721932; GILL PG, 1993, ANN ONCOL, V4, P741, DOI 10.1093/oxfordjournals.annonc.a058658; Goss PE, 1999, J CLIN ONCOL, V17, P52, DOI 10.1200/JCO.1999.17.1.52; Goss PE, 2001, J CLIN ONCOL, V19, P881, DOI 10.1200/JCO.2001.19.3.881; Hamilton A, 1999, ANN ONCOL, V10, P377, DOI 10.1023/A:1008368300827; Harper-Wynne C, 2002, CANCER EPIDEM BIOMAR, V11, P614; Harper-Wynne CL, 2002, J CLIN ONCOL, V20, P1026, DOI 10.1200/JCO.20.4.1026; HAYES DF, 1995, J CLIN ONCOL, V13, P2556, DOI 10.1200/JCO.1995.13.10.2556; HENDERSON BE, 1991, BREAST CANCER RES TR, V18, pS11, DOI 10.1007/BF02633520; Heshmati HM, 2002, J BONE MINER RES, V17, P172, DOI 10.1359/jbmr.2002.17.1.172; Howell A, 1997, BRIT MED J, V315, P863, DOI 10.1136/bmj.315.7112.863; INGLE JN, 1981, NEW ENGL J MED, V304, P16, DOI 10.1056/NEJM198101013040104; Jonat W, 1996, EUR J CANCER, V32A, P404, DOI 10.1016/0959-8049(95)00014-3; JONES AL, 1992, J CLIN ONCOL, V10, P1547, DOI 10.1200/JCO.1992.10.10.1547; Kaufmann M, 2000, J CLIN ONCOL, V18, P1399, DOI 10.1200/JCO.2000.18.7.1399; KELLOKUMPULEHTINEN P, 1987, CANCER, V60, P2376, DOI 10.1002/1097-0142(19871115)60:10<2376::AID-CNCR2820601005>3.0.CO;2-N; Lamb HM, 1998, DRUGS, V56, P1125, DOI 10.2165/00003495-199856060-00020; LIEN EA, 1990, CANCER RES, V50, P5851; LIPTON A, 1982, CANCER, V50, P2265, DOI 10.1002/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-#; LONGCOPE C, 1986, METABOLISM, V35, P235, DOI 10.1016/0026-0495(86)90206-4; Lonning PE, 2000, J CLIN ONCOL, V18, P2234, DOI 10.1200/JCO.2000.18.11.2234; LONNING PE, 1991, BRIT J CANCER, V63, P789, DOI 10.1038/bjc.1991.175; LOVE RR, 1994, ARCH INTERN MED, V154, P2585, DOI 10.1001/archinte.154.22.2585; MACNEILL FA, 1992, BRIT J CANCER, V66, P692, DOI 10.1038/bjc.1992.339; MCDONALD CC, 1995, BRIT MED J, V311, P977; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; Miller W R, 2000, Clin Breast Cancer, V1 Suppl 1, pS9, DOI 10.3816/CBC.2000.s.002; Miller William R, 2002, Cancer Control, V9, P9; MILLER WR, 1982, CANCER RES, V42, P3365; Miller WR, 2001, J STEROID BIOCHEM, V79, P93, DOI 10.1016/S0960-0760(01)00148-0; Mitwally MF, 2002, CURR OPIN OBSTET GYN, V14, P255, DOI 10.1097/00001703-200206000-00003; Mouridsen, 2001, J CLIN ONCOL, V19, P3302; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; MUSS HB, 1988, J CLIN ONCOL, V6, P1098, DOI 10.1200/JCO.1988.6.7.1098; MUSS HB, 1994, J CLIN ONCOL, V12, P1630, DOI 10.1200/JCO.1994.12.8.1630; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; Nelson LR, 2001, J AM ACAD DERMATOL, V45, pS116, DOI 10.1067/mjd.2001.117432; O'Meara ES, 2001, JNCI-J NATL CANCER I, V93, P754, DOI 10.1093/jnci/93.10.754; PLOURDE PV, 1995, J STEROID BIOCHEM, V53, P175, DOI 10.1016/0960-0760(95)00045-2; Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78; Pritchard KI, 1997, J CLIN ONCOL, V15, P2302, DOI 10.1200/JCO.1997.15.6.2302; ROSE C, 2002, P AN M AM SOC CLIN, V21, pA34; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; Saarto T, 1996, J CLIN ONCOL, V14, P429, DOI 10.1200/JCO.1996.14.2.429; SANTEN RJ, 1977, CANCER-AM CANCER SOC, V39, P2948, DOI 10.1002/1097-0142(197706)39:6<2948::AID-CNCR2820390681>3.0.CO;2-9; SANTEN RJ, 1978, J CLIN ENDOCR METAB, V47, P1257, DOI 10.1210/jcem-47-6-1257; Shaywitz SE, 1999, JAMA-J AM MED ASSOC, V281, P1197, DOI 10.1001/jama.281.13.1197; Simpson ER, 2002, RECENT PROG HORM RES, V57, P317, DOI 10.1210/rp.57.1.317; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Sinha S, 1998, BREAST CANCER RES TR, V48, P45, DOI 10.1023/A:1005937900788; SMITH IE, 1981, BRIT MED J, V283, P1432, DOI 10.1136/bmj.283.6304.1432; SMITH IE, 1978, LANCET, V2, P646, DOI 10.1016/S0140-6736(78)92759-9; Smith IE, 2001, LANCET ONCOL, V2, P561, DOI 10.1016/S1470-2045(01)00490-9; STEELE R E, 1987, Steroids, V50, P147, DOI 10.1016/0039-128X(83)90068-5; STEIN RC, 1990, CANCER CHEMOTH PHARM, V26, P75, DOI 10.1007/BF02940300; STEIN RC, 1990, BRIT J CANCER, V62, P679, DOI 10.1038/bjc.1990.356; STENBYGAARD LE, 1993, BREAST CANCER RES TR, V25, P57, DOI 10.1007/BF00662401; STUARTHARRIS R, 1984, LANCET, V2, P604; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; THIJSSEN JHH, 1989, EUR J CANCER CLIN ON, V25, P1953, DOI 10.1016/0277-5379(89)90377-5; Thurlimann B, 1996, ANN ONCOL, V7, P471; Thurlimann B, 1997, EUR J CANCER, V33, P1017, DOI 10.1016/S0959-8049(97)00105-6; Tominaga T, 2000, ANN ONCOL, V11, P25; Vassilopoulou-Sellin R, 1999, J CLIN ONCOL, V17, P1482, DOI 10.1200/JCO.1999.17.5.1482; Winer EP, 2002, J CLIN ONCOL, V20, P3317, DOI 10.1200/JCO.2002.06.020; Wiseman LR, 1998, DRUG AGING, V13, P321, DOI 10.2165/00002512-199813040-00008	108	639	664	2	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2003	348	24					2431	2442		10.1056/NEJMra023246	http://dx.doi.org/10.1056/NEJMra023246			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688HU	12802030				2022-12-28	WOS:000183428900010
J	Chauhan, AJ; Inskip, HM; Linaker, CH; Smith, S; Schreiber, J; Johnston, SL; Holgate, ST				Chauhan, AJ; Inskip, HM; Linaker, CH; Smith, S; Schreiber, J; Johnston, SL; Holgate, ST			Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children	LANCET			English	Article							RESPIRATORY SYMPTOMS; AIR-POLLUTION; RISK-FACTORS; IN-VITRO; ASSOCIATION; INFECTION; COOKING; ADULTS; CELLS; GAS	Background A link between exposure to the air pollutant nitrogen dioxide (NO2) and respiratory disease has been suggested. Viral infections are the major cause of asthma exacerbations. We aimed to assess whether there is a relation between NO2 exposure and the severity of asthma exacerbations caused by proven respiratory viral infections in children. Methods A cohort of 114 asthmatic children aged between 8 and 11 years recorded daily upper and lower respiratory-tract symptoms, peak expiratory flow (PEF), and measured personal NO2 exposures every week for up to 13 months. We took nasal aspirates during reported episodes of upper respiratory-tract illness and tested for infection by common respiratory viruses and atypical bacteria with RT-PCR assays. We used generalised estimating equations to assess the relation between low (<7.5 &mu;g/m(3) medium (7.5-14 &mu;g/m(3)), and high (>14 mug/m(3)) tertiles of NO2 exposure in the week before or after upper respiratory-tract infection and the severity of asthma exacerbation in the week after the start of an infection. Findings One or more viruses were detected in 78% of reported infection episodes, and the medians of NO2 exposure were 5 (IQR 3.6-6.3), 10 (8.7-12.0), and 21 mug/m(3) (16.8-42.9) for low, medium, and high tertiles, respectively. There were significant increases in the severity of lower respiratory-tract symptom scores across the three tertiles (0.6 for all viruses [p=0.05] and >2 for respiratory syncytial virus [p=0.01]) and a reduction in PEF of more than 12 L/min for picornavirus (p=0.04) for high compared with low NO2 exposure before the start of the virus-induced exacerbation. Interpretation High exposure to NO2 in the week before the start of a respiratory viral infection, and at levels within current air quality standards, is associated with an increase in the severity of a resulting asthma exacerbation.	Univ Southampton, Resp Cell & Mol Biol Res Div, Southampton, Hants, England; Univ Southampton, MRC, Environm Epidemiol Unit, Southampton, Hants, England; Natl Heart & Lung Inst, London, England; Univ London Imperial Coll Sci Technol & Med, Wright Fleming Inst Infect & Immun, London, England	University of Southampton; University of Southampton; Imperial College London; Imperial College London	Chauhan, AJ (corresponding author), St Marys Hosp, Portsmouth PO3 6AD, Hants, England.		Johnston, Sebastian Lennox/I-2423-2012; Inskip, Hazel/L-5467-2018	Johnston, Sebastian Lennox/0000-0003-3009-9200; Inskip, Hazel/0000-0001-8897-1749				*ADV GROUP MED ASP, 1993, 3 DEP HLTH ADV GROUP, P29; Ando M, 2001, ARCH ENVIRON HEALTH, V56, P227, DOI 10.1080/00039890109604446; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; BRUNEKREEF B, 1982, INT ARCH OCC ENV HEA, V50, P299, DOI 10.1007/BF00378091; CARSON JL, 1993, AM J RESP CELL MOL, V9, P264, DOI 10.1165/ajrcmb/9.3.264; Chauhan A. J., 1998, Reviews on Environmental Health, V13, P73; CLAUSING P, 1986, Environment International, V12, P413, DOI 10.1016/0160-4120(86)90056-5; Dennekamp M, 2001, OCCUP ENVIRON MED, V58, P511, DOI 10.1136/oem.58.8.511; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; EHRLICH R, 1966, BACTERIOL REV, V30, P604, DOI 10.1128/MMBR.30.3.604-614.1966; FRAMPTON MW, 1989, ENVIRON RES, V48, P179, DOI 10.1016/S0013-9351(89)80033-7; Frampton MW, 2002, AM J PHYSIOL-LUNG C, V282, pL155, DOI 10.1152/ajplung.2002.282.1.L155; GOINGS SAJ, 1989, AM REV RESPIR DIS, V139, P1075, DOI 10.1164/ajrccm/139.5.1075; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662, DOI 10.1080/10473289.1992.10467018; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834, DOI 10.1093/oxfordjournals.aje.a116745; JAKAB GJ, 1987, ENVIRON RES, V42, P215, DOI 10.1016/S0013-9351(87)80023-3; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KAWAMOTO T, 1993, ARCH ENVIRON CON TOX, V25, P534; Linaker CH, 2000, OCCUP ENVIRON MED, V57, P472, DOI 10.1136/oem.57.7.472; Linaker CH, 1996, OCCUP ENVIRON MED, V53, P200, DOI 10.1136/oem.53.3.200; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; NOY D, 1990, ATMOS ENVIRON A-GEN, V24, P2903, DOI 10.1016/0960-1686(90)90470-8; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258, DOI 10.1164/ajrccm/148.5.1258; SANDSTROM T, 1992, EUR RESPIR J, V5, P1092; SCHENKER MB, 1983, AM REV RESPIR DIS, V128, P1038; Siegel PD, 1997, TOXICOL APPL PHARM, V144, P356, DOI 10.1006/taap.1997.8148; Spannhake EW, 2002, ENVIRON HEALTH PERSP, V110, P665, DOI 10.1289/ehp.02110665; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; WHO, 2000, EUR SER, Vsecond; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	35	215	223	0	35	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1939	1944		10.1016/S0140-6736(03)13582-9	http://dx.doi.org/10.1016/S0140-6736(03)13582-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687DB	12801737	Green Published, Bronze			2022-12-28	WOS:000183359700009
J	Cohen, RA; Brown, RS				Cohen, RA; Brown, RS			Microscopic hematuria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASYMPTOMATIC MICROHEMATURIA; BLADDER-CANCER; EXCRETORY UROGRAPHY; RENAL MASSES; FOLLOW-UP; RED-CELL; ADULTS; CYTOLOGY; DIAGNOSIS; CT		Beth Israel Deaconess Med Ctr, Div Nephrol, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Cohen, RA (corresponding author), Beth Israel Deaconess Med Ctr, Div Nephrol, Dept Med, 330 Brookline Ave,DA517, Boston, MA 02115 USA.							BADALAMENT RA, 1987, CANCER, V60, P1423, DOI 10.1002/1097-0142(19871001)60:7<1423::AID-CNCR2820600702>3.0.CO;2-6; BARD RH, 1988, ARCH INTERN MED, V148, P2629, DOI 10.1001/archinte.148.12.2629; BIRCH DF, 1979, LANCET, V2, P845; BRITTON JP, 1992, J UROLOGY, V148, P788, DOI 10.1016/S0022-5347(17)36720-4; CARSON CC, 1979, JAMA-J AM MED ASSOC, V241, P149, DOI 10.1001/jama.241.2.149; CORWIN HL, 1988, J UROLOGY, V139, P1002, DOI 10.1016/S0022-5347(17)42747-9; CORWIN HL, 1988, J UROLOGY, V140, P1558; DAMICO G, 1985, MEDICINE, V64, P49, DOI 10.1097/00005792-198501000-00004; DAVIDES KC, 1986, UROLOGY, V28, P453, DOI 10.1016/0090-4295(86)90142-1; FROOM P, 1984, BRIT MED J, V288, P20, DOI 10.1136/bmj.288.6410.20; GREENE LF, 1956, JAMA-J AM MED ASSOC, V161, P610, DOI 10.1001/jama.1956.02970070042011; Grossfeld GD, 2001, UROLOGY, V57, P604, DOI 10.1016/S0090-4295(01)00920-7; HIATT RA, 1994, CANCER EPIDEM BIOMAR, V3, P439; Hiatt RA, 1994, CANCER EPIDEM BIOMAR, V3, P523; HOWARD RS, 1991, J UROLOGY, V145, P335, DOI 10.1016/S0022-5347(17)38331-3; JamisDow CA, 1996, RADIOLOGY, V198, P785, DOI 10.1148/radiology.198.3.8628872; JONES DJ, 1988, BRIT J UROL, V62, P541, DOI 10.1111/j.1464-410X.1988.tb04422.x; Khadra MH, 2000, J UROLOGY, V163, P524, DOI 10.1016/S0022-5347(05)67916-5; KITAMOTO Y, 1993, NEPHRON, V64, P32, DOI 10.1159/000187274; Kohler C, 1999, Lakartidningen, V96, P4911; KOHLER H, 1991, KIDNEY INT, V40, P115, DOI 10.1038/ki.1991.188; KOSS LG, 1985, ACTA CYTOL, V29, P810; Lang EK, 2002, J UROLOGY, V167, P547, DOI 10.1016/S0022-5347(01)69083-9; MARIANI AJ, 1989, J UROLOGY, V141, P350, DOI 10.1016/S0022-5347(17)40763-4; McGregor DO, 1998, CLIN NEPHROL, V49, P345; MESSING EM, 1992, J UROLOGY, V148, P289, DOI 10.1016/S0022-5347(17)36575-8; MOHR DN, 1986, JAMA-J AM MED ASSOC, V256, P224, DOI 10.1001/jama.256.2.224; MURAKAMI S, 1990, J UROLOGY, V144, P99, DOI 10.1016/S0022-5347(17)39379-5; OFFRINGA M, 1992, POSTGRAD MED J, V68, P648, DOI 10.1136/pgmj.68.802.648; PIPER JM, 1985, NEW ENGL J MED, V313, P292, DOI 10.1056/NEJM198508013130504; POLLOCK C, 1989, KIDNEY INT, V36, P1045, DOI 10.1038/ki.1989.299; RIFE CC, 1979, UROL CLIN N AM, V6, P599; RITCHIE CD, 1986, BRIT MED J, V292, P681, DOI 10.1136/bmj.292.6521.681; Sourtzis S, 1999, AM J ROENTGENOL, V172, P1491, DOI 10.2214/ajr.172.6.10350278; SPARWASSER C, 1994, BRIT J UROL, V74, P723, DOI 10.1111/j.1464-410X.1994.tb07114.x; Stein JP, 1998, J UROLOGY, V160, P645, DOI 10.1016/S0022-5347(01)62747-2; SUTTON JM, 1990, JAMA-J AM MED ASSOC, V263, P2475, DOI 10.1001/jama.263.18.2475; TalarWilliams C, 1996, ANN INTERN MED, V124, P477, DOI 10.7326/0003-4819-124-5-199603010-00003; TIEBOSCH ATMG, 1989, NEW ENGL J MED, V320, P14, DOI 10.1056/NEJM198901053200103; TOPHAM PS, 1994, Q J MED, V87, P329; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; VANSAVAGE JG, 1995, J UROLOGY, V153, P1594, DOI 10.1016/S0022-5347(01)67469-X; WARSHAUER DM, 1988, RADIOLOGY, V169, P363, DOI 10.1148/radiology.169.2.3051112; WOOLHANDLER S, 1989, JAMA-J AM MED ASSOC, V262, P1214, DOI 10.1001/jama.262.9.1214	44	159	163	0	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2003	348	23					2330	2338		10.1056/NEJMcp012694	http://dx.doi.org/10.1056/NEJMcp012694			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	686AA	12788998				2022-12-28	WOS:000183296300010
J	Michalek, J; Collins, RH; Hill, BJ; Brenchley, JM; Douek, DC				Michalek, J; Collins, RH; Hill, BJ; Brenchley, JM; Douek, DC			Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation	LANCET			English	Article							DISEASE	Allogeneic haemopoietic stem cell transplantation can be complicated by acute graft-versus-host disease (GVHD). If the alloreactive T-cell clones responsible for this disorder could be identified before stem cell transplantation, they could be quantitatively monitored afterwards to allow initiation of immunosuppression before GVHD becomes apparent. We identified an alloreactive CD4(+) T-cell clone from a donor before stem cell transplantation, and then monitored its frequency in the recipient's peripheral blood after transplantation by use of clonotypic quantitative real-time PCR. Greatly increased concentrations of this clone (nearly 100% of circulating CD4(+) T cells) preceded and closely correlated with the onset of clinical GVHD, suggesting that a sole alloreactive T-cell clone was responsible for initiation of this disease in vivo. This simple identification and monitoring of potentially GVHD-causing clones can be undertaken before stem cell transplantation with no previous knowledge of the alloantigen responsible, and could allow earlier diagnosis and intervention in GVHD.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Ctr Canc Immunobiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Bone Marrow Transplant Unit, Dallas, TX USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Douek, DC (corresponding author), NIAID, Vaccine Res Ctr, NIH, 40 Convent Dr, Bethesda, MD 20892 USA.		Brenchley, Jason/AAC-5085-2019	Brenchley, Jason/0000-0001-8357-2984				Andre-Schmutz I, 2002, LANCET, V360, P130, DOI 10.1016/S0140-6736(02)09413-8; Dickinson AM, 2002, NAT MED, V8, P410, DOI 10.1038/nm0402-410; Douek DC, 2002, J IMMUNOL, V168, P3099, DOI 10.4049/jimmunol.168.6.3099; Murphy WJ, 1999, CURR OPIN IMMUNOL, V11, P509, DOI 10.1016/S0952-7915(99)00002-3; Mutis T, 1999, NAT MED, V5, P839, DOI 10.1038/10563	5	66	93	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1183	1185		10.1016/S0140-6736(03)12917-0	http://dx.doi.org/10.1016/S0140-6736(03)12917-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12781582				2022-12-28	WOS:000182094600013
